

```

QY 173 -----QLELDQSG-----TWCTVLQNGKVFEDIIVPCAPAPSKSC 210
DB 170 VHTFPAVLQSSGLYSLSVTVTPSSSLGTQTTICNV--NHKSNTKVD---KAYEPKSC 223
QY 211 DKTHTC-----DELLGGPSVFLPPPKKDTLMISRPEVTCVVVDVSHEDPEVKFNWYVD 265
DB 224 DKTHTCPCPAPAPELLGGPSVFLPPPKKDTLMISRPEVTCVVVDVSHEDPEVKFNWYVD 283
QY 266 GVEVNNAKTKPREEOYNSTYRVVSVLTVTHQDWLNKEVKCKVSNKALPAPIEKTIISKAK 325
DB 284 GVEVNNAKTKPREEOYNSTYRVVSVLTVTHQDWLNKEVKCKVSNKALPAPIEKTIISKAK 343
QY 326 GQPREPQVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPPVLD 385
DB 344 GQPREPQVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPPVLD 403
QY 386 DGSFFLYSKLTVDKSRMGOGNVFSCSVMHEALHNHYTQKSLSLSPG 431
DB 404 DGSFFLYSKLTVDKSRMGOGNVFSCSVMHEALHNHYTQKSLSLSPG 449

```

RESULT 38
AAR42066
ID AAR42066 standard; protein; 459 AA.

```

XX AC AAR42066;
XX DT 25-MAR-2003 (revised)
XX DT 29-APR-1994 (first entry)
XX DE Human anti-HBs heavy chain.
XX KM Antibody; Ab; light; heavy; chain; hepatitis B; HB; surface antigen.
XX OS Homo sapiens.
XX FH Key location/Qualifiers
XX FT Peptide 1..9
XX FT Protein /label= sig_peptide
XX FT Protein 10..459
XX FT Protein /label= mat_protein
XX PN WO9320205-A1.
XX PD 14-OCT-1993.
XX PF 30-MAR-1993; 93WO-JP000396.
XX PR 30-MAR-1992; 92JP-00074678.
XX PA (SUNR ) SUNTORY LTD.
XX PI Kurihara T, Matsumura S, Tsuruoka N, Arima K, Nishihara T;
XX DR N-PSDB; AAQ49944.
XX DR N-PSDB; AAQ49944.
XX PT Human anti-hepatitis B surface antigen antibody gene - can be used to
XX PT produce L and H chains of the antibody in large quantity.
XX PS Disclosure; Fig 6-8; 46pp; Japanese.
XX CC Polynucleotides encoding the L and H chains of human anti-HBs Ab are
XX CC given in AAQ49943-Q49944. The Ab can be easily produced in large
XX CC quantities for therapeutic use. (Updated on 25-MAR-2003 to correct PN
XX CC field.)
XX SQ Sequence 459 AA;

```

Query Match 53.2%; Score 1284.5; DB 2; Length 459;
Best Local Similarity 59.4%; Pred. No. 1..le-64;
Matches 280; Conservative 30; Mismatches 68; Indels 93; Gaps 17;

```

QY 25 GNKVVLGGKGPVETLCTAS--QKKSIOFHW-----KNSNQIKIL--GNQGSFL--TK 71
DB 17 GGGVV--OPGKSLRSLCAASGFTSSNSMHWVROAPGKLEWVAIILYDGNHKKFADSVK 74
QY 72 GPSKLNDRADSRSLMDQGNPFLIIKNLIKEDSDTYICEVDQKEVQLVFGLTANSDT 131
DB 75 GRFTIS-RDNSKNTLY-----LEVKSLOTEDTGYYVC-IRDQ-----TYGV----- 113
QY 132 HLLQ--GQSLLTLESPPGSSPSVQCSPPRGKNIQCG-----KTLVS----- 172
DB 114 HRFDSWGQTLVTVTSASATKGPSVFLAPSSKSTSGGTAALGCLVKDYFPBPVTVSWNSG 173
QY 173 -----QLELDQSG-----TWCTVLQNGKVFEDIIVPCAP 205
DB 174 ALASGHTFPAVLQSSGLYSLSVTVTPSSSLGTQTTICNV--NHKSNTKVD---KKV 227
QY 206 EPKSCDKTHTC-----PELLGGPSVFLPPPKKDTLMISRPEVTCVVVDVSHEDPEVKF 260
DB 228 EPKSCDKTHTCPCPAPAPELLGGPSVFLPPPKKDTLMISRPEVTCVVVDVSHEDPEVKF 287
QY 261 NWYDGVVNNAKTKPREEOYNSTYRVVSVLTVTHQDWLNKEVKCKVSNKALPAPIEKT 320
DB 288 NWYDGVVNNAKTKPREEOYNSTYRVVSVLTVTHQDWLNKEVKCKVSNKALPAPIEKT 347
QY 321 ISKAGQPREPQVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTP 380
DB 348 ISKAGQPREPQVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTP 407
QY 381 PVLDSGDSFFLYSKLTVDKSRMGOGNVFSCSVMHEALHNHYTQKSLSLSPG 431
DB 408 PVLDSGDSFFLYSKLTVDKSRMGOGNVFSCSVMHEALHNHYTQKSLSLSPG 458

```

RESULT 39
AAM05829
ID AAM05829 standard; protein; 446 AA.

```

XX AC AAM05829;
XX DT 16-OCT-2003 (revised)
XX DT 27-JAN-1997 (first entry)
XX DE Humanised 1D10 antibody heavy chain.
XX KM B-cell lymphoma; humanised antibody; bispecific antibody; myeloma;
XX KM leukaemia; hybridoma; monoclonal antibody.
XX OS Homo: sapiens.
XX OS Mus sp.
XX OS Chimeric.
XX FH Key location/Qualifiers
XX FT Domain 1..116
XX FT Domain /label= Variable_domain
XX FT Region 31..35
XX FT Region /label= CDR1
XX FT Region 50..65
XX FT Region /label= CDR2
XX FT Region 98..105
XX FT Region /label= CDR3
XX FT Domain 117..214
XX FT Domain /label= CH1
XX FT Domain 215..229
XX FT Domain /label= Hinge
XX FT Domain 230..339
XX FT Domain /label= CH2
XX FT Domain 340..446
XX FT Domain /label= CH3

```

WO9626964-A1.
06-SEP-1996.

XX 29-FEB-1996; 96WO-US002754.
 PF
 XX 01-MAR-1995; 95US-00397411.
 PR
 XX (PROT-) PROTEIN DESIGN LABS INC.
 PA (IOWA-) IOWA IMMUNOTHERAPY INVESTIGATORS.
 XX
 PI Weiner G, Gingrich R, Link BK, Tso JY;
 DR WPI, 1996-412742/41.
 XX
 XX New bi-specific antibody reactive with both T or NK cells and malignant B
 PT cells - also their humanised forms and hybridomas producing them, useful
 PT for treating or preventing leukaemia, lymphoma and myeloma.
 XX
 XX Example 4; Fig 4e; 85pp; English.
 PS
 CC The humanised ID10 antibody heavy chain (AAW05829) includes a variable
 CC region (see also AAW05823) consisting of human R3.5HG heavy chain
 CC variable region framework and complementarity determining regions from
 CC the murine ID10 antibody specific for a 28/32 kDa antigen found on the
 CC surface of malignant B-cells. It can be coexpressed with humanised ID10
 CC light chain (see also AAW05828) in mammalian host cells. Bispecific
 CC antibodies can be constructed that include a first binding fragment
 CC comprising humanised M291 heavy and light chain variable regions (see
 CC also AAW05826, AAW05830), and a second binding fragment comprising
 CC humanised ID10 heavy and light chain variable regions. Such antibodies
 CC are reactive with both T or NK cells and malignant B cells, and have
 CC therapeutic and diagnostic applns. (Updated on 16-OCT-2003 to standardise
 CC OS field)
 CC
 XX Sequence 446 AA;
 SQ

Query Match 53.1%; Score 1282.5; DB 2; Length 446;
 Best Local Similarity 59.8%; Pred. No. 1.4e-64;
 Matches 274; Conservative 25; Mismatches 80; Indels 79; Gaps 10;

QY LGKKQDYELCTCTASQKSIQF--HMKNNSQIKILGNGSFLTKGSPKLNDRASRL- 86
 DB 11 LKPSRBTSLCTCTGSGFLTYGVHNVQSPKGLKEMGVKMSGSTYNAAFSLRLTIS 70
 QY 87 --WDQGNPLIITKLIKIEDSDPTIYICEVDQKEEVQLVFGLTANSDFHLQ--QGSLLT 142
 DB 71 KDTSKNQVSLKLNSTLTADTAIVYC-----ARRDRYAMDMWGQGLVT 113
 QY 143 LESPFGSSPVQCRSPRKNIQGG-----KTLSSVS-----QLEL 176
 DB 114 VSSASTKGPSVFPPLAPSSKSTSGGTAALGCLVKDYFPPSPVTVSNWNGALTISGVHFTPAVL 173
 QY 177 QDSG-----TWTCVLQNOQKVEFIDIVPCPAPPEKSCDKTHTC-- 216
 DB 174 QSSGLISSLSSVTVVSSSLGTQTYICNV--NHKPSNTKVD---KVEPKSCDKTHTCPP 227
 QY 217 ---PELLGGPSVFLPPEPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK 273
 DB 228 CPAPRLGPGSVFLPPEPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK 287
 QY 274 TKRPEEQVNSTYRVVSVTLVHQMNLNGEKYKCKVSNKALPAPLEKTI SKAKGQPREPOV 333
 DB 288 TKRPEEQVNSTYRVVSVTLVHQMNLNGEKYKCKVSNKALPAPLEKTI SKAKGQPREPOV 347
 QY 334 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPPENNYKTTTPVLDSDSFFLYS 393
 DB 348 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPPENNYKTTTPVLDSDSFFLYS 407
 QY 394 KLTVDKSRWQOGNPFSCSVMHGALHNHYTQKSLSLSPG 431
 DB 408 KLTVDKSRWQOGNPFSCSVMHGALHNHYTQKSLSLSPG 445

RESULT 40
 ABJ37106

ID ABJ37106 standard; protein; 617 AA.
 XX
 AC ABJ37106;
 XX
 DT 08-MAY-2003 (first entry)
 XX
 DE Concatameric immunoadhesion human protein sequence SEQ ID No 18.
 XX
 KM Antiinflammatory; antibacterial; immunosuppressive; antirheumatic;
 KM antiarthritic; immunomodulator; concatameric protein; soluble domain;
 KM dimeric protein; inflammation; septicemia; cytotoxicity;
 KM rheumatoid arthritis; cachexia; inflammation; human.
 OS
 XX Homo sapiens.
 XX
 PN WO2003010202-A1.
 XX
 PD 06-FEB-2003.
 XX
 PF 26-JUL-2002; 2002WO-KR001427.
 XX
 PR 26-JUL-2001; 2001KR-00045028.
 XX
 PA (MEDE-) MEDEXGEN CO LTD.
 XX
 PI Chung Y, Han J, Lee H, Choi E, Kim J;
 XX
 DR WPI; 2003-229639/22.
 DR N-PSDB; ABT32049.
 XX
 XX New concatameric protein having two soluble domains, useful for
 PT diagnosing and treating disorders associated with the dimeric protein or
 PT its glycosylated form, such as inflammation, septicemia, rheumatoid
 PT arthritis and cachexia.
 XX
 XX Claim 6; Page 171-174; 211pp; English.
 PS
 XX
 CC The invention relates to a novel concatameric protein comprising two
 CC biologically active protein domains, in which an N-terminus of a soluble domain of a
 CC biologically active protein is linked to a C-terminus of an identical
 CC soluble domain or a different soluble domain of a biologically active
 CC protein. The methods and compositions of the present invention are useful
 CC for the diagnosis and treatment of disorders associated with dimeric
 CC protein or its glycosylated form, such as inflammation, septicemia,
 CC cytotoxicity, rheumatoid arthritis, cachexia and other inflammation-
 CC related diseases. This sequence represents the human concatameric protein
 CC of the invention
 CC
 XX Sequence 617 AA;
 SQ

Query Match 53.1%; Score 1282.5; DB 6; Length 617;
 Best Local Similarity 64.5%; Pred. No. 2e-64;
 Matches 272; Conservative 22; Mismatches 63; Indels 65; Gaps 11;

QY 35 DTVELCTCTASQKSIQFHMKNNSQIKILGNGSFLTKGSPKLNDRASRLMDQGNFPL 94
 DB 235 DDIKEMKETSQKKTIADPRKEKE-----TFKEDDTYKLPK-----NGTL 272
 QY 95 IIRKLIKIEDSDPTIYICEVEDQK--EEVQLVFGLTANSDFHLQO-----SILLT 142
 DB 273 KIRKLIKIEDSDPTIYICEVEDQK--EEVQLVFGLTANSDFHLQO-----SILLT 142
 QY 143 LESPFGSSPVQCRSPRKNIQGGKTLSSVQLTLDPSGWT-----CTVQNOQKVE 194
 DB 326 CEVWNGTDPPLNL-----YQDGKLIKLSQRYI--THKTTTSLSAKFKCTA--GNKYSKE 375
 QY 195 FKIDIVPCPAPPEKSCDKTHTC-----PELLGGPSVFLPPEPKDITLMISRTPEVTCVV 249
 DB 376 SVSEVPVSCPA--EPKSCDKTHTCPPCPAPRLGPGSVFLPPEPKDITLMISRTPEVTCVV 434
 QY 250 DVSHEDPEVKFNWYVDGVEVHNAKTKRPEEQVNSTYRVVSVTLVHQMNLNGEKYKCKVS 309
 DB 435 DVSHEDPEVKFNWYVDGVEVHNAKTKRPEEQVNSTYRVVSVTLVHQMNLNGEKYKCKVS 494

```

QY 310 NKALPAPIEKTIISKAKGPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAVEMESN 369
DB 495 NKALPAPIEKTIISKAKGPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAVEMESN 554
QY 370 GQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRMOQGNVFCSCVMHEALHNNHYTKSLSLS 429
DB 555 GQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRMOQGNVFCSCVMHEALHNNHYTKSLSLS 614
QY 430 PG 431
DB 615 PG 616

RESULT 41
ABJ37108
ID ABJ37108 standard; protein; 617 AA.
AC ABJ37108;
XX
XX
XX 08-MAY-2003 (first entry)
DT
DE Concatameric immunoadhesion human protein sequence SEQ ID NO 22.
XX
XX Antinflammatory; antibacterial; immunosuppressive; antirheumatic;
XX antiarthritic; immunomodulator; concatameric protein; soluble domain;
XX dimeric protein; inflammation; septicemia; cytotoxicity;
XX rheumatoid arthritis; cachexia; inflammation; human.
XX
XX Homo sapiens.
XX
XX MO2003010202-A1.
XX
XX 06-FEB-2003.
XX
XX 26-JUL-2002; 2002WO-KR001427.
XX
XX 26-JUL-2001; 2001KR-00045028.
XX
XX (MEDE-) MEDEXGEN CO LTD.
XX
XX Chung Y, Han J, Lee H, Choi E, Kim J;
XX
XX MPI: 2003-229639/22.
XX
XX N-PSDB; ABT32051.
XX
XX
XX New concatameric protein having two soluble domains, useful for
XX diagnosing and treating disorders associated with the dimeric protein or
XX its glycosylated form, such as inflammation, septicemia, rheumatoid
XX arthritis and cachexia.
XX
XX Claim 27; Page 188-191; 21pp; English.
XX
XX The invention relates to a novel concatameric protein comprising two
XX soluble domains, in which an N-terminus of a soluble domain of a
XX biologically active protein is linked to a C-terminus of an identical
XX soluble domain or a different soluble domain of a biologically active
XX protein. The methods and compositions of the present invention are useful
XX for the diagnosis and treatment of disorders associated with dimeric
XX protein or its glycosylated form, such as inflammation, septicemia,
XX cytotoxicity, rheumatoid arthritis, cachexia and other inflammatory-
XX related diseases. This sequence represents the human concatameric protein
XX of the invention
XX
XX SQ Sequence 617 AA;

```

```

Query Match 53.1%; Score 1282.5; DB 6; Length 617;
Best Local Similarity 64.5%; Pred. No. 2e-64;
Matches 272; Conservative 22; Mismatches 63; Indels 65; Gaps 11;
QY 35 DTVELTCTASQKKSIOFHWKNSNQIKLGNQGSFLTGKPSKUNDRADSRSLMDQGNPL 94
DB 235 DDIKWEKTSDDKKKIAGFRKEKE-----TFPKDQVYKLFK-----NGTL 272

```

```

QY 95 IIKNLKIEDSPYICVEVDK-EEVQLLVFGLTANSDFHLQGO-----SLFLT 142
DB 273 KIKHLKTDQDIYKVISITDTYKKNVLEKIFDK-----IQRVSKRISWTCTINTLT 325
QY 143 LESPPSSPSVQCSFRGKNIOGKTLVSQLELDQSGTW-----CTVLQNKQVE 194
DB 326 CEVNMGTPELNL-----YQDGKHLKLSGRVI--THKMTTSLSAKRCRA-GNKVKE 375
QY 195 FKIDIVPCPAPBPYSCDKTHTC-----PELLGSPVFLPPPKQDTLMSRTPEVTCVV 249
DB 376 SSVEPVSCPA-EPKSCDKTHTCPPCAPBELIGSPVFLPPPKQDTLMSRTPEVTCVV 434
QY 250 DVSHEDPEKFMWYVDGVEVNAKTPREEOYNSYRVVSLTVLHOMLNGKEKCVS 309
DB 435 DVSHEDPEKFMWYVDGVEVNAKTPREEOYNSYRVVSLTVLHOMLNGKEKCVS 494
QY 310 NKALPAPIEKTIISKAKGPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAVEMESN 369
DB 495 NKALPAPIEKTIISKAKGPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAVEMESN 554
QY 370 GQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRMOQGNVFCSCVMHEALHNNHYTKSLSLS 429
DB 555 GQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRMOQGNVFCSCVMHEALHNNHYTKSLSLS 614
QY 430 PG 431
DB 615 PG 616

RESULT 42
AAB81991
ID AAB81991 standard; protein; 582 AA.
AC AAB81991;
XX
XX 03-JUL-2001 (first entry)
DT
DE Ganglioside GD3 specific antibody related protein SEQ ID NO: 57.
XX
XX Ganglioside; GD3; complementarity determining region; CDR; antibody;
XX cancer.
XX
XX Synthetic.
XX
XX WO200123432-A1.
XX
XX 05-APR-2001.
XX
XX 29-SEP-2000; 2000WO-JP006774.
XX
XX 30-SEP-1999; 99JP-00278291.
XX
XX 06-APR-2000; 2000JP-00105088.
XX
XX (KYOW) KYOWA HAKKO KOGYO KK.
XX
XX Hanai N, Shitara K, Nakamura K, Niwa R;
XX
XX MPI: 2001-266143/27.
XX
XX New human type complementation-determining region-transplanted antibody
XX and derivatives against ganglioside GD3, useful in diagnosis and therapy
XX of e.g. tumors, with low antigenicity, little side effects but potent
XX activity in cancer.
XX
XX Claim 39; Page 175-179; 183pp; Japanese.
XX
XX The present invention describes a monoclonal antibody which can react
XX specifically with ganglioside GD3. The antibody and its derivatives are
XX useful in the diagnosis and therapy of tumors, particularly cancer
XX diagnosis. The present sequence is a protein used in the exemplification
XX of the invention
XX

```


DB 448 NHYTKSLSPG 460

RESULT 44

AAW11639 standard; protein; 475 AA.

AC AAW11639;

DT 13-MAY-1997 (first entry)

XX Human anti-RSV monoclonal antibody RF-1 heavy chain.

DE Monoclonal antibody; Mab; RF-1; RF-2; respiratory syncytial virus; RSV;

KM fusion protein; F-protein; vaccine; immunotherapy; therapy;

KW Epstein Barr virus; immortalisation; recombinant antibody.

OS Homo sapiens.

XX Key Location/Qualifiers

FT Peptide 1..19

FT /label= Leader_peptide

FT Region 20..49

FT /label= FR1

FT /note= "framework region 1"

FT Region 50..56

FT /label= CDR1

FT /note= "complementarily determining region 1"

FT Region 57..70

FT /label= FR2

FT /note= "framework region 2"

FT Region 71..86

FT /label= CDR2

FT /note= "complementarily determining region 2"

FT Region 87..118

FT /label= FR3

FT /note= "framework region 3"

FT Region 119..134

FT /label= CDR3

FT /note= "complementarily determining region 3"

FT Region 135..145

FT /label= FR4

FT /note= "framework region 4"

FT Region 146..475

FT /label= Kappa

FT /note= "human gamma 1 constant region"

PN WO9640252-A1.

PD 19-DEC-1996.

XX 06-JUN-1996; 96WO-US010070.

XX 07-JUN-1995; 95US-00488376.

PR (IDEC-) IDEC PHARM CORP.

XX Brans P, Chamat SS, Pan L, Walsh EE, Heard CJ, Newman RA;

PI MPI: 1997-099892/09.

DR N-PSDB; AAT61241.

XX Human monoclonal antibody specific for respiratory syncytial virus fusion

PT protein - used for the prevention and treatment of RSV infection.

XX Example 6; Fig 9b-c; 85pp; English.

XX A polypeptide (AAW11639) comprises a leader sequence, RF-1 heavy chain

CC variable region (see also AAW11639), and human gamma 1 constant region.

CC RFI is a human monoclonal antibody (hMab) specific for the fusion protein

CC of respiratory syncytial virus (RSV). The polypeptide can be produced in

CC eukaryotic host (e.g. CHO) cells transfected with vector NEOSPLA

CC incorporating a DNA construct (AAT61241) including the RF-1 VH sequence.

CC RF-1 and RF-2 heavy and light chains (see also AAW11638, AAW11640-41) are

CC similarly produced. The transfected host cells provide a constant, stable

CC supply of anti-RSV F-protein hMabs for use in the treatment or prevention

CC of RSV infection

CC Sequence 475 AA;

SQ

Query Match 53.0%; Score 1280.5; DB 2; Length 475;

Best Local Similarity 57.3%; Pred. No. 2e-64; Mismatches 87; Indels 97; Gaps 12;

Matches 282; Conservative 26;

DB 10 LLLVQLALLPAATGKRVIGKKGVLTCTAS-----QKKSQFMK 54

DB 10 LVAATRVLSQVQDSESPVVKPTETLTCTSGFSLSPRMGVWIRQPGKALM- 68

QY 55 NSNOIKILGN-----QGSFLLTKGPKSLNDRADSRSLMDQGNFLLIKLIEDSDTYIC 109

DB 69 -----LGNIFSSDEKSFSPSLKSLRTTSQDTSRS-----QVVLSTNVDPVDTATYYC 116

QY 110 EVEDQKEVQLVPLTNSDTHL-LOGOSLTLTLESPPSSPSVQCRSPGKNIQGG-- 166

DB 117 -----ARVGLYDINAYVLYLDYWGQTLVTVSSASTGSPVFLPAPSKSTSGTA 168

QY 167 -----KTLVS-----OLEIQDSG-----TWTC 184

DB 169 ALGCLVKDYPPEPVVSNMGSALTSVHTFAVLQSSGLYSLSVTVPPSSSLGTQYIC 228

QY 185 TVLQNKQKVEFKIDVPCPAPBPXSCDKTHTC-----DELLGSPVFLPPPKKDTLMIS 239

DB 229 NV--NHRKPSNTKVD---KKAEPKSCDKTHTCPCPAPDELIGSPVFLPPPKKDTLMIS 282

QY 240 RTPETVTVVNDVSHEDPEVKFMVYDGVENNAKTKPREEOYNSTYRVSVLTVLHOML 299

DB 283 RTPETVTVVNDVSHEDPEVKFMVYDGVENNAKTKPREEOYNSTYRVSVLTVLHOML 342

QY 300 NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLTPSRDELTKNQVSLTCLVKGYFP 359

DB 343 NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLTPSRDELTKNQVSLTCLVKGYFP 402

QY 360 SDIAVESWESNGQPENNYKTTPPVLDSDGSFPLYSKLTVDKSRWQQGNVFCSSVMHEALHN 419

DB 403 SDIAVESWESNGQPENNYKTTPPVLDSDGSFPLYSKLTVDKSRWQQGNVFCSSVMHEALHN 462

QY 420 HYYTKSLSPG 431

DB 463 HYYTKSLSPG 474

RESULT 45

ABG70743

ID ABG70743 standard; protein; 473 AA.

AC ABG70743;

XX 02-DEC-2002 (first entry)

DT Mouse/human chimeric anti-MAG antibody heavy chain protein.

XX Stroke; neurological disease; neurodegeneration; brain injury;

XX spinal cord injury; chronic disease; Alzheimer's disease; tauopathy;

XX fronto-temporal dementia; peripheral neuropathy; Parkinson's disease;

XX Huntington's disease; multiple sclerosis; mouse; human; anti-MAG;

XX antibody; heavy chain.

XX Mus sp.

OS Homo sapiens.

OS Synthetic.

OS Chimeric.

XX WO200262383-A2.

XX 15-AUG-2002.

```

PF 08-FEB-2002; 2002MO-GB000551.
XX
XX 08-FEB-2001; 2001GB-00003174.
XX
XX (SMIX ) SMITHKLINE BEECHAM PLC.
XX
XX Irving EA, Vinson M;
XX
XX WPI; 2002-698554/75.
XX
PT Treating or preventing stroke and neurological diseases, e.g. Alzheimer's
PT disease, multiple sclerosis or Parkinson's disease, comprises
PT administering a myelin-associated glycoprotein (MAG) antagonist or anti-
XX MAG antibody.
XX
XX Discloure; Fig 5; 41pp; English.
XX
CC The present invention relates to a new method of treating or preventing
CC stroke and other neurological diseases in a human. The method involves
CC administering a myelin-associated glycoprotein (MAG) antagonist or anti-
CC MAG antibody, including altered antibodies or their functional fragment.
CC The MAG antagonist or anti-MAG antibody, including altered antibodies or
CC their functional fragments are useful in preparing a medicament for
CC treating or preventing stroke and other neurological diseases, or for
CC inhibiting neurodegeneration and/or promoting functional recovery in a
CC human patient suffering or at risk of developing stroke or other
CC neurological disease, such as stroke, traumatic brain injury and spinal
CC cord injury, chronic diseases including Alzheimer's disease, fronto-
CC temporal dementias (taupathies), peripheral neuropathy, Parkinson's
CC disease, Huntington's disease and multiple sclerosis. The present amino
CC acid sequence represents the mouse/human chimeric anti-MAG antibody heavy
CC chain protein
XX
SQ Sequence 473 AA;
Query Match 53.0%; Score 1280; DB 5; Length 473;
Best Local Similarity 58.3%; Pred. No. 2,1e-64;
Matches 281; Conservative 33; Mismatches 89; Indels 79; Gaps 14;
10 LLLVQLLPAAATQGNKVLGKGDVLELCTASQKSIQPHMNSQIKILNGQ--- 66
11 : : : : : : : : : : : : : : : : : : : : : : : : : : : :
12 LMAAQAQSEIQLVSGPE--LKKPGETNKKISCKAS--GYFTYNNMNMVQAPEKGLKW 64
13 : : : : : : : : : : : : : : : : : : : : : : : : : : : :
14 67 ----SFLTKGPSKLAND-RADSRRLMDQGNFP-LIINKLIEDSDPTVICEVEDQKEEYQL 120
15 : : : : : : : : : : : : : : : : : : : : : : : : : : : :
16 65 MGWINTYGEPTVADDFKTNFAFSLETSASTAVILQISLNKEDPTATYFC-----ARNPI 118
17 : : : : : : : : : : : : : : : : : : : : : : : : : : : :
18 121 LVFGLTANSDTHLQ--GQSLTLTESPPGSSPSVQCSPPKGNIQG----- 166
19 : : : : : : : : : : : : : : : : : : : : : : : : : : : :
20 119 NYVGI--NYEGVMDYWGQGSVTVSSASTKGPSVFPLAPSPSKYSTGGTALGCLVXDYF 176
21 : : : : : : : : : : : : : : : : : : : : : : : : : : : :
22 167 -KTLASV-----QLELDQSG-----TWCTVTLQNOKKVE 194
23 : : : : : : : : : : : : : : : : : : : : : : : : : : : :
24 177 PEPVAVSNMNSGALTSVGVTPPAVLQSSGLYSLSVTVTPSSSLGTGTYICNV--NHRKSN 234
25 : : : : : : : : : : : : : : : : : : : : : : : : : : : :
26 195 FKIDIVPCAPAPKSCDKTHTC-----PELLGSPVFLFPKPKQDTLMISRTPEVTCVV 249
27 : : : : : : : : : : : : : : : : : : : : : : : : : : : :
28 225 TKVD---KAVVEPKSCDKTHTCPCPAPELAGAPSVFLFPKPKQDTLMISRTPEVTCVV 290
29 : : : : : : : : : : : : : : : : : : : : : : : : : : : :
30 250 DVSHDEDEVKRWYVDGVEVNAKTKPRBEQYNSTYRVAVLTVLHQWMLNGEKYCKVYS 309
31 : : : : : : : : : : : : : : : : : : : : : : : : : : : :
32 291 DVSHDEDEVKRWYVDGVEVNAKTKPRBEQYNSTYRVAVLTVLHQWMLNGEKYCKVYS 350
33 : : : : : : : : : : : : : : : : : : : : : : : : : : : :
34 310 NKALPAPLEKTISSKAGQPREPOVTLTPSRDELTKNOVSLTCLVKGYPSPDIWEMESN 369
35 : : : : : : : : : : : : : : : : : : : : : : : : : : : :
36 351 NKALPAPLEKTISSKAGQPREPOVTLTPSRDELTKNOVSLTCLVKGYPSPDIWEMESN 410
37 : : : : : : : : : : : : : : : : : : : : : : : : : : : :
38 370 GQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQGNVFSQVMEHALHNHYTKQSLSL 429
39 : : : : : : : : : : : : : : : : : : : : : : : : : : : :
40 411 GQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQGNVFSQVMEHALHNHYTKQSLSL 470
41 : : : : : : : : : : : : : : : : : : : : : : : : : : : :
42 430 PG 431
43 : : : : : : : : : : : : : : : : : : : : : : : : : : : :

```

```

DB 471 PG 472
RESULT 46
AAW88464
ID AAW88464 standard; protein; 476 AA.
XX
XX AAW88464;
XX
XX 10-MAY-1999 (first entry)
XX
XX Monoclonal antibody 4B5 heavy chain variable region.
XX
XX Antigen binding fragment 4B5; monoclonal antibody; cancer; neoplasm;
XX diagnosis; therapy; melanoma; neuroblastoma; glioma; sarcoma;
XX lung carcinoma; metastasis; anti-idiotypic antibody; GD2 antigen; human.
XX
XX Homo sapiens.
XX
XX WO9902545-A2.
XX
XX 21-JAN-1999.
XX
XX 08-JUL-1998; 98MO-IB001046.
XX
XX 08-JUL-1997; 97US-0051945P.
XX
XX (NOVO-) NOVOPHARM BIOTECH INC.
XX
XX Dan MD;
XX
XX WPI; 1999-120769/10.
XX
XX N-PSDB; AAX06951.
XX
XX New antibody 4B5 polynucleotides and polypeptides - used to develop
XX products for the diagnosis and treatment of cancers and for prophylactic
XX therapy to reduce risk of recurrence.
XX
XX Claim 1; Page 79-80; 83pp; English.
XX
CC This polypeptide comprises the heavy chain variable region of the
CC recombinant human monoclonal antibody (Mab) 4B5. 4B5 recognises
CC antibodies specific for GD2 antigen antibodies. Antibodies specific for
CC GD2 recognise various cancers including glioblastoma, neuroblastoma,
CC malignant and/or metastatic melanoma, breast adenocarcinoma, lung
CC adenocarcinoma, small cell lung carcinoma, colon adenocarcinoma and
CC prostate adenocarcinoma. The invention encompasses 4B5 derivatives with
CC immunologic specificity for antibodies specific for GD2. These
CC derivatives, or antigen binding fragments, comprise regions of the 4B5
CC VDJ junction and regions spanning the 4B5 CDRs. Other derivatives include
CC Fab, F(ab')2, Fab', scfv and isolated heavy and light chains (see also
CC AAW88465). Polynucleotide fragments (see AAX06951-54) encoding 4B5
CC antibody V regions are also provided, and therapeutic plasmids and
CC vectors, including vaccinia virus vectors, comprising these
CC polynucleotides. 4B5 has been shown to mimic GD2, and is particularly
CC useful in generating a host immune response to cancer. Products of the
CC invention can be used in the detection and treatment of e.g. astrocytoma,
CC oligodendroglioma, ependyoma, medulloblastoma, primitive neural
CC ectodermal tumour (PNET), pancreatic ductal adenocarcinoma, small and
CC large cell lung adenocarcinomas, squamous cell carcinoma,
CC bronchioalveolar carcinoma, epithelial adenocarcinoma, and liver metastases,
CC hepatoma, cholangiocarcinoma, breast tumours such as ductal and lobular
CC adenocarcinoma, squamous and adenocarcinomas of the uterine cervix,
CC uterine and ovarian epithelial carcinoma, prostatic adenocarcinoma,
CC transitional squamous cell carcinoma of the bladder, B and T cell
CC lymphoma (nodular and diffuse), plasmacytoma, acute and chronic leukemia,
CC malignant melanoma, soft tissue sarcoma and leiomyosarcoma
XX
SQ Sequence 476 AA;
Query Match 53.0%; Score 1280; DB 2; Length 476;
Best Local Similarity 56.9%; Pred. No. 2,1e-64;
Matches 280; Conservative 27; Mismatches 91; Indels 94; Gaps 12;

```

Oy		1	LVLVQLALPLPAALQSGHKVVLG-----KKGEITVLCTASGKSSLOH-----	52
Dd		7	VLEFLVAALATSAKAGQVLVDSGAIEYKPKGASIVKSCASGYTFTSDLMMWQAQGGLEW	66
Oy		53	--WKNSNOIKILGNOSFLTTPGSPSKLMDRADSRSLMDQNPFLIIKNLKIEDSDTYICE	110
Dd		67	MGMNPNPSGK-----TGVAQKFQGRVMTTRMTSIRTAI-MELSGLRSEDTAVYA FCA	116
Oy		111	VEOQKEEVDLL--VFGLTANSSTHLIQGSLLTLLESPPGSPSYQCSPPKGKIQQG--	166
Dd		117	RNADNVEMAIYHYGMD-----VMGGGTIVTVSSASTKGPSPFYFLAPSSKTSISGTA	168
Oy		167	-----KTLSYS-----OLEDDSG-----TWTC	184
Dd		170	ALGCLVKDYRPEPEVTYSNNNGALTSGVHTFPAVLQSSGIYSSLYVTPRSSLTQTYYIC	228
Oy		185	TVLQNQKRYEFKIDIVCPAPBEPKSCDKTHTC----PELLGSPVFLFPKPXDTLMIS	239
Dd		230	NV--NHKPSNTKVD---KKVEPESCDKTHTCPCPAPELLGGSFVFLFPKPXDTLMIS	283
Oy		240	RTEBYTCVVWDVSHEDPEYKFMNYVDGVENNAKTKPREEQNSTYRVSVLTYLHDWL	299
Dd		284	RTEBYTCVVWDVSHEDPEYKFMNYVDGVENNAKTKPREEQNSTYRVSVLTYLHDWL	343
Oy		300	NGKEYCKVCYNKMLPAPIEKTIISKAKGPREPOVYTLTPSRDELTKONVS/LTCLVKGFYP	355
Dd		344	NGKEYCKVCYNKMLPAPIEKTIISKAKGPREPOVYTLTPSRDELTKOVSLTCLVKGFYP	403
Oy		360	SDIADVESWNGOEENNYKTTPLYLDSDGSFFLYSKLYTDKSRMOQGNYVSCSWHEALHN	419
Dd		404	SDIADVESWNGOEENNYKTTPLYLDSDGSFFLYSKLYTDKSRMOQGNYVSCSWHEALHN	463
Oy		420	HYTQKSLSLSPG 431	
Dd		464	HYTQKSLSLSPG 475	
RESULT 47				
ID	AAM49203	standard; protein; 448 AA.		
AC	AAM49203;			
XX				
DT	29-AUG-2003	(revised)		
DT	28-JUN-2002	(first entry)		
DE				
XX		Humanised monoclonal antibody 5c8 (hu5c8) heavy chain.		
KM		Monoclonal antibody; mAb; humanised; murine; mouse; 5c8; hu5c8;		
KM		heavy chain; anti-CD145; CD145-antibody complex; 3D structure;		
KM		three dimensional structure; drug design; drug discovery;		
KM		activated T cell; CD40 interaction; T cell dependent immune response;		
KM		agonist; antagonist; immune response; inflammatory response;		
KM		autoimmune disease; allergy; inhibitor response; organ graft rejection;		
KM		B cell cancer; Alzheimer's disease; multiple sclerosis; anti-inflammatory;		
KM		immunosuppressive; antiallergic; cytostatic; dermatological;		
KM		antiasthmatic; neurotropic; neuroprotective; antiseriosclerotic;		
KM		antiviral; antidiabetic; cardiac; antischaemic; vasodilator;		
KM		antirheumatic; antiarthritic; antipsoriatic; immunomodulator; antibody;		
KM		complementarity determining region; CDR; protein co-ordinate data.		
XX				
OS	Mus gp.			
OS	Homo sapiens.			
OS	Chimeric.			
XX				
FT	Key	Location/Qualifiers		
FT	Region	1..219		
FT	Region	/note= "Form part of the crystal of the invention"		
FT	Region	31..35 CDRI		
FT	Region	/label= "Complementarity determining region 1"		
FT	Binding-site	31..33		

FT	Region	/note= "Binds to CD145 (AAM49202) "
FT		50. .66
FT		/label= CDR2
FT	Binding-site	/note= "Complementarity determining region 2 "
FT		52
FT	Binding-site	/note= "Binds to CD145 (AAM49202) "
FT		54
FT	Binding-site	/note= "Binds to CD145 (AAM49202) "
FT		57
FT	Binding-site	/note= "Binds to CD145 (AAM49202) "
FT		59
FT	Binding-site	/note= "Binds to CD145 (AAM49202) "
FT		99. .106
FT	Region	/label= CDR3
FT		/note= "Complementarity determining region 3 "
FT	Binding-site	102. .103
FT		/note= "Binds to CD145 (AAM49202) "
XX		
PN	W0200218445-A2.	
XX		
XX	07-MAR-2002.	
PD		
XX		
XX	31-AUG-2001; 2001WO-US027352.	
PF		
XX		
PR	01-SEP-2000; 2000US-0229933P.	
PR	16-MAR-2001; 2001US-0276452P.	
XX		
PA	(BIOJ) BIOGEN INC.	
XX		
PI	Karpusas M, Hsu Y, Taylor FR, Zheng Z;	
XX	WPI; 2002-329760/36.	
DR		
XX		
PT	Crystal comprising a CD154 polypeptide complexed with an anti-CD154 antibody, or its antigen binding fragment, useful for designing drugs for the treatment of an autoimmune disease, an allergy, multiple sclerosis and Alzheimer's disease.	
PT		
XX		
PS	Example 1; Fig 8; 470p; English.	
XX		
CC	The invention relates to a crystal comprising a CD145 polypeptide in complex with an anti-CD15 antibody or its antigen-binding fragment, and the structure coordinates of such a crystal. In particular, the crystal comprises human CD145 (AAM49202) and a humanised version of the murine monoclonal antibody 5c8 (hu5c8; AAM49203, AAM49204). CD145, also known as CD40L, gp39, T-BAM, 5c8 antigen, CD40CR and TRAP) is a 32 kD type II membrane glycoprotein which is transiently expressed on activated T cells. It interacts with CD40 which is expressed on mature B cells, macrophages, dendritic cells, fibroblasts and activated endothelial cells. This CD40:CD145 interaction is required for T cell-dependent antibody response, type I T-helper cell responses, and nitric oxide (NO) production by macrophages. NO mediates many of the pro-inflammatory activities of macrophages, and disruption of the CD40:CD145 interaction via the use of an anti-CD145 antibody has been shown to reduce the symptoms of autoimmune and inflammatory conditions. The crystal structure of the invention can be used to determine the three dimensional structure of the CD145:anti-CD145 antibody complex, and thereby provide information about this interaction which may be of use in designing non-antibody CD145 agonists and antagonists which modulate the CD40:CD145 interaction.	
CC	Such compounds may be used in the treatment of an unwanted immune response, an unwanted inflammatory response, an autoimmune disease, an allergy, an inhibitor response to a therapeutic agent, rejection of a donor organ, or a B cell cancer. They may be specifically be used to treat systemic lupus erythematosus, lupus nephritis, lupus neuritis, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema, multiple sclerosis, uveitis, Alzheimer's disease, traumatic spinal cord injury, stroke, atherosclerosis, coronary restenosis, ischaemic congestive heart failure, cirrhosis, hepatitis C, diabetic neuropathy, glomerulonephritis, osteoarthritis, rheumatoid arthritis, psoriasis, atopic dermatitis, systemic sclerosis, radiation-induced fibrosis, Crohn's disease, ulcerative colitis, multiple myeloma and cachexia. Sequences AAM49203 and AAM49204 represent, respectively, the heavy and light chains of the humanised version of the murine monoclonal	
CC		

CC antibody 5c8 (hu5c8). (updated on 29-AUG-2003 to standardise OS field)
 XX SQ Sequence 448 AA;

Query Match 53.0%; Score 1279.5; DB 5; Length 448;
 Beest Local Similarity 58.9%; Pred. No. 2.1e-64;
 Matches 275; Conservative 31; Mismatches 74; Indels 87; Gaps 13;

QY 25 GNKVLGKGGDVEITCTASQK--KSIQFMKNSNQIKLGNQ--SFL-----TKGPSKL 76
 DB 8 GAEV--KPGASVKLSCKASGYIFTSYMW-----VQAPQGLGEMGELNPSGDTNF 60
 QY 77 NDRADSRSLW---DQGNFPLIIKMLKIEDSDTYICEVEDQKEVQLLVFGLTANSDTHL 133
 DB 61 NEKFKSKATLTIVDKASASTAYMELSLRSEDTLVYCTRSDDGRNDMD----- 106
 QY 134 LGGGLTLTLSPSSPSVQCRPRGNIOG-----KTLSSV----- 172
 DB 107 SMGGTLIVTSSASTKGPSVFPPLAPSSKSTSGTALGCLVKDYFPEPVTVSMNSGALTS 166
 QY 173 -----QLELDQSG-----TWCTVLQONKVEFKIDIVPCPAPRPS 209
 DB 167 GVHTFPAVLQSSGLXSLSSVTVPSSSLGTQTYICNV--NHKPSNTKYD----KVEPKS 220
 QY 210 CDKHTTC-----PELLGSPSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNNYV 264
 DB 221 CDKHTCPCPAPRPELLGSPSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNNYV 280
 QY 265 DGEVHNKKTREBOYNSTYRVSVLTVLHODMNGKEYCKYSNKLPAPIEKTISKAK 324
 DB 261 DGEVHNKKTREBOYNSTYRVSVLTVLHODMNGKEYCKYSNKLPAPIEKTISKAK 340
 QY 325 KQGPPEPVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPVLD 384
 DB 341 KQGPPEPVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPVLD 400
 QY 385 SDGSEFLYSKLTVDKSRWQGNVFCSVMEHALHNHYTQKSLSISPG 431
 DB 401 SDGSEFLYSKLTVDKSRWQGNVFCSVMEHALHNHYTQKSLSISPG 447

RESULT 48

AAV30201 standard; protein; 452 AA.

AC AAV30201;

DT 17-OCT-2003 (revised)
 DT 01-NOV-1999 (first entry)

XX Heavy chain sequence of chimeric anti-CD40 antibody ch1220.

XX Heavy chain variable region: chimeric antibody: anti-CD40 antibody;
 KM ch1220; humoral immune response; T cell dependent antigen;
 KM collagen induced arthritis; transplant induced rejection;
 KM T cell mediated disorder; autoimmune disease; inflammatory disease;
 XX transplantation.

OS Mus sp.
 OS Homo sapiens.
 OS Chimeric.

XX MO9942075-A2.

XX 26-AUG-1999.

XX 10-FEB-1999; 99WO-US002949.

XX 19-FEB-1998; 98US-00026291.

XX (BRIM) BRISTOL-MYERS SQUIBB CO.

XX PA Arnolfo AA, Hollenbaugh D, Siadak AW, Berry KK, Harris LJ;

PI Thorne BA, Bajorath J, Wu H, Huse WD, Watkins JD;
 XX WPI, 1999-527408/44.

XX Antibody that binds human CD40, for treating T cell mediated disorders.
 XX Claim 6; Page 20; 77pp; English.

CC The present sequence represents the heavy chain of a chimeric anti-CD40
 CC antibody designated ch1220. The antibodies are effective in modulating
 CC humoral immune response against T cell dependent antigens, collagen
 CC induced arthritis and transplant induced rejection. They are also useful
 CC for their anti-inflammatory properties. The antibodies have wide
 CC therapeutic applications, including autoimmune and inflammatory diseases
 CC and transplantation. The antibody can be used in a pharmaceutical
 CC composition for treating a patient suffering from a T cell mediated
 CC disorder. They can also be used to treat autoimmune diseases,
 CC inflammatory diseases, and transplantation. (updated on 17-OCT-2003 to
 CC standardise OS field)

XX SQ Sequence 452 AA;

Query Match 53.0%; Score 1279.5; DB 2; Length 452;
 Beest Local Similarity 59.8%; Pred. No. 2.1e-64;
 Matches 277; Conservative 23; Mismatches 80; Indels 83; Gaps 12;

QY 30 LGKKDVEITCTASQKSIQFMKNSNQIKLGNQSFLLTKGPSKLNDRADSRSLMD- 88
 DB 11 LKKGELTVRISCKAS---GVAFTTGMQVQEMRKGK---LKTGMINTSGVKKYEDF 64
 QY 89 QGNFP-----LIINKLKIEDSDTYICEVEDQKEVQLLVFGLTANSDTHLQOQ 137
 DB 65 KGRFAPSLKTSANTAYLQINLKNEDPATYFC--VRSGNGVYDLAYFA-----YWGQ 114
 QY 138 SLTTLSPSSPSVQCRPRGNIOG-----KTLSSV----- 172
 DB 115 GTLVTSAASTKGPSVFPPLAPSSKSTSGTALGCLVKDYFPEPVTVSMNSGALTS 174
 QY 173 -QLELDQSG-----TWCTVLQONKVEFKIDIVPCPAPRPSGDKT 213
 DB 175 FPAVLQSSGLXSLSSVTVPSSSLGTQTYICNV--NHKPSNTKYD----KVEPKSDDKT 228
 QY 214 HTC-----PELLGSPSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNNYVDGVE 268
 DB 229 HTCPCPAPRPELLGSPSVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNNYVDGVE 288
 QY 269 VHNKKTREBOYNSTYRVSVLTVLHODMNGKEYCKYSNKLPAPIEKTISKAKG 328
 DB 289 VHNKKTREBOYNSTYRVSVLTVLHODMNGKEYCKYSNKLPAPIEKTISKAKG 348
 QY 329 REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPVLDSDG 388
 DB 349 REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPVLDSDG 408
 QY 389 FFLYSKLTVDKSRWQGNVFCSVMEHALHNHYTQKSLSISPG 431
 DB 409 FFLYSKLTVDKSRWQGNVFCSVMEHALHNHYTQKSLSISPG 451

RESULT 49

AAV44721 standard; protein; 470 AA.

AC AAV44721;

DT 25-APR-2000 (first entry)

XX Human immune system molecule, ISMO-2.

XX Human immune system molecule, ISMO-2; Incyte clone 2849752; diagnosis;
 KM treatment; prevention; cell proliferation; immune system disorder.

XX OS Homo sapiens.

```
XX Key Location/Qualifiers
FH 1. .19
FH Peptide /label= Signal_peptide
FT 20. .470
FT Protein /label= Mature_ISMO-2
FT 31. .116
FT Domain /note= "shows similarity to Ig superfamily protein
FT domain"
FT 47
FT Modified-site /note= "Protein kinase C phosphorylation site"
FT 69
FT Modified-site /note= "Tyrosine kinase phosphorylation site"
FT 81
FT Modified-site /note= "Protein kinase C phosphorylation site"
FT 92
FT Modified-site /note= "Protein kinase C phosphorylation site"
FT 98
FT Modified-site /note= "Protein kinase C phosphorylation site"
FT 105
FT Modified-site /note= "Protein kinase C phosphorylation site"
FT 120
FT Modified-site /note= "Casein kinase II phosphorylation site"
FT 142
FT Modified-site /note= "N-glycosylated"
FT 154
FT Modified-site /note= "Protein kinase C phosphorylation site"
FT 160. .225
FT Domain /note= "Protein kinase C phosphorylation site"
FT 160. .225
FT Domain /note= "shows similarity to Ig superfamily protein
FT domain"
FT 232
FT Modified-site /note= "Casein kinase II phosphorylation site"
FT 230
FT Modified-site /note= "Casein kinase II phosphorylation site"
FT 319
FT Modified-site /note= "Tyrosine kinase phosphorylation site"
FT 320
FT Modified-site /note= "N-glycosylated"
FT 322
FT Modified-site /note= "Protein kinase C phosphorylation site"
FT 347
FT Modified-site /note= "Protein kinase C phosphorylation site"
FT 377
FT Modified-site /note= "Casein kinase II phosphorylation site"
FT 383. .450
FT Domain /note= "shows similarity to Ig superfamily protein
FT domain"
FT 387. .409
FT Region /note= "conserved Ig/MHC protein block"
FT 446. .463
FT Region /note= "conserved Ig/MHC protein block"
FT 460
FT Modified-site /note= "Protein kinase C phosphorylation site"
FT 460
FT Modified-site /note= "Protein kinase C phosphorylation site"
XX WO200000608-A2.
XX PD 06-JAN-2000.
XX PF 21-JUN-1999; 99WO-US013995.
XX PR 30-JUN-1998; 98US-00107223.
XX PA (INCY-) INCYTE PHARM INC.
XX lal P, Tang YT, Corley NC, Gorgone G, Guegler KJ, Patterson C;
XX Baughn MR;
XX MPI; 2000-170916/15.
XX DR N-PSDB; AA250012.
XX Immune system molecules used in the diagnosis, treatment and prevention
XX of disorders associated with the immune system and cell proliferation.
```

```
PS Claim 1; Page 60-61; 69pp; English.
XX The present sequence is an immune system molecule, ISMO-2 from an Incyte
CC clone 2849752 isolated from the human breast tumour cDNA library
CC (BRSTTUT13). This sequence is expressed in several libraries, generally
CC those associated with cancer, cell proliferation, immune response or
CC trauma. It shows homology to vertebrate immunoglobulin gamma heavy-chain.
CC The present sequence is useful in the diagnosis, treatment and prevention
CC of disorders associated with the immune system and cell proliferation
XX
SQ Sequence 470 AA;
Query Match 53.0%; Score 1279; DB 3; Length 470;
Best Local Similarity 57.0%; Pred. No. 2,4e-64;
Matches 278; Conservative 28; Mismatches 98; Indels 84; Gaps 12;
QY 8 RHLLVLQALALP-----AATGKVVVLGKKGDTVELCTASQKKSIOFWKSNQIXI 61
DB 2 KHLWFFLLVAPRNVLSOVOLQESGPGIYKPSFTLSLCTVSGSIRSYYW--NWIRL 58
QY 62 LGNQ-----GSFLTGPKSLNDRADSRSL--WQGNPPLIKLKIKEDSDTYICEVD 113
DB 59 PPGKLEWIGYITSGSTNVNPSLKSRYTVSVDSKQPSLKLSSVTADTAVVYCARPP 118
QY 114 QKEEVQLVFGITANSDFHLQG-OSLTLTLESPPGSSPSVQCRRSPGKNIQGG----- 166
DB 119 P-----NATTTWTVSGAKGALVTVSASATKGPSVPLAPSSKSTGTRALGC 167
QY 167 -----KTLVS-----QLELDQSG-----TWCTYVIQ 188
DB 168 LVKDYFPEPVTVMNSGALTSQVHTFPAPVLQSSGLYSVTVTPSSSLGTQYICNV-- 225
QY 189 NOKKVEFKIDIVPCAPRPSKCDKHTC-----PELGGPSVFLPPPKOTMLSRPE 243
DB 226 NHPKPSNTKVD---KVEPKSCDKHTHTCPCPAPRLGGPSVFLPPPKOTMLSRPE 281
QY 244 VTCVVVDVSHEDPEVKFMWYVDGVEVNAKTKPREEQYNSTYRVVSVLTVLIHQDMLNGKE 303
DB 282 VTCVVVDVSHEDPEVKFMWYVDGVEVNAKTKPREEQYNSTYRVVSVLTVLIHQDMLNGKE 341
QY 304 YKCKVSNKALPAPIEKTIISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGPYPSDIA 363
DB 342 YKCKVSNKALPAPIEKTIISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGPYPSDIA 401
QY 364 VEWESNGQPPENNYKTTTPVLDSGSPFLYSKLTVDKSRWQGNVSCSVMEHGLNHYTQ 423
DB 402 VEWESNGQPPENNYKTTTPVLDSGSPFLYSKLTVDKSRWQGNVSCSVMEHGLNHYTQ 461
QY 424 KSLSLSPG 431
DB 462 KSLSLSPG 469
RESULT 50
ADD25783
ID ADD25783 standard; protein; 492 AA.
XX AC ADD25783;
XX DT 15-JAN-2004 (first entry)
XX DE Binding domain-immunoglobulin fusion protein-associated protein #157.
XX Binding domain; immunoglobulin; fusion protein; cytostatic;
XX antiarthritis; immunosuppressive; antidiabetic; antichryoid;
XX neuroprotective; hinge region; immunoglobulin heavy chain;
XX CH2 constant region; CH3 constant region; IgG1;
XX antibody dependent cell-mediated cytotoxicity; ADCC; complement fixation;
XX malignant condition; B-cell disorder; melanoma; carcinoma; sarcoma;
XX rheumatoid arthritis; myasthenia gravis; Grave's disease;
XX type I diabetes mellitus; multiple sclerosis; autoimmune disease.
XX Unidentified.
```

```

XX  US2003118592-A1.
XX  26-JUN-2003.
XX  25-JUL-2002; 2002US-00207655.
XX  17-JAN-2001; 2001US-0367358P.
XX  17-JAN-2002; 2002US-00053530.
XX  03-JUN-2002; 2002US-0385691P.
XX  (GENE-) GENECAFT INC.
XX  Ledbetter JA, Hayden-Ledbetter MS, Thompson PA;
XX  MPI; 2003-801317/75.
XX  New binding domain-immunoglobulin fusion protein, useful for treating a
XX  subject having or suspected of having a malignant condition or a B-cell
XX  disorder, e.g. melanoma, Grave's disease or autoimmune disease.
XX  Disclosure; SEQ ID NO 344; 157pp; English.
XX  The invention relates to a binding domain-immunoglobulin fusion protein
XX  comprising a binding domain polypeptide that is fused to an
XX  immunoglobulin hinge region polypeptide, an immunoglobulin heavy chain
XX  CH2 constant region polypeptide that is fused to the hinge region
XX  polypeptide, and an immunoglobulin heavy chain CH3 constant region
XX  polypeptide that is fused to the CH2 constant region polypeptide. The
XX  hinge region polypeptide comprises: a wild-type human IgG1 immunoglobulin
XX  hinge region polypeptide; a mutated human IgG1 immunoglobulin hinge
XX  region polypeptide, derived from (a) having 3 or more cysteine residues;
XX  where the mutated human IgG1 immunoglobulin hinge region polypeptide
XX  contains 2 cysteine residues, where the first cysteine is not mutated; a
XX  mutated human IgG1 immunoglobulin hinge region polypeptide, derived from
XX  (a) having 3 or more cysteine residues, where the mutated human IgG1
XX  immunoglobulin hinge region polypeptide contains no more than one
XX  cysteine residue; and a mutated human IgG1 immunoglobulin hinge region
XX  polypeptide, derived from (a) having 3 or more cysteine residues; where
XX  the mutated human IgG1 immunoglobulin hinge region polypeptide contains
XX  no cysteine residues. The binding domain-immunoglobulin fusion protein is
XX  capable of at least one immunological activity comprising antibody
XX  dependent cell-mediated cytotoxicity (ADCC) and complement fixation. The
XX  binding domain polypeptide is capable of specifically binding to an
XX  antigen. Also included are an isolated polynucleotide encoding the
XX  binding domain-immunoglobulin fusion protein, a recombinant expression
XX  construct comprising the polynucleotide (operably linked to a promoter),
XX  a host cell transformed or transfected with a recombinant expression
XX  construct, producing the binding domain-immunoglobulin fusion protein, a
XX  pharmaceutical composition comprising the binding domain-immunoglobulin
XX  fusion protein or polynucleotide and a carrier, and treating a subject
XX  having or suspected of having a malignant condition or a B-cell disorder.
XX  The binding domain-immunoglobulin fusion protein is useful for treating a
XX  subject having or suspected of having a malignant condition or a B-cell
XX  disorder, e.g. melanoma, carcinoma or sarcoma, rheumatoid arthritis,
XX  myasthenia gravis, Grave's disease, type I diabetes mellitus, multiple
XX  sclerosis or autoimmune disease. The present sequence is a binding domain
XX  immunoglobulin fusion protein-associated protein sequence. Note: The
XX  sequence data for this patent formed part of the printed specification
XX  and is also available in electronic form directly from USPTO at
XX  seqdata.uspto.gov/sequence.html?DocID=20030118592. The authors have not
XX  identified the sequences in the printed specification by their SEQ ID
XX  number therefore none of the sequences can be explicitly identified.
XX  Sequence 492 AA:
XX
SQ

```

```

Query Match      53.0%; Score 1279; DB 7; Length 492;
Best Local Similarity 55.8%; Pred. No. 2,5e-64;
Matches 279; Conservative 33; Mismatches 92; Indels 96; Gaps 13;

```

```

QY  1 MNRGVPFRHLVLQALLPATQGNKVVLGKKGTVELTCTASQKSIQFMWKNQK 60
DB  19 MSRGVD-----IVL-----TQSPRTIAASPGKRVITTCRASSSVSYMYVYQOKS--- 62

```

```

QY  61 ILGNQGSFLLTKPSKLNDRADSRRLWDG-NFPLIIKLNLIKIEDSDPYICE----- 110
DB  63 --GASPKLMIYDISKLASGVNPNRSGSGSGSYSLAINTMETEDAAATYYCQWSTPLTF 120
QY  111 -----VEDQK-----EEVQLVFGILTANSSTHLLQGSLLTLLESPGSSP 151
DB  121 GSGTKLEIKKGCGSGSGSGGSGGVQLKEAGPLVQPTQL--SLTCTVSGFSFLTSD 177
QY  152 SVQ-CRSPRGKNIQ-----GGKT-----LSVQLLEQDSCT 181
DB  178 GVHWIRQPPGKGLWMCGLIYYDGGTDYNSAIKSLTISRDTSKQVFLKTNLSLQTDIAM 237
QY  182 WTCVTLQNOKKVEFK-----IDIVPCPAPEKSCDKHTTC-----PELLGSPVFLPPK 231
DB  238 YYCA-----RIHNDVWGQGVMTVSSDQPEKSCDKHTHTCPCPAPELLGSPVFLPPK 291
QY  232 PKDTLMTISRTPVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKYREBQINSTRYVSVL 291
DB  292 PKDTLMTISRTPVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKYREBQINSTRYVSVL 351
QY  292 TVLHODPLNGKEYKCKVSNKALPAPIEKTIISKAKGPREPQVYTLPSRDELTKNOVSLT 351
DB  352 TVLHODPLNGKEYKCKVSNKALPAPIEKTIISKAKGPREPQVYTLPSRDELTKNOVSLT 411
QY  352 CLVAGFYPSDIAVWESNNGCPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQGNVFSQS 411
DB  412 CLVAGFYPSDIAVWESNNGCPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQGNVFSQS 471
QY  412 VMEHALNHYTKQSLSLSPG 431
DB  472 VMEHALNHYTKQSLSLSPG 491

```

```

RESULT 51
AAB81972
ID AAB81972 standard; protein; 581 AA.
XX
AC AAB81972;
DT 03-JUL-2001 (first entry)
XX
DE Ganglioside GD2 specific antibody related protein SEQ ID NO: 31.
XX
KW Ganglioside; GD2; complementation determining region; CDR; antibody;
KW mouse; cancer.
XX
OS Synthetic.
XX
WO200123573-A1.
XX
PD 05-APR-2001.
XX
PF 29-SEP-2000; 2000WO-JP006773.
XX
PR 30-SEP-1999; 99JP-00278290.
XX
PA (KYOW ) KYOWA HAKKO KOGYO KK.
XX
PI Hanai N, Shitara K, Nakamura K, Niwa R;
XX
DR WPI; 2001-266163/27.
XX
PT Human type complementation-determining domain transplanted antibody and
PT derivatives against ganglioside GD2; useful in diagnosis and therapy of
PT e.g. tumors, has low antigenicity, little side effects but potent
PT activity in cancer.
XX
PS Example 3; Page 111-114; 123pp; Japanese.
XX
CC The present invention describes an antibody, which can react specifically
CC with ganglioside GD2, and is transplanted with a human type
CC complementation-determining domain (CDR), or its fragments. The antibody

```

CC and its derivatives are useful in diagnosis and therapy of tumours,
CC particularly cancer diagnosis. The present sequence is a protein used in
CC the exemplification of the invention

XX Sequence 581 AA:

Query Match 53.0%; Score 1278.5; DB 4; Length 581;
Best Local Similarity 57.7%; Pred. No. 3.1e-64;
Matches 275; Conservative 25; Mismatches 96; Indels 81; Gaps 10;

```

QY 30 LGKGDVTELTCTAS--QKKSIOFHKNSNQIKILNQGSLFKGPKSLNDRADRSRL- 86
DB 11 LKPSQTLSTICTVSQSFSLASVNIHWVROPKGLKMLVWAGSTNNYSALMSRLTIS 70
QY 87 WQGNRPILIKNLKIEDSDTYICEVDDQKEVQLVFGILANSDFHLLQGSLTTLLEBP 146
DB 71 KNSKNQVFLKNSSLPAADTAAYVYCAKRSDDYSWEAY-----WGQTLVIVSSA 119
QY 147 PGSSPVSQCRSPRKNIQCG-----KTLVS-----QLEIQDSG 180
DB 120 STKGPEVFLPLASSKSTSGTALAGLVADYFPEPTVSNAGLTSVHTFPAYLQSG 179
QY 181 -----TWCTVLQNKQKVEFKIDVPCAPRPSKCDKTHTC-----P 217
DB 180 LYSLSVTVTPSSSLGQTGYICNV--NHRPSNTKVD----KKEPRKCDKTHTCPCAP 233
QY 218 ELGGSVFLFPKPKDMLISTPREVTCVVDVSHEDPEYKFNWVDDEVHNAKTKR 277
DB 234 ELGGSVFLFPKPKDMLISTPREVTCVVDVSHEDPEYKFNWVDDEVHNAKTKR 293
QY 278 EEQYNSTYVSVLYLHODWLNKGEYKCKVSNKALPAIEKTIKAKGQPREPVYTL 337
DB 294 EEQYNSTYVSVLYLHODWLNKGEYKCKVSNKALPAIEKTIKAKGQPREPVYTL 353
QY 338 PERDELTKNQVSLTCLVKGPYPSPDAVEMESNGQPENNYKTPPVLDSDGSFELYSLTV 397
DB 354 PERDELTKNQVSLTCLVKGPYPSPDAVEMESNGQPENNYKTPPVLDSDGSFELYSLTV 413
QY 398 DSRMGGVFGSCSVNHEALHNHYTQKSLSLSPG-----LQDFTCAEQ 442
DB 414 DSRMGGVFGSCSVNHEALHNHYTQKSLSLSPGAPTSSTKTQLOLEHLLDLQ 470

```

RESULT 52

ADD25784
ID ADD25784 standard; protein; 543 AA.

AC ADD25784;

DT 15-JAN-2004 (first entry)

DE Binding domain-immunoglobulin fusion protein-aassociated protein #158.

XX Binding domain; immunoglobulin; fusion protein; cytoactive;
XX antiarthritis; immunosuppressive; antidiabetic; antithyroid;
XX neuroprotective; hinge region; immunoglobulin heavy chain;
KW CH2 constant region; CH3 constant region; IgG1;
KW antibody dependent cell-mediated cytotoxicity; ADCC; complement fixation;
KW malignant condition; B-cell disorder; melanoma; carcinoma; sarcoma;
KW rheumatoid arthritis; myasthenia gravis; Grave's disease;
KW type I diabetes mellitus; multiple sclerosis; autoimmune disease.

OS Unidentified.

XX US2003118592-A1.

XX 26-JUN-2003.

XX 25-JUL-2002; 2002US-00207655.

XX 17-JAN-2001; 2001US-0367358P.

XX 17-JAN-2002; 2002US-00053530.
PR 03-JUN-2002; 2002US-0385691P.

XX (GENE-) GENE-CRAFT INC.
PA Ledbetter JA, Hayden-Ledbetter MS, Thompson PA;

XX WIPI; 2003-801317/75.

XX New binding domain-immunoglobulin fusion protein, useful for treating a
PT subject having or suspected of having a malignant condition or a B-cell
PT disorder, e.g. melanoma, Grave's disease or autoimmune disease.

XX Disclosure; SEQ ID NO 345; 157bp; English.

XX The invention relates to a binding domain-immunoglobulin fusion protein
CC comprising a binding domain polypeptide that is fused to an
CC immunoglobulin hinge region polypeptide, an immunoglobulin heavy chain
CC CH2 constant region polypeptide that is fused to the hinge region
CC polypeptide, and an immunoglobulin heavy chain CH3 constant region
CC polypeptide that is fused to the CH2 constant region polypeptide. The
CC hinge region polypeptide comprises: a wild-type human IgG1 immunoglobulin
CC hinge region polypeptide; a mutated human IgG1 immunoglobulin hinge
CC region polypeptide, derived from (a) having 3 or more cysteine residues;
CC where the mutated human IgG1 immunoglobulin hinge region polypeptide
CC contains 2 cysteine residues, where the first cysteine is not mutated; a
CC mutated human IgG1 immunoglobulin hinge region polypeptide, derived from
CC (a) having 3 or more cysteine residues, where the mutated human IgG1
CC immunoglobulin hinge region polypeptide contains no more than one
CC cysteine residue; and a mutated human IgG1 immunoglobulin hinge region
CC polypeptide, derived from (a) having 3 or more cysteine residues; where
CC the mutated human IgG1 immunoglobulin hinge region polypeptide contains
CC no cysteine residues. The binding domain-immunoglobulin fusion protein is
CC capable of at least one immunological activity comprising antibody
CC dependent cell-mediated cytotoxicity (ADCC) and complement fixation. The
CC binding domain polypeptide is capable of specifically binding to an
CC antigen. Also included are an isolated polynucleotide encoding the
CC binding domain-immunoglobulin fusion protein, a recombinant expression
CC construct comprising the polynucleotide (operably linked to a promoter),
CC a host cell transformed or transfected with a recombinant expression
CC construct, producing the binding domain-immunoglobulin fusion protein, a
CC pharmaceutical composition comprising the binding domain-immunoglobulin
CC fusion protein or polynucleotide and a carrier, and treating a subject
CC having or suspected of having a malignant condition or a B-cell disorder.
CC The binding domain-immunoglobulin fusion protein is useful for treating a
CC subject having or suspected of having a malignant condition or a B-cell
CC disorder, e.g. melanoma, carcinoma or sarcoma, rheumatoid arthritis,
CC myasthenia gravis, Grave's disease, type I diabetes mellitus, multiple
CC sclerosis or autoimmune disease. The present sequence is a binding domain
CC -immunoglobulin fusion protein-associated protein sequence. Note: The
CC sequence data for this patent formed part of the printed specification
CC and is also available in electronic format directly from USPRO at
CC seqdata.uspro.gov/sequence.html?DocID=20030118592. The authors have not
CC identified the sequences in the printed specification by their SEQ ID
CC number therefore none of the sequences can be explicitly identified.

XX Sequence 543 AA;

Query Match 52.9%; Score 1277; DB 7; Length 543;
Best Local Similarity 55.8%; Pred. No. 3.6e-64;
Matches 279; Conservative 33; Mismatches 92; Indels 96; Gaps 13;

```

QY 1 MNRGVPFHLLLVLLALPAAQGNKVLKKGDTVTELTCTASQKSIQFNHKNKSNQIK 60
DB 19 MSRGVD-----IVL-----TQSPPTTAAPEKRVITCRASSVSVMYVYQKS--- 62
QY 61 ILNQGSLFKGPKSLNDRADRSRLWQGN--NFIPLIKNLKIEDSDTYICE----- 110
DB 63 --GASPKMIYDTSTLASGVNRRSGSGSGSYSLAINTMETEDATYYCCQWSTPLTF 120
QY 111 -----VEDQK-----EEVQLVFGILANSDFHLLQGSLTTLLEBPSSGP 151
DB 121 GSGTLEIKRGSGGSGGSGGSGGSGQVQLKEAGPGLVPTQTL---SLTCTVSGFSLTSD 177
QY 152 SVQ-CRSPRGNQI-----GKKT-----LSVQGLQLDQSGCT 181

```



```

Db      178 GVMHWRQPGKGLWGGIYYDGGFDYNSAIKSRLSISRDTSKSGVFLKINSLQTDPTAM 237
Qy      182 WTCTVLQNOQKVEFK-----IDIVPCPAPEPKSCDKTHTC-----PELLGGPSVFLFPPK 231
Db      228 YYCA-----RHFPYMGQGVWVWYSSDLEPKSCDKTHTCPCPAPELLGGPSVFLFPPK 291
Qy      232 PKDTLMISRTPEVTCVVVDVSHEDPEVKFNNYVDSGEVHNAKTKRREQDYNSTYRVSVL 291
Db      232 PKDTLMISRTPEVTCVVVDVSHEDPEVKFNNYVDSGEVHNAKTKRREQDYNSTYRVSVL 351
Qy      232 TVLHODWNLNGEKYKCKVKSNKALPAPIETKISKAKQPREPVYTLPPSRDELTKNQVSLT 351
Db      232 TVLHODWNLNGEKYKCKVKSNKALPAPIETKISKAKQPREPVYTLPPSRDELTKNQVSLT 411
Qy      352 CLVKGFPYSDIAVESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDSKRWQOGNVFSCS 411
Db      412 CLVKGFPYSDIAVESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDSKRWQOGNVFSCS 471
Qy      412 VMHEALHNHYTQKSLSLSPG 431
Db      472 VMHEALHNHYTQKSLSLSPG 491

```

```

RESULT 53
ABR39847
ID      ABR39847 standard; protein; 461 AA.
AC      ABR39847;
XX      18-AUG-2003 (first entry)
DT      18-AUG-2003 (first entry)
XX      Hu266 N56S heavy chain.
DE      Hu266 N56S heavy chain.
XX      Amyloid-beta; Abeta; antibody 266; nootropic; neuroprotective; CDR;
KW      immunostimulant.
OS      Homo sapiens.
XX      MO2003016466-A2.
PN      27-FEB-2003.
XX      14-AUG-2002; 2002MO-US021322.
PF      14-AUG-2002; 2002MO-US021322.
XX      17-AUG-2001; 2001US-0313224P.
PR      (ELIL ) LILLY & CO ELI.
XX      (ELIL ) LILLY & CO ELI.
PA      Jia AY, Tsurushita N, Vaequez MJ;
PI      WPI; 2003-278557/27.
DR      N-PSDB; ACC47231.
XX      New antibodies comprising a heavy chain and a light chain complementarily
PT      determining regions from antibody 266, for treating and preventing
PT      conditions associated with the A beta peptide, e.g. Alzheimer's disease
PT      or Down syndrome.
XX      Disclousure; Fig 6; 82pp; English.
XX      The invention relates to an anti-Abeta (amyloid-beta peptide) antibody
XX      266. The antibodies are useful for treating and preventing conditions
XX      associated with the Abeta peptide, such as Alzheimer's disease, Down
XX      syndrome, and cerebral amyloid angiopathy; for diagnosing diseases in
XX      humans; for determining whether a human subject will respond to treatment
XX      using humanized antibodies against Abeta; for treating, preventing and
XX      reversing cognitive decline in clinical or pre-clinical Alzheimer's
XX      disease, Down's syndrome or cerebral amyloid angiopathy; for inhibiting
XX      formation of amyloid plaques of the effects of toxic soluble Abeta
XX      species in humans. Treatment of the patients with antibody will inhibit
XX      or prevent cognitive decline typically associated with disease
XX      progression and reverse it. The present sequence represents a humanised
CC

```

```

CC      anti-Abeta antibody 266 N56S heavy chain
XX      Sequence 461 AA;
SQ

```

```

Query Match      52.8%; Score 1275.5; DB 6; Length 461;
Best Local Similarity 57.0%; Pred. No. 3.6e-64;
Matches 281; Conservative 31; Mismatches 86; Indels 95; Gaps 13;

```

```

Qy      1 MNRGVPFRHLTLVQLALPAATQGNKVLGKKDYTELTCTAS--OKKSIQFFMKNS-- 56
Db      1 MNRGLSLIFLVLVKGLVCEVQLVESGGGLVQCGSLRLCAASGFTFSRYSMSWVQAP 60
Qy      57 -----NQIKIIGNQGSF--LTGPKSLNDRADSRSLMDQGNFPIIINXKIEDSDTY 107
Db      61 GKGLDELVAQINSVSSSTYYPDYVKGKPTIS-RONAKVTLYLQNW-----SLRAEDTAVY 113
Qy      108 ICEVEDKEVEQLVRLTANSDTHLQGSILVLTLESFGSSPSVQCRRPRGNIOGG- 166
Db      114 YC-----ASGD--YWGQGLTVYSSASTKGPSVFPPLAPSSKSTSGGT 153
Qy      167 -----KTLASV-----QLELDPSG-----TWI 183
Db      154 AALGCLVKDYFPEPVYTVSNMGSALTSGVHTFPAVLQSSGLYSLSSVTVVPSSTSLGTQTYI 213
Qy      184 CTVLQNOQKVEFKIDIVPCPAPEPKSCDKTHTC-----PELLGGPSVFLFPPKDTLMT 238
Db      214 CNV--NHKPSNTKVD---KVEPKSCDKTHTCPCPAPELLGGPSVFLFPPKDTLMT 267
Qy      239 SRTPPEVTCVVVDVSHEDPEVKFNNYVDSGEVHNAKTKRREQDYNSTYRVSVLTVLHODW 298
Db      268 SRTPPEVTCVVVDVSHEDPEVKFNNYVDSGEVHNAKTKRREQDYNSTYRVSVLTVLHODW 327
Qy      299 LNGKEYKCKVSNKALPAPIETKISKAKQPREPVYTLPPSRDELTKNQVSLTCLVKGFY 358
Db      328 LNGKEYKCKVSNKALPAPIETKISKAKQPREPVYTLPPSRDELTKNQVSLTCLVKGFY 387
Qy      359 PSDIAVESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDSKRWQOGNVFSCSVMHEALH 418
Db      388 PSDIAVESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDSKRWQOGNVFSCSVMHEALH 447
Qy      419 NHTYQKSLSLSPG 431
Db      448 NHTYQKSLSLSPG 460

```

```

RESULT 54
ABR39843
ID      ABR39843 standard; protein; 461 AA.
AC      ABR39843;
XX      18-AUG-2003 (first entry)
DT      18-AUG-2003 (first entry)
XX      Hu266 N56S heavy chain.
DE      Hu266 N56S heavy chain.
XX      Amyloid-beta; Abeta; antibody 266; nootropic; neuroprotective; CDR;
KW      immunostimulant.
OS      Homo sapiens.
XX      MO2003016466-A2.
PN      27-FEB-2003.
XX      14-AUG-2002; 2002MO-US021322.
PF      14-AUG-2002; 2002MO-US021322.
XX      17-AUG-2001; 2001US-0313224P.
PR      (ELIL ) LILLY & CO ELI.
XX      (ELIL ) LILLY & CO ELI.
PA      Jia AY, Tsurushita N, Vaequez MJ;
PI      WPI; 2003-278557/27.
DR

```


DR	N-PEDB; ACC47227.
XX	New antibodies comprising a heavy chain and a light chain complementarity
PT	determining regions from antibody 266, for treating and preventing
PT	conditions associated with the A beta peptide, e.g. Alzheimer's disease
PT	or Down syndrome.
PS	Diclosure; Fig 2, 82pp; English.
XX	
CC	The invention relates to an anti-Abeta (amyloid-beta peptide) antibody
CC	266. The antibodies are useful for treating and preventing conditions
CC	associated with the Abeta peptide, such as Alzheimer's disease, Down
CC	syndrome, and cerebral amyloid angiopathy; for diagnosing diseases in
CC	humans; for determining whether a human subject will respond to treatment
CC	using humanized antibodies against Abeta; for treating, preventing and
CC	reversing cognitive decline in clinical or pre-clinical Alzheimer's
CC	disease, Down's syndrome or cerebral amyloid angiopathy; for inhibiting
CC	formation of amyloid plaques of the effects of toxic soluble Abeta
CC	species in humans. Treatment of the patients with antibody will inhibit
CC	or prevent cognitive decline typically associated with disease
CC	progression and reverse it. The present sequence represents a humanised
CC	anti-Abeta antibody 266 N566 heavy chain
XX	
SQ	Sequence 461 AA;
Query Match	52.8%; Score 1275.5; DB 6; Length 461;
Best Local Similarity	57.0%; Pred. No. 3.6e-64;
Matches 281; Conservative 31; Mismatches 86; Indels 95; Gaps 13	
OY	1 MNRGVPPFHLILVLQALIPATQGNKVVLGKKDTEVELTCTAS--QKKSIFPHKNIS-- 56
Db	1 MNFGSLFLVTLVGVCCEVOLVSGGGLVPGSLRLRSCAAGFTFRYSMSWVRQAP 60
OY	57 -----NQIKLGNQGSF--LTGPKSKUNDRADSRSRIMDGNPPLIKNKIEDSDTY 107
Db	61 GKGLELVADINSVSSSTYYPDTVKGRFTIS-RDNAKNTIYLQMN-----SLRAEDTAVY 113
OY	108 ICEVEDQKEEVOLFLGCLTANSDTHLLOGQSITLTLESPGSSPSVOCSPRKGNIQG- 166
Db	114 YC-----ASGD---YMGQGILVTIVSSASTSGPVFLAPLAPSKSMTSGGT 153
OY	167 -----KITLSV-----OLEIODSG-----TWTF 183
Db	154 AALGLVLDYFPPEPYTVSNWSGALTSGVHTFPFAVLQSSGLYSLSSVTVTPSSSLGTQFYI 213
OY	184 CTVLNOKKVEREKIDIVPCPAEPPSCDKTHRC-----PELLGSGSVLPFPKPXDIMI 238
Db	214 CNV--NHRPSPNTKV----KRYEPKSCDTHTCPPCPAPELLIGGSGVFLEPRKPYDTIMI 267
OY	239 SRTPEVTGVVDVSHDEPEVKFNMYVDGVEYNAAKTTPREEQYNSTYRVVSVLYLHDM 298
Db	268 SRTEPVTGVVDVSHDEPEVKFMNVYDGEVNAATKTPREEQYNSTYRVVSVLYLHDM 327
OY	299 LNGKEYKKCKVSKNALPAPIEKTISKAKGPREFPOVYTLPPRSDELTKQVSLTCLVKGFY 358
Db	328 LNGKEYKKCKVSKNALPAPIEKTISKAKGPREFPOVYTLPPRSDELTKQVSLTCLVKGFY 387
OY	359 PSDIAVESNSQNPENNYKTPPEVLDSDGSFELYSKLTYDKSRMOQGANVFCSSVNHGAH 418
Db	388 PSDIAVESNSQNPENNYKTPPEVLDSDGSFELYSKLTYDKSRMOQGANVFCSSVNHGAH 447
OY	419 NHYTQKSLSLSPG 431
Db	448 NHYTQKSLSLSPG 460
RESULT 55	
ID	AAB33444
AC	AAB33444 standard; protein; 579 AA.
XX	AAB33444;
DT	02-APR-2003 (first entry)

Query Match	Best Local Similarity	Score	DB	Length	579;
Matches	281;	Conservative	29;	Mismatches	70;
				Indels	107;
				Gaps	14;
Query	32	KKGPTVELTETASQKKSIOF--HMKNSQIKILGNQG--SFLTQGPSKLANDRGRSLM	87		
Db	13	KPGETVAKISCAASGYTFPTNYGMNWKQTPGKGLKMGHINITYTGEPTADD-----	63		
Query	88	DQGNFP-----LIINKLIEDSDTYICEVEDKEEVOLLVFGLTANSDTHLLOG	136		
Db	64	FKGRPAFSLETSTNAFLQINNLSSEDPATYFC-----VRFISK-----DYWGQ	109		
Query	137	QSLTILTESPPGSSPSVQCRSPRGKNIQG-----KTLVS-----	172		
Db	110	TSVTVSSASTKG--PSYFPLAPSSKTSSTGGTALGCLVKDYFPEEVTIVSMNSGALTSGVH	167		
Query	173	--QLEIDQSG-----TWTCVTLQONKQVPEPKDIDPCAPAREKSCDX	212		
Db	168	TFPAVLQSSGLYSLSSVTVTPSSSLGTQTYICNV--NKPSPNTKQ---KRVBKSCKX	221		
Query	213	THTC-----PELIGGPSVFLFPPPKDKDLMISRTPEVTCVVVDVSHEDPEVKFMNYVDGV	267		
Db	222	THTCPCPCAPRLDGGPSVFLFPPPKDKDLMISRTPEVTCVVVDVSHEDPEVKFMNYVDGV	281		
Query	268	EVNNAKTPREEQNSTYRVVSVLTVLHODMLNGKEYKCVSNKALPAPIEKTISKAKQ	327		
Db	282	EVNNAKTPREEQNSTYRVVSVLTVLHODMLNGKEYKCVSNKALPAPIEKTISKAKQ	341		
Query	328	PREPOVYTLPSRDELITNOVSLTCLVKGAFPSDIAVEMWENGGPENNKTTPPLVDSG	387		
Db	342	PREPOVYTLPSRREMTKNQVSLTCLVKGAFPSDIAVEMWENGGPENNKTTPPLVDSG	401		
Query	388	SFFLYSKLTVVKSQMOQGNVSCGVMEALNNHTQKSLSLSPG-----LQLD	435		

```

Db      402 SFFLYSKLTVDKSRWQGNVFCSCVMHEALHNHYTKSLSPGKAPRTSSSTKTKTQGLE 461
QY      436 ETCAEAQ 442
Db      462 HLLLDLQ 468

RESULT 56
AAW86003
ID      AAW86003 standard; protein; 595 AA.
AC      AAW86003;
XX      15-MAR-1999 (first entry)
XX      Anti-5T4 single chain antibody 5T4Sabl.
XX      Tumour interacting protein; cancer; gene therapy; vector; 5T4 antigen;
KW      monoclonal antibody; single chain antibody; mouse; human; 5T4Sabl.
XX
OS      Mus sp.
OS      Homo sapiens.
OS      Synthetic.
OS      Chimeric.
XX      WO9855607-A2.
XX      10-DEC-1998.
XX      04-JUN-1998; 98WO-GB001627.
XX      04-JUN-1997; 97GB-00011579.
XX      20-JUN-1997; 97GB-00013150.
XX      04-JUL-1997; 97GB-00014230.
XX      (OXFO-) OXFORD BIOMEDICA UK LTD.
XX      Kingman SM, Bebbington CR, Ellard FM, Carroll MW, Myers KA;
XX      WPI; 1999-059910/05.
XX      N-PSDB; AAV80291.
XX      New vector encoding a tumour interacting protein for treating cancer -
PT      contains a desired nucleotide sequence and/or protein which recognises
PT      tumour, and is used as a gene delivery system to treat cancer.
XX
PS      Example 1; Fig 1B; 82pp; English.
XX
CC      This is the amino acid sequence of a single chain antibody (Sabl), termed
CC      5T4Sabl, comprising an scFv derived from murine monoclonal antibody 5T4
CC      (see AAW86002) and the human g1 constant region. CDNA (see AAV80291)
CC      encoding the Sabl has been inserted into vector pCIneo to allow expression
CC      in mammalian cells. The trophoblast cell surface antigen defined by 5T4
CC      is expressed at high levels on the cells of a wide variety of human
CC      tumours. The invention relates to a vector comprising a nucleotide
CC      sequence coding for a tumour interacting protein (TIP) and optionally a
CC      nucleotide sequence of interest (NOI) which encodes a protein of interest
CC      (POI), the vector being capable of delivering the NOI and/or POI to the
CC      tumour recognised by the TIP. Delivery can be in vivo or ex vivo. The
CC      vector is used to treat cancer, and may also be used as a gene delivery
CC      system for introducing at least 1 gene encoding a TIP (preferably a
CC      tumour binding protein) into a haematopoietic cell lineage
XX
SQ      Sequence 595 AA;
Query Match      52.8%; Score 1275; DB 2; Length 595;
Best Local Similarity 59.4%; Pred. No. 5,1e-64;
Matches 277; Conservative .18; Mismatches 81; Indels 90; Gaps 11;
QY      23 TQGNKVVVGKGGDTVELTCTASOKSIOFHWKNSNQITILNQSGLTKGSKLNDRAIS 82
Db      162 TQTFLLVSAAGDVTITCKASQSVSNDVAVYQOKP-----GQSPTLLISYTS 210

```

```

QY      83 R-RLMDQ-----GNPPIIKNLKIEDSDTYICEVEDQKEVQLVGLTANSDTHL 134
Db      211 RYAGVPRRFIGSGVGTDFTTISTIGQAEDLAVVFCQD-----YNSPTFG 256
QY      135 QGOSLITLESPPGSSPSVOCRRPRGNIOG-----KTLNIS----- 172
Db      257 GGTLEIKRASTKG--PSVFPPLAPSSKSTSGTAAAGCLKDYFPPEPVTVMNSGALTSG 314
QY      173 -----QLEIDPSG-----TWTCVYLQNKQKVEFKIDIPCPAPRPPKSC 210
Db      315 VHTFPVAVLQSSGLXLSSTVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KKEVKSJC 368
QY      211 DKHTTC-----PELLGSPVSEFLPPPKKDTLMTSRPEVTCVVVDVSHEDPEVKFMYVD 265
Db      369 DKHTTCPPCAPELGLGSPVSEFLPPPKKDTLMTSRPEVTCVVVDVSHEDPEVKFMYVD 428
QY      266 GVEYHNAKTPREBOYNSTRVVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTISKAK 325
Db      429 GVEYHNAKTPREBOYNSTRVVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTISKAK 488
QY      326 GQPREPQVYTLPPSRDELTKNOVSLTCLVKGFPYPSDIAVEMESNGQEPENNYKTTTPVLDS 385
Db      489 GQPREPQVYTLPPSRDELTKNOVSLTCLVKGFPYPSDIAVEMESNGQEPENNYKTTTPVLDS 548
QY      386 DGSFFLYSKLTVDKSRWQGNVFCSCVMHEALHNHYTKSLSPG 431
Db      549 DGSFFLYSKLTVDKSRWQGNVFCSCVMHEALHNHYTKSLSPG 594

```

```

RESULT 57
AAO31101
ID      AAO31101 standard; protein; 445 AA.
XX
AC      AAO31101;
XX
DT      06-OCT-2003 (first entry)
XX
DE      Human A2-G8 SCF antibody heavy chain variable and constant region.
XX
KW      Human; antibody; stem cell factor; mast cell growth factor; asthma; SCF;
KW      steel factor; c-kit ligand; gene therapy.
XX
OS      Homo sapiens.
XX
PN      WO2003051311-A2.
XX
PD      26-JUN-2003.
XX
PF      16-DEC-2002; 2002WO-US040227.
XX
PR      17-DEC-2001; 2001US-0342174P.
XX
PA      (FARB ) BAYER CORP.
XX
PI      Takeuchi T, Tomkinson A, Neben S;
XX
DR      WPI; 2003-523500/49.
XX
PT      New purified human antibody that binds to stem cell factor protein,
PT      useful for preparing a composition for treating asthma.
XX
PS      Claim 9; Page 47; 94pp; English.
XX
CC      The invention provides human antibodies that bind to stem cell factor
CC      (SCF) protein. SCF is also known as mast cell growth factor, steel factor
CC      or c-kit ligand. Antibodies of the invention are useful for preparing
CC      compositions for treating asthma. They are also used in gene therapy. The
CC      present sequence is human SCF antibody heavy chain variable and constant
CC      region
XX
SQ      Sequence 445 AA;

```

Query Match 52.8%; Score 1274.5; DB 6; Length 445;
Best Local Similarity 59.2%; Pred. No. 4e-64;
Matches 277; Conservative 27; Mismatches 67; Indels 97; Gaps 13;

QY 30 LGKKDTELTCTAS-----QKSIQFHKNSNOIKILGNQGSFL---TYG 72
DB 8 LVQPGSLRLSCAASGFTFSYAMSWVRQAPGKLEWVA---ISGSGSTYYADSVKG 63
QY 73 PSLNDRADSRSLMDQGNPRLIKRLKIEDSTYCEVEDQKEEVLVFGITANSDPH 132
DB 64 RFTIS-RDMSKNTLYLQMN-----SLRAEDTAVVYCARDD-----PFAHFD-- 103
QY 133 LLOGSLTLTLSPSSPSVQCRSPRKNIOG-----KTLISVS----- 172
DB 104 -VMGQGLTVTVSSASTKGPSVFLPPLAPSSKSTSGCTALGLVQDYRPEPVYTSWNGALT 162
QY 173 -----QLEIQDSG-----TWCTTVLONOKVEFKIDIVPCAPAPRK 208
DB 163 SGVHTRPAVLQSSGLYSLSSVTVPPSSSLGTQTYICNV--NHKPSNTKYD---KVEPRK 216
QY 209 SCDKTHTC-----PELLGSPVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKENY 263
DB 217 SCDKTHTCPPCAPPELLGGSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKENY 276
QY 264 VDGVEVHNAKTKRREQYSTYRVSVLTVLDHQMINGKEVKCKVSNKALPAPIETISK 323
DB 277 VDGVEVHNAKTKRREQYSTYRVSVLTVLDHQMINGKEVKCKVSNKALPAPIETISK 336
QY 324 AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTPPV 383
DB 337 AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTPPV 396
QY 384 DDDGSEFLYKSLTVDSRWQGNVFSCSVMHEALHNHYTQKSLSLSPG 431
DB 397 DDDGSEFLYKSLTVDSRWQGNVFSCSVMHEALHNHYTQKSLSLSPG 444

RESULT 58
ABR39848
ID ABR39844 standard; protein; 461 AA.

AC ABR39844;
XX
DT 18-AUG-2003 (first entry)
XX
DE Hu266 N56T heavy chain.
XX
KW Amyloid-beta; Abeta; antibody 266; nootropic; neuroprotective; CDR;
XX immunostimulant.
XX
OS Homo sapiens.
XX
PN WO2003016466-A2.
XX
PD 27-FEB-2003.
XX
PF 14-AUG-2002; 2002WO-US021322.
XX
PR 17-AUG-2001; 2001US-0113224P.
XX
PA (ELIL) LILLY & CO ELI.
XX
PI Jia AY, Teurnehita N, Vazquez MJ;
XX
DR WPI; 2003-278557/27.
XX
DR N-PSDB; ACC47228.
XX
PT New antibodies comprising a heavy chain and a light chain complementarity
XX determining regions from antibody 266, for treating and preventing
XX conditions associated with the A beta peptide, e.g. Alzheimer's disease
XX or Down syndrome.
XX
PS Disclosure; Fig 3; 82pp; English.

XX
CC The invention relates to an anti-Abeta (amyloid-beta peptide) antibody
CC 266. The antibodies are useful for treating and preventing conditions
CC associated with the Abeta peptide, such as Alzheimer's disease, Down
CC syndrome, and cerebral amyloid angiopathy; for diagnosing diseases in
CC humans; for determining whether a human subject will respond to treatment
CC using humanized antibodies against Abeta; for treating, preventing and
CC reversing cognitive decline in clinical or pre-clinical Alzheimer's
CC disease, Down's syndrome or cerebral amyloid angiopathy; for inhibiting
CC formation of amyloid plaques of the effects of toxic soluble Abeta
CC species in humans. Treatment of the patients with antibody will inhibit
CC or prevent cognitive decline typically associated with disease
CC progression and reverses it. The present sequence represents a humanised
CC anti-Abeta antibody 266 N56T heavy chain

Sequence 461 AA;

Query Match 52.8%; Score 1274.5; DB 6; Length 461;
Best Local Similarity 57.0%; Pred. No. 4.2e-64;
Matches 281; Conservative 30; Mismatches 87; Indels 95; Gaps 13;

QY 1 NMRGVPFRHLIVLQALIPATQGNKYVLGKKGTVELTCTAS--QKSIQFHKNS-- 56
DB 1 NMFGSLIFLYLVLGKVEQVLVSGGGLVQPGSLRLSCAASGFTFSYMSWVRQAP 60
QY 57 -----NQIKILGNQGSF--LTGKPSKLNDRADSRSLMDQGNPRLIKRLKIEDSTY 107
DB 61 GKGLELVADINSVGSITYPTDKRFTIS-RDNKNTLYLQMN-----SLRAEDTAVY 113
QY 108 ICEVEDQKEEVLVFGITANSDPHLLQGSILTLTLSPSSPSVQCRSPRKNIOG- 166
DB 114 YC-----YMGQGLTVTVSSASTGTPSVFLPAPSSKSTSGT 153
QY 167 -----KTLISVS-----QLEIQDSG-----TWCTTVLONOKVEFKIDIVPCAPAPRK 183
DB 154 AALGCLVQDYRPEPVYTSWNSGALTSGVHTRPAVLQSSGLYSLSSVTVPPSSSLGTQTYI 213
QY 184 CTYLVONOKVEFKIDIVPCAPAPPELLGSPVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKENY 238
DB 214 CNV--NHKPSNTKYD---KVEPRKSCDTHTCPPCAPPELLGGSVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKENY 267
QY 239 SRTPEVTCVVVDVSHEDPEVKENYVDGVEVHNAKTKRREQYSTYRVSVLTVLDHQM 298
DB 266 SRTPEVTCVVVDVSHEDPEVKENYVDGVEVHNAKTKRREQYSTYRVSVLTVLDHQM 327
QY 299 INGKEVKCKVSNKALPAPIETISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY 358
DB 328 INGKEVKCKVSNKALPAPIETISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFY 387
QY 359 PSDIAVWESNGQPENNYKTPPVLDSDGSFPLYKSLTVDSRWQGNVFSCSVMHEALH 418
DB 388 PSDIAVWESNGQPENNYKTPPVLDSDGSFPLYKSLTVDSRWQGNVFSCSVMHEALH 447
QY 419 NHYTQKSLSLSPG 431
DB 448 NHYTQKSLSLSPG 460

RESULT 59
ABR39848
ID ABR39848 standard; protein; 461 AA.

AC ABR39848;
XX
DT 18-AUG-2003 (first entry)
XX
DE Hu266 N56T heavy chain.
XX
KW Amyloid-beta; Abeta; antibody 266; nootropic; neuroprotective; CDR;
XX immunostimulant.
XX
OS Homo sapiens.

Oy		191KKVEPRKIDVPCCPADPEPSCKDTHNC-----PELLGGSEVFLEPPPKQDTLMSRPPEVT	245
Dd		221KESNTKVD---KRAVEPNSCDKTHTCPCCPAPBLLGGSVFLEPPPKDTLMSRTP EVT	286
Oy		246CVVDVSHEDPEVKFNMYVDGVEVHNAKTRPREEQNSTYRVVSVLTVLHQDLNKGEXK	305
Dd		287CVVDVSHEDPEVKFNMYVDGVEVHNAKTRPREEQNSTYRVVSVLTVLHQDLNKGEXK	346
Oy		306CIVSNKALPAPIEKTISKAKGPREPOVYTLTPSRDELTKNOVSLTCLVKGFPSPDIAYE	365
Dd		347CIVSNKALPAPIEKTISKAKGPREFOVYTLTPSRREEMTKNOVSLTCLVKGFPSPDIAYE	406
Oy		366MESNQEPENNYTTPTPEVLDSGSSFFLYSKLTVDKSMOOGNVSCSVMEHALNHHTOKS	425
Dd		407MESNQEPENNYTTPTPEVLDSGSSFFLYSKLTVDKSMOOGNVSCSVMEHALNHHTOKS	466
Oy		426LSLSPG 431 	
Dd		467LSLSPG 472	
RESULT 61			
ID	AAE27928		
XX	AAE27928 standard; protein; 468 AA.		
AC	AAE27928;		
XX			
DT	27-DEC-2002 (first entry)		
XX			
De	Human C5E10 antibody heavy chain protein.		
XX			
KW	Human; C5A9 antibody; C2B8 antibody; tumor associated antigen; TAG-72;		
KM	neoplasia; neoplastic disorder; haematologic neoplasm; colon cancer;		
XX	non-Hodgkin's lymphoma; haematologic malignancy; tumour.		
OS	Homo sapiens.		
PN	WO200260955-A2.		
PD	08-AUG-2002.		
PF	29-JAN-2002; 2002WO-US002373.		
PR	29-JAN-2001; 2001US-0264318P.		
PR	16-NOV-2001; 2001US-0331481P.		
PA	(IDEC-) IDEC PHARM CORP.		
XX			
P1	Braeclawsky GR, Hanna N, Chinn P;		
DR	MPJ; 2002-698547/75.		
DR	N-PsDB; AAD45757.		
XX			
PT	Novel domain deleted C5A9 antibody reactive with tumor associated antigen		
PT	-72, or C2B8 antibody reactive with CD20, useful for treating		
XX	myelosuppressed patient suffering from a neoplastic disorder.		
Example 3; Fig 6A; 74pp; English.			
The present invention relates to domain deleted C5A9 or C2B8 antibodies.			
Domain deleted C5A9 antibodies comprise a heavy chain human C5A9 domain			
deleted sequence in which CH2 domain has been deleted and are reactive			
with tumour associated antigen (TAG)-72. The C2B8 antibodies are reactive			
with CD20 and comprise a heavy chain having a sequence of a derived			
domain deleted C2B8 construct where the CH2 domain has been deleted.			
Sequences of the invention are useful for imaging a neoplasm. They are			
also useful for treating myelosuppressed patients suffering from			
neoplastic disorder such as haematologic neoplasm, preferably non-			
Hodgkin's lymphoma. Antibodies of the invention are also used to treat			
neoplastic disorder, colon cancer and haematologic malignancy. They are			
useful for reducing tumour size, inhibiting tumour growth and/or			
prolonging the survival time of tumour-bearing animals and for treating			

CC tumours The present sequence is human CSE10 heavy chain protein. This
 CC sequence is used in the exemplification of the invention

XX SQ Sequence 468 AA;

Query Match	52.8%; Score 1274; DB 5; Length 468;
Best Local Similarity	58.0%; Pred. No. 4.5e-64;
Matches	280; Conservative
	Mismatches 95; Indels 80; Gaps 13;

```

OY      10 LLLVLTQALPAPATQGKKNVVLGGKK-----DTVELTCTAQQKSIOF--HMKNNOIK 60
DB       4 LALLFLCLVTPTSCIL-SQVQLKESGPGIVAPSGSLSTICTTVSGRLSDYGVMWRQPPGX 62
OY      61 ILGNQGSFLTKGPSKLNDRADSRSL-WDQGNPLLIK--NLKTEDSDTYICEVEDQKEE 117
DB       63 GLEWIGMIWDNGRDYNSSALKSRISINKDNSSQVFILKMISLQTDTPARYYC----- 114
OY     118 VQLLVFGLTANSDPHLLAQGSLLTLTSPSSPSVQCRRPKNIQGS----- 166
DB     115 -ARCYTGSSPYFD--YWGGTTLTVSSASTGPSPVEPLPSSKSTSGGTALAGCLVKDY 170
OY     167 --KTLVS-----QLELAQSG-----TWCTCVLQNOKV 193
DB     171 FPEEVTVSNMNGALTSGVHTFPALQSSGLYSLSVTVTPSSLSGTQTIICNV--NRKPS 228
OY     194 EFKIDIVPCPAPEPKSCDKTHTC----PELLGSPSVFLPFPKPXTLMISRTEVTCV 248
DB     229 NTKVD---KKVEBKSCDKTHTCPPCAPPELLGSPVFLPFPKPXDITMISRTEVTCV 284
OY     249 VDVSHEDEPVKFNMYGVGVENHNAKTPREHQNYSTRVVSVLTVAHQMDLNGKEYCKV 308
DB     285 VDVSHEDEVKFNMYGVGVENHNAKTPREHQNYSTRVVSVLTVAHQMDLNGKEYCKV 344
OY     309 SNKLNPAPIEKTIISKAKGPREPOVYTLPSRDELTNQVSLTCLVGAFYPSDIAYEMES 368
DB     345 SNKLNPAPIEKTIISKAKGPREPOVYTLPSRDELTNQVSLTCLVGAFYPSDIAYEMES 404
OY     369 NGQPENNYKTTTPVLDSGSEFFLYSKLTVDSRWQGNVFSCSVMBEALHNHYTOKSLSL 428
DB     405 NGQENNNYKTTTPVLDSGSEFFLYSKLTVDSRWQGNVFSCSVMBEALHNHYTOKSLSL 464
OY     429 SPG 431
DB     465 SPG 467

RESULT 62
ABB82837
1D ABB82837 standard; protein; 468 AA.
XX
XX ABB82837;
XX
XX 31-MAR-2003 (first entry)
XX
XX Antibody CSE10 heavy chain.
XX
XX DE
XX CSE10; antibody; cytototoxic; antitumorigenic; antiangiogenic; antiproliferative; antineoplastic; immunomodulator; proinflammatory; antidiabetic; nephroprotective; thyromimetic; hepatotropic; haemostatic; antileptotic; antibacterial; neuroprotective; antipsoriatic; antirheumatic; antiallergic; antitumor; dermatological; immunosuppressive; antiinflammatory.
XX
XX OS Homo sapiens.
XX
XX WO200296948-A2.
XX
XX 05-DEC-2002.
XX
XX PF 29-JAN-2002; 2002WO-US002374.
XX
XX PR 29-JAN-2001; 2001US-0264318P.
XX PR 16-NOV-2001; 2001US-031481P.
XX PR 21-DEC-2001; 2001US-0341858P.
XX

```

XX (IDEC-) IDEC PHARM CORP.
XX PA
XX Brahlawsky GR, Hanna N, Chinn P, Harinaran K;
XX WPI; 2003-140446/13.
XX N-PSDB; AB224021.
XX
XX Novel dimeric antibody useful for treating immune disorder and neoplastic
XX disorder, has several non-covalently associated monomeric subunits.
XX
XX Example 3; Fig 6; 78pp; English.
XX
XX The invention relates to a dimeric antibody (I) comprising several
XX monomeric subunits, where the monomeric subunits are non-covalently
XX associated. (I) is useful for treating a disorder, especially immune
XX disorder, and neoplastic disorder such as relapsed Hodgkin's disease,
XX resistant Hodgkin's disease high grade, low grade and intermediate grade
XX non-Hodgkin's lymphomas, B cell chronic lymphocytic leukemia (B-CLL),
XX lymphoplasmacytoid lymphoma (LP), mantle cell lymphoma (MCL), follicular
XX lymphoma (FL), diffuse large cell lymphoma (DLCL), Burkitt's lymphoma,
XX AIDS-related lymphomas, monocytic B cell lymphoma, angioimmunoblastic
XX lymphadenopathy, small lymphocytic, follicular, diffuse large cell,
XX diffuse small cleaved cell, large cell immunoblastic lymphoblastoma,
XX small, non-cleaved, Burkitt's and non-Burkitt's, follicular, mixed small
XX cleaved and large cell lymphomas, in a mammal (see AB224017 for a
XX detailed description of the various uses of (I)). The present sequence
XX represents the antibody CSE10 heavy chain

XX
SQ Sequence 468 AA;

Query Match 52.8%; Score 1274; DB 6; Length 468;
Best Local Similarity 58.0%; Pred. No. 4.5e-64;

Matches 280; Conservative 28; Mismatches 95; Indels 80; Gaps 13;

QY 10 LILVQLALLPAAFGKAVLVGKKG-----DTVELTCTASQKSIQF--HWKNSNOIK 60
DB 4 LALLPCLVTFPSCIL--SQVQLKESGPGVAPQSISITCTVSGFSLTYGVAVWVQPPGK 62
QY 61 ILNGSGFLTKGPKSLNDRADRSRL--WDQGNFPLIK--NKIEDSDTYICEVDQKEE 117
DB 63 GLEWLGMIWNGRTYNSALKSLRLSINKNSKSVQLKMTSLQTDVTAARYC----- 114
QY 118 VQLLVFGLTANSDFTHLQGSLLTLTLESPGSSPSVQCSPPRGKNIQGG----- 166
DB 115 -ARCYGSSPYFD---YMGQGTTLVSSASTGKPSVFLPAPBSKSTSGTALGCLVXDY 170
QY 167 --KTLVS-----OLEIQDSG-----TWCTVLOKOKV 193
DB 171 FPEPTVSNWNSGALTSVHTFPFPAVLQSSGLVSLSSVTVPPSSSLGTQTYICNV--NHRPS 228
QY 194 EKKIDIVPAPAPKSCDKTHTC-----PELLGGPSVFLPAPKPDITMISTPEVTV 248
DB 229 NTKVD---KVEPSPSCDKTHTCPCPAPBELGGSVFLPAPKPDITMISTPEVTV 284
QY 249 VDVSHEDEVEKENVVDGEVHNAAKTKPREEOYNSTYRVSVLTJVLHODMLNGKEYCKV 308
DB 265 VDVSHEDEVEKENVVDGEVHNAAKTKPREEOYNSTYRVSVLTJVLHODMLNGKEYCKV 344
QY 309 SNKALPAPLEKTIKAKQPREPOVYTLPPSDELTKQVSLTCLVKGFPYSDIAVEMES 368
DB 345 SNKALPAPLEKTIKAKQPREPOVYTLPPSDELTKQVSLTCLVKGFPYSDIAVEMES 404
QY 369 NGQPENNYKTPPVLDSGSPFLYSKLTJVDKSRMOQGVFSGSVNHEALHNHYTKSL 428
DB 405 NGQPENNYKTPPVLDSGSPFLYSKLTJVDKSRMOQGVFSGSVNHEALHNHYTKSL 464
QY 429 SPG 431
DB 465 SPG 467

RESULT 63

AAE35327
ID AAE35327 standard; protein; 444 AA.
XX
XX AAE35327;
XX
XX 17-JUN-2003 (first entry)
XX
XX Humanised murine antibody BIWA4 heavy chain protein.
XX
XX CD44; cytotoxic drug; therapy; cancer; tumour; minimal residual disease;
XX antigen; cytostatic; BIWA4 antibody; murine.
XX
XX Homo sapiens.
XX
XX EPI258255-A1.
XX
XX 20-NOV-2002.
XX
XX 18-MAY-2001; 2001EP-00112227.
XX
XX 18-MAY-2001; 2001EP-00112227.
XX
XX (BOEH) BOEHRINGER INGELHEIM INT GMBH.
XX
XX Adolf G, Heider K, Patzelt E, Sproll M;
XX WPI; 2003-177273/18.
XX N-PSDB; AAD53977.
XX
XX New compound useful for treatment of cancer comprises CD44 specific
XX antibody molecule conjugated to a highly cytotoxic drug, which cleaves
XX under intracellular conditions.
XX
XX Claim 7; Page 15-16; 31pp; English.
XX
XX
XX The invention relates to a compound comprising CD44 specific antibody
XX molecule conjugated to a highly cytotoxic drug, which cleaves under
XX intracellular conditions. The compound is used in pharmaceutical
XX composition for the treatment of cancer, solid tumours, and as an
XX adjuvant to surgical intervention to treat minimal residual disease. The
XX present sequence is humanised murine antibody BIWA4 heavy chain protein
XX used in the invention

XX
SQ Sequence 444 AA;

Query Match 52.8%; Score 1273.5; DB 6; Length 444;
Best Local Similarity 59.3%; Pred. No. 4.5e-64;

Matches 275; Conservative 27; Mismatches 69; Indels 93; Gaps 13;

QY 30 LGKKGDTVELTCTAS--QKSIQFHW-----KNSNOIKILNGSGFL-----TKGPSKL 76
DB 11 LVKGGSLRLSCAASGTFSSYDMSWVRQAPKGLKLEWSTISSGGSYTYIYDLSKGRFTI 70
QY 77 NDRAISRRLMDQGNFPLIINKLKIEDSDTYICEVDQKEEVQLLVFGLTANSDFTHLQ 136
DB 71 S-RDNAAKNSLYLQKN-----SLRAEDTAVYYCARQ-----GLD-----YWG 105
QY 137 QSLTLTLESPGSSPSVQCSPPRGKNIQGG-----KTLVS----- 172
DB 106 RGLLVTVSSASTKGPSVFLPAPBSKSTSGTALGCLVXDYFPEPTVSNWNSGALTSGVH 165
QY 173 --OLEIQDSG-----TWCTVLOKOKVEFKIDIVPAPAPKSCDK 212
DB 166 TFPFPAVLQSSGLVSLSSVTVPPSSSLGTQTYICNV--NHRPSNTKVD---KVEPSPKCDK 219
QY 213 THTC-----PELLGGPSVFLPAPKPDITMISTPEVTCVVDVSHDEPEVKFMVYVDGV 267
DB 220 THTCPCPAPBELGGPSVFLPAPKPDITMISTPEVTCVVDVSHDEPEVKFMVYVDGV 279
QY 268 EVHNAAKTKPREEOYNSTYRVSVLTJVLHODMLNGKEYCKVSNKALPAPLEKTIKAKQ 327
DB 280 EVHNAAKTKPREEOYNSTYRVSVLTJVLHODMLNGKEYCKVSNKALPAPLEKTIKAKQ 339

Qy	328 PREPQVYTLPRSRDELTKNQVSLTCLVKGFYPSDIAVEHESGQPENNYKTTTPRVLDSPG	387
Db	340 PREPQVYTLPRSRDELTKNQVSLTCLVKGFYPSDIAVEHESGQPENNYKTTTPRVLDSDG	399
Qy	388 SFPLYSKLTVDKSRWQGNVFSCSVHAEALAHNYTQKSLSPG	431
Db	400 SFPLYSKLTVDKSRWQGNVFSCSVHAEALAHNYTQKSLSPG	443
RESULT 64		
AC	AAE34876	ID
XX	AAE34876 standard; protein; 444 AA.	
AC	AAE34876;	
DT	28-MAY-2003 (first entry)	
XX		
DE	BIWA4/8 antibody heavy chain mature protein.	
XX		
KW	BIWA8 antibody; heavy chain variable region; light chain variable region;	
KM	VH; VL; CD44v6; medicament; cancer; antibody therapy.	
XX		
OS	Unidentified.	
XX		
PN	WO200294879-A1.	
XX		
PD	28-NOV-2002.	
XX		
PF	17-MAY-2002; 2002WO-EP005467.	
XX		
PR	18-MAY-2001; 2001EP-00112237.	
XX	26-SEP-2001; 2001US-0325147P.	
PA	(BOEH) BOEHRINGER INGELHEIM INT GMBH.	
XX	(BOEH) BOEHRINGER INGELHEIM PHARM INC.	
PI	Adolf G. Ostermann E, Patzelt E, Sproll M, Heider K;	
XX	Miglicetta JJ, Van Dongen AAMS;	
DR	WPI; 2003-129413/12.	
XX	N-PSDB; AAD53212, AAD53215.	
XX		
PT	New antibodies specific for an epitope coded by the variant exon of the	
PT	CD4 gene, useful for treating cancer, including non-small cell lung,	
PT	breast, head and neck, ovarian and lung cancer.	
XX		
PS	Claim 24; Col 44; 78pp; English.	
XX		
CC	The present invention relates to novel antibody molecules comprising a	
CC	variable region of the heavy (VH) and/or light chain (VL) of CD44v6	
CC	specific humanised antibody called BIWA8 and BIWA4. Sequences of the	
CC	invention are useful for manufacturing a medicament and for treating	
CC	cancer including colorectum, non-small cell lung, breast, head and neck,	
CC	ovarian, lung, bladder, pancreatic cancer or metastatic cancers of the	
CC	brain. They are also useful in antibody therapy. The present sequence is	
CC	BIWA4/8 antibody heavy chain mature protein. This sequence is used in the	
CC	exemplification of the invention	
XX		
XX		
Sequence	444 AA;	
Query Match	52.8%; Score 1273.5; DB 6; Length 444;	
Best Local Similarity	59.3%; Pred. No. 4.5e-64;	
Matches	275; Conservative 27; Mismatches 69; Indels 93; Gaps 13	
Qy	30 LGKKDVTVELTCTAS--QKKSIQFHW-----KNSNQIKILNGQSFL-----TKGPSYCL	76
Db	11 LVKPGGSLRLSCAASGFTFPSSSYDMGVWROAPGKGLEWVSTISGSGSYTYLDSIKRFTI	70
Qy	77 NDRAQSRRLWMOGNGPPLIIKULKIEDSDTYICEVEQDQBEVQVLVFGLTANSDFHLLOG	136
Db	71 S-RDNKAKSLIYQMN-----SRADTVIVYICARQ-----GLD-----YWG	105
Qy	137 GSLLTLLESPGSSPSPVQCRSPRGKNIQGG-----KTLSSVS-----	172

```

Db      : : : | | | : : : | |
106 RGLTVLVSSASTKGPVFPPLAPSSKSTSGGTRALGCLVKDYFPEEPYVSRNNGALTSQVH 165
QY      --OLELSDSG-----TWTCVVLQNKVKEFKIDIVCPAPKPSCDK 212
173
Db      TFPALVQSSGLVSLSSVTVTPSSLSGTQIYICNV--NHKPSNTRKYD---KKEVPKSCDK 219
166
QY      THTC-----PELLGSSVFLFPFKPKDTLMTSRPEVTCVYVVDYSHEDPEVKFMYVDGV 267
213
Db      THTCPCPAPABELLGGPSVFLFPFKPKDTLMTSRPEVTCVYVVDYSHEDPEVKFMYVDGV 279
220
QY      EYHNAKTKPREEOYNTYRVSVLVLYLHODMLNGEKYCKVSNKALPAPTEKTSKAGQ 327
268
Db      EYHNAKTKPREEOYNTYRVSVLVLYLHODMLNGEKYCKVSNKALPAPTEKTSKAGQ 339
280
QY      PREPOVYTLPPSHDELTKQVSLTCLVNGFYPSDIAVEMESNGQPENNYKTPPVLDSG 387
328
Db      PREPOVYTLPPSHDELTKQVSLTCLVNGFYPSDIAVEMESNGQPENNYKTPPVLDSG 399
340
QY      SFELYSKLTLYDKSRWQGVSCSVNHEALNHTYQKSLSPG 431
388
Db      SFELYSKLTLYDKSRWQGVSCSVNHEALNHTYQKSLSPG 443
400

```

RESULT 65
AAR93553
ID AAR93553 standard; protein; 475 AA.
XX
AC AAR93553;
XX
DT 20-AUG-1996 (first entry)
XX
DE Monoclonal antibody DNA heavy chain against 6S kD hCMV antigen.
XX
KW Polymerase chain reaction; primer; amplify; PCR; light chain; Mab;
XX 6S kD antigen; human cytomegalovirus; hCMV; heavy chain; diagnosis.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Peptide 1..19
FT /note= "Signal peptide"
FT Protein 20..475
FT /note= "Mature heavy chain"
PX JP08038178-A.
PN
PD 13-FEB-1996.
XX
PF 20-FEB-1995; 95UP-00030742.
XX
PR 18-FEB-1994; 94UP-00021628.
XX
PA (TANAKA/) TANAKA H.
(NINS) NISSHINBO IND INC.
XX
DR WPI; 1996-154852/16.
N-PSDB; AAT18059.
XX
PT Human monoclonal antibody binds to cytomegalovirus 6S kD antigen -
PT produced by primer amplification, used in the diagnosis of hCMV
PT infection.
XX
PS Claim 4; Page 16-18; 22pp; Japanese.
XX
CC The sequences given in AAR93553-54 represent the heavy and light chains
CC respectively of a monoclonal antibody against a 6S kD antigen of human
CC cytomegalovirus (hCMV). The DNA's encoding these sequences were amplified
CC using the sequences given in AAT18040-58. The monoclonal antibody may be
CC used in the diagnosis of hCMV
XX
SQ Sequence 475 AA;

Query Match	Similarity	52.8%	Score 1273.5	DB 2	Length 475
Best Local	Similarity	58.1%	Pred. NO.4.9e-64		
Matches	283	Conservative	29	Mismatches	98
				Indels	77
				Gaps	14
QY	8 RHLLVLQIALLP-----AATQGNKVVLGKKGDVETLCTAS--QKXSIQFMKNSNQI	59			
Db	2 KHLNPFLLVNAFRVVLVSQLQDQSGPGLVNPSELTSLTCTVSGNSIRSSVSWCICQP	61			
QY	60 KILGNQ--GSFLTKGPSKLNDRADSRSL-WDQGN--FPLIIKLIKIEDSDTYIC-EYED	113			
Db	62 PGKGLFEMIGTITVYSGSTVYNPSLKSRTVITISVDASNNQFSLKLSVTAADTAVVYCAFTSP	121			
QY	114 QKEVQLVLPGLTANSDTHLQDQSLTLTLBSPSSPSVQCSPFRGNIQG-----	166			
Db	122 QYIDL-----LTGSFSPYWGQGLVTVYSSASTKG--PSVFPPLASSKSTSGTALACL	173			
QY	167 -----KTLVSY-----OLEIODSG-----TWCTVLQN	189			
Db	174 VKDYPRPEVTVYSNMGALTSQVHTPRVVLQSSGLYSLSVTVTPSSSLGTQYICNV--N	231			
QY	190 QKQVEFKIDIVCPAPAEKSCDKHTQC-----PELLGGPSVFLFPPKPDYTLMSRTEV	244			
Db	232 HKPSATKVD----KAVEPKSCDKHTQCPCPAPAEIIGGPSVFLFPPKPDYTLMSRTEV	287			
QY	245 TCVVVVDVSHDEPVEKFNMYVDGVEVHNAKTKPREEQNNSTRVSVVLTVLHODMLNGKEY	304			
Db	288 TCVVVVDVSHDEPVEKFNMYVDGVEVHNAKTKPREEQNNSTRVSVVLTVLHODMLNGKEY	347			
QY	305 KCAVSNKALPAPIEKTISKAKQPREPOVYTLPRSRDELTKNQVELTCLVKGFPSPDIAY	364			
Db	348 KCAVSNKALPAPIEKTISKAKQPREPOVYTLPRSRDELTKNQVELTCLVKGFPSPDIAY	407			
QY	365 EMESNGQENNYKTPPVLDSDGSFFLYSKLTVDSRWQOQGNVFSCVMHEALHNHYQK	424			
Db	408 EMESNGQENNYKTPPVLDSDGSFFLYSKLTVDSRWQOQGNVFSCVMHEALHNHYQK	467			
QY	425 SLSLSPG 431				
Db	468 SLSLSPG 474				
RESULT 66					
AAW11641					
ID	AAW11641 standard; protein; 475 AA.				
XX	AAW11641;				
XX	13-MAY-1997 (first entry)				
DE	Human anti-RSV monoclonal antibody RF-2 heavy chain.				
XX	Monoclonal antibody; Mab; RF-1; RF-2; respiratory syncytial virus; RSV;				
KW	fusion protein; F-protein; vaccine; immunotherapy; therapy;				
KM	Epstein Barr virus; immortalisation; recombinant antibody.				
XX	Homo sapiens.				
OS					
XX					
Key	Location/Qualifiers				
FT	1..19				
FT	/label= Leader_peptide				
FT	20..49				
FT	/label= FR1				
FT	/note= "framework region 1"				
FT	50..56				
FT	/label= CDR1				
FT	/note= "complementarity determining region 1"				
FT	57..70				
FT	/label= FR2				
FT	/note= "complementarity determining region 1"				
FT	71..86				
FT	/label= CDR2				
FT	/note= "complementarity determining region 2"				
FT	87..118				
FT	Region				

FT	/label= FR3
FT	/note= "framework region 3"
FT	119..134
Region	/label= CDR3
FT	/note= "complementarity determining region 3"
FT	135..145
Region	/label= FR4
FT	/note= "framework region 4"
FT	146..175
FT	/label= Kappa
FT	/note= "human gamma 1 constant region"
PN	WO9640252-A1.
XX	
PD	19-DEC-1996.
XX	
PF	06-JUN-1996; 96WO-US010070.
XX	
PR	07-JUN-1995; 95US-00488376.
XX	
PA	(IDEC-) IDEC PHARM CORP.
PI	Brams P, Chamat SS, Pan L, Walsh ER, Heard CJ, Newman RA;
XX	
DR	WPI: 1997-099892/09.
N-PDSB; AAT61279.	
XX	
PT	Human monoclonal antibody specific for respiratory syncytial virus fusion protein - used for the prevention and treatment of RSV infection.
XX	
PS	Example 6; Fig 11b-c; 85pp; English.
CC	A polypeptide (AAW11641) comprises a leader sequence, RF-2 heavy chain variable region (see also AAW11635), and human gamma 1 constant region.
CC	RF-2 is a human monoclonal antibody (hmb) specific for the fusion protein of respiratory syncytial virus (RSV). The polypeptide can be produced in eukaryotic host (e.g. CHO) cells transfected with vector NEOSPRA incorporating a DNA construct (AAT61279) including the RF-2 VH sequence. RF-1 and RF-2 heavy and light chains (see also AAW11638-40) are similarly produced. The transfected host cells provide a constant, stable supply of anti-RSV F-protein hmbds for use in the treatment or prevention of RSV infection
CC	
SQ	Sequence 475 AA;
Query Match	52.8%; Score 1273.5; DB 2; Length 475;
Best Local Similarity	57.1%; Pred. No. 4.9e-64;
Matches	276; Conservative 29; Mismatches 99; Indels 79; Gaps 11
Dy	10 LLVLVQLALRLPAATGKNKLVLAGKKDVIETLTCTAS----OKKSIOFHMKNSNQIKL--- 62
Dd	10 LVAVATRVLSQVOLOESGPALVKPQTULTLTCTFGSFLSTRGMVMNIROPGRALWL 69
Dy	63 ----GNQSGLITKG-PSKTLNRADSRRLMOQGPNLLIKULKIEDSDTYITEVEDQKE 117
Dd	70 ARIDMDDTTFYASASLIKTRLSISKDTSKN-----QVLEMTIVNDPVDTATYFCARASLYDS 124
Dy	118 VQLLVFGLTANSDPHLQGGSLTTLTLPSSSPSPVOCRRSPRKNIOGS----- 166
Dd	125 DSFLVF-----YHAYWGCGTTVTVASASTKGPSVPFLAPLASKSTSGGTALGCLVUDY 177
Dy	167 --KTLSVS-----QLEILOSQ-----TWCTVLONOKKY 193
Dd	178 FREEVTVSMNGALTSGVHTFRPVLQSSGLVLSLSVTVTPSSLSGTGYICNV--NHKRS 235
Dy	194 EFKIDIVCPARPERSCDKTHTC-----PELLGABSVELPPPKXDTLMISRTPEVTCVV 248
Dd	236 NTKVD----KAABEPSCDKTHTCPPCRPARELLGSPSVLPFPKPXDITMI SRTPEVTCVV 291
Dy	249 VDVSHEDEPEVKFNMYVGVGVHNNAKTKRKREOYNSTYVVSGLTVLHADMLNGEKYCKV 308
Dd	292 VDVSHEDPEVKFNMYVGVGVHNNAKTKRKREOYNSTYVVSGLTVLHADMLNGEKYCKV 351


```
Qy 309 SNKALPAPLEKTSISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMES 368
    |||||
Db 352 SNKALPAPLEKTSISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMES 411
    |||||
Qy 369 NGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRMQGVNFGSCVMHEALHNHYTQKSLSL 428
    |||||
Db 412 NGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRMQGVNFGSCVMHEALHNHYTQKSLSL 471
    |||||
Qy 429 SPG 431
    |||
Db 472 SPG 474

RESULT 67
AA97172
ID AA97172 standard; protein; 497 AA.
AC
XX AA97172;
DT 04-DEC-2000 (first entry)
XX
XX Human FGF-R1 Extracellular domain-Ig Fc fusion protein 3.
XX
XX FGF-R; fibroblast growth factor receptor; extracellular domain; IgG1;
KM immunoglobulin; G1; oligomerization domain; Fc region; fusion protein;
KM inhibitor; dimer; antagonist; cytosstatic; anti-diabetic; vulnerary;
KM opthalmological; anti-proliferative.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH Peptide 1..21
FT Domain /label= FGF-R1_signal_peptide
FT Domain 22..257
FT FT /label= FGF-R1_extracellular_domain
FT FT /note= "The Ig I segment and acid box are deleted"
FT FT 59..111
FT Domain /label= Ig_I1_segment
FT FT 157..222
FT FT /label= Ig_I1_segment
FT Peptide 258..265
FT FT /label= Linker
FT FT 266..497
FT Region /label= Human IgG1_Fc_region
FT FT /note= "Contains hinge region and domains CH2 and CH3"
XX
XX MO200046380-A2.
XX
XX 10-AUG-2000.
XX
XX 07-FEB-2000; 2000MO-US003166.
XX
XX 08-FEB-1999; 99US-0119002P.
XX
XX (CHIR ) CHIRON CORP.
XX
XX Kavanaugh WM, Ballinger M;
XX PI
XX MPI; 2000-514961/46.
XX DR N-PSDB; AAA52129.
XX
XX New polypeptide comprising a fibroblast growth factor receptor
PT extracellular domain fused to a heterologous oligomerization domain for
PT treating FGF-, angiogenesis-, or FGF receptor-mediated disorders.
XX
XX Claim 14; Page 58-59; 70pp; English.
XX
XX Novel fusion protein constructs comprise a fibroblast growth factor (FGF)
CC receptor (FGF-R) extracellular domain (ECD) lacking the immunoglobulin
CC (Ig) I segment fused to a heterologous oligomerization domain that
CC comprises an immunoglobulin Fc region, hinge region, CH1, CH2, CH3 or CH4
CC region, or light chain of an immunoglobulin molecule, or a peptide with a
CC leucine zipper motif. The Ig I segment is not necessary for binding of
```

```
CC acidic FGF and basic FGF (bFGF). The Ig I deletion further increases the
CC affinity for aFGF and heparin, protects the core of the molecule from
CC proteolysis, and abrogates the heparin requirement for aFGF binding. The
CC new fusion polypeptides are better FGF inhibitors than FGF-R monomer
CC proteins. The FGF-R-Ig Fc fusion dimers are active as FGF antagonists at
CC subnanomolar concentrations and were 20-fold more potent than the FGF-R
CC monomer protein as competitors of bFGF binding to immobilized FGF-R. The
CC fusion constructs are useful to treat FGF-, angiogenesis-, or FGF-R-
CC mediated disorders, such as tumorigenesis (e.g. bladder, breast, lung,
CC rectal, testis and cervical tumours), neovascularization (e.g. diabetic
CC retinopathy, neovascular glaucoma, wound healing and corneal scarring)
CC and hyper-proliferation of vascular smooth muscle cells (e.g.
CC postangioplasty and postatherectomy restenosis)
XX
XX SQ Sequence 497 AA;
XX
XX Query Match 52.8%; Score 1273.5; DB 3; Length 497;
XX Best Local Similarity 57.5%; Pred. No. 5,1e-64;
XX Matches 276; Conservative 30; Mismatches 83; Indels 91; Gaps 12;
XX
XX Qy 15 QALLPAPATQGNKVVLLGKKGVVELTCTASQKKSITQFMH-KNSNQK---ILNGQSTL 69
    |||||
Db 45 KLAHPVPA-----KTVKFKCPSSGTPNPFTLRKKNKGEKPDHRIGYKVRVA 92
    |||||
Qy 70 TKG-----PKLNDRADSRSLMDQGNFLLIKNLKIEDSDTYICEVEDQKEEVQLLV 122
    |||||
Db 93 TWSIIMDSVPS-----DKGNVTCIVENEGSINHYYQLDIVERSPHRPIIQ 139
    |||||
Qy 123 FGLTANSDTHLQSGSLTLTLSP-----GSS-----PSVQCRSPRGKNI 163
    |||||
Db 140 AGLPANKKTVALLSANVEFMCKVSDPQPHIQMLKHIEVNGSKIGPDNLPRVQLKTAGVMT 199
    |||||
Qy 164 --QGKTLSSVQLIEDSGTWTG-----TVLONQKVEPKIDIVPCP--- 203
    |||||
Db 200 TKEMEVLHLIRVVSDEADGETYCLAGNSIGLSHNSAMLVLE---ALERRPVMTSPLYL 256
    |||||
Qy 204 -----APEPKSCDKTHC-----PELIGPSVFLFPKPKDMLMISRPVTCVVNV 251
    |||||
Db 257 ESGSGPGLQEPKSCDKTHCPCPPAPBELIGGSVFLFPKPKDMLMISRPVTCVVNV 316
    |||||
Qy 252 SHEDEPEKENVYVDGVEVNAKTKPREBOYNSTYVSVTLVLAHDMVNGKEYKCKVSNK 311
    |||||
Db 317 SHEDEPEKENVYVDGVEVNAKTKPREBOYNSTYVSVTLVLAHDMVNGKEYKCKVSNK 376
    |||||
Qy 312 ALPAPLEKTSISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQ 371
    |||||
Db 377 ALPAPLEKTSISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQ 436
    |||||
Qy 372 PENNYKTPPVLDSDGSFFLYSKLTVDKSRMQGVNFGSCVMHEALHNHYTQKSLSLSPG 431
    |||||
Db 437 PENNYKTPPVLDSDGSFFLYSKLTVDKSRMQGVNFGSCVMHEALHNHYTQKSLSLSPG 496
    |||||

RESULT 68
AA97171
ID AA97171 standard; protein; 525 AA.
AC
XX AA97171;
XX
XX 04-DEC-2000 (first entry)
XX
XX Human FGF-R1 Extracellular domain-Ig Fc fusion protein 2.
XX
XX FGF-R; fibroblast growth factor receptor; extracellular domain; IgG1;
KM immunoglobulin; G1; oligomerization domain; Fc region; fusion protein;
KM inhibitor; dimer; antagonist; cytosstatic; anti-diabetic; vulnerary;
KM opthalmological; anti-proliferative.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH Peptide 1..21
FT Domain /label= FGF-R1_signal_peptide
```

```

FT Domain 22..285
FT /label= FGF-R1 extracellular domain
FT /note= "Ig I segment is deleted"
FT 37..44
FT Domain /label= Acid_box_segment
FT 87..139
FT Domain /label= Ig_II_segment
FT 286..293
FT Peptide /label= Linker
FT 294..525
FT Region /label= Human IgG1 Fc region
FT /note= "Contains hinge region and domains CH2 and CH3"
FT 445..520
FT Domain /label= Ig_III_segment
FT 713..720
FT WO200046380-A2.
FT 10-AUG-2000.
FT 07-FEB-2000; 2000WO-US003166.
FT 08-FEB-1999; 99US-0119002P.
FT (CHIR ) CHIRON CORP.
FT Kavanaugh WM, Ballinger M;
FT MPI: 2000-514961/46.
FT N-PSDB; AAs52128.
FT
FT New polypeptide comprising a fibroblast growth factor receptor
FT extracellular domain fused to a heterologous oligomerization domain for
FT treating FGF-, angiogenesis-, or FGF receptor-mediated disorders.
FT
FT Claim 14; Page 54-55; 70pp; English.
XX
XX Novel fusion protein constructs comprise a fibroblast growth factor (FGF)
XX receptor (FGF-R) extracellular domain (ECD) lacking the immunoglobulin
XX (Ig) I segment fused to a heterologous oligomerization domain that
XX comprises an immunoglobulin Fc region, hinge region, CH1, CH2, CH3 or CH4
XX region, or light chain of an immunoglobulin molecule, or a peptide with a
XX leucine zipper motif. The Ig I segment is not necessary for binding of
XX acidic FGF and basic FGF (bFGF). The Ig I deletion further increases the
XX affinity for aFGF and heparin, protects the core of the molecule from
XX proteolysis, and abrogates the heparin requirement for aFGF binding. The
XX new fusion polypeptides are better FGF inhibitors than FGF-R monomer
XX proteins. The FGF-R-Ig Fc fusion dimers are active as FGF antagonists at
XX subnanomolar concentrations and were 20-fold more potent than the FGF-R
XX monomer protein as competitors of bFGF binding to immobilized FGF-Rs. The
XX fusion constructs are useful to treat FGF-, angiogenesis-, or FGF-R-
XX mediated disorders, such as tumorigenesis (e.g. bladder, breast, lung,
XX rectal, testis and cervical tumors), neovascularization (e.g. diabetic
XX retinopathy, neovascular glaucoma, wound healing and corneal scarring)
XX and hyper-proliferation of vascular smooth muscle cells (e.g.
XX postangioplasty and postatherectomy restenosis)
XX
XX Sequence 525 AA;
SQ
Query Match 52.8%; Score 1273.5; DB 3; Length 525;
Beet Local Similarity 57.5%; Pred. No. 5.4e-64;
Matches 276; Conservative 30; Mismatches 83; Indels 91; Gaps 12;
QY 15 QALPLPATQGNKVVLGKGGDTVELTCTASQKSIQPHV-KNSNOIK-----ILGNQGSFL 69
Db 73 KLIHAVPAA-----KTVKFCPSSTGTPNPTLKLKNGKCFKPDHRIGYKAVYA 120
QY 70 TKG-----PSKLNDRADRSRSRSLMDQGNFPLIKNLKIEDSYICEVEDQKEEVQLLV 122
Db 121 TWSITMDSVVPSS-----DKGNVTCIVENEGSINHVTQQLDIVERSPHRPIIQ 167
QY 123 FGLTANSDFHLLQGSGLTITLESPP-----GSS-----PSVQCRSRGRGKRI 163
Db 168 AGLPANKTVVAGSNVEFMCKVYSDPOPHIOMLKIEVNGSKIGPDNLPPVOILKTAGVNT 227

```

```

QY 164 --QGKTLVSVSOLELQDSGTWTC-----TVLQNKVVEFKIDIVPCP--- 203
Db 228 TDKEVEVLHLRNVSFEEDAGEVTCLAGNSIGLSHSAMLTYLE---ALBEERAVMTSPLYL 284
QY 204 -----APBPKSCDKTHTC-----PELLGSPVYFLFPFKPKDTLMSRPREVTGVVVDV 251
Db 285 EGSGPSGLQEPKSCDKTHCTPCPCAPPELLGSPVFLFPFKPKDTLMSRPREVTGVVVDV 344
QY 252 SHEDPEYKFMVYVDGVVNAKTKPREEOYNSYTRVSVTVLVLHQDMLNGKEYCKVSNK 311
Db 345 SHEDPEYKFMVYVDGVVNAKTKPREEOYNSYTRVSVTVLVLHQDMLNGKEYCKVSNK 404
QY 312 ALPAPIEKTSKAKGQREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQ 371
Db 405 ALPAPIEKTSKAKGQREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQ 464
QY 372 PENNYKTTTPYLDSDGSFFLYSKLTVDKSRWQGNVSCSVMEHALNHTYQKSLSPG 431
Db 465 PENNYKTTTPYLDSDGSFFLYSKLTVDKSRWQGNVSCSVMEHALNHTYQKSLSPG 524

RESULT 69
AA97170
ID AA97170 standard; protein; 622 AA.
AC
AA97170;
DT 04-DEC-2000 (first entry)
DE Human FGF-RI Extracellular domain-Ig Fc fusion protein 1.
XX FGF-R; fibroblast growth factor receptor; extracellular domain; IgG1;
XX immunoglobulin; G1; oligomerization domain; Fc region; fusion protein;
XX inhibitor; dimer; antagonist; cyostatic; anti-diabetic; vulnerary;
XX opthalmological; anti-proliferative.
XX
XX Homo sapiens.
OS
XX
XX Key location/Qualifiers
XX Peptide 1..21
XX /label= FGF-R1_signal_peptide
XX Domain 22..374
XX /label= FGF-R1_extracellular_domain
XX Domain 55..101
XX /label= Ig_I_segment
XX Domain 126..133
XX /label= Acid_box_segment
XX Domain 176..228
XX /label= Ig_II_segment
XX Domain 275..339
XX /label= Ig_III_segment
XX Peptide /note= "this is the I11c variant version"
XX 379..390
XX /label= Linker
XX Protein /note= "Contains trypsin cleavage site"
XX 391..622
XX /label= Human IgG1 Fc region
XX /note= "Contains hinge region and domains CH2 and CH3"
XX
XX WO200046380-A2.
XX 10-AUG-2000.
XX 07-FEB-2000; 2000WO-US003166.
XX 08-FEB-1999; 99US-0119002P.
XX (CHIR ) CHIRON CORP.
XX Kavanaugh WM, Ballinger M;
XX MPI: 2000-514961/46.
XX

```

DR N-PSDB; AAA52127.
XX
XX
XX New polypeptide comprising a fibroblast growth factor receptor extracellular domain fused to a heterologous oligomerization domain for treating FGF-, angiogenesis-, or RFR receptor-mediated disorders.
PT
PT
PT
PS Claim 14, Page 51-52; 70pp; English.

CC Novel fusion protein constructs comprise a fibroblast growth factor (FGF)
CC receptor (FGF-R) extracellular domain (ECD) lacking the immunoglobulin
CC (Ig) I segment fused to a heterologous oligomerization domain that
CC comprises an immunoglobulin Fc region, hinge region, CH1, CH2, CH3 or CH
CC region, or light chain of an immunoglobulin molecule, or a peptide with a
CC leucine zipper motif. The Ig I segment is not necessary for binding of
CC acidic FGF and basic FGF (bFGF). The Ig I deletion further increases the
CC affinity for aFGF and heparin, protects the core of the molecule from
CC proteolysis, and abrogates the heparin requirement for aFGF binding. The
CC new fusion polypeptides are better FGF inhibitors than FGF-R monomer
CC proteins. The FGF-R-Ig Fc fusion dimers are active as FGF antagonists at
CC subnanomolar concentrations and were 20-fold more potent than the FGF-R
CC monomer protein as competitors of bFGF binding to immobilized FGF-Rs. The
CC fusion constructs are useful to treat FGF-, angiogenesis-, or FGF-Rs-
CC mediated disorders, such as tumorigenesis (e.g. bladder, breast, lung,
CC rectal, testis and cervical tumours), neovascularization (e.g. diabetic
CC retinopathy, neovascular glaucoma), wound healing and corneal scarring)
CC and hyper-proliferation of vascular smooth muscle cells (e.g.
CC postangioplasty and postatherectomy restenosis)

SQ Sequence 622 AA;

Query Match	Score	DB	Length
52.8%	1273.5	3	622

QY	15	QTALLPAAICOGNNVYLGKKGDIVELCTIA	SQKKS	IOFHW	-KNSNI	IKILGNQGSFLTKGP	73		
Db	162	KLHAVPAA-----	KTVMKFCPS	SGGRNPFLRLK	KNKGKFK	DHRIIGCVK----	206		
QY	74	SKLNDADSRRLM-----	DOGNFLII	KNLKI	EDSDTYI	CEVEDQKEEYQILVF	12		
Db	207	-----	RYATMSIIMDS	VVPSDKN	YTCIVENE	SGSINHNTYQLDVVERSPHRILOA	257		
QY	124	GLTANSDTHLLOQS	LTLLTLESP	-----	SGS-----	PSVQCRSPRGXNI	166		
Db	258	GLPANTVVALGS	VEVEMCKVYSD	PPQHLOML	KHIEVNSKI	GPDLNLPYVQILKTAGVNTT	317		
QY	164	-QCGKTLVSQ	ELQDSGTWC-----	TVLQNOCK-----	VEFKI		197		
Db	318	DKEMEVLHIRNYS	FEDAGEYTCI	AGNSIGLSH	SHSAMLTVLEAL	ERPAVMTSPLYLEB	378		
QY	198	DIYF-----	GPA	-PEPS	CDKHTHC-----	PELLGASVFLP	PRKQDITMSRPEYTCV	24	
Db	378	GLVPKRGSG	PGIOEP	SCDKHTCP	PCPA	BELLGASVFLP	PRKQDITMSRPEYTCV	433	
QY	248	VVDVSHED	EVKFNMYD	GVENVHNA	KTKRE	EQVNSYSTRVVS	VLTVLHQDMLNGKEYCK	307	
Db	438	VVDVSHED	EVKFNMYD	GVENVHNA	KTKRE	EQVNSYSTRVVS	VLTVLHQDMLNGKEYCK	497	
QY	308	VSNKALPA	IEKTI	ISAKQ	QPREPOY	YTLPS	RDELTKQVSLTVLVGFP	PSDIABWE	367
Db	498	VSNKALPA	IEKTI	ISAKQ	QPREPOY	YTLPS	RDELTKQVSLTVLVGFP	PSDIABWE	557
QY	368	SNQOPENN	KTPPVL	VDSDGS	FFLYSK	LVDSKRNQ	QGNVFC	SVMBHALNNHTQKSL	427
Db	558	SNQOPENN	KTPPVL	VDSDGS	FFLYSK	LVDSKRNQ	QGNVFC	SVMBHALNNHTQKSL	617
QY	428	LSFG	431						
Db	618	LSFG	621						

RESULT 7C
AAB83838

ID	AA083838	standard; protein; 592 AA.
XX		
AC	AA083838;	
XX		
DT	23-JUL-2001	(first entry)
XX		
DE	Amino acid sequence of an Ig-5T4 fusion protein.	
XX		
KW	Single chain antibody; SCFv; inflammatory disease; arthritis; cancer;	
KW	hypersensitivity; autoimmune disease; central nervous system disorder;	
KW	Parkinson's disease; peridontal disease; cardiopulmonary disease;	
KW	cardiovascular disease; gastrointestinal disorder; infection; diabetes;	
KW	Helicobacter-related disease; immune disorder.	
XX		
OS	Synthetic.	
OS	Mus sp.	
XX		
XX		
PH	Key	Location/Qualifiers
FT	Misc-difference 503	
FT	/note="Wet encoded by CTG"	

PN	MO200136486-A2.
XX	
PD	25-MAY-2001.
XX	
PF	13-NOV-2000; 2000MO-GE004317.
XX	
PR	18-NOV-1999; 99MO-GE003859.
PR	15-FEB-2000; 2000GB-00005527.
PR	02-MAR-2000; 2000GB-00005071.

PA (OXFO-) OXFORD BIOMEDICA UK LTD.
XX
XX Kingsman A, Kingsman SM, Bebbington CR, Carroll MW, Ellard FM;
PI Myers KA;
XX
XX WPI: 2001-343805/36.
DR N-PSDB; AAF69733.
XX
XX Use of single chain antibody capable of recognizing a disease associated
PT molecule for manufacturing a medicament for preventing and/or treating a
PT disease condition associated with disease associated molecule.
XX
XX Disclosure, Fig 6, 118pp; English
DS

The specification describes the use of a single chain antibody (ScFv), which is capable of recognizing a disease associated molecule in the manufacture of a medicament for the prevention and treatment of a disease condition. The ScFv antibody is useful in the manufacture of a medicament, for affecting a disease in vivo, for preparing a pharmaceutical composition, for in vivo imaging and/or for adjuvant treatment of a disease. The ScFv antibody is also useful for treating inflammatory diseases including arthritis, hypersensitivity, autoimmune diseases, cancers, central nervous system disorders including Parkinson's disease, peridontal diseases, cardiopulmonary diseases, cardiovascular diseases, gastrointestinal disorders, infections, diabetes, Helicobacter related diseases, and other immune disorders. The present sequence represents an Ig-ST4 fusion protein

Sequence 592 AA;

	Query Match	52.7%	Score 1273;	DB 46	Length 592;
	Best Local Similarity	59.2%;	Pred. No.	6-58-64;	
	Matches 276;	Conservative 19;	Mismatches 81;	Indels 90;	Gaps 1
OY	23	TQGNKVLGKKDDTELCTTASOKKSIGFHMNSNQILNQGSLFKGPSKTLDADS	82		
	:	: : :			
Dd	159	TQTPTTLVSAGDRVITIKCASQSNVDVAHTQQKP-----GGSTLLISTSSS	207		
	:	: : :			
OY	83	R-RSLMDQ-----GNPLTIKNLKIEDSDTYICEVEDKEEVOALLFGLTANSDTHL	134		
	:	: : :			
Dd	208	KAVGVDPRIISGYGDFTPTLISTAQADBLWVFQQD-----YNSPRTFG	251		
	:	: : :			

```

Qy 135 QGQSLTLTLESPPGSSPVQCRSPRGKNIQGG-----KTLSSVS----- 172
Db 254 GGTKEIKKASTKRG--PSVFPLAPSSKSTSGGTALGCLVKDYFPEPTVMSNGALTNSG 311
Qy 173 ---QLELDDSG-----TWCTVYLNQKVKVEKIDIVPCPAPEPPSC 210
Db 312 VHTFPAVLQSSGLYSLSSVTVTPSSSLGQTYICNV--NHKPSNTKVD---KKVEPPKSC 365
Qy 211 DKTHTC-----PELLGSPSVFLPPPKPKDTLMISRTPEVTCVVNVVSHEDPEVKFNWYVD 265
Db 366 DKTHTCPCPAPELLGSPSVFLPPPKPKDTLMISRTPEVTCVVNVVSHEDPEVKFNWYVD 425
Qy 266 GVEVHNAAKTKPRBEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAK 325
Db 426 GVEVHNAAKTKPRBEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAK 485
Qy 326 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPPVLD 385
Db 486 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPPVLD 545
Qy 386 DGSFPLYSKLTVDKSRWQGQNVFSCSVMEHALHNHYTQKSLSPG 431
Db 546 DGSFPLYSKLTVDKSRWQGQNVFSCSVMEHALHNHYTQKSLSPG 591

```

```

RESULT 71
ADE64199
ID ADE64199 standard; protein; 465 AA.
AC ADE64199;
DE 29-JAN-2004 (first entry)
LL2HCF protein related to a novel antibody library.
XX antibody library; retroviral vector; antibody light chain;
XX antibody heavy chain; human therapy; multiplicity of infection; MOI;
XX plasmid; GATEWAY vector; LL2HCF.
OS Unidentified.
XX
XX
XX Key Location/Qualifiers
XX FT Misc-difference 153
XX PN W02003083077-A2.
XX PD 09-OCT-2003.
XX PF 28-MAR-2003; 2003WO-US009662.
XX PR 28-MAR-2002; 2002US-0368808P.
XX PR 10-APR-2002; 2002US-0371299P.
XX PR 28-MAR-2003; 2003US-00371299.
XX PA (GALA-) GALA DESIGN INC.
XX PI Bremel RD, Eakle K, Imboden M;
XX DR N-PSDB; ADE64205.
XX DR WPI; 2003-804051/75.
XX PT New antibody library comprising cells comprising at least one integrated
XX PT retroviral vector expressing an antibody light or heavy chain, useful in
XX PT preparing a composition for diagnosing or treating disorders.
XX PS Disclosure; Fig 5; 57bp; English.
XX
XX This invention relates to a new antibody library which comprises at least
XX 100 cells, each of which comprises at least one integrated retroviral
XX vector expressing an antibody light or heavy chain. Antibodies are of
XX increasing importance in human therapy, assay procedures and diagnostic
XX methods and a need exists for efficient methods of generating and

```

CC screening antibody libraries containing large numbers of antibodies. The
 CC antibody library of the invention addresses this need, with the
 CC additional advantage of strict control over multiplicity of infection
 CC (MOI), and is useful in preparing a composition for diagnosing or
 CC treating a wide variety of disorders. The present sequence is the amino
 CC acid sequence of the LL2HCF protein, which was encoded by the Gateway
 CC retroviral vectors used in the exemplification of the invention.

XX SQ Sequence 465 AA;

Query Match 52.7%; Score 1272.5; DB 7; Length 465;
 Best Local Similarity 58.7%; Pred. No. 5.4e-64;
 Matches 270; Conservative 27; Mismatches 76; Indels 87; Gaps 10;

```

Qy 32 KKQDVEVLTCTAS--QKSIQFHWNKSNQIKILNQGSFLLTKGPKSLNDRADSRSLMDQ 89
Db 32 KPGSSVAVSCAASGYTSTYWLHW----VRQAFQGLQEMIGYINPRDITRYNQNRKD 86
Qy 90 GNFP-----LIKNLKIEDSDTYICEVEDQKEVQLLVFGLTANSDTHLLOQSLLT 140
Db 87 ATTADESTNTAYVWELSSLSSEDTAFYFCARD-----ITTFWGGQGT 130
Qy 141 LTLESPPGSSPVQCRSPRGKNIQGG-----KTLSSVS-----QL 174
Db 131 VTVSSASTKGPSVFPLAPSSKSKSGGTALGCLVKDYFPEPTVMSNGALTSGVHTFPA 190
Qy 175 ELQDSG-----TWCTVYLNQKVKVEKIDIVPCPAPEPKSCDKTHTC 216
Db 191 VLGSSGLYSLSSVTVTPSSSLGTYTYICNV--NHKPSNTKVD---KRVKPSDKTHTC 244
Qy 217 -----PELLGSPSVFLPPPKPKDTLMISRTPEVTCVVNVVSHEDPEVKFNWYVDGVEVHN 271
Db 245 PCPAPELLGSPSVFLPPPKPKDTLMISRTPEVTCVVNVVSHEDPEVKFNWYVDGVEVHN 304
Qy 272 AKTKPREQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAGQPREP 331
Db 305 AKTKPREQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAGQPREP 364
Qy 332 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPPVLDSDGSFFL 391
Db 365 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPPVLDSDGSFFL 424
Qy 392 YSKLTVDKSRWQGQNVFSCSVMEHALHNHYTQKSLSPG 431
Db 425 YSKLTVDKSRWQGQNVFSCSVMEHALHNHYTQKSLSPG 464

```

```

RESULT 72
AAB49243
ID AAB49243 standard; protein; 476 AA.
AC AAB49243;
DE 15-MAR-2001 (first entry)
XX
XX Chimeric 4H6 anti-DR4 antibody heavy chain protein.
XX
XX Anti-Death receptor 4; DR4; antibody; apoptosis; cancer; arthritis;
XX autoimmune.
XX
XX Homo sapiens.
XX OS Synthetic.
XX OS
XX PN W02000073349-A1.
XX PD 07-DEC-2000.
XX PF 25-MAY-2000; 2000WO-US014599.
XX PR 28-MAY-1999; 99US-00322875.
XX
XX (GERTH ) GENENTECH INC.
XX

```

PI Aehkenazi AJ, Chuntharapai A, Dodge KH, Kim KJ;
XX
DR WPI; 2001-041145/05.
XX
PT Novel anti-death receptor 4 antibodies useful for treating cancer and
XX immune related disorders such as rheumatoid arthritis, Sjogren's
PT syndrome, Grave's disease and diabetes mellitus.
XX
PS Claim 16; Fig 18; 126pp; English.
XX
CC The present invention relates to an anti-Death receptor 4 (DR4) antibody.
CC The antibodies of the invention are useful for inducing apoptosis in
CC mammalian cancer cells such as colon cancer cells and for treating an
CC immune-related disease in a mammal such as arthritis and autoimmune
CC disease
XX
SQ Sequence 476 AA;

Query Match 52.7%; Score 1272; DB 4; Length 476;
Best Local Similarity 60.4%; Pred. No. 5.9e-64;
Matches 273; Conservative 29; Mismatches 82; Indels 68; Gaps 12;

QY 36 TWELCTAS--QKSIQPHWKNNSQIKILGNQGSFLTKGPKSLNDRADSRSL--WDQGNF 92
DB 36 SLSTCTVSGFSLTSGVHWVRQPPGKLEMLGVINAVGSTNYSALMSRLSISKNSKS 95
QY 93 PLIIR--NKIEDSDTYICEVDQKEVQLVGLTRANSPTLLQ--GQSLTTLTLESPPG 148
DB 96 QVFLKNNSLQTDPTAMVYCARBESEFD---YVGSLSL--YHSMNFWGQGTSVTVSSAKT 149
QY 149 SPSVOCRSRGNKIOGS-----KTLSSV-----QLELDQSG-- 180
DB 150 TGSVPEPLABSSKSGGTALGLCYKDVFPPEPVTVSNMGSALTGVHFFPAVLQSSGLY 209
QY 181 -----TWCTVLQNOQKVEFKIDIVPCPAPRPSCKDTHTC-----PEL 219
DB 210 SLSSVTVBPSSSLGTGTICNV--NKKPSNTKVD---KKEPKSCDKHTTCCPAPAPL 263
QY 220 LGSPSFLPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNYYVGVENNAKTPRRE 279
DB 264 LGSPSFLPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNYYVGVENNAKTPRRE 323
QY 280 QVSTRVAVSLTVLHODMLNGKEVKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPS 339
DB 324 QVSTRVAVSLTVLHODMLNGKEVKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPS 383
QY 340 RDELTKNOVSLTCLVKGFPYPSDIAVEMESNGQPENNYKTTPTVLDSDGSFFLYSKLTVDK 399
DB 384 REEMTKNOVSLTCLVKGFPYPSDIAVEMESNGQPENNYKTTPTVLDSDGSFFLYSKLTVDK 443
QY 400 SRWQGNVPSGCVMEHALNHHYTKSLISLSPG 431
DB 444 SRWQGNVPSGCVMEHALNHHYTKSLISLSPG 475

RESULT 73
AAVS0151
ID AAVS0151 standard; protein; 453 AA.
XX
AC AAVS0151;
XX
DT 17-OCT-2003 (revised)
DT 31-JUN-2000 (first entry)
XX
DE Antibody F19 chimeric mouse/human heavy chain variable region (chF19HC).
XX
KW Antibody; monoclonal; F19; fibrinogen activation protein alpha; PAP;
KW humanization; complementarity determining region; CDR; CDR grafting;
KW reactive stroma; fibroblast; epithelial cancer; diagnosis;
KW immune response; framework sequence; constant region; variable region;
KW producibility; treatment; cancer; colorectal; lung; breast; head; neck;
KW ovarian; lung; bladder; pancreatic; metastasis; detection; wound healing;
KW skin inflammation; tumour; immunogenicity; chimeric; heavy chain.

XX
OS Mus sp.
OS Homo sapiens.
OS Chimeric.
XX
PN EP953639-A1.
XX
PD 03-NOV-1999.
XX
PF 30-APR-1998; 98EP-001079925.
XX
PR 30-APR-1998; 98EP-001079925.
XX
PA (BOEH) BOEHRINGER INGELHEIM INT GMBH.
XX
PI Park JE, Garin-Chesa P, Bamberger U, Leger O, Saldanha J;
PI Rettig WJ;
XX
DR WPI; 1999-621833/54.
XX
PT New antibody protein, useful for treating cancer and for imaging presence
PT of activated stromal fibroblasts in healing wound or inflamed skin.
XX
PS Example 1; Fig 18; 143pp; English.
XX
CC This sequence represents the heavy chain variable region of a chimeric
CC mouse/human F19 antibody (chF19HC). F19 (ATCC Accession number HB 8269)
CC is a murine monoclonal antibody against fibroblast activation protein
CC alpha (FAP). FAP is a cell surface molecule of reactive stromal
CC fibroblasts, and its induction is a highly consistent molecular trait of
CC the reactive stroma of many types of epithelial cancer. Although F19 may
CC be useful in vitro, e.g., for diagnosis, its applications for in vivo use
CC in humans are problematic as it elicits a human anti-mouse response which
CC reduces the efficacy of the antibody in patients and impairs continued
CC administration. This chimeric antibody was humanised by joining entire
CC murine variable regions to human constant regions. However, humanised
CC antibodies produced by this method can still elicit an anti-mouse
CC response in humans, whereas antibodies humanised via CDR (complementarity
CC determining region) grafting are less immunogenic in humans. Humanised
CC F19 antibodies are useful for treating cancers e.g., colorectal cancer,
CC non-small cell lung cancers, breast cancers, head and neck cancers,
CC ovarian cancers, lung cancers, bladder cancers, pancreatic cancers and
CC metastatic cancers. They are also useful for the detection of activated
CC stromal fibroblasts in a healing wound, inflamed skin or a tumour in a
CC human patient. (Updated on 17-OCT-2003 to standardise OS field)
XX
SQ Sequence 453 AA;

Query Match 52.7%; Score 1271.5; DB 2; Length 453;
Best Local Similarity 59.0%; Pred. No. 6e-64; Indels 73; Gaps 12;
Matches 271; Conservative 31; Mismatches 84;

QY 30 LCKKDPVELTCTASQKSIQF--HWKNSNQIKILGNQSF--LTGPKSLNDRADSRSL 86
DB 10 LVKPGASVMSCKSTRYFTETHTIMVNGSHKSLJEMIGIIPNNGIPRYNKKFGRAVL 69
QY 87 W---DQGNFPLIKNLKIEDSDTYICEVDQKEVQLVGLTRANSPTLLQ--GQSLTL 141
DB 70 TWGKSSSTAYWELRSLTSEDSAVYFC-----ARRRIAYGY--DEGHAMDWGQGTISV 119
QY 142 TLESPPGSSPSVQCSRPGKNIQGS-----KTLSSV-----QLE 175
DB 120 TVSSASTKGPSVFPPLAPSSKSTSGGTALGLCYKDVFPPEPVTVSNMGSALTGVHFFPAV 179
QY 176 LDQSG-----TWCTVLQNOQKVEFKIDIVPCPAPRPSCKDTHTC-- 216
DB 180 LQSSGGLYSLSSVTVTPSSSLGTGTICNV--NKKPSNTKVD---KKEPKSCDKHTTCCP 233
QY 217 ----PELLGSPVFLPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNYYVGVENNA 272
DB 234 PCPAPAPPELLGSPVFLPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNYYVGVENNA 293
QY 273 KTKRPEQVNSYRVAVSLTVLHODMLNGKEVKCKVSNKALPAPIEKTISKAKGQPREPO 332

```

|||||
Db 294 KTKPREQYNSTYRVVSLTVLHODMLNGKEYCKCKSNKALPAPIEKTISKAKGQPREPQ 353
333 VYTPPSRELTKNOVSLTCLVKGFPSPDIAVENSGNPENNYKTPPVLDSDSFLY 392
Db 354 VYTPPSREMTKNQVSLTCLVKGFPSPDIAVENSGNPENNYKTPPVLDSDSFLY 413
Qy 393 SKLTVDKSRWQGNVFSCSVMEALHNHYTKSLSPG 431
Db 414 SKLTVDKSRWQGNVFSCSVMEALHNHYTKSLSPG 452

RESULT 74
ABG31025
ID ABG31025 standard; protein; 499 AA.
XX
AC ABG31025;
XX
DT 05-NOV-2002 (first entry)
XX
DE Synthetic mouse/human chimeric fusion protein #1.
XX
KW Immunosuppressive; antirheumatic; antidiabetic; mouse;
KW neutroprotective; gene therapy; single chain antibody; variable fragment;
KW scFv; binding domain-immunoglobulin fusion protein; B-cell disorder;
KW malignant condition; rheumatoid arthritis; myasthenia gravis; psoriasis;
KW Grave's disease; Hashimoto's thyroiditis; type I diabetes mellitus;
KW multiple sclerosis; systemic lupus erythematosus; Sjogrens syndrome;
KW immune thrombocytopenic purpura; scleroderma; cancer; Chrons disease;
KW ulcerative colitis; inflammatory bowel disease; immunological effector;
KW cell mediated cytotoxicity; complement dependent cytotoxicity;
KW complement fixation; mouse; human.
XX
OS Mus musculus.
OS Homo sapiens.
OS Synthetic.
OS Chimeric.
XX
FH Key Location/Qualifiers
FT 1. 265
FT Region /note= "mouse anti-human CD20 single chain variable
FT fragment (scFv)"
FT Domain 266..499
FT /note= "Human immunoglobulin1 (IgG1) wild type hinge,
FT fragment of crystallization, CH2 and CH3 domains"
XX
PN WO200256910-A1.
XX
PD 25-JUL-2002.
XX
PF 17-JAN-2002; 2002WO-US001487.
XX
PR 17-JAN-2001; 2001US-00765208.
XX
PA (GENE-) GENE-CRAFT INC.
XX
PI Ledbetter JA, Hayden-Ledbetter M;
XX N-PSDB; ABK89848.
XX
PT WPI: 2002-599691/64.
PT N-PSDB; ABK89848.
XX
PT New human binding domain-immunoglobulin fusion protein useful for
PT treating a subject having or suspected of having a B-cell disorder or
PT malignant condition e.g. rheumatoid arthritis.
XX
PS Disclosure; Page 120-121; 136p; English.
XX
CC The invention describes a binding domain-immunoglobulin fusion protein
CC that is capable of at least one immunological activity, comprising a
CC binding domain polypeptide fused to an immunoglobulin hinge region
CC polypeptide capable of specifically binding to an antigen, or an
CC immunoglobulin heavy chain CH2 or CH3 constant region polypeptide fused
CC to the hinge region polypeptide or to the CH2 constant region

```

```

CC polypeptide. The fusion protein is useful for treating a subject having
CC or suspected of having a B-cell disorder or malignant condition e.g.
CC rheumatoid arthritis, myasthenia gravis, Grave's disease, Hashimoto's
CC thyroiditis, type I diabetes mellitus, multiple sclerosis, systemic lupus
CC erythematosus, Sjogrens syndrome, immune thrombocytopenic purpura,
CC psoriasis, scleroderma, cancer and inflammatory bowel disease such as
CC Chrons disease and ulcerative colitis. The fusion protein retains the
CC ability to participate in well known immunological effector activities
CC including antibody dependent cell mediated cytotoxicity and/or complement
CC fixation in complement dependent cytotoxicity, despite having structures
CC that would not be expected to be capable of promoting the effector
CC activities. It can be produced in substantial quantities that are
CC typically greater than those routinely attained with single-chain
CC antibody constructs. This is the amino acid sequence of a chimeric fusion
CC protein created from the mouse anti-human CD20 single chain antibody
CC variable fragment (scFv) and the human immunoglobulin G (IgG) fragment of
CC crystallisation (Fv) tail, wild type hinge, CH2 and CH3 domains
XX
SQ Sequence 499 AA;
XX
Query Match 52.7%; Score 1271.5; DB 5; Length 499;
Best Local Similarity 56.6%; Pred. No. 6.7e-64;
Matches 275; Conservative 27; Mismatches 93; Indels 91; Gaps 12;
23 TQGNKVVIGKKGDVVELTCTASQKKSIOFMKNKSNQIKILGNQGSFLTKGPSKLNDRADS 82
Db 27 SQSPALIASAGEKVTMTCASSSVS-YMEHYQQKX--GSSPKPMIVAPSNLASGVPA 81
Qy 83 RRSIMDQG-NFPLIIKMLKEDSDTYICEVEDQKEVQLVFLG----- 125
Db 82 RFSGSGSGTSYSLTISVVEADEATYYC---QQMSFNPTFGAGTKLELKDGGSGGGG 137
Qy 126 ---TANSDTHLQ-QGSILTLTLESPSPSPVQCR-----SPR----- 159
Db 138 SGGGSSQAYIQSGGALV-----RPASVMSCKASGYRTTSYNNMVKOTPPQGLBMT 192
Qy 160 -----GNIGGKTLV-----SQLELDQSGTWTCTVLQNGKVEFK 196
Db 193 GAIRPGNDTSYNGKFGKATLTVDKSSSTAYMQLSLTSDSALVFCARVYVYNSNGY 252
Qy 197 IDI-----VPCPAPERKSCDKHTC-----PELLGSPVFLPPPKRDTLMISRTPEVT 245
Db 253 FDIWGTGTVTVSDQDEKSCDKHTCPCPAPELLGGSPVFLPPPKRDTLMISRTPEVT 312
Qy 246 CVVVDVSHEDPEVFENNYVDGVEVYHNAKTKPREQYNSTYRVVSLTVLHODMLNGKEYK 305
Db 313 CVVVDVSHEDPEVFENNYVDGVEVYHNAKTKPREQYNSTYRVVSLTVLHODMLNGKEYK 372
Qy 306 CKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE 365
Db 373 CKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE 432
Qy 366 WESNGQPENNYKTPPVLDSDGSFPLYSKLTVDKSRWQGNVFSCSVMEALHNHYTKS 425
Db 433 WESNGQPENNYKTPPVLDSDGSFPLYSKLTVDKSRWQGNVFSCSVMEALHNHYTKS 492
Qy 426 LSLSPG 431
Db 493 LSLSPG 498

RESULT 75
ADD25587
ID ADD25587 standard; protein; 499 AA.
XX
AC ADD25587;
XX
DT 15-JAN-2004 (first entry)
XX
DE Binding domain-immunoglobulin fusion protein-associated protein #71.
XX
KW Binding domain-immunoglobulin; fusion protein; cytosstatic;
KW antirheumatic; immunosuppressive; antidiabetic; antidiabetic;

```

KW neuroprotective; hinge region; immunoglobulin heavy chain;
 KW CH2 constant region; CH3 constant region; IgG1;
 KW antibody dependent cell-mediated cytotoxicity; ADCC; complement fixation;
 KW human condition; B-cell disorder; melanoma; carcinoma; sarcoma;
 KW rheumatoid arthritis; myasthenia gravis; Grave's disease;
 KW type I diabetes mellitus; multiple sclerosis; autoimmune disease.
 XX
 OS unidentified.
 XX
 PV US2003118592-A1.
 XX
 PD 26-JUN-2003.
 XX
 PF 25-JUL-2002; 2002US-00207655.
 XX
 PR 17-JAN-2001; 2001US-0367358P.
 XX
 PR 17-JAN-2002; 2002US-00053530.
 XX
 PR 03-JUN-2002; 2002US-0385691P.
 XX
 PA (GENE-) GENE/CRAFT INC.
 XX
 PI Ledbetter JA, Hayden-Ledbetter MS, Thompson PA;
 DR WPI; 2003-801317/75.
 XX
 PT New binding domain-immunoglobulin fusion protein, useful for treating a
 PT subject having or suspected of having a malignant condition or a B-cell
 PT disorder, e.g. melanoma, Grave's disease or autoimmune disease.
 XX
 PS Disclosure; SEQ ID NO 148; 157bp; English.
 XX
 XX The invention relates to a binding domain-immunoglobulin fusion protein
 XX comprising a binding domain polypeptide that is fused to an
 CC immunoglobulin hinge region polypeptide, an immunoglobulin heavy chain
 CC CH2 constant region polypeptide that is fused to the hinge region
 CC polypeptide, and an immunoglobulin heavy chain CH3 constant region
 CC polypeptide that is fused to the CH2 constant region polypeptide. The
 CC hinge region polypeptide comprises: a wild-type human IgG1 immunoglobulin
 CC hinge region polypeptide; a mutated human IgG1 immunoglobulin hinge
 CC region polypeptide; derived from (a) having 3 or more cysteine residues;
 CC where the mutated human IgG1 immunoglobulin hinge region polypeptide
 CC contains 2 cysteine residues, where the first cysteine is not mutated; a
 CC mutated human IgG1 immunoglobulin hinge region polypeptide, derived from
 CC (a) having 3 or more cysteine residues, where the mutated human IgG1
 CC immunoglobulin hinge region polypeptide contains no more than one
 CC cysteine residue; and a mutated human IgG1 immunoglobulin hinge region
 CC polypeptide, derived from (a) having 3 or more cysteine residues, where
 CC no cysteine residues. The binding domain-immunoglobulin fusion protein is
 CC capable of at least one immunological activity complement antibody
 CC dependent cell-mediated cytotoxicity (ADCC) and complement fixation. The
 CC binding domain polypeptide is capable of specifically binding to an
 CC antigen. Also included are an isolated polynucleotide encoding the
 CC binding domain-immunoglobulin fusion protein, a recombinant expression
 CC construct comprising the polynucleotide (operably linked to a promoter),
 CC a host cell transformed or transfected with a recombinant expression
 CC construct, producing the binding domain-immunoglobulin fusion protein, a
 CC pharmaceutical composition comprising the binding domain-immunoglobulin
 CC fusion protein or polynucleotide and a carrier, and treating a subject
 CC having or suspected of having a malignant condition or a B-cell disorder.
 CC The binding domain-immunoglobulin fusion protein is useful for treating a
 CC subject having or suspected of having a malignant condition or a B-cell
 CC disorder, e.g. melanoma, carcinoma or sarcoma, rheumatoid arthritis,
 CC myasthenia gravis, Grave's disease, type I diabetes mellitus, multiple
 CC sclerosis or autoimmune disease. The present sequence is a binding domain-
 CC immunoglobulin fusion protein-associated protein sequence. Note: The
 CC sequence data for this patent formed part of the printed specification
 CC and is also available in electronic format directly from USPTO at
 CC www.uspto.gov/sequence.html?docID=20030118592. The authors have not
 CC identified the sequences in the printed specification by their SEQ ID
 CC number therefore none of the sequences can be explicitly identified.
 XX
 XQ Sequence 499 AA;

	Query Match	52.74; Score 1271.5; DB 7; Length 499;
	Beet Local Similarity 56.6%; Pred. No. 6,7e-64;	
	Matches 275; Conservative 27; Mismatches 93; Indels 91; Gaps 12	
Qy	23 TQGNKVVYLGKKGDPTVELTCTASOKKSIQIFHWKNSNQIKLGNQGSFLLTKGPKLNDRADRS 82	
Db	27 SQSPAILLSASGEKVTMTCRASSVS-YMHYYQKP-----GSPKPMIYAPENLNLASGVPA 81	
Qy	83 RRLIMDQG-NPEPLIIKNIKIEDSDTYICEVEDQKEEVLLVFGI----- 125	
Db	82 RFSGSGSGTSLTISRVEADATYYC-----QQWSFNPPTFGACTKLELKGCGSGGGG 137	
Qy	126 ---TANSDTHLLO-QGSITLTLESPGSSPSVQCR-----SPR----- 159	
Db	138 SGGGSSGSAVYIQGSGAELV-----RPGASVKNKSCASGYTTSTYNNMHVKKQTPROGLEMI 192	
Qy	160 -----GKNIQGGKTLV-----SOLEDDSGTWCTCTVLQNKKVEK 196	
Db	193 GAIRPNGDITSYNQKFKOKATLTVDKSSSTAYMQLSLSBSAVYFCARVYYNSNSWY 252	
Qy	197 IDI-----VPCPAPEPKSCDKHTC-----PELIGPSVFLPPPKYDTLMSIRTPET 245	
Db	253 FDMVGITGTTVVSQDEPKSCDKHTCPCPABELLGGPSVFLFPKPKDITLMSIRTPET 312	
Qy	246 CVAVDVSHEDPEVKNVYVDGVENATKPREBOYNSYTVRVSLTVLHQMNGKEK 305	
Db	313 CVAVDVSHEDPEVKNVYVDGVENATKPREBOYNSYTVRVSLTVLHQMNGKEK 372	
Qy	306 CKVSNKALPAIEIKTISKAKQPREPQVYTLPPSHDELTKNOVSLTCLVKGFPSDIAVE 365	
Db	373 CKVSNKALPAIEIKTISKAKQPREPQVYTLPPSHDELTKNOVSLTCLVKGFPSDIAVE 432	
Qy	366 WESNGQPENNYKTTTPVLDSGSPFLYSKLTVDYSRMQGGNVFSCSVNHEALHNHYTKS 425	
Db	433 WESNGQPENNYKTTTPVLDSGSPFLYSKLTVDYSRMQGGNVFSCSVNHEALHNHYTKS 492	
Qy	426 LSLSPG 431	
Db	493 LSLSPG 498	
RESULT 76		
ADD25454		
ID	ADD25454 standard; protein; 499 AA.	
AC	ADD25454;	
XX		
DT	15-JUN-2004 (first entry)	
XX		
DE	Binding domain-Immunoglobulin fusion protein-associated protein #5.	
XX		
KW	Binding domain; immunoglobulin; fusion protein; cytostatic;	
KW	antiarthritic; immunosuppressive; antidiabetic; antithyroid;	
KW	neuroprotective; hinge region; immunoglobulin heavy chain;	
KW	CH2 constant region; CH3 constant region; IgG1;	
KW	antibody dependent cell-mediated cytotoxicity; ADCC; complement fixation;	
KW	malignant condition; B-cell disorder; melanoma; carcinoma; sarcoma;	
KW	rheumatoid arthritis; myaesthesia gravis; Grave's disease;	
KW	type I diabetes mellitus; multiple sclerosis; autoimmune disease.	
XX		
OS	Unidentified.	
XX		
PN	US2003118592-A1.	
XX		
PD	26-JUN-2003.	
XX		
PF	25-JUL-2002; 2002US-00207655.	
XX		
PR	17-JAN-2001; 2001US-0367358P.	
FR	17-JAN-2002; 2002US-00053530.	
FR	03-JUN-2002; 2002US-0385691P.	
XX		

(GENE-) GENE-CRAFT INC.

Leibetter JA, Hayden-Leibetter MS, Thompson PA;
WPI, 2003-801317/75.

New binding domain-immunoglobulin fusion protein, useful for creating a subject having or suspected of having a malignant condition or a B-cell disorder, e.g. melanoma, Grave's disease or autoimmune disease.

Discloure; SEQ ID NO 15; 157pp; English.

The invention relates to a binding domain-immunoglobulin fusion protein comprising a binding domain polypeptide that is fused to an immunoglobulin hinge region polypeptide, an immunoglobulin heavy chain CH2 constant region polypeptide that is fused to the hinge region polypeptide, and an immunoglobulin heavy chain CH3 constant region polypeptide that is fused to the CH2 constant region polypeptide. The hinge region polypeptide comprises: a wild-type human IgG1 immunoglobulin hinge region polypeptide; a mutated human IgG1 immunoglobulin hinge region polypeptide, derived from (a) having 3 or more cysteine residues; where the mutated human IgG1 immunoglobulin hinge region polypeptide contains no more than one cysteine residue; and a mutated human IgG1 immunoglobulin hinge region polypeptide, derived from (a) having 3 or more cysteine residues; where the mutated human IgG1 immunoglobulin hinge region polypeptide contains no more than one cysteine residue; and a mutated human IgG1 immunoglobulin hinge region polypeptide, derived from (a) having 3 or more cysteine residues; where the mutated human IgG1 immunoglobulin hinge region polypeptide contains no more than one cysteine residue. The binding domain-immunoglobulin fusion protein is capable of at least one immunological activity comprising antibody dependent cell-mediated cytotoxicity (ADCC) and complement fixation. The binding domain polypeptide is capable of specifically binding to an antigen. Also included are an isolated polynucleotide encoding the binding domain-immunoglobulin fusion protein, a recombinant expression construct comprising the polynucleotide (operably linked to a promoter), a host cell transformed or transfected with a recombinant expression construct, producing the binding domain-immunoglobulin fusion protein, a pharmaceutical composition comprising the binding domain-immunoglobulin fusion protein or polynucleotide and a carrier, and treating a subject having or suspected of having a malignant condition or a B-cell disorder. The binding domain-immunoglobulin fusion protein is useful for treating a subject having or suspected of having a malignant condition or a B-cell disorder, e.g. melanoma, carcinoma or sarcoma, rheumatoid arthritis, myasthenia gravis, Grave's disease, type I diabetes mellitus, multiple sclerosis or autoimmune disease. The present sequence is a binding domain-immunoglobulin fusion protein-associated protein sequence. Note: The sequence data for this patent formed part of the printed specification and is also available in electronic format directly from USPRO at seqdata.uspto.gov/sequence.html?DocID=20030118592. The authors have not identified the sequences in the printed specification by their SEQ ID number therefore none of the sequences can be explicitly identified.

Sequence 499 AA;

Query Match 52.7%; Score 1271.5; DB 7; Length 499;
Best Local Similarity 56.6%; Pred. No. 6.7e-64;
Matches 275; Conservative 27; Mismatches 93; Indels 91; Gaps 12;

QY 23 TQGNKVVLAGKGDVVELTCTASQKKSIOFHWKNSQIKLNGSFLTKGPKSLNDRADS 82
DB 27 SOSPAILSASPEKVTMTCRASSVS-YVHWYQQR-----GSSPKRWIYAPSNLASGVA 81
QY 83 RSLINDOG-NPFLIIKNLKIEDSDYICVEDOKREVLVGL----- 125
DB 82 RFSGGSGSTYSLLTISRAVEDAATYYC---QQWSFNPTFGAGTKLELDGGSGGCG 137
QY 126 ---TANSDTHLQ-CQSLTLTLESPGSSPVQCR-----SPR----- 159
DB 138 SGGGSSQAYVLOGSAGELV-----RFGASVMSKSCASGTTFTSYMMHWVKQPRGCLMI 192
QY 160 -----GKNIQGGKTLV-----SQLELDGSGTWCTCTVONQKVEFK 196

DB 193 GAIVPGNDTSYNQKFKAKTLTVDKSSSTAYMQLSLTSDSAVYFCARVYVYNSNSWY 252
QY 197 IDI-----VPCAPAEKSCDKHTC-----PELLGGPSVFLPDKKDTLMISRTPEVT 245
DB 253 FQVWGCTGTVTSQGEKSCDKHTCCPCAPAEELGGPSVFLPDKKDTLMISRTPEVT 312
QY 246 CVVVDVSHEDPEVKNVYVDGVEVHNAKTRPREQYNSTYRVSVLTFLVQDMLNGKEYK 305
DB 313 CVVVDVSHEDPEVKNVYVDGVEVHNAKTRPREQYNSTYRVSVLTFLVQDMLNGKEYK 372
QY 306 CKVSNKALPAPIETKISKAGQPREPOVYTLPPSRDELTKQVSLTCLVKGFTYSDIAVE 365
DB 373 CKVSNKALPAPIETKISKAGQPREPOVYTLPPSRDELTKQVSLTCLVKGFTYSDIAVE 432
QY 366 WESNGQPENNYKTPPVLDSDGSPFLYSKLTVDKSRMOQGVFSCVHHEALHNHYTQKS 425
DB 433 WESNGQPENNYKTPPVLDSDGSPFLYSKLTVDKSRMOQGVFSCVHHEALHNHYTQKS 492
QY 426 LSLSPG 431
DB 493 LSLSPG 498

RESULT 77
ABP58275
ID ABP58275 standard; protein; 468 AA.
XX AC
XX ABP58275;
DT 23-OCT-2003 (revised)
DT 31-MAR-2003 (first entry)
XX
DE Humanised 3D6 antibody heavy chain.
XX
KM Monoclonal antibody; 3D6; complementarity determining region; CDR; mouse;
KW human; humanised antibody; antibody; Alzheimer's disease;
XX Down's syndrome; cerebral amyloid angiopathy; neuroprotective; nootropic.
OS Mus sp.
OS Homo sapiens.
OS Chimeric.
XX
FH Key Location/Qualifiers
FT Peptide 1..19
FT Protein 20..468
FT /label=Signal_peptide
FT /label=Mature_peptide
FT /note="the mature heavy chain is claimed in Claim 5"
FT Region 20..138
FT /note="heavy chain variable region, claimed in Claim 4"
FT Region 50..54
FT /note="CDR1"
FT Region 69..85
FT /note="CDR2"
FT Region 118..127
FT /note="CDR3"
XX
PN WO200288306-A2.
XX
XX 07-NOV-2002.
PD 26-APR-2002; 2002WO-US011853.
XX PF
XX 30-APR-2001; 2001US-0287539P.
XX
XX (ELIL) LILLY & CO ELI.
XX
XX Teunushita N, Vasquez M;
XX WPI: 2003-183835/18.
DR N-PSDB; ABZ24633, ABZ24635.
XX
XX New humanized forms of mouse 3D6 antibodies, useful for treating Down's


```

OY 218 ELLGGPSVLEFPPEKPDITMISRTPEVTCVVVDVSHEDPEVKENNYVDGVEVHNAKTPR 277
    |||||
DB 258 ELLGGPSVLEFPPEKPDITMISRTPEVTCVVVDVSHEDPEVKENNYVDGVEVHNAKTPR 317
    |||||
OY 278 EEQYNSTYRVSVLTGLVHODMNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLR 337
    |||||
DB 318 EEQYNSTYRVSVLTGLVHODMNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLR 377
    |||||
OY 338 PERDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTIV 397
    |||||
DB 378 PERDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTIV 437
    |||||
OY 398 DKSRRMOQGNVFCSCVNHGALHNHYTQKSLSLSPG 431
    |||||
DB 438 DKSRRMOQGNVFCSCVNHGALHNHYTQKSLSLSPG 471
    |||||

RESULT 79
AAW01822
ID AAW01822 standard; protein; 476 AA.
XX
AC AAW01822;
XX
DT 17-OCT-2003 (revised)
DT 25-MAY-1997 (first entry)
XX
DE Primatized anti-human B7.1 antigen antibody 16C10 heavy chain.
XX
KW Monoclonal antibody; cynomolgus monkey; macaque; 16C10;
KW primatized antibody; B7 antigen; CD28; immunosuppressive;
KW autoimmune disease; idiopathic thrombocytopenia purpura;
KW systemic lupus erythematosus; rheumatoid arthritis; psoriasis;
KW type 1 diabetes mellitus; graft versus host disease; hetero-hybridoma;
KW transflectoma.
XX
OS Macaca; cynomolgus.
OS Homo sapiens.
OS Chimeric.
XX
PN WO9640878-A1.
XX
PD 19-DEC-1996.
XX
PF 06-JUN-1996; 96WO-US010053.
XX
PR 07-JUN-1995; 95US-00487550.
XX
PA (IDEC-) IDEC PHARM CORP.
XX
PI Anderson DR, Brame P, Hanna N, Shestowsky WS;
XX
DR WPI, 1997-108638/10.
DR N-PSDB; AAT62513.
XX
PT Monkey monoclonal antibody binding human B7.1 or B7.2 antigen - useful
PT for treating auto-immune disease or graft-versus-host disease.
XX
PS Claim 14; Fig 10B; 81pp; English.
XX
CC 2 Polypeptides (AAW01821 and AAW01822) respectively comprise primatized
CC forms of the light and heavy chains of cynomolgus monkey anti-human B7.1
CC antigen monoclonal antibody 16C10. Cloned 16C10 light and heavy variable
CC genes (see also AAT62512 and AAT62513) are inserted into an expression
CC vector (pref. NEOSPLA) which contains human light and heavy chain
CC constant region genes to allow prodn. of the primatized antibody in e.g.
CC CHO cells. Primatized 7C10 and 7B6 anti-B7.1 antibodies have also been
CC produced (see also AAW01817-20). The primatized antibodies inhibit the
CC B7:CD28 pathway, making them useful immunosuppressants for the treatment
CC of autoimmune disorders and graft-versus-host disease. (Updated on 17-OCT
CC -2003 to standardise OS field)
XX
SQ Sequence 476 AA;

```

```

Query Match 52.7%; Score 1271; DB 2; Length 476;
Best Local Similarity 59.8%; Pred. No. 6,86-64;
Matches 274; Conservative 29; Mismatches 87; Indels 68; Gaps 11;

OY 30 LGKKQDITVELICTASQ--KKSIOFHWKNSNQIKLNGQSF-L-TKGPSKLNADRSRRS 85
    |||||
DB 30 LVKSEFTLSLTCAVSGSISGGYGMWIRQPPGKGLMEIGFYSSSGNTYVNPALKSQVT 89
    |||||
OY 86 L---WDQGNFPLIKNLKIEDSDPYICEVEBQKEVQLVPLGFLANDTHLLOQSLLTL 142
    |||||
DB 90 ISTDTSKQFSLKLNSTADTAAYYC-VDRPLFSVVGMY----NNWFDWGPGLVLT 143
    |||||
OY 143 LESPSPSSPYQSCSPKGNIQG-----KTLSSV-----QLEL 176
    |||||
DB 144 VSSASTKGPSVFPLAPSSKSTSGGTALGCLVHDYFPEPVVSMNSGALTISGHTFPAYL 203
    |||||
OY 177 QDSG-----TWCTYVLOQKVEFKIDIVPCPAPESKCDKTHTC-- 216
    |||||
DB 204 QSSGLYSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KKAEPKSCDKTHTCPP 257
    |||||
OY 217 ---PELLGGPSVLEFPPEKPDITMISRTPEVTCVVVDVSHEDPEVKFWMYVDGVEVHNAK 273
    |||||
DB 258 CPAPELLGGPSVLEFPPEKPDITMISRTPEVTCVVVDVSHEDPEVKFWMYVDGVEVHNAK 317
    |||||
OY 274 TKPREEQNSTYRVSVLTGLVHODMNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV 333
    |||||
DB 318 TKPREEQNSTYRVSVLTGLVHODMNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV 377
    |||||
OY 334 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYS 393
    |||||
DB 378 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYS 437
    |||||
OY 394 KLTVDKSRMOQGNVFCSCVNHGALHNHYTQKSLSLSPG 431
    |||||
DB 438 KLTVDKSRMOQGNVFCSCVNHGALHNHYTQKSLSLSPG 475
    |||||

RESULT 80
AAW63765
ID AAW63765 standard; protein; 476 AA.
XX
AC AAW63765;
XX
DT 29-SEP-1998 (first entry)
XX
DE Macaque primatized 16C10 heavy chain protein.
XX
KW Monoclonal antibody; Mab; macaque; heavy chain; primate; antigen; CD80;
KW CD86; inhibitor; immunosuppressant; treatment; autoimmune disease; IL-2;
KW T cell/B cell interaction; tumour; inflammation; imaging agent; vaccine;
KW immunogen; anti-idiotype reagent; interleukin-2; IgG; immunoglobulin G;
KW T cell proliferation.
XX
OS Macaca fascicularis.
XX
PN WO9819706-A1.
XX
PD 14-MAY-1998.
XX
PF 29-OCT-1997; 97WO-US019906.
XX
PR 08-NOV-1996; 96US-00746361.
XX
PA (IDEC-) IDEC PHARM CORP.
XX
PI Anderson DR, Hanna N, Brame P;
XX
DR WPI, 1998-286601/25.
DR N-PSDB; AAV35489.
XX
PT New monoclonal antibodies specific for B7.1 or B7.2 antigens and
PT inhibiting binding to CD28 - useful as specific immunosuppressants for

```



```
QY 217 ---PELLGSPVFLPEPKKDTLMTSRTPETVCVVVDVSHEDPEVKFMYVDGVEVNAK 273
DB 258 CAPELGGSPVFLPPPKKDTLMTSRTPETVCVVVDVSHEDPEVKFMYVDGVEVNAK 317
QY 274 TYPREBOVNSTYRVVSVLTVLHODWLNGKEYCKVSNKALPAPIEKTISKAKGPREPOV 333
DB 318 TYPREBOVNSTYRVVSVLTVLHODWLNGKEYCKVSNKALPAPIEKTISKAKGPREPOV 377
QY 334 YTLPSRDELTKNOVSLTCLVGFYPSDIAVEMESNGOENNYYKTPPLVDSGSPFLYS 393
DB 378 YTLPSRDELTKNOVSLTCLVGFYPSDIAVEMESNGOENNYYKTPPLVDSGSPFLYS 437
QY 394 KLTVDKSRWQGNVSCSVMEHALNHNYTQKSLSPG 431
DB 438 KLTVDKSRWQGNVSCSVMEHALNHNYTQKSLSPG 475

RESULT 82
ADD25787
ID ADD25787 standard; protein; 504 AA.
AC ADD25787;
DT 15-JAN-2004 (first entry)
XX
XX Binding domain-immunoglobulin fusion protein-associated protein #160.
XX
XX Binding domain; immunoglobulin; fusion protein; cyrostatic;
XX antiarthritic; immunosuppressive; antidiabetic; antihypertoid;
XX neuroprotective; hinge region; immunoglobulin heavy chain;
XX CH2 constant region; CH3 constant region; IgG1;
XX antibody dependent cell-mediated cytotoxicity; ADCC; complement fixation;
XX malignant condition; B-cell disorder; melanoma; carcinoma; sarcoma;
XX rheumatoid arthritis; myasthenia gravis; Grave's disease;
XX type I diabetes mellitus; multiple sclerosis; autoimmune disease.
XX
XX Unidentified.
XX
XX US2003118592-A1.
XX
XX PN 26-JUN-2003.
XX
XX PF 25-JUL-2002; 2002US-00207655.
XX
XX PR 17-JAN-2001; 2001US-0367358P.
XX 17-JAN-2002; 2002US-00053530.
XX PR 03-JUN-2002; 2002US-0385691P.
XX
XX PA (GENE-) GENE-CRAFT INC.
XX
XX PI Ledbetter JA, Hayden-Ledbetter MS, Thompson PA;
XX WPI, 2003-801317/75.
XX
XX PT New binding domain-immunoglobulin fusion protein, useful for treating a
XX PT subject having or suspected of having a malignant condition or a B-cell
XX PT disorder, e.g. melanoma, Grave's disease or autoimmune disease.
XX
XX PS Disclosure; SEQ ID NO 348; 157pp; English.
XX
XX CC The invention relates to a binding domain-immunoglobulin fusion protein
XX CC comprising a binding domain polypeptide that is fused to an
XX CC immunoglobulin hinge region polypeptide, an immunoglobulin heavy chain
XX CC CH2 constant region polypeptide that is fused to the hinge region
XX CC polypeptide, and an immunoglobulin heavy chain CH3 constant region
XX CC polypeptide that is fused to the CH2 constant region polypeptide. The
XX CC hinge region polypeptide comprises a wild-type human IgG1 immunoglobulin
XX CC hinge region polypeptide; a mutated human IgG1 immunoglobulin hinge
XX CC region polypeptide; derived from (a) having 3 or more cysteine residues;
XX CC where the mutated human IgG1 immunoglobulin hinge region polypeptide
XX CC contains 2 cysteine residues, where the first cysteine is not mutated; a
XX CC mutated human IgG1 immunoglobulin hinge region polypeptide, derived from
```

```
CC (a) having 3 or more cysteine residues, where the mutated human IgG1
CC immunoglobulin hinge region polypeptide contains no more than one
CC cysteine residue; and a mutated human IgG1 immunoglobulin hinge region
CC polypeptide, derived from (a) having 3 or more cysteine residues; where
CC the mutated human IgG1 immunoglobulin hinge region polypeptide contains
CC no cysteine residues. The binding domain-immunoglobulin fusion protein is
CC capable of at least one immunological activity comprising antibody
CC dependent cell-mediated cytotoxicity (ADCC) and complement fixation. The
CC binding domain polypeptide is capable of specifically binding to an
CC antigen. Also included are an isolated polynucleotide encoding the
CC binding domain-immunoglobulin fusion protein, a recombinant expression
CC construct comprising the polynucleotide (operably linked to a promoter),
CC a host cell transformed or transfected with a recombinant expression
CC construct, producing the binding domain-immunoglobulin fusion protein, a
CC pharmaceutical composition comprising the binding domain-immunoglobulin
CC fusion protein or polynucleotide and a carrier, and treating a subject
CC having or suspected of having a malignant condition or a B-cell disorder.
CC The binding domain-immunoglobulin fusion protein is useful for treating a
CC subject having or suspected of having a malignant condition or a B-cell
CC disorder, e.g. melanoma, carcinoma or sarcoma, rheumatoid arthritis,
CC myasthenia gravis, Grave's disease, type I diabetes mellitus, multiple
CC sclerosis or autoimmune disease. The present sequence is a binding domain
CC -immunoglobulin fusion protein-associated protein sequence. Note: The
CC sequence data for this patent formed part of the printed specification
CC and is also available in electronic format directly from USPTO at
CC seqdata.uspto.gov/sequence.html?DocID=20030118592. The authors have not
CC identified the sequences in the printed specification by their SEQ ID
CC number therefore none of the sequences can be explicitly identified.
```

SQ Sequence 504 AA;

Query Match 52.7%; Score 1271; DB 7; Length 504;

Best Local Similarity 55.0%; Pred. No. 7-26-64;

Matches 282; Conservative 29; Mismatches 92; Indels 110; Gaps 11;

```
QY 1 MNRGVPFRHLILVQLALPRAIQGNKVLAKKQDTVELTCTASQKSIQFN--KNSN 57
DB 19 MSRGVDIQ-----MTQTSSLSASLDRAVTISCRASODIRNLYNMYQOKPDG 65
QY 58 QIKILNGSGSFLTGPKSKNDNRADRSRLMOC-NFLPIIKNLKIEDSDTYICEVDQKE 116
DB 66 TVKLL---IYLT---SRLHSGVPSRFGSGSGGHDVSLTANLPEDATATFCQ----- 112
QY 117 EVQLVFEGLTANSDTHLLOGQSL-----TTLTSP-----GSSPSV 153
DB 113 --QNTLPTWTRGGGTXLTKRELGGSGGGSGGGSIDVVOIQGSPRELVKGASMSC 170
QY 154 QC-----RSPRKNIQ-----GAKTISVSQ----- 173
DB 171 KASGVSTGYIWNMKOSHGNLEWIGLINPYKGLTYYNQFKGKATLTVDKSSSTAYME 230
QY 174 ---LELDGSGWTCVTVLONQKVEFKID-----IYPCAPREPSCDKTHTC-----PE 218
DB 231 LLSLTSEDSAVYYCARSGYGDSDYFDWAGATTVTIVSSDQEPKSCDKTTPCPAPPE 290
QY 219 LLGGSPVFLPPPKKDTLMTSRTPETVCVVVDVSHEDPEVKFMYVDGVEVNAKTKPRE 278
DB 291 LLGGSPVFLPPPKKDTLMTSRTPETVCVVVDVSHEDPEVKFMYVDGVEVNAKTKPRE 350
QY 279 EQYNSTYRVVSVLTVLHODWLNGKEYCKVSNKALPAPIEKTISKAKGPREPOVYTLTP 338
DB 351 EQYNSTYRVVSVLTVLHODWLNGKEYCKVSNKALPAPIEKTISKAKGPREPOVYTLTP 410
QY 339 SRDELTKNOVSLTCLVGFYPSDIAVEMESNGOENNYYKTPPLVDSGSPFLYSKLTVD 398
DB 411 SRDELTKNOVSLTCLVGFYPSDIAVEMESNGOENNYYKTPPLVDSGSPFLYSKLTVD 470
QY 399 KSRWQGNVSCSVMEHALNHNYTQKSLSPG 431
DB 471 KSRWQGNVSCSVMEHALNHNYTQKSLSPG 503

RESULT 83
```

ABP58289 ID ABP58289 standard; protein; 472 AA.
XX AC
XX ABP58289;
XX 23-OCT-2003 (revised)
DT 31-MAR-2003 (first entry)
XX
XX Humanised 10D5 antibody heavy chain.
XX Monoclonal antibody; 10D5; complementarity determining region; CDR;
KW mouse; human; humanised antibody; antibody; Alzheimer's disease;
XX Down's syndrome; cerebral amyloid angiopathy; neuroprotective; nootropic.
OS Mus sp.
OS Homo sapiens.
OS Chimeric.
XX
XX Key Location/Qualifiers
FH Peptide 1..19
FT /label= Signal_peptide
FT 20..472
FT /label= Mature_protein
FT /note= "the mature light chain is claimed in Claim 5"
FT Region 20..142
FT /note= "light chain variable region, claimed in Claim 4"
FT Region 50..56
FT /note= "CDR1"
FT Region 71..86
FT /note= "CDR2"
FT Region 119..131
FT /note= "CDR3"
PN WO200283307-A2.
XX
XX 07-NOV-2002.
PD
XX 26-APR-2002; 2002WO-US011854.
PF
PR 30-APR-2001; 2001US-0287653P.
XX
XX (BLIL) LILLY & CO ELI.
PA
PI Hanton PR, Vasquez M;
DR WPI, 2003-183836/18.
DR N-PADB; ABZ24639, ABZ24641.
XX
XX New humanized 10D5 antibody, useful for the manufacture of a medicament
PT for treating Down's syndrome, clinical or pre-clinical Alzheimer's
PT disease or cerebral amyloid angiopathy.
PS
PS Disclosure; Page 13-15; 52pp; English.

The present sequence is the proteien sequence of the heavy chain of a humanised antibody of the present invention. In the variable portion, the complementarity determining regions (CDRs) originate from murine monoclonal antibody 10D5 and the framework region originates from human germline VH segment DP-28 and J segment JH4. Novel humanised antibodies of the invention have CDRs from 10D5 and human framework sequences. These humanised antibodies have binding affinities (affinity and epitope location) approximately the same as those of the mouse 10D5 antibody. The invention includes antibodies, single chain antibodies, and their fragments, as well as nucleotide sequences, vectors, transformed host cells, and methods of using the humanised antibody to treat, prevent, alleviate, reverse or otherwise ameliorate symptoms and/or pathology associated with Down's syndrome, (pre-)clinical Alzheimer's disease or (pre-)clinical cerebral amyloid angiopathy, and to inhibit formation or reduce A-beta plaque in the brain. (Updated on 23-OCT-2003 to standardise OS field)

Sequence 472 AA:
XX

Query Match	Similarity	52.6%	Score 1270.5	DB 6	Length 472
Best Local Match	Conservative	27	Mismatches 100	Indels 73	Gaps 11
Query	10	LLVLVLQALDPAAT--QGNKVLGKGGDVELTCTAS---- <td>64</td> <td></td> <td></td>	64		
Db	9	LLLIIVAVLVLSQVTLKESGFLVVKPTEITLTITCTFSGESLSTSGMGVSMIRQPGKALEM	68		
Query	65	QGSFLTKGPSKLNDRADSRSL--WDQGNFPLIKKLIKEDSDTYICEVDQKEVQLL	121		
Db	69	LAHIYWDGDKRYNPSLKSRITFTISKDTSKSGVLLMTMMDPVDATATYCV--RRPIIPVL	125		
Query	122	VFGLTASDTHLLOQGSITLTLSEPPSSPSVQCRSPRGKNIQGG-----KT	168		
Db	126	V-----DAMDYWGQGTLLVTVSSASTKGPSVFPELAPSSKSTSGTAALGCLVDPPEP	178		
Query	169	LSVS-----QLELDQSG-----TWTCVVLQNKQKVEFKI	197		
Db	179	VTVSMNSGALTVSGVHTPPRAVLQSSGLYSLSLVTVVPSSSLGTQYIICNV--NHKPSNTKV	236		
Query	198	DIVPCAPAEPSKCDKTHTC-----PELIGPSVLEFPKPKDITLMISRTPEVTCVVVDVS	252		
Db	227	D-----KKYEPKSCDKHTCCPCAPPELLGSPSVLPPPKPKDITLMISRTPEVTCVVVDVS	292		
Query	253	HEDEPVAKNMYVDGVEVHNNAATKREBEQYNSTRVSVLYLVHODMLNGEKYKCKVSNKA	312		
Db	293	HEDEPVAKNMYVDGVEVHNNAATKREBEQYNSTRVSVLYLVHODMLNGEKYKCKVSNKA	352		
Query	313	LPAPLEKTIKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQP	372		
Db	353	LPAPLEKTIKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQP	412		
Query	373	ENNYKTPRPVLDSDGSEFFLYSKLTVDXSRMQGVFSCVNHGALAHNYTQKSLSPG	431		
Db	413	ENNYKTPRPVLDSDGSEFFLYSKLTVDXSRMQGVFSCVNHGALAHNYTQKSLSPG	471		
RESULT 84					
AAB81987					
ID	AAB81987	standard; protein; 582 AA.			
AC	AAB81987;				
DT	03-JUN-2001	(first entry)			
DE	Ganglioside GD3 specific antibody related protein SEQ ID NO: 53.				
XX	Ganglioside; GD3; complementarity determining region; CDR; antibody;				
KM	Cancer.				
XX	Synthetic.				
OS	WO200123432-A1.				
PN	05-APR-2001.				
PD	29-SEP-2000; 2000WO-JP006774.				
XX	30-SEP-1999; 99JP-00278291.				
PR	06-APR-2000; 2000JP-00105088.				
XX	(KYOW) KYOWA HAKKO KOGYO KK.				
PA	Hanai N, Shitara K, Nakamura K, Niwa R;				
XX	WPI; 2001-266143/27.				
DR	New human type complementation-determining region-transplanted antibody				
PT	and derivatives against ganglioside GD3, useful in diagnosis and therapy				
PT	of e.g. tumors, with low antigenicity, little side effects but potent				
PT	activity in cancer.				
XX	Claim 41; Page 168-172; 183pp; Japanese.				

```

XX CC The present invention describes a monoclonal antibody which can react
CC specifically with ganglioside GD3. The antibody and its derivatives are
CC useful in the diagnosis and therapy of tumours, particularly cancer
CC diagnosis. The present sequence is a protein used in the exemplification
CC of the invention
XX
SQ Sequence 582 AA;
XX
Query Match 52.6%; Score 1270; DB 4; Length 582;
Best Local Similarity 61.0%; Pred. No. 9.5e-64;
Matches 271; Conservative 26; Mismatches 57; Indels 90; Gaps 12;
QY 63 GNGSFLT---KGPSRLNDRADSRSLMDQGNFPLIKKLIKEDSPDYICEVEDQKEEYQ 119
DB 54 GSGSYTSDSVKGRFITS-RDMSKNTLY-----LQMSLRADSDAVYFC-----TRVK 100
QY 120 LLVFGILTANSDTHLLOGSLTTLTLESPPSSSPSVOCRSFRKNTQGG----- 166
DB 101 LCTYVFDS-----WGQCTLLTVSSASTKGPSVFLPAPSSKSTSGTALGLVQDYFP 153
QY 167 KTLTSSV-----QLELDQSG-----TWCTVQONKQYEF 195
DB 154 ERYTVSSMNSGALTSGVHTPRPAVLQSSGLYSLSSVTVTPSSSLGTOTYICNV--NHKPSNT 211
QY 196 KIDIVPCPAPBPKSCDKHTC-----PELLGSPSVFLPFPKPKDTLMTSRTEPVCVVD 250
DB 212 KYD---KVEPKSCDKHTCPCPAPBELLGSPSVFLPFPKPKDTLMTSRTEPVCVVD 267
QY 251 VSHEDPEVKFNMYVDGVEVNAKTKPREQYNSTRVSVTLVLDQWLNKGYCKRYN 310
DB 268 VSHEDPEVKFNMYVDGVEVNAKTKPREQYNSTRVSVTLVLDQWLNKGYCKRYN 327
QY 311 KALPAPIEKTISKAKQPREPOVYTLPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNG 370
DB 328 KALPAPIEKTISKAKQPREPOVYTLPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNG 387
QY 371 QENNNYKTTTPVLDSDGSFFLYSKLTVDKSRMQQGNVFCSVNHEALNHYTKSLISLP 430
DB 388 QENNNYKTTTPVLDSDGSFFLYSKLTVDKSRMQQGNVFCSVNHEALNHYTKSLISLP 447
QY 431 G-----LQLEDFCAEAQ 442
DB 448 GRAPTSSSTKKTQLQLEHLLDLQ 471
XX
RESULT 85
AAU87089
ID AAU87089 standard; protein; 619 AA.
XX
AC AAU87089;
XX
DT 05-JUN-2002 (first entry)
XX
DE Siglec-BMS-L3a-hlg fusion protein (Siglec-BMS-L3a-hlg).
XX
KW Human; sialic acid-binding Ig-related lectin; SIGLEC; asthma;
KW immune system disease; leukaemia; allergy; inflammatory disease;
KW tissue damage; allergic rhinitis; osteoarthritis; Crohn's disease;
KW psoriasis; rheumatoid arthritis; conjunctivitis.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200208257-A2.
XX
PD 31-JAN-2002.
XX
PF 20-JUL-2001; 2001WO-US023082.
XX
PR 21-JUL-2000; 2000US-0220139P.
XX
PA (BRIM ) BRISTOL-MYERS SQUIBB CO.

```

```

XX PI Longphre M, Chang H, Whitney G;
XX DR MPI: 2002-241565/29.
XX DR N-PSDB; ABK43375.
XX
PT Novel isolated SIGLEC (sialic acid-binding Ig-related lectin) protein
PT molecules useful for treating immune system diseases such as asthma,
PT leukaemia, allergic rhinitis, psoriasis, conjunctivitis, Crohn's disease.
XX
PS Example 11; Fig 23; 209pp; English.
XX
CC The invention relates to an isolated SIGLEC (sialic acid-binding Ig-
CC related lectin) protein (I). Pharmaceutical compositions comprising (I)
CC are useful for treating immune system diseases such as asthma, leukaemia
CC or other allergic or inflammatory diseases. Extracellular domains of (I)
CC represent potential markers for screening, diagnosis, prognosis, follow-
CC up assays, and imaging methods. (I) is useful as a target for drugs which
CC inhibit inflammation, tissue damage and remodeling in asthma, and
CC inflammatory diseases such as allergic rhinitis, osteoarthritis, Crohn's
CC disease, psoriasis, rheumatoid arthritis, conjunctivitis, etc. (I) is
CC also useful for monitoring the course of disease or disorders, and for
CC identifying agents that bind with and/or modulate the biological activity
CC of SIGLEC-BMS proteins. The nucleic acid molecules (II) encoding (I) are
CC useful in diagnosis and/or prognosis methods, and to detect the presence
CC and/or amount of SIGLEC-BMS nucleotide sequences and/or SIGLEC-BMS
CC proteins in a biological sample. (II) are useful as nucleic acid probes
CC are useful for screening genomic library to isolate a genomic clone of
CC SIGLEC gene. SIGLEC-BMS gene copy number is determined for detecting
CC diseases or disorders associated with SIGLEC-BMS transcripts or proteins.
CC The SIGLEC-BMS antibodies are also used to detect, sort or isolate cells
CC expressing SIGLEC-BMS proteins and in diagnostic imaging technology.
CC AAU87074-AAU87089 represent human SIGLEC amino acid sequences of the
CC invention
XX
SQ Sequence 619 AA;
XX
Query Match 52.6%; Score 1270; DB 5; Length 619;
Best Local Similarity 57.8%; Pred. No. 1e-63;
Matches 273; Conservative 27; Mismatches 90; Indels 82; Gaps 11;
QY 8 RHLLIVQLALPR---ATQGNKVVL-GKKGDVLTCTNQSOKKSIOFHWKNSQIKILG 63
DB 181 RDLVISISRDNTPALREPOGNVYFLAOKQGFRLICADSDPPATLSW----- 230
QY 64 NQGSFLTKGPSKLNDRADSRSLMDQGNFPLIKKLIKEDSPDYICEVEDQ----- 114
DB 231 -----VLQNRVLISSHPGPRPLGELRGVARGDSGRYTCRAENLISGQORALD 279
QY 115 -----KEEVQLVLF-----GLTANSDTHLLOGSLTL---TLSPGSSSPVOCRS 157
DB 280 LSYQYPPENLAKVWVSQANRTVLENLGNGTSLPVLEGSLCLVCYTHSSPRA----- 330
QY 158 PRKNITQGGKTLISQ-----LELDQSGTWCTTVLQ--NOKKVEFKIDIVPCA 204
DB 331 -RLSMTORGVLTSPSPQSDPGLVLPVQVYEHGEFCTHARHPVLSQHSVLSLV---HD 386
QY 205 PEPSCKDTHC-----PELLGSPSVFLPFPKPKDTLMTSRTEPVCVVDVSHEDPEVK 259
DB 387 PEPSCKDTHCPCPAPBEPGAPSVFLPFPKPKDTLMTSRTEPVCVVDVSHEDPEVK 446
QY 260 FMYVVDGVEVNAKTKPREQYNSTRVSVTLVLDQWLNKGYCKRYNKAAPAPIEK 319
DB 447 FMYVVDGVEVNAKTKPREQYNSTRVSVTLVLDQWLNKGYCKRYNKAAPAPIEK 506
QY 320 TISRAKQPREPOVYTLPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQENNYKTT 379
DB 507 TISRAKQPREPOVYTLPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQENNYKTT 566
QY 380 PPVLDSDGSFFLYSKLTVDKSRMQQGNVFCSVNHEALNHYTKSLISLSPG 431
DB 567 PPVLDSDGSFFLYSKLTVDKSRMQQGNVFCSVNHEALNHYTKSLISLSPG 618

```

```

RESULT 86
ABB99224
ID ABB99224 standard; protein; 448 AA.
XX
AC ABB99224;
XX
DT 05-DEC-2002 (first entry)
XX
DE Chimeric CD45RO/RB binding molecule heavy chain.
XX
KW Human; CD45; CD45RO; CD45RB; binding molecule; CDR1; CDR2; CDR3;
KM immunosuppressive; antiportatic; antiinflammatory; antiallergic;
KM CD45-Antagonist; autoimmune disease; transplant rejection; psoriasis;
KM inflammatory bowel disease; allergy; heavy chain.
XX
OS Homo sapiens.
OS Unidentified.
XX
FH Key Location/Qualifiers
FT Region 31..35
FT /label= CDR1
FT Region 50..66
FT /label= CDR2
FT Region 99..107
FT /label= CDR3
XX
PN WO200272832-A2.
XX
PD 19-SEP-2002.
XX
PF 11-FEB-2002; 2002WO-EP001420.
XX
PR 12-FEB-2001; 2001GB-00003389.
XX
PA (NOVS ) NOVARTIS AG.
XX (NOVS ) NOVARTIS-ERFINDUNGEN VERW GES MBH.
XX
PI Avera G, Kolbinger F, Carballido Herrera JM, Aszodi A;
PI Saldanha JM, Hall BM;
XX
DR WPI; 2002-723357/78.
XX
PT New binding molecule having at least one antigen binding site, useful as
PT a pharmaceutical in the treatment of autoimmune diseases, transplant
PT rejection, psoriasis, inflammatory bowel disease and allergies.
XX
PS Claim 5; Page 31; 67pp; English.
XX
CC The invention relates to a novel binding molecule comprising at least one
CC antigen binding site comprising in sequence the hypervariable regions
CC CDR1, CDR2 and CDR3. The molecule of the invention has immunosuppressive,
CC antipsoriatic, antiinflammatory, and antiallergic activity. The molecule
CC of the invention is a CD45-Antagonist. The binding molecule or humanised
CC antibody is useful as a pharmaceutical in the treatment of autoimmune
CC diseases, transplant rejection, psoriasis, inflammatory bowel disease and
CC allergies. The binding molecule has a binding specificity for both CD45RO
CC and CD45RB in medicine, where the binding molecule is a chimeric, a
CC humanised or a fully human monoclonal antibody. The sequence represents
CC the heavy chain of the CD45RO/RB binding molecule
XX
SQ Sequence 448 AA;

```

```

Db 64 FGGRATLTADKSNATAYMDLSLTSBDAIYYCARSS-----GPYAWFDI---WG 109
Qy 137 QSLTTLTLESPPGSSPSVQCRSPRGKNIQGG-----KILSVS----- 172
Db 110 QGTTVTWSSASTKGPSPVFLAPSSKSTSGTALGCLVKDYRPEPVYVSWNSGALTSQVH 169
Qy 173 --QLELDSSG-----TWTCVQLONOKKVEFKIDIVCPAPEPKSCDK 212
Db 170 TRPAVLQSSGLYSLSSVTVTPSSSLGTQYICNV--NKPSTKVD---KVEPKSCDK 223
Qy 213 THTC-----PELLGSPVFLPPPKPXDLMISRTBEVTCVVDVSHEDBEVFNMYDGV 267
Db 224 THTCPCPAPPELLGGPSVFLPPKPDLMISRTBEVTCVVDVSHEDBEVFNMYDGV 283
Qy 268 EYHNKTKRERQYNSTRVSVLVTLVHODMLNGKYEKKVSNKALPAIEKTISSAKQ 327
Db 284 EYHNKTKRERQYNSTRVSVLVTLVHODMLNGKYEKKVSNKALPAIEKTISSAKQ 343
Qy 328 PREPOVYTLPPSRDELTKQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTPPVLDSDG 387
Db 344 PREPOVYTLPPSRDELTKQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTPPVLDSDG 403
Qy 388 SFFLYSKLTVDKSRMQQGNVFSQVHEBALHNNHYTQKSLSPG 431
Db 404 SFFLYSKLTVDKSRMQQGNVFSQVHEBALHNNHYTQKSLSPG 447

RESULT 87
AA94408
ID AA94408 standard; protein; 744 AA.
XX
AC AA94408;
XX
DT 11-SEP-2000 (first entry)
XX
DE Human VCAM-1/IgG1-Fc fusion protein.
XX
KW Human; cellular adhesion molecule; ACAM; noctropic; anti epileptic;
KW neuroleptic; renal-active; antidiabetic; neuroactive; neuroprotectant;
KW dementia; epilepsy; schizophrenia; peripheral nerve injury;
KW diabetic neuropathy; fusion protein.
XX
OS Homo sapiens.
XX
PN WO200032633-A1.
XX
PD 08-JUN-2000.
XX
PF 02-DEC-1999; 99WO-US028878.
XX
PR 02-DEC-1998; 98US-00203462.
XX
PA (ICOS-) ICOS CORP.
XX
PI Hoekstra DM, Loughney K, Stauton DE, Vazeux R;
XX
DR WPI; 2000-422952/36.
XX N-PSDB; AAA30442.
XX
PT Nucleic acids encoding ACAM, a human cellular adhesion molecule, useful
PT for diagnosing, preventing and treating diseases associated with ACAM
PT expression and activity, e.g. epilepsy and schizophrenia.
XX
PS Example 5; Page 174-176; 187pp; English.
XX
CC The present sequence is a fusion protein comprising part of human VCAM-1
CC and the Fc region of human IgG1. The sequence encoding this protein was
CC generated by integrating the VCAM-1 coding region into a plasmid
CC designated pDEF24/IgG1, which encodes the hinge and constant CH2-CH3
CC domains of human IgG1. The sequence was then ligated to the expression
CC vector pDEF24 and transformed into DH5a competent cells. The fusion
CC protein was used as a control in adhesion experiments involving
CC ACAM#4/IgG-Fc and ACAM#6/IgG4-Fc fusion proteins. ACAM#4 and ACAM#6 are

```



```

CC human foetal brain cDNA clones containing alternatively spliced full-
CC length variants of a novel adhesion molecule designated ACAM. ACAM
CC nucleic acids and polypeptides may be used in the prevention, treatment
CC and diagnosis of diseases associated with inappropriate ACAM expression
CC and activity such as dementia, epilepsy, schizophrenia, peripheral nerve
CC injuries and diabetic neuropathies. They may be used to rectify mutations
CC or deletions in a patient's genome that affect the activity of ACAM or to
CC supplement insufficient ACAM production in a patient. Conversely,
CC antisense nucleic acid molecules may be administered to down-regulate
CC ACAM expression. The nucleotide sequence may also be used as a DNA probe
CC in diagnostic assays (e.g. PCR) to detect and quantitate the presence of
CC similar nucleic acid sequences in samples, and hence determine which
CC patients may be in need of restorative therapy. ACAM polypeptides may be
CC used as antigens in the production of antibodies against ACAM and in
CC assays to identify modulators (agonists and antagonists) of ACAM
CC expression and activity
CC
XX
SQ Sequence 744 AA;
Query Match 52.6%; Score 1269.5; DB 3; Length 744;
Best Local Similarity 59.1%; Pred. No. 1.3e-63;
Matches 264; Conservative 38; Mismatches 65; Indels 80; Gaps 11;
QY 34 GTTVELTCTASQKSIQFHWKNSNQIKILGNQSFUTKGPSTKLNDRADSRRLMGNFP 93
DB 328 GDSVMLTCSVMGCESPSFSWR-----TQIDSPLSGKVSSEGT-----NST 367
QY 94 LIIKMLKIEDSDTYICEV-----EDQKEVQLLVFGLTANSDPHILQGGSLTTLSPPGS 149
DB 368 LTLSPVSPFENHSLCTVTCGHKLEKGIQVELISPPRDELLEMGG-----LVNGS 419
QY 150 SPSPVQCRSP-----RGNKIQGG-----KTLVSQLE-----LQDSG- 180
DB 420 STVASCCKVSVYPLDRLEIEILKGETILNIFLEDTDKMSLENSLMTFTPTIEDGK 479
QY 181 TTTCTVQLNQKQKVERK-----IDIVCPAPPEPSCKTTC-----PELLGGS 224
DB 480 ALVCAKALHIDMEFEPRKOROSTQTLVYNAVAV---DPKSCDKTHTCPCPAPPELLGGS 536
QY 225 VFLPPPKDQTLMIISTPEVTCVVDVSHEDPEVKFNWVDVVEVHNAKTKRREQVNST 284
DB 537 VFLPPPKDQTLMIISTPEVTCVVDVSHEDPEVKFNWVDVVEVHNAKTKRREQVNST 596
QY 285 YRVSVSLTVLHODWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL 344
DB 597 YRVSVSLTVLHODWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL 656
QY 345 KQVNSLTCLVKGFIYPSDIAVWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRMQ 404
DB 657 KQVNSLTCLVKGFIYPSDIAVWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRMQ 716
QY 405 GNVFSCSVMEHALHNHYTOKSLSLSPG 431
DB 717 GNVFSCSVMEHALHNHYTOKSLSLSPG 743
RESULT 88
ABBB2300
ID ABBB2300 standard; protein; 634 AA.
XX ABBB2300;
XX
XX 22-JAN-2003 (first entry)
XX
XX CD19:zeta chimeric immunoreceptor.
XX
XX CD19; chimeric; CD19:zeta; cytosolic; immunosuppressive; CD4;
XX antiarthritic; antiinflammatory; gene therapy; CD8; immunotherapy.
XX
XX Synthetic.
XX Homo sapiens.
XX
XX Key Location/Qualifiers

```

```

FT Peptide 23..634
FT /note= "specifically claimed fragment"
XX
XX MO200277029-A2.
XX
XX 03-OCT-2002.
XX
XX 07-NOV-2001; 2001WO-US042997.
XX
XX 07-NOV-2000; 2000US-0246117P.
XX
XX (CITY ) CITY OF HOPE.
XX
XX Jensen MC, Forman S, Raubitschek A;
XX WPI: 2003-01888/01.
XX N-PSDB; ABV73341.
XX
XX Genetically engineered CD19-specific immune cells, useful for cellular
XX immunotherapy of CD19 malignancies and for abrogating any untoward B cell
XX function in autoimmune disorders such as lupus or rheumatoid arthritis.
XX
XX Claim 12; Fig 1A-C; 8pp; English.
XX
XX The invention relates to genetically engineered CD19-specific immune
XX cells which express, and bear on the cell surface membrane, a CD19-
XX specific chimeric receptor. The CD19-specific chimeric T cell receptor
XX consists of: (a) an intracellular signaling domain selected from zeta,
XX eta, delta, gamma or epsilon chain of CD3, MB1 chain, B29, FcgammaRIII
XX and FcgammaRIIIc, for an effector function of the immune cell; (b) at
XX least 1 transmembrane domain and (c) at least 1 extracellular domain
XX comprising a CD19-specific receptor. The compositions and methods of the
XX present invention are useful for cellular immunotherapy of CD19
XX malignancies and for abrogating any untoward B cell function in
XX autoimmune disorders such as lupus or rheumatoid arthritis. The present
XX sequence represents a CD19:zeta chimeric immunoreceptor amino acid
XX extension and consists of human GM-CSF receptor alpha chain leader
XX peptide, FMC63 Vh, Gly-Ser linker, FMC63 Vh, human IgG1 FC, human CD4
XX transmembrane domain and human cytoplasmic zeta chain
XX
SQ Sequence 634 AA;
Query Match 52.5%; Score 1268; DB 6; Length 634;
Best Local Similarity 56.2%; Pred. No. 1.3e-63;
Matches 287; Conservative 28; Mismatches 94; Indels 102; Gaps 16;
QY 10 LLVVLQAL--LP-----AATGAKVVLGKKGDVYELTTASQKSIQFHW---K 54
DB 2 LLVTVSLTLCFLPPAPFLIPDIQMTQTSLSASLSDRYTISCRASODISKYLNWQOK 61
QY 55 NSNQGKILGNGSGFLTKG-PSKLNDRADSRRLSDQGNFPLIINKLIEDSDTYICEVED 113
DB 62 PDGTVKLLIYTHSRHSGVSPRFSGSGST-----DYSLTINLEQEDATATFCQGN 114
QY 114 QKE-----EVQLVFGLTANSDTHLQGGSLT-----LTLESPPG-----SSPSVQC----- 155
DB 115 TLPTFGGKTLBITGTSYSGKP-GSGEGSTKEVNLQESGPELVAPSGSLSTCTVSG 173
QY 156 -----RSPRGKNIQ-----GKLT-----LSVSOLE 175
DB 174 VSLPDYGVSWIRQPPRKGLEWLVGIWGSSETTYNSALKSRLLTIKNSKSGVFLKMSLQ 233
QY 176 LQDSGWTCTVQLNQKQK---EFKIDI-----VPCPAPPEPSCKTHTC-----PELL 220
DB 234 TDDTAIYYCA-----KHYTGGSTAMDYWGQGSIVTSSVEPSSDKTHTCPPCPAPELL 288
QY 221 GGPSPVFLPPPKDQTLMIISTPEVTCVVDVSHEDPEVKFNWVDVVEVHNAKTKRREQ 280
DB 289 GGPSPVFLPPPKDQTLMIISTPEVTCVVDVSHEDPEVKFNWVDVVEVHNAKTKRREQ 348
QY 281 YNSTYRVSVSLTVLHODWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR 340

```


Dd		349	VNSTRTAVSVLTIVLHQDMLNGEYKCKRSNKALPAPIETKTISKAGQPREPOVYLTPPER	408
Oy		341	DELTKNQVSLTFLVKGFYPSPDIAVEMESNGPENNYKTTPTVLDSGSEFLLYSKLTVDKS	400
Dd		409	DELTGNQVSLTCLVKGFPYPSDIIVEMESNGPENNYKTTPTVLDSGSEFLLYSKLTVDKS	468
Oy		401	RWQGQNVFSCSVMEHALNHHTYQKSLSLSPG	431
Dd		469	RWQGQNVFSCSVMEHALNHHTYQKSLSLSPG	499
 RESULT 89				
ID	ABR39465	standard; protein; 442 AA.		
AC	ABR39465;			
XX				
DT	12-JUN-2003	(first entry)		
DE	Humanised anti-Abeta antibody 266 heavy chain.			
XX				
KM	Amyloid-beta; Abeta; antibody 266; neurotropic; neuroprotective; CDR;			
KW	immunostimulant.			
XX				
OS	Homo sapiens.			
PN	WO2003016467-A2.			
PD	27-FEB-2003.			
XX				
PF	14-AUG-2002; 2002MO-US021324.			
PR	17-AUG-2001; 2001US-0313576P.			
PR	28-MAY-2002; 2002US-0383851P.			
XX				
PA	(ELIL) LILLY & CO ELI.			
P1	Bales KR, Paul SM,			
XX				
DR	WPI; 2003-289975/28.			
XX				
PT	Treating or reducing the progression of diseases associated with amyloid-			
PT	beta peptide, e.g. Alzheimer's disease, vascular dementia or mild			
PT	cognitive impairment, comprises administering an anti-amyloid-beta			
PT	peptide antibody.			
XX				
BS	Disclosure; Page 20-22; 84pp; English.			
CC	The invention relates to creating cognitive symptoms or reducing disease			
CC	progression in a subject having a condition or disease associated with			
CC	amyloid-beta peptide (Abeta). The method involves administering an amount			
CC	of an anti-Abeta antibody that has greater affinity for soluble Abeta			
CC	than 10 ⁻⁹ M, that has affinity (KD) for soluble Aβeta1-40 or Aβeta1-42			
CC	higher than 10 ⁻⁹ M, or that has greater affinity for soluble Aβeta1-42			
CC	antibody 266 has. The method or the anti-Abeta antibody is useful in			
CC	preparing a medicament for treating cognitive symptoms or reducing			
CC	disease progression in a subject having a condition or disease associated			
CC	with Aβeta. The condition or disease is Alzheimer's disease, Down's			
CC	syndrome, cerebral amyloid angiopathy, vascular dementia, or mild			
CC	cognitive impairment. The present sequence represents a humanised anti-			
CC	Aβeta antibody 266 heavy chain			
XX				
SQ	Sequence 442 AA;			
 Query Match 52.5%; Score 1267.5; DB 6; Length 442; Best Local Similarity 59.1%; Pred. No. 9, 9e-64; Matches 274; Conservative 26; Mismatches 69; Indels 95; Gaps 13				
Oy	30	LGGKDDTYLVCTTAS--OKSKIOPHNKN-----NQIKLGNQSF--LTGPSKL	76	
Dd	11	LVQPQGSRLTSCASGFTTSRSMSVMWRAPGKGLVLAQINSVGNSITYYPTDVKKRPFI	70	
Oy	77	NDRASRRSLWDQGNFPLIIKNLKIEDSDTYICEVEDKEEVOLLVFGLTANSDFHLLQG	136	

Ds	71	S-DNNAKNTLYLQMN-----SLRADDAVYYC-----ASGD---YWG	103
Qy	137	QSLTLTLESPPGSSPSPQCRSPRGKNIQSG-----KTLSSVS-----	172
Ds	104	QGLTVTVSSASSTKGPSPVPLPLASSKSTSGTAAALGCLVKQYFPPRPTVYSNMNSGALTSGVH	163
Qy	173	--OLEIQDSG-----TWCTVLQONQKVEFKIDIVPCPAPEPKSCDK	212
Ds	164	TPPAVLQSSGLSYLSLSSVTVTPSSSLGTOTYICNV--NHKPSANTKYD---KKEVPEKSCDK	217
Qy	213	THHC-----PELLGSSVFLFPKPKDITLMSRPEVTCVVVDVSHDDPEVKKFMMWYDGV	267
Ds	218	THCTPCPAPELLGGSSVFLFPPKPKDITLMSRPEVTCVVVDVSHDDPEVKKFMMWYDGV	277
Qy	268	EYVNAKTKPREEOYNSTYRVSVLVTVLIHODMNLGKEYCKCSKNALPAPIEKTISKAKGQ	327
Ds	278	EYVNAKTKPREEOYNSTYRVSVLVTVLIHODMNLGKEYCKCSKNALPAPIEKTISKAKGQ	337
Qy	328	PREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPVLDSDG	387
Ds	338	PREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPVLDSDG	397
Qy	388	SFFLYSKLTVDYKSRMQGVSCSVMEHRLNHNHTYQKSLSLSPG	431
Ds	398	SFFLYSKLTVDYKSRMQGVSCSVMEHRLNHNHTYQKSLSLSPG	441
RESULT 90			
ID	ABU08311	standard; protein; 442 AA.	
AC	ABU08311;		
DT	22-MAY-2003	(first entry)	
DE	Humanised 266 antibody heavy chain.		
XX			
XX			
KM	Mouse; cognition; Abeta peptide associated disorder; anti-Abeta antibody;		
KM	cognitive impairment; Alzheimer's disease; Down's syndrome;		
KM	cerebral amyloid angiopathy; vascular dementia; neurotropic; neurotropic;		
KM	mild cognitive impairment; antibody 266; heavy chain; humanised; mutant;		
XX	mutelin.		
XX			
OS	Mus sp.		
OS	Synthetic.		
XX			
XX	WO2003015691-A2.		
XX			
PD	27-FEB-2003.		
XX			
PE	14-AUG-2002; 2002MO-US021323.		
XX			
XX	17-AUG-2001; 2001US-0313222P.		
PR	28-MAY-2002; 2002US-0383846P.		
XX			
PA	(EIL) LILLY & CO ELI.		
XX			
PI	Bales KR, Dodart JF, Paul SM;		
XX			
DR	WPI; 2003-268234/26.		
XX			
PT	Effecting rapid improvement of cognition in a subject having Alzheimer's		
PT	disease, Down's syndrome, cerebral amyloid angiopathy, or mild cognitive		
PT	impairment, comprises administering anti-A beta antibody.		
XX			
PS	Disclosure; Page 21-23; 85pp; English.		
CC	The present invention relates to a method for effecting rapid improvement		
CC	of cognition in a subject having a condition or disease related to the		
CC	Abeta peptide. The method comprises administering an anti-Abeta antibody.		
CC	The method is useful for treating cognitive impairments associated with		
CC	Abeta peptide including those involved in Alzheimer's disease, Down's		

CC syndrome, cerebral amyloid angiopathy, certain vascular dementia, and
 CC certain forms of mild cognitive impairment. The anti-beta antibody is
 CC useful for preparing a medicament for effecting rapid improvement in
 CC cognition in a subject having Alzheimer's disease, Down's syndrome,
 CC cerebral amyloid angiopathy, or mild cognitive impairment. The present
 CC sequence represents a preferred heavy chain for a humanised 266 antibody
 XX
 SQ Sequence 442 AA;

Query Match 52.5%; Score 1267.5; DB 6; Length 442;

Best Local Similarity 59.1%; Pred. No. 9.9e-64;

Matches 274; Conservative 26; Mismatches 69; Indels 95; Gaps 13;

```

QY 30 LGKGDVVELTCTAS--QKSIQPHWKN-----NQIKLGNQGSF--LTKGPSKL 76
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 11 LVQPGSLRLSCAASGFTSRYSMSWVRQAPGKGLVLAQINSVGNSTYYPDTYKGRFTI 70
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 77 NDRADSRRLMDQGNFPLIIKLIKEDSDTYICEVEDQKEVQLVFGLTANSPTHLLOG 136
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 71 S-RDNAKNTLYLQMN-----SLRAEDTAVYYC-----ASGD---YWG 103
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 137 QSLTLTLESPPGSSPVQCRSPRGKNIQGS-----KTLVS----- 172
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 104 QGTLVTSSASTKGPSVFPPLAPSSKSTSGTALGCLVKDYRPPPTVSMNSGALTSGVN 163
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 173 --QLELDSG-----TWCTVLQNOKKVEFKIDIVCPAPRPSCKD 212
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 164 TTPPAVLQSSGLVSLSSVTPVSSSLGTQTYICNV--NHKPSNTKVD---KVEPRKSCDK 217
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 213 THTC-----PELLGSPSVLPFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFMYVDGV 267
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 218 THTCPPCPAPPELLGSPSVLPFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFMYVDGV 277
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 268 EVHNAKTKPREEOYNSTYRVVSVLTVLDHQMNLNGEKYCKVSNKALPAPIEKTIISKAKGQ 327
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 278 EVHNAKTKPREEOYNSTYRVVSVLTVLDHQMNLNGEKYCKVSNKALPAPIEKTIISKAKGQ 337
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 328 PREPOVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTTPVLDSDG 387
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 338 PREPOVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTTPVLDSDG 397
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 388 SFPLYSKLTVDKSRMQGNVFGSCVMHEALHNHTYQKSLSLSPG 431
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 398 SFPLYSKLTVDKSRMQGNVFGSCVMHEALHNHTYQKSLSLSPG 441
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|

```

RESULT 91

ID ABB80109 standard; protein; 442 AA.

AC ABB80109;

DT 13-JUN-2003 (first entry)

DE Heavy chain.

XX Complementary determining region; CDR; humanised; mouse; 266; light;

KM heavy; variable; domain; antibody; preclinical; clinical;

KM Alzheimer's disease; epitope; amyloid beta peptide; Abeta;

XX central nervous system; plasma.

OS Homo sapiens.

XX Mus musculus.

PN WO2003015617-A2.

PD 27-FEB-2003.

PF 16-AUG-2002; 2002WO-US026321.

PR 17-AUG-2001; 2001US-031322P.

PR 17-AUG-2001; 2001US-031322P.

PR 23-OCT-2001; 2001US-0334987P.

XX (UNIT) UNIV WASHINGTON.
 PA (ELI) LILLY & CO ELI.
 XX
 PI Holtzman DM, Dematos R, Bales KR, Cummins DJ, Paul SM;
 XX WPI; 2003-278505/27.

XX
 DR
 PT diagnosing preclinical or clinical Alzheimer's disease in a subject by
 XX administering an antibody which specifically binds an epitope.

XX Disclosure; Page 15-16; 64pp; English.

XX The sequences given in AAG80104-09 represent preferred antibodies of the
 CC invention. This sequence represents the preferred heavy chain. The
 CC humanised antibody of the invention may be used for diagnosing
 CC preclinical or clinical Alzheimer's disease. The antibody specifically
 CC binds an epitope, preferably the amyloid beta peptide (Abeta). The
 CC antibodies sequester Abeta from its bound, circulating form in blood and
 CC alter clearance of soluble and bound forms of Abeta in central nervous
 CC system and plasma. The antibodies specifically bind an epitope
 CC representing amino acids 13-28 of the Abeta molecule

XX SQ Sequence 442 AA;

Query Match 52.5%; Score 1267.5; DB 6; Length 442;

Best Local Similarity 59.1%; Pred. No. 9.9e-64;

Matches 274; Conservative 26; Mismatches 69; Indels 95; Gaps 13;

```

QY 30 LGKGDVVELTCTAS--QKSIQPHWKN-----NQIKLGNQGSF--LTKGPSKL 76
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 11 LVQPGSLRLSCAASGFTSRYSMSWVRQAPGKGLVLAQINSVGNSTYYPDTYKGRFTI 70
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 77 NDRADSRRLMDQGNFPLIIKLIKEDSDTYICEVEDQKEVQLVFGLTANSPTHLLOG 136
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 71 S-RDNAKNTLYLQMN-----SLRAEDTAVYYC-----ASGD---YWG 103
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 137 QSLTLTLESPPGSSPVQCRSPRGKNIQGS-----KTLVS----- 172
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 104 QGTLVTSSASTKGPSVFPPLAPSSKSTSGTALGCLVKDYRPPPTVSMNSGALTSGVN 163
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 173 --QLELDSG-----TWCTVLQNOKKVEFKIDIVCPAPRPSCKD 212
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 164 TTPPAVLQSSGLVSLSSVTPVSSSLGTQTYICNV--NHKPSNTKVD---KVEPRKSCDK 217
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 213 THTC-----PELLGSPSVLPFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFMYVDGV 267
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 218 THTCPPCPAPPELLGSPSVLPFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFMYVDGV 277
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 268 EVHNAKTKPREEOYNSTYRVVSVLTVLDHQMNLNGEKYCKVSNKALPAPIEKTIISKAKGQ 327
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 278 EVHNAKTKPREEOYNSTYRVVSVLTVLDHQMNLNGEKYCKVSNKALPAPIEKTIISKAKGQ 337
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 328 PREPOVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTTPVLDSDG 387
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 338 PREPOVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTTPVLDSDG 397
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 388 SFPLYSKLTVDKSRMQGNVFGSCVMHEALHNHTYQKSLSLSPG 431
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB 398 SFPLYSKLTVDKSRMQGNVFGSCVMHEALHNHTYQKSLSLSPG 441
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|

```

RESULT 92

ID ABB81109 standard; protein; 470 AA.

AC ABB81109;

DT 05-NOV-2002 (first entry)

DE Anti-tissue factor (TF) heavy chain fragment.

XX Immunoglobulin; promoter; cytosolic; antiinflammatory; immunomodulator;

KM neuroprotective; CD11; tissue factor; vascular endothelial growth factor;
 KM TF.
 XX
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FT Peptide 1..23
 FT /note= "STII signal sequence TIR-1"
 FT Protein 24..470
 FT /note= "anti-tissue factor heavy chain"
 XX
 XX MO200261090-A2.
 XX
 XX 08-AUG-2002.
 XX
 XX 13-DEC-2001; 2001MO-US048691.
 XX
 XX 14-DEC-2000; 2000US-0256164P.
 XX
 XX (GETH) GENENTECH INC.
 XX
 XX Simmons LC, Klimoweki L, Reilly DE, Yansura DG,
 DR MPI; 2002-619253/66.
 DR N-PSDB; ABN86645.
 XX
 XX
 PT New polynucleotide comprising first and second promoter-cistron pairs,
 PT useful for diagnosing, treating or preventing diseases associated with
 PT abnormal expression and/or activity of antigens such as inflammatory
 PT disorders.
 XX
 XX
 PS Disclosure; Fig 20A-C; 104pp; English.
 XX
 CC The invention provides a polynucleotide, which encodes an immunoglobulin
 CC (Ig), comprising a first or second promoter-cistron pair consisting of a
 CC first or second promoter and cistron, respectively. The first cistron of
 CC the first promoter-cistron pair comprises a first translational
 CC initiation region (TIR-I) operably linked to a nucleic acid sequence
 CC encoding an Ig light chain and the second cistron of the second promoter-
 CC cistron pair comprises a second translational initiation region (TIR-H)
 CC operably linked to a nucleic acid sequence encoding an Ig heavy chain.
 CC Upon expression of the polynucleotide in a prokaryotic host cell, light
 CC and heavy chains are folded and assembled to form a biologically active
 CC Ig. The antibody of the invention is useful for diagnosing, treating or
 CC preventing diseases or conditions associated with abnormal expression and
 CC /or activity of one or more antigen molecules e.g. lymphoid malignancies,
 CC inflammatory, angiotenic, immunologic, neuronal, glial, astrocytal,
 CC hyperthalamic or other glandular disorders. The present sequence
 CC represents the amino acid sequence of an anti-tissue factor (TF) heavy
 CC chain fragment of the cistron vector patf50
 CC
 XX
 XX
 SQ Sequence 470 AA;
 Query Match 52.4%; Score 1266; DB 5; Length 470;
 Best Local Similarity 58.8%; Pred. No. 1,3e-63;
 Matches 275; Conservative 26; Mismatches 69; Indels 98; Gaps 14;
 QY 30 LGKKGDTVELTCTAS--QKKSIOFHW-----KNSNOIKILG-NGSFLTKGSPSKLNDRA 80
 DB 34 LVPGGSLRLSCAASGFINIKKEYMHWRAQPAKGLEWVGLIDPEGQN--TIYDPKFDRA 91
 QY 81 -----DSRSILMOGPNPLILIKLKTEDSTYICEVEDQKEBQVLVFGLTANSDPHL-- 133
 DB 92 TISADNSKNTAYIQMN-----SLRAEDTAVVYCA-----RDTAAVYF 127
 QY 134 -LOGQSILTLIESPPGSSPSPVQCRSPGKNIQGG-----KTLVS----- 172
 DB 128 DYVGGQCTLVTVSSASTGSPVFPFLAPBSKSTSGGTALGCLVADYRPFEPYTVWMSGALT 187
 QY 173 -----QLEIQDSG-----TWCTVLONOKKVEFKIDIVCPAPEPK 208
 DB 188 SGVHTFPAVLQSSGLVSLSSVTVTPSSSLGTGYICNV--NHKPSMTKVD-----KKEVEPK 241

QY 209 SCDKTHTC-----PELLGSPSVFLFPKPKDITLMSRTPEVTCVVVDVSHEDPEVKENMY 263
 DB 242 SCDKTHTCPCCAPPELLGGPSVFLFPPPKDITLMSRTPEVTCVVVDVSHEDPEVKENMY 301
 QY 264 VDGEVHNAKTRPREQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK 323
 DB 302 VDGEVHNAKTRPREQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK 361
 QY 324 ARGQPREPQVYTLTPSPRDLTKNOVSLTCLVYGFPSPDIAVWESNGQPENNYKTPPVL 383
 DB 362 ARGQPREPQVYTLTPSPREMTKNQVSLTCLVYGFPSPDIAVWESNGQPENNYKTPPVL 421
 QY 384 DSDGSFPLYSKLTVDPSRMQGNVSCSVMEHALNHYTKSLSPG 431
 DB 422 DSDGSFPLYSKLTVDPSRMQGNVSCSVMEHALNHYTKSLSPG 469
 RESULT 93
 ID ABP72748
 ABP72748 standard; protein; 470 AA.
 XX
 XX ABP72748;
 XX
 DT 11-JUN-2003 (first entry)
 XX
 DE Anti-tissue factor antibody heavy chain.
 XX
 KW CD18; antibody; heavy chain; pXRF-7T3FL; immunosuppressive.
 XX
 OS Unidentified.
 OS Escherichia coli.
 OS Chimeric.
 OS
 XX
 XX Key Location/Qualifiers
 FH Peptide 1..23
 FT /label= "Signal peptide
 FT /note= "heat stable enterotoxin II (STII) signal"
 FT Protein 24..470
 FT /note= "Heavy chain"
 FT
 XX
 XX MO2003018771-A2.
 XX
 XX 06-MAR-2003.
 XX
 PD 26-AUG-2002; 2002MO-US027220.
 XX
 PF 27-AUG-2001; 2001US-0315209P.
 XX
 PR (GETH) GENENTECH INC.
 PA
 PI Andersen DC, Simmons LC;
 PI
 PI MPI; 2003-278654/27.
 DR N-PSDB; ABZ82072.
 DR
 XX
 PT Producing an antibody for treating cancer or autoimmune diseases by
 PT culturing the host cell under suitable conditions so that the light chain
 PT and heavy chain are expressed in a sequential fashion.
 XX
 XX
 XX Claim 56; Fig 10; 73pp; English.
 CC The present sequence is that of an anti-tissue factor (TF) antibody heavy
 CC chain including a heat stable enterotoxin II (STII) secretion signal.
 CC This recombinant heavy chain is produced by host cells transformed with
 CC a plasmid vector pXRF-7T3FL (see ABZ82072). The plasmid contains 2
 CC translational units that temporally separate the transcription of the
 CC antibody light (see ABP72747) and heavy chains. Expression of the light
 CC chain is under the control of the phoA promoter, while expression of the
 CC heavy chain is under the control of the inducible TacII promoter. In an
 CC example from the invention, Escherichia coli 60H4 was transformed with
 CC pXRF-7T3FL. The light chain was expressed initially and secreted into the
 CC periplasmic space. Heavy chain production was then induced by addition of
 CC IPTG. A yield of 2.6 +/- 0.3 g/l assembled Flab'2 was obtained, compared

CC with a yield of 1 g/l obtained using a single promoter system. This is an
 CC example of the process of the invention for production of recombinant
 CC antibodies in a host cell system, with temporally separated expression of
 CC the light and heavy chains. Properly assembled, soluble and functional
 CC antibodies (or their fragments) can be produced in high yields for
 CC diagnostic or therapeutic applications, including treatment of cancer or
 CC autoimmune diseases

XX
 CC
 SQ Sequence 470 AA;

Query Match 52.4%; Score 1266; DB 6; Length 470;
 Best Local Similarity 58.8%; Pred. No. 1.3e-63;

Matches 275; Conservative 26; Mismatches 69; Indels 98; Gaps 14;

QY 30 LGKKDPTVELTCTAS--OKKSIQPHW-----KNSNQIKILG-NGSGFLTKGSPKLNRA 80
 DB 34 LVQPGSGRLSCAASGFNFYSYAMSWRQAPGKLEWVSA--ISASG-STYLSADSVGR 91
 QY 81 -----DSRRSLWDQGNFPLIINLKIEDSDTYICEVEDQKEVQLLVFGLTANSPTHL-- 133
 DB 92 TISADNSKNTAVLYQNW-----SLRAEDTAVVYCA-----RDTAAYF 127
 QY 134 -LQGSILTLTLESPSSPSVOCRSRPGKNIOG-----KTLSS----- 172
 DB 128 DYWGQGTIVTSSASTKGPSPFLAPSSKSTSGTALGCLVKDYFPEPEVTYSWNSGALT 187
 QY 173 -----QLELDQSG-----TWCTVYLQNKQVFEFKIDIVPCAPPEPK 208
 DB 188 SGVHTFPAYLQSSGLYSLSVVTVPSSSLGTOTYICNV--NHKPSNTKVD---KRVPEK 241
 QY 209 SCDKTHTC-----PELLGSPSVFLPFPKPKDTLMTSRTPETVCVVVDVSHEDPEVKFMY 263
 DB 242 SCDKTHTCPCPAPBELLGSPSVFLPFPKPKDTLMTSRTPETVCVVVDVSHEDPEVKFMY 301
 QY 264 VQGVENHNAKTKPREQVNSTYRVVSVLTVLHQDMLNGEKYCKYSNKLPAPIEKTISK 323
 DB 302 VQGVENHNAKTKPREQVNSTYRVVSVLTVLHQDMLNGEKYCKYSNKLPAPIEKTISK 361
 QY 324 AKGPREPQVYTLPPSRDELTKNOVSLTCLVKGFPYPSDIAVEMESNGOENNYYKTTTPVL 383
 DB 362 AKGPREPQVYTLPPSRDELTKNOVSLTCLVKGFPYPSDIAVEMESNGOENNYYKTTTPVL 421
 QY 384 SDGSFFLYSKLTVDKSRWQGNVSCSYMHGALHNHYTKSLSPG 431
 DB 422 SDGSFFLYSKLTVDKSRWQGNVSCSYMHGALHNHYTKSLSPG 469

RESULT 94

AA014065
 ID AA014065 standard; protein; 474 AA.

XX
 AC AA014065;

XX
 DT 07-MAY-2002 (first entry)

DE Heavy chain protein of the monoclonal antibody from clone JA.

XX
 KM HRIG; human rabies-immune globulin; monoclonal; virucide; heavy chain;

XX
 KM human monoclonal rabies virus neutralising antibody; immunoglobulin;

XX
 KM light chain; central nervous system; CNS; prophylactic therapy; clone JA.

XX
 OS Homo sapiens.

XX
 PN WO20018132-A2.

XX
 PD 22-NOV-2001.

XX
 PF 04-MAY-2001; 2001WO-US014468.

XX
 PR 16-MAY-2000; 2000US-0204518P.

XX
 PA (UYJE-) UNIV JEFFERSON THOMAS.

PI Hooper DC, Dietzschold B;

XX
 DR WPI; 2002-062381/08.

XX
 DR N-PSDB; AAK98701.

XX
 PT Novel isolated human monoclonal rabies virus neutralizing antibody useful
 PT for treating individual exposed to rabies virus and for preventing spread
 PT of rabies virus to central nervous system.

XX
 PS Claim 4; Page 23-24; 25pp; English.

CC This sequence represents the heavy chain protein of the monoclonal
 CC antibody from clone JA. The invention relates to an isolated human
 CC monoclonal rabies virus neutralising antibody (virucide) derived from
 CC CDNA clones encoding the antibody heavy and light chains expressed in
 CC heterologous expression systems and purified away from deleterious
 CC contaminants. The invention provides a fused gene encoding a chimeric
 CC immunoglobulin light chain and a fused gene encoding a chimeric
 CC immunoglobulin heavy chain. The antibody of the invention is useful for
 CC treating an individual exposed to a rabies virus by administering to the
 CC individual a therapeutically effective amount of the antibody, and
 CC preventing a spread of the rabies virus to the central nervous system
 CC (CNS). The antibody of the invention provides a safe and efficacious post
 CC -exposure prophylactic therapy for individuals exposed to a rabies virus

XX
 SQ Sequence 474 AA;

Query Match 52.4%; Score 1266; DB 5; Length 474;
 Best Local Similarity 59.1%; Pred. No. 1.3e-63;

Matches 276; Conservative 32; Mismatches 71; Indels 88; Gaps 15;

QY 30 LGKKDPTVELTCTAS--OKKSIQPHWKNNSQIKILGNGSFL--TKGP 73
 DB 30 LVQPGSGRLSCAASGFNFYSYAMSWRQAPGKLEWVSA--ISASG-STYLSADSVGR 86
 QY 74 SKLNDRADSRSLWDQGNFPLIINLKIEDSDTYICEVEDQKEVQLLVFGLTANSPTHL 133
 DB 87 FTIS-RDMSKNTAVLYQNW-----SLRAEDTAVVYCA---KREVTMIVV-LNGGFD--- 132
 QY 134 LQGSILTLTLESPSSPSVOCRSRPGKNIOG-----KTLSS----- 172
 DB 133 YWGQGTIVTSSASTKGPSPFLAPSSKSTSGTALGCLVKDYFPEPEVTYSWNSGALT 192
 QY 173 -----QLELDQSG-----TWCTVYLQNKQVFEFKIDIVPCAPPEKS 209
 DB 193 GVHTFPAYLQSSGLYSLSVVTVPSSSLGTOTYICNV--NHKPSNTKVD---KRVPEK 246
 QY 210 CDKTHTC-----PELLGSPSVFLPFPKPKDTLMTSRTPETVCVVVDVSHEDPEVKFMY 264
 DB 247 CDKTHTCPCPAPBELLGSPSVFLPFPKPKDTLMTSRTPETVCVVVDVSHEDPEVKFMY 306
 QY 265 DQVEVHNAKTKPREQVNSTYRVVSVLTVLHQDMLNGEKYCKYSNKLPAPIEKTISKA 324
 DB 307 DQVEVHNAKTKPREQVNSTYRVVSVLTVLHQDMLNGEKYCKYSNKLPAPIEKTISKA 366
 QY 325 KGPPEPQVYTLPPSRDELTKNOVSLTCLVKGFPYPSDIAVEMESNGOENNYYKTTTPVL 384
 DB 367 KGPPEPQVYTLPPSRDELTKNOVSLTCLVKGFPYPSDIAVEMESNGOENNYYKTTTPVL 426
 QY 385 SDGSFFLYSKLTVDKSRWQGNVSCSYMHGALHNHYTKSLSPG 431
 DB 427 SDGSFFLYSKLTVDKSRWQGNVSCSYMHGALHNHYTKSLSPG 473

RESULT 95

ABU08017
 ID ABU08017 standard; protein; 474 AA.

XX
 AC ABU08017;

XX
 DT 10-MAY-2003 (first entry)

DE Human monoclonal rabies virus antibody heavy chain, clone JH, protein.

```

XX Human; antibody; constant region; monoclonal antibody 57; Mab 57;
KM variable region; Rabies; neurological disease; infection;
KM central nervous system; rabies virus; Lyssaviridae;
KM pathogen; vaccine; virucide; heavy chain.
OS Homo sapiens.
PN MO2003016501-A2.
PD 27-FEB-2003.
PF 21-AUG-2002; 2002MO-US026584.
PR 21-ANG-2001; 2001US-0314023P.
XX (UYJE-) UNIV JEFFERSON THOMAS.
XX Hooper DC, Dietzschold B;
PI WPI; 2003-278566/27.
XX N-PSDB; ABX12855.
XX New recombinant antibody comprising a constant region of Mab 57 linked to
PT a non-Mab 57 variable region, useful for treating an individual exposed
PT to a pathogen, e.g. rabies infection.
XX Example 1; Page 32-33; 38pp; English.
XX The invention discloses a recombinant antibody comprising a constant
XX region of monoclonal antibody (Mab) 57 linked to a non-Mab 57 variable
XX region. Rabies is an acute, neurological disease caused by infection of
XX the central nervous system with the rabies virus, a member of the
XX Lyssavirus genus of the family Rhabdoviridae. Also disclosed are methods
XX for producing an isolated recombinant antibody by culturing a host cell,
XX containing a recombinant expression vector comprising the nucleic acid
XX molecule encoding the antibody, and isolating the recombinant antibody
XX expressed and treating an individual exposed to a pathogen by
XX administering to the individual the recombinant antibody. The recombinant
XX antibodies are useful for preventing (vaccine) and treating an individual
XX exposed to a pathogen, e.g. rabies infection. They are also useful for
XX the qualitative and quantitative determination of the rabies virus. The
XX sequences presented are the antibody protein fragments, the nucleic acids
XX encoding them or the PCR primers used to construct the recombinant
XX expression vector
XX
XX Sequence 474 AA:
SQ
Query Match 52.4%; Score 1266; DB 6; Length 474;
Best Local Similarity 59.1%; Pred. No. 1.3e-63;
Matches 276; Conservative 32; Mismatches 71; Indels 88; Gaps 15;
30 LGKGGDTVELTCTAS-----QKKSIOFHKNKSNQIKILGNQSPF---TKGP 73
30 LVPGGSLRLSCAASGFTFSNYAMSWVRQAPKGLEWVSA--ISASH-STYLDASVKGR 86
74 SKLNDRADSRRLSDQGNFPLIKNLKIEDSDTYICEVEDQKEVQLVGLTRANSDTHL 133
87 FTIS-RDNSKNTLYLQWN-----SLRAEDTAAYVCA---KDBREVTIV-LNGGFD--- 132
134 LQOOSLTLTLESPGSSPSVQCSPRKNIQGG-----KITLSVS----- 172
133 YWQGGTRLVTVSSASTGKPSVFLPLAPSSKSTSGGTAALGLVKQYFPFPVTVSNNGALTS 192
173 -----QLELDQSG-----TWTCYVLQNKVFEKIDIVPCPAPPEPKS 209
193 GYHTFPAVLQSSGSLYSLSVTVSSSLGQTYICNV--NKKSNKTVVD---KRYEPKS 246
210 CDKTHTC-----PELLGSPVFLFPPPKDQTLMSRTPEVTCVVDVSHEDPEVKENWY 264
247 CDTHHTCPPCPAPPELLGSPSVFLFPPPKDQTLMSRTPEVTCVVDVSHEDPEVKENWY 306
265 DGVENVNAKTRPREBOYNSTRVAVSVLTVLHODMLNKEKCKVSNKALPAPLEKTISSKA 324

```

```

DB 307 DGVENVNAKTRPREBOYNSTRVAVSVLTVLHODMLNKEKCKVSNKALPAPLEKTISSKA 366
QY 325 KQGPREFQYITLPPSDELTKQVSLTCLVKGFYPSDIAVWESNQPENNYKTTTPVLD 384
DB 367 KQGPREFQYITLPPSDEMTKNQVSLTCLVKGFYPSDIAVWESNQPENNYKTTTPVLD 426
QY 385 SDGSFFLYSKLTVDKSRMQGVNFSGVNHEALNNHYTKSLSLSPG 431
DB 427 SDGSFFLYSKLTVDKSRMQGVNFSGVNHEALNNHYTKSLSLSPG 473
RESULT 96
ADD25837
ID ADD25837 standard; protein; 500 AA.
XX ADD25837;
XX 15-JAN-2004 (first entry)
XX Binding domain-immunoglobulin fusion protein-associated protein #181.
XX Binding domain; immunoglobulin; fusion protein; cytosolic;
XX antiarthritic; immunosuppressive; antidiabetic; antihypoid;
XX neuroprotective; hinge region; immunoglobulin heavy chain;
XX CH2 constant region; CH3 constant region; IgG1;
XX antibody dependent cell-mediated cytotoxicity; ADCC; complement fixation;
XX malignant condition; B-cell disorder; melanoma; carcinoma; sarcoma;
XX rheumatoid arthritis; myasthenia gravis; Grave's disease;
XX type I diabetes mellitus; multiple sclerosis; autoimmune disease.
XX Unidentified.
XX US2003118592-A1.
XX 26-JUN-2003.
XX 25-JUL-2002; 2002US-00207655.
XX 17-JAN-2001; 2001US-0367358P.
XX 17-JUN-2002; 2002US-00053530.
XX 03-JUN-2002; 2002US-0385691P.
XX (GENE-) GENE-CRAFT INC.
XX Ledbetter JA, Hayden-Ledbetter MS, Thompson PA;
XX WPI; 2003-801317/75.
XX New binding domain-immunoglobulin fusion protein, useful for treating a
XX subject having or suspected of having a malignant condition or a B-cell
XX disorder, e.g. melanoma, Grave's disease or autoimmune disease.
XX Disclosure; SEQ ID NO 398; 157pp; English.
XX The invention relates to a binding domain-immunoglobulin fusion protein
XX comprising a binding domain polypeptide that is fused to an
XX immunoglobulin hinge region polypeptide, an immunoglobulin heavy chain
XX CH2 constant region polypeptide that is fused to the hinge region
XX polypeptide, and an immunoglobulin heavy chain CH3 constant region
XX polypeptide that is fused to the CH2 constant region polypeptide. The
XX hinge region polypeptide comprises: a wild-type human IgG1 immunoglobulin
XX hinge region polypeptide; a mutated human IgG1 immunoglobulin hinge
XX region polypeptide, derived from (a) having 3 or more cysteine residues;
XX where the mutated human IgG1 immunoglobulin hinge region polypeptide
XX contains 2 cysteine residues, where the first cysteine is not mutated; a
XX mutated human IgG1 immunoglobulin hinge region polypeptide, derived from
XX (a) having 3 or more cysteine residues, where the mutated human IgG1
XX immunoglobulin hinge region polypeptide contains no more than one
XX cysteine residue; and a mutated human IgG1 immunoglobulin hinge region
XX polypeptide, derived from (a) having 3 or more cysteine residues; where
XX the mutated human IgG1 immunoglobulin hinge region polypeptide contains
XX no cysteine residues. The binding domain-immunoglobulin fusion protein is

```

capable of at least one immunological activity comprising antibody dependent cell-mediated cytotoxicity (ADCC) and complement fixation. The binding domain polypeptide is capable of specifically binding to an antigen. Also included are an isolated polynucleotide encoding the binding domain-immunoglobulin fusion protein, a recombinant expression construct comprising the polynucleotide (operably linked to a promoter), a host cell transformed or transfected with a recombinant expression construct, producing the binding domain-immunoglobulin fusion protein, a pharmaceutical composition comprising the binding domain-immunoglobulin fusion protein or polynucleotide and a carrier, and treating a subject having or suspected of having a malignant condition or a B-cell disorder. The binding domain-immunoglobulin fusion protein is useful for treating a CC subject having or suspected of having a malignant condition or a B-cell disorder, e.g. melanoma, carcinoma or sarcoma, rheumatoid arthritis, myasthenia gravis, Grave's disease, Type I diabetes mellitus, multiple sclerosis or autoimmune disease. The present sequence is a binding domain -immunoglobulin fusion protein-associated protein sequence. Note: The sequence data for this patent formed part of the printed specification and is also available in electronic format directly from USPTO at seqdata.uspto.gov/sequence.html?docId=20030118952. The authors have not identified the sequences in the printed specification by their SEQ ID number therefore none of the sequences can be explicitly identified.

SQ Sequence 500 AA;

Query Match	52.4%	Score 1266	DB 7	Length 500
Best Local Similarity	56.3%	Pred. No. 1.4e-63		
Matches 274; Conservative	27	Mismatches 94	Indels 92	Gaps 12

QY	23	TOGNKVVVLGKGGDPAVELTCTASQKKSIOGFHMKNNSNQIKILGNQGSFLLTGSPKLNDRADS	82
Db	27	SQSPAILTASFEKCKTMTCTCRASSVS-YHMTQCKP-----GSPKRWIYAFSNILASGVPA	81
QY	83	RRSLMDQG-NPPLILIKNLKIEDSDPYICEVEDQKEVOLLVGL-----	125
Db	82	RFSGSGSSTSYSLTISRVEAEADAFTYCC---QKMSFNPPTGAGTKLELKDGSGSGGG	137
QY	126	---TANSDTHLLQ-QGSLTLTLESPPGSPSVQCR-----SPR-----	159
Db	138	SGGGGSSQAVLQQSSAELV-----RPGASVKMKSCAKSGYTFTSYNNHMYKQTPRQGLEMI	192
QY	160	-----GKNIQGGKTLV-----SOLELQDGTWCTVLQNOKKVEFK	196
Db	193	GAIVPQNGDTSYNQAFKGAATLVTDKSSSTAYMQLSLTSBEDSAVYFCARVVYYSNWMY	252
QY	197	ID-----IYPCRAPEKSCCKHTTC-----PELLGGSGSVLFFPKPKDTLMISTRPBV	244
Db	253	FDWMGTGTTVVVSSDOEPKSCDKHTCPSPAPPELLGGSVLFFPKPKDTLMISTRPBV	312
QY	245	TCVVVDVSHEDPEVKFNMYVDSGEVYHNAKTKRREQDYNSTYRVVSLTGLHDQWLNGKEY	304
Db	313	TCVVVDVSHEDPEVKFNMYVDSGEVYHNAKTKRREQDYNSTYRVVSLTGLHDQWLNGKEY	372
QY	305	KCKYNNKALLPAPIETKTISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAV	364
Db	373	KCKYNNKALLPAPIETKTISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAV	432
QY	365	EMESNGQPENNYKTPRPVLDSDGSFFLYSKLTVDSKRWQGNVFCSVYHGAELAHNHYTK	424
Db	433	EMESNGQPENNYKTPRPVLDSDGSFFLYSKLTVDSKRWQGNVFCSVYHGAELAHNHYTK	492
QY	425	SLSLSPG 431	
Db	493	SLSLSPG 499	

RESULT 97
 ADD25679
 ID ADD25679 standard; protein; 500 AA.
 XX ADD25679;
 AC
 XX 15-JAN-2004 (first entry)

XX Binding domain-immunoglobulin fusion protein-associated protein #114.
DE
XX Binding domain; immunoglobulin; fusion protein; cytostatic;
KW antihistytic; immunosuppressive; antidiabetic; antithyroid;
KW neuroprotective; hinge region; immunoglobulin heavy chain;
KW CH2 constant region; CH3 constant region; IgG1;
KW antibody dependent cell-mediated cytotoxicity; ADCC; complement fixation;
KW rheumatoid arthritis; B-cell disorder; melanoma; carcinoma; sarcoma;
KW myasthenia gravis; myasthenia gravis; Grave's disease;
XX type I diabetes mellitus; multiple sclerosis; autoimmune disease.
OS unidentified.
XX
XX US2003118592-A1.
PN
XX
PD 26-JUN-2003.
PP
XX 25-JUL-2002; 2002US-00207655.
PR 17-JAN-2001; 2001US-0367358P.
PR 17-JAN-2002; 2002US-00053530.
PR 03-JUN-2002; 2002US-0385691P.
PA (GENE-) GENE-CRAFT INC.
PI Ledbetter JA, Hayden-Ledbetter MS, Thompson PA;
DR WPI; 2003-801317/75.
PT New binding domain-immunoglobulin fusion protein, useful for treating a
PT subject having or suspected of having a malignant condition or a B-cell
PT disorder, e.g. melanoma, Grave's disease or autoimmune disease.
PS Disclosure; SEQ ID NO 240; 157bp; English.

The invention relates to a binding domain-immunoglobulin fusion protein comprising a binding domain polypeptide that is fused to an immunoglobulin hinge region polypeptide, an immunoglobulin heavy chain CH2 constant region polypeptide that is fused to the hinge region polypeptide, and an immunoglobulin heavy chain CH3 constant region polypeptide that is fused to the CH2 constant region polypeptide. The hinge region polypeptide comprises a wild-type human IgG1 immunoglobulin hinge region polypeptide, a mutated human IgG1 immunoglobulin hinge region polypeptide, derived from (a) having 3 or more cysteine residues; where the mutated human IgG1 immunoglobulin hinge region polypeptide contains 2 cysteine residues, where the first cysteine is not mutated; a mutated human IgG1 immunoglobulin hinge region polypeptide, derived from (a) having 3 or more cysteine residues, where the mutated human IgG1 immunoglobulin hinge region polypeptide contains no more than one cysteine residue; and a mutated human IgG1 immunoglobulin hinge region polypeptide, derived from (a) having 3 or more cysteine residues; where the mutated human IgG1 immunoglobulin hinge region polypeptide contains no cysteine residues. The binding domain-immunoglobulin fusion protein is capable of at least one immunological activity comprising antibody dependent cell-mediated cytotoxicity (ADCC) and complement fixation. The binding domain polypeptide is capable of specifically binding to an antigen. Also included are an isolated polynucleotide encoding the binding domain-immunoglobulin fusion protein, a recombinant expression construct comprising the polynucleotide (operably linked to a promoter), a host cell transformed or transfected with a recombinant expression construct, producing the binding domain-immunoglobulin fusion protein, a pharmaceutical composition comprising the binding domain-immunoglobulin fusion protein or polynucleotide and a carrier, and treating a subject having or suspected of having a malignant condition or a B-cell disorder. The binding domain-immunoglobulin fusion protein is useful for treating a subject having or suspected of having a malignant condition or a B-cell disorder, e.g. melanoma, carcinoma or sarcoma, rheumatoid arthritis, myasthenia gravis, Grave's disease, type I diabetes mellitus, multiple sclerosis or autoimmune disease. The present sequence is a binding domain-immunoglobulin fusion protein-associated protein sequence. Note: The sequence data for this patent formed part of the printed specification and is also available in electronic format directly from USPTO at

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 3, 2004, 13:14:00 ; Search time 38.4271 Seconds
(without alignments)
3706.029 Million cell updates/sec

Title: SEQ4
Perfect score: 2414
Sequence: 1 NMRGVFRRLLVLQLALP.....DETCARQGDGLGWTTPD 454

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1291235 seqs, 313682936 residues

Total number of hits satisfying chosen parameters: 1291235

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 125 summaries

Database : Published Applications AA.*

1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09B_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US09C_PUBCOMB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
15: /cgn2_6/ptodata/1/pubpaa/US10C_PUBCOMB.pep.*
16: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
17: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
18: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2122	87.9	432	8	US-08-485-163-3
2	2122	87.9	432	9	US-09-766-995-2
3	2085	86.4	530	8	US-08-485-163-5
4	2085	86.4	530	9	US-09-766-995-4
5	1338.5	55.4	254	10	US-09-939-537-33
6	1291.5	53.5	465	12	US-10-404-724-8
7	1289	53.4	713	16	US-10-679-620-64
8	1289	53.4	713	16	US-10-679-620-62
9	1287.5	53.3	437	12	US-10-363-427-14
10	1285.5	53.3	437	12	US-10-412-406-32
11	1285.5	53.3	4852	12	US-10-412-406-33
12	1282.5	53.1	446	12	US-10-435-299-7
13	1282.5	53.1	617	14	US-10-363-427-18
14	1282.5	53.1	617	14	US-10-363-427-22
15	1282.5	53.1	972	15	US-10-410-836-38

16	1282.5	53.1	975	15	US-10-418-836-39	Sequence 39, Appl
17	1281.5	53.1	465	12	US-10-404-724-23	Sequence 23, Appl
18	1280	53.0	467	16	US-10-656-769-32	Sequence 32, Appl
19	1280	53.0	476	9	US-09-747-669-3	Sequence 3, Appl
20	1280	53.0	476	14	US-10-290-703-3	Sequence 3, Appl
21	1279.5	53.0	448	15	US-10-378-567-2	Sequence 2, Appl
22	1279	53.0	492	14	US-10-207-655-344	Sequence 344, App
23	1277.5	52.9	470	15	US-10-108-260A-4292	Sequence 4292, App
24	1277	52.9	543	14	US-10-207-655-345	Sequence 345, App
25	1276.5	52.9	475	9	US-09-740-002-25	Sequence 25, Appl
26	1276.5	52.9	475	16	US-10-325-698-25	Sequence 25, Appl
27	1275.5	52.8	579	14	US-10-138-727A-41	Sequence 41, Appl
28	1275	52.8	600	16	US-10-334-235-38	Sequence 38, Appl
29	1274.5	52.8	445	14	US-10-320-231A-79	Sequence 79, Appl
30	1273.5	52.8	444	14	US-10-150-475A-6	Sequence 6, Appl
31	1273.5	52.8	444	16	US-10-704-532-6	Sequence 6, Appl
32	1273.5	52.8	444	16	US-10-645-215-6	Sequence 6, Appl
33	1273.5	52.8	475	16	US-09-740-002-27	Sequence 27, Appl
34	1273.5	52.8	475	16	US-10-325-698-27	Sequence 27, Appl
35	1273.5	52.8	497	12	US-10-683-255-6	Sequence 6, Appl
36	1273.5	52.8	525	12	US-10-683-255-4	Sequence 4, Appl
37	1273.5	52.8	622	12	US-10-683-255-2	Sequence 2, Appl
38	1272.5	52.7	474	15	US-10-108-260A-4282	Sequence 4282, Ap
39	1272	52.7	476	16	US-10-159-006-18	Sequence 18, Appl
40	1271.5	52.7	453	14	US-10-159-006-18	Sequence 18, Appl
41	1271.5	52.7	465	12	US-10-404-724-25	Sequence 25, Appl
42	1271.5	52.7	499	14	US-10-207-655-15	Sequence 15, Appl
43	1271.5	52.7	499	14	US-10-207-655-15	Sequence 15, Appl
44	1271.5	52.7	499	14	US-10-207-655-15	Sequence 15, Appl
45	1271.5	52.7	499	14	US-10-207-655-15	Sequence 15, Appl
46	1271	52.7	476	12	US-09-758-173-12	Sequence 12, Appl
47	1271	52.7	476	12	US-10-124-905-12	Sequence 12, Appl
48	1271	52.7	476	14	US-10-124-907-12	Sequence 12, Appl
49	1271	52.7	476	14	US-10-291-532-12	Sequence 12, Appl
50	1271	52.7	504	14	US-10-207-655-348	Sequence 348, App
51	1270	52.6	473	15	US-10-108-260A-4278	Sequence 4278, Ap
52	1270	52.6	619	15	US-09-910-600-32	Sequence 32, Appl
53	1269.5	52.6	448	16	US-10-467-546-4	Sequence 4, Appl
54	1269.5	52.6	469	16	US-10-656-769-20	Sequence 20, Appl
55	1269	52.6	472	15	US-10-108-260A-4073	Sequence 4073, Ap
56	1268.5	52.5	471	15	US-10-108-260A-4285	Sequence 4285, Ap
57	1268	52.5	634	16	US-10-416-011-2	Sequence 2, Appl
58	1267.5	52.5	442	12	US-10-226-435A-12	Sequence 12, Appl
59	1266.5	52.5	631	15	US-10-120-1988-12	Sequence 2, Appl
60	1266	52.4	451	10	US-09-925-179-68	Sequence 68, Appl
61	1266	52.4	451	15	US-10-423-259-4	Sequence 4, Appl
62	1266	52.4	470	14	US-10-020-786-9	Sequence 9, Appl
63	1266	52.4	470	14	US-10-227-694-5	Sequence 5, Appl
64	1266	52.4	474	10	US-09-848-832-3	Sequence 3, Appl
65	1266	52.4	474	14	US-10-225-108A-3	Sequence 3, Appl
66	1266	52.4	474	15	US-10-461-148-1	Sequence 1, Appl
67	1266	52.4	500	14	US-10-207-655-240	Sequence 240, App
68	1266	52.4	500	14	US-10-207-655-398	Sequence 398, App
69	1265.5	52.4	468	14	US-10-071-485-67	Sequence 67, Appl
70	1265.5	52.4	711	14	US-10-071-485-90	Sequence 90, Appl
71	1265	52.4	445	16	US-10-408-901-42	Sequence 42, Appl
72	1265	52.4	445	16	US-10-411-037-56	Sequence 56, Appl
73	1265	52.4	448	12	US-10-411-026-56	Sequence 56, Appl
74	1265	52.4	448	16	US-10-410-962-56	Sequence 56, Appl
75	1265	52.4	448	16	US-10-411-049-56	Sequence 56, Appl
76	1265	52.4	448	16	US-10-410-930-56	Sequence 56, Appl
77	1265	52.4	448	16	US-10-410-930-56	Sequence 56, Appl
78	1265	52.4	448	16	US-10-411-012-56	Sequence 56, Appl
79	1265	52.4	448	16	US-10-281-994-56	Sequence 56, Appl
80	1265	52.4	448	16	US-10-410-913-56	Sequence 56, Appl
81	1265	52.4	462	12	US-09-773-877A-18	Sequence 18, Appl
82	1265	52.4	567	12	US-09-773-877A-12	Sequence 12, Appl
83	1265	52.4	698	9	US-09-875-338-9	Sequence 9, Appl
84	1265	52.4	698	14	US-10-077-023-9	Sequence 9, Appl
85	1264	52.3	567	12	US-09-773-877A-20	Sequence 20, Appl
86	1263.5	52.3	450	9	US-09-796-848A-17	Sequence 17, Appl
87	1263.5	52.3	450	9	US-09-796-848A-15	Sequence 15, Appl
88	1263.5	52.3	450	9	US-09-996-288-220	Sequence 220, App

89 1263.5 52.3 450 9 US-09-996-288-226 Sequence 226, App
90 1263.5 52.3 450 9 US-09-996-288-232 Sequence 232, App
91 1263.5 52.3 450 9 US-09-996-288-234 Sequence 234, App
92 1263.5 52.3 450 9 US-09-996-288-236 Sequence 236, App
93 1263.5 52.3 450 9 US-09-996-288-238 Sequence 238, App
94 1263.5 52.3 450 9 US-09-996-288-242 Sequence 242, App
95 1263.5 52.3 450 9 US-09-996-288-244 Sequence 244, App
96 1263.5 52.3 450 9 US-09-996-288-246 Sequence 246, App
97 1263.5 52.3 450 9 US-09-996-288-252 Sequence 252, App
98 1263.5 52.3 450 9 US-09-996-288-254 Sequence 254, App
99 1263.5 52.3 450 9 US-09-996-288-256 Sequence 256, App
100 1263.5 52.3 450 10 US-09-996-265-220 Sequence 220, App
101 1263.5 52.3 450 10 US-09-996-265-226 Sequence 226, App
102 1263.5 52.3 450 10 US-09-996-265-232 Sequence 232, App
103 1263.5 52.3 450 10 US-09-996-265-234 Sequence 234, App
104 1263.5 52.3 450 10 US-09-996-265-236 Sequence 236, App
105 1263.5 52.3 450 10 US-09-996-265-238 Sequence 238, App
106 1263.5 52.3 450 10 US-09-996-265-242 Sequence 242, App
107 1263.5 52.3 450 10 US-09-996-265-244 Sequence 244, App
108 1263.5 52.3 450 10 US-09-996-265-246 Sequence 246, App
109 1263.5 52.3 450 10 US-09-996-265-252 Sequence 252, App
110 1263.5 52.3 450 10 US-09-996-265-254 Sequence 254, App
111 1263.5 52.3 450 10 US-09-996-265-256 Sequence 256, App
112 1263.5 52.3 452 10 US-09-726-258-71 Sequence 71, App
113 1263.5 52.3 480 14 US-10-077-023-133 Sequence 133, App
114 1263 52.3 472 14 US-10-159-006-30 Sequence 30, App
115 1262.5 52.3 450 9 US-09-796-848A-39 Sequence 39, App
116 1262.5 52.3 450 9 US-09-796-848A-41 Sequence 41, App
117 1262.5 52.3 450 9 US-09-796-848A-47 Sequence 47, App
118 1262.5 52.3 450 9 US-09-996-288-222 Sequence 222, App
119 1262.5 52.3 450 9 US-09-996-288-224 Sequence 224, App
120 1262.5 52.3 450 9 US-09-996-288-228 Sequence 228, App
121 1262.5 52.3 450 10 US-09-996-265-222 Sequence 222, App
122 1262.5 52.3 450 10 US-09-996-265-224 Sequence 224, App
123 1262.5 52.3 450 10 US-09-996-265-228 Sequence 228, App
124 1262.5 52.3 469 16 US-10-656-769-26 Sequence 26, App
125 1262.5 52.3 480 14 US-10-077-023-135 Sequence 135, App

ALIGNMENTS

RESULT 1
US-08-485-163-3
; Sequence 3, Application US/08485163
; Publication No. US20020098191A1
; GENERAL INFORMATION:
; APPLICANT: Beaudry, Gary A.
; APPLICANT: Maddon, Paul J.
; TITLE OF INVENTION: CD4-GAMMA2 CD4-IgG2 CHIMERAS
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooper & Dunham LLP
; STREET: 1185 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.24
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/485,163
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: White, John P.
; REGISTRATION NUMBER: 28,678
; REFERENCE/DOCKET NUMBER: 37690-II-1-PCT-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 278-0400

TELEFAX: (212) 391-0525
; TELEX:
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 432 amino acids
; TYPE: amino acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: protein
; ORIGINAL SOURCE:
; ORGANISM: homo sapien
; CELL TYPE: lymphocyte
US-08-485-163-3
Query Match 87.9%; Score 2122; DB 8; Length 432;
Best Local Similarity 91.2%; Pred. No. 1.9e-141;
Matches 405; Conservative 8; Mismatches 5; Indels 26; Gaps 2;
1 MNRGVPFRHLIVQLALPAAATGKRVLGKKDTELCTASQKSIQPHMNSNQIK 60
1 MNRGVPFRHLIVQLALPAAATGKRVLGKKDTELCTASQKSIQPHMNSNQIK 60
1 MNRGVPFRHLIVQLALPAAATGKRVLGKKDTELCTASQKSIQPHMNSNQIK 60
61 ILNGQSFLLTKGPKSKNDRAKRSRLWDQGNFLLIKLTKEDSDTYICEVEDQKEVQL 120
61 ILNGQSFLLTKGPKSKNDRAKRSRLWDQGNFLLIKLTKEDSDTYICEVEDQKEVQL 120
61 ILNGQSFLLTKGPKSKNDRAKRSRLWDQGNFLLIKLTKEDSDTYICEVEDQKEVQL 120
121 LVFGLTNSDPTHLQSGSLTLTLESPGSSPSVOCSPRGKNIQKTLASVQLDQSG 180
121 LVFGLTNSDPTHLQSGSLTLTLESPGSSPSVOCSPRGKNIQKTLASVQLDQSG 180
121 LVFGLTNSDPTHLQSGSLTLTLESPGSSPSVOCSPRGKNIQKTLASVQLDQSG 180
181 TWTCVLQNKQKVEFKIDIV-----PCPAPEPKSCDKHTCELLGPGSVFL 227
181 TWTCVLQNKQKVEFKIDIV-----PCPAPEPKSCDKHTCELLGPGSVFL 227
181 TWTCVLQNKQKVEFKIDIV-----PCPAPEPKSCDKHTCELLGPGSVFL 227
228 FPPKPKTLMISRPETVCVVVDYSHDEPKFMYIYDGEVHNAKTKPREQNSTYRV 287
228 FPPKPKTLMISRPETVCVVVDYSHDEPKFMYIYDGEVHNAKTKPREQNSTYRV 287
228 FPPKPKTLMISRPETVCVVVDYSHDEPKFMYIYDGEVHNAKTKPREQNSTYRV 287
288 VSVLTVLHDPMLNKEKCYKSNKALPAPIEKTISKAGOPREPOVYTLPPSRDELTKNQ 347
288 VSVLTVLHDPMLNKEKCYKSNKALPAPIEKTISKAGOPREPOVYTLPPSRDELTKNQ 347
288 VSVLTVLHDPMLNKEKCYKSNKALPAPIEKTISKAGOPREPOVYTLPPSRDELTKNQ 347
348 VSLTCLVKGFPSPDIAVWESNGOPENNYKTPPEVLDSGDFLYSKLTVDKSRMOQGNV 407
348 VSLTCLVKGFPSPDIAVWESNGOPENNYKTPPEVLDSGDFLYSKLTVDKSRMOQGNV 407
408 FSCGVMEBALNHTQKSLSPG 431
408 FSCGVMEBALNHTQKSLSPG 431

RESULT 2
US-09-766-995-2
; Sequence 2, Application US/09766995
; Patent No. US20020052481A1
; GENERAL INFORMATION:
; APPLICANT: Graham P. Allaway et al.
; TITLE OF INVENTION: NON-PEPTIDYL MOIETY-CONJUGATED CD4-GAMMA2 AND CD4-IgG2 IMMUNOCONJ
; FILE REFERENCE: 2048/41215-CB/JPW/SHS
; CURRENT APPLICATION NUMBER: US/09/766,995
; CURRENT FILING DATE: 2001-01-22
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 432
; TYPE: PRT
; ORGANISM: homo sapiens
US-09-766-995-2
Query Match 87.9%; Score 2122; DB 9; Length 432;
Best Local Similarity 91.2%; Pred. No. 1.9e-141;
Matches 405; Conservative 8; Mismatches 5; Indels 26; Gaps 2;

```

QY 1 MRGVPFRLLLVLTQALLPAATQGNKVVLGKKGDVTELTCTASOKKSIQPHMKNNOIK 60
   |||||
Db 1 MRGVPFRLLLVLTQALLPAATQGNKVVLGKKGDVTELTCTASOKKSIQPHMKNNOIK 60
QY 61 IIGNGSFLTKGPSKLNDRADSRSLMDQGNPFLIKNLIKEDSDTYICEVDQKEEYQL 120
   |||||
Db 61 IIGNGSFLTKGPSKLNDRADSRSLMDQGNPFLIKNLIKEDSDTYICEVDQKEEYQL 120
QY 121 LVFGLTANSDBTHLLOQOSLTLTLESPPGSSPSVQCSPPRGKNIQGGKTLVSQLELQDSG 180
   |||||
Db 121 LVFGLTANSDBTHLLOQOSLTLTLESPPGSSPSVQCSPPRGKNIQGGKTLVSQLELQDSG 180
QY 181 TWTCTVLQWQKKVEFKIDIV-----PCBAPPEKSCDKHTHTEPELLGSGSVL 227
   |||||
Db 181 TWTCTVLQWQKKVEFKIDIVLAFAERKCCVCEPCPPAP-----VAGSVFL 227
QY 228 PPKPKDITMISRTPEVTCVVVDVSHEDPEVKENMYVDGVEVHNAKTKRREEQYNSTYRV 287
   |||||
Db 228 PPKPKDITMISRTPEVTCVVVDVSHEDPEVKENMYVDGVEVHNAKTKRREEQYNSTYRV 287
QY 288 VSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISAKQPREPOVYTLPPSRDELTKNQ 347
   |||||
Db 288 VSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISAKQPREPOVYTLPPSRDELTKNQ 347
QY 348 VSLTCLVKGFPYPSDIAVEMESNGQPENNYKTPPVLDSDGPFYLSKLTVDKSRMQQGNV 407
   |||||
Db 348 VSLTCLVKGFPYPSDIAVEMESNGQPENNYKTPPVLDSDGPFYLSKLTVDKSRMQQGNV 407
QY 408 FSCSVMEHALHNHYTKSLSLSPG 431
   |||||
Db 408 FSCSVMEHALHNHYTKSLSLSPG 431

```

```

RESULT 3
US-08-485-163-5
; Sequence 5, Application US/08485163
; Publication No. US20020098191A1
; GENERAL INFORMATION:
; APPLICANT: Beaudry, Gary A.
; APPLICANT: Maddon, Paul J.
; TITLE OF INVENTION: CD4-GAMMA2 CD4-IgG2 CHIMERAS
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooper & Dunham LLP
; STREET: 1185 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.24
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/485,163
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: White, John P.
; REGISTRATION NUMBER: 28,678
; REFERENCE/DOCKET NUMBER: 37690-II-1-PCT-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 278-0400
; TELEFAX: (212) 391-0525
; TELEX:
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 530 amino acids
; TYPE: amino acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown

```

```

; MOLECULE TYPE: cDNA
; ORIGINAL SOURCE:
; ORGANISM: homo sapien
; CELL TYPE: lymphocyte
; US-08-485-163-5

```

```

Query Match      86.4%; Score 2085; DB 8; Length 530;
Best Local Similarity 77.3%; Pred. No. 9.9e-139;
Matches 409; Conservative 9; Mismatches 13; Indels 98; Gaps 4;

```

```

QY 1 MRGVPFRLLLVLTQALLPAATQGNKVVLGKKGDVTELTCTASOKKSIQPHMKNNOIK 60
   |||||
Db 1 MRGVPFRLLLVLTQALLPAATQGNKVVLGKKGDVTELTCTASOKKSIQPHMKNNOIK 60
QY 61 IIGNGSFLTKGPSKLNDRADSRSLMDQGNPFLIKNLIKEDSDTYICEVDQKEEYQL 120
   |||||
Db 61 IIGNGSFLTKGPSKLNDRADSRSLMDQGNPFLIKNLIKEDSDTYICEVDQKEEYQL 120
QY 121 LVFGLTANSDBTHLLOQOSLTLTLESPPGSSPSVQCSPPRGKNIQGGKTLVSQLELQDSG 180
   |||||
Db 121 LVFGLTANSDBTHLLOQOSLTLTLESPPGSSPSVQCSPPRGKNIQGGKTLVSQLELQDSG 180
QY 181 TWTCTVLQWQKKVEFKIDIV-----PCBAPPEKSCDKHTHTEPELLGSGSVL 227
   |||||
Db 181 TWTCTVLQWQKKVEFKIDIVLAFASTKGPVSFPLAPCSRSTSESTAALGCLVKDYFPEP 240
   |||||
QY 208 ----- 207
Db 241 VTSWNSGALTSVHTFPAVLQSSGLYSLSVTVTVSSNFGTQTYTCNVDRKPSNTKYDK 300
   |||||
QY 208 ----KSCDKHTPC-ELLGQPSVFLPPPKDITMISRTPEVTCVVVDVSHEDPEVKFN 262
   |||||
Db 301 TYERKCCVCEPCPPAPPAAGSVFLPPPKDITMISRTPEVTCVVVDVSHEDPEVKFN 360
   |||||
QY 263 YVDGVEVHNAKTKRREEQYNSTYRVVSVLTVLDHODWLNKGEYKCKVSNKALPAPIEKTIS 322
   |||||
Db 361 YVDGVEVHNAKTKRREEQYNSTYRVVSVLTVLDHODWLNKGEYKCKVSNKALPAPIEKTIS 420
QY 323 KAKQPREPOVYTLPPSRDELTKNQVSLTCLVKGYPSDIAVEMESNGQPENNYKTPPV 382
   |||||
Db 421 KTKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGYPSDIAVEMESNGQPENNYKTPPV 480
QY 383 LPSDSFFLYSKLTVDKSRMQQGNVFCSCVMEHALHNHYTKSLSLSPG 431
   |||||
Db 481 LPSDSFFLYSKLTVDKSRMQQGNVFCSCVMEHALHNHYTKSLSLSPG 529

```

```

RESULT 4
US-09-766-995-4
; Sequence 4, Application US/09766995
; Patent No. US20020052481A1
; GENERAL INFORMATION:
; APPLICANT: Graham P. Allaway et al.
; TITLE OF INVENTION: NON-PEPTIDYL MOIETY-CONJUGATED CD4-GAMMA2 AND CD4-IgG2 IMMUNOCONJ
; FILE REFERENCE: 2048/41215-CB/JPW/SHS
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/766,995
; FILING DATE: 2001-01-22
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: Patent In version 3.0
; SEQ ID NO 4
; LENGTH: 530
; TYPE: PRT
; ORGANISM: homo sapiens
US-09-766-995-4

```

```

Query Match      86.4%; Score 2085; DB 9; Length 530;
Best Local Similarity 77.3%; Pred. No. 9.9e-139;
Matches 409; Conservative 9; Mismatches 13; Indels 98; Gaps 4;

```

```

QY 1 MRGVPFRLLLVLTQALLPAATQGNKVVLGKKGDVTELTCTASOKKSIQPHMKNNOIK 60
   |||||
Db 1 MRGVPFRLLLVLTQALLPAATQGNKVVLGKKGDVTELTCTASOKKSIQPHMKNNOIK 60

```

```

OY 61 ILGNQSFLLTKGPKSLNDRADSRSLMPOGNFLLIKULKIDSDPTIICEVEDOKEEVQL 120
DB 61 ILGNQSFLLTKGPKSLNDRADSRSLMPOGNFLLIKULKIDSDPTIICEVEDOKEEVQL 120
OY 121 LVFGLTANSDFHLQGGSLTTLLESPPSSPSVQCRSPRGKNIQGGKTLVSQLELODSG 180
DB 121 LVFGLTANSDFHLQGGSLTTLLESPPSSPSVQCRSPRGKNIQGGKTLVSQLELODSG 180
OY 181 TWTCTVLNOKKVEEKIIV-----PCPA-----DEP 207
DB 181 TWTCTVLNOKKVEEKIIV-----PCPA-----DEP 207
OY 208 ----- 207
DB 208 ----- 207
OY 241 VIVSNNSGALTSQVHTFPAVLQSSGLYSLSSVTVVPSNFGQTYTCNVDHKPSNTKDX 300
DB 241 VIVSNNSGALTSQVHTFPAVLQSSGLYSLSSVTVVPSNFGQTYTCNVDHKPSNTKDX 300
OY 208 ---KSCDKHTCP-ELLGGPSVFLPPPKPKDTLMIISRTPEVTCVVDVSHEDPEVKFN 262
DB 208 ---KSCDKHTCP-ELLGGPSVFLPPPKPKDTLMIISRTPEVTCVVDVSHEDPEVKFN 262
OY 301 TVERKCCVECPCPAPVAGPSVFLPPPKKDTLMIISRTPEVTCVVDVSHEDPEVKFN 360
DB 301 TVERKCCVECPCPAPVAGPSVFLPPPKKDTLMIISRTPEVTCVVDVSHEDPEVKFN 360
OY 263 YVDGVEVHNAKTKPREEOYNSTYRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTIS 322
DB 263 YVDGVEVHNAKTKPREEOYNSTYRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTIS 322
OY 361 YVDGVEVHNAKTKPREEOYNSTYRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTIS 420
DB 361 YVDGVEVHNAKTKPREEOYNSTYRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTIS 420
OY 323 KAKGQPREPOVYTLTPSRDELTKNOVSLTCLVKGFPSPDIAVEMESNGOPENNYKTPPV 382
DB 323 KAKGQPREPOVYTLTPSRDELTKNOVSLTCLVKGFPSPDIAVEMESNGOPENNYKTPPV 382
OY 421 KTKGQPREPOVYTLTPSRDELTKNOVSLTCLVKGFPSPDIAVEMESNGOPENNYKTPPV 480
DB 421 KTKGQPREPOVYTLTPSRDELTKNOVSLTCLVKGFPSPDIAVEMESNGOPENNYKTPPV 480
OY 383 LQSDGSFPLYSKLTVDKSRMOQGNVSCSVHMEALHNYTKSLSLSPG 431
DB 383 LQSDGSFPLYSKLTVDKSRMOQGNVSCSVHMEALHNYTKSLSLSPG 431
OY 481 LQSDGSFPLYSKLTVDKSRMOQGNVSCSVHMEALHNYTKSLSLSPG 529
DB 481 LQSDGSFPLYSKLTVDKSRMOQGNVSCSVHMEALHNYTKSLSLSPG 529

```

RESULT 5

```

US-09-939-537-33
; Sequence 33, Application US/09939537
; Publication No. US20030138410A1
; GENERAL INFORMATION:

```

```

APPLICANT: Seed, Brian

```

```

Banapour, Babak
Romeo, Charles

```

```

Kolanus, Waldemar

```

```

TITLE OF INVENTION: TARGETED CYTOLYSIS OF HIV-INFECTED

```

```

CELLS BY CHIMERIC CD4 RECEPTOR- BEARING CELLS

```

```

NUMBER OF SEQUENCES: 53

```

```

CORRESPONDENCE ADDRESS:

```

```

ADDRESS: Clark & Elbling LLP
STREET: 176 Federal Street

```

```

CITY: Boston

```

```

STATE: MA

```

```

COUNTRY: USA

```

```

ZIP: 02110

```

```

COMPUTER READABLE FORM:

```

```

MEDIUM TYPE: Diskette

```

```

COMPUTER: IBM Compatible

```

```

OPERATING SYSTEM: DOS

```

```

SOFTWARE: Pasteo for Windows Version 2.0

```

```

CURRENT APPLICATION DATA:

```

```

APPLICATION NUMBER: US/09/939,537

```

```

FILING DATE: 24-Aug-2001

```

```

CLASSIFICATION: <Unknown>

```

```

PRIORITY APPLICATION DATA:

```

```

APPLICATION NUMBER: 08/284,391

```

```

FILING DATE: 02-Aug-1994

```

```

APPLICATION NUMBER: 08/195,395

```

```

FILING DATE: 14-Feb-1994

```

```

APPLICATION NUMBER: 07/847,566

```

```

FILING DATE: 06-Mar-1992

```

```

APPLICATION NUMBER: 07/665,961

```

```

FILING DATE: 07-Mar-1991

```

```

ATTORNEY/AGENT INFORMATION:

```

```

NAME: Elbling, Karen L

```

```

; REGISTRATION NUMBER: 35,238
; REFERENCE/DOCKET NUMBER: 00786/247001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-428-0200
; TELEFAX: 617-428-7045
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 254 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-09-939-537-33

```

```

Query Match 55.4%; Score 1338.5; DB 10; Length 254;
Best Local Similarity 98.0%; Pred. No. 1.86-86;
Matches 249; Conservative 0; Mismatches 0; Indels 5; Gaps 1;

```

```

OY 206 EPKSCDKHTHC-----PELLGGPSVFLPPPKPKDTLMIISRTPEVTCVVDVSHEDPEVKF 260
DB 1 EPKSCDKHTHCPCPAPVAGPSVFLPPPKPKDTLMIISRTPEVTCVVDVSHEDPEVKF 60
OY 261 NWYVDGVEVHNAKTKPREEOYNSTYRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKT 320
DB 61 NWYVDGVEVHNAKTKPREEOYNSTYRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKT 120
OY 321 ISKAKGQPREPOVYTLTPSRDELTKNOVSLTCLVKGFPSPDIAVEMESNGOPENNYKTPPV 380
DB 121 ISKAKGQPREPOVYTLTPSRDELTKNOVSLTCLVKGFPSPDIAVEMESNGOPENNYKTPPV 180
OY 381 PVLDSDGSFPLYSKLTVDKSRMOQGNVSCSVHMEALHNYTKSLSLSPGLQDETCAE 440
DB 181 PVLDSDGSFPLYSKLTVDKSRMOQGNVSCSVHMEALHNYTKSLSLSPGLQDETCAE 240
OY 441 AQDGLDGLWTTDP 454
DB 241 AQDGLDGLWTTDP 254

```

RESULT 6

```

US-10-404-724-8
; Sequence 8, Application US/10404724
; Publication No. US20030203447A1
; GENERAL INFORMATION:

```

```

APPLICANT: Horwitz, Arnold H.

```

```

TITLE OF INVENTION: Methods and Materials For Increasing Expression of Recombinant

```

```

FILE REFERENCE: 13698US01

```

```

CURRENT APPLICATION NUMBER: US/10/404,724

```

```

CURRENT FILING DATE: 2003-03-31

```

```

PRIOR APPLICATION NUMBER: US 60/368,530

```

```

PRIOR FILING DATE: 2002-03-29

```

```

NUMBER OF SEQ ID NOS: 79

```

```

SOFTWARE: PatentIn version 3.2

```

```

SEQ ID NO 8

```

```

LENGTH: 465

```

```

TYPE: PRT

```

```

ORGANISM: Homo Sapiens

```

```

US-10-404-724-8

```

```

Query Match 53.5%; Score 1291.5; DB 12; Length 465;

```

```

Best Local Similarity 58.1%; Pred. No. 7.9e-83;

```

```

Matches 286; Conservative 23; Mismatches 78; Indels 105; Gaps 13;

```

```

OY 11 LVLVQLALLPAAQGNKRVLG---KKGDVVELTCTASQKKSIOFMKNSNQIKILGNQ 66
DB 7 LFLPMAAAGSAGQIQIVGSGPELKKPGETVTKSKKS---GYFTFYGMWVWQAGK 63
OY 67 -----SFLTKGPKSLNDRADSRSLMPOGNF-----LIINKKIEDSTYI 108
DB 64 LKMMGWINTYTEPTYGD-----FKGRFAFSLETSASTANLIQINNLSKSDTATYF 114

```

```

0Y 109 CEVEDEQKEVQLLVGLTANSDTHLLQGSLLTLETSPRESSPSYQCRSPRGKNIOGG-- 166
Db 115 C-----ARRGSAVD---YMGQSTSVTASASTKGPSPVPLAPSSKSTSGGTA 158
0Y 167 -----XLSVS-----QLELOQSG-----TWTC 184
Db 159 ALGCLVKVOYFPPRYIVSNMGSALGTSGVHFFPAVLQSSGLXSLSSVVTVPBSSLGTQTYIC 218
0Y 185 TYLONQKQKVEFKIDIVPCAPAPERPKSCDKTHTC-----PELLGSPSVFLPPPKKDTLMIS 239
Db 219 NV--NHKPSNTKYD-----KRVPEPKSCDKHTCTPCPAPELLGSPSVFLPPPKKDTLMIS 272
0Y 240 RTPEVTCVAVDVDSHDEPEYKFMWYVDGVEVHNAKTPREBQYNSTRVYSVLTVLHODML 299
Db 273 RTPEVTCVAVDVDSHDEPEYKFMWYVDGVEVHNAKTPREBQYNSTRVYSVLTVLHODML 332
0Y 300 NGKEYCKKVNKALPAPIEKTISKAKGQPREPOVYLLPSRDELTKNQVSLTCLVKGFYR 359
Db 333 NGKEYCKKVNKALPAPIEKTISKAKGQPREPOVYLLPSRDELTKNQVSLTCLVKGFYR 392
0Y 360 SDIAVEMESNGQPENNYKTPPVLVDSGSEFLYSKLTVDKSRMQQGNVFSCSYMHREALHN 419
Db 393 SDIAVEMESNGQPENNYKTPPVLVDSGSEFLYSKLTVDKSRMQQGNVFSCSYMHREALHN 452
0Y 420 HYTQKSLSLSPG 431
Db 453 HYTQKSLSLSPG 464

```

Db	30	LGKKGDYELTCTAS-----QKKSIOFHWNKSNQIKIGNQSPITKGPSKL	76
Qy	30	LGKKGDYELTCTAS-----QKKSIOFHWNKSNQIKIGNQSPITKGPSKL	76
Db	267	LVPKPGSGLSCAAGFTFSPHSGMSVWRQTPDKRLEW-----VATIGSGTY-THYPDSV	320
Qy	267	LVPKPGSGLSCAAGFTFSPHSGMSVWRQTPDKRLEW-----VATIGSGTY-THYPDSV	320
Db	321	KGRFTISDN-DKNALYLQWNSLKSEDTAMYYC---ARSEFYFYGNYYTSAMDYWG	374
Qy	321	KGRFTISDN-DKNALYLQWNSLKSEDTAMYYC---ARSEFYFYGNYYTSAMDYWG	374
Db	137	QSLTILLESPPGSSPVQCRSPRGKNIQGG-----KTLVS-----	172
Qy	137	QSLTILLESPPGSSPVQCRSPRGKNIQGG-----KTLVS-----	172
Db	375	QGAASVTYSSASTKGRSVFPLAPLASSKSTSGTALAGLTVNDYFPEPPTVEMNSGALTSVH	434
Qy	375	QGAASVTYSSASTKGRSVFPLAPLASSKSTSGTALAGLTVNDYFPEPPTVEMNSGALTSVH	434
Db	173	--QLELQNSG-----TWCTCYLQNKQKVEFKIDIVCPAPBPSCDK	212
Qy	173	--QLELQNSG-----TWCTCYLQNKQKVEFKIDIVCPAPBPSCDK	212
Db	435	TPPAVLQSSGLVSLASVVTVPSSSLGTOTYICNV--NHRPSNTKYD---KRVEPSCDK	488
Qy	435	TPPAVLQSSGLVSLASVVTVPSSSLGTOTYICNV--NHRPSNTKYD---KRVEPSCDK	488

QY	213	THHC-----PELLGSSVFLFPFKKOTLMTSRPEVTCVVVVDVSHDEPVEKFMWYVDGV	267
Db	489	THHCPCPCAPBELLGGSSVFLFPFKPKDTLMTSRPEVTCVVVVDVSHDEPVEKFMWYVDGV	548
QY	268	EYVNAKTKPREEOYNSYTVVSVLTVLHODMLNGEKYCKVSNALPAPIEKTISKAKGQ	327
Db	549	EYVNAKTKPREEOYNSYTVVSVLTVLHODMLNGEKYCKVSNALPAPIEKTISKAKGQ	608
QY	328	PREPOVYTLPPSKDELTKNOVSLTCLVNGFYPSDIAVEMBSNGQ	PENNYKTTPEVLDSG 387
Db	609	PREPOVYTLPPSKDELTKNOVSLTCLVNGFYPSDIAVEMBSNGQ	PENNYKTTPEVLDSG 668
QY	388	SFPLYSKLTVDKSRMOQGVSCSYMHDLNHNHTYQKSLSPG	431
Db	669	SFPLYSKLTVDKSRMOQGVSCSYMHDLNHNHTYQKSLSPG	712

```

RESULT 8
US-10-679-620-62
; Sequence 62; Application US/10679620
; Publication No. US20040110930A1
; GENERAL INFORMATION:
; APPLICANT: Large Scale Biology
; APPLICANT: Reinl, Stephen J.
; APPLICANT: Edwards, Patricia C.
; TITLE OF INVENTION: MULTIMERIC PROTEIN ENGINEERING
; FILE REFERENCE: 34150-004A
; CURRENT APPLICATION NUMBER: US/10/679,620
; CURRENT FILING DATE: 2003-10-03
; PRIOR APPLICATION NUMBER: 60/415,940
; PRIOR FILING DATE: 2002-10-03
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 62
; LENGTH: 715
; TYPE: PR1
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: p9E10chimericv1-1, see Example 15
US-10-679-620-62

Query Match          53.4%; Score 1289; DB 16; Length 715;
Best Local Similarity 59.3%; Pred. No. 2e-02; Mismatches 81; Indels 80; Gaps 111
Matches 275; Conservative 28;

Qy      30 LGKKGVDELCTAS-----QKSKIQFMWKNNSQIKILNGQSPLTKGPSKL 76
Db      269 LVKPGSKLTKSCAAGSFTHSHYGMSWNRQTDPDKLEW-----VATISRGTY-THYDVS 3222

Qy      77 NDPAISRRLMOQGNFPLIIKKLIEDSDTYICEVEDQKEVQLVLGGLTANSPTHLLOG 136
Db      323 KGFRTISRNL-DKMLTYLQNMNLSKSEDTAMYYC-----ARRSEFYVYGNYYYSAMDYWG 3760

Qy      137 QSRITLLESPPSSPSVQOCSPRGNIQG-----TSLSVS----- 1722
Db      377 QGASVYSSASASTKGPSVFLPAPLASSKSTGCGTALGCLVKDYFFEPPTVYVSNMGSALTSGVH 4366

Qy      173 --OLELQDSG-----TWTCTVLQNOKVKEFKIDIVPCPAPBPSKCDK 2122
Db      437 TFPAYVQSSGLVSLSSVVTVPSSSLGTQTYICNV--NHKPSNTRKVD---KRVBPSKCDK 4900

Qy      213 THTC-----PELLGSPVTLPPRKQKOTLMTSRTPETCCVYVNVSHSDPEVKRWYVDGV 267
Db      491 THTCPCPAPPELLGGSVFLFPKPKKOTLMTSRTPETCCVYVNVSHSDPEVKRWYVDGV 5500

Qy      268 EVYNAATKREKEQVNSTRVVSVLTVLHQDMLNKEKVKCKVSNALPAPIEKTISKAKGQ 327
Db      551 EVYNAATKREKEQVNSTRVVSVLTVLHQDMLNKEKVKCKVSNALPAPIEKTISKAKGQ 610

Qy      328 PREPQVYTLPPSRDELTKVNSVLTCLVKGYFSPDIAVWESNGCPENNYKTPFVLDSDG 387
Db      611 PREPQVYTLPPSRDELTKVNSVLTCLVKGYFSPDIAVWESNGCPENNYKTPFVLDSDG 6700

```



```
Oy 388 SFFLYSKLTVDKSRWQGNVFCSCVMHEALHNHYTKSLSPG 431
Db 611 SFFLYSKLTVDKSRWQGNVFCSCVMHEALHNHYTKSLSPG 714

RESULT 9
US-10-363-427-14
; Sequence 14, Application US/10363427
; Publication No. US20030195538A1
; GENERAL INFORMATION:
; APPLICANT: MedexGen Inc.
; APPLICANT: CHUNG, Yong Hoon
; APPLICANT: HAN, Ji Woong
; APPLICANT: LEE, Hye Ja
; APPLICANT: CHOI, Eun Yong
; APPLICANT: KIM, Jin Mi
; APPLICANT: YIM, Soo Bin
; TITLE OF INVENTION: Concatameric Immunoadhesion
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/10/363,427
; CURRENT FILING DATE: 2003-02-28
; NUMBER OF SEQ ID NOS: 52
; SOFTWARE: Kopatentin 1.71
; SEQ ID NO 14
; LENGTH: 437
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-363-427-14

Query Match 53.3%; Score 1287.5; DB 14; Length 437;
Best Local Similarity 64.7%; Pred. No. 1.4e-82;
Matches 273; Conservative 22; Mismatches 62; Indels 65; Gaps 11;

Oy 35 DTELTCTASQKKSIOFMKNSNOIKIINGSGFLTKPSPKLNDRADSRSLMDGNPPL 94
Db 55 DDKMEKTSDDKKKIAQFRKEK-----TFREKDTYKLFK-----NGTL 92
Oy 95 IIKNLIKEDSDTYICEVEDOK-EEVQLVFGLTANS DTHLQGG-----SLTTLT 142
Db 93 KIKHLKTDQDIDYKISITDTGKNVLEKIFDLK-----IOERVKRISMTICNTTLT 145
Oy 143 LESPPSSPSVQCRSPRKNIOGGKTLVSQLELODSGTWT-----CTVLONQKVE 194
Db 146 CEVNMGTDPBLNL-----YDDGKGLKSGKVI--TKMTLSAKFKCTA-GNKVSK 195
Oy 195 FKIDIVPCPAPBPSCDTHTC-----PELLGSPSVFLPPPKKDTLMISRTPEVTCVV 249
Db 196 SSVEPVSQPA-EPKSCDHTHTCPCPAPBELLGGPSVFLPPPKKDTLMISRTPEVTCVV 254
Oy 250 DVSHDDPEVKFMWYDGVVHNKAKTPREBOYNSTYRVVSVLTVLHODMLNGKEYCKVKS 309
Db 255 DVSHDDPEVKFMWYDGVVHNKAKTPREBOYNSTYRVVSVLTVLHODMLNGKEYCKVKS 314
Oy 310 NKALPAPIEKTISKAKGPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAMWESN 369
Db 315 NKALPAPIEKTISKAKGPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAMWESN 374
Oy 370 GQPENNYKTTTPVLDSDGSFLLYSKLTVDKSRWQGNVFCSCVMHEALHNHYTKSLSPG 429
Db 375 GQPENNYKTTTPVLDSDGSFLLYSKLTVDKSRWQGNVFCSCVMHEALHNHYTKSLSPG 434

Oy 430 PG 431
Db 435 PG 436

RESULT 10
US-10-412-406-32
; Sequence 32, Application US/10412406
; Publication No. US20040058394A1
; GENERAL INFORMATION:
; APPLICANT: BIOGEN, INC.
```

```
APPLICANT: GARBER, Ellen
APPLICANT: LYNE, Paul
APPLICANT: SAIDHANA, Jose W.
TITLE OF INVENTION: HUMANIZED ANTI-LT-BETA-R ANTIBODIES
FILE REFERENCE: BINA100CN
CURRENT APPLICATION NUMBER: US/10/412,406
CURRENT FILING DATE: 2003-04-10
PRIOR APPLICATION NUMBER: 60/240,285
PRIOR FILING DATE: 2000-10-13
PRIOR APPLICATION NUMBER: 60/275,289
PRIOR FILING DATE: 2001-03-13
PRIOR APPLICATION NUMBER: 60/299,987
PRIOR FILING DATE: 2001-06-21
PRIOR APPLICATION NUMBER: PCT/US01/32140
PRIOR FILING DATE: 2001-10-12
NUMBER OF SEQ ID NOS: 33
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 32
LENGTH: 663
TYPE: PRT
ORGANISM: Homo Sapien
US-10-412-406-32

Query Match 53.3%; Score 1285.5; DB 12; Length 663;
Best Local Similarity 59.0%; Pred. No. 3.3e-82;
Matches 275; Conservative 29; Mismatches 71; Indels 91; Gaps 13;

Oy 30 LGKKGDTELTCTAS--QKSIQFHW-----KNSNOIKIINGSGFLTKPSPKLN----- 77
Db 225 LVKPGGSLRLSCAASGTFSDYVMWFRQAPGKLEVAATISQGSY-TYPPDSVKGRFT 283
Oy 78 -DRADSRSLMDQGNFPLIKLIKIEDSDTYICEVEDOKEEVQLVFGLTANS DTHLQ- 135
Db 284 ISRNMAKSLY-----LQMSLRADDTAVYCARER-----NGFYFDY 323
Oy 136 -GGSLTLTLESPPSSPSVQCRSPRKNIOGG-----KTLVS----- 172
Db 324 WGGTQTVTVSSASATGKSPVPLAPSSKSTSGTALGCLVKDYFPEPVTVSWNSGALTSG 383
Oy 173 -----QLELODSC-----TWCTVTLQNKQVEFKIDIVPCPAPBPSC 210
Db 384 VHTFPAVLQSSGLYSLSSVTVTPSSSLGTQTYICNV--NKPSTKVD---KVEKSKC 437
Oy 211 DKHTTC-----PELLGSPSVFLPPPKKDTLMISRTPEVTCVVVDVSHDDPEVKFMWYD 265
Db 438 DKHTTCPCPAPBELLGGPSVFLPPPKKDTLMISRTPEVTCVVVDVSHDDPEVKFMWYD 497
Oy 266 GVEVHNKAKTPREBOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAK 325
Db 498 GVEVHNKAKTPREBOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAK 557
Oy 326 GQPEPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAMWESNGQPENNYKTTTPVLD 385
Db 558 GQPEPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAMWESNGQPENNYKTTTPVLD 617
Oy 386 DGSFFLYSKLTVDKSRWQGNVFCSCVMHEALHNHYTKSLSPG 431
Db 618 DGSFFLYSKLTVDKSRWQGNVFCSCVMHEALHNHYTKSLSPG 663

RESULT 11
US-10-412-406-33
; Sequence 33, Application US/10412406
; Publication No. US20040058394A1
; GENERAL INFORMATION:
; APPLICANT: BIOGEN, INC.
; APPLICANT: GARBER, Ellen
; APPLICANT: LYNE, Paul
; APPLICANT: SAIDHANA, Jose W.
TITLE OF INVENTION: HUMANIZED ANTI-LT-BETA-R ANTIBODIES
FILE REFERENCE: BINA100CN
CURRENT APPLICATION NUMBER: US/10/412,406
CURRENT FILING DATE: 2003-04-10
```

```

; PRIOR APPLICATION NUMBER: 60/240,285
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: 60/275,289
; PRIOR FILING DATE: 2001-03-13
; PRIOR APPLICATION NUMBER: 60/299,987
; PRIOR FILING DATE: 2001-06-21
; PRIOR APPLICATION NUMBER: PCT/US01/32140
; PRIOR FILING DATE: 2001-10-12
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatsSeq for Windows Version 4.0
; SEQ ID NO 33
; LENGTH: 4852
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-412-406-33

Query Match      53.3%; Score 1285.5; DB 12; Length 4852;
Best Local Similarity 59.0%; Pred. No. 4.1e-81;
Matches 275; Conservative 29; Mismatches 71; Indels 91; Gaps 13;

QY 30 LKKGDTVELTCTAS--QKKSIOFW-----KNSQIKILGNQGSFLTKGFSKLN---- 77
DB 4414 LVKPGSLRLSCAASGFTFSDDYMYWFOAPGKLEWVATISDGSY--TYPDVSVKGRPT 4472
QY 78 -BRADSRRLMDQGNFPLIIKNIKIEDSPYICEVEDQKEVQLVFGLTANSDTHLQ- 135
DB 4473 ISRDNAKSLY-----LQMSLRADDTAVYICARBE-----NONFYEDY 4512
QY 136 -GOSLTLTLESPPGSSPVQCRSPRGKNIQGG-----KTLSSVS----- 172
DB 4513 WCGGTTVTVSASTKPSVFPPLAPSSKSTSGTALGCLVKDYFPEPVTVSNMNSGALTSG 4572
QY 173 ---QLELDSCG-----TWCTYVLOQKKVEFKIDIVPCAPAPKSC 210
DB 4573 VHTFPAVLQSSGSLSSVTVVPSLSLGTQTYICNV--NHKPSNTKYD---KQVEPKSC 4626
QY 211 DKHTTC-----PELLGSPSVFLPPPKKDTLMISRTPEVTCVAVDVSHEDEPKFMWYVD 265
DB 4627 DKHTTCPCPAPPELLGGPSVFLFPPKPKDTLMISRTPEVTCVAVDVSHEDEPKFMWYVD 4686
QY 266 GVEVHNAKTKPRBEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAK 325
DB 4687 GVEVHNAKTKPRBEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAK 4746
QY 326 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNNGQPENNYKTTPPVLD 385
DB 4747 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNNGQPENNYKTTPPVLD 4806
QY 386 DGSFPLYSKLTIVDKSRMOQGNVPSGVMHEALHNHYTOKSLSPG 431
DB 4807 DGSFPLYSKLTIVDKSRMOQGNVPSGVMHEALHNHYTOKSLSPG 4852

RESULT 12
US-10-435-299-7
; Sequence 7, Application US/10435299
; Publication No. US20040052783A1
; GENERAL INFORMATION:
; APPLICANT: Weiner, George
; APPLICANT: Gingsrich, Roger
; APPLICANT: Link, Brian
; APPLICANT: Teo, J. Yun
; TITLE OF INVENTION: HUMANIZED ANTIBODIES AGAINST CD3
; FILE REFERENCE: 05862-0176-CNUS04
; CURRENT APPLICATION NUMBER: US/10/435,299
; CURRENT FILING DATE: 2003-05-09
; PRIOR APPLICATION NUMBER: US 09/618,380
; PRIOR FILING DATE: 2000-07-18
; PRIOR APPLICATION NUMBER: US 08/397,411
; PRIOR FILING DATE: 1995-03-01
; PRIOR APPLICATION NUMBER: US 07/859,583
; PRIOR FILING DATE: 1992-03-27
; NUMBER OF SEQ ID NOS: 14

```

```

; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 446
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Complete heavy chain of Humanized 1D10 Ab
US-10-435-299-7

Query Match      53.1%; Score 1282.5; DB 12; Length 446;
Best Local Similarity 59.8%; Pred. No. 3.2e-82;
Matches 274; Conservative 25; Mismatches 80; Indels 79; Gaps 10;

QY 30 LKKGDTVELTCTAOKKSIOF--HWKSNQIKILGNQGSFLTKGFSKLNBRADSRRL- 86
DB 11 LVKPSRTLSLTCTVSGFLTNVGHVWQSPKGLWIGVKNVSGSTERYNAFISRLTIS 70
QY 87 --WDQGNFPLIIKNIKIEDSPYICEVEDQKEVQLVFGLTANSDTHLQ--GOSLTLT 142
DB 71 KOTSKNQVSLKLNLSLTADTAVYIC-----ARDRIAMDYWGQGLVLT 113
QY 143 LESPPGSSPVQCRSPRGKNIQGG-----KTLSSVS-----QLEL 176
DB 114 VSSASTKGPSVFPPLAPSSKSTSGTALGCLVKDYFPEPVTVSNMNSGALTSGVHTFPAVL 173
QY 177 QDSG-----TWCTYVLOQKKVEFKIDIVPCAPAPKSCDKHTTC-- 216
DB 174 QSSGSLSSVTVVPSLSLGTQTYICNV--NHKPSNTKYD---KQVEPKSCDKHTTCPP 227
QY 217 ---PELLGSPSVFLPPPKKDTLMISRTPEVTCVAVDVSHEDEPKFMWYDGVVHNAK 273
DB 228 CPAPPELLGGPSVFLFPPPKKDTLMISRTPEVTCVAVDVSHEDEPKFMWYDGVVHNAK 287
QY 274 TKPREQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQV 333
DB 288 TKPREQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQV 347
QY 334 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNNGQPENNYKTTPPVLDSDGSFPLYS 393
DB 348 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNNGQPENNYKTTPPVLDSDGSFPLYS 407
QY 394 KLTIVDKSRMOQGNVPSGVMHEALHNHYTOKSLSPG 431
DB 408 KLTIVDKSRMOQGNVPSGVMHEALHNHYTOKSLSPG 445

RESULT 13
US-10-363-427-18
; Sequence 18, Application US/10363427
; Publication No. US20030195338A1
; GENERAL INFORMATION:
; APPLICANT: MedexGen Inc.
; APPLICANT: CHUNG, Yong Hoon
; APPLICANT: HAN, Ji Moong
; APPLICANT: LEE, Hye Ja
; APPLICANT: CHOI, Sun Yong
; APPLICANT: KIM, Jin Mi
; APPLICANT: YIM, Soo Bin
; TITLE OF INVENTION: Concatametric Immunoadhesion
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/10/363,427
; CURRENT FILING DATE: 2003-02-28
; NUMBER OF SEQ ID NOS: 52
; SOFTWARE: KopatentIn 1.71
; SEQ ID NO 18
; LENGTH: 617
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-363-427-18

Query Match      53.1%; Score 1282.5; DB 14; Length 617;
Best Local Similarity 64.5%; Pred. No. 4.9e-82;
Matches 272; Conservative 22; Mismatches 63; Indels 65; Gaps 11;

```

Qy	33	DTYVELTCTSAQKXSIOFHFKNSNOIKILQNOGSFLTKGPRSLNDRADSRBSLMQGNFPL	94
Dh	235	DDIKWEKTSIDKKLIAQFREKE-----TFREKDTYKLFK-----NGTL	2722
Qy	95	IINKLIEDSDTYICEVEDOK-EEVOLLVFGLTANSPTHLLOQ-----SLTLT	1422
Dh	273	KIKHLKTDODDIKYKSIYDTKGKNVLEKIFDK-----IQERNSKPKISWTCINTLT	3255
Qy	143	LESPPGSSPSVOCRSFRGKNIOGGKTLVSQLELODSGTW-----CTVLONQKVE	194
Dh	326	CEWNGDDELNLN-----YODGKHLKLSQFVI--TKWTTSLSAKFKCJA-GNKYSKE	375
Qy	195	FKIDIVCPALPEBPKSCDKHTHC-----PELLGSPSVFLFPPPKDPTLMIISTREPTCVV	249
Dh	376	SSVSRPNSCRA-EPKSCDKHTHTCPRCAPARILLGSPSVFLFPPPKDPTLMIISTREPTCVV	434
Qy	250	DVSHEDPEYKFNMYVDGVEVHNAAKTPREEQYNSTRYVSVYLTVLHODMLNGKEYKCVS	309
Dh	435	DVSHEDPEYKFNMYVDGVEVHNAAKTPREEQYNSTRYVSVYLTVLHODMLNGKEYKCVS	494
Qy	310	NKLLPAPRIEKTISKAGQPREPOVYTLPSRDELTKNOVSLTCLYKGFPSDIAVEHESN	359
Dh	495	NKLLPAPRIEKTISKAGQPREPOVYTLPSRDELTKNOVSLTCLYKGFPSDIAVEHESN	554
Qy	370	GQEPENNYKTPPVLIDSDGSFFLYSKLTVYKSRMQGNFSCSVNHEALHNHYTKSLSLS	429
Dh	555	GQEPENNYKTPPVLIDSDGSFFLYSKLTVYKSRMQGNFSCSVNHEALHNHYTKSLSLS	614
Qy	430	PG 431	
Dh	615	PG 616	

```

RESULT 14
US-10-363-427--22
Sequence 22, Application US/10363427
Publication No. US20030195338A1
GENERAL INFORMATION:
APPLICANT: MedexGen Inc.
APPLICANT: CHUNG, Yong Hoon
APPLICANT: HAN, Ji Woong
APPLICANT: LEE, Hye Ja
APPLICANT: CHOI, Eun Yong
APPLICANT: KIM, Jin Mi
APPLICANT: YIM, Soo Bin
TITLE OF INVENTION: Concatametric Immunoadhesion
FILE REFERENCE:
CURRENT APPLICATION NUMBER: US/10/363,427
CURRENT FILING DATE: 2003-02-28
NUMBER OF SEQ ID NOS: 52
SOFTWARE: kopatentlin 1.71
SEQ ID NO 22
LENGTH: 617
TYPE: PRT
ORGANISM: Homo sapiens
US-10-363-427--22

```

Query Match	53.1%	Score 1282.5;	DB 14;	Length 617;
Best Local Similarity	64.5%	Pred. NO. 4.9e-82;		
Matches 272; Conservative	22;	Mismatches 63;	Indels 65;	Gaps 11;

```

QY      35 DTVALFCTAQQKSIQFMHMSNQIILIGNQSFLTKPSPSKLNBRADRSRLMDQGAFPL 94
        |||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||
Db      235 DDIKWETSISKKIIAQFRKEKE-----TFEKDTYLYLFF-----NGTL 272
QY      95 IIRKLKLEDSPTYICEVEDQK-EEVQLLVFGTANSDFHLLOGQ-----SLTTT 142
        |||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||
Db      273 KIRHLKLTDDDDIKVASIVPTKGANVLKEDFK-----IQERSVKPKISWTICINTLTT 325
QY      143 LBSPPSSPSVOCRRSGRGNKIIGGGKGLSVSÖLELDOSGTWT-----CTLONÖRKVE 194
        |||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||
Db      326 CEVMANGDPEPLNL-----YDGGRKLTKLSÖCVI--THKWSTLSAKRCKTA-CNKRYSKE 375

```

QY	195	EKIDIVPECPABEPPKSCDTHTC----	PELLGGSEVFLPPPKXDTIMTSRTPEVYCVVV	243
		::::		
Db	376	SSVEVSCPA-BPKSCDTHTC	PPCPABELLGGSEVFLPPPKXDTIMTSRTPEVYCVVV	434
QY	250	DVSHDEPEVKFNMYVDGVEVHNAKTPREEOYNSTYRVVSVLTJVLHODWLNGKEYCKKYS		309
Db	435	DVSHDEPEVKFNMYVDGVEVHNAKTPREEOYNSTYRVVSVLTJVLHODWLNGKEYCKKYS		494
QY	310	NKALPAPLEKITSKAKGPREPOVYTLPPSPBELTKNOVSLTCLYKGFPPSDIAVMEBN		369
Db	495	NKALPAPLEKITSKAKGPREPOVYTLPPSPBELTKNOVSLTCLYKGFPPSDIAVMEBN		554
QY	370	GQPENNYKTPPEVLDSGDSFFLYSKLTVDKSRMOOGNVSFCSVMHEALNNHYTKQSLSLSS		429
Db	555	GQPENNYKTPPEVLDSGDSFFLYSKLTVDKSRMOOGNVSFCSVMHEALNNHYTKQSLSLSS		614
QY	430	PG 431		
Db	615	PG 616		

```

RESULT 15
US-10-418-836-38
; Sequence 38, Application US/10418836
; Publication No. US20040018573a1
; GENERAL INFORMATION:
; APPLICANT: Power, Scott D.
; APPLICANT: Wang, Huaming
; APPLICANT: Ward, Michael
; TITLE OF INVENTION: Production of Functional Antibodies in
; TITLE OF INVENTION: Filamentous Fungi
; FILE REFERENCE: GC741-2
; CURRENT APPLICATION NUMBER: US/10/418, 836
; CURRENT FILING DATE: 2003-04-17
; PRIOR APPLICATION NUMBER: US 60/373, 889
; PRIOR FILING DATE: 2002-04-18
; PRIOR APPLICATION NUMBER: US 60/411,540
; PRIOR FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: US 60/452,134
; PRIOR FILING DATE: 2003-03-04
; PRIOR APPLICATION NUMBER: US 60/411,537
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 40
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 38
; LENGTH: 972
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: fusion protein
US-10-418-836-38

```

Query Match	53.1%	Score 1282.5;	DB 15;	Length 972;
Best Local Similarity	59.8%	Pred. NO. 8.7e-82;		
Matches 274; Conservative	25;	Mismatches 79;	Gaps 10;	

QY 30 LGKKDPTVELTCTASQKSIQF--HWKSNQIKILGNQGSFLTKRPSKLNDAADSRSL- 86
Db 537 LKPESETSLTCTVSGFPLTNGVMVWQSPCKGLMWGVKWSGSGSTENAAFISSLTIS 596
QY 87 --WDGNGPPLIIKLNKIEDSPYICEVEBDQKEVQLVLFGLTPANSPTHLIQ--GGSLTLT 142
Db 557 KDTSKNQVSLKLNKSLTAAIDTAVTYC-----ARNDRYAMDWGGSTLYT 639
QY 143 LSPGSSPSVQCRSPRGKNIQGG-----KLSYS-----OLEI 176
Db 640 VSSAETKPSFPLPAPSRSKTSNGGALACLWKDYFPEPVYVSWMSGALTSGVHTPEAYL 699
QY 177 QDSG-----TMTCTVLQONQKVEFKDIDVPCPAPEKSCDKTHTC-- 216
Db 700 QSSGLYLSAVTVVSSSLGTQTYICNV--NHKPNNTKVD-----KVEEKSCKDHTKCP 753


```
/ PRIOR FILING DATE: 2000-12-21
/ PRIOR APPLICATION NUMBER: US 09/111,286
/ PRIOR FILING DATE: 1998-07-07
/ PRIOR APPLICATION NUMBER: US 60/051,945
/ PRIOR FILING DATE: 1997-07-08
/ NUMBER OF SEQ ID NOS: 7
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 3
/ LENGTH: 476
/ TYPE: PRT
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic construct
US-10-290-703-3

Query Match      53.0%; Score 1280; DB 14; Length 476;
Best Local Similarity 56.9%; Pred. No. 5.3e-82;
Matches 280; Conservative 27; Mismatches 91; Indels 94; Gaps 12;

QY 11 LVVLQALLPAATQGNKVLG-----KKGDTVELTCTASOKSIQFH----- 52
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 7 VLFLVAATARSASQVQLVQSGAEVKKPKPGASVKVSCAKSGYTTFTSFDLNVNRQAPGGLEW 66
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 53 --WKNSNQIKILGNQGSFLTKGPSKLNDRADSRSLMDQGNFPLIKNLKIEDSDTYICE 110
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 67 MGNMNMNSGK-----TGYAQKFGQAVTMTNMTSITAY-MELSGLRSEDTAVYFCA 116
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 111 VEDQKEVOLL--VFGLTANSDTLLIQGSLTLLTLESPPGSSPSVQCRSPRGKNIQGG-- 166
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 117 RNADVEMAAIHYHYGMD-----VMGQGTIVTASASTKGPVPLAPSSKSTSGTA 169
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 167 -----KTLSTV-----QLELDQSG-----TWTC 184
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 170 ALGCLVKDYFPEPVYTVSNMNGALTSQVHTFPAVLQSSGLYSLSVTVPSSSLGQTLYIC 229
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 185 TYLQNKQKVEFKIDIVPCPAPEPKSCDXTHTC-----PELLGSPVFLFPPPKDTLMTS 239
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 230 NV--NHKPSNTKVD---KKEPKSCDKHTHCPCPAPELLGGPSVFLFPPPKDTLMTS 283
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 240 RRPPEVTCVVVDVSHEDPEVKFMNYVDGVEVHNAKTRPREEQYNSTRYVSVLTVLHODWL 299
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 284 RRPPEVTCVVVDVSHEDPEVKFMNYVDGVEVHNAKTRPREEQYNSTRYVSVLTVLHODWL 343
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 300 NKEKYCKTSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFEP 359
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 344 NKEKYCKTSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYP 403
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 360 SDIAVWESNGQPENNYKTTTPVLVDSGSPFLYSKLTVDKSRMQGQNVFSCVMHEALHN 419
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 404 SDIAVWESNGQPENNYKTTTPVLVDSGSPFLYSKLTVDKSRMQGQNVFSCVMHEALHN 463
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 420 HYTQKSLSLSPG 431
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 464 HYTQKSLSLSPG 475
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |

RESULT 21
/ Sequence 2, Application US/10378567
/ Publication No. US20040006208A1
/ GENERAL INFORMATION:
/ APPLICANT: KARBUSAS, MICHAEL
/ APPLICANT: HSU, YEN-MING
/ APPLICANT: TAYLOR, FREDERICK R.
/ APPLICANT: ZHENG, ZHONGLI
/ TITLE OF INVENTION: CO-CRYSTAL STRUCTURE OF MONOCLONAL ANTIBODY 5C8 AND
/ TITLE OF INVENTION: C0154, AND USE THEREOF IN DRUG DESIGN
/ FILE REFERENCE: A096CON1
/ CURRENT APPLICATION NUMBER: US/10/378,567
/ CURRENT FILING DATE: 2003-02-28
/ PRIOR APPLICATION NUMBER: PCT/US01/27352
/ PRIOR FILING DATE: 2001-08-31
/ PRIOR APPLICATION NUMBER: 60/276,452
```

```
/ PRIOR FILING DATE: 2001-03-16
/ PRIOR APPLICATION NUMBER: 60/229,933
/ PRIOR FILING DATE: 2000-09-01
/ NUMBER OF SEQ ID NOS: 3
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 2
/ LENGTH: 448
/ TYPE: PRT
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Synthetic
/ OTHER INFORMATION: humanized 5c8 heavy chain amino acid
US-10-378-567-2

Query Match      53.0%; Score 1279.5; DB 15; Length 448;
Best Local Similarity 58.9%; Pred. No. 5.3e-82;
Matches 275; Conservative 31; Mismatches 74; Indels 87; Gaps 13;

QY 25 GNKVVILGKKDVELTCTASOK--KSIQFHMKNQIKILGNQ--SFL-----TKGPSKL 76
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 8 GAEVY--KPGASVKLSCKASGYTFSTYMYW-----VKQAPQGLEWIGELNPSNGDTNF 60
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 77 NDRADSRSLW---DQGNFPLIKNLKIEDSDTYICEVEDQKEVOLLVFGLTANSDTLL 133
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 61 NEKFSKATLTVDKASASTAYMELSLRSEDTAVYCTHSDGRNDMD----- 106
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 134 LOGSLTLLTLESPPGSSPSVQCRSPRGKNIQGG-----KTLSTV----- 172
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 107 SWGQGLTIVTASASTKGPVPLAPSSKSTSGTALGCLVKDYFPEPVYTVSNMNGALTS 166
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 173 -----QLELDQSG-----TWTCVQLQNKQKVEFKIDIVPCPAPEPKS 209
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 167 GVHTFPAVLQSSGLYSLSVTVPSSSLGQTLYICNV--NHKPSNTKVD---KKEPKS 220
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 210 CDKHTHTC-----PELLGSPVFLFPPPKDTLMTSRTPEVTCVVVDVSHEDPEVKFMNY 264
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 221 CDKHTHTCPCPAPELLGGPSVFLFPPPKDTLMTSRTPEVTCVVVDVSHEDPEVKFMNY 280
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 265 DGEVHNAKTRPREEQYNSTRYVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKA 324
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 281 DGEVHNAKTRPREEQYNSTRYVSVLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKA 340
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 325 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTTPVLVD 384
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 341 KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTTPVLVD 400
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
QY 365 SDGSFFLYSKLTVDKSRMQGQNVFSCVMHEALHNHYTQKSLSLSPG 431
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 401 SDGSFFLYSKLTVDKSRMQGQNVFSCVMHEALHNHYTQKSLSLSPG 447
   | | | | | | | | | | | | | | | | | | | | | | | | | | | |

RESULT 22
/ Sequence 344, Application US/10207655
/ Publication No. US20030118592A1
/ GENERAL INFORMATION:
/ APPLICANT: Ledbetter, Jeffrey A.
/ APPLICANT: Hayden-Ledbetter, Martha S.
/ TITLE OF INVENTION: BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS
/ FILE REFERENCE: 390069, 401C1
/ CURRENT APPLICATION NUMBER: US/10/207,655
/ CURRENT FILING DATE: 2002-07-25
/ NUMBER OF SEQ ID NOS: 426
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 344
/ LENGTH: 492
/ TYPE: PRT
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: fusion polypeptide
US-10-207-655-344

Query Match      53.0%; Score 1279; DB 14; Length 492;
```

Best Local Similarity 55.8%; Pred. No. 6.5e-82;
Matches 279; Conservative 33; Mismatches 92; Indels 96; Gaps 13;

```
OY 1 MNRGVPFRHLILVQLALLPATQGNKVLGKGGDTVELTCTASQKKSIOGHMKNNOIK 60
Db 19 MSRGVD-----IVL-----TQSPPTTIAASPGKRVITTCRASSSVMTWYQOKS--- 62
OY 61 ILGNQGSFLTGPBKLNDRADSRSLMDQG-NFPLIINKLKIEDSDTYICE----- 110
Db 63 --GASPKLMIYDTSKLASGVPMRFSGSGSGTSYSLAINTMETEDATATYYCCQMSSTPLTF 120
OY 111 -----VEDOK-----BEVOLVFGLTANSDTHLLOGQSITLTLESPPGSSP 151
Db 121 GSGTKLEIKRGGSGSGSGSGSQVQLKEAGPGLVQPTQL---SLTCTVSGFSLSD 177
OY 152 SVQ-CRSPRGKNIQ-----GKKT-----LSVQLELDQSGT 181
Db 178 GVMHIRQPPGKLEMMGIITYDGGTDYNSAIKSLRSLISRDTSKQVFLKINSLOTDDTAM 237
OY 182 WTCTVLQNOQKVEFK-----IDIVPCPAPEPKSCDKHTTC-----PELLGSPSVFLPPPK 231
Db 238 YYCA-----RIHFYWGQVWVTVSSDQEPKSCDKHTICPCPAPELLGGSVFLPPPK 291
OY 232 PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKRREQYNSTYRVSVL 291
Db 232 PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKRREQYNSTYRVSVL 351
OY 232 TVLHODMLNGEKYCKVSKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLT 351
Db 332 TVLHODMLNGEKYCKVSKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLT 411
OY 352 CLVKGFPYSDIAVEMESNQGPENNYKTPPVLDSDGSFELYSKLTVDKSRMWOQGNVFSCS 411
Db 412 CLVKGFPYSDIAVEMESNQGPENNYKTPPVLDSDGSFELYSKLTVDKSRMWOQGNVFSCS 471
OY 412 VMHEALHNHYTOKSLSLSPG 431
Db 472 VMHEALHNHYTOKSLSLSPG 491
```

RESULT 23
US-10-108-260A-4292
; Sequence 4292, Application US/10108260A
; Publication No. US20040005560A1
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: No. US20040005560A1e1 full length cDNA
; FILE REFERENCE: H1-A0106
; CURRENT APPLICATION NUMBER: US/10/108,260A
; CURRENT FILING DATE: 2002-03-27
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4292
; LENGTH: 470
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-108-260A-4292

Query Match 52.9%; Score 1277.5; DB 15; Length 470;
Best Local Similarity 58.8%; Pred. No. 7.8e-82;
Matches 281; Conservative 31; Mismatches 77; Indels 89; Gaps 14;

```
OY 15 QIALPPATQGNKVLGKGGDTVELTCTAS--QKKSIOGHMKN-----SNQIKIL 62
Db 20 QVQLVQSGRE-----VKRPGSSVKVSKRASGSSFSYFTWYRKAPRGLEGMSGITPL 74
OY 63 GNQGSFLTGPBKLNDRADSRSLMDQGNFPLIINKLKIEDSDTYICEVEDQKEEVOLLV 122
Db 75 G-RPMYAGQFQDRVYISADESSI-----VYMDLRLTIEDTAIFYCAI-----LLE 120
OY 123 FGLTANSDTHLLOGQSITLTLESPPGSSSVQCRSPRGKNIOG-----KTL 169
Db 121 HEVRLAFD-HWQGGTLVTVSSASTKG--PSVPLAPSSKSTSGTALGLCLVKDYFPPPV 177
```

OY 170 SVS-----OLELDQSG-----TWCTVLQNOQKVEFKID 198

Db 178 TVSNNSGALTSGVHTFPFPAVIGSSGLYSLSVVTVPSSSLGIGQYICNV--NHKSNRKVD 235

OY 199 IVPCPAPEPKSCDKHTTC-----PELLGSPSVFLPPPKPKDTLMISRTPEVTCVVVDVSH 253

Db 236 ---KVEPKSCDKHTICPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH 291

OY 254 EDPVKFNWYVDGVEVHNAKTKRREQYNSTYRVSVLTVLHODMLNGEKYCKVSKAL 313

Db 292 EDPVKFNWYVDGVEVHNAKTKRREQYNSTYRVSVLTVLHODMLNGEKYCKVSKAL 351

OY 314 PAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGE 373

Db 352 PAPIEKTISKAKGQPREPOVYALPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGE 411

OY 374 NNYKTPPVLDSDGSFELYSKLTVDKSRMWOQGNVFSCVMHEALHNHYTOKSLSLSPG 431
Db 412 NNYKTPPVLDSDGSFELYSKLTVDKSRMWOQGNVFSCVMHEALHNHYTOKSLSLSPG 469

RESULT 24
US-10-207-655-345
; Sequence 345, Application US/10207655
; Publication No. US20030118592A1
; GENERAL INFORMATION:
; APPLICANT: Ledbetter, Jeffrey A.
; TITLE OF INVENTION: BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS
; FILE REFERENCE: 390069.401C1
; CURRENT APPLICATION NUMBER: US/10/207,655
; CURRENT FILING DATE: 2002-07-25
; NUMBER OF SEQ ID NOS: 426
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 345
; LENGTH: 543
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: fusion polypeptide
US-10-207-655-345

Query Match 52.9%; Score 1277; DB 14; Length 543;
Best Local Similarity 55.8%; Pred. No. 1e-81;
Matches 279; Conservative 33; Mismatches 92; Indels 96; Gaps 13;

```
OY 1 MNRGVPFRHLILVQLALLPATQGNKVLGKGGDTVELTCTASQKKSIOGHMKNNOIK 60
Db 19 MSRGVD-----IVL-----TQSPPTTIAASPGKRVITTCRASSSVMTWYQOKS--- 62
OY 61 ILGNQGSFLTGPBKLNDRADSRSLMDQG-NFPLIINKLKIEDSDTYICE----- 110
Db 63 --GASPKLMIYDTSKLASGVPMRFSGSGSGTSYSLAINTMETEDATATYYCCQMSSTPLTF 120
OY 111 -----VEDOK-----BEVOLVFGLTANSDTHLLOGQSITLTLESPPGSSP 151
Db 121 GSGTKLEIKRGGSGSGSGSGSQVQLKEAGPGLVQPTQL---SLTCTVSGFSLSD 177
OY 152 SVQ-CRSPRGKNIQ-----GKKT-----LSVQLELDQSGT 181
Db 178 GVMHIRQPPGKLEMMGIITYDGGTDYNSAIKSLRSLISRDTSKQVFLKINSLOTDDTAM 237
OY 182 WTCTVLQNOQKVEFK-----IDIVPCPAPEPKSCDKHTTC-----PELLGSPSVFLPPPK 231
Db 238 YYCA-----RIHFYWGQVWVTVSSDLEPKSCDKHTICPCPAPELLGGSVFLPPPK 291
OY 232 PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKRREQYNSTYRVSVL 291
Db 292 PKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKRREQYNSTYRVSVL 351
OY 352 TVLHODMLNGEKYCKVSKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQVSLT 351
```



```

US-10-138-727A-41
; Sequence 41, Application US/10138727A
; Publication No. US20030157054A1
; GENERAL INFORMATION:
; APPLICANT: Gillies, Stephen
; APPLICANT: Lo, Kin-Ming
; APPLICANT: Qian, Susan
; TITLE OF INVENTION: Recombinant Tumor Specific Antibody And Use Thereof
; FILE REFERENCE: LEX-019
; CURRENT APPLICATION NUMBER: US/10/138,727A
; PRIOR FILING DATE: 2002-05-03
; PRIOR APPLICATION NUMBER: US 60/288,564
; NUMBER OF SEQ ID NOS: 42
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 41
; LENGTH: 579
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: heavy chain-IL2
US-10-138-727A-41

```

```

Query Match      52.8%; Score 1275.5; DB 14; Length 579;
Best Local Similarity 57.7%; Pred. No. 1.4e-81;
Matches 281; Conservative 29; Mismatches 70; Indels 107; Gaps 14;

```

```

QY 32 KKGDVVELCTASQKKSIOF--HMKNSNQIKILGNQ--SFLTKGSKLNDRADSRRLW 87
DB 13 KGEIVTKISCRASGYTFNNYGMWVKQTPGKGLKMMGMINITYGTGPTAAD----- 63
QY 88 DQGNFP-----LIIKULKIEDSDTYICEVEDQKEEVLVFGILTANSDTHLLQ 136
DB 64 FKGRFAFSLSTSTAFIQLNNLRASEDTATYFC-----VRFISKG-----DYWGQ 109
QY 137 QSLITLTSPGSSSVQCRSPRGKNIQGG-----KTLVS----- 172
DB 110 TSVYSSASATKG--DSVFPPLAPSSKSTGGTALGLVADYFPEPVTVSMNSGALTSGVH 167
QY 173 --QELDQSG-----TWCTVQLONKQVFKIDIVPCAPPEPKSCDK 212
DB 168 TFPRAVLQSSGLYSLSSVTVTPSSSLGTOTYICNV--NHRPSNTKVD---KRVPEKSCDK 221
QY 213 THTC-----PELLGSPSVFLPPPKPKDITLMSRTEPVTCVVVDVSHEDPEVKFNNYVVDG 267
DB 222 THTCPCPCAPPELLGSPSVFLPPPKPKDITLMSRTEPVTCVVVDVSHEDPEVKFNNYVVDG 281
QY 268 EYHNAKTKPREQVNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG 327
DB 282 EYHNAKTKPREQVNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG 341
QY 328 PREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOEENNYKTTTPVLDSDG 387
DB 342 PREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOEENNYKTTTPVLDSDG 401
QY 388 SFFLYSKLTVDSKRWQGNVFSQVMHEALHNHYTQKSLSLSPG-----LQLD 435
DB 402 SFFLYSKLTVDSKRWQGNVFSQVMHEALHNHYTQKSLSLSPGAKAPTSSTTKTKQLDLE 461
QY 436 ETCARQ 442
DB 462 HLLDLQ 468

```

```

RESULT 28
US-10-334-235-38
; Sequence 38, Application US/10334235
; Publication No. US20040131591A1
; GENERAL INFORMATION:
; APPLICANT: Oxford Biomedica (UK) Ltd.
; APPLICANT: Kingsman, Alan
; APPLICANT: Bedington, Christopher
; APPLICANT: Carroll, Miles

```

```

; APPLICANT: Ellard, Fiona
; APPLICANT: Kingsman, Susan
; APPLICANT: Myers, Kevin
; APPLICANT: Lamikandra, Abigail
; TITLE OF INVENTION: VECTOR SYSTEM
; FILE REFERENCE: 5326200920
; CURRENT APPLICATION NUMBER: US/10/334,235
; PRIOR FILING DATE: 2002-12-30
; PRIOR APPLICATION NUMBER: US 10/060,585
; PRIOR FILING DATE: 2002-01-29
; PRIOR APPLICATION NUMBER: PCT/GB00/04317
; PRIOR FILING DATE: 2000-11-13
; PRIOR APPLICATION NUMBER: US 09/445,375
; NUMBER OF SEQ ID NOS: 40
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 38
; LENGTH: 600
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: peptide of 574sabl
US-10-334-235-38

```

```

Query Match      52.8%; Score 1275; DB 16; Length 600;
Best Local Similarity 59.4%; Pred. No. 1.6e-81;
Matches 277; Conservative 18; Mismatches 81; Indels 90; Gaps 11;

```

```

QY 23 TQGNKVVLGKKGDVVELCTASQKKSIOFHMKNSNQIKILGNOSFLTKGSKLNDRADSR 82
DB 162 TQTPFLVSAAGDVTITTCASQSSVNDVAMYQKP-----GQSTFLIISTYSS 210
QY 83 R-RSLMDQ-----GNFPLIKULKIEDSDTYICEVEDQKEEVLVFGILTANSDTHLL 134
DB 211 RYAGVPDRFISGSGYGTPTFTISTLQADLAVYCOOD-----YNSPTFG 256
QY 135 QGQSLTLTSPGSSSVQCRSPRGKNIQGG-----KTLVS----- 172
DB 257 GGTLEIKRSTAKG--DSVFPPLAPSSKSTGGTALGLVADYFPEPVTVSMNSGALTSG 314
QY 173 --QELDQSG-----TWCTVQLONKQVFKIDIVPCAPPEPKSCDK 210
DB 315 VHTFPAVLQSSGLYSLSSVTVTPSSSLGTOTYICNV--NHRPSNTKVD---KRVPEKSCDK 368
QY 211 DKTHTC-----PELLGSPSVFLPPPKPKDITLMSRTEPVTCVVVDVSHEDPEVKFNNYVD 265
DB 369 DKTHTCPCPCAPPELLGSPSVFLPPPKPKDITLMSRTEPVTCVVVDVSHEDPEVKFNNYVD 428
QY 266 EYHNAKTKPREQVNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 325
DB 429 EYHNAKTKPREQVNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 488
QY 326 GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOEENNYKTTTPVLDSDG 385
DB 489 GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOEENNYKTTTPVLDSDG 548
QY 386 DGSFFLYSKLTVDSKRWQGNVFSQVMHEALHNHYTQKSLSLSPG 431
DB 549 DGSFFLYSKLTVDSKRWQGNVFSQVMHEALHNHYTQKSLSLSPG 594

```

```

RESULT 29
US-10-320-231A-79
; Sequence 79, Application US/10320231A
; Publication No. US20030194405A1
; GENERAL INFORMATION:
; APPLICANT: Neben, Steven
; APPLICANT: Takeuchi, Toshiniko
; APPLICANT: Tomkinson, Adrian
; TITLE OF INVENTION: Antibody Inhibiting Stem Cell Factor Activity And Use For
; FILE REFERENCE: 7430*163
; CURRENT APPLICATION NUMBER: US/10/320,231A

```

```

1  CURRENT FILING DATE: 2002-12-19
2  PRIOR APPLICATION NUMBER: US 60/342,174
3  PRIOR FILING DATE: 2001-12-17
4  NUMBER OF SEQ ID NOS: 85
5  SOFTWARE: PatentIn version 3.2
6  SEQ ID NO 79
7  LENGTH: 445
8  TYPE: prt
9  ORGANISM: Artificial
10 FEATURE:
11 OTHER INFORMATION: synthetic sequence
12 US-10-320-231A-79

```

Query Match	52.8%;	Score 1274.5;	DB 14;	Length 445;
Best Local Similarity	59.2%;	Pred. No. 1.2e-81;		
Matches 277;	Conservative 27;	Mismatches 67;	Indels 97;	Gaps 13

Qy	30	LGKKSDPVELTCTAS-----	-OKKSIOPHMKNSNGIKILNQGSFL----	TKG	72	
Db	8	LVQGGSLRUSCAASGFTSSSYAMKVTROAPGKGLBWSA----	-ISGGSGSTYYADSVKG	63		
Qy	73	PSKLNDRADRSRLMDQGNFPLLIKULKJEDSDTYICEVEDOKHEVQLVGLTANSDTH	132			
Db	64	RFTIS--RDNSKNITLYIQMN-----	-SLRADYAVYYCARD-----	-FPAHND--	103	
Qy	133	LLOGQSILTLBESPGGSPSPVOCRSRGNIOGG-----	-KTLSSVS-----	117		
Db	104	-VWGQGLTVLTVSSASTKGPSVFPPLAPSSKSTGGGTAALGCLVQYFPBPVTVSMNSGALT	162			
Qy	173	-----QLELDDSG-----	-----TMTCTVLONOKKVEPIFIDIVPCPAPBPK	208		
Db	163	SGVHTPAFVAVQSSGLYSLSSVTVVPBSSLGCTQTYICNV--	-NHKPSNTKYD----	-KKVEPK	216	
Qy	209	SCDKTHTC-----	PELLGGPSVFLFPBPKDQTLMI	SRTPBVT	CVVVDVSHEDPBEKENVY	263
Db	217	SCDKTHTCPCPAPBELLGGPSVFLFPBPKDQTLMI	SRTPBVT	CVVVDVSHEDPBEKENVY	276	
Qy	264	VDDVEVHNATIKRREQOYNSTRVVSVLTVLHODMLNGEKYCKKSNQALPAPLEKTIISK	323			
Db	277	VDDVEVHNATIKRREQOYNSTRVVSVLTVLHODMLNGEKYCKKSNQALPAPLEKTIISK	336			
Qy	324	AKGQPREPQVYTLPPSRDELTKNQVSLTCLGVGFPSDIAVEMESNGQPRENNYKTTPEPVL	383			
Db	337	AKGQPREPQVYTLPPSRDELTKNQVSLTCLGVGFPSDIAVEMESNGQPRENNYKTTPEPVL	386			
Qy	384	DSDGSPFLYSKLTVDKSRMQQGNVFSQVMEBALNHNHYTQKSLSLSPG	431			
Db	397	DSGSPFLYSKLTVDKSRMQQGNVFSQVMEBALNHNHYTQKSLSLSPG	444			

Query Match	52.8%	Score 1273.5;	DB 14;	Length 444;
Best Local Similarity	59.3%;	Pred. No. 1.4e-81;		
Matches 275;	Conservative 27;	Mismatches 69;	Indels 93;	Gaps 13

```

Qy 30 LGKKGDTVELLTCTAS--QKKSIQPHW-----KSNNOIKILGNGSFL-----TKGSKL 76
Db 11 LVPPGSLRLRSCLASAEFTTSSYDMSGMWRAPBKGLEWSTTSSGSGTYYLYDSTIKGFRTI 70
Qy 77 NDRADRSRSIMDQGNFPLIKLKIEDSDTYICEVEDQKEVQLLVGLTANSDPHLLOG 136
Db 71 S-RDNKNSLYIQMN-----SLRADPAAVYYCARQ-----GLD-----YWG 105
Qy 137 QSLTLLLEBPQSSSPVOCRSPKGNKIOG-----KTLSS----- 172
Db 106 RGLTVLVSSASSTKGPVFPAPLAPSSKSTSGGTAALGCLVKDYPFPPLVTVSMNSGALTSVH 165
Qy 173 --QLEIODSG-----TMTCTVLQNOKKVFEYIDIVCPAPRPPSKCDK 212
Db 166 TFPALVLOQSSGLYLSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKYD---KXPEPSSCDK 219
Qy 213 THTC-----PELLGSGVFLEPPPKPKDTLMTSRTEPVTCVVVDVSHEDPEVKFMVYDGV 267
Db 220 THTCPKCPAPPELLGSGSVLEFPKPKDTLMTSRTEPVTCVVVDVSHEDPEVKFMVYDGV 279
Qy 268 EYVNAKTRAREQYNSTRAVSUVTLVLHODMLNGEYKCKVSNALPAPLEKITSKAKG 327
Db 280 EYVNAKTRAREQYNSTRAVSUVTLVLHODMLNGEYKCKVSNALPAPLEKITSKAKG 339
Qy 328 PREPQVYTLPPSRDELTKQVNSLTCLVNGFFPSDIIVAVEMESNGQPENNNYKTPTEVLDSDG 387
Db 340 PREPQVYTLPPSRDELTKQVNSLTCLVNGFFPSDIIVAVEMESNGQPENNNYKTPTEVLDSDG 399
Qy 388 SFFLYSKLTVYDSRWQOGVNSCSYMHALNNHTQVSLSPG 431
Db 400 SFFLYSKLTVYDSRWQOGVNSCSYMHALNNHTQVSLSPG 443

```

	Query Match	Similarity	Score	1273.5;	DB	16;	Length	444;
Best Local	59.3%	Pred.	No. 1.4e-81;					
Matches	275;	Conservative	27;	Mismatches	61;	Indels	93;	Gaps
Qy	30	LGKGGDTVELTCTAS--OKKSIOFW-----KNSNOIKILGNOGSFL-----TKGPKL	76					
Db	11	LVKGGSGSRILSCAASGFTTSSYSDMSWROAPGKGLIEWSTTSSGGSGYYRLLSDISIKGRFTI	70					
Qy	77	NDRADSRRLSDQGNFPLIKNLKIEDSDTYICEVEDEQKEVOLLVFGLTANSPTHLHG	136					

```

Db      71 S-RDNKSKSLYLQNM-----SLRAEDTAIVYVCARQ-----GLD-----YWG 105
Qy      137 QSLTTLESPPSSSSVQCRRPKGNKIOGG-----KTLSS----- 172
Db      106 RGLTVTSSASTKGPSVFLPAPLAPSSKSTSGGTALACLVKDYFPPEVTVSNMNGALTSGVH 165
Qy      173 --QLELDQSG-----TWCTVLQNKQKVEFKDIDYPCAPAPKPSGDK 212
Db      166 TFPVALQSSGLYSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KKEPKSCDK 219
Qy      213 THTC-----PELLGSPSVFLPPEPKKDTLMSRTEVTCVVVDVSHEDPEVKFMYYVDGV 267
Db      220 THTCPCPAPABELLGSPSVFLPPEPKKDTLMSRTEVTCVVVDVSHEDPEVKFMYYVDGV 279
Qy      268 EVHNAKTPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIKSKAQG 327
Db      280 EVHNAKTPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIKSKAQG 339
Qy      328 PREPOVYTLPPSRDELTKNOVSLTCLVKGFPYPSDIAVEMESNGQPENNYKTPPVLDSDG 387
Db      340 PREPOVYTLPPSRDELTKNOVSLTCLVKGFPYPSDIAVEMESNGQPENNYKTPPVLDSDG 399
Qy      368 SFFLYSKLTVDKSRMQGNVFCSCVMHEALHNHYTQKSLSLSPG 431
Db      400 SFFLYSKLTVDKSRMQGNVFCSCVMHEALHNHYTQKSLSLSPG 443

```

RESULT 32

US-10-645-215-6

```

; Sequence 6, Application US/10645215
; Publication No. US20040126379A1

```

GENERAL INFORMATION:

APPLICANT: Adolf, Guenther

APPLICANT: Baum, Anke

TITLE OF INVENTION: Compositions and Methods for Treating Cancer using

TITLE OF INVENTION: Cytoxic CD4 Antibody Immunocongulates and

TITLE OF INVENTION: Chemotherapeutic Agents

FILE REFERENCE: 1/1383

CURRENT APPLICATION NUMBER: US/10/645,215

CURRENT FILING DATE: 2003-08-21

PRIOR APPLICATION NUMBER: EP 02 018 686.2

PRIOR FILING DATE: August 21, 2002

PRIOR APPLICATION NUMBER: US 60/405,956

NUMBER OF SEQ ID NOS: 9

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 6

LENGTH: 444

TYPE: PRT

ORGANISM: Artificial Sequence

OTHER INFORMATION: Humanised Murine Antibody B1W4 4 Heavy Chain

US-10-645-215-6

```

Query Match      52.8%; Score 1273.5; DB 16; Length 444;
Best Local Similarity 59.3%; Pred. No. 1.4e-81;
Matches 275; Conservative 27; Mismatches 69; Indels 93; Gaps 13;

```

```

Qy      30 LGKKDITVELTCTAS--QKSIQFMH-----KNSNQIKILNQGSFL-----TKGPSKL 76
Db      11 LKPGGSLRLSCAAGGFTSSYDMGWAPKGLGEMVSTISSGSIYYDISIGRFTI 70
Qy      77 NDRADSRSLMDQGNFPLIINKLKIEDSDTYICEVEDQKEVQLVFGLTANSTHLLQG 136
Db      71 S-RDNKSKSLYLQNM-----SLRAEDTAIVYVCARQ-----GLD-----YWG 105
Qy      137 QSLTTLESPPSSSVQCRRPKGNKIOGG-----KTLSS----- 172
Db      106 RGLTVTSSASTKGPSVFLPAPLAPSSKSTSGGTALACLVKDYFPPEVTVSNMNGALTSGVH 165
Qy      173 --QLELDQSG-----TWCTVLQNKQKVEFKDIDYPCAPAPKPSGDK 212

```

```

Db      166 TFPVALQSSGLYSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KKEPKSCDK 219
Qy      213 THTC-----PELLGSPSVFLPPEPKKDTLMSRTEVTCVVVDVSHEDPEVKFMYYVDGV 267
Db      220 THTCPCPAPABELLGSPSVFLPPEPKKDTLMSRTEVTCVVVDVSHEDPEVKFMYYVDGV 279
Qy      268 EVHNAKTPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIKSKAQG 327
Db      280 EVHNAKTPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIKSKAQG 339
Qy      328 PREPOVYTLPPSRDELTKNOVSLTCLVKGFPYPSDIAVEMESNGQPENNYKTPPVLDSDG 387
Db      340 PREPOVYTLPPSRDELTKNOVSLTCLVKGFPYPSDIAVEMESNGQPENNYKTPPVLDSDG 399
Qy      368 SFFLYSKLTVDKSRMQGNVFCSCVMHEALHNHYTQKSLSLSPG 431
Db      400 SFFLYSKLTVDKSRMQGNVFCSCVMHEALHNHYTQKSLSLSPG 443

```

RESULT 33

US-09-740-002-27

Sequence 27, Application US/09740002

Patent No. US20020001798A1

GENERAL INFORMATION:

APPLICANT: BRAMS, PETER

APPLICANT: MORROW, PHILLIP

TITLE OF INVENTION: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES

TITLE OF INVENTION: SPECIFIC TO RSV F-PROTEIN AND METHODS FOR THEIR

FILE REFERENCE: 037003-0275759

CURRENT APPLICATION NUMBER: US/09/740,002

CURRENT FILING DATE: 2000-12-20

PRIOR APPLICATION NUMBER: 09/335,697

PRIOR FILING DATE: 1999-06-18

PRIOR APPLICATION NUMBER: 08/488,376

PRIOR FILING DATE: 1995-06-07

NUMBER OF SEQ ID NOS: 27

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 27

LENGTH: 475

TYPE: PRT

ORGANISM: Homo sapiens

US-09-740-002-27

```

Query Match      52.8%; Score 1273.5; DB 9; Length 475;
Best Local Similarity 57.1%; Pred. No. 1.5e-81;
Matches 276; Conservative 29; Mismatches 99; Indels 79; Gaps 11;

```

```

Qy      10 LLVYQLALLPATQGNKVVYLGKKDITVELTCTAS--QKSIQFMHKNNSQIKIL-- 62
Db      10 LVNATRVLSGVYQDSGPAIVKPTQTLTCTSSGSLSTRGNSVMWIRPPKALEWL 69
Qy      63 ---GNQSPITKG-PSKLNDRADSRSLMDQGNFPLIINKLKIEDSDTYICEVEDQKEE 117
Db      70 ARIDMDDTFYSASLTKRLSISKDTSKN-----QVLRMTNVVDVDTATYCAASLYDS 124
Qy      118 VQLLVFGLTANSTHLLQGSLTTLESPPSSSVQCRRPKGNKIOGG----- 166
Db      125 DSFLYF-----YHAYWGQTVVTVSSASTKGPSVFLPAPLAPSSKSTSGGTALACLVKDY 177
Qy      167 --KTLSS-----QLELDQSG-----TWCTVLQNKQK 193
Db      178 PREPVTVSNMNGALTSGVHFPAPLAPSSGLYSLSSVTVTPSSSLGTQTYICNV--NHKPS 235
Qy      194 EFKDIDYPCAPAPKPSGDKTHTC-----PELLGSPSVFLPPEPKKDTLMSRTEVTCV 248
Db      236 NTKVD---KKEPKSCDKTHTCPCPAPABELLGSPSVFLPPEPKKDTLMSRTEVTCV 291
Qy      249 VDVSHEDPEVKFMYYVDGVSEVHNAKTPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV 308
Db      292 VDVSHEDPEVKFMYYVDGVSEVHNAKTPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV 351

```



```

Db      11 LAVAAGANSGAOLGSGPEVRKPGASVKSCAKS---GFDTRDPLQWVRAQAPGQGLEWM 67
QY      66 GSFLLTKSPKLT-----NDRADSRSLMDQGNPLIINKLKIEDSDTYC--EVED 113
Db      68 GFIDPDSGSLTYANQNGRVMTREKSTTVY-----MELSLKSEDTATYFCCGSVN- 120
QY      114 QKEEVQLVFLGRLTANSDDLHLLGQSLTLTLESPGSSPSVQCRSPRGKNIQGG----- 166
Db      121 -----IVSTTSGGPDCLMDGGTVVTVSSASTKGPSPFLAPLSPKSKTSGGTALGCL 172
QY      167 -----KTLSTVS-----OLELDSG-----TWTCVLYON 189
Db      173 VVDYFPEPVTVSNMNSGALTSQVHTFPAYVLSQSGISLSSVTVTPSSSLGTQTYICNV--N 230
QY      190 QKVEFKIDIVPCPAPPEKSCDKTHTC-----PELLGSPVFLPPPKKDTLMISRPV 244
Db      231 HKSNSTKVD---KKVEPKSCDKTHTCPPCPAPPELLGSPVFLPPPKKDTLMISRPV 286
QY      245 TCVVVDVSHEDPEVKFNMYVDGVEVHNAKTPREEDQNSTYRVSVYLVTLVHQMNLNGKEY 304
Db      287 TCVVVDVSHEDPEVKFNMYVDGVEVHNAKTPREEDQNSTYRVSVYLVTLVHQMNLNGKEY 346
QY      305 KCVSNKALPAPLEKTIISKAKGPREPQVTLPPSRDELTKNQVSLTCLVKGFYPSDIAV 364
Db      347 KCVSNKALPAPLEKTIISKAKGPREPQVTLPPSRDELTKNQVSLTCLVKGFYPSDIAV 406
QY      365 EMESNGOPENNYKTPPVLDSDGSFLYSKLTVDKSRMGOGNVFCSSVMHEALHNYTOK 424
Db      407 EMESNGOPENNYKTPPVLDSDGSFLYSKLTVDKSRMGOGNVFCSSVMHEALHNYTOK 466
QY      425 SLSLSPG 431
Db      467 SLSLSPG 473

RESULT 39
US-10-660-128-12
; Sequence 12, Application US/10660128
; Publication No. US20040120947A1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Chuncharapai, Anan
; APPLICANT: Dodge, Kelly
; APPLICANT: Kim, Kyung Jin
; TITLE OF INVENTION: DR4 Antibodies and Uses Thereof
; FILE REFERENCE: P1245R1P2B
; CURRENT APPLICATION NUMBER: US/10/660,128
; CURRENT FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: US/09/584,166
; PRIOR FILING DATE: 2000-05-25
; PRIOR APPLICATION NUMBER: US 09/322,875
; PRIOR FILING DATE: 1999-05-28
; PRIOR APPLICATION NUMBER: US 09/237,299
; PRIOR FILING DATE: 1999-01-25
; PRIOR APPLICATION NUMBER: US 60/072,481
; PRIOR FILING DATE: 1998-01-26
; NUMBER OF SEQ ID NOS: 12
; SEQ ID NO 12
; LENGTH: 476
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Sequence is synthesized.
; NAME/KEY: Misc_Feature
; LOCATION: 20
; OTHER INFORMATION: Xaa may be glutamine or glutamic acid
US-10-660-128-12

Query Match      52.7%; Score 1272; DB 16; Length 476;
Best Local Similarity 60.4%; Pred. No. 1.9e-81;
Matches 273; Conservative 29; Mismatches 82; Indels 68; Gaps 12;

```

```

QY      36 TWELICTAS--OKKSIOFHKMKNNOIKILNGSGFLTKGPKSLNDRADSRSL-WDQGNF 92
Db      36 SLSITCTVSGFLTSGVHMVWQPGCKGLEWLGVMVAVGSTYNNKALMSRLSISKDNKS 95
QY      93 PLIIR-NIKIEDSDTYICEVEDQKEEVQLVFLGLTANSDDLHLLQ--GQSLTLTLESPPG 148
Db      96 QVFLKNNISLQTDITAMYYCAREGEFD---YGSLSLS-YHSMFMWCGGTSTVTSASAKT 149
QY      149 SSGPSVQCRSPRGKNIQGG-----KTLSTVS-----OLELDSG-- 180
Db      150 TGPVSFPLAPSSKTSISGGTALGCLVKDYFPEPVTVSNMNSGALTSQVHTFPAYVLSQSGLY 209
QY      181 -----TWTCVLYONQKVEFKIDIVPCPAPPEKSCDKTHTC-----PEL 219
Db      210 SLSVTVTPSSSLGTQTYICNV--HKPSNTKVD---KKVEPKSCDKTHTCPPCPAPEL 263
QY      220 LGSPSVFLPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNMYVDGVEVHNAKTPRE 279
Db      264 LGSPSVFLPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNMYVDGVEVHNAKTPRE 323
QY      280 QVNSTYRVSVYLVTLVHQMNLNGKEYKCVSNKALPAPLEKTIISKAKGPREPQVTLPPS 339
Db      324 QVNSTYRVSVYLVTLVHQMNLNGKEYKCVSNKALPAPLEKTIISKAKGPREPQVTLPPS 383
QY      340 RDELTKNQVSLTCLVKGFYPSDIAVEESNGOPENNYKTPPVLDSDGSFLYSKLTVDK 399
Db      384 RDELTKNQVSLTCLVKGFYPSDIAVEESNGOPENNYKTPPVLDSDGSFLYSKLTVDK 443
QY      400 SRMGOGNVFCSSVMHEALHNYTOKSLSLSPG 431
Db      444 SRMGOGNVFCSSVMHEALHNYTOKSLSLSPG 475

RESULT 40
US-10-159-006-18
; Sequence 18, Application US/10159006
; Publication No. US20030143229A1
; GENERAL INFORMATION:
; APPLICANT: Park, John E.
; APPLICANT: Garin-Chesa, Pilar
; APPLICANT: Bamberger, Uwe
; APPLICANT: Leger, Olivier
; APPLICANT: Saidana, Jose W.
; APPLICANT: Rettig, Wolfgang J.
; TITLE OF INVENTION: FcR4-specific Antibody with Improved Producibility
; FILE REFERENCE: 0652.1890002
; CURRENT APPLICATION NUMBER: US/10/159,006
; CURRENT FILING DATE: 2002-06-03
; PRIOR APPLICATION NUMBER: US 09/301,593
; PRIOR FILING DATE: 1999-04-29
; PRIOR APPLICATION NUMBER: EP 98107925.4
; PRIOR FILING DATE: 1998-04-30
; PRIOR APPLICATION NUMBER: US 60/086,049
; PRIOR FILING DATE: 1998-05-18
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 18
; LENGTH: 453
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-159-006-18

Query Match      52.7%; Score 1271.5; DB 14; Length 453;
Best Local Similarity 59.0%; Pred. No. 2e-81;
Matches 271; Conservative 31; Mismatches 84; Indels 73; Gaps 12;

```

```

QY      30 LGKSDTYELCTASQKSIQF--HKMKNNOIKILNGSGF-LTGPCSKLNDRAASRSL 86
Db      10 LVKPGASVMSCKTSKTSRYFTETTHVWROSHGKSLWETGINPNNGINPNVQKFGKRAVL 69
QY      87 W---DQGNFPLIINKLIKIEDSDTYICEVEDQKEEVQLVFLGLTANSDDLHLLQ--GQSLTL 141
Db      70 TVGKSSSTAYMELRSLTSEDSAVYFC-----ARRIAYGV---DEGHANDYMGQGISV 119

```



```

0Y      142 TLSPSSSSVOCRAEPRGNIQGG-----KITLSV-----QLE 175
      120 TVSSASTKGPBPVPLPSSKSTISGGTALGCLVKDYFPEPPTVSNMNGALTSGYHTPRAV 179
0Y      176 LQSSG-----TWTCYVLQNKVFEKIDIVPCAPAPKSCDKTTC- 216
      180 LQSSGLYSLSSVYTVPSSSLSGTQTYICNV--NHRKSNRKVD----KAYEPKSCDKHTTCP 223
0Y      217 ----PELLGGPSVLEFPKPKDTLMSRTPEVTCVVDVSHEDPEVKFNNYVDGVEYHNA 272
      234 PCPAPELLGGPSVFLEFPKPKDTLMSRTPEVTCVVDVSHEDPEVKFNNYVDGVEYHNA 293
0Y      273 KTPPREQGNSTYRVVSVLTVLHODMLNGKEYCKCVSNKALPAPIEKTISKAKQPREPQ 332
      294 KTPPREQGNSTYRVVSVLTVLHODMLNGKEYCKCVSNKALPAPIEKTISKAKQPREPQ 353
Db      333 VYTLPPSRDELTLNQVSLTCLVKGFPSDIAVEMESNQPENNYKTPPVLDISGSPFLY 392
      354 VYTLPPSRREMTNQVSLTCLVKGFPSDIAVEMESNQPENNYKTPPVLDISGSPFLY 413
0Y      393 SKLTVDKSRMQQGNVSCSVMEHALHNHYTQSLSG 431
      414 SKLTVDKSRMQQGNVSCSVMEHALHNHYTQSLSG 452
Db

```

RESULT 41
US-10-404

```

Sequence 25 Application US/10404724
Publication No. US20030203477A1
GENERAL INFORMATION:
APPLICANT: Horwitz, Arnold H.
TITLE OF INVENTION: Methods and Materials For Increasing Expression of Recombinant
FILE REFERENCE: 13698US01
CURRENT APPLICATION NUMBER: US/10/404,724
CURRENT FILING DATE: 2003-03-31
PRIOR APPLICATION NUMBER: US 60/368,530
PRIOR FILING DATE: 2002-03-29
NUMBER OF SEQ ID NOS: 79
SOFTWARE: PatentIn version 3.2
SEQ ID NO 25
LENGTH: 465
TYPE: PRT
ORGANISM: Homo Sapiens
US-10-404-724-25

```

Query Match	52.7%;	Score 1271.5;	DB 12;	Length 465;
Best Local Similarity	57.2%;	Pred. No. 2e-81;		
Matches 283;	Conservative 23;	Mismatches 78;	Indels 111;	Gaps 14

```

QY      11 LVVLQCLALLPAAVQGNKVVLG---KKGYVVELTCTAASQKSIQFHMKNSIQIKILANOG 66
Db      7  LLEFLMAAASAOAOIOLVOSGAIEVKKPGESVXISCKAS--GYTFTRYKGMNWRQAPDGG 63
QY      67 -----SPLTKGPS---KLNRADSRSLMDQGNF-----LIIKLIKIEDSD 105
Db      64 LEWMGMINVTYTEPTYGQKF-----QGFFTLDTSTALTEISLSRSDTA 111
QY      106 TYICEVEDQKEEVQLVFGELTANSOTHLIOGSLTTLTLESPGSSPSVQCSRPGKNIOG 165
Db      112 VYFC-----ARFGSAVD-----YWGQGLTVTSSASTKGPVFPLAPSSKSTSG 155
QY      166 G-----KTLVSS-----QLELDQSG-----T 181
Db      156 GTALAGCLVKDYFPEPVYIVSNNSGALTSCHTTPAVLVDSGLYSLSSVTVVPSSLSGTQT 215
QY      182 WTCTVLONQKQKFEKIDIVCPAPRPSKSCDKTHTC---PELIGSEVLEFPKPKDTL 236
Db      216 YICNV--NHKPSNTKVD---KRVEPKSCDKHTCTRPCAPPELLIGPSVFLFPKPKDTL 269
QY      237 MISRTPEVTCVVVDVSHEDPEVKFMWYDQGEVFNAAKTKPRREDOYNSTIRVSVLTLYAQ 296

```

D5	270	MISRTETVTCVVVDVSHEDPEVKFMWVYDVGYENAKTKKREEDQYNSYTRVSVLTPLVHQ	32.29
QY	297	DLINGEKYKCKVSNKALPAPIEKTTSAKGGPRPQVYTTLPSPSDELTKQVSTLCVKG	35.66
D5	330	DLINGEKYKCKVSNKALPAPIEKTTSAKGGPREPQVYTTLPSPSDELTKQVSTLCVKG	38.89
QY	357	FYPSDILAVEMESNGRPENNYKTTTPVLDDSGSFYLKSLTLYDKSRMOQGNVFSGSVNHAA	41.66
D5	390	FYPSDILAVEMESNGRPENNYKTTTPVLDDSGSFYLKSLTLYDKSRMOQGNVFSGSVNHAA	44.99
QY	417	LHNHYTQKSLSLSPG 431	
D5	450	LHNHYTQKSLSLSPG 464	

RESULT 42

```

US-10-207-655-15
; Sequence 15, Application US/10207655
; Publication No. US20030118592A1
; GENERAL INFORMATION:
; APPLICANT: Lebedev, Jeffrey A.
; APPLICANT: Hayden-Lebedev, Marcha S.
; TITLE OF INVENTION: BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS
; FILE REFERENCE: 350059.401C1
; CURRENT APPLICATION NUMBER: US/10/207,655
; CURRENT FILING DATE: 2002-07-25
; NUMBER OF SEQ ID NOS: 426
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 15
; LENGTH: 499
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: MOUSE-HUMAN HYBRID FUSION PROTEIN

```

```

? NAME/KEY: SITE
? LOCATION: (1)..(265)
? OTHER INFORMATION: MOUSE ANTI-HUMAN CD20 SCFV: 2H7
? FEATURE:
? NAME/KEY: DOMAIN
? LOCATION: (266)..(499)
? OTHER INFORMATION: HUMAN IGS1 WILD TYPE HINGE, CH2, CH3 FC
US-10-207-655-15

```

Query Match	52.7%;	Score 1271.5;	DB 14;	Length 499;
Best Local Similarity	56.6%;	Pred. No. 2.2e-81;		
Matches 275;	Conservative 27;	Mismatches 93;	Indels 91;	Gaps 12;

```

Oy      2  TQGNKVLAKKDDPYELTCTGASQKKSIQFHKNKSNQIKILGNQGSFLTCKGSPKLNLRADG  82
Db      27  SGPSPAILSSPGCKATMTCTCRASSVS-YMHMYQQR-----GSSPKMTYAPSNLASCVA  81
Oy      83  RRLSLMDQG-NPFLIIKLNKLEDSPTYICEVDDQKEVOLLVFGI-----  125
Db      82  RFGSGSGSYSLTISRVAEDMAITYYC-----QQMSFNPRFAGTKLKLKDGSGSGGG  137
Oy      126  ---TANSDTHLIQ-QGSLTTLTLESPGSSPSVQCR-----SPR-----  159
Db      138  SGGGSGSQAYLQQSGAEIV-----RPGASVMSCKASGYPFTSYNMHWKQTPROGLEWI  192
Oy      160  -----GKNIQGGKTLSTV-----SQLELDQSGTWTCTYLQNKVKEFK  196
Db      193  GAIYPGNQDTSYNQKFKGKATLTKDKSSSTAYMQLSLTSEDSYAVPCARVVVSYNSMY  252
Oy      197  IDI-----VPCAPAPKSPCKDTHNC-----PELLGGSPVFLPPKCKDTLMTSRPEVT  245
Db      253  FDWMGIGTTIYVSDQEPKSCDKTHICPPCCPAPPELLGGSPVFLPPKCKDTLMTSRPEVT  312
Oy      246  CUVVDVDSHEDPEVKFNMYVDGVEYVNAKTKREEQNSYSTRVVSVLTVLHQDMLNGKEYK  3050
Db      313  CUVVDVDSHEDPEVKFNMYVDGVEYVNAKTKREEQNSYSTRVVSVLTVLHQDMLNGKEYK  3722
Oy      306  CKVSNKALPAPILEKTIKRAKQGPREPQVYTLPSRDELTKNQNSLTCVXGFFPSDIABE  3655

```

```
Db 373 CKVSNKALPAPRIEKTISKAKGPREPQVYTLPSRDELTKNQVSLTCLVKGFYPSDIAVE 432
|||
Qy 366 MESNGQPENNYKTTPPVLDSDGSFLYSKLTVDKSRMQQGVNFSQSVMEALAHNHYTQKS 425
|||
Db 433 MESNGQPENNYKTTPPVLDSDGSFLYSKLTVDKSRMQQGVNFSQSVMEALAHNHYTQKS 492
|||
Qy 426 LSLSPG 431
|||
Db 493 LSLSPG 498
```

```
RESULT 43
US-10-207-655-148
; Sequence 148, Application US/10207655
; Publication No. US20030118592A1
; GENERAL INFORMATION:
; APPLICANT: Ledbetter, Jeffrey A.
; APPLICANT: Hayden-Ledbetter, Martha S.
; TITLE OF INVENTION: BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS
; FILE REFERENCE: 390069.401C1
; CURRENT APPLICATION NUMBER: US/10/207,655
; CURRENT FILING DATE: 2002-07-25
; NUMBER OF SEQ ID NOS: 426
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 148
; LENGTH: 499
; TYPE: PR1
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Mouse-Human hybrid fusion protein
US-10-207-655-148
```

```
Query Match 52.7%; Score 1271.5; DB 14; Length 499;
Best Local Similarity 56.6%; Pred. No. 2,2e-81;
Matches 275; Conservative 27; Mismatches 93; Indels 91; Gaps 12;
```

```
Qy 23 TQGNKVVLGKKDPTVELTCTASQKSIQFHMKNNOIKILGNQGSFLTGPSKLNDRADS 82
|||
Db 27 SQSPAILLASPGEKVTMTCRASSVS-YMHWYQQR-----GSSPKWIYAPNLSAGVPA 81
|||
Qy 83 RRLSLMDQGFNPLIILKLIKEDSDTYICEVEDQKEVQLLVFGL----- 125
|||
Db 82 RFGSGSGTSYSLTISRVEADEATYYC---QQMSFNPTFGAGTKLELKGSGSGGGG 137
|||
Qy 126 ---TANSDTHLQ-GQSLTLTLSPPGSSPSVQCR-----SPR----- 159
|||
Db 138 SGGGSSQAYLQSGAEV-----RPGASVKNMCKASGYTFSTYNNHMWVKQTPROGLEMI 192
|||
Qy 160 -----GKNIQGGKTLV-----SOLELDQSGTWCTVLQNKVVERK 196
|||
Db 193 GAIIYPNGDTSYNQKFGKATLTVDKSSSTAYMQLSLTSEDSAVYFCARVYYNSNY 252
|||
Qy 197 IDI-----VPCPAPEPKSCDKHTHTC-----PELLGGPSVFLFPPPKDTLMISRTPEVT 245
|||
Db 253 FDVWGIGTITVTVDDQEKSCDKHTHTCPCPAPELLGGPSVFLFPPPKDTLMISRTPEVT 312
|||
Qy 246 CVVVDVSHEDPEVKFNMYVDGVEVHNAKTPREEDYNSTYRVSVLTVLHQMVLNGKEYK 305
|||
Db 313 CVVVDVSHEDPEVKFNMYVDGVEVHNAKTPREEDYNSTYRVSVLTVLHQMVLNGKEYK 372
|||
Qy 306 CKVSNKALPAPRIEKTISKAKGPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE 365
|||
Db 373 CKVSNKALPAPRIEKTISKAKGPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE 432
|||
Qy 366 MESNGQPENNYKTTPPVLDSDGSFLYSKLTVDKSRMQQGVNFSQSVMEALAHNHYTQKS 425
|||
Db 433 MESNGQPENNYKTTPPVLDSDGSFLYSKLTVDKSRMQQGVNFSQSVMEALAHNHYTQKS 492
|||
Qy 426 LSLSPG 431
|||
Db 493 LSLSPG 498
```

```
RESULT 44
US-10-053-530-15
; Sequence 15, Application US/10053530
; Publication No. US20030133939A1
; GENERAL INFORMATION:
; APPLICANT: Ledbetter, Jeffrey
; APPLICANT: Hayden-Ledbetter, Martha
; TITLE OF INVENTION: Binding Domain-Immunoglobulin Fusion Proteins
; FILE REFERENCE: 390069.401
; CURRENT APPLICATION NUMBER: US/10/053,530
; CURRENT FILING DATE: 2002-01-17
; PRIOR APPLICATION NUMBER: US 09/765,208
; PRIOR FILING DATE: 2001-01-17
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 15
; LENGTH: 499
; TYPE: PR1
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: MOUSE-HUMAN HYBRID FUSION PROTEIN
; NAME/KEY: SITE
; LOCATION: (1)..(265)
; OTHER INFORMATION: MOUSE ANTI-HUMAN CD20 SCFV. 2H7
; NAME/KEY: DOMAIN
; LOCATION: (266)..(499)
; OTHER INFORMATION: HUMAN IGG1 WILD TYPE HINGE, CH2, CH3 FC
US-10-053-530-15
```

```
Query Match 52.7%; Score 1271.5; DB 14; Length 499;
Best Local Similarity 56.6%; Pred. No. 2,2e-81;
Matches 275; Conservative 27; Mismatches 93; Indels 91; Gaps 12;
```

```
Qy 23 TQGNKVVLGKKDPTVELTCTASQKSIQFHMKNNOIKILGNQGSFLTGPSKLNDRADS 82
|||
Db 27 SQSPAILLASPGEKVTMTCRASSVS-YMHWYQQR-----GSSPKWIYAPNLSAGVPA 81
|||
Qy 83 RRLSLMDQGFNPLIILKLIKEDSDTYICEVEDQKEVQLLVFGL----- 125
|||
Db 82 RFGSGSGTSYSLTISRVEADEATYYC---QQMSFNPTFGAGTKLELKGSGSGGGG 137
|||
Qy 126 ---TANSDTHLQ-GQSLTLTLSPPGSSPSVQCR-----SPR----- 159
|||
Db 138 SGGGSSQAYLQSGAEV-----RPGASVKNMCKASGYTFSTYNNHMWVKQTPROGLEMI 192
|||
Qy 160 -----GKNIQGGKTLV-----SOLELDQSGTWCTVLQNKVVERK 196
|||
Db 193 GAIIYPNGDTSYNQKFGKATLTVDKSSSTAYMQLSLTSEDSAVYFCARVYYNSNY 252
|||
Qy 197 IDI-----VPCPAPEPKSCDKHTHTC-----PELLGGPSVFLFPPPKDTLMISRTPEVT 245
|||
Db 253 FDVWGIGTITVTVDDQEKSCDKHTHTCPCPAPELLGGPSVFLFPPPKDTLMISRTPEVT 312
|||
Qy 246 CVVVDVSHEDPEVKFNMYVDGVEVHNAKTPREEDYNSTYRVSVLTVLHQMVLNGKEYK 305
|||
Db 313 CVVVDVSHEDPEVKFNMYVDGVEVHNAKTPREEDYNSTYRVSVLTVLHQMVLNGKEYK 372
|||
Qy 306 CKVSNKALPAPRIEKTISKAKGPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE 365
|||
Db 373 CKVSNKALPAPRIEKTISKAKGPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE 432
|||
Qy 366 MESNGQPENNYKTTPPVLDSDGSFLYSKLTVDKSRMQQGVNFSQSVMEALAHNHYTQKS 425
|||
Db 433 MESNGQPENNYKTTPPVLDSDGSFLYSKLTVDKSRMQQGVNFSQSVMEALAHNHYTQKS 492
|||
Qy 426 LSLSPG 431
|||
Db 493 LSLSPG 498
```

```
RESULT 45
US-09-948-429B-12
```

Sequence 12, Application US/09948429B
Patent No. US20020177689A1
GENERAL INFORMATION:
APPLICANT: Anderson, Darrell R.
TITLE OF INVENTION: "MONKEY MONOCLONAL ANTIBODIES SPECIFIC
TO HUMAN B7.1 AND/OR B7.2 PRIMATIZED FORMS THEREOF,
TITLE OF INVENTION: PHARMACEUTICAL COMPOSITIONS CONTAINING, AND USE THEREOF AS
IMMUNOSUPPRESSANTS"
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
STREET: 699 Prince Street
CITY: Alexandria
STATE: VA
COUNTRY: USA
ZIP: 22314
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/948,429B
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/383,916
FILING DATE:
APPLICATION NUMBER: US 08/487,550
FILING DATE: 07-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: Teskin, Robin L.
REGISTRATION NUMBER: 35,030
REFERENCE/DOCKET NUMBER: 012712-131
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-836-6620
FAX: 703-836-6620
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 476 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-09-948-429B-12

Query Match 52.7%; Score 1271; DB 9; Length 476;
Best Local Similarity 59.8%; Pred. No. 2,3e-81;
Matches 274; Conservative 29; Mismatches 87; Indels 68; Gaps 11;
QY 30 LGKKGDVLELTCTASQ---KKSIOFHWKNSNOIKILNGSGSFL-TKGPSKLNDRADSRRS 85
DB 30 LVKPSFTSLTCAVSGSGSISGGYGMWIRQPGKGLWISGYSNGTYYNPSLKSQVT 89
QY 86 L---WDQGNFPLIINKLKIEDSDTYICEVEDQKEEVQLVFGLTANS DTHLQGS LTLT 142
DB 90 ISTDTSKQFSKLKNSMTADTAAYYC-VRDLFSVGVGVY---NNWFDVWGPGVLVT 143
QY 143 LSSPPSSSVQCRSPRGKNIQGG-----KTLSSV-----QLEL 176
DB 144 VSSASTKGSPVPLAPSSKSTSGGTAALGCLVKDYFPEPEVTVSNNSGALTSCHTTPAVL 203
QY 177 QDSG-----TWCTVLQNOKKVEFKIDIVPCPAPRPSCKDXTHTC-- 216
DB 204 QSSGLYSLSVTVTPSSLSGTOTYICNV--NHKPSNTKVD-----KKAEPKSGCDKHTHCP 257
QY 217 ---PELLGSPVFLPPPKKDTLMTSKRPEVTCVVVDVSHEDPEVKFMYVDGVEVNAK 273
DB 258 CPAPILLGSPVFLPPPKKDTLMTSKRPEVTCVVVDVSHEDPEVKFMYVDGVEVNAK 317
QY 274 TKPREEOYNSTYRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTTISKAKGPREPOV 333
DB 318 TKPREEOYNSTYRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTTISKAKGPREPOV 377

QY 334 YTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNQENNYKTTPEVLDSDGSFPLYS 393
DB 378 YTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNQENNYKTTPEVLDSDGSFPLYS 437
QY 394 KLTVDKSRWQGNVFCSSVWHEALHNYTQKSLSLSG 431
DB 438 KLTVDKSRWQGNVFCSSVWHEALHNYTQKSLSLSG 475

RESULT 46
US-09-758-173-12
Sequence 12, Application US/09758173
Publication No. US20010024648A1
GENERAL INFORMATION:
APPLICANT: Anderson, Darrell R.
TITLE OF INVENTION: "MONKEY MONOCLONAL ANTIBODIES SPECIFIC
TO HUMAN B7.1 AND/OR B7.2 PRIMATIZED FORMS THEREOF,
TITLE OF INVENTION: PHARMACEUTICAL COMPOSITIONS CONTAINING, AND USE THEREOF AS
IMMUNOSUPPRESSANTS"
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
STREET: 699 Prince Street
CITY: Alexandria
STATE: VA
COUNTRY: USA
ZIP: 22314
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/758,173
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/383,916
FILING DATE:
APPLICATION NUMBER: US 08/487,550
FILING DATE: 07-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: Teskin, Robin L.
REGISTRATION NUMBER: 35,030
REFERENCE/DOCKET NUMBER: 012712-131
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-836-6620
FAX: 703-836-6620
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 476 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-09-758-173-12

Query Match 52.7%; Score 1271; DB 12; Length 476;
Best Local Similarity 59.8%; Pred. No. 2,3e-81;
Matches 274; Conservative 29; Mismatches 87; Indels 68; Gaps 11;
QY 30 LGKKGDVLELTCTASQ---KKSIOFHWKNSNOIKILNGSGSFL-TKGPSKLNDRADSRRS 85
DB 30 LVKPSFTSLTCAVSGSGSISGGYGMWIRQPGKGLWISGYSNGTYYNPSLKSQVT 89
QY 86 L---WDQGNFPLIINKLKIEDSDTYICEVEDQKEEVQLVFGLTANS DTHLQGS LTLT 142
DB 90 ISTDTSKQFSKLKNSMTADTAAYYC-VRDLFSVGVGVY---NNWFDVWGPGVLVT 143
QY 143 LSSPPSSSVQCRSPRGKNIQGG-----KTLSSV-----QLEL 176
DB 144 VSSASTKGSPVPLAPSSKSTSGGTAALGCLVKDYFPEPEVTVSNNSGALTSCHTTPAVL 203
QY 177 QDSG-----TWCTVLQNOKKVEFKIDIVPCPAPRPSCKDXTHTC-- 216

Db 204 QSSGLVSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKYD----KKAEPKSCDKHTTCTP 257
Qy 217 ---PELLGSPVFLPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNNYV DGEVHNAAK 273
Db 258 CPAPELLGSPVFLPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNNYV DGEVHNAAK 317
Qy 274 TKREQVNSTYRVAVSLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOV 333
Db 318 TKREQVNSTYRVAVSLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOV 377
Qy 334 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYS 393
Db 378 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYS 437
Qy 394 KLTVDKSRWQGNVFCSCVMHEALHNNHYTQKSLSLSPG 431
Db 438 KLTVDKSRWQGNVFCSCVMHEALHNNHYTQKSLSLSPG 475

RESULT 47
US-10-124-905-12
; Sequence 12, Application US/10124905
; Publication No. US20020166136A1
; GENERAL INFORMATION:
; APPLICANT: Anderson, Darrell R.
; TITLE OF INVENTION: "MONKEY MONOCLONAL ANTIBODIES SPECIFIC
; TITLE OF INVENTION: TO HUMAN B7.1 AND/OR B7.2 PRIMATIZED FORMS THEREOF,
; TITLE OF INVENTION: PHARMACEUTICAL COMPOSITIONS CONTAINING, AND USE THEREOF AS
; TITLE OF INVENTION: IMMUNOSUPPRESSANTS"
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: 699 Prince Street
; CITY: Alexandria
; STATE: VA
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/124,905
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/383,916
; FILING DATE:
; APPLICATION NUMBER: US 08/487,550
; FILING DATE: 07-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Teskin, Robin L.
; REGISTRATION NUMBER: 35,030
; REFERENCE/DOCKET NUMBER: 012712-131
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-836-6620
; TELEFAX: 703-836-2021
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 476 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-10-124-905-12

Query Match 52.7%; Score 1271; DB 13; Length 476;
Best Local Similarity 59.8%; Pred. No. 2.3e-81;
Matches 274; Conservative 29; Mismatches 87; Indels 68; Gaps 11;
Qy 30 LGKGGTVELTCTASQ---KKSIOFHWKNSNQIKLIGNOSFL-TKGPSKLNBRADSRSS 85

Db 30 LVKPSSETLSLTCAVSGSISGGYGWGMIRQPPGKGLMWTIGSFYSSSGNTYNNPSLKSQVT 89
Qy 86 L---WDQGFPLITIKMLKIEDSDTYICEVEDQKEEVQLVFLQTLANSDTHLLQGSLLIT 142
Db 90 ISTDTSKQNFSLKLMSTAAADTAAYYC--VRDLFSVWGMY-----NNMFVWGPGVLT 143
Qy 143 LESPPSSPSVOCRSPRGNIQGG-----KTLISV-----QLEL 176
Db 144 VSSASTKGPSVFLPAPLSSKSTSGGTAALGCLVKDYFPEPVYISNNSGALTSGVHTFPAVL 203
Qy 177 QDSG-----TWTCYVLQNKQKVEFKIDVPCAPAPKSCDKHTCT-- 216
Db 204 QSSGLVSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKYD----KKAEPKSCDKHTTCTP 257
Qy 217 ---PELLGSPVFLPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNNYV DGEVHNAAK 273
Db 258 CPAPELLGSPVFLPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFNNYV DGEVHNAAK 317
Qy 274 TKREQVNSTYRVAVSLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOV 333
Db 318 TKREQVNSTYRVAVSLTVLHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOV 377
Qy 334 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYS 393
Db 378 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYS 437
Qy 394 KLTVDKSRWQGNVFCSCVMHEALHNNHYTQKSLSLSPG 431
Db 438 KLTVDKSRWQGNVFCSCVMHEALHNNHYTQKSLSLSPG 475

RESULT 48
US-10-124-807-12
; Sequence 12, Application US/10124807
; Publication No. US20030166207A1
; GENERAL INFORMATION:
; APPLICANT: Anderson, Darrell R.
; TITLE OF INVENTION: "MONKEY MONOCLONAL ANTIBODIES SPECIFIC
; TITLE OF INVENTION: TO HUMAN B7.1 AND/OR B7.2 PRIMATIZED FORMS THEREOF,
; TITLE OF INVENTION: PHARMACEUTICAL COMPOSITIONS CONTAINING, AND USE THEREOF AS
; TITLE OF INVENTION: IMMUNOSUPPRESSANTS"
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: 699 Prince Street
; CITY: Alexandria
; STATE: VA
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/124,807
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/383,916
; FILING DATE:
; APPLICATION NUMBER: US 08/487,550
; FILING DATE: 07-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Teskin, Robin L.
; REGISTRATION NUMBER: 35,030
; REFERENCE/DOCKET NUMBER: 012712-131
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-836-6620
; TELEFAX: 703-836-2021
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 476 amino acids


```

Db      113  --QGNLTPTWTFGGGTLVTKRELGGGGSGGGGGGSDVQLQDSPELVKFGASMSC 170
Qy      154  QC-----RSPGKNIQ-----GKTLVSQ----- 173
Db      171  KAGSYPTGYIVNMKQSHGKNLEWIGLIPYKGLTTVNQKFKKATLTVDKSSATYME 230
Qy      174  ---LELDSSWTWCTYLOQONKVEFKID-----IVCPAPEPKSCDKTHTC-----PE 218
Db      231  LLSLTSEDSAVVYCCASGGYGDSDWYFDWGAGTTVTVSSDQEPKSCDKTHTCPCPAPE 290
Qy      219  LIGGSPFLEPPPKPKDTLMSRTPETCVVVDVSHDEDEVKPNMVGVGVHNAKTPRE 278
Db      291  LIGGSPVLEPPPKPKDTLMSRTPETCVVVDVSHDEDEVKPNMVGVGVHNAKTPRE 350
Qy      279  EGVNSTRVVSVTLVHODMLNGKEKCKVSNKALPAPLEKTIISAKQPREPQVYTLPP 338
Db      351  EGVNSTRVVSVTLVHODMLNGKEKCKVSNKALPAPLEKTIISAKQPREPQVYTLPP 410
Qy      339  SRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPVLDSDGSFFLYSKLTV 398
Db      411  SRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPVLDSDGSFFLYSKLTV 470
Qy      399  KSRKQGNVPSGVGMEHALHNHTQKSLSLSG 431
Db      471  KSRKQGNVPSGVGMEHALHNHTQKSLSLSG 503

```

```

RESULT 51
US-10-108-260A-4278
; Sequence 4278, Application US/10108260A
; Publication No. US20040005560A1
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: NO. US20040005560A1el full length cdna
; FILE REFERENCE: HI-A0106
; CURRENT APPLICATION NUMBER: US/10/108,260A
; CURRENT FILING DATE: 2002-03-27
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4278
; LENGTH: 473
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-108-260A-4278

```

Query Match	52.6%	Score 1270;	DB 15;	Length 473;
Best Local Similarity	57.6%	Pred. No. 2.7e-81;		
Matches 279; Conservative	29;	Mismatches 92;	Indels 84;	Gaps 14

```

Qy 13 VLQALLLPAL-TQGNKVVLG-----KKGDVVELTCTAS-QKKSIOFHH-----KASNOI 59
Db 8 VFVLALLRGVHCQQLVQSGGGVVGQGRSLRLSCSESGSFPEFNMHVNRQAPKGLGLMW 67
Qy 60 KIILNQCS---FLTGKPSKLINDRARSRLMPOGNFPIIKLIKIEDDTYICEVEOKE 116
Db 68 AVISFDGTKKXYADVSVKGRFTVSRDNRNTLD-----LLMGLREDPTAVYSCKAPFN- 121
Qy 117 EVQLLVFGLTANSDTHLQOQSILTLTLEBPSSPSVYQCRSPKRNIOG----- 166
Db 122 ----LVNGVHGFAD--LWGGTLTVVSSASTKGPSVFPPLAASSKTSGGPALGCLVKD 174
Qy 167 ---KTLVS-----QLELQDGS-----TWTCVLQNOKK 192
Db 175 YFPEPPTVSVNNSGALTSGVHTFPAVLQSSGLYSLSAVTVBPSSLSGTICYCNV--NHKP 232
Qy 193 VEFKIDIVPCPAPEPSCDKTHTC-----PELLGASVFLPRPKDQTLMSRPETVCV 247
Db 233 SNTTVYD---KRAVEPSCDKTHTCPCPCAPPELLGGSVFLPLPRKQDQLMSRPETVCV 288
Qy 248 VVDVSHDEPVEKFNWYVDGVEVNAKTKRBEQYNSTYRVSVLTVLHQDLNKEVKCK 307
Db 289 VVDVSHDEPVEKFNWYVDGVEVNAKTKRBEQYNSTYRVSVLTVLHQDLNKEVKCK 348

```

QY	308	VSNAKAPAPLEKTSIAKAKQPREPOVYTLPPSRBDLTNQVSLTCLVKGFPSPDIAVME	367
Db	349	VSNAKAPAPLEKTSIAKAKQPREPOVYTLPPSRBMTNQVSLTCLVKGFPSPDIAVME	408
QY	368	SNQPPENNYKTPPVLDSDGSFFLYSKLTVDKSRMQQGNVPSCSVMHEALHNHYTOKSL	427
Db	409	SNQPPENNYKTPPVLDSDGSFFLYSKLTVDKSRMQQGNVPSCSVMHEALHNHYTOKSL	468
QY	428	LSPG 431	
Db	469	LSPG 472	

RESULT 52
US-09-910-600-32
Sequence 32, Application US/09910600
Publication No. US20030036631A1
GENERAL INFORMATION:
APPLICANT: Longphire, Malinda
APPLICANT: Chang, Han
APPLICANT: Whitney, Gena
TITLE OF INVENTION: NOVEL SINGLETS AND USES THEREOF
FILE REFERENCE: D0003MD
CURRENT APPLICATION NUMBER: US/09/910,600
CURRENT FILING DATE: 2001-07-20
PRIOR APPLICATION NUMBER: 60/220,139
PRIOR FILING DATE: 2000-07-21

```

; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO: 32
; LENGTH: 619
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: L3a-hlg
US-09-910-600-32

```

Query Match	52.6%	Score 1270;	DB 10;	Length 619;
Best Local Similarity	57.8%;	Pred. No. 3.7e-81;		
Matches 273; Conservative	27;	Mismatches 90;	Indels 82;	Gaps 11

[illegible]


```
Db 30 LAQPGSLRLSCASGFRLLINVAVMWRQAPGKGLEMSAISGSGGNTYHADV----- 84
Qy 90 GNPPL---IIRK-----LKTEDDTYCEVEDQKEVQLLVFGLTANSDTHLQGS 138
Db 85 GRFTIRSDISKNNVFWQMSGLRAEDTAIVFCAKGNQPR-----VIVASIEN---WGQG 135
Qy 139 LTTLESPPGSSPVQCSRPRGKNIQGG-----KTLVS----- 172
Db 136 TLVTVSASTKGFSPVPLAASSKSTSGTALGCLVKDYFPPEVTVSMMNSGALTSGVHTF 195
Qy 173 QLELQDSG-----TWCTVLQONKVEFKIDIVPCAPAPKSCDKTH 214
Db 196 PAVLQSSGLYSLSSVTVVPSSSLGTOTYICNV--NKKPSNTKYD----KKEVKSCKDKTH 249
Qy 215 TC-----PELLGGPSVFLPPPKPKDTLMSRTPREVTGVVDVSHEDPEVKENMYVDGVEY 269
Db 250 TCPPCPAPPELLGGPSVFLPPPKPKDTLMSRTPREVTGVVDVSHEDPEVKENMYVDGVEY 309
Qy 270 HNAKTPREBOYASTRYVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKGPR 329
Db 310 HNAKTPREBOYASTRYVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKGPR 369
Qy 330 EPQVYTLPPSRDELTKNOVSLTCLVKGFPYSDIAVEMESNGQPENNYKTPPYLDSGSP 389
Db 370 EPQVYTLPPSRDELTKNOVSLTCLVKGFPYSDIAVEMESNGQPENNYKTPPYLDSGSP 429
Qy 390 FLYSKLTVDKSRMOQGNVFSQSVMEHALNHNHYOKSLISLSPG 431
Db 430 FLYSKLTVDKSRMOQGNVFSQSVMEHALNHNHYOKSLISLSPG 471
```

```
RESULT 56
US-10-108-260A-4285
; Sequence 4285, Application US/10108260A
; Publication No. US20040005560A1
; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: NO. US20040005560A1 full length cDNA
; FILE REFERENCE: H1-A0106
; CURRENT APPLICATION NUMBER: US/10/108,260A
; CURRENT FILING DATE: 2002-03-27
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: Patentln Ver. 2.1
; SEQ ID NO 4285
; LENGTH: 471
; TYPE: PR
; ORGANISM: Homo sapiens
US-10-108-260A-4285
```

```
Query Match 52.5%; Score 1268.5; DB 15; Length 471;
Best Local Similarity 57.2%; Pred. No. 3,4e-81;
Matches 277; Conservative 37; Mismatches 85; Indels 85; Gaps 14;

Qy 10 LLLVL-----QLALLPAATQGNKVVLAGKGDVTELCTASQKKSIF--HMKN---SNQI 59
Db 10 LLAIVISGGGQVPLVSGTE---VKPEASVNIISCKAPGYFTTFYMWWRQAFQGGI 64
Qy 60 KILGNQGSFLTKGPSKLNDRADRSRLMDQGNP---LIINKLIEDSDTYICEVEDQK 116
Db 65 EMMGINP---SSGRSSVQKFEGRLLTLTADTSTTTAHMELRNLTSDTGVYCTTTRMK 122
Qy 117 EVOQLLVFGLTANSDTHLQGSILTLTESPPGSSPVQCSRPRGKNIQGG----- 166
Db 123 VVR-----GSDNYWGQGLTVIVSSASTKG--PSVFLPAPBSKSTSGTALGCLVND 172
Qy 167 ---KTLVS-----QLEIVQDSG-----TWCTVLQONK 192
Db 173 YPEPEVTVSMMNSGALTSGVHTFPAVLQSSGLYSLSSVTVVPSSSLGTOTYICNV--NKKP 230
Qy 193 VEPKIDIVPCAPAPKSCDKTHTC-----PELLGGPSVFLPPPKPKDTLMSRTPREVT 247
Db 231 SNTKVD---EKVEPKSCDKTHTCPPCPAPPELLGGPSVFLPPPKPKDTLMSRTPREVT 286
```

```
Qy 248 VVDVSHEDPEVKENMYVDGVEYHNAKTPREBOYASTRYVSVLTVLHODMLNGKEYCK 307
Db 287 VVDVSHEDPEVKENMYVDGVEYHNAKTPREBOYASTRYVSVLTVLHODMLNGKEYCK 346
Qy 308 VSNKALPAPIEKTISKAKQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPYSDIAVEME 367
Db 347 VSNKALPAPIEKTISKAKQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPYSDIAVEME 406
Qy 368 SNGQPENNYKTPPYLDSGSPFLYSKLTVDKSRMOQGNVFSQSVMEHALNHNHYOKSLIS 427
Db 407 SNGQPENNYKTPPYLDSGSPFLYSKLTVDKSRMOQGNVFSQSVMEHALNHNHYOKSLIS 466
Qy 428 LSPG 431
Db 467 LSPG 470
```

```
RESULT 57
US-10-416-011-2
; Sequence 2, Application US/10416011
; Publication No. US20040126363A1
; GENERAL INFORMATION:
; APPLICANT: Jensen, Michael
; APPLICANT: Forman, Stephen
; APPLICANT: Raubitschek, Andrew
; TITLE OF INVENTION: CD19-specific redirected immune cells
; FILE REFERENCE: 1954-338
; CURRENT APPLICATION NUMBER: US/10/416,011
; CURRENT FILING DATE: 2003-05-07
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: Patentln version 3.1
; SEQ ID NO 2
; LENGTH: 634
; TYPE: PR
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: CD19R: zeta chimeric receptor
US-10-416-011-2
```

```
Query Match 52.5%; Score 1268; DB 16; Length 634;
Best Local Similarity 56.2%; Pred. No. 5,3e-81;
Matches 287; Conservative 28; Mismatches 94; Indels 102; Gaps 16;

Qy 10 LLLVLQAL--LP-----AATQGNKVVLAGKGDVTELCTASQKKSIOFHW---K 54
Db 2 LLLVTSLLLCGLPAPFLIPDIQMTOTTSSIASLGDRTVISCRAODISKYLMWYQOK 61
Qy 55 NSNQIKILGNQGSFLTKG--PSKLNDRADRSRLMDQGNPPLIYKLIKIEDSDTYICEVED 113
Db 62 PGGTVKLLIYHTSRILHSGVPSRFGSGSGT-----DLSLITSMLBEDDIATTCQOQN 114
Qy 114 QKE-----EVOQLLVFGLTANSDTHLQGSILTLTESPPG-----SPSVQVOC--- 155
Db 115 TLPTFGGTGKLEIGTISGSGKP--GSGEGSTKGEVLUQESGELVAPQSISVTCYVSG 173
Qy 156 -----RSPRGKNIQ-----GKKT-----LSVSQLE 175
Db 174 VELPVDGVSWIQPAPRKGLEMLGVIMGSETTYNSALSKSLTIINKNSKQVFLKMNISIO 233
Qy 176 LODSGTWCTVLQONKVV---EFKIDI-----VPCAPAPKSCDKTHTC-----PELL 220
Db 234 TDDTAIYYCA-----KHYYGGSYAMDWGQGSTVIVSSVEPKSDKTHTCPPCPAPELL 288
Qy 221 GGPVFLPPPKPKDTLMSRTPREVTGVVDVSHEDPEVKENMYVDGVEYHNAKTPREBO 280
Db 289 GGPVFLPPPKPKDTLMSRTPREVTGVVDVSHEDPEVKENMYVDGVEYHNAKTPREBO 348
Qy 281 YNSTRVSVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKQPREPOVYTLPPSR 340
Db 349 YNSTRVSVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKQPREPOVYTLPPSR 408
Qy 341 DELTKNOVSLTCLVKGFPYSDIAVEMESNGQPENNYKTPPYLDSGSPFLYSKLTVDKS 400
```



```

Db      409 DELTKQVSLTCLVKGFPYSDIAVEMESNGQPENNYKTPVLVDSGDFLYSKLTVDKS 468
QY      401 RMQGNVFCSCVMHEALHNHYTKSLSPG 431
Db      469 RMQGNVFCSCVMHEALHNHYTKSLSPG 499

```

RESULT 58

```

US-10-226-435A-12
; Sequence 12, Application US/10226435A
; Publication No. US20040043418A1
; GENERAL INFORMATION:
; APPLICANT: ELI LILLY AND COMPANY AND WASHINGTON UNIVERSITY
; TITLE OF INVENTION: Humanized Antibodies that Sequester Amyloid Beta Peptide
; FILE REFERENCE: 8792/293
; CURRENT APPLICATION NUMBER: US/10/226,435A
; PRIOR FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: PCT/US01/06191
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: 60/184,601
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: 60/254,465
; PRIOR FILING DATE: 2000-12-08
; PRIOR APPLICATION NUMBER: 60/254,498
; PRIOR FILING DATE: 2000-12-08
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
; LENGTH: 442
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Humanized antibodies
US-10-226-435A-12

```

```

Query Match      52.5%; Score 1267.5; DB 12; Length 442;
Best Local Similarity 59.1%; Pred. No. 3.7e-81;
Matches 274; Conservative 26; Mismatches 69; Indels 95; Gaps 13;

```

```

QY      30 LGKGDYVELTGTAS--QKKSIOFMKNS-----NQIKLNGQSF--LTGSPKL 76
Db      11 LVQPGSLRLSCAAGFTFSRYSMSWVRQAPGKGLVLAQINSVNSTYPPDTVVGKRPFI 70
QY      77 NDRADSRRLMDOGNFPLIKKLIKIEDSDTYICEVEDQKEVQLLVFGLTANSDTHLQ 136
Db      71 S-RDAKATLYQM-----SLRADTAVYIC-----ASGD---YWG 103
QY      137 GSLTLTLSPGSSSPSVOCSPRGKNIQGG-----KTLVS----- 172
Db      104 QGTLTVSSASTKGPSVFLAPSSKSTSGTALGCLVMDYPRPVTVMNSGALTSGVH 163
QY      173 --QLELDGSG-----TWCTVYQONQKVEFKDIDYPCRPAREKSCDK 212
Db      164 TFPVAVLQSSGLVSLSSVTVTPSSSLGTQTYICNV--NHPSPNTKYD---KKEPEKSCDK 217
QY      213 THTC-----PELLGSPVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNMYVDGV 267
Db      218 THTCPCPAPPELLGSPVFLPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNMYVDGV 277
QY      268 EVHNAKTKPREBOYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQ 327
Db      278 EVHNAKTKPREBOYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQ 337
QY      328 PREPOVYTLPPSRDELTKQVSLTCLVKGFPYSDIAVEMESNGQPENNYKTPVLVDSG 387
Db      338 PREPOVYTLPPSRDELTKQVSLTCLVKGFPYSDIAVEMESNGQPENNYKTPVLVDSG 397
QY      368 SFFLYSKLTVDSKRMQGNVFCSCVMHEALHNHYTKSLSPG 431
Db      398 SFFLYSKLTVDSKRMQGNVFCSCVMHEALHNHYTKSLSPG 441

```

```

RESULT 59
US-10-120-198B-2
; Sequence 2, Application US/10120198B
; Publication No. US20030215427A1
; GENERAL INFORMATION:
; APPLICANT: Jensen, Michael
; TITLE OF INVENTION: CE7-SPECIFIC REDIRECTED IMMUNE CELLS
; FILE REFERENCE: 1954-337
; CURRENT APPLICATION NUMBER: US/10/120,198B
; PRIOR FILING DATE: 2002-04-11
; PRIOR APPLICATION NUMBER: 60/282,859
; PRIOR FILING DATE: 2001-04-11
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 631
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: mouse-human chimera
US-10-120-198B-2

```

```

Query Match      52.5%; Score 1266.5; DB 15; Length 631;
Best Local Similarity 54.2%; Pred. No. 6.8e-81;
Matches 277; Conservative 39; Mismatches 84; Indels 111; Gaps 14;

```

```

QY      5 VPRFHLVYLQALLPATGKNKVLGKGDYVELTGTASQKSIQF--HW---KNSNQI 59
Db      13 LHPAFILIPQVQLQDQGA-----LVKPGASVRLSKASGYRTGTYMMHWKVRPGHGL 67
QY      60 KILNGQSFLLTKGSPSKINDRADSRRLM--DQGNP--LIKNIKIEDSDTYICEVEDQKE 116
Db      68 EWIGEINP--SNGRITNNEPKSKATLTVDKSSTTAFMQLSGLTSEDSAVYFCARD---- 121
QY      117 EVQLVFGITRANSTHLQGSITLTLESPPGSS----- 150
Db      122 ----YGTSYNFD---YWGQGTTLTVSSGGGSGGGSGGGSDIQMTQSSSPSVSLG 173
QY      151 --PSVQGR-----SPR-----GKNIQGGKTLVS 172
Db      174 DRVITTCANEDINNRLAMTQOTFGNSPRLISGATNLVGVPSRFSGSGSKDYTLIT 233
QY      173 QLELDGSGTWCT-----VLQNKVPEFKIDIVPCRPAREKSCDKTHTC---DELT 220
Db      234 SLQEDPATYTCQGYWSTPFTFGSGTELEIKV-----EPKSSDKTHTCPCPAPREL 285
QY      221 GGPVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNMYVDGVVHNAKTKPREEQ 280
Db      286 GGPVFLPPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNMYVDGVVHNAKTKPREEQ 345
QY      281 YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGPREPOVYTLPPSR 340
Db      346 YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGPREPOVYTLPPSR 405
QY      341 DELTKQVSLTCLVKGFPYSDIAVEMESNGQPENNYKTPVLVDSGDFLYSKLTVDKS 400
Db      406 DELTKQVSLTCLVKGFPYSDIAVEMESNGQPENNYKTPVLVDSGDFLYSKLTVDKS 465
QY      401 RMQGNVFCSCVMHEALHNHYTKSLSPG 431
Db      466 RMQGNVFCSCVMHEALHNHYTKSLSPG 496

```

RESULT 60

```

US-09-925-179-68
; Sequence 68, Application US/09925179
; Publication No. US20030044858A1
; GENERAL INFORMATION:
; APPLICANT: Jardieu, Paula M.
; TITLE OF INVENTION: Anti-19E Antibodies (as amended)
; FILE REFERENCE: P0718P2CID1C1US
; CURRENT APPLICATION NUMBER: US/09/925,179

```

```

; CURRENT FILING DATE: 2001-08-08
; PRIOR APPLICATION NUMBER: US 08/466,163
; PRIOR FILING DATE: 1995-06-06
; PRIOR APPLICATION NUMBER: US 08/405,617
; PRIOR FILING DATE: 1995-03-15
; PRIOR APPLICATION NUMBER: US 08/185,899
; PRIOR FILING DATE: 1994-01-26
; PRIOR APPLICATION NUMBER: PCT/US92/06860
; PRIOR FILING DATE: 1992-08-14
; PRIOR APPLICATION NUMBER: US 07/879,495
; PRIOR FILING DATE: 1992-05-07
; PRIOR APPLICATION NUMBER: US 07/744,768
; PRIOR FILING DATE: 1991-08-14
; NUMBER OF SEQ ID NOS: 68
; SEQ ID NO 68
; LENGTH: 451
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Full-length heavy chain sequence corresponding to F(ab)9 of Table
US-09-925-179-68

```

```

Query Match      52.4%; Score 1266; DB 10; Length 451;
Best Local Similarity 58.6%; Pred. No. 4.8e-81;
Matches 273; Conservative 25; Mismatches 78; Indels 90; Gaps 12;

QY 30 LGKGDVELTCTASQ---KKSIOFHMKNSNOIKILGNQSFITKGPSKLNDR-----78
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 11 LVQPGSLRLSCAAS-GYSGFTGHMNNVWROAPGKLEWGMHIPSDBETRYNQKEDRFT 70
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 79 -RADSRSLMDQGNFPLIKNLKIEDSDTYICEVEDQKEEVQLVFGLTANSPTH---LL 134
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 71 SRDSDSKNT-----FLQLNSARAEDTAYVYCGARSH-----YFG-----HMFAY 110
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 135 QGSLTLTLSPSPSSPVQCRSPRGKNIQCG-----KTLSSVS-----172
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 111 WGCGTLVTVSASATKGPVSFPLAPSSKSTSGTALGCLVKDYFPEPTVSNMNSGALTSG 170
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 173 ---QLELQDSG-----TWTCYVLQNOKKVEFKIDIVPCAPAPKSCD 210
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 171 VHTFPAVLQSSGLYSLSVTVTPSSSLGTQTYICNV--NHKPSNTYVD---KVEPKSC 224
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 211 DKHTTC-----PELGGPSVFLPFPKPKDTLMTSRTPEYTCVVDVSHEDPEVKFMWYD 265
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 225 DKHTTCPPCPAPFLDLGGPSVFLEPFPKPKDTLMTSRTPEYTCVVDVSHEDPEVKFMWYD 284
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 266 GVEVHNAKTKPREEQYNSTRVVSVLTVLHODMLNGKEYKCKVSNKALPAPIEKTISKAK 325
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 285 GVEVHNAKTKPREEQYNSTRVVSVLTVLHODMLNGKEYKCKVSNKALPAPIEKTISKAK 344
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 326 GQPREQVYTLTPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTPPVLDSD 385
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 345 GQPREQVYTLTPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTPPVLDSD 404
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 386 DGSFPLYSKLTVDKSRMNOGQNVFSCSVMEHALHNHTOKSLSLSPG 431
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 405 DGSFPLYSKLTVDKSRMNOGQNVFSCSVMEHALHNHTOKSLSLSPG 450
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :

```

```

RESULT 61
US-10-423-299-4
; Sequence 4, Application US/104232299
; Publication No. US20030229212A1
; GENERAL INFORMATION:
; APPLICANT: FAHRNER, ROBERT
; APPLICANT: FOLLMAN, DEBORAH
; APPLICANT: LEBRETTON, BENEDICTE
; APPLICANT: VAN REIS, ROBERT
; TITLE OF INVENTION: NON-AFFINITY PURIFICATION OF PROTEINS
; FILE REFERENCE: 39766-0121A
; CURRENT APPLICATION NUMBER: US/10/423,299
; CURRENT FILING DATE: 2003-04-25
; PRIOR APPLICATION NUMBER: US 60/375,953

```

```

; PRIOR FILING DATE: 2002-04-26
; NUMBER OF SEQ ID NOS: 4
; SEQ ID NO 4
; LENGTH: 451
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Sequence is synthesized
US-10-423-299-4

```

```

Query Match      52.4%; Score 1266; DB 15; Length 451;
Best Local Similarity 58.9%; Pred. No. 4.8e-81;
Matches 274; Conservative 28; Mismatches 75; Indels 88; Gaps 13;

QY 30 LGKGDVELTCTAQSIOFHMKN-----SNQIKILG--NQSFITKGPSKLNDR--79
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 11 LVQPGSLRLSCAAS-GYSGFTGHMNNVWROAPGKLEWGMHIPSDBETRYNQKEDRFT 69
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 80 ---ADSRSLMDQGNFPLIKNLKIEDSDTYICEVEDQKEEVQLVFGLTANSPTH--LQ 135
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 70 ISVDKSKNTLYLQNN-----SLRAEDTAYVYCGARSH-----ARGIYFGITTFDYW 111
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 136 QGSLTLTLSPSPSSPVQCRSPRGKNIQCG-----KTLSSVS-----172
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 112 WGCGTLVTVSASATKGPVSFPLAPSSKSTSGTALGCLVKDYFPEPTVSNMNSGALTSG 171
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 173 ---QLELQDSG-----TWTCYVLQNOKKVEFKIDIVPCAPAPKSCD 211
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 172 VHTFPAVLQSSGLYSLSVTVTPSSSLGTQTYICNV--NHKPSNTYVD---KVEPKSCD 225
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 212 DKHTTC-----PELGGPSVFLPFPKPKDTLMTSRTPEYTCVVDVSHEDPEVKFMWYD 266
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 226 DKHTTCPPCPAPFLDLGGPSVFLEPFPKPKDTLMTSRTPEYTCVVDVSHEDPEVKFMWYD 285
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 267 VEVHNAKTKPREEQYNSTRVVSVLTVLHODMLNGKEYKCKVSNKALPAPIEKTISKAKG 326
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 286 VEVHNAKTKPREEQYNSTRVVSVLTVLHODMLNGKEYKCKVSNKALPAPIEKTISKAKG 345
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 327 QPREQVYTLTPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTPPVLDSD 386
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 346 QPREQVYTLTPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTPPVLDSD 405
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 387 GSFPLYSKLTVDKSRMNOGQNVFSCSVMEHALHNHTOKSLSLSPG 431
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 406 GSFPLYSKLTVDKSRMNOGQNVFSCSVMEHALHNHTOKSLSLSPG 450
| : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :

```

```

RESULT 62
US-10-020-786-9
; Sequence 9, Application US/10020786
; Publication No. US20030073164A1
; GENERAL INFORMATION:
; APPLICANT: Simmons, Laura C.
; APPLICANT: Klimowski, Laura
; APPLICANT: Reilly, Dorothea
; APPLICANT: Yansura, Daniel G.
; TITLE OF INVENTION: PROKARYOTICALLY PRODUCED ANTIBODIES AND USES THEREOF
; FILE REFERENCE: P1793R1
; CURRENT APPLICATION NUMBER: US/10/020,786
; CURRENT FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/256,164
; PRIOR FILING DATE: 2000-12-14
; NUMBER OF SEQ ID NOS: 11
; SEQ ID NO 9
; LENGTH: 470
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: anti-TF heavy chain
US-10-020-786-9

```

```

Query Match      52.4%; Score 1266; DB 14; Length 470;
Best Local Similarity 58.8%; Pred. No. 5.1e-81;

```

```

Matches 275; Conservative 26; Mismatches 69; Indels 98; Gaps 14;
QY 30 LGKKGDTVELTCTAS--QKKSIOFHM-----KNSNOIKILG-NGSGFLTKGSPKLANRA 80
DB 34 LVQPGGSLRLSCAAGFNKEYYMMWVQAQPKGLEWGLIDPEGN--TIYDPKFORA 91
QY 81 ----DSRRSLWDQGNFLLIKNLKIEDSDYICEVEDOKEBVLVGLTANSDTHL-- 133
DB 92 TISANSKVTALQNM-----SLRAEDTAVYYCA-----RDTAAYF 127
QY 134 -LOGSGLTLTLSPSGSSPSVQCRSPRGKNIOG-----KTLSSV----- 172
DB 128 DYGEGTTLVTVSSASTKGSPVFLPAPSSKSTSGTALGCLVKDYFPEPVTVSNMGSALT 187
QY 173 -----QLELDQSG-----TWCTVLQNOKKVEFKIDIVPCPAPBPX 208
DB 168 SGVHTFPRAVLQSSGLYSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKVD----KVEPK 241
QY 209 SCDKTHTC-----PELLGSPVFLFPPPKPDITLMSRTPEVTCVAVDVSHEDPEVKFMWY 263
DB 242 SCDKTHTCPCPAPBELLGGPSVFLFPPPKPDITLMSRTPEVTCVAVDVSHEDPEVKFMWY 301
QY 264 VDGEVHNAKTKPREEQNSTYRVVSVTLVHQMVLNGKEYCKVSNKALPAPIEKTISK 323
DB 302 VDGEVHNAKTKPREEQNSTYRVVSVTLVHQMVLNGKEYCKVSNKALPAPIEKTISK 361
QY 324 AKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSDIAVEMESNGQPENNYKTTTPVL 383
DB 362 AKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSDIAVEMESNGQPENNYKTTTPVL 421
QY 384 DSDGSFFLYSKLTVDKSRMOQGNVFCSSVMHEALHNHYTQKSLSLSPG 431
DB 422 DSDGSFFLYSKLTVDKSRMOQGNVFCSSVMHEALHNHYTQKSLSLSPG 469

RESULT 63
US-10-227-694-5
; Sequence 5, Application US/10227694
; Publication No. US2003007739A1
; GENERAL INFORMATION:
; APPLICANT: Simmons, Laura
; APPLICANT: Andersen, Dana
; TITLE OF INVENTION: A SYSTEM FOR ANTIBODY EXPRESSION AND ASSEMBLY
; FILE REFERENCE: P1867R1
; CURRENT APPLICATION NUMBER: US/10/227,694
; CURRENT FILING DATE: 2002-08-26
; PRIOR APPLICATION NUMBER: US 60/315,209
; PRIOR FILING DATE: 2001-08-27
; NUMBER OF SEQ ID NOS: 6
; SEQ ID NO 5
; LENGTH: 470
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-227-694-5

Query Match 52.4%; Score 1266; DB 14; Length 470;
Best Local Similarity 58.8%; Pred. No. 5.1e-81;
Matches 275; Conservative 26; Mismatches 69; Indels 98; Gaps 14;
QY 30 LGKKGDTVELTCTAS--QKKSIOFHM-----KNSNOIKILG-NGSGFLTKGSPKLANRA 80
DB 34 LVQPGGSLRLSCAAGFNKEYYMMWVQAQPKGLEWGLIDPEGN--TIYDPKFORA 91
QY 81 ----DSRRSLWDQGNFLLIKNLKIEDSDYICEVEDOKEBVLVGLTANSDTHL-- 133
DB 92 TISANSKVTALQNM-----SLRAEDTAVYYCA-----RDTAAYF 127
QY 134 -LOGSGLTLTLSPSGSSPSVQCRSPRGKNIOG-----KTLSSV----- 172
DB 128 DYGEGTTLVTVSSASTKGSPVFLPAPSSKSTSGTALGCLVKDYFPEPVTVSNMGSALT 187

```

```

QY 173 -----QLELDQSG-----TWCTVLQNOKKVEFKIDIVPCPAPBPX 208
DB 168 SGVHTFPRAVLQSSGLYSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKVD----KVEPK 241
QY 209 SCDKTHTC-----PELLGSPVFLFPPPKPDITLMSRTPEVTCVAVDVSHEDPEVKFMWY 263
DB 242 SCDKTHTCPCPAPBELLGGPSVFLFPPPKPDITLMSRTPEVTCVAVDVSHEDPEVKFMWY 301
QY 264 VDGEVHNAKTKPREEQNSTYRVVSVTLVHQMVLNGKEYCKVSNKALPAPIEKTISK 323
DB 302 VDGEVHNAKTKPREEQNSTYRVVSVTLVHQMVLNGKEYCKVSNKALPAPIEKTISK 361
QY 324 AKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSDIAVEMESNGQPENNYKTTTPVL 383
DB 362 AKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSDIAVEMESNGQPENNYKTTTPVL 421
QY 384 DSDGSFFLYSKLTVDKSRMOQGNVFCSSVMHEALHNHYTQKSLSLSPG 431
DB 422 DSDGSFFLYSKLTVDKSRMOQGNVFCSSVMHEALHNHYTQKSLSLSPG 469

RESULT 64
US-09-848-832-3
; Sequence 3, Application US/09848832
; Publication No. US2003016507A1
; GENERAL INFORMATION:
; APPLICANT: Hooper, Douglas
; APPLICANT: Dietzschold, Bernhard
; TITLE OF INVENTION: RABIES VIRUS-SPECIFIC NEUTRALIZING HUMAN
; FILE REFERENCE: H0001.NP0002
; CURRENT APPLICATION NUMBER: US/09/848,832
; CURRENT FILING DATE: 2001-05-04
; PRIOR APPLICATION NUMBER: 60/204,518
; PRIOR FILING DATE: 2000-05-16
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 474
; TYPE: PRT
; ORGANISM: Homo sapien
US-09-848-832-3

Query Match 52.4%; Score 1266; DB 10; Length 474;
Best Local Similarity 59.1%; Pred. No. 5.1e-81;
Matches 276; Conservative 32; Mismatches 71; Indels 88; Gaps 15;
QY 30 LGKKGDTVELTCTAS-----QKKSIOFHMKNSNOIKILGQSGFL--TKGP 73
DB 30 LVQPGGSLRLSCAAGFTPSNYAMSVWQAQPKGLEWVSA--ISASGH-STYLADSVYGR 86
QY 74 SKLNDRAISRSLWDQGNFLLIKNLKIEDSDYICEVEDOKEBVLVGLTANSDTHL 133
DB 87 FTIS-RDNSKVTALQNM-----SLRAEDTAVYYCA--KDRVTHIVV-LNGGFD-- 132
QY 134 LOGSGLTLTLSPSGSSPSVQCRSPRGKNIOG-----KTLSSV----- 172
DB 133 YMGGSTRVTVSSASTKGSPVFLPAPSSKSTSGTALGCLVKDYFPEPVTVSNMGSALT 192
QY 173 -----QLELDQSG-----TWCTVLQNOKKVEFKIDIVPCPAPBPX 209
DB 193 GVHTFPRAVLQSSGLYSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKVD----KVEPK 246
QY 210 CDKTHTC-----PELLGSPVFLFPPPKPDITLMSRTPEVTCVAVDVSHEDPEVKFMWY 264
DB 247 CDKTHTCPCPAPBELLGGPSVFLFPPPKPDITLMSRTPEVTCVAVDVSHEDPEVKFMWY 306
QY 265 DGVEVHNAKTKPREEQNSTYRVVSVTLVHQMVLNGKEYCKVSNKALPAPIEKTISKA 324
DB 307 DGVEVHNAKTKPREEQNSTYRVVSVTLVHQMVLNGKEYCKVSNKALPAPIEKTISKA 366
QY 325 KQGREPOVYTLPPSRDELTKNOVSLTCLVKGFPSDIAVEMESNGQPENNYKTTTPVL 384

```

```

Db          167 KQPREPQYVTLPSREEMTKQVSLTCLVKGPISDIAVEMESNGPENNYKTTTPYLD 426
Cr          365 SSGSFYLSKLTVDKSRMOQGVFGSVNHEALHNHYTQKSLSLSPG 431
           |||||
Db          427 SSGSFYLSKLTVDKSRMOQGVFGSVNHEALHNHYTQKSLSLSPG 473

RESULT 65
US-10-225-108A-3
; Sequence 3, Application US/10225108A
; Publication No. US20030157112A1
; GENERAL INFORMATION:
; APPLICANT: HOOVER, Craig
; APPLICANT: DIETZSCHOLD, Bernhard
; TITLE OF INVENTION: Recombinant Antibodies, and Compositions
; TITLE OF INVENTION: and Methods for Making Them
; FILE REFERENCE: 8321-110
; CURRENT APPLICATION NUMBER: US/10/225,108A
; CURRENT FILING DATE: 2003-04-10
; PRIOR APPLICATION NUMBER: US 09/848,832
; PRIOR FILING DATE: 2001-05-04
; PRIOR APPLICATION NUMBER: US 60/204,518
; PRIOR FILING DATE: 2001-05-16
; PRIOR APPLICATION NUMBER: US 60/314,023
; PRIOR FILING DATE: 2001-08-21
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: FaSTSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 474
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-225-108A-3

```

Query Match	52.4%	Score 1266	DB 14	Length 474
Best Local Similarity	59.1%	Pred. No. 5	1e-81	
Matches	276	Conservative	32	Mismatches 81; Indels 88; Gaps 15

QY	30	LGKKDVTVELTCTAS-----QKSIQFHMKNSNQIKILNGSPL---TKGP	73
		: : : :	: : :
Db	30	LVQCGGSLRLSCAASGFTFSNYAMSWVAQPEKGLIEWSA--ISASGH-STYLADSVKGR	86
		: : : :	: : :
QY	74	SKLNDRADSRRLSDQGNFPLIKNLKIEDSPDYICEVEDQKEEVOLLVFGILTANSDTHL	133
		: : : : : : : :	: : : : : : : :
Db	87	FTIS-RONSKOTLVLQNM-----SLRADPTAVYCA---KDEVTMTIVV-LANGFD---	132
		: : : :	: : :
QY	134	LOGGSLLTLESPPGSSPSVQCRSPRKNIOGG-----KTLVS-----	172
		: : : :	: : :
Db	133	YMGQGTIRVTVASASATKGPSVFPLAPSSKSTSGTALGCLVKDYPPRPVATSNMGALTS	192
		: : : :	: : :
QY	173	-----QLELDQSG-----TWTTTVLQNGKKVCFKDIYFCRAPPERKS	209
		: : :	: : :
Db	193	GVHTFPRAVLQSSGLYSLSVVTVTPSSLSGTQYICNV--NNHPSNTKYD---KRVPERKS	246
		: : :	: : :
QY	210	CDKHTHTC-----PELLGGPSVFLFPPKPRDITMIISRTPEVTCVVVDVSHEDPEVKFNYY	264
		: : : :	: : :
Db	247	CDKHTHTCPCCAPPELLGGSPVFLFPPKPRDITMIISRTPEVTCVVVDVSHEDPEVKFNYY	306
		: : : :	: : :
QY	265	DGVEVHNAKTKPREQOYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPAPIETKTISKA	324
		: : : :	: : :
Db	307	DGVEVHNAKTKPREQOYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPAPIETKTISKA	366
		: : : :	: : :
QY	325	KGQREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGOEENNYKTTTPPYLD	384
		: : : :	: : :
Db	367	KGQREPOVYTLPPSRDEMTKNQVSLTCLVKGFYPSDIAVEWESNGOEENNYKTTTPPYLD	426
		: : : :	: : :
QY	385	SDGSFFLYSKLTVDKSRWQQGNVFCSSYMHENLHNHYQKSLSLSPG	431
		: : : :	: : :
Db	427	SDGSFFLYSKLTVDKSRWQQGNVFCSSYMHENLHNHYQKSLSLSPG	473
		: : : :	: : :

RESULT	66
US-10-461-148-1	
Sequence 1, Application US/10461148	

```

Publication No. US20040013672A1
GENERAL INFORMATION:
APPLICANT: Dietzschold, Bernhard
APPLICANT: Hooper, Douglas C.
TITLE OF INVENTION: RECOMBINANT ANTIBODIES AND COMPOSITIONS
TITLE OF INVENTION: AND METHODS FOR MAKING AND USING THE SAME
FILE REFERENCE: 8321-110C11-185685
CURRENT APPLICATION NUMBER: US/10/461,148
PRIORITY FILING DATE: 2003-06-13
PRIORITY APPLICATION NUMBER: US 10/225,108
PRIORITY FILING DATE: 2002-08-21
PRIORITY APPLICATION NUMBER: US 60/314,023
PRIORITY FILING DATE: 2001-08-21
PRIORITY APPLICATION NUMBER: US 09/848,832
PRIORITY FILING DATE: 2001-05-04
PRIORITY APPLICATION NUMBER: US 60/204,518
PRIORITY FILING DATE: 2000-05-16
NUMBER OF SEQ ID NOS: 24
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 1
LENGTH: 474
TYPE: PRT
ORGANISM: Human
US-10-461-148-1

```

```

Query Match      52.4% Score 1266; DB 15; Length 474;
Best Local Similarity 59.1%; Pred. No. 5, 1e-81;
Matches 276; Conservative 32; Mismatches 71; Indels 88; Gaps 15;

QY          30 LGKKGDVVELVTAS-----OKKSIOFHWNKSNQIKILNQGSLF---TKGP 73
   | : : : : |
Db          30 LVPGCGSLRLSCAAGCFTFNSYAMSWRQAIPGKLFWWSA--ISAGH-STYLADSVYGR 86
   | : : : : |

QY          74 SKANDRADSRSLMDGNFPFLIITKNLKIERSDPTICYEVEOKEVEQLLVFGLTANSPTH 133
   | : : : : |
Db          87 FTTS-RDNSSKNTLYLQNN-----SLAEPTAVYYCA--KDREVTMIIV-LANGFD-- 132
   | : : : : |

QY          134 LQGGSLTLTLESPPGSSPSVOCRSSPRGKNIQGG-----KTLSSV----- 172
   | : : : : |
Db          133 YMGQGRIVTYSSASTKGTPSPVPLAPASSKISGGLAALGCLVKDYFPEPVTVSNNGALT 192
   | : : : : |

QY          173 -----OLEIQDSG-----TWCTVLONOKKVEFKIDIVPCPAPERP 209
   | : : : : |
Db          193 GVHTFPAVLQSSGLYSLSVVTPSSSLGTGYICNV--NHKDSNTKVD----KRVEPKS 246
   | : : : : |

QY          210 CDKTHTC-----PELLGSBSVFLPPPXPOTLMISRPEVTCVYVDVSHEDPEYKFWMYV 264
   | : : : : |
Db          247 CDKHTHTPCCPABELLGGPSVFLEPPKPXTLMSRPBEVTCVVDVSHSDPEYKFMVYV 306
   | : : : : |

QY          265 DGEVHNAAKTPREEOYNSTRVVSVYTLVHOMLNKKEYCKRYSNALPAPIETKISK 324
   | : : : : |
Db          307 DGDEVHNAAKTPREEOYNSTRVVSVYTLVHOMLNKEYCKRYSNALPAPIETKISK 366
   | : : : : |

QY          325 KGQPREPOVYTLPPSRDELTKNOVSLTCLVGKGFPSDI AEWESNQGPENNYKTTPEVLD 384
   | : : : : |
Db          367 KGQPREPOVYTLPPSRREMTKNOVSLTCLVGKGFPSDI AEWESNQGPENNYKTTPEVLD 426
   | : : : : |

QY          385 SDSSEFLYKSLTYDKSRWQOGANFSGCVHEALHNHYTQSLSLSPG 431
   | : : : : |
Db          427 SDGSFFLYKSLTYDKSRWQOGANFSCGVHEALHNHYTQSLSLSPG 473
   | : : : : |

RESULT 67
US-10-207-655-240
; Sequence 240, Application US/10207655
; Publication No. US20030118592A1
; GENERAL INFORMATION:
; APPLICANT: Ledbetter, Jeffrey A.
; APPLICANT: Hayden-Ledbetter, Marsha S.
; TITLE OR INVENTION: BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS
; FILE REFERENCE: 390069.401CI
; CURRENT APPLICATION NUMBER: US/10/207, 655
; CURRENT FILING DATE: 2002-07-25

```

```

? NUMBER OF SEQ ID NOS: 426
? SOFTWARE: PatentIn version 3.0
? SEQ ID NO: 240
? LENGTH: 500
? TYPE: prt
? ORGANSIM: Artificial Sequence
? FEATURE:
? OTHER INFORMATION: fusion polypeptide
US-10-207-655-240

```

Query Match	52.4%	Score 1266	DB 14	Length 500
Best Local Similarity	56.3%	Pred NO. 5.5e-81		
Matches 274	Conservative 27	Mismatches 94	Indels 92	Gaps 12

Qy	23	TOGNKVLJGKGGTJVLCTGASQKSIQPHMKNQNDIKLGNQGSFLTKGSKLNRADS	82
Db	27	SQSPALISABPGKVMTCRASSVS-YMHVQQR-----GSPPEFWIYASNLASGVA	81
Qy	83	RRSLMDQG-NPLIITKMLKIEDSDTYICEVEDQKEVOLLYFGL-----	125
Db	82	RFSQSGSGTYSLTISRVEADEATYYC-----QQWSFNPPTFGAGTKLELKDGGSGGG	137
Qy	126	----TANSDTMLD-QGSLTLTLESPPGSSPVQCR-----SPR-----	159
Db	138	SGGGSGQATVLOQSGAEV-----RFGASVMSKASAGTFFSYMHVVKQTPRQGLEW	192
Qy	160	-----GKNIQGGKTLV-----SOLELDGSGTWTCTVLQNOKVEFK	196
Db	193	GAIVPGNGDTSYNQKPKGKATLLTVDKSSSTAYMQLSLTSEDSAYFCARVYVYNSYMY	252
Qy	197	ID-----IVPCPAPBPKSQCDKTHC-----PELLGSPVLPKPKQDMLMSRPEV	244
Db	253	FDWVGITCTTVVSSDQBPSCDTHHCPCPAPBELLGSGSVFLPFPKQDMLMSRPEV	312
Qy	245	TCVVVDVSHEDPEVKENMYVDGYEVNNAKTKRREQNSTYRVVSVLTVLHQDWLNGKEY	304
Db	313	TCVVVDVSHEDPEVKFNMYVDGYEVNNAKTKRREQNSTYRVVSVLTVLHQDWLNGKEY	372
Qy	305	KCRVSNALPAPLEKITSKAKQPRRPQYVTLPPSRDELTKQVSLTCLVNGFFPSIAV	364
Db	373	KCRVSNALPAPLEKITSKAKQPRRPQYVTLPPSRDELTKQVSLTCLVNGFFPSIAV	432
Qy	365	EMESNGCPENNYKTPPEVLVSDGSFFLYSKLTVDKSRMQQGVFSCSVMEHALNNHTQK	424
Db	433	EMESNGCPENNYKTPPEVLVSDGSFFLYSKLTVDKSRMQQGVFSCSVMEHALNNHTQK	492
Qy	425	SLSLSPG	431
Db	493	SLSLSPG	499

```

RESULT 68
US-10-207-655-398
Sequence 398: Application US/10207655
Publication No. US20030118592A1
GENERAL INFORMATION:
APPLICANT: Ledbetter, Jeffrey A.
APPLICANT: Hayden-Ledbetter, Martha S.
TITLE OF INVENTION: BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS
FILE REFERENCE: 390069.401C1
CURRENT APPLICATION NUMBER: US/10/207,655
CURRENT FILING DATE: 2002-07-25
NUMBER OF SEQ ID NOS: 426
SOFTWARE: PatentIn version 3.0
SEQ ID NO 398
LENGTH: 500
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: fusion polypeptide
US-10-207-655-398

```

Query Match 52.4%; Score 1266; DB 14; Length 500;

Best Local Similarity 56.3%; Pred. No. 5.5e-81;
Matches 274; Conservative 27; Mismatches 94; Indels 92; Gaps 122

```

Oy 23 TOGNKVLGKKGGTYELFTJASOKKSIQFMHNSNQIKILDNQSGFLTKGSKLNDRAD5 82
Db 27 SOSPALMSPEBKMTMCRBASSYS-YMHYQOKP-----GSPKPMIYAPSNLASGVA 81
Oy 83 RRLMDQG-NPFLITKNTKIEDSDTYICEVEDQKEVQVLVFL-----125
Db 82 RFGSGSGTYSLTISRVAEDAAATYC-----QQWSFNPPTFGAGTKLELNDGGSGGG 137
Oy 126 ---TANSDFHLQ-GOSLFTLLESPGSSPSVOC-----SPR-----159
Db 138 SGGGSSQAVLQDSAEVY-----RFGASVYMSCASGYTTSTYNMHYKOTPPQGLEMI 132
Oy 160 -----GKNIQGGKTLV-----SOLEODSGTWTYVLQONQKVEFK 196
Db 193 GAIRPGNGDTSYQOKFKGKATLTVWKSSTAYMOLSLTSEDSAVYFCARVYVYNSYMY 252
Oy 197 ID-----IVPCNAPBPKSCDKHTC-----PELLGSPSFLPPPKDTLMTSRTPEV 244
Db 253 FDMWGCTTAYVSSDOBPBSCDKHTCPBPAPBELLGGSPSFLPPPKDTLMTSRTPEV 312
Oy 245 TCVVVDVSHEDPEVKFMYVDGVEVHNAKTRKREQYNSTYRVVSVLTVLHQDWLNGKEY 304
Db 313 TCVVVDVSHEDPEVKFMYVDGVEVHNAKTRKREQYNSTYRVVSVLTVLHQDWLNGKEY 372
Oy 305 KCVYRKALPAPIEKTIISAKGQPREPOVITLPPSRDELTKNQVSLTCLVKGFPSIDAV 364
Db 373 KCVYRKALPAPIEKTIISAKGQPREPOVITLPPSRDELTKNQVSLTCLVKGFPSIDAV 432
Oy 365 EWESNQPENNYKTTTPVLDSDGSFFLYSKLTVDSRMQGNVPSCSVMHEALHNHTQK 424
Db 433 EWESNQPENNYKTTTPVLDSDGSFFLYSKLTVDSRMQGNVPSCSVMHEALHNHTQK 492
Oy 425 SLSLSPG 431
Db 493 SLSLSPG 499

```

```

RESULT 69
US-10-071-485-67
; Sequence 67, Application US/10071485
; Publication No. US20030099648A1
; GENERAL INFORMATION:
; APPLICANT: Buysse, Marie-Ange
; APPLICANT: Sablon, Erwin
; TITLE OF INVENTION: INTERFERON-gamma-BINDING MOLECULES FOR TREATING SEPTIC
; TITLE OF INVENTION: SHOCK,
; TITLE OF INVENTION: CACHEXIA, IMMUNE DISEASES AND SKIN DISORDERS
; FILE REFERENCE: INNS:015
; CURRENT APPLICATION NUMBER: US/10/071,485
; CURRENT FILING DATE: 2002-02-07
; PRIOR APPLICATION NUMBER: 09/485,737
; PRIOR FILING DATE: 2000-02-14
; PRIOR APPLICATION NUMBER: PCT/EP 98/05165
; PRIOR FILING DATE: 1998-08-14
; PRIOR APPLICATION NUMBER: EPO 98870139.7
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: EPO 97870122.5
; PRIOR FILING DATE: 1997-08-18
; NUMBER OF SEQ ID NOS: 104
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 67
; LENGTH: 468
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: SYNTHETIC
US-10-071-485-67

```

Query Match	52.4%;	Score 1265.5;	DB 14;	Length 468;
Best Local Similarity	57.2%;	Pred. No. 5.5e-81;		

Matches 277; Conservative 31; Mismatches 79; Indels 97; Gaps 13;

```
QY 11 LVLQALLPATQGNKVVIGKKGDVVELTCTASQKSIQFHKNSNOIKILGNQSFLL 70
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 17 VLSQVQLVQSGSE-----LKKPGASVKISCKAS---GYTFDYGMMWKQAPGG--L 65
QY 71 KGPSKLNDRAADSRSLMD--QGNFP-----LIINKLKIEDSDTYICEVEDQKEV 118
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 66 KMMGMINTYTGSESTYVDDPKGRFVPSLDTSVSAAYLIQISLKAEDTATYFC----- 116
QY 119 QLLVGLTANSDTHLLQ--GQSLTLTLESPSSPSVQCRSPRGKNIQGG----- 166
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 117 -----ARRGFYAMDYWGQGTIVTVSSASTKGPVFLAPSSKSTSGTALACLVD 168
QY 167 ---KTLTSS-----QLELDQSG-----TWCTVLAONOK 192
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 169 YPEPEPTVSMNSGALTSGVHTFPRAVLQSSGLVSLSSVTVTPSSSLGTOTYICNV--NHKP 226
QY 193 VEFKIDIVPCPAPPEPKSCDKHTC-----PELLGSPVFLPPPKDPTLMISRTPEVTCV 247
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 227 SNTKYD----KRVPEKSCDKHTCPCPAPPELLGSPVFLPPPKDPTLMISRTPEVTCV 282
QY 248 VVDVSHEDPEVKFNMYVDGVEVHNAKTKPREEQYNSTYRVSVLTVLHODWLNGKEYCK 307
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 283 VVDVSHEDPEVKFNMYVDGVEVHNAKTKPREEQYNSTYRVSVLTVLHODWLNGKEYCK 342
QY 308 VSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFPYSDIAVEWE 367
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 343 VSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFPYSDIAVEWE 402
QY 368 SNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRMQGNVFCSCVMHEALHNHYTQKSLS 427
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 403 SNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRMQGNVFCSCVMHEALHNHYTQKSLS 462
QY 428 LSPG 431
   : : : : :
Db 463 LSPG 466
```

```
RESULT 70
US-10-071-485-90
; Sequence 90, Application US/10071485
; Publication No. US20030099648A1
; GENERAL INFORMATION:
; APPLICANT: Buyse, Marie-Ange
; APPLICANT: Sablon, Ewlyn
; TITLE OF INVENTION: INTERFERON-gamma-BINDING MOLECULES FOR TREATING SEPTIC
; TITLE OF INVENTION: SHOCK,
; FILE REFERENCE: CACHEXIA, IMMUNE DISEASES AND SKIN DISORDERS
; CURRENT APPLICATION NUMBER: US/10/071,485
; CURRENT FILING DATE: 2002-02-07
; PRIOR APPLICATION NUMBER: 09/485,737
; PRIOR FILING DATE: 2000-02-14
; PRIOR APPLICATION NUMBER: PCT/EP 98/05165
; PRIOR FILING DATE: 1998-08-14
; PRIOR APPLICATION NUMBER: EPO 98870139.7
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: EPO 97870122.5
; PRIOR FILING DATE: 1997-08-18
; NUMBER OF SEQ ID NOS: 104
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 90
; LENGTH: 711
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: SYNTHETIC
US-10-071-485-90
```

Query Match 52.4%; Score 1265.5; DB 14; Length 711;
Best Local Similarity 57.2%; Pred. No. 9,2e-81;
Matches 277; Conservative 31; Mismatches 79; Indels 97; Gaps 13;

```
QY 11 LVLQALLPATQGNKVVIGKKGDVVELTCTASQKSIQFHKNSNOIKILGNQSFLL 70
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 17 VLSQVQLVQSGSE-----LKKPGASVKISCKAS---GYTFDYGMMWKQAPGG--L 65
QY 71 KGPSKLNDRAADSRSLMD--QGNFP-----LIINKLKIEDSDTYICEVEDQKEV 118
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 66 KMMGMINTYTGSESTYVDDPKGRFVPSLDTSVSAAYLIQISLKAEDTATYFC----- 116
QY 119 QLLVGLTANSDTHLLQ--GQSLTLTLESPSSPSVQCRSPRGKNIQGG----- 166
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 117 -----ARRGFYAMDYWGQGTIVTVSSASTKGPVFLAPSSKSTSGTALACLVD 168
QY 167 ---KTLTSS-----QLELDQSG-----TWCTVLAONOK 192
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 169 YPEPEPTVSMNSGALTSGVHTFPRAVLQSSGLVSLSSVTVTPSSSLGTOTYICNV--NHKP 226
QY 193 VEFKIDIVPCPAPPEPKSCDKHTC-----PELLGSPVFLPPPKDPTLMISRTPEVTCV 247
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 227 SNTKYD----KRVPEKSCDKHTCPCPAPPELLGSPVFLPPPKDPTLMISRTPEVTCV 282
QY 248 VVDVSHEDPEVKFNMYVDGVEVHNAKTKPREEQYNSTYRVSVLTVLHODWLNGKEYCK 307
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 283 VVDVSHEDPEVKFNMYVDGVEVHNAKTKPREEQYNSTYRVSVLTVLHODWLNGKEYCK 342
QY 308 VSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFPYSDIAVEWE 367
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 343 VSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFPYSDIAVEWE 402
QY 368 SNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRMQGNVFCSCVMHEALHNHYTQKSLS 427
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 403 SNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRMQGNVFCSCVMHEALHNHYTQKSLS 462
QY 428 LSPG 431
   : : : : :
Db 463 LSPG 466
```

```
RESULT 71
US-10-408-901-42
; Sequence 42, Application US/10408901
; Publication No. US2004002313A1
; GENERAL INFORMATION:
; APPLICANT: Boyle, William
; APPLICANT: Huang, Hachun
; APPLICANT: Elliott, Robin
; APPLICANT: Sullivan, John
; APPLICANT: Medlock, Eugene
; APPLICANT: Martin, Francis
; TITLE OF INVENTION: Human Anti-ORGL Neutralizing Antibodies As Selective ORGL Pathway
; TITLE OF INVENTION: Inhibitors
; FILE REFERENCE: MBH 01-1145-A
; CURRENT APPLICATION NUMBER: US/10/408,901
; CURRENT FILING DATE: 2003-04-07
; NUMBER OF SEQ ID NOS: 76
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 42
; LENGTH: 445
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-408-901-42
```

Query Match 52.4%; Score 1265; DB 16; Length 445;
Best Local Similarity 59.0%; Pred. No. 5,5e-81;
Matches 271; Conservative 27; Mismatches 71; Indels 90; Gaps 12;

```
QY 34 GDTVELTCTASQ--KKSIOFHW-----KNSNQIKILGNQ-----SFLTKGPSKLNDRAD 81
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 15 GGSRLTSCVSGSRFTSAIPMHVROAPKGLJEWVSGISGGGTNYADSVKGGFTTS--RDT 73
QY 82 SRSRLMDQGNFPLIKNLKIEDSDTYICEVEDQKEVQLLVFGLTANSDTHLLQGSQSLTL 141
   : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 74 ANGSIXLQMN-----SLRAEDMAYYC-----ARGNSFPYWGQGTLLV 111
```

```

OY      142 TLSPSPSSSSVOCASBPGRN1GG-----KITLSVS-----QLE 175
           ||| ||| :| :|
Db      112 TVSSASTKGPSPVPLPAPSSKTSIGGTAALGCLVKDYPPEPTVIVSNNGALTSVHTPEPAV 1711
           ||| ||| :| :|
OY      176 LODSG-----TWTCYLOJOKKVEFKIDIVPCPAPBPSCDKTHTC- 216
           ||| ||| :| :|
Db      172 LOSSSGLYSLSSVYTWBSSSLGTOTYICNV--NHKSNKTVD---KKVEPKSCDKHTCP 2255
           ||| ||| :| :|
OY      217 ----PELLGGPSVLEPPPKPKDTLMI SRTPEVTCVAVDVSHDEPVEKNMYVDGEVHNA 2727
           ||| ||| :| :|
Db      226 PCPAPPELLGGPSVFLPPEPKKDITLMI SRTPEVTCVAVDVSHDEPVEKNMYVDGEVHNA 2855
           ||| ||| :| :|
OY      273 KTKPREEQNYSYTRVAVSVLTVLHODMLNKGKCYKYSNKALPAPIEKTISPAKQPREPQ 3222
           ||| ||| :| :|
Db      286 KTKPREEQNYSYTRVAVSVLTVLHODMLNKGKCYKYSNKALPAPIEKTISPAKQPREPQ 3454
           ||| ||| :| :|
OY      333 VYTLPERDELTKNOVSLTCLVKGFPSDIAVWESNQGPENNYKTPPVLDISGSFFLY 3522
           ||| ||| :| :|
Db      346 VYTLPERDELTKNOVSLTCLVKGFPSDIAVWESNQGPENNYKTPPVLDISGSFFLY 4053
           ||| ||| :| :|
OY      393 SKLTVDKSRMOQGNVPSCSVMHEALNNHTQKSLSPG 431
           ||| ||| :| :|
Db      406 SKLTVDKSRMOQGNVPSCSVMHEALNNHTQKSLSPG 444
           ||| ||| :| :|

```

```

RESULT 72
US-10-411-037-56
; Sequence 56, Application US/10411037
; Publication No. US20040043446A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: ALPHA GALACTOSIDASE A
; TITLE OF INVENTION: GALACTOSIDASE A
; FILE REFERENCE: 040853-01-5082
; CURRENT APPLICATION NUMBER: US/10/411,037
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 56
; LENGTH: 448
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-411-037-56

```

	52.4%	Score 1265	DB 12	Length 448
Query March Similarity	58.7%	Pred. No. 5,6e-81		
Best Local Similarity				
Matches 270	Conservative 26	Mismatches 80	Indels 84	Gaps 11
Oy	32	KKGDVLELTCTASOKKSIOF--HWKNSNOIKILGNQ-----SFLTQSPSKLNDPADSR	83	
Ob	13	KPGSSVKKSCSKAGSAFTNYLLEW----VRAPQGGLEWIGIVIPGSGCTVYNEKFKR	67	

```

QY      84  RSLM-----DQGNFLLIKNKLIEDSTQYCEVEDQKEBEVQLLVFGLTANSPTHLLQGSFLT 140
Db      68  VTLTVDNSTNTAYMELSSLRSDSDIATVYFCARRD-----GNYCMFAWGGCTL 114

QY      141  LTLSPPGSSPSVOCSPKRGKNIQGG-----KTLSSVS-----QL 174
Db      115  VTYVSASTKGPVSFFPLAPSSKTSQGTALGLVDYDPEPEYVTSNMGALITSGVHFPFA 174

QY      175  ELDDSG-----TWCTVLONQKVEFKIDYPCAPAPKSCDKTHTC 216
Db      175  VLQSSGLYSLSSVTVTPSSSLGTQTYICNV--NHKPSMTKVD---KKVEKSCDKTHTC 228

QY      217  -----PELLGSPSVFLFRPKPKDTLMISRTEPVTCVVVDVSHEDPEVKPMNYVDGAEVHN 271
Db      229  PRCAPAPELLGGPSEVLFPPPKDTLMISRTPEVTCVVVDVSHEDPEVKFPMNYVDGAEVHN 288

QY      272  AKTRPEEQNSIYRVAIVLTVLHODMYLNGKEYCKSNKALPAPIEKTISKAKGQPREP 331
Db      289  AKTRPEEQNSIYRVAIVLTVLHODMYLNGKEYCKSNKALPAPIEKTISKAKGQPREP 348

QY      332  QVYTLPPSRDELTKQVSLTCLVKGFPYPSDIAVEWESNGQRPENNYKTTTPPYLSDSGSFLL 391
Db      349  QVYTLPPSRDELTKQVSLTCLVKGFPYPSDIAVEWESNGQRPENNYKTTTPPYLSDSGSFLL 408

QY      392  YSKLTIVDKSRMOQGANFCSGVNHGELAHNHYYQKSLSTSPG 431
Db      409  YSKLTIVDKSRMOQGANFCSGVNHGELAHNHYYQKSLSTSPG 448

```

```

RESULT 73
US-10-411-026-56
/ Sequence 56, Application US/10411026
/ Publication No. US20040063911A1
/ GENERAL INFORMATION:
/ APPLICANT: Neose Technologies, Inc.
/ APPLICANT: DeFrees, Shawn
/ APPLICANT: Zopf, David
/ APPLICANT: Bayer, Robert
/ APPLICANT: Hakes, David
/ APPLICANT: Chen, Xi
/ TITLE OF INVENTION: PROTEIN REMODELING METHODS AND PROTEINS/PEPTIDES PRODUCED BY THEM
/ TITLE OF INVENTION: METHODS
/ FILE REFERENCE: 040853-01-5053
/ CURRENT APPLICATION NUMBER: US/10/411,026
/ CURRENT FILING DATE: 2003-04-09
/ PRIOR APPLICATION NUMBER: US 60/328,523
/ PRIOR FILING DATE: 2001-10-10
/ PRIOR APPLICATION NUMBER: US 60/344,692
/ PRIOR FILING DATE: 2001-10-19
/ PRIOR APPLICATION NUMBER: US 60/387,292
/ PRIOR FILING DATE: 2002-06-07
/ PRIOR APPLICATION NUMBER: US 60/391,777
/ PRIOR FILING DATE: 2002-06-25
/ PRIOR APPLICATION NUMBER: US 60/396,594
/ PRIOR FILING DATE: 2002-07-17
/ PRIOR APPLICATION NUMBER: US 60/404,249
/ PRIOR FILING DATE: 2002-08-16
/ PRIOR APPLICATION NUMBER: US 60/407,527
/ PRIOR FILING DATE: 2002-08-28
/ NUMBER OF SEQ ID NOS: 75
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 56
/ LENGTH: 448
/ TYPE: PRT
/ ORGANISM: Homo sapiens
US-10-411-026-56

```

Query Match	52.4%	Score 1265	DB 12	Length 448
Best Local Similarity	58.7%	Pred. No. 5.6e-81		
Matches 270	Conservative 26	Mismatches 80	Indels 84	Gaps 11

Db 13 KPGSSVAVSCAKSGAFTNYLIEW-----VRQAPGGGLEWIGVITPGSGGTNYNEKFKGR 67
Qy 84 RSLM---DQGNFLLIKNLKIEDSDTYICEVDQKEEVQLVFGLTANSDFHLQOQSFLT 140
Db 68 VTLTVDESTNTAYMELSSLRSEDTAVYFCARD-----GNYGMFAYMGQGT 114
Qy 141 LTLSEPPGSSPSVQCRSPRGKNIQGG-----KTLVS-----QL 174
Db 115 VTVSSASTKGPSVFPFLAPSSKSTSGGTAALGCLVKDYFPEPVTVSNNGALTSVHTFPA 174
Qy 175 ELQDSG-----TWCTVLONQKVEFKIDIVPCPAPPEKSCDKTHTC 216
Db 175 VQSSGLVSLSSVTVTPSSSLGTQYICNV--NHKPSNTKVD---KYPEKSCDKTHTC 228
Qy 217 -----PELLGSPSVLPFPKPKDTLMISRTPEVTCVVDVSHEDPEVKFMWYVDGEVHN 271
Db 229 PCPAPPELLGSPSVLPFPKPKDTLMISRTPEVTCVVDVSHEDPEVKFMWYVDGEVHN 288
Qy 272 AKTKPREEOYNSTYRVSVTLVLDQMLNGKEYKCKVSNKALPAPIEKTISAKKGQPREP 331
Db 289 AKTKPREEOYNSTYRVSVTLVLDQMLNGKEYKCKVSNKALPAPIEKTISAKKGQPREP 348
Qy 332 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTTPVLDSDGSFPL 391
Db 349 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTTPVLDSDGSFPL 408
Qy 392 YSKLTVDKSRWQGNVFCGSVMHEALHNHYTQKSLSLSPG 431
Db 409 YSKLTVDKSRWQGNVFCGSVMHEALHNHYTQKSLSLSPG 448

RESULT 74
US-10-410-962-56
; Sequence 56, Application US/10410962
; Publication No. US20040077836A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defreese, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: GRANULOCYTE COLONY STIMULATING FACTOR: REMODELING AND
; FILE REFERENCE: 040853-01-5054
; CURRENT APPLICATION NUMBER: US/10/410,962
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 56
; LENGTH: 448
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-410-962-56

Query Match 52.4%; Score 1265; DB 16; Length 448;
Best Local Similarity 58.7%; Pred. No. 5.6e-81;
Matches 270; Conservative 26; Mismatches 80; Indels 84; Gaps 11;

Qy 32 KKGDTVELTCTASQKKSIOF--HMKNSQIKILNQG-----SFLTKGSPKLTNDRASR 83
Db 13 KPGSSVAVSCAKSGAFTNYLIEW-----VRQAPGGGLEWIGVITPGSGGTNYNEKFKGR 67
Qy 84 RSLM---DQGNFLLIKNLKIEDSDTYICEVDQKEEVQLVFGLTANSDFHLQOQSFLT 140
Db 68 VTLTVDESTNTAYMELSSLRSEDTAVYFCARD-----GNYGMFAYMGQGT 114
Qy 141 LTLSEPPGSSPSVQCRSPRGKNIQGG-----KTLVS-----QL 174
Db 115 VTVSSASTKGPSVFPFLAPSSKSTSGGTAALGCLVKDYFPEPVTVSNNGALTSVHTFPA 174
Qy 175 ELQDSG-----TWCTVLONQKVEFKIDIVPCPAPPEKSCDKTHTC 216
Db 175 VQSSGLVSLSSVTVTPSSSLGTQYICNV--NHKPSNTKVD---KYPEKSCDKTHTC 228
Qy 217 -----PELLGSPSVLPFPKPKDTLMISRTPEVTCVVDVSHEDPEVKFMWYVDGEVHN 271
Db 229 PCPAPPELLGSPSVLPFPKPKDTLMISRTPEVTCVVDVSHEDPEVKFMWYVDGEVHN 288
Qy 272 AKTKPREEOYNSTYRVSVTLVLDQMLNGKEYKCKVSNKALPAPIEKTISAKKGQPREP 331
Db 289 AKTKPREEOYNSTYRVSVTLVLDQMLNGKEYKCKVSNKALPAPIEKTISAKKGQPREP 348
Qy 332 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTTPVLDSDGSFPL 391
Db 349 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTTPVLDSDGSFPL 408
Qy 392 YSKLTVDKSRWQGNVFCGSVMHEALHNHYTQKSLSLSPG 431
Db 409 YSKLTVDKSRWQGNVFCGSVMHEALHNHYTQKSLSLSPG 448

RESULT 75
US-10-411-049-56
; Sequence 56, Application US/10411049
; Publication No. US20040082026A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defreese, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: INTERFERON ALPHA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; FILE REFERENCE: 040853-01-5055
; CURRENT APPLICATION NUMBER: US/10/411,049
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 56
; LENGTH: 448
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-411-049-56


```

Query Match 52.4%, Score 1265; DB 16; Length 448;
Best Local Similarity 58.7%, Fred. No. 5.6e-81;
Matches 270; Conservative 26; Mismatches 80; Indels 84; Gaps 11;

OY KKGDTVELTCTASQKKSIOF--HMKNSNQIKILGNQ-----SFLTKGPEKLNDRADR 83
DB 13 KPSSSVKVCASGSAFNNYLIEM-----VQAGGQGLEMLGVYPPSGGNTNYEKKGR 67
OY 84 RSLW---DQGNFPLIKNLKIEDSDTYICEVEDQKEEVLVFLGLTANSPTHLLOQSLT 140
DB 68 VTLTVDSTNAYMELSLRSEDYAVVFCARD-----GNYGFAWGGCTL 114
OY 141 LTLESPPSSSVQCRSRKNIQGG-----KTLSSV-----QL 174
DB 115 TVSSASATKGPVFPPLAPSSKSTSGTAALGCLVADYFPPEVTVSNMNGALTSQHTFPA 174
OY 175 ELQDSG-----TWCTVLDNQNKVEFKDIDYPCAPAPPKSCDKTHTC 216
DB 175 VLOSSGLYSLSVTVTPSSLSGTOTYICNV--NHKPSNTKVD---KKVPEKSCDKTHTC 228
OY 217 -----PELLGSPSYFLFPFKPKDTLMTSRPEVTCVVVDVSHEDPEVKFMNYYDGEVHN 271
DB 229 PCPAPBELLGSPSYFLFPFKPKDTLMTSRPEVTCVVVDVSHEDPEVKFMNYYDGEVHN 288
OY 272 AKTPREBQNVNSTRVSVLTVLHODWLNKGEYKCKYSNKLPAPIEKTISKAGQREP 331
DB 289 AKTPREBQNVNSTRVSVLTVLHODWLNKGEYKCKYSNKLPAPIEKTISKAGQREP 348
OY 332 QVYTLPPREBDLTKNOVSLTCLVKGFPSPDIAVEMESNGQENNYKTTPTPLSDSGSFFL 391
DB 349 QVYTLPPSRDLTKNOVSLTCLVKGFPSPDIAVEMESNGQENNYKTTPTPLSDSGSFFL 408
OY 392 YSKLTVDKSRWQOGNVFSCSVMEHALNHNYTQKSLSPG 431
DB 409 YSKLTVDKSRWQOGNVFSCSVMEHALNHNYTQKSLSPG 448

RESULT 76
US-10-410-930-56
; Sequence 56, Application US/10410930
; Publication No. US20040115168A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFreese, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: INTERFERON BETA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; FILE REFERENCE: 040853-01-5056
; CURRENT APPLICATION NUMBER: US/10/410,930
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 56
; LENGTH: 448
; TYPE: PRT

```

```

; ORGANISM: Homo sapiens
US-10-410-930-56

Query Match          52.4%; Score 1265; DB 16; Length 448;
Best Local Similarity 58.7%; Pred. No.5-6e-81;
Matches 270; Conservative 26; Mismatches 80; Indels 84; Gaps 11;

QY      32 KKGDVELTCTASQKSIQF--HMKNSNQIKILNGQ-----SFLTGPSTLNDRAISR 83
           |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB      13 KPGSSVKKVCASGAGFAFTNYLIEW----VQAPQGLIEWIGIVIPSGSGTVMNEKFKGR 67
           |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY      84 RSLW---DQGNFPLIKKLKTEDSDTYICEVEDQKEEYQLVFGLTANSDTHLLOGQSIT 140
           |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB      68 VTLTVDESTNTAYMELSSLRSEBDTAVYFCARRD-----GNVGFAYWGQGTLL 114
           |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY      141 LTLSEPPSSPSVVOCSRPRGNKIQSG-----KTLVS-----QL 174
           |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB      115 VTVSSASATKGSVFPFLABSSKSTSGGTALALGLVNDYFPEPYTVSMNSGALTSGVHTPPA 174
           |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY      175 ELQDSG-----TWCTVLQNOKEVFKIDIVPCAPAEPRKSCDKHTTC 216
           |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB      175 VLQSGGLYLSLVVTPPSSLGTCGYICNV--NHKPSNTKVD---KKVEPRKCDKHTTC 228
           |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY      217 -----PELLGSPSVLFPKPKDITMISRTPEYTCVVVDVSHEDPEVKFNWYVDQEVYN 271
           |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB      229 PCPAPELLGGSPSVLFPKPKDITMISRTPEYTCVVVDVSHEDPEVKFNWYVDQEVYN 288
           |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY      272 AKTPREEQVNSTRVVSVLTVLHODMNGEKYCKCKVSNKALPAPIEKTIISKAKGQPREP 331
           |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB      289 AKTPREEQVNSTRVVSVLTVLHODMNGEKYCKCKVSNKALPAPIEKTIISKAKGQPREP 348
           |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY      332 QVYTLTPSRDELTKNQVSLTCLVKNGFYPYSDIAVWESNGQPENNYKTTIPVLDSGSFPL 391
           |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB      349 QVYTLTPSRDELTKNQVSLTCLVKNGFYPYSDIAVWESNGQPENNYKTTIPVLDSGSFPL 408
           |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY      392 YSKLTVDKSRNQGNVFSCSYMHEALHNHYTQKSISLSPG 431
           |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
DB      409 YSKLTVDKSRNQGNVFSCSYMHEALHNHYTQKSISLSPG 448
           |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|

RESULT 77
US-10-410-997-56
; Sequence 56, Application US/10410997
; Publication No. US20040126838A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFreeze, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: POLYCLIC STIMULATING HORMONE: REMODELING AND GLYCOCONJUGATION OF
; FILE REFERENCE: 040853-01-5059
; CURRENT APPLICATION NUMBER: US/10/410, 997
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328, 523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344, 692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387, 292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391, 777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396, 594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404, 249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407, 527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2

```

SEQ ID NO 56
LENGTH: 448
TYPE: PR
ORGANISM: Homo sapiens
US-10-410-997-56

Query Match 52.4%; Score 1265; DB 16; Length 448;
Best Local Similarity 58.7%; Pred. No. 5.6e-81;
Matches 270; Conservative 26; Mismatches 80; Indels 84; Gaps 11;

QY 32 KKGDTVELTCTASOKKSIQF--HMKNNOIKILGNQ-----SFLTKGPSKLNDRADR 83
D 13 KGGSSVKKVSCKASGYAFNTYLIEM-----VRQAPQGLEWIGVIYPGSGGTINNEKFKGR 67
QY 84 RSLM---DQGNFPLIIKNLKIEDSDTYICEVEDEQKEEVQLVFGLTANSDTLLQGOSLT 140
D 68 VTLTVDSEINTAYMELSSLSRSEDYAVFCARD-----GNYGMFAVYGQGT 114
QY 141 LTLSPGSSPSVQCRSPRGKNIQGG-----KTLSSVS-----QL 174
D 115 VTVSSASTKGPVFLPAPSSKSTSGTALGCLVADYFPEPVTVSMNSGALTSVHTFPA 174
QY 175 ELQDSG-----TWCTVLOKQKVEFKIDIVPCPAPBPKSCDKTHTC 216
D 175 VQSSGLVSLSSVTVTPSSSLGTOTYICNV--NHRKPSNTKVD---KQVEPKSCDKTHTC 228
QY 217 -----PELLGSPVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHN 271
D 229 PCPAPBELLGGSPVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHN 288
QY 272 AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKQPRP 331
D 289 AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKQPRP 348
QY 332 QVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFPL 391
D 349 QVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFPL 408
QY 392 YSKLTVDKSRMQGNVFCSCVMHEALHNHYTOKSLSLSPG 431
D 409 YSKLTVDKSRMQGNVFCSCVMHEALHNHYTOKSLSLSPG 448

RESULT 78

US-10-411-012-56
Sequence 56, Application US/10411012
Publication No. US20040132640A1
GENERAL INFORMATION:
APPLICANT: Neose Technologies, Inc.
APPLICANT: Defreese, Shawn
APPLICANT: Zopf, David
APPLICANT: Bayer, Robert
APPLICANT: Hakes, David
APPLICANT: Chen, Xi
APPLICANT: Bower, Caryn
TITLE OF INVENTION: GLYCOSYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
FILE REFERENCE: 040853-01-5051
CURRENT APPLICATION NUMBER: US/10/411,012
CURRENT FILING DATE: 2003-04-09
PRIOR APPLICATION NUMBER: US 60/328,523
PRIOR FILING DATE: 2001-10-10
PRIOR APPLICATION NUMBER: US 60/344,692
PRIOR FILING DATE: 2001-10-19
PRIOR APPLICATION NUMBER: US 60/387,292
PRIOR FILING DATE: 2002-06-07
PRIOR APPLICATION NUMBER: US 60/391,777
PRIOR FILING DATE: 2002-06-25
PRIOR APPLICATION NUMBER: US 60/396,594
PRIOR FILING DATE: 2002-07-17
PRIOR APPLICATION NUMBER: US 60/404,249
PRIOR FILING DATE: 2002-08-16
PRIOR APPLICATION NUMBER: US 60/407,527

PRIOR FILING DATE: 2002-08-28
NUMBER OF SEQ ID NOS: 75
SOFTWARE: PatentIn version 3.2
SEQ ID NO 56
LENGTH: 448
TYPE: PR
ORGANISM: Homo sapiens
US-10-411-012-56

Query Match 52.4%; Score 1265; DB 16; Length 448;
Best Local Similarity 58.7%; Pred. No. 5.6e-81;
Matches 270; Conservative 26; Mismatches 80; Indels 84; Gaps 11;

QY 32 KKGDTVELTCTASOKKSIQF--HMKNNOIKILGNQ-----SFLTKGPSKLNDRADR 83
D 13 KGGSSVKKVSCKASGYAFNTYLIEM-----VRQAPQGLEWIGVIYPGSGGTINNEKFKGR 67
QY 84 RSLM---DQGNFPLIIKNLKIEDSDTYICEVEDEQKEEVQLVFGLTANSDTLLQGOSLT 140
D 68 VTLTVDSEINTAYMELSSLSRSEDYAVFCARD-----GNYGMFAVYGQGT 114
QY 141 LTLSPGSSPSVQCRSPRGKNIQGG-----KTLSSVS-----QL 174
D 115 VTVSSASTKGPVFLPAPSSKSTSGTALGCLVADYFPEPVTVSMNSGALTSVHTFPA 174
QY 175 ELQDSG-----TWCTVLOKQKVEFKIDIVPCPAPBPKSCDKTHTC 216
D 175 VQSSGLVSLSSVTVTPSSSLGTOTYICNV--NHRKPSNTKVD---KQVEPKSCDKTHTC 228
QY 217 -----PELLGSPVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHN 271
D 229 PCPAPBELLGGSPVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHN 288
QY 272 AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKQPRP 331
D 289 AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKQPRP 348
QY 332 QVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFPL 391
D 349 QVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPVLDSDGSFPL 408
QY 392 YSKLTVDKSRMQGNVFCSCVMHEALHNHYTOKSLSLSPG 431
D 409 YSKLTVDKSRMQGNVFCSCVMHEALHNHYTOKSLSLSPG 448

RESULT 79

US-10-287-994-56
Sequence 56, Application US/10287994
Publication No. US2004013757A1
GENERAL INFORMATION:
APPLICANT: Neose Technologies, Inc.
APPLICANT: Defreese, Shawn
APPLICANT: Zopf, David
APPLICANT: Bayer, Robert
APPLICANT: Hakes, Caryn
APPLICANT: Chen, Xi
TITLE OF INVENTION: REMODELING AND GLYCOCONGUGATION OF PEPTIDES
FILE REFERENCE: 040853-01-5052-00
CURRENT APPLICATION NUMBER: US/10/287,994
CURRENT FILING DATE: 2002-11-05
PRIOR APPLICATION NUMBER: US 60/328,523
PRIOR FILING DATE: 2001-10-10
PRIOR APPLICATION NUMBER: US 60/344,692
PRIOR FILING DATE: 2001-10-19
PRIOR APPLICATION NUMBER: US 60/387,292
PRIOR FILING DATE: 2002-06-07
PRIOR APPLICATION NUMBER: US 60/391,777
PRIOR FILING DATE: 2002-06-25
PRIOR APPLICATION NUMBER: US 60/396,594
PRIOR FILING DATE: 2002-07-17
PRIOR APPLICATION NUMBER: US 60/404,249

/ PRIOR FILING DATE: 2002-08-16
/ PRIOR APPLICATION NUMBER: US 60/407,527
/ PRIOR FILING DATE: 2002-08-28
/ NUMBER OF SEQ ID NOS: 62
/ SOFTWARE: Patentin version 3.1
/ SEQ ID NO 56
/ LENGTH: 448
/ TYPE: PRT
/ ORGANISM: Homo sapiens
US-10-287-994-56

Query Match 52.4%; Score 1265; DB 16; Length 448;
Best Local Similarity 58.7%; Pred. No. 5.6e-81;
Matches 270; Conservative 26; Mismatches 80; Indels 84; Gaps 11;

QY 32 KKGDVLELTCTASQKSIQF--HWKNSNQIKILGNQ-----SFLTKGSPKLNDRADSR 83
DB 13 KPGSSVAVSCKASGYAFNTYLIEM-----VRQAPQGLEMIQVYIPSGGNTNTEKFKGR 67
QY 84 RSLW---DQGNFPLIINKLIKIEDSDTYICEVEDQKEEVQLVFGLTANSDTHLQGSFLT 140
DB 68 VTLTVDESTNTAYMELSLRSSEDTAVYFCARD-----GNYGMFAWYGQGT 114
QY 141 LTLESPPGSSPSVQCRSPRKNIOGQ-----KTLVS-----QL 174
DB 115 VTVSSASTKGPSPVFLPAPSKTSKGTALGCLVQDFPEPVTVSMNSGALTSVHTFPA 174
QY 175 ELQDSG-----TWTCVLONOKKVEFKIDIVPCPAPERSCKDTHTC 216
DB 175 VLOSSGLYLSVSVTVPPSSLSGTQTYICNV--NHPKSPNTKVD---KVEPKSCDKTHTC 228
QY 217 -----PELIGSPSVFLFPKPDKDTLMSRTPEVTCVVDVSHEDPEVKFMYVDGVEVHN 271
DB 229 PCPAPPELLGSPSVFLFPKPDKDTLMSRTPEVTCVVDVSHEDPEVKFMYVDGVEVHN 288
QY 272 AKTPREEOYNSTYRVSVTLVHODMLNGEKYCKVSNKALPAPIEKTISKAKGQPREP 331
DB 289 AKTPREEOYNSTYRVSVTLVHODMLNGEKYCKVSNKALPAPIEKTISKAKGQPREP 348
QY 332 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTTPVLDSGSEFLL 391
DB 349 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTTPVLDSGSEFLL 408
QY 392 YSKLTVDKSRWQGNVFCSCVMHEALHNHYTOKSLISPG 431
DB 409 YSKLTVDKSRWQGNVFCSCVMHEALHNHYTOKSLISPG 448

RESULT 80
US-10-410-913-56
/ Sequence 56, Application US/10410913
/ Publication No. US20040142856A1
/ GENERAL INFORMATION:
/ APPLICANT: Neose Technologies, Inc.
/ APPLICANT: Defreese, Shawn
/ APPLICANT: Zopf, David
/ APPLICANT: Bayer, Robert
/ APPLICANT: Hakee, David
/ APPLICANT: Chen, Xi
/ TITLE OF INVENTION: GLYCOCONJUGATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
/ FILE REFERENCE: 040853-01-5081
/ CURRENT APPLICATION NUMBER: US/10/410,913
/ PRIOR FILING DATE: 2003-04-09
/ PRIOR APPLICATION NUMBER: US 60/328,523
/ PRIOR FILING DATE: 2001-10-10
/ PRIOR APPLICATION NUMBER: US 60/344,692
/ PRIOR FILING DATE: 2001-10-19
/ PRIOR APPLICATION NUMBER: US 60/387,292
/ PRIOR FILING DATE: 2002-06-07
/ PRIOR APPLICATION NUMBER: US 60/391,777
/ PRIOR FILING DATE: 2002-06-25

/ PRIOR APPLICATION NUMBER: US 60/396,594
/ PRIOR FILING DATE: 2002-07-17
/ PRIOR APPLICATION NUMBER: US 60/404,249
/ PRIOR FILING DATE: 2002-08-16
/ PRIOR APPLICATION NUMBER: US 60/407,527
/ PRIOR FILING DATE: 2002-08-28
/ NUMBER OF SEQ ID NOS: 75
/ SOFTWARE: Patentin version 3.2
/ SEQ ID NO 56
/ LENGTH: 448
/ TYPE: PRT
/ ORGANISM: Homo sapiens
US-10-410-913-56

Query Match 52.4%; Score 1265; DB 16; Length 448;
Best Local Similarity 58.7%; Pred. No. 5.6e-81;
Matches 270; Conservative 26; Mismatches 80; Indels 84; Gaps 11;

QY 32 KKGDVLELTCTASQKSIQF--HWKNSNQIKILGNQ-----SFLTKGSPKLNDRADSR 83
DB 13 KPGSSVAVSCKASGYAFNTYLIEM-----VRQAPQGLEMIQVYIPSGGNTNTEKFKGR 67
QY 84 RSLW---DQGNFPLIINKLIKIEDSDTYICEVEDQKEEVQLVFGLTANSDTHLQGSFLT 140
DB 68 VTLTVDESTNTAYMELSLRSSEDTAVYFCARD-----GNYGMFAWYGQGT 114
QY 141 LTLESPPGSSPSVQCRSPRKNIOGQ-----KTLVS-----QL 174
DB 115 VTVSSASTKGPSPVFLPAPSKTSKGTALGCLVQDFPEPVTVSMNSGALTSVHTFPA 174
QY 175 ELQDSG-----TWTCVLONOKKVEFKIDIVPCPAPERSCKDTHTC 216
DB 175 VLOSSGLYLSVSVTVPPSSLSGTQTYICNV--NHPKSPNTKVD---KVEPKSCDKTHTC 228
QY 217 -----PELIGSPSVFLFPKPDKDTLMSRTPEVTCVVDVSHEDPEVKFMYVDGVEVHN 271
DB 229 PCPAPPELLGSPSVFLFPKPDKDTLMSRTPEVTCVVDVSHEDPEVKFMYVDGVEVHN 288
QY 272 AKTPREEOYNSTYRVSVTLVHODMLNGEKYCKVSNKALPAPIEKTISKAKGQPREP 331
DB 289 AKTPREEOYNSTYRVSVTLVHODMLNGEKYCKVSNKALPAPIEKTISKAKGQPREP 348
QY 332 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTTPVLDSGSEFLL 391
DB 349 QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTTPVLDSGSEFLL 408
QY 392 YSKLTVDKSRWQGNVFCSCVMHEALHNHYTOKSLISPG 431
DB 409 YSKLTVDKSRWQGNVFCSCVMHEALHNHYTOKSLISPG 448

RESULT 81
US-09-773-877A-18
/ Sequence 18, Application US/09773877A
/ Publication No. US20030017977A1
/ GENERAL INFORMATION:
/ APPLICANT: Xia, Yu-Ping et al.
/ TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES
/ FILE REFERENCE: REG 710B
/ CURRENT APPLICATION NUMBER: US/09/773,877A
/ PRIOR FILING DATE: 2001-01-31
/ NUMBER OF SEQ ID NOS: 27
/ SOFTWARE: Patentin version 3.0
/ SEQ ID NO 18
/ LENGTH: 462
/ TYPE: PRT
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: F1C1(2-3)-Fc (Mut3)
US-09-773-877A-18

Query Match 52.4%; Score 1265; DB 12; Length 462;
Best Local Similarity 65.7%; Pred. No. 5.8e-81;

	Matches	255; Conservative	24; Mismatches	71; Indels	38; Gaps	7
QY	81	DSRRSLMDQGNFPLIIKNLIKIEDSDTYICEVE-----DQKEVQLLVFGILTANS	129			
DB	75	DGKRILIMDSRK-GFIISNATYYEIGLTTEALVNHGLYKNTYVLTNRQNTIITIDVQISIPR	133			
QY	130	PTHLLIQGSRLV--TLSPRGSSPSVQCRSPRGKNIQGG-----KTLSP	171			
DB	134	PVKLLRGHTVLVNCATTPRPLNTRVQMTMSYPDEKKRKASVRRRIQDSNSHANI FYSVLTI	193			
QY	172	SOLEIQDSGWTCTVYLQNO--KVEEFKIDIVBCAP-EPKSCDKYHTC-----PELLGSP	223			
DB	194	DKMQKIDKGLYTCRVRSGPSFKSVNTSVYIYDKAPGEPEKSCDKYHTCPCAPPELLGSP	253			
QY	224	SVFLFPPPKPQDTLMISRTPEVTCVVVDVSHEDPEVKFMWYVDGVEVHNAKTPREEQYNS	283			
DB	254	SVFLFPPPKPQDTLMISRTPEVTCVVVDVSHEDPEVKFMWYVDGVEVHNAKTPREEQYNS	313			
QY	284	TYRVVSVLTVLHQDWLNGKEYKCKSNKAALPAPIEKTISKAKGQRRPEQVYTLPPSRDEL	343			
DB	314	TYRVVSVLTVLHQDWLNGKEYKCKSNKAALPAPIEKTISKAKGQRRPEQVYTLPPSRDEL	373			
QY	344	TKNQVSLTCLVKGFIPSDIAVEWESNGQPENNYKTTPRPILDSGSFPLYSKLTIVYKSRWQ	403			
DB	374	TKNQVSLTCLVKGFIPSDIAVEWESNGQPENNYKTTPRPILDSGSFPLYSKLTIVYKSRWQ	433			
QY	404	QGNVSSGVMHGALHNHYTQKSLSLSPG	431			
DB	434	QGNVSSGVMHGALHNHYTQKSLSLSPG	461			

```

RESULT 82
US-09-773-877A-12
; Sequence 12, Application US/09773877A
; Publication No. US20030017977A1
; GENERAL INFORMATION:
; APPLICANT: Xia, Yu-Ping et al.
; TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES
; FILE REFERENCE: REG 710b
; CURRENT APPLICATION NUMBER: US/09/773, 877A
; CURRENT FILING DATE: 2001-01-31
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 12
; LENGTH: 567
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Flt(1-3)-Fc
US-09-773-877A-12

Query Match          52.4%; Score 1265; DB 12; Length 567;
Best Local Similarity 65.7%; Pred. No. 7.5e-81;
Matches 255; Conservative 24; Mismatches 71; Indels 38; Gaps 7

Oy      81  DSRRLDQGNFPLIIKLIKIEDSDTYICEV-----DQKEVQLIVFGLTANS 129
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db      180 DGRRIIMSRK-GFIIISNATYKEIILTCFAVNGHLKYNTNYLTRQNTIIDVQISIPR 238
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Oy      130 DTHLQGSGLT--TLSPPGSSPSVQCRSPRKNIIQGS-----KTLSTV 171
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db      239 PVKILRGHTLVLCATITPPLNTRVQMTSYSPDEKKNRKRASVRRRIQSSHANIFYSULTI 298
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Oy      172 SOLEIQDSGWTCTVLQANO--KKEVEKIDIVPCPAP-EPKSCDKTHTC-----PELIGGP 223
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db      299 DKMKQKMDGLYTCRVRSGSPFSKSVNTSVHIIYDKAPGEEKSCDKTHTCPCPAPPELLGGP 358
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Oy      224 SVFLPPPKQDTLMISRTPEVTCVVVDVSHEDPEVKFMNMYDGVGVNNAKTKPRREOYNS 283
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db      359 SVFLPPPKQDTLMISRTPEVTCVVVDVSHEDPEVKFMNMYDGVGVNNAKTKPRREOYNS 418
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Oy      284 TYRIVSVLTIVHQDLNGEKYCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDEL 343
      : : : : : : : : : : : : : : : : : : : : : : : : : : : :

```

Db	413	TRWVSVLVYHQMIDMLNGEKYKCYXNKALPAPIEIKTISKAKGQPREQVYITLPPSRDEL	478
Qy	344	TKRQVSLTLCYKGFPSDIAYWESNQGCPENNYKTTTPVLDSDGSFLYKSLATYDKRMQ	403
Db	479	TKRQVSLTLCYKGFPSDIAYWESNQGCPENNYKTTTPVLDSDGSFLYKSLATYDKRMQ	538
Qy	404	QGNVFSQSVMEALHNHYTKSLSLSPG	431
Db	539	QGNVFSQSVMEALHNHYTKSLSLSPG	566

[illegible]

Db 673 VFSSCVMEALHNHYTKSLSPG 697

RESULT 84

US-10-077-023-9

Sequence 9, Application US/10077023

Publication No. US20030031675A1

GENERAL INFORMATION:

APPLICANT: MIKESSELL, GLEN E.

APPLICANT: CHANG, HAN

APPLICANT: FINGER, JOSHUA N.

APPLICANT: YANG, GUOCHEN

APPLICANT: LU, PIN

APPLICANT: ZHOU, XIA-DI

APPLICANT: PEACH, ROBERT

TITLE OF INVENTION: B7-RELATED NUCLEIC ACIDS AND POLYPEPTIDES USEFUL FOR

TITLE OF INVENTION: IMMUNOMODULATION

FILE REFERENCE: 3053-4071US3

CURRENT APPLICATION NUMBER: US/10/077,023

CURRENT FILING DATE: 2002-02-15

PRIOR FILING DATE: 2001-02-28

PRIOR APPLICATION NUMBER: 60/209,811

PRIOR FILING DATE: 2000-06-06

NUMBER OF SEQ ID NOS: 138

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 9

LENGTH: 698

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: Synthetic

OTHER INFORMATION: fusion construct

US-10-077-023-9

Query Match 52.4%; Score 1265; DB 14; Length 698;

Best Local Similarity 67.8%; Pred. No. 9, 8e-81;

Matches 261; Conservative 18; Mismatches 57; Indels 49; Gaps 7;

QY 89 QGNFLLIKNLKIEDSDTYICEVEDQKEVOLVFGLTANSDTHLLOQSILTLIES--- 145

Db 320 QGNASLRQVRVNADEGSFTC-----FVSLRFGSAVSLQVAPYKSDMTLEPNKD 372

QY 146 -PPGSSPVQCRSPRG-----KNIQG-KTILSVSOLIED 178

Db 373 LRPGDTVITTCSSYRGYBEAEVFMQDGGVPLTGAVTTISQMANEGLELDVHSVLKRVLGA 432

QY 179 SGTWTCT---TYLQNKQKVEFKIDIVPCPAP--EPKSCDKTHTC-----PELLGSPSVF 226

Db 433 NGTYSCLVRNPVLQODAHGSVITITGQPMTPPEFEPKSCDKTHTCPCPAPPELLGSPSVF 492

QY 227 LFPPEKDTLMSRTPREYTCVVVDVSHEDPEVKFMWYVDGVEVNAKTRPEEQNSTYR 286

Db 493 LFPPEKDTLMSRTPREYTCVVVDVSHEDPEVKFMWYVDGVEVNAKTRPEEQNSTYR 552

QY 287 VVSVLTIVLHODMLNGKEYKCKVSNKALPAPIEKTISSAKGQPREPQVYTLPPSRDELTKN 346

Db 553 VVSVLTIVLHODMLNGKEYKCKVSNKALPAPIEKTISSAKGQPREPQVYTLPPSRDELTKN 612

QY 347 QVSLTCLVKGFPYSDIAVEMESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRMQGN 406

Db 613 QVSLTCLVKGFPYSDIAVEMESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRMQGN 672

QY 407 VFSSCVMEALHNHYTKSLSPG 431

Db 673 VFSSCVMEALHNHYTKSLSPG 697

RESULT 85

US-09-773-877A-20

Sequence 20, Application US/09773877A

Publication No. US20030017977A1

GENERAL INFORMATION:

APPLICANT: Xia, Yu-ping et al.

TITLE OF INVENTION: METHODS FOR TREATING INFLAMMATORY SKIN DISEASES

FILE REFERENCE: REG 710b

CURRENT APPLICATION NUMBER: US/09/773,877A

CURRENT FILING DATE: 2001-01-31

NUMBER OF SEQ ID NOS: 27

SOFTWARE: PatentIn version 3.0

SEQ ID NO 20

LENGTH: 567

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Flt1(1-3 R->N)-Fc (Muc4)

US-09-773-877A-20

Query Match 52.4%; Score 1264; DB 12; Length 567;

Best Local Similarity 65.7%; Pred. No. 8, 9e-81;

Matches 255; Conservative 23; Mismatches 72; Indels 38; Gaps 7;

QY 81 DSRSLMDQGNFLLIKNLKIEDSDTYICEVE-----DQKEVOLVFGLTANS 129

Db 180 DGRKIIDSKR-GRTINATYKEIGLTCEATYNGHLYKTNVLTNRQTNTIIVQISTPR 238

QY 130 DTHLLOQSILTL--TLSPGSSPSVQCRSPRGKNIQG-----KTLSV 171

Db 239 PVKLLRGHTLVNCTATTPINTRVQMTWSYDEKKNQASVRRIDQNSHANIFYSVLTI 298

QY 172 SQLELOSDGTWTCYVLQNO--KVEFEKIDIVPCPAP--EPKSCDKTHTC-----PELLGSP 223

Db 299 DKMNKDKGLYTCVRSRGSFSPKSVNTSVHLYDKAGPEPSCDKTHTCPCPAPPELLGSP 358

QY 224 SVFLFPPEKDTLMSRTPREYTCVVVDVSHEDPEVKFMWYVDGVEVNAKTRPEEQNSTYR 283

Db 359 SVFLFPPEKDTLMSRTPREYTCVVVDVSHEDPEVKFMWYVDGVEVNAKTRPEEQNSTYR 418

QY 284 TYRVSVLTIVLHODMLNGKEYKCKVSNKALPAPIEKTISSAKGQPREPQVYTLPPSRDEL 343

Db 419 TYRVSVLTIVLHODMLNGKEYKCKVSNKALPAPIEKTISSAKGQPREPQVYTLPPSRDEL 478

QY 344 TKQNVSLTCLVKGFPYSDIAVEMESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRMQ 403

Db 479 TKQNVSLTCLVKGFPYSDIAVEMESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRMQ 538

QY 404 QGNVFCSCVMHEALHNHYTKSLSPG 431

Db 539 QGNVFCSCVMHEALHNHYTKSLSPG 566

RESULT 86

US-09-796-848A-37

Sequence 37, Application US/09796848A

Patent No. US20020098189A1

GENERAL INFORMATION:

APPLICANT: Young, James F.

APPLICANT: Johnson, Leslie S.

APPLICANT: Huse, William D.

APPLICANT: Wu, Herren

APPLICANT: Watkins, Jeffrey D.

TITLE OF INVENTION: High Potency Recombinant Antibodies and Methods of

TITLE OF INVENTION: Producing Them

FILE REFERENCE: 469201-526

CURRENT APPLICATION NUMBER: US/09/796,848A

CURRENT FILING DATE: 2001-10-30

PRIOR APPLICATION NUMBER: U.S. 60/186,252

PRIOR FILING DATE: 2000-03-01

NUMBER OF SEQ ID NOS: 59

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 37

LENGTH: 450

TYPE: PRT

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: Heavy chain of

```
; OTHER INFORMATION: high potency antibody.
US-09-796-848A-37

Query Match      52.3%; Score 1263.5; DB 9; Length 450;
Best Local Similarity 57.8%; Pred. No. 7.2e-81;
Matches 271; Conservative 27; Mismatches 74; Indels 97; Gaps 11;

QY 30 LGKKGDVVELTCTASQKKSIOFHMKNSNQIKILGNQGSFLTQGPSKL-----NDRA 80
DB 11 LKPKQTTLTLTCTFS-----GFSISTAGMSVGMIRQPGKALEMLADIWMDGK 59
QY 81 DSRRLSMD-----QGNFPLIINKLKIENSDTYICEVEDQKEVQLLVFGLTANSPT 131
DB 60 DYNPSLKRLTLISKOTSKNQVVLKVTNMDPADATATYYCARD-----MIFNYFD--- 108
QY 132 HLLOGQSLLTLTSPSPSSPVQCRSPRGKNIOGG-----KTLSSVS----- 172
DB 109 --VMGGTTVTYSSASTKGPSVFLPAPSPSKSTSGGTALGCLVKDYFPPEPVTSWNSGAL 166
QY 173 -----QLELDQSG-----TWCTVLQNKQKVEFKIDIVPCAPAP 207
DB 167 TSGVHTFPFVAVLQSSGLYSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KRVBP 220
QY 208 KSCDKTHTC-----PELLGSPVFLPPPKKDTLMISRTPEVTCVVDVSHEDPEVKFNW 262
DB 221 KSCDKTHTCPCPCAPPELLGSPVFLPPPKKDTLMISRTPEVTCVVDVSHEDPEVKFNW 280
QY 263 YVDGVEVHNAKTPREBOYNSTYRVVSVLTVLHQDLNMEKEVKCYSNKAIPAPIEKTIS 322
DB 281 YVDGVEVHNAKTPREBOYNSTYRVVSVLTVLHQDLNMEKEVKCYSNKAIPAPIEKTIS 340
QY 323 KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTPPV 382
DB 341 KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTPPV 400
QY 383 LPSDGSFFLYSKLTVDKSRMQQGNVSCSVMEHALHNHYTQKSLSLSPG 431
DB 401 LPSDGSFFLYSKLTVDKSRMQQGNVSCSVMEHALHNHYTQKSLSLSPG 449

RESULT 87
US-09-796-848A-45
; Sequence 45, Application US/09796848A
; Patent No. US20020098189A1
; GENERAL INFORMATION:
; APPLICANT: Young, James F.
; APPLICANT: Johnson, Leslie S.
; APPLICANT: Huse, William D.
; APPLICANT: Wu, Herren
; APPLICANT: Watkins, Jeffrey D.
; TITLE OF INVENTION: High Potency Recombinant Antibodies and Methods of
; TITLE OF INVENTION: Producing Them
; FILE REFERENCE: 469201-526
; CURRENT APPLICATION NUMBER: US/09/796,848A
; CURRENT FILING DATE: 2001-10-30
; PRIOR APPLICATION NUMBER: U.S. 60/186,252
; PRIOR FILING DATE: 2000-03-01
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: PatentIn Ver. 2.1
; LENGTH: 450
; SEQ ID NO 45
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Heavy chain of
; OTHER INFORMATION: high potency antibody.
US-09-796-848A-45

Query Match      52.3%; Score 1263.5; DB 9; Length 450;
Best Local Similarity 57.8%; Pred. No. 7.2e-81;
Matches 271; Conservative 27; Mismatches 74; Indels 97; Gaps 11;

QY 30 LGKKGDVVELTCTASQKKSIOFHMKNSNQIKILGNQGSFLTQGPSKL-----NDRA 80
```

```
DB 11 LKPKQTTLTLTCTFS-----GFSISTAGMSVGMIRQPGKALEMLADIWMDGK 59
QY 81 DSRRLSMD-----QGNFPLIINKLKIENSDTYICEVEDQKEVQLLVFGLTANSPT 131
DB 60 HYNPSLKRLTLISKOTSKNQVVLKVTNMDPADATATYYCARD-----MIFNYFD--- 108
QY 132 HLLOGQSLLTLTSPSPSSPVQCRSPRGKNIOGG-----KTLSSVS----- 172
DB 109 --VMGGTTVTYSSASTKGPSVFLPAPSPSKSTSGGTALGCLVKDYFPPEPVTSWNSGAL 166
QY 173 -----QLELDQSG-----TWCTVLQNKQKVEFKIDIVPCAPAP 207
DB 167 TSGVHTFPFVAVLQSSGLYSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KRVBP 220
QY 208 KSCDKTHTC-----PELLGSPVFLPPPKKDTLMISRTPEVTCVVDVSHEDPEVKFNW 262
DB 221 KSCDKTHTCPCPCAPPELLGSPVFLPPPKKDTLMISRTPEVTCVVDVSHEDPEVKFNW 280
QY 263 YVDGVEVHNAKTPREBOYNSTYRVVSVLTVLHQDLNMEKEVKCYSNKAIPAPIEKTIS 322
DB 281 YVDGVEVHNAKTPREBOYNSTYRVVSVLTVLHQDLNMEKEVKCYSNKAIPAPIEKTIS 340
QY 323 KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTPPV 382
DB 341 KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTTPPV 400
QY 383 LPSDGSFFLYSKLTVDKSRMQQGNVSCSVMEHALHNHYTQKSLSLSPG 431
DB 401 LPSDGSFFLYSKLTVDKSRMQQGNVSCSVMEHALHNHYTQKSLSLSPG 449

RESULT 88
US-09-996-288-220
; Sequence 220, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 220
; LENGTH: 450
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-220

Query Match      52.3%; Score 1263.5; DB 9; Length 450;
Best Local Similarity 57.8%; Pred. No. 7.2e-81;
Matches 271; Conservative 27; Mismatches 74; Indels 97; Gaps 11;

QY 30 LGKKGDVVELTCTASQKKSIOFHMKNSNQIKILGNQGSFLTQGPSKL-----NDRA 80
DB 11 LKPKQTTLTLTCTFS-----GFSISTAGMSVGMIRQPGKALEMLADIWMDGK 59
QY 81 DSRRLSMD-----QGNFPLIINKLKIENSDTYICEVEDQKEVQLLVFGLTANSPT 131
DB 60 DYNPSLKRLTLISKOTSKNQVVLKVTNMDPADATATYYCARD-----MIFNYFD--- 108
QY 132 HLLOGQSLLTLTSPSPSSPVQCRSPRGKNIOGG-----KTLSSVS----- 172
DB 109 --VMGGTTVTYSSASTKGPSVFLPAPSPSKSTSGGTALGCLVKDYFPPEPVTSWNSGAL 166
QY 173 -----QLELDQSG-----TWCTVLQNKQKVEFKIDIVPCAPAP 207
DB 167 TSGVHTFPFVAVLQSSGLYSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KRVBP 220
```


NUMBER OF SEQ ID NOS: 259
 SOFTWARE: Patentin version 3.1
 SEQ ID NO 234
 LENGTH: 450
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-09-996-288-234

Query Match 52.3%; Score 1263.5; DB 9; Length 450;
 Best Local Similarity 57.8%; Pred. No. 7.2e-81;
 Matches 271; Conservative 27; Mismatches 74; Indels 97; Gaps 11;

QY 30 LKKGDTVELTCTAOKKSIOFHMKNSNOIKILGNQGSFLTNGPSKL-----NDRA 80
 DB 11 LVKPTOTLTLCTFS-----GFLSTAGMSVGMIRPPKALEMLADIWDDKK 59
 QY 81 DSRRL-----WDQNFPLIKNLKIEDSDTYICEVEDQKEEVOLLVGLTANSPT 131
 DB 60 DYNPSLKSRLTISKOTSKNQVVLKTNMADPATATYTCARD-----MIENWYFD--- 108
 QY 132 HLLOGQSLLTLSPGSSPSVOCSPRGKNIOGG-----KTLSSVS----- 172
 DB 109 --VMGQGTIVTVSSASTKGPSPVPLAPSSKSTSGGTALGCLVKDYFPPEPVTVSNNSGAL 166
 QY 173 -----QLELQDSG-----TWTCTVLQNKQVEFKIDIVPCPAPPP 207
 DB 167 TSGVHTFPVAVLQSSGLYSLSVTVTPSSSLGTOTYICNV--NHKPSNTKVD---KRVAP 220
 QY 208 KSCDKTHTC-----PELLGSPVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 262
 DB 221 KSCDKTHTCPCPAPPELLGSPVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 280
 QY 263 YVDGVEVHNAKTKPREEOYNSTYRVVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTIS 322
 DB 281 YVDGVEVHNAKTKPREEOYNSTYRVVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTIS 340
 QY 323 KAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTTPV 382
 DB 341 KAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTTPV 400
 QY 383 LQSDGSFLYSKLTVDKSRMQQGNVSCSVMEALHNHYTOKSLSLSPG 431
 DB 401 LQSDGSFLYSKLTVDKSRMQQGNVSCSVMEALHNHYTOKSLSLSPG 449

RESULT 92
 US-09-996-288-236
 Sequence 236, Application US/09996288
 Patent No. US20020177126A1
 GENERAL INFORMATION:

APPLICANT: Young, James
 APPLICANT: Scott, Koenig
 APPLICANT: Leslie, Johnson
 TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
 FILE REFERENCE: 10271-047-999
 CURRENT APPLICATION NUMBER: US/09/996,288
 NUMBER OF SEQ ID NOS: 259
 SOFTWARE: Patentin version 3.1
 SEQ ID NO 236
 LENGTH: 450
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-09-996-288-236

Query Match 52.3%; Score 1263.5; DB 9; Length 450;
 Best Local Similarity 57.8%; Pred. No. 7.2e-81;
 Matches 271; Conservative 27; Mismatches 74; Indels 97; Gaps 11;
 QY 30 LKKGDTVELTCTAOKKSIOFHMKNSNOIKILGNQGSFLTNGPSKL-----NDRA 80
 DB 11 LVKPTOTLTLCTFS-----GFLSTAGMSVGMIRPPKALEMLADIWDDKK 59

QY 81 DSRRL-----WDQNFPLIKNLKIEDSDTYICEVEDQKEEVOLLVGLTANSPT 131
 DB 60 DYNPSLKSRLTISKOTSKNQVVLKTNMADPATATYTCARD-----MIENWYFD--- 108
 QY 132 HLLOGQSLLTLSPGSSPSVOCSPRGKNIOGG-----KTLSSVS----- 172
 DB 109 --VMGQGTIVTVSSASTKGPSPVPLAPSSKSTSGGTALGCLVKDYFPPEPVTVSNNSGAL 166
 QY 173 -----QLELQDSG-----TWTCTVLQNKQVEFKIDIVPCPAPPP 207
 DB 167 TSGVHTFPVAVLQSSGLYSLSVTVTPSSSLGTOTYICNV--NHKPSNTKVD---KRVAP 220
 QY 208 KSCDKTHTC-----PELLGSPVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 262
 DB 221 KSCDKTHTCPCPAPPELLGSPVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 280
 QY 263 YVDGVEVHNAKTKPREEOYNSTYRVVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTIS 322
 DB 281 YVDGVEVHNAKTKPREEOYNSTYRVVSVLTVLHQDLNKGKEYCKVSNKALPAPIEKTIS 340
 QY 323 KAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTTPV 382
 DB 341 KAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTTPV 400
 QY 383 LQSDGSFLYSKLTVDKSRMQQGNVSCSVMEALHNHYTOKSLSLSPG 431
 DB 401 LQSDGSFLYSKLTVDKSRMQQGNVSCSVMEALHNHYTOKSLSLSPG 449

RESULT 93
 US-09-996-288-238
 Sequence 238, Application US/09996288
 Patent No. US20020177126A1
 GENERAL INFORMATION:

APPLICANT: Young, James
 APPLICANT: Scott, Koenig
 APPLICANT: Leslie, Johnson
 TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
 FILE REFERENCE: 10271-047-999
 CURRENT APPLICATION NUMBER: US/09/996,288
 NUMBER OF SEQ ID NOS: 259
 SOFTWARE: Patentin version 3.1
 SEQ ID NO 238
 LENGTH: 450
 TYPE: PRT
 ORGANISM: Homo sapiens
 US-09-996-288-238

Query Match 52.3%; Score 1263.5; DB 9; Length 450;
 Best Local Similarity 57.8%; Pred. No. 7.2e-81;
 Matches 271; Conservative 26; Mismatches 75; Indels 97; Gaps 11;

QY 30 LKKGDTVELTCTAOKKSIOFHMKNSNOIKILGNQGSFLTNGPSKL-----NDRA 80
 DB 11 LVKPTOTLTLCTFS-----GFLSTAGMSVGMIRPPKALEMLADIWDDKK 59
 QY 81 DSRRL-----WDQNFPLIKNLKIEDSDTYICEVEDQKEEVOLLVGLTANSPT 131
 DB 60 DYNPSLKSRLTISKOTSKNQVVLKTNMADPATATYTCARD-----MIENWYFD--- 108
 QY 132 HLLOGQSLLTLSPGSSPSVOCSPRGKNIOGG-----KTLSSVS----- 172
 DB 109 --VMGQGTIVTVSSASTKGPSPVPLAPSSKSTSGGTALGCLVKDYFPPEPVTVSNNSGAL 166
 QY 173 -----QLELQDSG-----TWTCTVLQNKQVEFKIDIVPCPAPPP 207
 DB 167 TSGVHTFPVAVLQSSGLYSLSVTVTPSSSLGTOTYICNV--NHKPSNTKVD---KRVAP 220
 QY 208 KSCDKTHTC-----PELLGSPVFLFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 262


```

Db      221 KSCDKTHTCPCPAPBELLGGPSVFLPPPKKDTLMI SRTPEVTCVAVDVSHEDPEVKFNW 280
Qy      263 YVDGEVHNAAKTKPREBOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 322
Db      281 YVDGEVHNAAKTKPREBOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 340
Qy      323 KAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPPV 382
Db      341 KAKGQPREPOVYTLPPSRDEMTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPPV 400
Qy      383 LDSDSGFFLYSKLTVDKSRMOQGNVFCSCVHMEALHNHYTQKSLSLSPG 431
Db      401 LDSDSGFFLYSKLTVDKSRMOQGNVFCSCVHMEALHNHYTQKSLSLSPG 449

```

```

RESULT 94
US-09-996-288-242

```

```

; Sequence 242, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:

```

```

; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 242
; LENGTH: 450
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-242

```

```

Query Match      52.3%; Score 1263.5; DB 9; Length 450;
Best Local Similarity 57.8%; Pred. No. 7.2e-81;
Matches 271; Conservative 26; Mismatches 75; Indels 97; Gaps 11;

```

```

Qy      30 LGKKDDIVELTCTAQSOKSIQFHMKNQNOIKILGNQGSFLTKGPKL-----NDRA 80
Db      11 LVKPTQTLLTCTFS-----GFSLSTAGMSVGWIRQPGKALEMLADIWMDKK 59
Qy      81 DSRASL-----WDQGNFPLIINKLIKIEDSDTYICEVEDQKEVOLVFGLTANSDT 131
Db      60 DYNPSLKRRLTISKDTSKNQVSLKVTNMDPADTATYYC-----ARDMINTFYD----- 108
Qy      132 HLLQGSLLTLSPSSPSVQCRSPRGKNIQGG-----KTLVS----- 172
Db      109 --VMQGGTTVVSASATKGPSVFPLAPSSKSTSGGTAALGCLVKDYRPEPTVSWNSGAL 166
Qy      173 -----QLELQDSG-----TWCTCVLONQKVEKIDIVPCPAEP 207
Db      167 TSGVHTFPAAVLQSSGLYSLSVTVPPSSSLGTQTYICNV--NHKPSNTKVD---KRVEP 220
Qy      208 KSCDKTHTC-----PELLGSPSVFLPPPKKDTLMI SRTPEVTCVAVDVSHEDPEVKFNW 262
Db      221 KSCDKTHTCPCPAPBELLGGPSVFLPPPKKDTLMI SRTPEVTCVAVDVSHEDPEVKFNW 280
Qy      263 YVDGEVHNAAKTKPREBOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 322
Db      281 YVDGEVHNAAKTKPREBOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 340
Qy      323 KAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPPV 382
Db      341 KAKGQPREPOVYTLPPSRDEMTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPPV 400
Qy      383 LDSDSGFFLYSKLTVDKSRMOQGNVFCSCVHMEALHNHYTQKSLSLSPG 431
Db      401 LDSDSGFFLYSKLTVDKSRMOQGNVFCSCVHMEALHNHYTQKSLSLSPG 449

```

```

RESULT 95
US-09-996-288-244

```

```

; Sequence 244, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:

```

```

; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 244
; LENGTH: 450
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-996-288-244

```

```

Query Match      52.3%; Score 1263.5; DB 9; Length 450;
Best Local Similarity 57.8%; Pred. No. 7.2e-81;
Matches 271; Conservative 26; Mismatches 75; Indels 97; Gaps 11;

```

```

Qy      30 LGKKDDIVELTCTAQSOKSIQFHMKNQNOIKILGNQGSFLTKGPKL-----NDRA 80
Db      11 LVKPTQTLLTCTFS-----GFSLSTAGMSVGWIRQPGKALEMLADIWMDKK 59
Qy      81 DSRASL-----WDQGNFPLIINKLIKIEDSDTYICEVEDQKEVOLVFGLTANSDT 131
Db      60 DYNPSLKRRLTISKDTSKNQVSLKVTNMDPADTATYYC-----ARDMINTFYD----- 108
Qy      132 HLLQGSLLTLSPSSPSVQCRSPRGKNIQGG-----KTLVS----- 172
Db      109 --VMQGGTTVVSASATKGPSVFPLAPSSKSTSGGTAALGCLVKDYRPEPTVSWNSGAL 166
Qy      173 -----QLELQDSG-----TWCTCVLONQKVEKIDIVPCPAEP 207
Db      167 TSGVHTFPAAVLQSSGLYSLSVTVPPSSSLGTQTYICNV--NHKPSNTKVD---KRVEP 220
Qy      208 KSCDKTHTC-----PELLGSPSVFLPPPKKDTLMI SRTPEVTCVAVDVSHEDPEVKFNW 262
Db      221 KSCDKTHTCPCPAPBELLGGPSVFLPPPKKDTLMI SRTPEVTCVAVDVSHEDPEVKFNW 280
Qy      263 YVDGEVHNAAKTKPREBOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 322
Db      281 YVDGEVHNAAKTKPREBOYNSTYRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 340
Qy      323 KAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPPV 382
Db      341 KAKGQPREPOVYTLPPSRDEMTKNQVSLTCLVKGFYPSDIAVEMESNGOPENNYKTTPPV 400
Qy      383 LDSDSGFFLYSKLTVDKSRMOQGNVFCSCVHMEALHNHYTQKSLSLSPG 431
Db      401 LDSDSGFFLYSKLTVDKSRMOQGNVFCSCVHMEALHNHYTQKSLSLSPG 449

```

```

RESULT 96
US-09-996-288-246

```

```

; Sequence 246, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:

```

```

; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: Patentin version 3.1

```

```
/ SEQ ID NO 246
/ LENGTH: 450
/ TYPE: PRF
/ ORGANISM: Homo sapiens
US-09-996-288-246

Query Match      52.3%; Score 1263.5; DB 9; Length 450;
Best Local Similarity 57.8%; Pred. No. 7.2e-81;
Matches 271; Conservative 26; Mismatches 75; Indels 97; Gaps 11;

30 LGKKDDTVELCTAAGKKSIOFHMKNSNOIKILNGSGSFLTKGPKSL-----NDRA 80
11 LVKPTQTLTLCTFS-----GFSLSAGMSVGMIKQPPKALEMLADIWDDKK 59
81 DSRRL-----WDQNFPLIKLKIEDSDTYICEVEDQKEVOLVGLTANSOT 131
60 DYNPSLKSRLTTSKOTSKNQVVLKVTNMDPADATATYCC---ARDMITNFFD----- 108
132 HLLQGSLTLTLSPGSSPSVQCRSPRGKNIQGG-----KTLVS----- 172
109 --VMGCTTVTVSSASTKGSVFPLAPSSKSTSGGTALAGCLVKDYFPEPVTVSNMNGAL 166
173 -----QELQDSG-----TWTCVLQNKVKEFKIDIVPCPAPR 207
167 TSGVHTFPVAVLQSSGLYSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KRVPR 220
208 KSCDKTHTC-----PELIGSPSVFLPPPKDITLMSRTPEVTCVVVDVSHEDPEVKFNW 262
221 KSCDKTHTCPCPAPPELLGSPSVFLPPPKDITLMSRTPEVTCVVVDVSHEDPEVKFNW 280
263 YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDLNMGKEYCKVSNKALPAPIEKTIS 322
281 YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDLNMGKEYCKVSNKALPAPIEKTIS 340
323 KAKGQPREPQVYTLTPSRDELTKNOVSLTCLVKGFYPSDIAVWESNNGQPENNYKTTTPV 382
341 KAKGQPREPQVYTLTPSRDELTKNOVSLTCLVKGFYPSDIAVWESNNGQPENNYKTTTPV 400
383 LQSDGSFPLYSKLTVDKSRMQQGNVSCSYMEALHNHTQKSLSPG 431
401 LQSDGSFPLYSKLTVDKSRMQQGNVSCSYMEALHNHTQKSLSPG 449

RESULT 97
US-09-996-288-252
/ Sequence 252; Application US/09996288
/ Patent No. US20020177126A1
/ GENERAL INFORMATION:
/ APPLICANT: Young, James
/ APPLICANT: Scott, Koenig
/ APPLICANT: Leslie, Johnson
/ TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
/ FILE REFERENCE: 10271-047-999
/ CURRENT APPLICATION NUMBER: US/09/996,288
/ NUMBER OF SEQ ID NOS: 259
/ SOFTWARE: PatentIn version 3.1
/ SEQ ID NO 252
/ LENGTH: 450
/ TYPE: PRF
/ ORGANISM: Homo sapiens
US-09-996-288-252

Query Match      52.3%; Score 1263.5; DB 9; Length 450;
Best Local Similarity 57.8%; Pred. No. 7.2e-81;
Matches 271; Conservative 27; Mismatches 74; Indels 97; Gaps 11;

30 LGKKDDTVELCTAAGKKSIOFHMKNSNOIKILNGSGSFLTKGPKSL-----NDRA 80
11 LVKPTQTLTLCTFS-----GFSLSAGMSVGMIKQPPKALEMLADIWDDKK 59
81 DSRRL-----WDQNFPLIKLKIEDSDTYICEVEDQKEVOLVGLTANSOT 131
60 DYNPSLKSRLTTSKOTSKNQVVLKVTNMDPADATATYCC---ARDMITNFFD----- 108
132 HLLQGSLTLTLSPGSSPSVQCRSPRGKNIQGG-----KTLVS----- 172
109 --VMGCTTVTVSSASTKGSVFPLAPSSKSTSGGTALAGCLVKDYFPEPVTVSNMNGAL 166
173 -----QELQDSG-----TWTCVLQNKVKEFKIDIVPCPAPR 207
167 TSGVHTFPVAVLQSSGLYSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KRVPR 220
208 KSCDKTHTC-----PELIGSPSVFLPPPKDITLMSRTPEVTCVVVDVSHEDPEVKFNW 262
221 KSCDKTHTCPCPAPPELLGSPSVFLPPPKDITLMSRTPEVTCVVVDVSHEDPEVKFNW 280
263 YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDLNMGKEYCKVSNKALPAPIEKTIS 322
281 YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDLNMGKEYCKVSNKALPAPIEKTIS 340
323 KAKGQPREPQVYTLTPSRDELTKNOVSLTCLVKGFYPSDIAVWESNNGQPENNYKTTTPV 382
341 KAKGQPREPQVYTLTPSRDELTKNOVSLTCLVKGFYPSDIAVWESNNGQPENNYKTTTPV 400
383 LQSDGSFPLYSKLTVDKSRMQQGNVSCSYMEALHNHTQKSLSPG 431
401 LQSDGSFPLYSKLTVDKSRMQQGNVSCSYMEALHNHTQKSLSPG 449
```

```
DB 60 HYNPSLKSRLTTSKOTSKNQVVLKVTNMDPADATATYCCARD-----MINPFFD--- 108
QY 132 HLLQGSLTLTLSPGSSPSVQCRSPRGKNIQGG-----KTLVS----- 172
DB 109 --VMGCTTVTVSSASTKGSVFPLAPSSKSTSGGTALAGCLVKDYFPEPVTVSNMNGAL 166
QY 173 -----QELQDSG-----TWTCVLQNKVKEFKIDIVPCPAPR 207
DB 167 TSGVHTFPVAVLQSSGLYSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KRVPR 220
QY 208 KSCDKTHTC-----PELIGSPSVFLPPPKDITLMSRTPEVTCVVVDVSHEDPEVKFNW 262
DB 221 KSCDKTHTCPCPAPPELLGSPSVFLPPPKDITLMSRTPEVTCVVVDVSHEDPEVKFNW 280
QY 263 YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDLNMGKEYCKVSNKALPAPIEKTIS 322
DB 281 YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDLNMGKEYCKVSNKALPAPIEKTIS 340
QY 323 KAKGQPREPQVYTLTPSRDELTKNOVSLTCLVKGFYPSDIAVWESNNGQPENNYKTTTPV 382
DB 341 KAKGQPREPQVYTLTPSRDELTKNOVSLTCLVKGFYPSDIAVWESNNGQPENNYKTTTPV 400
383 LQSDGSFPLYSKLTVDKSRMQQGNVSCSYMEALHNHTQKSLSPG 431
401 LQSDGSFPLYSKLTVDKSRMQQGNVSCSYMEALHNHTQKSLSPG 449
```

```
RESULT 98
US-09-996-288-254
/ Sequence 254; Application US/09996288
/ Patent No. US20020177126A1
/ GENERAL INFORMATION:
/ APPLICANT: Young, James
/ APPLICANT: Scott, Koenig
/ APPLICANT: Leslie, Johnson
/ TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
/ FILE REFERENCE: 10271-047-999
/ CURRENT APPLICATION NUMBER: US/09/996,288
/ NUMBER OF SEQ ID NOS: 259
/ SOFTWARE: PatentIn version 3.1
/ SEQ ID NO 254
/ LENGTH: 450
/ TYPE: PRF
/ ORGANISM: Homo sapiens
US-09-996-288-254

Query Match      52.3%; Score 1263.5; DB 9; Length 450;
Best Local Similarity 57.8%; Pred. No. 7.2e-81;
Matches 271; Conservative 27; Mismatches 74; Indels 97; Gaps 11;

30 LGKKDDTVELCTAAGKKSIOFHMKNSNOIKILNGSGSFLTKGPKSL-----NDRA 80
11 LVKPTQTLTLCTFS-----GFSLSAGMSVGMIKQPPKALEMLADIWDDKK 59
81 DSRRL-----WDQNFPLIKLKIEDSDTYICEVEDQKEVOLVGLTANSOT 131
60 HYNPSLKSRLTTSKOTSKNQVVLKVTNMDPADATATYCCARD-----MINPFFD--- 108
132 HLLQGSLTLTLSPGSSPSVQCRSPRGKNIQGG-----KTLVS----- 172
109 --VMGCTTVTVSSASTKGSVFPLAPSSKSTSGGTALAGCLVKDYFPEPVTVSNMNGAL 166
173 -----QELQDSG-----TWTCVLQNKVKEFKIDIVPCPAPR 207
167 TSGVHTFPVAVLQSSGLYSLSSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KRVPR 220
208 KSCDKTHTC-----PELIGSPSVFLPPPKDITLMSRTPEVTCVVVDVSHEDPEVKFNW 262
221 KSCDKTHTCPCPAPPELLGSPSVFLPPPKDITLMSRTPEVTCVVVDVSHEDPEVKFNW 280
```

```

Qy 263 YVDGVEVHNAKTPREBOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 322
Db 261 YVDGVEVHNAKTPREBOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 340
Qy 323 KAKGQPREQVYTLTPSRDELTKNQVSLTCLVKGYFPPSDIAVEMESNGQPENNYKTTTPV 382
Db 341 KAKGQPREQVYTLTPSRDELTKNQVSLTCLVKGYFPPSDIAVEMESNGQPENNYKTTTPV 400
Qy 383 LDSDSFFLYSKLTVDKSRMOQGNVFCSCVMEALHNHYTQKSLSLSPG 431
Db 401 LDSDSFFLYSKLTVDKSRMOQGNVFCSCVMEALHNHYTQKSLSLSPG 449

```

RESULT 99
US-09-996-288-256

```

; Sequence 256, Application US/09996288
; Patent No. US20020177126A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-047-999
; CURRENT APPLICATION NUMBER: US/09/996,288
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 256
; LENGTH: 450
; TYPE: PRF
; ORGANISM: Homo sapiens
US-09-996-288-256

```

Query Match 52.3%; Score 1263.5; DB 9; Length 450;

Best Local Similarity 57.8%; Pred. No. 7.2e-81;

Matches 271; Conservative 27; Mismatches 74; Indels 97; Gaps 11;

```

Qy 30 LGKKGDVVELTCTASQKKSIOFHMKNSNQIKILGNQGSFLTKGPKL-----NDRA 80
Db 11 LVKPTQTTLTCTFS-----GFSLTAGMSVGMIRQPGKALEMLADIWMDKK 59
Qy 81 DSRSLMD-----QGNPFLIKNLKIEDSTYICEVEDQKEVQLVFGLTANS DT 131
Db 60 HNPFLKDRLTISKDTSKNQVVKVTNMDPADTATYTCARD-----MIFNFFD--- 108
Qy 132 HLLQGSLLTLLESPPGSSPSVQCRSPRGKNIQGG-----KTLVS----- 172
Db 109 --VMGQGTIVYSSASTKGPSVFLPPLAAPSSTSGGTALGCLVKDYFPEPTVSMNSGAL 166
Qy 173 -----QLELDQSG-----TWCTTVLONQKVEFKIDIVPCPAP 207
Db 167 TSGVTFPRAVLQSSGLYSLSVVTVPSSSLGTQTYICNV--NHKPSNTKVD---KVEP 220
Qy 208 KSCDKTHTC-----PELLGGSVFLPFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 262
Db 221 KSCDKTHTCPCPAPPELLGGSVFLPFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 280
Qy 263 YVDGVEVHNAKTPREBOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 322
Db 281 YVDGVEVHNAKTPREBOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 340
Qy 323 KAKGQPREQVYTLTPSRDELTKNQVSLTCLVKGYFPPSDIAVEMESNGQPENNYKTTTPV 382
Db 341 KAKGQPREQVYTLTPSRDELTKNQVSLTCLVKGYFPPSDIAVEMESNGQPENNYKTTTPV 400
Qy 383 LDSDSFFLYSKLTVDKSRMOQGNVFCSCVMEALHNHYTQKSLSLSPG 431
Db 401 LDSDSFFLYSKLTVDKSRMOQGNVFCSCVMEALHNHYTQKSLSLSPG 449

```

```

; Sequence 220, Application US/09996265
; Publication No. US20030091584A1
; GENERAL INFORMATION:
; APPLICANT: Young, James
; APPLICANT: Scott, Koenig
; APPLICANT: Leslie, Johnson
; TITLE OF INVENTION: Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
; TITLE OF INVENTION: and Treatment
; FILE REFERENCE: 10271-048-999
; CURRENT APPLICATION NUMBER: US/09/996,265
; CURRENT FILING DATE: 2001-11-28
; NUMBER OF SEQ ID NOS: 259
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 220
; LENGTH: 450
; TYPE: PRF
; ORGANISM: Homo sapiens
US-09-996-265-220

```

Query Match 52.3%; Score 1263.5; DB 10; Length 450;

Best Local Similarity 57.8%; Pred. No. 7.2e-81;

Matches 271; Conservative 27; Mismatches 74; Indels 97; Gaps 11;

```

Qy 30 LGKKGDVVELTCTASQKKSIOFHMKNSNQIKILGNQGSFLTKGPKL-----NDRA 80
Db 11 LVKPTQTTLTCTFS-----GFSLTAGMSVGMIRQPGKALEMLADIWMDKK 59
Qy 81 DSRSLMD-----QGNPFLIKNLKIEDSTYICEVEDQKEVQLVFGLTANS DT 131
Db 60 DYNPFLKDRLTISKDTSKNQVVKVTNMDPADTATYTCARD-----MIFNFFD--- 108
Qy 132 HLLQGSLLTLLESPPGSSPSVQCRSPRGKNIQGG-----KTLVS----- 172
Db 109 --VMGQGTIVYSSASTKGPSVFLPPLAAPSSTSGGTALGCLVKDYFPEPTVSMNSGAL 166
Qy 173 -----QLELDQSG-----TWCTTVLONQKVEFKIDIVPCPAP 207
Db 167 TSGVTFPRAVLQSSGLYSLSVVTVPSSSLGTQTYICNV--NHKPSNTKVD---KVEP 220
Qy 208 KSCDKTHTC-----PELLGGSVFLPFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 262
Db 221 KSCDKTHTCPCPAPPELLGGSVFLPFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW 280
Qy 263 YVDGVEVHNAKTPREBOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 322
Db 281 YVDGVEVHNAKTPREBOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 340
Qy 323 KAKGQPREQVYTLTPSRDELTKNQVSLTCLVKGYFPPSDIAVEMESNGQPENNYKTTTPV 382
Db 341 KAKGQPREQVYTLTPSRDELTKNQVSLTCLVKGYFPPSDIAVEMESNGQPENNYKTTTPV 400
Qy 383 LDSDSFFLYSKLTVDKSRMOQGNVFCSCVMEALHNHYTQKSLSLSPG 431
Db 401 LDSDSFFLYSKLTVDKSRMOQGNVFCSCVMEALHNHYTQKSLSLSPG 449

```

Search completed: August 3, 2004, 13:47:37

Job time : 46.4271 secs

RESULT 100
US-09-996-265-220

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 3, 2004, 13:01:34 ; Search time 13.3604 Seconds
(without alignments)
1754.300 Million cell updates/sec

Title: SEQ4
Perfect score: 2414
Sequence: 1 MRGVFPRHLVLVLALP.....DENCARDGELGLWTTDP 454

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 389414 seqs, 51625971 residues

Total number of hits satisfying chosen parameters: 389414

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 125 summaries

Database : Issued Patents AA:*
1: /cgn2_6/prodata/2/1aa/5A_COMB.pep.*
2: /cgn2_6/prodata/2/1aa/5B_COMB.pep.*
3: /cgn2_6/prodata/2/1aa/6A_COMB.pep.*
4: /cgn2_6/prodata/2/1aa/6B_COMB.pep.*
5: /cgn2_6/prodata/2/1aa/PCITUS_COMB.pep.*
6: /cgn2_6/prodata/2/1aa/backfile1.pep.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	* Query Match	Length	DB ID	Description
1	2122	87.9	432	3	US-08-477-460B-2
2	2122	87.9	432	3	US-08-379-516-2
3	2122	87.9	432	3	US-09-329-916-2
4	2122	87.9	432	3	US-08-485-372A-2
5	2122	87.9	432	4	US-09-409-006A-2
6	2122	87.9	432	4	US-08-484-681-2
7	2122	87.9	432	5	PCT-US93-07422-2
8	2092	86.7	630	4	US-08-472-888A-6
9	2085	86.4	530	3	US-08-477-460B-4
10	2085	86.4	530	3	US-08-379-516-4
11	2085	86.4	530	3	US-09-329-916-4
12	2085	86.4	530	4	US-08-485-372A-4
13	2085	86.4	530	4	US-09-409-006A-4
14	2085	86.4	530	4	US-08-484-681-4
15	2085	86.4	530	5	PCT-US93-07422-4
16	1647.5	68.2	410	3	US-08-630-172-17
17	1647.5	68.2	410	3	US-09-375-419-17
18	1338.5	55.4	254	2	US-08-284-391B-33
19	1338.5	55.4	254	3	US-09-218-950-33
20	1284.5	53.2	459	1	US-08-157-101A-7
21	1282.5	53.1	446	3	US-08-397-411-7
22	1276.5	52.9	455	4	US-09-740-002-25
23	1274.5	52.8	454	2	US-07-934-373C-22
24	1274.5	52.8	454	3	US-08-437-642B-22
25	1274.5	52.8	454	4	US-08-146-206C-22
26	1274.5	52.8	454	4	US-09-705-686-22
27	1274.5	52.8	454	5	PCT-US93-07832-22

28	1274.5	52.8	473	3	US-09-049-672A-4	Sequence 4, Appl
29	1273.5	52.8	475	4	US-09-740-002-27	Sequence 27, Appl
30	1273.5	52.8	497	4	US-09-499-846-6	Sequence 6, Appl
31	1273.5	52.8	525	4	US-09-499-846-4	Sequence 4, Appl
32	1273.5	52.8	622	4	US-09-499-846-2	Sequence 2, Appl
33	1271.5	52.7	453	4	US-09-301-593-18	Sequence 18, Appl
34	1271	52.7	476	3	US-08-487-550-12	Sequence 12, Appl
35	1271	52.7	476	4	US-09-526-098-12	Sequence 12, Appl
36	1265.5	52.4	468	4	US-09-485-737B-67	Sequence 67, Appl
37	1265.5	52.4	711	4	US-09-485-737B-90	Sequence 90, Appl
38	1265	52.4	449	1	US-08-458-516-13	Sequence 13, Appl
39	1264	52.4	451	4	US-09-247-352-3	Sequence 3, Appl
40	1264	52.4	451	4	US-09-466-635-3	Sequence 3, Appl
41	1263.5	52.3	452	3	US-09-027-449-71	Sequence 71, Appl
42	1263.5	52.3	452	3	US-09-026-988-71	Sequence 71, Appl
43	1263.5	52.3	452	4	US-09-121-952A-71	Sequence 71, Appl
44	1263.5	52.3	452	4	US-09-334-340A-71	Sequence 71, Appl
45	1263	52.3	472	4	US-09-301-593-30	Sequence 30, Appl
46	1262	52.3	451	2	US-08-887-352B-18	Sequence 18, Appl
47	1262	52.3	451	3	US-09-109-207C-18	Sequence 18, Appl
48	1262	52.3	451	3	US-09-282-505-2	Sequence 2, Appl
49	1262	52.3	451	3	US-09-054-255-2	Sequence 2, Appl
50	1262	52.3	451	3	US-09-296-005-18	Sequence 18, Appl
51	1262	52.3	451	4	US-09-282-846-2	Sequence 2, Appl
52	1262	52.3	451	4	US-09-680-145-2	Sequence 2, Appl
53	1262	52.3	451	4	US-09-920-171-18	Sequence 18, Appl
54	1261.5	52.3	467	3	US-09-049-672A-8	Sequence 8, Appl
55	1261	52.2	488	4	US-09-499-846-12	Sequence 12, Appl
56	1259	52.2	453	3	US-08-466-151-8	Sequence 8, Appl
57	1259	52.2	453	4	US-08-466-163B-8	Sequence 8, Appl
58	1259	52.2	453	4	US-09-802-096-8	Sequence 8, Appl
59	1259	52.2	476	2	US-08-378-936-10	Sequence 10, Appl
60	1259	52.2	476	3	US-08-487-550-8	Sequence 8, Appl
61	1259	52.2	478	4	US-09-526-098-8	Sequence 8, Appl
62	1258.5	52.1	497	4	US-09-499-846-10	Sequence 10, Appl
63	1258.5	52.1	525	4	US-09-499-846-8	Sequence 8, Appl
64	1257	52.1	451	2	US-08-887-352B-14	Sequence 14, Appl
65	1257	52.1	451	2	US-08-887-352B-16	Sequence 16, Appl
66	1257	52.1	451	3	US-08-466-151-65	Sequence 65, Appl
67	1257	52.1	451	3	US-09-109-207C-14	Sequence 14, Appl
68	1257	52.1	451	3	US-09-109-207C-16	Sequence 16, Appl
69	1257	52.1	451	3	US-09-296-005-14	Sequence 14, Appl
70	1257	52.1	451	3	US-09-296-005-16	Sequence 16, Appl
71	1257	52.1	451	4	US-09-920-171-14	Sequence 14, Appl
72	1257	52.1	451	4	US-09-920-171-16	Sequence 16, Appl
73	1257	52.1	472	4	US-08-793-450-8	Sequence 8, Appl
74	1256.5	52.1	472	4	US-09-301-593-43	Sequence 43, Appl
75	1254.5	52.0	462	4	US-09-289-942A-7	Sequence 7, Appl
76	1254.5	52.0	449	4	US-09-679-397-2	Sequence 2, Appl
77	1254.5	52.0	449	4	US-09-680-148-2	Sequence 2, Appl
78	1254.5	52.0	449	4	US-09-304-465A-2	Sequence 2, Appl
79	1248	51.7	476	4	US-08-487-550-4	Sequence 4, Appl
80	1248	51.7	476	4	US-09-526-098-4	Sequence 4, Appl
81	1240.5	51.4	951	4	US-09-313-942-9	Sequence 9, Appl
82	1238	51.3	442	4	US-08-472-888A-7	Sequence 7, Appl
83	1238	51.3	442	5	PCT-US96-10043-9	Sequence 9, Appl
84	1238	51.3	547	4	US-09-746-359A-54	Sequence 54, Appl
85	1238	51.3	571	4	US-09-746-359A-53	Sequence 53, Appl
86	1236.5	51.2	371	1	US-08-236-311-7	Sequence 7, Appl
87	1236.5	51.2	371	3	US-08-457-918-7	Sequence 7, Appl
88	1234.5	51.1	446	4	US-09-157-452B-12	Sequence 12, Appl
89	1232	51.0	704	4	US-09-590-656-2	Sequence 2, Appl
90	1232	51.0	704	4	US-09-733-764-2	Sequence 2, Appl
91	1226	50.8	442	1	US-08-462-571-5	Sequence 5, Appl
92	1226	50.8	442	2	US-08-462-571-5	Sequence 5, Appl
93	1224	50.7	437	5	PCT-US96-10043-11	Sequence 11, Appl
94	1221.5	50.6	530	4	US-09-301-593-22	Sequence 22, Appl
95	1221	50.6	532	4	US-09-313-942-8	Sequence 8, Appl
96	1219	50.5	424	5	PCT-US95-03866-12	Sequence 12, Appl
97	1219	50.5	424	5	PCT-US95-03866-14	Sequence 14, Appl
98	1215	50.3	360	4	US-09-180-100-11	Sequence 11, Appl
99	1215	50.3	376	4	US-09-180-100-22	Sequence 22, Appl
100	1215	50.3	424	4	US-09-333-593A-8	Sequence 8, Appl

```

101 1212 50.2 331 3 US-09-178-869-2 Sequence 2, Appl1
102 1212 50.2 331 4 US-09-761-413-2 Sequence 2, Appl1
103 1211.5 50.2 232 2 US-08-595-043A-50 Sequence 50, Appl1
104 1211.5 50.2 396 2 US-08-784-512-3 Sequence 3, Appl1
105 1211.5 50.2 396 3 US-09-176-228-3 Sequence 3, Appl1
106 1211.5 50.2 859 4 US-09-313-942-7 Sequence 7, Appl1
107 1211.5 50.2 977 4 US-09-590-656-1 Sequence 1, Appl1
108 1211.5 50.2 977 4 US-09-733-764-1 Sequence 1, Appl1
109 1210 50.1 377 4 US-09-227-595-24 Sequence 24, Appl1
110 1207.5 50.0 552 1 US-08-243-010-6 Sequence 6, Appl1
111 1207 50.0 680 3 US-08-227-496C-15 Sequence 15, Appl1
112 1206.5 50.0 388 3 US-09-131-247-16 Sequence 16, Appl1
113 1205.5 49.9 664 3 US-08-957-063-16 Sequence 16, Appl1
114 1205.5 49.9 664 4 US-09-487-685-16 Sequence 16, Appl1
115 1205.5 49.9 664 4 US-08-802-805D-16 Sequence 16, Appl1
116 1205.5 49.9 911 2 US-08-484-438-10 Sequence 10, Appl1
117 1204.5 49.9 235 3 US-09-131-247-6 Sequence 6, Appl1
118 1204.5 49.9 389 3 US-09-131-247-14 Sequence 14, Appl1
119 1203.5 49.9 488 3 US-08-776-511-2 Sequence 2, Appl1
120 1203.5 49.9 559 4 US-09-746-359A-62 Sequence 62, Appl1
121 1203.5 49.9 594 4 US-09-746-359A-23 Sequence 23, Appl1
122 1203 49.8 387 1 US-08-470-299-4 Sequence 4, Appl1
123 1202 49.8 442 1 US-08-480-036-2 Sequence 2, Appl1
124 1202 49.8 442 1 US-08-461-968A-2 Sequence 2, Appl1
125 1202 49.8 442 2 US-08-462-571-2 Sequence 2, Appl1

```

ALIGNMENTS

RESULT 1
US-08-477-460B-2
Sequence 2, Application US/08477460B

Patent No. 6034223

GENERAL INFORMATION:

APPLICANT: Progenics Pharmaceuticals, Inc.

TITLE OF INVENTION: NON-PEPTIDYL MOIETY-CONJUGATED

TITLE OF INVENTION: CD4-GAMMA2 AND CD4-IGG2 IMMUNOCONJUGATES, AND USES THEREOF

NUMBER OF SEQUENCES: 9

CORRESPONDENCE ADDRESS:

ADDRESSEE: Cooper & Dunham

STREET: 30 Rockefeller Plaza

CITY: New York

STATE: New York

COUNTRY: USA

ZIP: 10112

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.24

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/477,460B

FILING DATE: 07-JUN-1995

CLASSIFICATION: 530

PRIOR APPLICATION NUMBER:

APPLICATION NUMBER: US 07/927,931

FILING DATE: 07-AUG-1992

ATTORNEY/AGENT INFORMATION:

NAME: White, John P.

REGISTRATION NUMBER: 28,678

REFERENCE/DOCKET NUMBER: 41215-A-PCT/JPW/AJM

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 977-9550

TELEFAX: (212) 977-9809

TELEX: 422523 COOP UI

INFORMATION FOR SEQ ID NO: 2:

SEQUENCE CHARACTERISTICS:

LENGTH: 432 amino acids

TYPE: amino acid

STRANDEDNESS: unknown

TOPOLOGY: unknown

MOLECULE TYPE: protein

ORIGINAL SOURCE:
ORGANISM: homo sapien
CELL TYPE: lymphocyte
US-08-477-460B-2

Query Match 87.9%; Score 2122; DB 3; Length 432;
Best Local Similarity 91.2%; Pred. No. 3e-164;
Matches 405; Conservative 8; Mismatches 5; Indels 26; Gaps 2;

```

QY 1 MNRGVPFRHLILVQLALPPATGKNVYLGKDDIVELTCTASOKSIOGHMKNNSQIK 60
   |||
DB 1 MNRGVPFRHLILVQLALPPATGKNVYLGKDDIVELTCTASOKSIOGHMKNNSQIK 60
QY 61 ILNGQSFLLTGPKSLNDRADRSRSIWDQGNFPIIKLKIEDSDTYICEVEDQKEEYQL 120
   |||
DB 61 ILNGQSFLLTGPKSLNDRADRSRSIWDQGNFPIIKLKIEDSDTYICEVEDQKEEYQL 120
QY 121 LVFGLTANSDFHLLQGGSLTTLSPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
   |||
DB 121 LVFGLTANSDFHLLQGGSLTTLSPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
QY 181 TWTCVLOQOKKVEFKIDIVLAFERKCCVECPCPAPR-----VAGPSVFL 227
   |||
DB 181 TWTCVLOQOKKVEFKIDIVLAFERKCCVECPCPAPR-----VAGPSVFL 227
QY 228 FPKPKDTLMSRTPPEVTCVVVDVSHEDPEVKFMWYDGVVHNAKTKPREEQYNSTYRV 287
   |||
DB 228 FPKPKDTLMSRTPPEVTCVVVDVSHEDPEVKFMWYDGVVHNAKTKPREEQYNSTYRV 287
QY 288 VSVLTIVHODMLNKEKYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQ 347
   |||
DB 288 VSVLTIVHODMLNKEKYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQ 347
QY 348 VSLTCLVKGFPSPDIAVWESNNGPENNYKTPPVLDSDGFFLYSKLTVDKSRMQQGNV 407
   |||
DB 348 VSLTCLVKGFPSPDIAVWESNNGPENNYKTPPVLDSDGFFLYSKLTVDKSRMQQGNV 407
QY 408 FSCSVMEHALNHYTOKSLSLSPG 431
   |||
DB 408 FSCSVMEHALNHYTOKSLSLSPG 431

```

RESULT 2
US-08-379-516-2
Sequence 2, Application US/08379516
Patent No. 6083478
GENERAL INFORMATION:
APPLICANT: Allaway, Graham P.
TITLE OF INVENTION: No. 6083478-PeptideY1 Moiety-Conjugated CD4-Gamma2 and CD4-IGG2
TITLE OF INVENTION: Immunconjugates and Uses Thereof
FILE REFERENCE: 41215-A-PCT-US
CURRENT APPLICATION NUMBER: US/08/379,516
CURRENT FILING DATE: 1996-06-10
EARLIER APPLICATION NUMBER: PCT/US93/07422
EARLIER FILING DATE: 1993-08-06
EARLIER APPLICATION NUMBER: 07/927,931
EARLIER FILING DATE: 1992-08-07
NUMBER OF SEQ ID NOS: 9
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 2
LENGTH: 432
TYPE: PRT
ORGANISM: Homo sapiens
US-08-379-516-2

Query Match 87.9%; Score 2122; DB 3; Length 432;
Best Local Similarity 91.2%; Pred. No. 3e-164;
Matches 405; Conservative 8; Mismatches 5; Indels 26; Gaps 2;
QY 1 MNRGVPFRHLILVQLALPPATGKNVYLGKDDIVELTCTASOKSIOGHMKNNSQIK 60
DB 1 MNRGVPFRHLILVQLALPPATGKNVYLGKDDIVELTCTASOKSIOGHMKNNSQIK 60

```

QY 61 IIGNGSFLTKGSKINDRADSRSLMDQGNPLIIKNLIKIEDSDTYICEVEDQKEEVL 120
    |||
Db 61 IIGNGSFLTKGSKINDRADSRSLMDQGNPLIIKNLIKIEDSDTYICEVEDQKEEVL 120
QY 121 LVFGLTANSDTHLLQGOSLTLTLESPPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
    |||
Db 121 LVFGLTANSDTHLLQGOSLTLTLESPPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
QY 181 TWCTVLOQOKKVEFKIDIV-----PCPAPEPKSCDKHTHCPPELLGSPVPL 227
    |||
Db 181 TWCTVLOQOKKVEFKIDIVLVLAFAERKCCVECPPEPAP-----VAGPSVPL 227
QY 228 FPKPKDITLMISTPEVTCVVVDVSHEDPEVKFNMYVDGVEVHNAKTKRREQDYNSTYRV 287
    |||
Db 228 FPKPKDITLMISTPEVTCVVVDVSHEDPEVKFNMYVDGVEVHNAKTKRREQDYNSTYRV 287
QY 288 VSVLTIVHODMLNGKEYCKVSNKGLPAPIEKTISKAKGPREPQVYTLPPSRDELTKNQ 347
    |||
Db 288 VSVLTIVHODMLNGKEYCKVSNKGLPAPIEKTISKAKGPREPQVYTLPPSRDELTKNQ 347
QY 348 VSLTCLVKGFFYPSDIAVEMESNGQPENNYKTTTPVLDSGSEFLYSKLTVDKSRMQQGV 407
    |||
Db 348 VSLTCLVKGFFYPSDIAVEMESNGQPENNYKTTTPVLDSGSEFLYSKLTVDKSRMQQGV 407
QY 408 FSCSVNHEALHNHYTQKSLSLSPG 431
    |||
Db 408 FSCSVNHEALHNHYTQKSLSLSPG 431

```

RESULT 3

US-09-329-916-2
Sequence 2, Application US/09329916

GENERAL INFORMATION:

APPLICANT: Progenice Pharmaceuticals, Inc.
TITLE OF INVENTION: NON-PEPTIDYL MOIETY-CONJUGATED
TITLE OF INVENTION: CD4-GAMMA2 AND CD4-19G2 IMMUNOCONJUGATES, AND USES THEREOF
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cooper & Dunham
STREET: 30 Rockefeller Plaza
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10112

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09329,916
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/477,460
FILING DATE: 07-JUN-1995
APPLICATION NUMBER: US 07/927,931
FILING DATE: 07-AUG-1992
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 41215-A-PCT/JWP/AJM
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 977-9550
TELEFAX: (212) 977-9809
TELEX: 422523 COOP UT
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 432 amino acids
TYPE: amino acid
STRANDEDNESS: unknown

TOPOLOGY: unknown
MOLECULE TYPE: protein
ORIGINAL SOURCE:
ORGANISM: homo sapien
CELL TYPE: lymphocyte
US-09-329-916-2

Query Match 87.9%; Score 2122; DB 3; Length 432;
Best Local Similarity 91.2%; Pred. No. 36-164;
Matches 405; Conservative 8; Mismatches 5; Indels 26; Gaps 2;

```

QY 1 NMRGVPFRLLLVLLQALLPAATQGNKVLGKKGTVELTCTASQKSIQFMKSNQIK 60
    |||
Db 1 NMRGVPFRLLLVLLQALLPAATQGNKVLGKKGTVELTCTASQKSIQFMKSNQIK 60
QY 61 IIGNGSFLTKGSKINDRADSRSLMDQGNPLIIKNLIKIEDSDTYICEVEDQKEEVL 120
    |||
Db 61 IIGNGSFLTKGSKINDRADSRSLMDQGNPLIIKNLIKIEDSDTYICEVEDQKEEVL 120
QY 121 LVFGLTANSDTHLLQGOSLTLTLESPPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
    |||
Db 121 LVFGLTANSDTHLLQGOSLTLTLESPPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
QY 181 TWCTVLOQOKKVEFKIDIV-----PCPAPEPKSCDKHTHCPPELLGSPVPL 227
    |||
Db 181 TWCTVLOQOKKVEFKIDIVLVLAFAERKCCVECPPEPAP-----VAGPSVPL 227
QY 228 FPKPKDITLMISTPEVTCVVVDVSHEDPEVKFNMYVDGVEVHNAKTKRREQDYNSTYRV 287
    |||
Db 228 FPKPKDITLMISTPEVTCVVVDVSHEDPEVKFNMYVDGVEVHNAKTKRREQDYNSTYRV 287
QY 288 VSVLTIVHODMLNGKEYCKVSNKGLPAPIEKTISKAKGPREPQVYTLPPSRDELTKNQ 347
    |||
Db 288 VSVLTIVHODMLNGKEYCKVSNKGLPAPIEKTISKAKGPREPQVYTLPPSRDELTKNQ 347
QY 348 VSLTCLVKGFFYPSDIAVEMESNGQPENNYKTTTPVLDSGSEFLYSKLTVDKSRMQQGV 407
    |||
Db 348 VSLTCLVKGFFYPSDIAVEMESNGQPENNYKTTTPVLDSGSEFLYSKLTVDKSRMQQGV 407
QY 408 FSCSVNHEALHNHYTQKSLSLSPG 431
    |||
Db 408 FSCSVNHEALHNHYTQKSLSLSPG 431

```

RESULT 4

US-08-485-372A-2
Sequence 2, Application US/08485372A

GENERAL INFORMATION:

APPLICANT: Beaudry, Gary A.
TITLE OF INVENTION: Maddon, Paul J.
TITLE OF INVENTION: CD4-GAMMA2 CD4-19G2 CHIMERAS
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cooper & Dunham LLP
STREET: 1185 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/485,372A
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/476,227
FILING DATE: 07-JUN-1995
ATTORNEY/AGENT INFORMATION:

NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 37690-II-A
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 278-0400
TELEFAX: (212) 391-0525
TELEX:
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 432 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: protein
ORIGINAL SOURCE:
ORGANISM: homo sapien
CELL TYPE: lymphocyte
US-08-485-372A-2

Query Match 87.9%; Score 2122; DB 3; Length 432;
Best Local Similarity 91.2%; Pred. No. 3e-164;

Matches 405; Conservative 8; Mismatches 5; Indels 26; Gaps 2;

QY 1 NMRGVPFRHLILVQLALPAAATGKNVYLGKKGDTVELTCTASQKSIQFMKNSNOIK 60
DB 1 NMRGVPFRHLILVQLALPAAATGKNVYLGKKGDTVELTCTASQKSIQFMKNSNOIK 60
QY 61 ILGNQGSFLTKGSPSKLNDRADRSRLMDQGNFPLIINKLKIEDSDTYICEVEDQKEEYQL 120
DB 61 ILGNQGSFLTKGSPSKLNDRADRSRLMDQGNFPLIINKLKIEDSDTYICEVEDQKEEYQL 120
QY 121 LVFGTLANSDBTHLLOQGSILTLTLESPPGSSPVQCRSPRGKNIQSGKTLVSQLELDQSG 180
DB 121 LVFGTLANSDBTHLLOQGSILTLTLESPPGSSPVQCRSPRGKNIQSGKTLVSQLELDQSG 180
QY 181 TWCTCTVLQNOQKVEFKIDIVLAFERKCCVECPCPAPP-----VAGPSVFL 227
DB 181 TWCTCTVLQNOQKVEFKIDIVLAFERKCCVECPCPAPP-----VAGPSVFL 227
QY 228 PPPKPDITLMSRTPEVTCVVVDVSHEDPEVKFMNYYVDGVEVHNAKTKPREEOYNSTRV 287
DB 228 PPPKPDITLMSRTPEVTCVVVDVSHEDPEVKFMNYYVDGVEVHNAKTKPREEOYNSTRV 287
QY 288 VSVLTVLVHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQ 347
DB 288 VSVLTVLVHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQ 347
QY 348 VSLTCLVKGFPYSDIAVEMESNGQPENNYKTTTPVLDSGDFLYSKLTVDKSRMQQGNV 407
DB 348 VSLTCLVKGFPYSDIAVEMESNGQPENNYKTTTPVLDSGDFLYSKLTVDKSRMQQGNV 407
QY 408 FSCSVMEALHNHYTOKSLSLSPG 431
DB 408 FSCSVMEALHNHYTOKSLSLSPG 431

RESULT 5
US-09-409-006A-2
Sequence 2, Application US/09409006A

Patent No. 6342586
GENERAL INFORMATION:
APPLICANT: Progenics Pharmaceuticals, Inc.
TITLE OF INVENTION: NON-PEPTIDYL MOIETY-COMUTATED
TITLE OF INVENTION: CD4-GAMMA2 AND CD4-1GG2 IMMUNOCOMUTATES, AND USES THEREOF
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cooper & Dunham
STREET: 30 Rockefeller Plaza
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10112
COMPUTER READABLE FORM:

MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/409,006A
FILING DATE: 29-SEP-1999
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/927,931
FILING DATE: 07-AUG-1992
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 41215-A-PCT/JPW/AJM
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 977-9550
TELEFAX: (212) 977-9809
TELEX: 422523 COOP UI
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 432 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: protein
ORIGINAL SOURCE:
ORGANISM: homo sapien
CELL TYPE: lymphocyte
US-09-409-006A-2

Query Match 87.9%; Score 2122; DB 4; Length 432;
Best Local Similarity 91.2%; Pred. No. 3e-164;

Matches 405; Conservative 8; Mismatches 5; Indels 26; Gaps 2;

QY 1 NMRGVPFRHLILVQLALPAAATGKNVYLGKKGDTVELTCTASQKSIQFMKNSNOIK 60
DB 1 NMRGVPFRHLILVQLALPAAATGKNVYLGKKGDTVELTCTASQKSIQFMKNSNOIK 60
QY 61 ILGNQGSFLTKGSPSKLNDRADRSRLMDQGNFPLIINKLKIEDSDTYICEVEDQKEEYQL 120
DB 61 ILGNQGSFLTKGSPSKLNDRADRSRLMDQGNFPLIINKLKIEDSDTYICEVEDQKEEYQL 120
QY 121 LVFGTLANSDBTHLLOQGSILTLTLESPPGSSPVQCRSPRGKNIQSGKTLVSQLELDQSG 180
DB 121 LVFGTLANSDBTHLLOQGSILTLTLESPPGSSPVQCRSPRGKNIQSGKTLVSQLELDQSG 180
QY 181 TWCTCTVLQNOQKVEFKIDIVLAFERKCCVECPCPAPP-----VAGPSVFL 227
DB 181 TWCTCTVLQNOQKVEFKIDIVLAFERKCCVECPCPAPP-----VAGPSVFL 227
QY 228 PPPKPDITLMSRTPEVTCVVVDVSHEDPEVKFMNYYVDGVEVHNAKTKPREEOYNSTRV 287
DB 228 PPPKPDITLMSRTPEVTCVVVDVSHEDPEVKFMNYYVDGVEVHNAKTKPREEOYNSTRV 287
QY 288 VSVLTVLVHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQ 347
DB 288 VSVLTVLVHODWLNKGEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRDELTKNQ 347
QY 348 VSLTCLVKGFPYSDIAVEMESNGQPENNYKTTTPVLDSGDFLYSKLTVDKSRMQQGNV 407
DB 348 VSLTCLVKGFPYSDIAVEMESNGQPENNYKTTTPVLDSGDFLYSKLTVDKSRMQQGNV 407
QY 408 FSCSVMEALHNHYTOKSLSLSPG 431
DB 408 FSCSVMEALHNHYTOKSLSLSPG 431

RESULT 6
US-08-484-681-2

Sequence 2, Application US/08484681
Patent No. 6451313
GENERAL INFORMATION:

```
/ APPLICANT: Beaudry, Gary A.
/ APPLICANT: Maddon, Paul J.
/ TITLE OF INVENTION: CD4-GAMMA2 CD4-IGG2 CHIMERAS
/ NUMBER OF SEQUENCES: 9
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Cooper & Dunham LLP
/ STREET: 1185 Avenue of the Americas
/ CITY: New York
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 10036
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent Release #1.24
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/484,681
/ FILING DATE: 07-JUN-1995
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: White, John P.
/ REGISTRATION NUMBER: 28,678
/ REFERENCE/DOCKET NUMBER: 37690-II-B
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (212) 278-0400
/ TELEFAX: (212) 391-0525
/ TELEX:
/ INFORMATION FOR SEQ ID NO: 2:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 432 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: unknown
/ TOPOLOGY: unknown
/ MOLECULE TYPE: protein
/ ORIGINAL SOURCE:
/ ORGANISM: homo sapien
/ CELL TYPE: lymphocyte
/
US-08-484-681-2

Query Match      87.9%; Score 2122; DB 4; Length 432;
Best Local Similarity 91.2%; Pred. No. 3e-164;
Matches 405; Conservative 8; Mismatches 5; Indels 26; Gaps 2;

QY      1 NMRGVFRRLLLVLTQALLPAATQGNKVVLGKKGDTVELTCTASQKSIQFHWKNSNQIK 60
DB      1 NMRGVFRRLLLVLTQALLPAATQGNKVVLGKKGDTVELTCTASQKSIQFHWKNSNQIK 60
QY      61 ILGNQSFLLTKGPSKLNDRADSRSLMDQGNPFLIIKNLKITBDSPTYICEVEDQKEEYQL 120
DB      61 ILGNQSFLLTKGPSKLNDRADSRSLMDQGNPFLIIKNLKITBDSPTYICEVEDQKEEYQL 120
QY      121 LVFGLTANSDFTHLLOQOSLTLTLSPSPGSSPVQCRSPRGKNIQGGKTLVSQLELDQSG 180
DB      121 LVFGLTANSDFTHLLOQOSLTLTLSPSPGSSPVQCRSPRGKNIQGGKTLVSQLELDQSG 180
QY      121 LVFGLTANSDFTHLLOQOSLTLTLSPSPGSSPVQCRSPRGKNIQGGKTLVSQLELDQSG 180
DB      121 LVFGLTANSDFTHLLOQOSLTLTLSPSPGSSPVQCRSPRGKNIQGGKTLVSQLELDQSG 180
QY      181 TWTCTVLTQOKKVEKIDIV-----PCPAPEPKSCDKTHTCPPELIGSPVFL 227
DB      181 TWTCTVLTQOKKVEKIDIVLVLAFERKCCVECPCPAP-----VAGPSVFL 227
QY      228 FPKPKDITLMISTPEVTCVVVDVSHEDPEVKFNMYVDGVEVYNAKTKRREOYNSTYRV 287
DB      228 FPKPKDITLMISTPEVTCVVVDVSHEDPEVKFNMYVDGVEVYNAKTKRREOYNSTYRV 287
QY      288 VSVLTVLHODMLNGEKYKCKVSNKALPAPIEKTISAKGQPREPQVYTLPPSRDELTKNQ 347
DB      288 VSVLTVLHODMLNGEKYKCKVSNKALPAPIEKTISAKGQPREPQVYTLPPSRDELTKNQ 347
QY      348 VSLTCLVKGFPYSPDIAVEESNQPENNYKTTIPVLDSDGSFPLVSKLTIVDSRWQGNV 407
DB      348 VSLTCLVKGFPYSPDIAVEESNQPENNYKTTIPVLDSDGSFPLVSKLTIVDSRWQGNV 407
QY      408 FSCSVVHEALHNHYTQKSLSLSPG 431
```

```
DB      408 FSCSVVHEALHNHYTQKSLSLSPG 431

RESULT 7
PCT-US93-07422-2
Sequence 2, Application PC/TUS9307422
GENERAL INFORMATION:
/ APPLICANT: Progenics Pharmaceuticals, Inc.
/ TITLE OF INVENTION: NON-PEPTIDYL MOIETY-CONJUGATED
/ NUMBER OF SEQUENCES: 9
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Cooper & Dunham
/ STREET: 30 Rockefeller Plaza
/ CITY: New York
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 10112
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent Release #1.24
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: PCT/US93/07422
/ FILING DATE: 19930806
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 07/927,931
/ FILING DATE: 07-AUG-1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: White, John P.
/ REGISTRATION NUMBER: 28,678
/ REFERENCE/DOCKET NUMBER: 41215-A-PCT/JPM/AJM
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (212) 977-9550
/ TELEFAX: (212) 977-9809
/ TELEX: 422523 COOP UT
/ INFORMATION FOR SEQ ID NO: 2:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 432 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: unknown
/ TOPOLOGY: unknown
/ MOLECULE TYPE: protein
/ ORIGINAL SOURCE:
/ ORGANISM: homo sapien
/ CELL TYPE: lymphocyte
/
PCT-US93-07422-2

Query Match      87.9%; Score 2122; DB 5; Length 432;
Best Local Similarity 91.2%; Pred. No. 3e-164;
Matches 405; Conservative 8; Mismatches 5; Indels 26; Gaps 2;

QY      1 NMRGVFRRLLLVLTQALLPAATQGNKVVLGKKGDTVELTCTASQKSIQFHWKNSNQIK 60
DB      1 NMRGVFRRLLLVLTQALLPAATQGNKVVLGKKGDTVELTCTASQKSIQFHWKNSNQIK 60
QY      61 ILGNQSFLLTKGPSKLNDRADSRSLMDQGNPFLIIKNLKITBDSPTYICEVEDQKEEYQL 120
DB      61 ILGNQSFLLTKGPSKLNDRADSRSLMDQGNPFLIIKNLKITBDSPTYICEVEDQKEEYQL 120
QY      121 LVFGLTANSDFTHLLOQOSLTLTLSPSPGSSPVQCRSPRGKNIQGGKTLVSQLELDQSG 180
DB      121 LVFGLTANSDFTHLLOQOSLTLTLSPSPGSSPVQCRSPRGKNIQGGKTLVSQLELDQSG 180
QY      121 LVFGLTANSDFTHLLOQOSLTLTLSPSPGSSPVQCRSPRGKNIQGGKTLVSQLELDQSG 180
DB      121 LVFGLTANSDFTHLLOQOSLTLTLSPSPGSSPVQCRSPRGKNIQGGKTLVSQLELDQSG 180
QY      181 TWTCTVLTQOKKVEKIDIV-----PCPAPEPKSCDKTHTCPPELIGSPVFL 227
DB      181 TWTCTVLTQOKKVEKIDIVLVLAFERKCCVECPCPAP-----VAGPSVFL 227
QY      228 FPKPKDITLMISTPEVTCVVVDVSHEDPEVKFNMYVDGVEVYNAKTKRREOYNSTYRV 287
DB      228 FPKPKDITLMISTPEVTCVVVDVSHEDPEVKFNMYVDGVEVYNAKTKRREOYNSTYRV 287
```


Db 228 PEPKEDTLMISRTPEVTCVVVDVSHEDPEVQFNMYVDGVEVHNAKTKPREQFNSTRV 287
 QY 288 VSVLTVLVHODMLNGKEYCKVSNKALPAPIEKTISKAKGPREPOVYTLPPSRDLTQNO 347
 Db 288 VSVLTVLVHODMLNGKEYCKVSNKGLPAPIEKTISKAKGPREPOVYTLPPSRDMTQNO 347
 QY 348 VSLTCLVKGFPYSDIAVEMESNGQPENNYKTPPVLDSDGSFFLYSKLTVDSRMQGNV 407
 Db 348 VSLTCLVKGFPYSDIAVEMESNGQPENNYKTPPVLDSDGSFFLYSKLTVDSRMQGNV 407
 QY 408 FSCSVMEALHNHYTQKSLSLSPG 431
 Db 408 FSCSVMEALHNHYTQKSLSLSPG 431

RESULT 8
 US-08-472-888A-6
 / Sequence 6, Application US/08472888A
 / Patent No. 6613746
 / GENERAL INFORMATION:

/ APPLICANT: Seed, Brian
 / TITLE OF INVENTION: AGP-ANTIBODY FUSION PROTEINS
 / NUMBER OF SEQUENCES: 9
 / CORRESPONDENCE ADDRESS:
 / STREET: 176 Federal Street
 / CITY: Boston
 / STATE: MA
 / COUNTRY: USA
 / ZIP: 02110

/ COMPUTER READABLE FORM:
 / MEDIUM TYPE: Diskette
 / COMPUTER: IBM Compatible
 / OPERATING SYSTEM: DOS
 / SOFTWARE: FASTSEQ for Windows Version 2.0
 / CURRENT APPLICATION DATA:
 / APPLICATION NUMBER: US/08/472,888A
 / FILING DATE: 07-JUN-1995
 / CLASSIFICATION: 424

/ PRIORITY APPLICATION DATA:
 / APPLICATION NUMBER: 07/618,314
 / FILING DATE: 23-NOV-1990
 / ATTORNEY/AGENT INFORMATION:
 / NAME: Ribling, Karen L.
 / REGISTRATION NUMBER: 35,238
 / REFERENCE/DOCKET NUMBER: 00786/258001
 / TELECOMMUNICATION INFORMATION:
 / TELEPHONE: 617-428-0200
 / TELEFAX: 617-428-7045
 / TELEX:

/ INFORMATION FOR SEQ ID NO: 6:
 / SEQUENCE CHARACTERISTICS:
 / LENGTH: 630 amino acids
 / TYPE: amino acid
 / STRANDEDNESS: unknown
 / TOPOLOGY: linear
 / MOLECULE TYPE: protein
 / US-08-472-888A-6

Query Match 86.7%; Score 2092; DB 4; Length 630;
 Best Local Similarity 67.2%; Pred. No. 1,4e-161;
 Matches 424; Conservative 0; Mismatches 5; Indels 202; Gaps 5;

QY 1 NMRGVFRRLLLVLTALIPATQGNKVVLGKKGTVELTCTAAGKKSIOFHMKNSNOIK 60
 Db 1 NMRGVFRRLLLVLTALIPATQGNKVVLGKKGTVELTCTAAGKKSIOFHMKNSNOIK 60
 QY 61 ILNGGSELTGKPSKLNDAASRSLSMOGNFLLIKLNKIDSDTYICEVDDQEEVQL 120
 Db 61 ILNGGSELTGKPSKLNDAASRSLSMOGNFLLIKLNKIDSDTYICEVDDQEEVQL 120

QY 121 LVFELTANSDTHLLQGSLLTLLSPSSPSVQCRSPRGKNIQGGKTLVSOQLQDSG 180
 Db 121 LVFELTANSDTHLLQGSLLTLLSPSSPSVQCRSPRGKNIQGGKTLVSOQLQDSG 180
 QY 181 TWCTTVLQNGKVEFKIDIV----- 200
 Db 181 TWCTTVLQNGKVEFKIDIVLAFQKASSIVYKKEGQVBSFPLAFTVEKLTGSGELMW 240
 QY 201 ----- 200
 Db 241 QAERASSKSNITFDLKNKEVSVKRVTQDPKLQMGKPLHLTLPOLPOYAGSGNLTIA 300
 QY 201 ----- 200
 Db 301 LEAKTGKLGQEVNLVWBRATQLOKNLTCFVWGPTSPKMLSLKENKAKVSKREKPVW 360
 QY 201 -----PC-----PAPBPSGCTYHTC-----PELL 220
 Db 361 LNPEAGMWQCLSDSGVLLSNIKVLPTWSTPVHADPEGEPKSCDXHTCTPCPAPPELL 420
 QY 221 GGSVFLPPPKKDTLMISRTPEVTCVVVDVSHEDPEVKFMVYDGVVHNAKTKPREEQ 280
 Db 421 GGSVFLPPPKKDTLMISRTPEVTC-VVDVSHEDPEVKFMVYDGVVHNAKTKPREEQ 479
 QY 281 YNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKGPREPOVYTLPPSR 340
 Db 480 YNSTYR-MSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKGPREPOVYTLPPSR 538
 QY 341 DELTKNOVSLTCLVKGFPYSDIAVEMESNGQPENNYKTPPVLDSDGSFFLYSKLTVDS 400
 Db 539 DELTKNOVSLTCLVKGFPYSDIAVEMESNGQPENNYKTPPVLDSDGSFFLYSKLTVDS 598
 QY 401 RMQGNVFSQSVMEALHNHYTQKSLSLSPG 431
 Db 599 RMQGNVFSQSVMEALHNHYTQKSLSLSPG 629

RESULT 9
 US-08-477-4608-4

/ Sequence 4, Application US/084774608
 / Patent No. 6034223
 / GENERAL INFORMATION:

/ APPLICANT: Progenics Pharmaceuticals, Inc.
 / TITLE OF INVENTION: NON-DEPTIDYL MOIETY-CONJUGATED
 / NUMBER OF SEQUENCES: 9
 / CORRESPONDENCE ADDRESS:
 / ADDRESS: Cooper & Dunham
 / STREET: 30 Rockefeller Plaza
 / CITY: New York
 / STATE: New York
 / COUNTRY: USA

/ ZIP: 10112
 / COMPUTER READABLE FORM:
 / MEDIUM TYPE: Floppy disk
 / COMPUTER: IBM PC compatible
 / OPERATING SYSTEM: PC-DOS/MS-DOS
 / SOFTWARE: Patent In Release #1.24

/ CURRENT APPLICATION DATA:
 / APPLICATION NUMBER: US/08/477,4608
 / FILING DATE: 07-JUN-1995
 / CLASSIFICATION: 530
 / PRIORITY APPLICATION DATA:
 / APPLICATION NUMBER: US 07/927,931
 / FILING DATE: 07-AUG-1992
 / ATTORNEY/AGENT INFORMATION:

/ NAME: White, John P.
 / REGISTRATION NUMBER: 28,678
 / REFERENCE/DOCKET NUMBER: 41215-A-PCT/JPW/AJM
 / TELECOMMUNICATION INFORMATION:
 / TELEPHONE: (212) 977-9550
 / TELEFAX: (212) 977-9809
 / TELEX: 422523 COOP UI

```
/ INFORMATION FOR SEQ ID NO: 4:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 530 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: unknown
/ TOPOLOGY: unknown
/ MOLECULE TYPE: cDNA
/ ORIGINAL SOURCE:
/ ORGANISM: homo sapien
/ CELL TYPE: lymphocyte
/ US-08-477-460B-4

Query Match      86.4%; Score 2085; DB 3; Length 530;
Best Local Similarity 77.3%; Pred. No. 4e-161;
Matches 409; Conservative 9; Mismatches 13; Indels 98; Gaps 4;

QY      1  MNRGVPRHLLLVLTALLPAATQGNKVLGKKGDVLTCTASQKKSIOFHMKNNOIK 60
DB      1  MNRGVPRHLLLVLTALLPAATQGNKVLGKKGDVLTCTASQKKSIOFHMKNNOIK 60
QY      61  ILNGSGSLTKGPSKLNDRADSRSLMDQGNFPLIIKLIKIEDSDTYICEVEDQKEEYQL 120
DB      61  ILNGSGSLTKGPSKLNDRADSRSLMDQGNFPLIIKLIKIEDSDTYICEVEDQKEEYQL 120
QY      121  LVFGLTANSDFHLLOGSLTTLTLESPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
DB      121  LVFGLTANSDFHLLOGSLTTLTLESPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
QY      181  TWCTVTLQNKQKVEFKIDIVLAFATKGPVSFPLAPCSRSTSESTALGCLVKDYFPEP 240
DB      181  TWCTVTLQNKQKVEFKIDIVLAFATKGPVSFPLAPCSRSTSESTALGCLVKDYFPEP 240
QY      208  -----PCPA-----PEP 207
DB      208  -----PCPA-----PEP 207
QY      241  VTVSMNSGALTSQHTFPAVLQSSGLYSLSVTVTPSSNFGQTYTCNVDHKPSMTKYDK 300
DB      241  VTVSMNSGALTSQHTFPAVLQSSGLYSLSVTVTPSSNFGQTYTCNVDHKPSMTKYDK 300
QY      208  ----KSCDKHTCP-ELLGSPSVFLPPPKKDTLMISRPEVTCVVDVSHEDPEVKFNW 262
DB      208  ----KSCDKHTCP-ELLGSPSVFLPPPKKDTLMISRPEVTCVVDVSHEDPEVKFNW 262
QY      301  TVERCVCVECPCPAPVAGPSVFLPPPKKDTLMISRPEVTCVVDVSHEDPEVKFNW 360
DB      301  TVERCVCVECPCPAPVAGPSVFLPPPKKDTLMISRPEVTCVVDVSHEDPEVKFNW 360
QY      263  YVDGVEVNAKTKPREEQNSTFRVSVLTVHQDMLNGKEYKCKVSNKALPAPIEKTIS 322
DB      263  YVDGVEVNAKTKPREEQNSTFRVSVLTVHQDMLNGKEYKCKVSNKALPAPIEKTIS 322
QY      361  YVDGVEVNAKTKPREEQNSTFRVSVLTVHQDMLNGKEYKCKVSNKALPAPIEKTIS 420
DB      361  YVDGVEVNAKTKPREEQNSTFRVSVLTVHQDMLNGKEYKCKVSNKALPAPIEKTIS 420
QY      323  KAKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSDIAVEMESNQGPENNYKTTTPV 382
DB      323  KAKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSDIAVEMESNQGPENNYKTTTPV 382
QY      421  KTKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSDIAVEMESNQGPENNYKTTTPM 480
DB      421  KTKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSDIAVEMESNQGPENNYKTTTPM 480
QY      383  LDSDSGFFLYSKLTVDKSRMOQGNVSCSVMEHALHNHYTOKSLSPG 431
DB      383  LDSDSGFFLYSKLTVDKSRMOQGNVSCSVMEHALHNHYTOKSLSPG 431
QY      481  LDSDSGFFLYSKLTVDKSRMOQGNVSCSVMEHALHNHYTOKSLSPG 529
DB      481  LDSDSGFFLYSKLTVDKSRMOQGNVSCSVMEHALHNHYTOKSLSPG 529

RESULT 10
US-08-379-516-4
/ Sequence 4, Application US/08379516
/ Patent No. 6083478
/ GENERAL INFORMATION:
/ APPLICANT: Allaway, Graham P.
/ TITLE OF INVENTION: No. 6083478-Peptideyl Molecy-Conjugated CD4-Gamma2 and CD4-IgG2
/ TITLE OF INVENTION: Immunocjugates and Uses Thereof
/ FILE REFERENCE: 41215-A-PCT-US
/ CURRENT APPLICATION NUMBER: US/08/379, 516
/ CURRENT FILING DATE: 1996-06-10
/ EARLIER APPLICATION NUMBER: PCT/US93/07422
/ EARLIER FILING DATE: 1993-08-06
/ EARLIER APPLICATION NUMBER: 07/927, 931
/ EARLIER FILING DATE: 1992-08-07
/ NUMBER OF SEQ ID NOS: 9
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 4
/ LENGTH: 530
```

```
/ TYPE: PRT
/ ORGANISM: Homo sapiens
/ US-08-379-516-4

Query Match      86.4%; Score 2085; DB 3; Length 530;
Best Local Similarity 77.3%; Pred. No. 4e-161;
Matches 409; Conservative 9; Mismatches 13; Indels 98; Gaps 4;

QY      1  MNRGVPRHLLLVLTALLPAATQGNKVLGKKGDVLTCTASQKKSIOFHMKNNOIK 60
DB      1  MNRGVPRHLLLVLTALLPAATQGNKVLGKKGDVLTCTASQKKSIOFHMKNNOIK 60
QY      61  ILNGSGSLTKGPSKLNDRADSRSLMDQGNFPLIIKLIKIEDSDTYICEVEDQKEEYQL 120
DB      61  ILNGSGSLTKGPSKLNDRADSRSLMDQGNFPLIIKLIKIEDSDTYICEVEDQKEEYQL 120
QY      121  LVFGLTANSDFHLLOGSLTTLTLESPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
DB      121  LVFGLTANSDFHLLOGSLTTLTLESPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
QY      181  TWCTVTLQNKQKVEFKIDIVLAFATKGPVSFPLAPCSRSTSESTALGCLVKDYFPEP 240
DB      181  TWCTVTLQNKQKVEFKIDIVLAFATKGPVSFPLAPCSRSTSESTALGCLVKDYFPEP 240
QY      208  -----PCPA-----PEP 207
DB      208  -----PCPA-----PEP 207
QY      241  VTVSMNSGALTSQHTFPAVLQSSGLYSLSVTVTPSSNFGQTYTCNVDHKPSMTKYDK 300
DB      241  VTVSMNSGALTSQHTFPAVLQSSGLYSLSVTVTPSSNFGQTYTCNVDHKPSMTKYDK 300
QY      208  ----KSCDKHTCP-ELLGSPSVFLPPPKKDTLMISRPEVTCVVDVSHEDPEVKFNW 262
DB      208  ----KSCDKHTCP-ELLGSPSVFLPPPKKDTLMISRPEVTCVVDVSHEDPEVKFNW 262
QY      301  TVERCVCVECPCPAPVAGPSVFLPPPKKDTLMISRPEVTCVVDVSHEDPEVKFNW 360
DB      301  TVERCVCVECPCPAPVAGPSVFLPPPKKDTLMISRPEVTCVVDVSHEDPEVKFNW 360
QY      263  YVDGVEVNAKTKPREEQNSTFRVSVLTVHQDMLNGKEYKCKVSNKALPAPIEKTIS 322
DB      263  YVDGVEVNAKTKPREEQNSTFRVSVLTVHQDMLNGKEYKCKVSNKALPAPIEKTIS 322
QY      361  YVDGVEVNAKTKPREEQNSTFRVSVLTVHQDMLNGKEYKCKVSNKALPAPIEKTIS 420
DB      361  YVDGVEVNAKTKPREEQNSTFRVSVLTVHQDMLNGKEYKCKVSNKALPAPIEKTIS 420
QY      323  KAKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSDIAVEMESNQGPENNYKTTTPV 382
DB      323  KAKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSDIAVEMESNQGPENNYKTTTPV 382
QY      421  KTKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSDIAVEMESNQGPENNYKTTTPM 480
DB      421  KTKGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSDIAVEMESNQGPENNYKTTTPM 480
QY      383  LDSDSGFFLYSKLTVDKSRMOQGNVSCSVMEHALHNHYTOKSLSPG 431
DB      383  LDSDSGFFLYSKLTVDKSRMOQGNVSCSVMEHALHNHYTOKSLSPG 431
QY      481  LDSDSGFFLYSKLTVDKSRMOQGNVSCSVMEHALHNHYTOKSLSPG 529
DB      481  LDSDSGFFLYSKLTVDKSRMOQGNVSCSVMEHALHNHYTOKSLSPG 529

RESULT 11
US-09-329-916-4
/ Sequence 4, Application US/09329916
/ Patent No. 617549
/ GENERAL INFORMATION:
/ APPLICANT: Progenice Pharmaceuticals, Inc.
/ TITLE OF INVENTION: NON-PEPTIDYL MOLETY-CONJUGATED
/ TITLE OF INVENTION: CD4-GAMMA2 AND CD4-IgG2 IMMUNOCJUGATES, AND USES THEREOF
/ NUMBER OF SEQUENCES: 9
/ CORRESPONDENCE ADDRESS:
/ ADDRESS: Cooper & Dunham
/ STREET: 30 Rockefeller Plaza
/ CITY: New York
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 10112
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.24
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/329, 916
/ FILING DATE:
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/477, 460
/ FILING DATE: 07-JUN-1995
```

```

APPLICATION NUMBER: US 07/927,931
FILING DATE: 07-AUG-1992
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 41215-A-PCT/JPM/ALM
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 977-9550
TELEFAX: (212) 977-9809
TELEX: 422523 COOP UT
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 530 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: CDNA
ORIGINAL SOURCE:
ORGANISM: homo sapien
CELL TYPE: lymphocyte
US-09-329-916-4

```

```

Query Match      86.4%; Score 2085; DB 3; Length 530;
Best Local Similarity 77.3%; Pred. No. 4e-161;
Matches 409; Conservative 9; Mismatches 13; Indels 98; Gaps 4;

```

```

QY 1 MNRGVPFRHLILVQLALPRAATQGNKVLGKGGDTVELCTASQKKSIOFHMKNSNQIK 60
DB 1 MNRGVPFRHLILVQLALPRAATQGNKVLGKGGDTVELCTASQKKSIOFHMKNSNQIK 60
QY 61 ILNGQSFLLTKGPKSLNDRADSRSLMDQGNFPLIIKMLKIEDSDTYICEVEDQKEEVQL 120
DB 61 ILNGQSFLLTKGPKSLNDRADSRSLMDQGNFPLIIKMLKIEDSDTYICEVEDQKEEVQL 120
QY 121 LVFGILTANSDTHLLQGOSLITLTLESPPGSSPVQCRSPRGKNIQGGKTLVSQLELDQSG 180
DB 121 LVFGILTANSDTHLLQGOSLITLTLESPPGSSPVQCRSPRGKNIQGGKTLVSQLELDQSG 180
QY 181 TWTCTVLONQKKVEFKIDIV-----PCPA-----PEP 207
DB 181 TWTCTVLONQKKVEFKIDIVLAFASTKGPSVFLAPCSSTSESTALGCLVKDYFPEP 240
QY 208 ----- 207
DB 241 VTWSNMGALTSGVHTPAVLQSSGLYSLSVTVTPSSNFGTQTYTCNVDHKPSNTKYDK 300
QY 208 ----KSCDKHTHCP-ELLGGPSVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNW 262
DB 301 TVERKCCVECPCPAPVAGPSVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNW 360
QY 263 YVDGVEVHNAKTKPREEOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 322
DB 361 YVDGVEVHNAKTKPREEOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 420
QY 323 KAKGQPREPOVYTLPPSDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPV 382
DB 421 KTKGQPREPOVYTLPPSDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPV 480
QY 383 LDSDSGFLYSLKLTVDKSRMVGQGNVPSGVMEALHNHYTQKSLSLSPG 431
DB 481 LDSDSGFLYSLKLTVDKSRMVGQGNVPSGVMEALHNHYTQKSLSLSPG 529

```

RESULT 12
US-08-485-372A-4
Sequence 4, Application US/08485372A

Patent No. 6187748
GENERAL INFORMATION:
APPLICANT: Beaudry, Gary A.
APPLICANT: Maddon, Paul J.
TITLE OF INVENTION: CD4-GAMMA2 CD4-1gG2 CHIMERAS
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESS:

ADDRESSEE: Cooper & Dunham LLP
STREET: 1185 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/485,372A
FILING DATE:

CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/476,227
FILING DATE: 07-JUN-1995

ATTORNEY/AGENT INFORMATION:
NAME: White, John P.

REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 37690-II-A
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 278-0400
TELEFAX: (212) 391-0525

TELEX:
INFORMATION FOR SEQ ID NO: 4:

SEQUENCE CHARACTERISTICS:

LENGTH: 530 amino acids

TYPE: amino acid

STRANDEDNESS: unknown

TOPOLOGY: unknown

MOLECULE TYPE: CDNA

ORIGINAL SOURCE:

ORGANISM: homo sapien

CELL TYPE: lymphocyte

```

Query Match      86.4%; Score 2085; DB 3; Length 530;
Best Local Similarity 77.3%; Pred. No. 4e-161;
Matches 409; Conservative 9; Mismatches 13; Indels 98; Gaps 4;

```

```

QY 1 MNRGVPFRHLILVQLALPRAATQGNKVLGKGGDTVELCTASQKKSIOFHMKNSNQIK 60
DB 1 MNRGVPFRHLILVQLALPRAATQGNKVLGKGGDTVELCTASQKKSIOFHMKNSNQIK 60
QY 61 ILNGQSFLLTKGPKSLNDRADSRSLMDQGNFPLIIKMLKIEDSDTYICEVEDQKEEVQL 120
DB 61 ILNGQSFLLTKGPKSLNDRADSRSLMDQGNFPLIIKMLKIEDSDTYICEVEDQKEEVQL 120
QY 121 LVFGILTANSDTHLLQGOSLITLTLESPPGSSPVQCRSPRGKNIQGGKTLVSQLELDQSG 180
DB 121 LVFGILTANSDTHLLQGOSLITLTLESPPGSSPVQCRSPRGKNIQGGKTLVSQLELDQSG 180
QY 181 TWTCTVLONQKKVEFKIDIV-----PCPA-----PEP 207
DB 181 TWTCTVLONQKKVEFKIDIVLAFASTKGPSVFLAPCSSTSESTALGCLVKDYFPEP 240
QY 208 ----- 207
DB 241 VTWSNMGALTSGVHTPAVLQSSGLYSLSVTVTPSSNFGTQTYTCNVDHKPSNTKYDK 300
QY 208 ----KSCDKHTHCP-ELLGGPSVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNW 262
DB 301 TVERKCCVECPCPAPVAGPSVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNW 360
QY 263 YVDGVEVHNAKTKPREEOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 322
DB 361 YVDGVEVHNAKTKPREEOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTIS 420
QY 323 KAKGQPREPOVYTLPPSDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPV 382
DB 421 KTKGQPREPOVYTLPPSDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPV 480

```

QY 383 LDDSGSFFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTOKSLSPG 431
DB 481 LDDSGSFFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTOKSLSPG 529

RESULT 13

US-09-409-006A-4
Sequence 4, Application US/09409006A
Patent No. 6342586
GENERAL INFORMATION:
APPLICANT: Progenics Pharmaceuticals, Inc.
TITLE OF INVENTION: NON-PEPTIDYL MOIETY-CONJUGATED
NUMBER OF INVENTIONS: CD4-GAMMA2 AND CD4-IGG2 IMMUNOCONJUGATES, AND USES THEREOF
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cooper & Dunham
STREET: 30 Rockefeller Plaza
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10112
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/409,006A
FILING DATE: 29-SEP-1999
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/927,931
FILING DATE: 07-AUG-1992
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 41215-A-PCT/JPW/ALM
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 977-9550
TELEFAX: (212) 977-9809
TELEX: 422523 COOP UI
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 530 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: CDNA
ORIGINAL SOURCE:
ORGANISM: homo sapien
CELL TYPE: lymphocyte
US-09-409-006A-4

Query Match 86.4%; Score 2085; DB 4; Length 530;
Best Local Similarity 77.3%; Pred. No. 46-161;
Matches 409; Conservative 9; Mismatches 13; Indels 98; Gaps 4;
QY 1 MNRGVFRLHLVQLALPAAATQGNKVYAGKKGTVELTCTASOKKSIOFHMKNSNOIK 60
DB 1 MNRGVFRLHLVQLALPAAATQGNKVYAGKKGTVELTCTASOKKSIOFHMKNSNOIK 60
QY 61 ILGNQGSFLTKGSKLNDRAADSRSLMDQGNFLLIKNLKIEDSDTYICEVEDQKEEVOI 120
DB 61 ILGNQGSFLTKGSKLNDRAADSRSLMDQGNFLLIKNLKIEDSDTYICEVEDQKEEVOI 120
QY 121 LVFGLTANSPDTHLLOGOSLTLTLESPPGSSPVQCSPPRGKNIQGGKTLISVSQLELQDSG 180
DB 121 LVFGLTANSPDTHLLOGOSLTLTLESPPGSSPVQCSPPRGKNIQGGKTLISVSQLELQDSG 180
QY 181 TWTCTVLQNGKVEFKIDIV-----PCPA-----PPB 207
DB 181 TWTCTVLQNGKVEFKIDIVLAFATKSGPSVFLPAPCSRSTSESTALGCLVKDYFPER 240

QY 208 ----- 207
DB 241 VIVSNKSGALTGCHTFPAVLOSGLYLSVVYTPSSNFGTQTYTCNVDKRPSNTKDX 300
QY 208 ----KSCDKTHTCP-ELIGPSVFLPPRPKDTLMISRTPEYTCVVVDVSHEDPEVKFNW 262
DB 301 TVERKCCVCEPCPPAPVAGPSVFLPPRPKDTLMISRTPEYTCVVVDVSHEDPEVKFNW 360
QY 263 YVDGVEVNAKTKPREEQNSTFRVSVLTIVHOMLNKEIKCKSNALPAPIEKTIS 322
DB 361 YVDGVEVNAKTKPREEQNSTFRVSVLTIVHOMLNKEIKCKSNALPAPIEKTIS 420
QY 323 KKGQREPOVYTLPPSRDELTKNOVSLCLVKGFPSPDIABWESNGQPENNYKTPPV 382
DB 421 KTGQREPOVYTLPPSRDELTKNOVSLCLVKGFPSPDIABWESNGQPENNYKTPPV 480
QY 383 LDDSGSFFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTOKSLSPG 431
DB 481 LDDSGSFFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTOKSLSPG 529

RESULT 14

US-08-484-681-4
Sequence 4, Application US/08484681
Patent No. 6451313
GENERAL INFORMATION:
APPLICANT: Beaudry, Gary A.
APPLICANT: Maddon, Paul J.
TITLE OF INVENTION: CD4-GAMMA2 CD4-IGG2 CHIMERAS
NUMBER OF INVENTIONS: 9
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cooper & Dunham LLP
STREET: 1185 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/484,681
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 37690-II-B
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 278-0400
TELEFAX: (212) 391-0525
TELEX:
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 530 amino acids
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: CDNA
ORIGINAL SOURCE:
ORGANISM: homo sapien
CELL TYPE: lymphocyte
US-08-484-681-4

Query Match 86.4%; Score 2085; DB 4; Length 530;
Best Local Similarity 77.3%; Pred. No. 46-161;
Matches 409; Conservative 9; Mismatches 13; Indels 98; Gaps 4;
QY 1 MNRGVFRLHLVQLALPAAATQGNKVYAGKKGTVELTCTASOKKSIOFHMKNSNOIK 60

```
Db      1  MNRGVPFRHLLVLQALLPAATGKRVVLGKKGDTELTCTASQKKSIOFHMKNSNOIK 60
Oy      61  ILNGSGFLTKGSPKLNDRADSRSLMDQGNFPLIINKLKIEDSDTYICEVEDQKEEYQL 120
Db      61  ILNGSGFLTKGSPKLNDRADSRSLMDQGNFPLIINKLKIEDSDTYICEVEDQKEEYQL 120
Oy      121  LVFGLTANSDBTHLQOGSLTTLTLESPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
Db      121  LVFGLTANSDBTHLQOGSLTTLTLESPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
Oy      181  TWTCTVLQNKQKVEFKIDIV-----PCPA-----PEP 207
Db      181  TWTCTVLQNKQKVEFKIDIVLAFSTKGPSVFLAPCSRSSTSESTALGCLVKDYFPBP 240
Oy      208  ----- 207
Db      241  VTWSNMGALTSGVHTFPAVLQSSGLYSLSVVTVPSNFGOTYTTCNVDHKPSNTKVDK 300
Oy      208  ----KSCDKHTICP-ELLGSPSVFLFPPPKDITMISRTPEVTCVVDVSHEDPEVKPNW 262
Db      301  TVERKCCVCEPCPAPVAGSVFLFPPPKDITMISRTPEVTCVVDVSHEDPEVKPNW 360
Oy      263  YVDGEVHNNAKTKPREEOYNSTYRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTIS 322
Db      361  YVDGEVHNNAKTKPREEOYNSTYRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTIS 420
Oy      323  KAKQPREPOVYTLPPSRDELTKQVSLTCLVKGFPYSDIAVEMESNGQPNNTKTPPV 382
Db      421  KTKGQPREPOVYTLPPSRDELTKQVSLTCLVKGFPYSDIAVEMESNGQPNNTKTPPV 480
Oy      383  LDSGSPFLYSKLTVDKSRMQGNVFSQVMEHALHNHYTKSLSPG 431
Db      481  LDSGSPFLYSKLTVDKSRMQGNVFSQVMEHALHNHYTKSLSPG 529
```

RESULT 15

PCT-US93-07422-4

Sequence 4, Application PC/TUS9307422

GENERAL INFORMATION:

APPLICANT: Progenice Pharmaceuticals, Inc.

TITLE OF INVENTION: NON-PEPTIDYL MOIETY-COMJUGATED

TITLE OF INVENTION: CD4-GAMMA2 AND CD4-IGG2 IMMUNOCOMJUGATES, AND USES THEREOF

NUMBER OF SEQUENCES: 9

CORRESPONDENCE ADDRESSES:

ADDRESSEE: Cooper & Dunham

STREET: 30 Rockefeller Plaza

CITY: New York

STATE: New York

COUNTRY: USA

ZIP: 10112

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.24

CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US93/07422

FILING DATE: 19930806

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/927,931

FILING DATE: 07-AUG-1992

ATTORNEY/AGENT INFORMATION:

NAME: White, John P.

REGISTRATION NUMBER: 28,678

REFERENCE/DOCKET NUMBER: 41215-A-PCT/JPM/AJM

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 977-9550

TELEFAX: (212) 977-9809

TELEX: 422523 COOP UI

INFORMATION FOR SEQ ID NO: 4:

SEQUENCE CHARACTERISTICS:

LENGTH: 530 amino acids

```
TYPE: amino acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
MOLECULE TYPE: CDNA
ORIGINAL SOURCE:
ORGANISM: homo sapien
CELL TYPE: lymphocyte
PCT-US93-07422-4
```

Query Match 86.4%; Score 2085; DB 5; Length 530;
Best Local Similarity 77.3%; Pred. No. 4e-161;
Matches 409; Conservative 9; Mismatches 13; Indels 98; Gaps 4;

```
Oy      1  MNRGVPFRHLLVLQALLPAATGKRVVLGKKGDTELTCTASQKKSIOFHMKNSNOIK 60
Db      1  MNRGVPFRHLLVLQALLPAATGKRVVLGKKGDTELTCTASQKKSIOFHMKNSNOIK 60
Oy      61  ILNGSGFLTKGSPKLNDRADSRSLMDQGNFPLIINKLKIEDSDTYICEVEDQKEEYQL 120
Db      61  ILNGSGFLTKGSPKLNDRADSRSLMDQGNFPLIINKLKIEDSDTYICEVEDQKEEYQL 120
Oy      121  LVFGLTANSDBTHLQOGSLTTLTLESPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
Db      121  LVFGLTANSDBTHLQOGSLTTLTLESPGSSPSVQCRSPRGKNIQGGKTLVSQLELDQSG 180
Oy      181  TWTCTVLQNKQKVEFKIDIV-----PCPA-----PEP 207
Db      181  TWTCTVLQNKQKVEFKIDIVLAFSTKGPSVFLAPCSRSSTSESTALGCLVKDYFPBP 240
Oy      208  ----- 207
Db      241  VTWSNMGALTSGVHTFPAVLQSSGLYSLSVVTVPSNFGOTYTTCNVDHKPSNTKVDK 300
Oy      208  ----KSCDKHTICP-ELLGSPSVFLFPPPKDITMISRTPEVTCVVDVSHEDPEVKPNW 262
Db      301  TVERKCCVCEPCPAPVAGSVFLFPPPKDITMISRTPEVTCVVDVSHEDPEVKPNW 360
Oy      263  YVDGEVHNNAKTKPREEOYNSTYRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTIS 322
Db      361  YVDGEVHNNAKTKPREEOYNSTYRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTIS 420
Oy      323  KAKQPREPOVYTLPPSRDELTKQVSLTCLVKGFPYSDIAVEMESNGQPNNTKTPPV 382
Db      421  KTKGQPREPOVYTLPPSRDELTKQVSLTCLVKGFPYSDIAVEMESNGQPNNTKTPPV 480
Oy      383  LDSGSPFLYSKLTVDKSRMQGNVFSQVMEHALHNHYTKSLSPG 431
Db      481  LDSGSPFLYSKLTVDKSRMQGNVFSQVMEHALHNHYTKSLSPG 529
```

RESULT 16

US-08-630-172-17

Sequence 17, Application US/08630172

Patent No. 6060054

GENERAL INFORMATION:

APPLICANT: Staerz, Uwe

TITLE OF INVENTION: NOVEL PRODUCT AND PROCESS FOR T

TITLE OF INVENTION: LYMPHOCYTE VETO

NUMBER OF SEQUENCES: 41

CORRESPONDENCE ADDRESSES:

ADDRESSEE: Sheridan Ross & McIntosh

STREET: 1700 Lincoln Street, 35th Floor

CITY: Denver

STATE: Colorado

COUNTRY: U.S.

ZIP: 80203

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/630.172

```
/ FILING DATE:
/ CLASSIFICATION: 514
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Connell, Gary J.
/ REGISTRATION NUMBER: 32,020
/ REFERENCE/DOCKET NUMBER: 2879-36
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (303) 863-9700
/ TELEFAX: (303) 863-0223
/ INFORMATION FOR SEQ ID NO: 17:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 410 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
US-08-630-172-17

Query Match      68.2%; Score 1647.5; DB 3; Length 410;
Best Local Similarity 75.8%; Pred. No. 9,4e-126;
Matches 316; Conservative 31; Mismatches 51; Indels 19; Gaps 4;

QY 26 NKVVLGKGGDTVELTCTASQKSIQPHMKNNSQIKILNQGSFLTQGPSKLNDRADSRSS 85
   |||||
DB 1 NKVVLGKGGDTVELTCTASQKSIQPHMKNNSQIKILNQGSFLTQGPSKLNDRADSRSS 60

QY 86 LMDQGNFPLIKLKIEDSDTYICEVEDQKEEVQLLVFGLTANSDTHLLQGSFLTLES 145
   |||||
DB 61 LMDQGNFPLIKLKIEDSDTYICEVEDQKEEVQLLVFGLTANSDTHLLQGSFLTLES 120

QY 146 PGSSPSVQCRSPRKNIOGKTLVSQLELDQSGTWCTVLQNKQKVEFKIDIV----- 200
   |||||
DB 121 PGSSPSVQCRSPRKNIOGKTLVSQLELDQSGTWCTVLQNKQKVEFKIDIVLALP 180

QY 201 -----PCAPPEKSCDKHTHTEPELLGGPSVFLPPEPKDPTLMISTPEVTCVVDVSH 254
   |||||
DB 181 RGPETIKPCP-----PCCK-----PAPNLLGGPSVFLPPEPKDPTLMISTPEVTCVVDVSD 233

QY 255 DPEVKNMYVDGVEVHNAKTKPREEOYNSTYRVSVLTVLHODWLNGKEYKCKVSNKALP 314
   |||||
DB 234 DPEVQISWVNNVEVHTAQOTHRREDYNSRLRVVSALPIQHDWMSGKEFKCKVNNKDL 293

QY 315 APIEKTISKAKQPREPOVYTLPPSRDELTKQVSLTCLVKGFYPSDIAVEMESNQPEN 374
   |||||
DB 294 APIERTISKPKGSVRAPQVYVLPPE-EEMTKKQVTLTCWTDPMFEDIYVEWTNNGKTEL 352

QY 375 NYKTTPEVLDSGSPFLYSKLTVDKSRMOQGVFSCVHHEALHNHYTQKSLSLSPG 431
   |||||
DB 353 NYKNTPEVLDSGSPFLYSKLTVDKSRMOQGVFSCVHHEALHNHYTQKSLSLSPG 409

RESULT 17
US-09-375-419-17
/ Sequence 17, Application US/09375419
/ Patent No. 6264950
/ GENERAL INFORMATION:
/ APPLICANT: Straetz, Uwe
/ TITLE OF INVENTION: NOVEL PRODUCT AND PROCESS FOR T
/ NUMBER OF SEQUENCES: 41
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Sheridan Ross & McIntosh
/ STREET: 1700 Lincoln Street, 35ch Floor
/ CITY: Denver
/ STATE: Colorado
/ COUNTRY: U.S.
/ ZIP: 80203
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/375,419
```

```
/ FILING DATE:
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/630,172
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Connell, Gary J.
/ REGISTRATION NUMBER: 32,020
/ REFERENCE/DOCKET NUMBER: 2879-36
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (303) 863-9700
/ TELEFAX: (303) 863-0223
/ INFORMATION FOR SEQ ID NO: 17:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 410 amino acids
/ TYPE: amino acid
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
US-09-375-419-17

Query Match      68.2%; Score 1647.5; DB 3; Length 410;
Best Local Similarity 75.8%; Pred. No. 9,4e-126;
Matches 316; Conservative 31; Mismatches 51; Indels 19; Gaps 4;

QY 26 NKVVLGKGGDTVELTCTASQKSIQPHMKNNSQIKILNQGSFLTQGPSKLNDRADSRSS 85
   |||||
DB 1 NKVVLGKGGDTVELTCTASQKSIQPHMKNNSQIKILNQGSFLTQGPSKLNDRADSRSS 60

QY 86 LMDQGNFPLIKLKIEDSDTYICEVEDQKEEVQLLVFGLTANSDTHLLQGSFLTLES 145
   |||||
DB 61 LMDQGNFPLIKLKIEDSDTYICEVEDQKEEVQLLVFGLTANSDTHLLQGSFLTLES 120

QY 146 PGSSPSVQCRSPRKNIOGKTLVSQLELDQSGTWCTVLQNKQKVEFKIDIV----- 200
   |||||
DB 121 PGSSPSVQCRSPRKNIOGKTLVSQLELDQSGTWCTVLQNKQKVEFKIDIVLALP 180

QY 201 -----PCAPPEKSCDKHTHTEPELLGGPSVFLPPEPKDPTLMISTPEVTCVVDVSH 254
   |||||
DB 181 RGPETIKPCP-----PCCK-----PAPNLLGGPSVFLPPEPKDPTLMISTPEVTCVVDVSD 233

QY 255 DPEVKNMYVDGVEVHNAKTKPREEOYNSTYRVSVLTVLHODWLNGKEYKCKVSNKALP 314
   |||||
DB 234 DPEVQISWVNNVEVHTAQOTHRREDYNSRLRVVSALPIQHDWMSGKEFKCKVNNKDL 293

QY 315 APIEKTISKAKQPREPOVYTLPPSRDELTKQVSLTCLVKGFYPSDIAVEMESNQPEN 374
   |||||
DB 294 APIERTISKPKGSVRAPQVYVLPPE-EEMTKKQVTLTCWTDPMFEDIYVEWTNNGKTEL 352

QY 375 NYKTTPEVLDSGSPFLYSKLTVDKSRMOQGVFSCVHHEALHNHYTQKSLSLSPG 431
   |||||
DB 353 NYKNTPEVLDSGSPFLYSKLTVDKSRMOQGVFSCVHHEALHNHYTQKSLSLSPG 409

RESULT 18
US-08-284-391B-33
/ Sequence 33, Application US/08284391B
/ Patent No. 5851828
/ GENERAL INFORMATION:
/ APPLICANT: Seed, Brian
/ APPLICANT: Banapour, Babak
/ APPLICANT: Romeo, Charles
/ APPLICANT: Kolanus, Waldemar
/ TITLE OF INVENTION: TARGETED CYTOLYSIS OF HIV-INFECTED
/ NUMBER OF SEQUENCES: 53
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Clark & Biding LLP
/ STREET: 176 Federal Street
/ CITY: Boston
/ STATE: MA
/ COUNTRY: USA
/ ZIP: 02110
/ COMPUTER READABLE FORM:
```

```
/ MEDIUM TYPE: Diskette
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: DOS
/ SOFTWARE: FASTSEQ for Windows Version 2.0
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/284,391B
/ FILING DATE: 02-AUG-1994
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/195,395
/ FILING DATE: 14-FEB-1994
/ APPLICATION NUMBER: 07/847,566
/ FILING DATE: 06-MAR-1992
/ APPLICATION NUMBER: 07/665,961
/ FILING DATE: 07-MAR-1991
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Eibing, Karen L.
/ REGISTRATION NUMBER: 35,238
/ REFERENCE/DOCKET NUMBER: 00786/247001
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 617-428-0200
/ TELEFAX: 617-428-7045
/
/ INFORMATION FOR SEQ ID NO: 33:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 254 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
/
/ US-08-284-391B-33
```

```
Query Match 55.4%; Score 1338.5; DB 2; Length 254;
Best Local Similarity 98.0%; Pred. No. 6e-101;
Matches 249; Conservative 0; Mismatches 0; Indels 5; Gaps 1;
```

```
QY 206 EPKSCDKHTHC-----PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKF 260
DB 1 EPKSCDKHTHCPCPAPPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKF 60
QY 261 NWYVDGVEVHNAAKTRPREEOYNSTRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKT 320
DB 61 NWYVDGVEVHNAAKTRPREEOYNSTRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKT 120
QY 321 ISKAGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPYPSDIAVEMESNGQPENNYKTT 380
DB 121 ISKAGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPYPSDIAVEMESNGQPENNYKTT 180
QY 381 PVLDSGSPFLYSKLTVDKSRWQGNVFSCSVMEALAHNYTKSLSPGLQDETCAE 440
DB 181 PVLDSGSPFLYSKLTVDKSRWQGNVFSCSVMEALAHNYTKSLSPGLQDETCAE 240
QY 441 AODGELDGLWTTDP 454
DB 241 AODGELDGLWTTDP 254
```

```
RESULT 19
US-09-218-950-33
; Sequence 33, Application US/09218950
; Patent No. 6284240
```

```
/ GENERAL INFORMATION:
/ APPLICANT: Seed, Brian
/ APPLICANT: Banapour, Babak
/ APPLICANT: Romeo, Charles
/ APPLICANT: Kolanus, Waldemar
/ TITLE OF INVENTION: TARGETED CYTOLYSIS OF HIV-INFECTED
/ TITLE OF INVENTION: CELLS BY CHIMERIC CD4 RECEPTOR- BEARING CELLS
/ NUMBER OF SEQUENCES: 53
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Clark & Eibing LLP
/ STREET: 176 Federal Street
/ CITY: Boston
```

```
/ STATE: MA
/ COUNTRY: USA
/ ZIP: 02110
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: DOS
/ SOFTWARE: FASTSEQ for Windows Version 2.0
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/218,950
/ FILING DATE:
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US/08/284,391
/ FILING DATE: 02-AUG-1994
/ APPLICATION NUMBER: 08/195,395
/ FILING DATE: 14-FEB-1994
/ APPLICATION NUMBER: 07/847,566
/ FILING DATE: 06-MAR-1992
/ APPLICATION NUMBER: 07/665,961
/ FILING DATE: 07-MAR-1991
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Eibing, Karen L.
/ REGISTRATION NUMBER: 35,238
/ REFERENCE/DOCKET NUMBER: 00786/247001
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 617-428-0200
/ TELEFAX: 617-428-7045
/
/ INFORMATION FOR SEQ ID NO: 33:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 254 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
/
/ US-09-218-950-33
```

```
Query Match 55.4%; Score 1338.5; DB 3; Length 254;
Best Local Similarity 98.0%; Pred. No. 6e-101;
Matches 249; Conservative 0; Mismatches 0; Indels 5; Gaps 1;
```

```
QY 206 EPKSCDKHTHC-----PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKF 260
DB 1 EPKSCDKHTHCPCPAPPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKF 60
QY 261 NWYVDGVEVHNAAKTRPREEOYNSTRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKT 320
DB 61 NWYVDGVEVHNAAKTRPREEOYNSTRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKT 120
QY 321 ISKAGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPYPSDIAVEMESNGQPENNYKTT 380
DB 121 ISKAGQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPYPSDIAVEMESNGQPENNYKTT 180
QY 381 PVLDSGSPFLYSKLTVDKSRWQGNVFSCSVMEALAHNYTKSLSPGLQDETCAE 440
DB 181 PVLDSGSPFLYSKLTVDKSRWQGNVFSCSVMEALAHNYTKSLSPGLQDETCAE 240
QY 441 AODGELDGLWTTDP 454
DB 241 AODGELDGLWTTDP 254
```

```
RESULT 20
US-08-157-101A-7
; Sequence 7, Application US/08157101A
; Patent No. 5808032
```

```
/ GENERAL INFORMATION:
/ APPLICANT: KURIHARA, TATSUYA
/ APPLICANT: MATSUKURA, SHIGEKAZU
/ APPLICANT: TSURUOKA, NOBUO
/ APPLICANT: ARIMA, KENJI
/ APPLICANT: NISHIHARA, TATSURO
```

```

/ TITLE OF INVENTION: ANTI-HBs ANTIBODY GENES AND EXPRESSION
/ TITLE OF INVENTION: PLASMIDS THEREFOR
/ NUMBER OF SEQUENCES: 9
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: FILLSBURY, MADISON & SUTRO
/ STREET: 1100 NEW YORK AVENUE, N.W.
/ CITY: WASHINGTON
/ STATE: D.C.
/ COUNTRY: USA
/ ZIP: 20005
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/157,101A
/ FILING DATE: 05-APR-1994
/ CLASSIFICATION: 530
/ ATTORNEY/AGENT INFORMATION:
/ NAME: TITUS, MARLANA K
/ REGISTRATION NUMBER: 35843
/ REFERENCE/DOCKET NUMBER: 9437/204199
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 202-861-3711
/ TELEFAX: 202-822-0944
/ TELEX: 6714627 CUCH
/ INFORMATION FOR SEQ ID NO: 7:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 459 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ US-08-157-101A-7

```

```

Query Match      53.2%; Score 1284.5; DB 1; Length 459;
Best Local Similarity 59.4%; Pred. No. 3.3e-96;
Matches 280; Conservative 30; Mismatches 68; Indels 93; Gaps 17;

QY 25 GKNVVLAKKGVDELCTCTAS--OKKSIQFHW-----KNSNOIKIL--GNQGSFL--TK 71
DB 17 GCGVV--QPGRSIRLSCAASGTFSSNSMHWQAPKGLIEWAVILLYGNHMFYADSVK 74
QY 72 GPGKLNDRADSRSLMDQGFPLIKNLKIEDSDTYICEVEDQKEVOLLVGLTANSDT 131
DB 75 GRTTIS-RDMSKNVTL-----LEVKSLOTEDTGVYYC-IRQ-----TYGV----- 113
QY 132 HLLQ--GQSLTLTLESPPGSSPVGCRSPGKNIQGG-----KTLVS----- 172
DB 114 HRDMSGCGTLVYSSASTGSPVFPPLABSKSTSGTALGCLVKDYFPEPYTVSMNG 173
QY 173 -----OLEIQDSG-----TWCTVLONOKKEVFKIDIVPCPAP 205
DB 174 ALASGVHTPEPAVLQSSGLYSLSSVTVTPSSSLGTQYICNV--NHKPSNTKVD---KKV 227
QY 206 EPKSCDKTHTC-----PELLGSPVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKF 260
DB 228 EPPSCDKTHTCPCPAPPELLGSPVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKF 287
QY 261 NMYVDGEVNAKTKRREQYNSTYRVSVLTVLHODMLNGEKYCKKVSNNKALPAPIEKT 320
DB 288 NMYVDGEVNAKTKRREQYNSTYRVSVLTVLHODMLNGEKYCKKVSNNKALPAPIEKT 347
QY 321 ISKAKQPREPQYTLPPSRDELTKNQVSLTCLVKGFPSDIAVEMESNGOPENNYKTP 380
DB 348 ISKAKQPREPQYTLPPSRDELTKNQVSLTCLVKGFPSDIAVEMESNGOPENNYKTP 407
QY 381 PVLDSGSPFLYSKLTVDKSRMQGVNFGSGVNHGLAHNYTKOKSLSPG 431
DB 408 PVLDSGSPFLYSKLTVDKSRMQGVNFGSGVNHGLAHNYTKOKSLSPG 458

```

```

RESULT 21
US-08-397-411-7
/ Sequence 7, Application US/08397411
/ Patent No. 6129914
/ GENERAL INFORMATION:
/ APPLICANT: Weiner, George
/ APPLICANT: Gingrich, Roger
/ APPLICANT: Link, Brian
/ APPLICANT: Tso, J. Yun
/ TITLE OF INVENTION: Bisppecific Antibody Effective to Treat
/ TITLE OF INVENTION: B-Cell Lymphoma and Cell Line
/ NUMBER OF SEQUENCES: 14
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Townsend and Townsend and Crew
/ STREET: One Market Plaza, Stewart Tower, Suite 2000
/ CITY: San Francisco
/ STATE: California
/ COUNTRY: USA
/ ZIP: 94105
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/397,411
/ FILING DATE: 01-MAR-1995
/ CLASSIFICATION: 424
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 07/859,583
/ FILING DATE: 27-MAR-1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Smith, William M.
/ REGISTRATION NUMBER: 30,223
/ REFERENCE/DOCKET NUMBER: 011823-004901
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 415-326-2400
/ TELEFAX: 415-326-2422
/ INFORMATION FOR SEQ ID NO: 7:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 446 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: peptide
/ US-08-397-411-7

Query Match      53.1%; Score 1282.5; DB 3; Length 446;
Best Local Similarity 59.8%; Pred. No. 4.6e-96;
Matches 274; Conservative 25; Mismatches 80; Indels 79; Gaps 10;

QY 30 LKKKGDVYELTCTASQKSIQF--HWKNSNOIKILGNQGSFLTKGPKSLNDRADSRSL- 86
DB 11 LVKPSSETLSLCTVSGFSLTVNGVHWQSPGKGLIEWIGVKWSSGSTEYNAFISRLTIS 70
QY 87 --WDQGNPFLIKNLKIDSPTYICEVEDQKEVOLLVGLTANSDTHLLQ--GQSLTLT 142
DB 71 KQTSKNQVSLKINSLTAADTAAYTC-----ARNDRYAMDYWGQGLTVT 113
QY 143 LESPPGSSPVQCRSPGKNIQGG-----KTLVS-----OLEI 176
DB 114 VSSASTGKSPVFPPLAPSSKSTSGTALGCLVKDYFPEPYTVSMNGALTSQVHTFPAPVL 173
QY 177 QDSG-----TWCTVLONOKKEVFKIDIVPCPAPPKSCDKTHTC-- 216
DB 174 QSSGLYSLSSVTVTPSSSLGTQYICNV--NHKPSNTKVD---KVEPKSGCDKTHTCP 227
QY 217 ---PELLGSPVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFWNYVDGVEVNAK 273
DB 228 CPAPPELLGSPVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFWNYVDGVEVNAK 287
QY 274 TKRREQYNSTYRVSVLTVLHODMLNGEKYCKKVSNNKALPAPIEKTISKAKQPREPQV 333

```



```

Db      288 TKPREOYNSTYRVVSVLTVLHQMNGEKYKCVSNKALPAPIEKTISKAGQPREPOV 347
Qy      334 YTLPSRDELTKNOYSLTCLVKGFPSPDAVEMESNGOENNYYKTPPVLDSDGSFFLYS 393
Db      348 YTLPSRDELTKNOYSLTCLVKGFPSPDAVEMESNGOENNYYKTPPVLDSDGSFFLYS 407
Qy      394 KLTVDKSRMOQGNVSCSVMEHALNHYTOKSLSLSPG 431
Db      408 KLTVDKSRMOQGNVSCSVMEHALNHYTOKSLSLSPG 445

RESULT 22
US-09-740-002-25
; Sequence 25, Application US/09740002
; Patent No. 6537809
; GENERAL INFORMATION:
; APPLICANT: BRAMS, PETER
; APPLICANT: MORROW, PHILIP
; TITLE OF INVENTION: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES
; TITLE OF INVENTION: SPECIFIC TO RSV F-PROTEIN AND METHODS FOR THEIR
; FILE REFERENCE: 037003-0275759
; CURRENT APPLICATION NUMBER: US/09/740,002
; CURRENT FILING DATE: 2000-12-20
; PRIOR APPLICATION NUMBER: 09/335,697
; PRIOR FILING DATE: 1999-06-18
; PRIOR APPLICATION NUMBER: 08/488,376
; PRIOR FILING DATE: 1995-06-07
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: Patencin Ver. 2.1
; SEQ ID NO 25
; LENGTH: 475
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-740-002-25

Query Match      52.9%; Score 1276.5; DB 4; Length 475;
Best Local Similarity 57.1%; Pred. No. 1.5e-95;
Matches 281; Conservative 27; Mismatches 87; Indels 97; Gaps 12;

Qy      10 LLLVQLALPAAATGQNKVYLGKGDYVLTCTAS-----QKKSITQFHWK 54
Db      10 LVAVATRVLSQVQLQESGPVVKPTEITLTCTVSGFSLSNRMGVWIRPPGKALBW- 68
Qy      55 NSNQIKIIGN-----QGSLTKGPKSLNDRADSRSLMDQGNFPLIKLKTIEDSDTYIC 109
Db      69 -----LGNITSSDEKSPSLKSLRLTTSQDTSRS-----QVSLTNVDPVDATATYIC 116
Qy      110 EVEDQKEVEQLLVFGLTANSDTHL-LQGQSLTLTLTSPGSSPSVQCRSPRGKNIQGG-- 166
Db      117 -----ARVGLYDINAYLYLYLDYWGQGLVTVSSASTKGPVFLPLAPSKSTSGGTA 168
Qy      167 -----KTLNYS-----QLELDQSG-----TWTC 184
Db      169 ALGCLVKDYFPEPVTVSNMGSALTSGLVHTFPAVLQSSGLYSLSVTVAPSSSLGTQTYIC 228
Qy      185 TYLONOKVEFKIDIVPCAPAPKSCDKTHTC-----PELLGSPVFLPFPKPKDTLMIS 239
Db      229 NV--NHKPSNTKVD-----KKAEPKSCDKTHTCPCPAPAEFLGGPSVFLPFPKPKDTLMIS 282
Qy      240 RTEPVTCVVVDVSHEDPEVKFMWYVDGVEVNAKTKPREEOYNSTYRVVSVLTVLHQMNL 299
Db      283 RTEPVTCVVVDVSHEDPEVKFMWYVDGVEVNAKTKPREEOYNSTYRVVSVLTVLHQMNL 342
Qy      300 NGKEVKCKSNKALPAPIEKITSKAGQPREPOVYTLTPSRDELTKNOYSLTCLVKGFP 359
Db      343 NGKEVKCKSNKALPAPIEKITSKAGQPREPOVYTLTPSRDELTKNOYSLTCLVKGFP 402
Qy      360 SDIAVEMESNGOENNYYKTPPVLDSDGSFFLYSKLTVQSKRMQGNVSCSVMEHALN 419
Db      403 SDIAVEMESNGOENNYYKTPPVLDSDGSFFLYSKLTVQSKRMQGNVSCSVMEHALN 462
Qy      420 HYTOKSLSLSPG 431

```

```

Db      463 HYTOKSLSLSPG 474

RESULT 23
US-07-934-373C-22
; Sequence 22, Application US/07934373C
; Patent No. 5821337
; GENERAL INFORMATION:
; APPLICANT: Paul J. Carter
; APPLICANT: Leonard G. Presta
; TITLE OF INVENTION: Immunoglobulin Variants
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Winpatin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/934,373C
; FILING DATE: 21-Aug-1992
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/05126
; FILING DATE: 15-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/715272
; FILING DATE: 14-JUN-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Lee, Wendy M.
; REGISTRATION NUMBER: 40,378
; REFERENCE/DOCKET NUMBER: P0709P2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-1994
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 454 amino acids
; TYPE: Amino Acid
; TOPOLOGY: Linear
US-07-934-373C-22

Query Match      52.8%; Score 1274.5; DB 2; Length 454;
Best Local Similarity 59.9%; Pred. No. 2.1e-95;
Matches 275; Conservative 24; Mismatches 87; Indels 73; Gaps 11;

Qy      30 LGKKGDTVELTCTNAGKKSITQF--HWKNSQIKILNQGSFLTK-GPSKLNDRADSRSL 86
Db      11 LVKPGASVNIKISCKTSGTFTLEYTHMMKSHGSLLEWIGGFNPKNCGSSSHNQRMDXATL 70
Qy      87 ---WDQGNFPLIKNLKTIEDSDTYICEVEDQKEVEQLLVFGLTANSDTHLQ--GQSLTL 141
Db      71 AVDKSTSTAYWELSLTSEDSGIYTC-----ARMGLNGFVRRYFDVWAGATTV 120
Qy      142 TLESPPSSPSVQCRSPRGKNIQGG-----KTLNYS-----QLE 175
Db      121 TVSSASTKGPVFLPLABSSKSTSGTAAAGCLVVDYFPEPVTVSNMGSALTSGLVHTFPAV 180
Qy      176 LQDSG-----TWCTVLYONOKVEFKIDIVPCAPAPKSCDKTHTC- 216
Db      181 LQSSGLYSLSSVTVAPSSSLGTQTYICNV--NHKPSNTKVD-----KVEPKSCDKTHTCP 234
Qy      217 ---PELLGSPVFLPFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFMWYVDGVEVNA 272
Db      235 PCPAPPELLGSPVFLPFPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFMWYVDGVEVNA 294

```

0y	273	KTPIREQOVNSTRVSVLTVLHOMLNGKEYKCVSKALPAPLEKTSIAKQOPPEQ	332
Db	295	KTPREBQVNSTVRVSVLTVLHOMLNGKEYKCVSKALPAPLEKTSIAKQOPPEQ	354
0y	333	VYTLPSRDELTLGNQVSLTCLVKGFPSPDIAVEMESNQPENNYKTPPVLDSDGSFFLY	392
Db	355	VYTLPSRDEMTNQVSLTCLVKGFPSPDIAVEMESNQPENNYKTPPVLDSDGSFFLY	414
0y	393	SKLTVDKSRMOQGNVFCSCVMHEALHNHTQKSLSLSPG	431
Db	415	SKLTVDKSRMOQGNVFCSCVMHEALHNHTQKSLSLSPG	453

RESULT 24
US-08-437-642B-22

Sequence 22, Application US/08437642B
Patent No. 6054297

GENERAL INFORMATION:

APPLICANT: Paul J. Carter
APPLICANT: Leonard G. Presta
TITLE OF INVENTION: Immunoglobulin Variants
NUMBER OF SEQUENCES: 47
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpac1n (Genentech)

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/437,642B
FILING DATE: 09-May-1995

CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/934373
FILING DATE: 21-AUG-1992

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/146206
FILING DATE: 17-NOV-1993

PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/05126
FILING DATE: 15-JUN-1992

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/715272
FILING DATE: 14-JUN-1991

ATTORNEY/AGENT INFORMATION:
NAME: Lee, Wendy M.
REGISTRATION NUMBER: 40,378
REFERENCE/DOCKET NUMBER: P0709P2C1

TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-1994
TELEFAX: 650/952-9881

INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 454 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear

US-08-437-642B-22

Query Match	52.8%;	Score 1274.5;	DB 3;	Length 454;
Best Local Similarity	59.9%;	Pred. No. 2.1e-95;		
Matches 275; Conservative	24;	Mismatches 87;	Indels 73;	Gaps 11

[illegible]

```

Db      71  AWDKSTSTAYMELRSLTSEDSGITTC-----AAKRLANGFDVRIFDVMGACTTV 120
Qy      142  TLESPPGSSVQVOCSPRGKNIQGG-----KTLSSV-----OLE 175
      121  TVSSASTKGPVPLPAPSKSSGSGTAAALGCLVYDFFPEPTVSWNGSALTSVHTPEAV 160
Qy      176  LODSG-----TWTCVLONQKVEFKIDIVBCPAPEPKSCDKHTTC- 216
      181  LQSSGGLYSLSSVVTVWSSSLGTQYIICNV--NHKRSNTKVD----KVEPKSCDKHTTCP 234
Qy      217  ----PELLGSPVYFLPPPKKQDTLMSRTPEYTCVYVDVSHEDPEVKFNMYVDGVEYHNA 272
      235  PCPAPELLGSPVYFLPPPKKQDTLMSRTPEYTCVYVDVSHEDPEVKFNMYVDGVEYHNA 294
Db      273  KTRPREQYNSTRVYVSVTLVHQQWLNQKEYKCCVNSKALPAIEKTIISAKAQPREPQ 332
      295  KTRPREQYNSTRVYVSVTLVHQQWLNQKEYKCCVNSKALPAIEKTIISAKAQPREPQ 354
Qy      333  VYTLPPSRDELTKNQVSLTCLVKGYGSPSDIAWMESNQGPENNYKTTIPVLDSDGSFELY 352
      355  VYTLPPSRDELTKNQVSLTCLVKGYGSPSDIAWMESNQGPENNYKTTIPVLDSDGSFELY 414
Qy      393  SKLTVDSRMQOGNVSCSWMEHAALHNYTKSLSLSPG 431
      415  SKLTVDSRMQOGNVSCSWMEHAALHNYTKSLSLSPG 453

```

RESULT 25

```

US-08-146-206C-22
Sequence 22, Application US/08146206C
Patent No. 6407213
GENERAL INFORMATION:
APPLICANT: Carter, Paul J.
APPLICANT: Presta, Leonard G.
TITLE OF INVENTION: Method for Making Humani
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpatlin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/146, 206C
FILING DATE: 17-No. 6407213-1993
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/715272
FILING DATE: 14-JUN-1991
ATTORNEY/AGENT INFORMATION:
NAME: Lee, Wendy M.
REGISTRATION NUMBER: 40,378
REFERENCE/DOCKET NUMBER: P0709P1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-1994
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 454 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
US-08-146-206C-22

```

Query Match	52.8%	Score 1274.5;	DB 4;	Length 454;
Best Local Similarity	59.9%	Pred. No. 2.4e-95;		
Matches 275; Conservative	24;	Mismatches 87;	Indels 73;	Gaps 11;

```

QY      30 LGKGGDYELTCTAQSOKSIQF--HWKNSNQIKILNQGSLFLTK-GPSKLANDRADSRSL 86
      11 LVKPGASVAMISCKTSGYTFEYTHMMKQSHGKSLLEWIGFNPKNQSSSHNQRFMDKATL 70
QY      87 ---WDQGNFLIIKNLKIEDSDTYICEVEDQKEEVQLVGLTANSDTHLQ--GQSILTL 141
      71 AVDKSTSTAYWELRLSLTSEDGIIYC-----ARWGLNYGFVIRFVDMGAGTTV 120
QY      142 TLESPPGSSPSVQCRSPRGKNIQGG-----KTLVS-----QLE 175
      121 TVSSASTKGPSPVPLAPSSKSTSGTALGCLVKDYFPEPVTVSNMNGALTSVHTFPAY 180
QY      176 LODSG-----TWCTVLOQNKVFEKIDIVPCPAPRPSKCDKTHTC- 216
      181 LQSSGLYSLSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KVEPKSCDKTHTCP 234
QY      217 ---PELLGSPSVFLFPKPKDITMISRTPEVTCVVDVSHEDPEVKENWYVDGEVHNA 272
      235 PCPAPPELLGSPSVFLFPKPKDITMISRTPEVTCVVDVSHEDPEVKENWYVDGEVHNA 294
QY      273 KTKPREQYNSTYRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTISKAKGQPREPQ 332
      295 KTKPREQYNSTYRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTISKAKGQPREPQ 354
Db      333 VYTLPPSRDELTKQVSLTCLVKGFPSPDIAYEWESNGQPENNYKTPPVLDSDGSFFLY 392
      355 VYTLPPSRDELTKQVSLTCLVKGFPSPDIAYEWESNGQPENNYKTPPVLDSDGSFFLY 414
QY      393 SKLTVDKSRMOQGNVFCSCVMHEALHNHYTQKSLSLSPG 431
      415 SKLTVDKSRMOQGNVFCSCVMHEALHNHYTQKSLSLSPG 453
Db

```

RESULT 26

US-09-705-686-22
Sequence 22, Application US/09705686
Patent No. 6639055

GENERAL INFORMATION:

APPLICANT: Carter, Paul J.

TITLE OF INVENTION: Method for Making Humanized Antibodies

NUMBER OF SEQUENCES: 26

CORRESPONDENCE ADDRESSES:

ADDRESSEE: Genentech, Inc.

STREET: 1 DNA Way

CITY: South San Francisco

STATE: California

COUNTRY: USA

ZIP: 94080

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Winpatin (Genentech)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/705,686

FILING DATE: 02-NO. 6639055-2000

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/146206

FILING DATE: 17-NOV-1993

APPLICATION NUMBER: 07/715272

FILING DATE: 14-JUN-1991

ATTORNEY/AGENT INFORMATION:

NAME: Lee, Wendy M.

REGISTRATION NUMBER: 40,378

REFERENCE/DOCKET NUMBER: P0709P1D3

TELECOMMUNICATION INFORMATION:

TELEPHONE: 650/225-1994

TELEFAX: 650/952-9881

INFORMATION FOR SEQ ID NO: 22:

SEQUENCE CHARACTERISTICS:

LENGTH: 454 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-09-705-686-22

Query Match 52.8%; Score 1274.5; DB 4; Length 454;
Best Local Similarity 59.9%; Pred. No. 2.1e-95;
Matches 275; Conservative 24; Mismatches 87; Indels 73; Gaps 11;

```

QY      30 LGKGGDYELTCTAQSOKSIQF--HWKNSNQIKILNQGSLFLTK-GPSKLANDRADSRSL 86
      11 LVKPGASVAMISCKTSGYTFEYTHMMKQSHGKSLLEWIGFNPKNQSSSHNQRFMDKATL 70
QY      87 ---WDQGNFLIIKNLKIEDSDTYICEVEDQKEEVQLVGLTANSDTHLQ--GQSILTL 141
      71 AVDKSTSTAYWELRLSLTSEDGIIYC-----ARWGLNYGFVIRFVDMGAGTTV 120
QY      142 TLESPPGSSPSVQCRSPRGKNIQGG-----KTLVS-----QLE 175
      121 TVSSASTKGPSPVPLAPSSKSTSGTALGCLVKDYFPEPVTVSNMNGALTSVHTFPAY 180
QY      176 LODSG-----TWCTVLOQNKVFEKIDIVPCPAPRPSKCDKTHTC- 216
      181 LQSSGLYSLSVTVTPSSSLGTQTYICNV--NHKPSNTKVD---KVEPKSCDKTHTCP 234
QY      217 ---PELLGSPSVFLFPKPKDITMISRTPEVTCVVDVSHEDPEVKENWYVDGEVHNA 272
      235 PCPAPPELLGSPSVFLFPKPKDITMISRTPEVTCVVDVSHEDPEVKENWYVDGEVHNA 294
Db      273 KTKPREQYNSTYRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTISKAKGQPREPQ 332
      295 KTKPREQYNSTYRVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTISKAKGQPREPQ 354
QY      333 VYTLPPSRDELTKQVSLTCLVKGFPSPDIAYEWESNGQPENNYKTPPVLDSDGSFFLY 392
      355 VYTLPPSRDELTKQVSLTCLVKGFPSPDIAYEWESNGQPENNYKTPPVLDSDGSFFLY 414
QY      393 SKLTVDKSRMOQGNVFCSCVMHEALHNHYTQKSLSLSPG 431
      415 SKLTVDKSRMOQGNVFCSCVMHEALHNHYTQKSLSLSPG 453
Db

```

RESULT 27

PCT-US93-07832-22
Sequence 22, Application PC/TUS9307832

GENERAL INFORMATION:

APPLICANT: Genentech, Inc.

TITLE OF INVENTION: Immunoglobulin Variants

NUMBER OF SEQUENCES: 40

CORRESPONDENCE ADDRESSES:

ADDRESSEE: Genentech, Inc.

STREET: 460 Point San Bruno Blvd

CITY: South San Francisco

STATE: California

COUNTRY: USA

ZIP: 94080

COMPUTER READABLE FORM:

MEDIUM TYPE: 5.25 inch, 360 kb floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: patin (Genentech)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US93/07832

FILING DATE: 19930820

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/715272

FILING DATE: 14-JUN-1991

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/US92/05126

FILING DATE: 15-JUN-1992

PRIOR APPLICATION DATA:


```
RESULT 29
US-09-740-002-27
; Sequence 27, Application US/09740002
; Patent No. 6537809
; GENERAL INFORMATION:
; APPLICANT: BRAMS, PETER
; APPLICANT: MORROW, PHILLIP
; TITLE OF INVENTION: NEUTRALIZING HIGH AFFINITY HUMAN MONOCLONAL ANTIBODIES
; TITLE OF INVENTION: SPECIFIC TO RSV F-PROTEIN AND METHODS FOR THEIR
; FILE REFERENCE: 037003-0275759
; CURRENT APPLICATION NUMBER: US/09/740,002
; PRIOR FILING DATE: 2000-12-20
; PRIOR APPLICATION NUMBER: 09/335,697
; PRIOR FILING DATE: 1999-06-18
; PRIOR APPLICATION NUMBER: 08/489,376
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 27
; LENGTH: 475
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-740-002-27

Query Match      52.8%; Score 1273.5; DB 4; Length 475;
Best Local Similarity 57.1%; Pred. No. 2.7e-95;
Matches 276; Conservative 29; Mismatches 99; Indels 79; Gaps 11;

QY 10 LLLVQLALLPATQGNKVVLGKGDVLELTCTAS-----QKKSIOFHMKNNOIKL--- 62
DB 10 LVAVATRVLSVQVQLDSGSLAVKPTQTLTLCTFGSFLSTRGSMVMNIROPGALML 69
QY 63 ---GNQGSFELTKG-PSKINDRADSRSLMDQGNPPLIKNKIEDSPYICEVEDQKEE 117
DB 70 ARIDMDDDTFYASLKTSLISKDTSKN-----QVLEMTNVDPVDITATYFCARASLYDS 124
QY 118 VQLLVFGLTANSDTHLQGSLLTLTLESPPSSSPVQCRSPRGKNIQGS----- 166
DB 125 DSFYLF-----YHAYWQGVTVVSSASTKGPSPVFLPPLAPSSKSTSGTALAGCLVXDY 177
QY 167 --KTLVS-----OLELDQSG-----TWCTVLQNOKKV 193
DB 178 FEEPTVTSNMGSLTSGVHTFPVAVQSSGLVSLSSVTVWSSSLGTQYICNV--NHKPS 235
QY 194 EFKIDIVPCPAPPEPKSCDKHTHC-----PELLGSPSVFLPPPKYDTLMISRTPEVTCV 248
DB 236 NTKVD---KKAEPKSCDKHTHCPCPAPPELLGSPSVFLPPPKYDTLMISRTPEVTCV 291
QY 249 VVSHEDPEVKFNWYVDGVEVHNNAKTPREEOYNSTYRVSVLTVLHODMLNGKEYCKKV 308
DB 292 VVSHEDPEVKFNWYVDGVEVHNNAKTPREEOYNSTYRVSVLTVLHODMLNGKEYCKKV 351
QY 309 SNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMES 368
DB 352 SNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMES 411
QY 369 NCQPPENNYKTPPVLDSDGSFFLYSKLTVDKSRMQQGNVSCSVMEALAHNYTQKSLSL 428
DB 412 NCQPPENNYKTPPVLDSDGSFFLYSKLTVDKSRMQQGNVSCSVMEALAHNYTQKSLSL 471
QY 429 SPG 431
DB 472 SPG 474
```

```
RESULT 30
US-09-499-846-6
; Sequence 6, Application US/09499846
; Patent No. 6656728
; GENERAL INFORMATION:
```

```
; APPLICANT: Kavanaugh et al.
; TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR
; TITLE OF INVENTION: RECEPTOR-IMMUNOGLOBULIN FUSION
; FILE REFERENCE: 035784/195012 (5784-
; CURRENT APPLICATION NUMBER: US/09/499,846
; CURRENT FILING DATE: 2000-02-07
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 6
; LENGTH: 497
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-499-846-6

Query Match      52.8%; Score 1273.5; DB 4; Length 497;
Best Local Similarity 57.5%; Pred. No. 2.9e-95;
Matches 276; Conservative 30; Mismatches 83; Indels 91; Gaps 12;

QY 15 QLLLPATQGNKVVLGKGDVLELTCTASQKKSIOFHW-KNSNQIK---ILNQGSFL 69
DB 45 KLHAVPAA-----KTVKFCPSSTGTPPFLRLMLKNGKEFKPDHRIIGYKVRVA 92
QY 70 TKG-----PSKINDRADSRSLMDQGNPPLIKNKIEDSPYICEVEDQKEVQLLV 122
DB 93 TWSIIMDSVPS-----DKGNVTCIYENEGYSINHTYQLDIVERSPHRPILQ 139
QY 123 FGLTANSDTHLQGSLLTLTLESPP-----GSS-----PSVQCRSPRGKNI 163
DB 140 AGLPANKTVALLGSLVNEVMCKVYSDPQHICMLKHEIVNGSKIGPDNLPLYOILKTAGVNT 199
QY 164 --QGKTLVSQLELDQSGTWTG-----TVLQNOKKVEFKIDIVPCP--- 203
DB 200 TDKMEVHLIRNVSFEADAGEVYTCLAGNSIGLSHSAWLTYLE--ALBERRAVMTSPLYL 256
QY 204 -----APEPKSCDKHTHC-----PELLGSPSVFLPPPKYDTLMISRTPEVTCVYVDV 251
DB 257 EGSGSPGLQEPKSCDKHTHCPCPAPPELLGSPSVFLPPPKYDTLMISRTPEVTCVYVDV 316
QY 252 SHEDPEVKFNWYVDGVEVHNNAKTPREEOYNSTYRVSVLTVLHODMLNGKEYCKVSNK 311
DB 317 SHEDPEVKFNWYVDGVEVHNNAKTPREEOYNSTYRVSVLTVLHODMLNGKEYCKVSNK 376
QY 312 ALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQ 371
DB 377 ALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQ 436
QY 372 PENNYKTPPVLDSDGSFFLYSKLTVDKSRMQQGNVSCSVMEALAHNYTQKSLSPG 431
DB 437 PENNYKTPPVLDSDGSFFLYSKLTVDKSRMQQGNVSCSVMEALAHNYTQKSLSPG 496
```

```
RESULT 31
US-09-499-846-4
; Sequence 4, Application US/09499846
; Patent No. 6656728
; GENERAL INFORMATION:
; APPLICANT: Kavanaugh et al.
; TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR
; TITLE OF INVENTION: RECEPTOR-IMMUNOGLOBULIN FUSION
; FILE REFERENCE: 035784/195012 (5784-
; CURRENT APPLICATION NUMBER: US/09/499,846
; CURRENT FILING DATE: 2000-02-07
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 4
; LENGTH: 525
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-499-846-4

Query Match      52.8%; Score 1273.5; DB 4; Length 525;
Best Local Similarity 57.5%; Pred. No. 3.1e-95;
Matches 276; Conservative 30; Mismatches 83; Indels 91; Gaps 12;
```

```
QY 15 QALALPAATQGNKVLGGKGDVLTCTASQKSIQPHW-KNSNQIK-----ILGNQSF 69
   ||:|||||
Db 73 KLAIVPAA-----KTVKFKCPSSGTPNPTLRMLKNGKEFKPDHRIGGYKRYA 120
QY 70 TKG-----PSKLNDRADSRRLMDQNEPLIIKNLKIEDSDTYICEVEDQKEEVLV 122
   ||:|||||
Db 121 TWSIIMDSVVP-----DKGNVTCIENVEYGSINHTYQLDVVERSPHPIIQ 167
QY 123 FGLTANSPTHLLOGQSITLTLESPP-----GSS-----PSVQCRSPRKNI 163
   ||:|||||
Db 168 AGIPARKTVAGSNVEMFCVYSDPQPHIQMLKIEVNGSKIGPDNLPIYQILKTAGVNT 227
QY 164 --QGKTLVSQLELDQSGTWTG-----TTLQNKQKVEFKIDIVPC--- 203
   ||:|||||
Db 228 TDKMEVLIHRNVSFEDEAGETCTLAGNSIGLSHHSAMLVLE--ALIEEPRAVMTSPLYI 284
QY 204 -----APEPKSCDKTHTC-----PELLGSPSVFLPPPKDITLMSRTEVTCVVVDY 251
   ||:|||||
Db 285 EGGSGPGLQEPKSCDKTHTCPCPAPPELLGSPSVFLPPPKDITLMSRTEVTCVVVDY 344
QY 252 SHEDPEVKENWYVDGVEVHNAKTKPREBOYNSTYRVSVLTVLHODMLNGEYKCKVSNK 311
   ||:|||||
Db 345 SHEDPEVKENWYVDGVEVHNAKTKPREBOYNSTYRVSVLTVLHODMLNGEYKCKVSNK 404
QY 312 ALPAPIEKTISKAKQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAMEMSNQ 371
   ||:|||||
Db 405 ALPAPIEKTISKAKQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAMEMSNQ 464
QY 372 PENNYKTTTPVLDSDSFPLYSKLTVDKSRMOQGNVFCSVMEALAHNHYTQKLSLSPG 431
   ||:|||||
Db 465 PENNYKTTTPVLDSDSFPLYSKLTVDKSRMOQGNVFCSVMEALAHNHYTQKLSLSPG 524

RESULT 32
US-09-499-846-2
; Sequence 2, Application US/09499846
; Patent No. 6656728
; GENERAL INFORMATION:
; APPLICANT: Kavanaugh et al.
; TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR
; FILE REFERENCE: 035784/195012 (5784-
; CURRENT APPLICATION NUMBER: US/09/499, 846
; CURRENT FILING DATE: 2000-02-07
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 622
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-499-846-2

Query Match 52.8%; Score 1273.5; DB 4; Length 622;
Best Local Similarity 57.0%; Pred. No. 3.9e-95;
Matches 276; Conservative 31; Mismatches 86; Indels 91; Gaps 12;

QY 15 QALALPAATQGNKVLGGKGDVLTCTASQKSIQPHW-KNSNQIKILGNQSF 73
   ||:|||||
Db 162 KLAIVPAA-----KTVKFKCPSSGTPNPTLRMLKNGKEFKPDHRIGGYKRV 206
QY 74 SKLNDRADSRRLM-----DQGNFPLIIKNLKIEDSDTYICEVEDQKEEVLV 123
   ||:|||||
Db 207 -----RYATWSIIMDSVVP-----DKGNVTCIENVEYGSINHTYQLDVVERSPHPIIQ 257
QY 124 GLTANSPTHLLOGQSITLTLESPP-----GSS-----PSVQCRSPRKNI- 163
   ||:|||||
Db 258 GLPANKTVAGSNVEMFCVYSDPQPHIQMLKIEVNGSKIGPDNLPIYQILKTAGVNT 317
QY 164 --QGKTLVSQLELDQSGTWTG-----TTLQNKQK-----VEFKI 197
   ||:|||||
Db 318 DKMEVLIHRNVSFEDEAGETCTLAGNSIGLSHHSAMLVLEALIEEPRAVMTSPLYLESNG 377
```

```
QY 198 DIVP-----CPA-PEPKSCDKTHTC-----PELLGSPSVFLPPPKDITLMSRTEVTCV 247
   ||:|||||
Db 378 GLVPRGSGSPGLQEPKSCDKTHTCPCPAPPELLGSPSVFLPPPKDITLMSRTEVTCV 437
QY 248 VVDVSHEDPEVKENWYVDGVEVHNAKTKPREBOYNSTYRVSVLTVLHODMLNGEYKCK 307
   ||:|||||
Db 438 VVDVSHEDPEVKENWYVDGVEVHNAKTKPREBOYNSTYRVSVLTVLHODMLNGEYKCK 497
QY 308 VSNKALPAPIEKTISKAKQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAMEM 367
   ||:|||||
Db 498 VSNKALPAPIEKTISKAKQPREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAMEM 557
QY 368 SNGQPENNYKTTTPVLDSDSFPLYSKLTVDKSRMOQGNVFCSVMEALAHNHYTQKLS 427
   ||:|||||
Db 558 SNGQPENNYKTTTPVLDSDSFPLYSKLTVDKSRMOQGNVFCSVMEALAHNHYTQKLS 617
QY 428 LSPG 431
   ||:|||||
Db 618 LSPG 621

RESULT 33
US-09-301-593-18
; Sequence 18, Application US/09301593A
; Patent No. 6455677
; GENERAL INFORMATION:
; APPLICANT: Park, John E.
; APPLICANT: Garin-Chesa, Pilar
; APPLICANT: Bamberger, Uwe
; APPLICANT: Leger, Olivier
; APPLICANT: Saldanha, Jose W.
; APPLICANT: Rettig, Wolfgang J.
; TITLE OF INVENTION: FAP-specific Antibody with Improved Producibility
; FILE REFERENCE: 0652.1890001
; CURRENT APPLICATION NUMBER: US/09/301,593A
; EARLIER FILING DATE: 1999-04-29
; EARLIER APPLICATION NUMBER: EP 98107925.4
; EARLIER FILING DATE: 1998-04-30
; EARLIER APPLICATION NUMBER: US 60/086,049
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 18
; LENGTH: 453
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-301-593-18

Query Match 52.7%; Score 1271.5; DB 4; Length 453;
Best Local Similarity 59.0%; Pred. No. 3.7e-95;
Matches 271; Conservative 31; Mismatches 84; Indels 73; Gaps 12;

QY 30 LCKKGDVLTCTASQKSIQPHW-KNSNQIKILGNQSF-LTKGPSKLNDRADSRRL 86
   ||:|||||
Db 10 LKRPASVSMGSKTRRYTETTHWVROSHGKSLFEMIGINPNNGIPRYNOKFKGRATL 69
QY 87 W---DQGNFPLIIKNLKIEDSDTYICEVEDQKEEVLVFGLTANSPTHLQ--QQSITL 141
   ||:|||||
Db 70 TWGKSSSTAYMELARLTSEDSAVFC-----ARRLAIVGY--DEGHAMDYMGQSTSV 119
QY 142 TLESPPGSSPSVQCRSPRKNIQGG-----KITLSVS-----QLE 175
   ||:|||||
Db 120 TVSSASTGKSPVPLAPSSKTSYGGTALGCLVKDYFPEPVTVSNMNGALTSVGHVTPFAV 179
QY 176 LQDSG-----TWTCVTLQNKQKVEFKIDIVPCAPPEPKSCDKTHTC- 216
   ||:|||||
Db 180 LQDSGLYSLSVSVTVYVSSSLGTYICNV--NHRKSNKVD---KXPEPKSCDKTHTCP 233
QY 217 ---PELLGSPSVFLPPPKDITLMSRTEVTCVVVDVSHEDPEVKENWYVDGVEVHNA 272
   ||:|||||
Db 234 PCPAPPELLGSPSVFLPPPKDITLMSRTEVTCVVVDVSHEDPEVKENWYVDGVEVHNA 293
QY 273 KTKPREBOYNSTYRVSVLTVLHODMLNGEYKCKVSNKALPAPIEKTISKAKQPREBO 332
```

```

Db      294 KTKPREEOYNSTRYVSVLTVLHODWLNKKEYCKCVSNKALPAPIEKTISKAKGQPREPQ 353
      333 YTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNQPENNYKTTTPPVLDSDGSFPLY 392
      354 VTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNQPENNYKTTTPPVLDSDGSFPLY 413
Qy      393 SKLTVDKSRMOQGNVFSCSVMEHALHNHYTKSLSLSPG 431
      414 SKLTVDKSRMOQGNVFSCSVMEHALHNHYTKSLSLSPG 452
Db
Qy
Db
RESULT 34
US-08-487-550-12
; Sequence 12, Application US/08487550
; Patent No. 6113898
; GENERAL INFORMATION:
; APPLICANT: Anderson, Darrell R.
; TITLE OF INVENTION: "MONKEY MONOCLONAL ANTIBODIES SPECIFIC
; TITLE OF INVENTION: TO HUMAN B7.1 AND/OR B7.2 PRIMATIZED FORMS THEREOF,
; TITLE OF INVENTION: PHARMACEUTICAL COMPOSITIONS CONTAINING, AND USE THEREOF AS
; TITLE OF INVENTION: IMMUNOSUPPRESSANTS"
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: 699 Prince Street
; CITY: Alexandria
; STATE: VA
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/487,550
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Teskin, Robin L.
; REGISTRATION NUMBER: 35,030
; REFERENCE/DOCKET NUMBER: 012712-131
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-836-6620
; TELEFAX: 703-836-6620
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 476 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-487-550-12

Query Match      52.7%; Score 1271; DB 3; Length 476;
Best Local Similarity 59.8%; Pred. No. 4.3e-95;
Matches 274; Conservative 29; Mismatches 87; Indels 68; Gaps 11;
Qy      30 LGKGDVVELTCTAQ---KKSIOFHWNKSNQIKILGNOSFL-TRGSKLNDRADRSRS 85
      30 LKPSSETLSLTCAVSGSGISGGYGMGWIROPKPGKLEWIGSYSSGNTYNNPSLKSQVT 89
Db      86 L---MDQGNFPLIIRKLKIEDSDTYICEVEDQKEEVQLLVFGLTANSDTHLLQGSLLT 142
      90 ISTDTSKNGFSLKLSMTADTAAYYC-VRDLRFVVGNTY-----NMFPDWGPGVLVT 143
Qy      143 LESPPGSSSVQCRSPRGKNIGG-----KTLVS-----QLEL 176
      144 VSSASTKGPVFPPLAPSSKSTSGGTALGCLVKDYFPEPVTVSNMGSALTSVHTFPAVL 203
Qy      177 QDSG-----TWCTYVLOKNOKVEPKIDIVYCPARPESDKTHTC-- 216
      204 QSSGLYSLSVTVDPSSSLGTQTYICNV--NHKPSNTKVD---KKAEPKSCDKTHTCPP 257
Db

```

```

Qy      217 ---BELIGSSEVFLPPPKDITLMISRTPEYTCVVVDVSHEDPEVKENMYVDGVEVNAK 273
      258 CPAPELLGSPVFLPPPKDITLMISRTPEYTCVVVDVSHEDPEVKENMYVDGVEVNAK 317
Db      274 TKPREEOYNSTRYVSVLTVLHODWLNKKEYCKCVSNKALPAPIEKTISKAKGQPREPQV 333
      318 TKPREEOYNSTRYVSVLTVLHODWLNKKEYCKCVSNKALPAPIEKTISKAKGQPREPQV 377
Qy      334 YTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNQPENNYKTTTPPVLDSDGSFPLY 393
      378 YTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNQPENNYKTTTPPVLDSDGSFPLY 437
Db
Qy      394 KLTVDKSRMOQGNVFSCSVMEHALHNHYTKSLSLSPG 431
      438 KLTVDKSRMOQGNVFSCSVMEHALHNHYTKSLSLSPG 475
Db
RESULT 35
US-09-526-098-12
; Sequence 12, Application US/09526098
; Patent No. 6492134
; GENERAL INFORMATION:
; APPLICANT: Anderson, Darrell R.
; TITLE OF INVENTION: "MONKEY MONOCLONAL ANTIBODIES SPECIFIC
; TITLE OF INVENTION: TO HUMAN B7.1 AND/OR B7.2 PRIMATIZED FORMS THEREOF,
; TITLE OF INVENTION: PHARMACEUTICAL COMPOSITIONS CONTAINING, AND USE THEREOF AS
; TITLE OF INVENTION: IMMUNOSUPPRESSANTS"
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: 699 Prince Street
; CITY: Alexandria
; STATE: VA
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/526,098
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/383,916
; FILING DATE:
; APPLICATION NUMBER: US 08/487,550
; FILING DATE: 07-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Teskin, Robin L.
; REGISTRATION NUMBER: 35,030
; REFERENCE/DOCKET NUMBER: 012712-131
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-836-6620
; TELEFAX: 703-836-6620
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 476 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-09-526-098-12

Query Match      52.7%; Score 1271; DB 4; Length 476;
Best Local Similarity 59.8%; Pred. No. 4.3e-95;
Matches 274; Conservative 29; Mismatches 87; Indels 68; Gaps 11;
Qy      30 LGKGDVVELTCTAQ---KKSIOFHWNKSNQIKILGNOSFL-TRGSKLNDRADRSRS 85
      30 LKPSSETLSLTCAVSGSGISGGYGMGWIROPKPGKLEWIGSYSSGNTYNNPSLKSQVT 89
Db

```

```

OY 86 L --- WDQGNFLIILXKLIKEDSDTYICEVDEQKEEYVLAFGLTANSDFHLQGSILTLT 142
Db 90 ISTDTSKNOFSLKLTNSMTADTAIVYYC - YDRLFPSVGMYY --- NNMFDVGMPSGLVLT 143
OY 143 LESPPGSSPSPVOCRSRPRKNIQCG --- KTLVS --- OLEL 176
Db 144 VSSASTKGSPVFLPAPLAPSSKSTSGCTALAGCLVADYFPEEPTVSMNGSALTSQHTFPAYL 203
OY 177 QDSG-----TWCTVLONQKVEFKIDIVPCAPEPKSCDKTHTC- 216
Db 204 QSSGLYSLSSVTVPPSSSLGTQYICNV - NHKPSNTKVB --- KKAEPKSCDKTHTCPP 257
OY 217 --- PELGGSPLVFLPPPKPDITMISRTPEVTCVVVDVSHEDPEVKNNWYVDGVEYHNAAK 273
Db 258 CPAPELIGSPSVFLFPPPKPDITMISRTPEVTCVVVDVSHEDPEVKNNWYVDGVEYHNAAK 317
OY 274 TKPREEQNVSTYRVAVSVLTIVLHODMNLNGEKYCKCKVSNKALPAPLEKTIISAKGQPRPEOV 333
Db 318 TKPREEQNVSTYRVAVSVLTIVLHODMNLNGEKYCKCKVSNKALPAPLEKTIISAKGQPRPEOV 377
OY 334 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTPRPVLDSQGSFPLYS 393
Db 378 YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTPRPVLDSQGSFPLYS 437
OY 394 KLTIVDKSRWQOQGVNFCSVNHEALNHNHYTKSLSPG 431
Db 438 KLTIVDKSRWQOQGVNFCSVNHEALNHNHYTKSLSPG 475

```

```

RESULT 36
US-09-485-737B-67
: Sequence 67, Application US/09485737B
: Patent No. 6350860
: GENERAL INFORMATION:
: APPLICANT: Buysse, Marie-Ange
: APPLICANT: Sablon, Erwin
: TITLE OF INVENTION: INTERFERON-gamma-BINDING MOLECULES FOR TREATING SEPTIC SHOCK
: TITLE OF INVENTION: CACHEXIA, IMMUNE DISEASES AND SKIN DISORDERS
: FILE REFERENCE: INNS:015
: CURRENT APPLICATION NUMBER: US/09/485,737B
: CURRENT FILING DATE: 2000-02-14
: PRIOR APPLICATION NUMBER: PCT/EP 98/05165
: PRIOR FILING DATE: 1998-08-14
: PRIOR APPLICATION NUMBER: EPO 98870139.7
: PRIOR FILING DATE: 1998-06-18
: PRIOR APPLICATION NUMBER: EPO 97870122.5
: PRIOR FILING DATE: 1997-08-18
: NUMBER OF SEQ ID NOS: 104
: SOFTWARE: Patencin version 3.0
: SEQ ID NO 67
: LENGTH: 468
: TYPE: PRT
: ORGANISM: Artificial Sequence
: FEATURE:
: OTHER INFORMATION: SYNTHETIC
US-09-485-737B-67

```

```

Query Match 52.4%; Score 1265.5; DB 4; Length 468;
Best Local Similarity 57.2%; Pred. No. 1.2e-94;
Matches 277; Conservative 31; Mismatches 79; Indels 97; Gaps 13;

QY 11 LVLQALPAATQGNKVVLGKKGVDELCTASOKSLQPHMKNSTQIKILGNQGSFLR 70
   :::::  :::::  :::::  :::::  :::::  :::::  :::::  :::::  :::::  :::::
Db 17 VLSQVQLVQSSSE-----LKKPGASVKISCKAS-----GYFTDYGMNWVQAQPGQ---L 65

QY 71 KGPSKLNDRADSRSLMD--QGNFP-----LIINKLTIEDSDTYICEVEDQKEV 118
   ::  ::  ::  ::  ::  ::  ::  ::  ::  ::  ::  ::  ::  ::  ::  ::  ::  ::
Db 66 KMMGMINFTYGESTVDPEKGRFVSLDTSVSAAYLIQISLKABDRTATYC----- 116

QY 119 QLVVGLTNSDTHLQ--QGSITLTLESPPSSSPVQCSPPGKNIQGG----- 166
   ::  ::  ::  ::  ::  ::  ::  ::  ::  ::  ::  ::  ::  ::  ::  ::  ::  ::
Db 117 -----ARRGFADYWGCGGTTTAVVSSASTGKPSFPLAPSPSKSTSGGTAALGLVKD 168

```

```

Qy      167  ---KITSVS-----QLELDQSG-----TMTCTYLQNRK 192
           : : :
Db      169  YFPEPYTWMNSGALTSVGHTEPPAVLQSSGLYSLSVTVBSSLSGTQTYICNT--MHRK 226

Qy      193  VEPKRIIVCPAPEPKSCDKHTTC-----PELLGGSPSVFLPPPKDITLMISRTPEYTCV 247
           : :
Db      227  SNTKVD---KVEPKSCDKHTTCPPCPAPPELLGGSPSVFLPPPKDITLMISRTPEYTCV 282

Qy      248  VDVDSHEDPEVKFNWVDGVEVYHNAKTRPREQVNSTYRVSVYLTVLHODWLNGKEYCK 307
Db      283  VDVDSHEDPEVKFNWVDGVEVYHNAKTRPREQVNSTYRVSVYLTVLHODWLNGKEYCK 342

Qy      308  VSNKALPAPIEKTISKAKQPREPOVYTLPPSRDELITNQVSLTCLVKGFPSPDAIEME 367
Db      343  VSNKALPASIEKTIKAKAQPREPOVYTLPPSRBEMTNGVSLTCLVKGFPSPDAIEME 402

Qy      368  SNOQPENNYKTTTPPVLDSGFFLYSKLTVDSKSRQOQNVSCSVMHBAALHNHTQKSL 422
Db      403  SNOQPENNYKTTTPPVLDSGFFLYSKLTVDSKSRQOQNVSCSVMHBAALHNHTQKSL 462

Qy      428  LSPG 431
           |||
Db      463  LSPG 466
           |||

```

RESULT 37
 US-09-485-737B-90
 ; Sequence 90, Application US/09485737B
 ; Patent No. 6350860
 ; GENERAL INFORMATION:
 ; APPLICANT: Buysse, Marie-Ange
 ; APPLICANT: Sablon, Erwin
 ; TITLE OF INVENTION: INTERPERON-GAMMA-BINDING MOLECULES FOR TREATING SEPTIC SHOCK
 ; TITLE OF INVENTION: CACHEXIA, IMMUNE DISEASES AND SKIN DISORDERS
 ; FILE REFERENCE: INNS-015
 ; CURRENT APPLICATION NUMBER: US/09/485,737B
 ; CURRENT FILING DATE: 2000-02-14
 ; PRIOR APPLICATION NUMBER: PCT/EP 98/05165
 ; PRIOR FILING DATE: 1998-08-14
 ; PRIOR APPLICATION NUMBER: EPO 98870139..7
 ; PRIOR FILING DATE: 1998-06-18
 ; PRIOR APPLICATION NUMBER: EPO 97870122..5
 ; PRIOR FILING DATE: 1997-08-18
 ; NUMBER OF SEQ ID NOS: 104
 ; SOFTWARE: Patemlin version 3.0
 ; SEQ ID NO 90
 ; LENGTH: 711
 ; TYPE: PRT
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: SYNTHETIC
 US-09-485-737B-90

[illegible]

RESULT 38
US-08-458-516-13
; Sequence 13, Application US/08458516

```

1  GENERAL INFORMATION:
2  APPLICANT: Co, Man Sung
3  APPLICANT: Teo, J. Yun
4  TITLE OF INVENTION: Humanized Antibodies Reactive with
5  TITLE OF INVENTION: GPIIb/IIIa
6  NUMBER OF SEQUENCES: 23
7  CORRESPONDENCE ADDRESS:
8  ADDRESSEE: William M. Smith
9  STREET: One Market Plaza, Steuart Tower, Suite 2000
10 CITY: San Francisco
11 STATE: California
12 COUNTRY: USA
13 ZIP: 94105
14 COMPUTER READABLE FORM:
15 MEDIUM TYPE: Floppy disk
16 COMPUTER: IBM PC compatible
17 OPERATING SYSTEM: PC-DOS/MS-DOS
18 SOFTWARE: Patent Release #1.0, Version #1.25
19 CURRENT APPLICATION DATA:
20 APPLICATION NUMBER: US/08/458,516
21 FILING DATE:
22 CLASSIFICATION: 424
23 PRIOR APPLICATION DATA:
24 APPLICATION NUMBER: US 08/059,159
25 FILING DATE: 03-MAY-1993
26 ATTORNEY/AGENT INFORMATION:
27 NAME: Smith, William M.
28 REGISTRATION NUMBER: 30,223
29 REFERENCE/DOCKET NUMBER: 11823-37-3
30 TELECOMMUNICATION INFORMATION:
31 TELEPHONE: 415-326-2400
32 TELEFAX: 415-326-2422
33 INFORMATION FOR SEQ ID NO: 13:
34 SEQUENCE CHARACTERISTICS:
35 LENGTH: 449 amino acids
36 TYPE: amino acid
37 STRANDEDNESS: single
38 TOPOLOGY: linear
39 MOLECULE TYPE: protein
40 IS-08-458-516-13

```

Query Match	52.4%;	Score 1265;	DB 1;	Length 449;
Best Local Similarity	58.7%;	Pred. No. 1.2e-94;		
Matches 270; Conservative	26;	Mismatches 80;	Indels 84;	Gaps 11;

```

QY      32  KKGDFVELTCTASQKKSIOF--HWKNSNQIKILNGQ-----SFLTKGPSKLNDRADSR 833
      | | : : : | | : : : | | : : : | | : : : |
DB      13  KPSSSVKVCSCASGYAFNYLIEN-----VRQAPQGLEWIVGYIPSGSGGNTYNEKKRGR 678

```

[illegible]

RESULT 39
US-09-247-352-3
; Sequence 3, Application US/09247352

```

GENERATED INFORMATION.
APPLICANT: Aruffo, Alejandro A.
APPLICANT: Siadak, Anthony W.
APPLICANT: Berry, Karen K.
APPLICANT: Harris, Linda
APPLICANT: Thorne, Barbara A.
APPLICANT: Bajoreath, Jürgen
APPLICANT: Huse, William D.
APPLICANT: Wu, Herren
APPLICANT: Watkins, Jeffrey D.
TITLE OF INVENTION: ANTIBODIES AGAINST HUMAN CD40
FILE REFERENCE: DB2A SEQUENCE
CURRENT APPLICATION NUMBER: US/09/247,352
CURRENT FILING DATE: 1999-02-10
EARLIER APPLICATION NUMBER: 09/026,291
EARLIER FILING DATE: 1998-02-19
NUMBER OF SEQ ID NOS: 14
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 3
LENGTH: 451
TYPE: PRT
ORGANISM: Human and Mouse
US-09-247-352-3

```

Query Match	52.4%	Score 1264	DB 4	Length 451
Best Local Similarity	59.6%	Pred. No. 1.5e-94		
Matches 276	Conservative 23	Mismatches 80	Indels 84	Gaps 13

```
QY      30 LGKGGDVEITCTASQKKSIQFHWKNSNQIKLNGQSFLLTGPSPKLNDRADRSRLSMD - 88
      | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db      11 LKRGETVAISCKAS--GYAFFTTGMOWQEMPGK--LKMIGINTHSGVPKYVEDF 64
```

QY 89 QGNP-----LIINKLKIEDSDFYICEVEDQKEVQLLVGGTANSDTHLIGQ 137
: | | | | : | | | |
Db 65 KGRFAFSLTSANTAYLQISNLKNEDTATYFC-VASGNGAYDLATYA-----YWGQ 114

QY 138 SLTVLLESPGSSPSVQCRSPRGKIQG-----KTLSVS-----172

DB 115 GTLVTVSAASTKGPSPVFLPLPSSKSTSGGTAALGCLVKDYPPEPVTWMSNGALTSQVHT 174

```
QY 173 -QLELDGSG-----TWCTVLQNGKKVEFIDIVPCAPAPKSCDXT 213
      |||
      175 FPAVLSSGLYSLSSVYTVVSSSLGTOTTCNV--NHKPSNTKVD---KKEVPKSCDXT 228
QY 214 HTC-----BELLGPSVFLFPPPKDLMISRTPEYTCVVVDVSHEDPEVKFMWYDGYE 268
      |||
      229 HTCPCPAPBELLGPSVFLFPPPKDITL-ISRTPETTCVVVDVSHEDPEVKFMWYDGYE 287
QY 269 VHNAKTKPREBOYNSTYRVVSVLTVLIHOMLNGKEYCKVSNKALPAPIEKTIISKAKGQP 328
      |||
      288 VHNAKTKPREBOYNSTYRVVSVLTVLIHOMLNGKEYCKVSNKALPAPIEKTIISKAKGQP 347
QY 329 REPQVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAVEMESNGQPENNYKTTTPVLDSDS 388
      |||
      348 REPQVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAVEMESNGQPENNYKTTTPVLDSDS 407
QY 389 FFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTQKSLSLSPG 431
      |||
      408 FFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTQKSLSLSPG 450
Db
```

RESULT 40

```
US-09-466-635-3
; Sequence 3, Application US/09466635
; Patent No. 6413514
; GENERAL INFORMATION:
; APPLICANT: Arutic, Alejandro A.
; APPLICANT: Sladak, Anthony W.
; APPLICANT: Berry, Karen K.
; APPLICANT: Harris, Linda
; APPLICANT: Thorne, Barbara A.
; APPLICANT: Bajorath, Jurgen
; TITLE OF INVENTION: ANTIBODIES AGAINST HUMAN CD40
; FILE REFERENCE: DB2 SEQUENCE
; CURRENT APPLICATION NUMBER: US/09/466,635
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 451
; TYPE: PRT
; ORGANISM: Human and Mouse
US-09-466-635-3
```

```
Query Match 52.4%; Score 1264; DB 4; Length 451;
Best Local Similarity 59.6%; Pred. No. 1.5e-94;
Matches 276; Conservative 23; Mismatches 80; Indels 84; Gaps 13;
```

```
QY 30 LGKKGDVTELTCTASQKSIQFHWKNSNOIKILGNGSFLTKGPSKLNDRASRLMP- 88
      |||
      11 LKPGESTVATISCKAS--GYAFITTMQWQVEMPGRG---LKWIGINHTSGVPRKVEDF 64
QY 89 OGNFP-----LIINKLKIEDSDTYICEVEDQKEEVQLVFGLTANSPTHLQOQ 137
      |||
      65 KGFAPASLETSANTALQISNLKNEBDTATYFC-VBSGNGNYDLATYR-----YNGQ 114
Db 138 SLTTLESPPGSSPVQCSPPRGKNIQGG-----KTLVS----- 172
      |||
      115 GTLVTVSAASTKQPSVFLPASPSSKTSSTGTAALGCLVKDYFPPPTVSNMNGALTSQVHT 174
QY 173 -QLELDGSG-----TWCTVLQNGKKVEFIDIVPCAPAPKSCDXT 213
      |||
      175 FPAVLSSGLYSLSSVYTVVSSSLGTOTTCNV--NHKPSNTKVD---KKEVPKSCDXT 228
QY 214 HTC-----BELLGPSVFLFPPPKDLMISRTPEYTCVVVDVSHEDPEVKFMWYDGYE 268
      |||
      229 HTCPCPAPBELLGPSVFLFPPPKDITL-ISRTPETTCVVVDVSHEDPEVKFMWYDGYE 287
QY 269 VHNAKTKPREBOYNSTYRVVSVLTVLIHOMLNGKEYCKVSNKALPAPIEKTIISKAKGQP 328
      |||
      288 VHNAKTKPREBOYNSTYRVVSVLTVLIHOMLNGKEYCKVSNKALPAPIEKTIISKAKGQP 347
Db
```

```
QY 329 REPQVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAVEMESNGQPENNYKTTTPVLDSDS 388
      |||
      348 REPQVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAVEMESNGQPENNYKTTTPVLDSDS 407
QY 389 FFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTQKSLSLSPG 431
      |||
      408 FFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTQKSLSLSPG 450
Db
```

RESULT 41

```
US-09-027-449-71
; Sequence 71, Application US/09027449
; Patent No. 6025158
; GENERAL INFORMATION:
; APPLICANT: Gonzalez, Tania R.
; APPLICANT: Leong, Steven R.
; APPLICANT: Presta, Leonard G.
; TITLE OF INVENTION: Antibody Fragment-Polymer Conjugates and
; TITLE OF INVENTION: Humanized Anti-IL-8 Monoclonal Antibodies
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
```

COMPUTER READABLE FORM:

```
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Winpatin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/027,449
; FILING DATE: 20-Feb-1998
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/074,330
; FILING DATE: 22-Jan-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/038,664
; FILING DATE: 21-Feb-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Love, Richard B.
; REGISTRATION NUMBER: 34,659
; REFERENCE/DOCKET NUMBER: P1085R3-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-5530
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 71:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 452 amino acids
; TYPE: Amino Acid
; TOPOLOGY: Linear
US-09-027-449-71
```

```
Query Match 52.3%; Score 1263.5; DB 3; Length 452;
Best Local Similarity 59.6%; Pred. No. 1.6e-94;
Matches 273; Conservative 26; Mismatches 86; Indels 73; Gaps 11;
```

```
QY 30 LGKKGDVTELTCTAS--QKSIQFHWKNSNOIKILGNGSFLTKGPSKLNDRASRLMP- 86
      |||
      11 LVQPGSLKLSCKASAGYSPSSHYHWMVROAPEKGLWVGYYIDPSNGETTYNOKFRGRFTL 70
QY 87 W---DOGNFPLIKLKIEDSDTYICEVEDQKEEVQLVFGLTANSPTHL-LOGSLTLT 142
      |||
      71 SMDNKNATYALQMSLNRABDTAVYYCARGDYR-----YNGDWFPFDWGGTLYT 119
Db 143 LESPPGSSPVQCSPPRGKNIQGG-----KTLVS-----QLEL 176
      |||
      120 VSSASTKQPSVFLPASPSSKTSSTGTAALGCLVKDYFPPPTVSNMNGALTSQVHTFPVL 179
QY 177 QDQSG-----TWCTVLQNGKKVEFIDIVPCAPAPKSCDXTHTC-- 216
```

```
Db      180 QSSGLYSLSSVTVVPSSSLGTQTYICNV--NHRKPSNTKVD---KKVEPKSCDKTHTCPP 233
Qy      217 ---PELLGSPVFLFPPEPKDITLMI SRPEVTCVVVDSHEDPEVKFMNYVDGEVHNAAK 273
Db      234 CPAPELLGGPSVFLFPPEPKDITLMI SRPEVTCVVVDSHEDPEVKFMNYVDGEVHNAAK 293
Qy      274 TKPREQYNSTYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOV 333
Db      294 TKPREQYNSTYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOV 353
Qy      334 YTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPVLDSGDSFPLYS 393
Db      354 YTLPPSRDEMTKNOVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPVLDSGDSFPLYS 413
Qy      394 KLTVDKSRMOQGNVFCSCVMHEALHNHYTQKSLSLSPG 431
Db      414 KLTVDKSRMOQGNVFCSCVMHEALHNHYTQKSLSLSPG 451
```

RESULT 42

```
US-09-026-985-71
; Sequence 71, Application US/09026985
; Patent No. 6133426
; GENERAL INFORMATION:
; APPLICANT: Gonzalez, Tania R.
; APPLICANT: Leong, Steven R.
; APPLICANT: Presta, Leonard G.
; TITLE OF INVENTION: Antibody Fragment-Polymer Conjugates and
; TITLE OF INVENTION: Humanized Anti-IL-8 Monoclonal Antibodies
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Winpatin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/026,985
; FILING DATE: 20-Feb-1998
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Love, Richard B.
; REGISTRATION NUMBER: 34,659
; REFERENCE/DOCKET NUMBER: P1085R3-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/952-5530
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 71:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 452 amino acids
; TYPE: Amino Acid
; TOPOLOGY: Linear
US-09-026-985-71
```

```
Query Match      52.3%; Score 1263.5; DB 3; Length 452;
Best Local Similarity 59.6%; Pred. No. 1,6e-94;
Matches 273; Conservative 26; Mismatches 86; Indels 73; Gaps 11;
```

```
Qy      30 LKKKEDTVLITCTAS--QKKSIOFWKSNQKIITIGNQSGF-LTGGPSKANDRADRSRL 86
Db      11 LVQPGSGSLSCAAGYSPSSHYMWMVQAPKGLWVGXYIDPSNGETTYNQKFGKRFPL 70
Qy      87 W---DOGNPPLIKLIKIEDSDTYICEVDOKEEVQLLVFGLTANSDFHL-LGGQSLFLT 142
Db      71 SRDNKNTATYLOMNSLRABEDTAVTYTCARGDYR-----YNGDFPFDVWGQGLTAVT 119
```

```
Qy      143 LESPGGSPSVQCSRPGRKNIQGG-----KTLSSV-----OLEL 176
Db      120 VSSASTKGPVSFPLAPSKSTSGGTALGCLVKDYFPEPTVSWNSGALTGVAHPFAVL 179
Qy      177 QDSG-----TWTCYVLONQKRYEKIDIVPAPAEPPSGCDTHTC-- 216
Db      180 QSSGLYSLSSVTVVPSSSLGTQTYICNV--NHRKPSNTKVD---KKVEPKSCDKTHTCPP 233
Qy      217 ---PELLGSPVFLFPPEPKDITLMI SRPEVTCVVVDSHEDPEVKFMNYVDGEVHNAAK 273
Db      234 CPAPELLGGPSVFLFPPEPKDITLMI SRPEVTCVVVDSHEDPEVKFMNYVDGEVHNAAK 293
Qy      274 TKPREQYNSTYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOV 333
Db      294 TKPREQYNSTYRVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOV 353
Qy      334 YTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPVLDSGDSFPLYS 393
Db      354 YTLPPSRDEMTKNOVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPVLDSGDSFPLYS 413
Qy      394 KLTVDKSRMOQGNVFCSCVMHEALHNHYTQKSLSLSPG 431
Db      414 KLTVDKSRMOQGNVFCSCVMHEALHNHYTQKSLSLSPG 451
```

RESULT 43

```
US-09-121-952A-71
; Sequence 71, Application US/09121952A
; Patent No. 6458355
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc., Hsai, Vanessa
; APPLICANT: Komnits, Iphigenia
; APPLICANT: Leong, Steven R.
; APPLICANT: Presta, Leonard G.
; APPLICANT: Shahrrok, Zahra
; APPLICANT: Zapata, Gerardo A.
; TITLE OF INVENTION: METHODS OF TREATING INFLAMMATORY DISEASES
; TITLE OF INVENTION: WITH ANTI-IL-8 ANTIBODY FRAGMENT-POLYMER CONJUGATES
; NUMBER OF SEQUENCES: 72
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Winpatin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/121,952A
; FILING DATE: 24-Jul-1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/074330
; FILING DATE: 22-JAN-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/075467
; FILING DATE: 20-FEB-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Love, Richard B.
; REGISTRATION NUMBER: 34,659
; REFERENCE/DOCKET NUMBER: P1085R4
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/952-5530
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 71:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 452 amino acids
; TYPE: Amino Acid
; TOPOLOGY: Linear
```

US-09-121-952A-71

Query Match	52.3%;	Score 1263.5;	DB 4;	Length 452;
Best Local Similarity	59.6%;	Pred. NO. 1.6e-94;		
Matches 273; Conservative	26;	Mismatches 86;	Indels 73;	Gaps 11

QY	30	LGKGGGTVELTCTAS--QKKSIOFHKNKSNQKILGNQGSF-LTGGPEKLNDRADSRRL	86
Db	11	LVNPGGSLNLSCAASGYSSFSHYHMHVQAPEKGLEWNGYIDPSNGETTYNQKKGAFYL	70
QY	87	W---DQGNPELIIKNLIKEDSDTYICEVEDQEEVOLLVFGLYANSDTHL-LQGQSLLTL	142
Db	71	SRDNSKNTAYLQNNSLRADDTAYVYCARGDYR-----YNGDWFFDVMQGTLVLT	119
QY	143	LESPESSPSVOCRSRGNIOGG-----KTLSSYS-----QLEL	176
Db	120	VSSASTKGPVPEPLAPSSKSTSGGTAALGLVKDYFPPEPYTVSMNGSLTSGVHTPAVL	179
QY	177	QDSG-----TWTCVYLQNKQYEFKIDIVCPAPEPKSCDKTHTC-	216
Db	180	QSSGLKLSGSVTVPESSLSGTQTYICNV--NNKPSTKYD----KKPEPKCDKTHCP	233
QY	217	---PELLGSPVFLFPPEPKPDITLMSRPEVTCVVVDVSHEDPEYKENVYDGEVHNAK	273
Db	234	CPAPELIGGSPVFLFPPEPKPDITLMSRPEVTCVVVDVSHEDPEYKFMVYDGEVHNAK	293
QY	274	TKAREOYNSTYAVSVLTVLHODPMNGEKYCKYSNALPAPIEKTISKAKGPRPEOV	333
Db	294	TKREBOYNSTYAVSVLTVLHODPMNGEKYCKYSNALPAPIEKTISKAKGPRPEOV	355
QY	334	YTLPEPSRDELTKQNVSLTCLVKGFPSPDIAVEMESNGOPENNYKTTPEVLDSDSFPLYS	393
Db	354	YTLPEPSREBMTKQNVSLTCLVKGFPSPDIAVEMESNGOPENNYKTTPEVLDSDSFPLYS	413
QY	394	KLTVDSKRMQGNVFCSSVMHEALNHHYIQKSLSPG	431
Db	414	KLTVDSKRMQGNVFCSSVMHEALNHHYIQKSLSPG	451

RESULT 44
 US-09-234-340A-71
 : Sequence 71. Application US/09234340A
 : Patent No. 6468532
 :
 : GENERAL INFORMATION:
 :
 : APPLICANT: Genentech, Inc., Hseel, Vanessa
 : APPLICANT: Kouments, Iphigenia
 : APPLICANT: Leong, Steven R.
 : APPLICANT: Presta, Leonard G.
 : APPLICANT: Shamrokh, Zahra
 : APPLICANT: Zapata, Gerardo A.
 : TITLE OF INVENTION: METHODS OF TREATING INFLAMMATORY DISEASES
 : TITLE OF INVENTION: WITH ANTI-IL-8 ANTIBODY FRAGMENT-POLYMER CONJUGATES
 : NUMBER OF SEQUENCES: 72
 :
 : CORRESPONDENCE ADDRESS:
 : ADDRESS: Genentech, Inc.
 : STREET: 1 DNA Way
 : CITY: South San Francisco
 : STATE: California
 : COUNTRY: USA
 :
 : ZIP: 94080
 :
 : COMPUTER READABLE FORM:
 :
 : MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
 : COMPUTER: IBM PC compatible
 : OPERATING SYSTEM: PC-DOS/MS-DOS
 : SOFTWARE: WinPatIn (Genentech)
 :
 : CURRENT APPLICATION DATA:
 : APPLICATION NUMBER: US/09/234,340A
 : FILING DATE:
 : CLASSIFICATION:
 : PRIOR APPLICATION DATA:
 : APPLICATION NUMBER: US/09/121,952
 : FILING DATE: 24-Jul-1998
 : APPLICATION NUMBER: 60/074330

```

: FILING DATE: 22-JAN-1998
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 60/075467
: FILING DATE: 20-FEB-1998
: ATTORNEY/AGENT INFORMATION:
: NAME: Love, Richard B.
: REGISTRATION NUMBER: 34,659
: REFERENCE/DOCKET NUMBER: P1085R4
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 650/225-5530
: TELEFAX: 650/952-9881
: INFORMATION FOR SEQ ID NO: 71:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 452 amino acids
: TYPE: Amino Acid
: TOPOLOGY: Linear
:
: US-09-234-340A-71

```

Query Match	52.3%;	Score 1263.5;	DB 4;	Length 452;
Best Local Similarity	-59.6%;	Pred. No. 1.6e-94;		
Matches 273; Conservative	26;	Mismatches 86;	Indels 73;	Gaps 11;

QY 30 LGKGGTYELTCTTA--OKKSIQFWMKNSNIKILGNQGSF-LTKGPSKINDPADSRSL 86
11 LVQGGSLRLSCAAGSGYFSSHYHMWQAQKGLBWWGYIDPSNGFTYNNQKFKARFTL 70
QY 87 M--DQGNPLIIIKLKLIKEDSDTYICEVEDQKEEVOLLVGLTANSTHLL-LOGQSILTLT 142
Db 71 SRDNSKNTATYILOMNSLRAEDTAVVYCAAGDYR-----YNGDMFEDVWGQGLTYT 119
QY 143 LSSPPSSSPVOCSPRGKNIQGG-----KTLVS-----QLEL 176
Db 120 VSSASTKGPSPVPLAPSSKSTSGTALGLCVKYFPEPTVSNNSGALISGHTTPAVL 179
QY 177 QDSG-----TWCTVLONQKVEEKIDIVPCPAEPKSCDKTHTC- 216
Db 180 QSSGLYSLSVTVTPSSSLGTQTYICNV--NHKDSNTKVD---KVEPKSCDKTHTCPP 233
QY 217 ---PELLGSPVFLFPFKPKDTLMSRPPEYTCVVDVSHEDPEVKNNVVDGVEYNNAK 273
Db 234 CPAPELLGGSPVFLFPFKPKDTLMSRPPEYTCVVDVSHEDPEVKNNVVDGVEYNNAK 293
QY 274 TKPREQVYSTRVVSVYTLVHOMLANKKEYCKVSNKALPAPIEKTISKAKQPREPQV 333
Db 294 TKPREQVNSTRVVSVLTVLHOMLANKKEYCKVSNKALPAPIEKTISKAKQPREPQV 353
QY 334 YTLPPGRDELTKQVNSLTCLVKGVPSPDIIVEMESNGQPENNYKTPPVLDSDGSFFLYS 393
Db 354 YTLPPREBMTNQVNSLTCLVKGFPSPDIIVEMESNGQPENNYKTPPVLDSDGSFFLYS 413
QY 394 KLTVDKSRWQGNVSCSVMEHALHNHTQKSLSLSPG 431
Db 414 KLTVDKSRWQGNVSCSVMEHALHNHTQKSLSLSPG 451

RESULT 45
 US-09-301-593-30
 Sequence 30. Application US/09301593A
 Patent No 6455677
 GENERAL INFORMATION:
 APPLICANT: Park, John E.
 APPLICANT: Garin-Chesa, Pilar
 APPLICANT: Bambergner, Uwe
 APPLICANT: Legier, Olivier
 APPLICANT: Saldanha, Jose W.
 APPLICANT: Retzlig, Wolfgang J.
 TITLE OF INVENTION: FAP-specific Antic body with Improved Productibility
 FILE REFERENCE: 0657.1890001
 CURRENT APPLICATION NUMBER: US/09/301,593A
 CURRENT FILING DATE: 1999-04-29
 EARLIER APPLICATION NUMBER: EP 96107925.4
 EARLIER FILING DATE: 1998-04-30
 EARLIER APPLICATION NUMBER: US 60/086,049

```

; EARLIER FILING DATE: 1998-05-18
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 30
; LENGTH: 472
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-301-593-30

```

Query Match	52.3%;	Score 1263;	DB 4;	Length 472;
Best Local Similarity	59.0%;	Pred. No. 1.9e-94;		
Matches 271;	Conservative 31;	Mismatches 83;	Indels 74;	Gaps 13;

```

QY 30 LGKGGIVELVETLQASQKKSIOF--NHKKSNOIKILGNQGSF-LTKGPEKLNDRADSRSL 86
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Db 30 LVKPGASVKKMSCKTSRYTFLEYTILHNVROSHQKSLWEMIGLNPNNIGIPNNYQKFKGRATL 89
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 87 W---DQGNFPLIILKNIKIDSDTYICEVDQKEBYQVLVFGLTANSPTHLIQ--GGSILT 141
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Db 90 TVKSSSTAYMELRSLTSDSDSAVYFC-----ARRIAYG--DEGHADYWGQSTY 139
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 142 TLESPPGSSPSPVOCSPRGNIIQGG-----KTLVS-----QLE 175
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Db 140 TVSSST-KGPESVPLAPSKSTSGGTALGCLVKDYFPEPTVSWNSGALTSYHTPRAY 198
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 176 LQDSG-----TWTCVLONQKVEFEKIDIVPCPAPEPKSCDKTHTC- 216
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Db 199 LQSSGLYLSLSSVVTVPSSSLGTQYICNY--NHKSNKTKVD---KKEPEKSCDKTHTCP 252
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 217 ----PELGGPSVFLPPPKPKDTIMLSRPEVTCVVNDVSHEDPEVKNWVVDDEVHNA 272
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Db 253 PCPAPELGGPSVFLPPPKPKDTIMLSRPEVTCVVNDVSHEDPEVKNWVVDDEVHNA 312
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 273 KTRPREQVNSTYRVVSVTLVLHODMLNKEKCYKSVKALPAPIEKTISAKAQPREPQ 332
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Db 313 KTRPREQVNSTYRVVSVTLVLHODMLNKEKCYKSVKALPAPIEKTISAKAQPREPQ 372
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 333 VYTLPPSRDELTKNOVSLTCLVKGYPSDIAVEMESNQPENNYKTTTPVLVDSGSEFLY 392
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Db 373 VYTLPPSRDEMTKNQVSLTCLVKGYPSDIAVEMESNQPENNYKTTTPVLVDSGSEFLY 432
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
QY 393 SKLTVDKSRMQGNSVSCSVMEHALNHNHTQKSLSLSPG 431
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
Db 433 SKLTVDKSRMQGNSVSCSVMEHALNHNHTQKSLSLSPG 471
   |:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|

```

RESULT 46
US-08-887-352B-18

GENERAL INFORMATION:
APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
TITLE OF INVENTION: Improved Anti-IGE Antibodies and Method of
TITLE OF INVENTION: Improving Polypeptides
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpacin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/887,352B
FILING DATE: 03-Jul-1997
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: Svoboda, Craig G.

? REGISTRATION NUMBER: 39,044
 ? REFERENCE/DOCKET NUMBER: P1122
 ? TELECOMMUNICATION INFORMATION:
 ? TELEPHONE: 650/225-1489
 ? TELEFAX: 650/952-9881
 ? INFORMATION FOR SEQ ID NO: 18:
 ? SEQUENCE CHARACTERISTICS:
 ? LENGTH: 451 amino acids
 ? TYPE: Amino Acid
 ? TOPOLOGY: Linear

Query Match	52.3%;	Score 1262;	DB 2;	Length 451;
Best Local Similarity	58.6%;	Pred. No. 2.2e-94;		
Matches 273; Conservative	25;	Mismatches 78;	Indels 90;	Gaps 12;

[illegible]

RESULT 47
US-09-109-207C-18
; Sequence 18, Application US/09109207C

```

, GENERAL INFORMATION:
, APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardiou, John Lowe
, TITLE OF INVENTION: Improved Anti-19E Antibodies and Method of Improving Polypeptides
, FILE REFERENCE: P1123R1
, CURRENT APPLICATION NUMBER: US/09/109,207C
, CURRENT FILING DATE: 1998-06-30
, PRIOR APPLICATION NUMBER: US 60/051,554
, PRIOR FILING DATE: 1997-07-03
, NUMBER OF SEQ ID NOS: 4
, SEQ ID NO 18
, LENGTH: 451
, TYPE: PRT
, ORGANISM: Artificial
, FEATURE:
, NAME/KEY: Artificial
, LOCATION: 1-451
, OTHER INFORMATION: Heavy chain sequence derived from MAb11
US-09-109-207C-18

```

Query Match 52.3%; Score 1262; DB 3; Length 451;

Best Local Similarity 58.6%; Pred. No. 2.2e-94;
Matches 273; Conservative 25; Mismatches 78; Indels 90; Gaps 12;

Qy	30	LGKKGDVLTCTASQ----	KKSIQFMKNKSNQIKILNGSGSLRTKGPKLN-----	77
Dh	11	LVPQSGSLRLSCAVSGYITSGYSNMWITQAPBGKLEWASITKISGEIKTPSVKGRIT	70	
Qy	78	DRADSRSLWDQGNFPFLIIKNLIKIEDSDTYICEVEDQKEVQLVFGLTANSDPH---	134	
Dh	71	SRDSSKNTFYLNQNN-----	SLRAEDTAVYYCARGSH-----YFG-----HMHFAV 11.0	
Qy	135	QCGSLTITLESPPGSSPSVQCRRSPKRNIOG-----	KLTSVSY-----1722	
Dh	111	WGGGTLVATVSSASTKGPVFPFLAPSSKSTSGGTALGCLVNDYPEEPVTVSWNSGALTSG	170	
Qy	173	-----OLELDSG-----	TWTCTVLONOKKVEFKDITVCPAPEKSC 21.0	
Dh	171	VHTFPRAVLQSSGLXLSLSVYTPSSSLGTYITICNV--	NHKPSNTRKD---KAYEKKSC 224	
Qy	211	DKTHTC-----	PELLGSPVFLPPPKPKDTLMSIRTPETVCVVDVSHEDBEVKFNMYD 265	
Dh	225	DKTHTCPPCPAPELLGSPVFLPPPKPKDTLMSIRTPETVCVVDVSHEDBEVKFNMYD	284	
Qy	266	GUVVHNAKKTREEOVNSTFYRVSVYLTVLHQMNLNGEKYCKVSUKALPAIIEKTTISAK	325	
Dh	285	GVEVHNAKKTREEOVNSTFYRVSVYLTVLHQMNLNGEKYCKVSUKALPAIIEKTTISAK	344	
Qy	326	GOBREPQVYTLPPSRDELTKNOVSLTCLVKGFPSDIAVEMESNGOPENNYKTTPPVLDS	365	
Dh	345	GOBREPQVYTLPPSRDEMTKNQVSLTCLVKGFPSDIAVEMESNGOPENNYKTTPPVLDS	404	
Qy	386	DGSEFLYSKLTVDKSKRMQOQNVFSGVWHEALHNHYTKSLSLSPG 431		
Dh	405	DGSEFLYSKLTVDKSKRMQOQNVFSGVWHEALHNHYTKSLSLSPG 450		

RESULT 48
US-09-282-505-2

```

1 Sequence 2, Application US/09282505A
2 Patent No. 6194551
3 GENERAL INFORMATION:
4 APPLICANT: Esche Ekinnuene Idueogie et al.
5 TITLE OF INVENTION: Polypeptide Variants
6 FILE REFERENCE: P1266R1
7 CURRENT APPLICATION NUMBER: US/09/282,505A
8 CURRENT FILING DATE: 1999-03-31
9 NUMBER OF SEQ ID NOS: 2
10 SEQ ID NO 2
11 LENGTH: 451
12 TYPE: PRT
13 ORGANISM: Artificial Sequence
14 FEATURE:
15 NAME/KEY: Artificial Sequence
16 LOCATION: 1-451
17 OTHER INFORMATION: Sequence is completely synthesized
18 Patent No. 6194551
19 US-09-282-505-2
20
21 Query Match 52.3%; Score 1262; DB 3; Length 451;
22 Best Local Similarity 58.6%; Pred. No. 2,2e-94;
23 Matches 273; Conservative 25; Mismatches 76; Indels 90; Gaps 12
24
25 QY 30 LGKGGDYVELTCTASQ---KKSIOPHMKNSNOIKILNGSGELTTPGPKLN----- 77
26      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
27 Db 11 LVDPGSLRLSCAVSGYSITSGYSNMWTRQAPGKLEWASIKYSGETKINPSVKGRIIT 70
28
29 QY 78 DRASRRRLMQGNEPLRIIKNLKIDSDTYICEVEADQKEVGLVFGTANDTH---LL 134
30      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
31 Db 71 SRDSKNTFYIQM-----SLRADTAVTYCARSSH-----YFG-----HMHFAV 110
32
33 QY 135 QGGSITLTLESPPGSSPSVQCRSPGKNIQGS-----KTLISV----- 172
34      : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
35 Db 111 WGQGLLVVSSASTSGPSVFLPLAPSSKSTGCTALGCIKVDKPEEPLTVSNNGALTS 170
36

```

Qy	175	-----QLELDSDG-----	-----TWCTCVLONOKKBAFKLIDVPCAPAEKSC	21
Db	171	VHFFPAVLSSGLYSLSSVYVTPSSSLGTQYICNV	--NHKPSNTRKD---KRYEKSC	224
Qy	211	DKTHTC-----PELLGSPVFLPPPKDITLMSRTP	EVTCVVYDVSHEDBEVKNYYD	265
Db	225	DKTHTCGPCPAPELLGSPVFLPPPKDITLMSRTP	EVTCVVYDVSHEDBEVKNYYD	284
Qy	266	GVEVNAKTKPRPEQVNSTFRVSVLYLHODMLNGK	KKCVKSNKLPAPIENTISKAK	325
Db	285	GVEVNAKTKPRPEQVNSTFRVSVLYLHODMLNGK	KKCVKSNKLPAPIENTISKAK	344
Qy	326	GOEPREPOVYTLPPSRDELTKNOVSLTCLVKGFP	SPSDIAVEMESNGOPENNKTPPYLDS	385
Db	345	GOEPREPOVYTLPPSRDELTKNOVSLTCLVKGFP	SPSDIAVEMESNGOPENNKTPPYLDS	404
Qy	386	DGSEFLYSKLTJYDKSRMOQGNFSCSVNHEALHN	HYTKSLSLSPG	431
Db	405	DGSEFLYSKLTJYDKSRMOQGNFSCSVNHEALHN	HYTKSLSLSPG	450

```

RESULT 49
US-09-054-255-2
; Sequence 2, Application US/09054255
; Patent No. 6242195
; GENERAL INFORMATION:
; APPLICANT: Esche Kinaduese Idusogie et al.
; TITLE OF INVENTION: Polypeptide Variants
; FILE REFERENCE: P1266
; CURRENT APPLICATION NUMBER: US/09/054,255
; CURRENT FILING DATE: 1998-04-02
; NUMBER OF SEQ ID NOS: 2
; SEQ ID NO 2
; LENGTH: 451
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: E27 anti-IGF antibody heavy chain
US-09-054-255-2

```

Query Match	Similarity	52.3%	Score 1262;	DB 3;	Length 451;
Best Local	Similarity	58.6%	Fred. No. 2.2e-94;		
Matches	Conservative	25;	Mismatches 78;	Indels 90;	Gaps 12
QY	30	LGKKDVTYELCTASQ--	KKSIQFHMKNISQIKILGQSGFLTGPSKLN-----	77	
Db	11	LVQGGGSLRLSCAVSGYIS	TSGYSMMWTRQAPGKGLEWVASIKYSGEGRKYNPSVAGRITI	70	
QY	78	DRADSRSLMDQGNPFLII	KNKLIKEDSDTYICEVEDQKEVQLVFGLTANSDTH--LL	134	
Db	71	SRDSKMTFYIQMN-----	SLRAEDTLVYYCARGSH-----YFG-----HMFAY	110	
QY	135	QGGSLLTLLESPPSSP	SPGCRSGRKNIGG-----KTLVS-----	172	
Db	111	WGQGLTVIVSASTKGS	VSFPPLAPSSKSTSGGTALGCLVKDYPPEPPTVSNNSGALTSG	170	
QY	173	-----QLBLDQSG-----	-----TWCTVLQNOKKVEFKIDIVPCPAPRPSK	210	
Db	171	VHFPRAVLQSSGLVLS	SVTVTPSSLDGTQIYICNV--NHKPSNKTVD---KKEPSPK	224	
QY	211	DKHTTC-----	PILLGSPVFLFPFKPQDTLMISRTPEVTCVYVDVSHEDPEVKNNMYVD	265	
Db	225	DKHTTCPCPAPELLG	SGSVFLFPFKPQDTLMISRTPEVTCVYVDVSHEDPEVKNNMYVD	284	
QY	266	GVEVHNAKTREREQ	SNSTYRVSVLTVLHODMLNGKCYKCKSVSKALPAPIEKTISKAK	325	
Db	285	GVEVHNAKTREREQ	SNSTYRVSVLTVLHODMLNGKCYKCKSVSKALPAPIEKTISKAK	344	
QY	326	GQPEPPOVYTLPSR	BDLTKNQVSLTLCVKGFYPSDIAVEMESNQEPENNYKTTTPVIDS	385	
Db	345	GQPEPPOVYTLPSR	EMTKNOVSLTLCVKGFYPSDIAVEMESNQEPENNYKTTTPVIDS	404	

QY 386 DGSFFLYSKLTVDKSRWQGVVFSCSVMHEALHNHYTQKSLSPG 431
DB 405 DGSFFLYSKLTVDKSRWQGVVFSCSVMHEALHNHYTQKSLSPG 450

```

RESULT 50
US-09-236-005-18
; Sequence 18, Application US/09296005
; Patent No. 6290957
; GENERAL INFORMATION:
; APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
; TITLE OF INVENTION: Improved Anti-IgE Antibodies and Method of Improving Polypeptides
; FILE REFERENCE: P112301r
; CURRENT APPLICATION NUMBER: US/09/236,005
; CURRENT FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 08/887,352
; EARLIER FILING DATE: 1997-07-02
; NUMBER OF SEQ ID NOS: 26
; SEQ ID NO 18
; LENGTH: 451
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: Artificial
; LOCATION: 1-451
; OTHER INFORMATION: Heavy chain sequence derived from MAE11
US-09-236-005-18

```

Query Match	Similarity	Score	DB 3:	Length
Best Local	58.6%	Pred. No. 2, 2e-94		
Matches	273;	Conservative	25;	Mismatches 78; Indels 90; Gaps 12

QY	30	LKKGGDVELTCTASQ---	KXSIQFHMKNSNOIKILGNQSFLLTKPSKLN-----	77
Db	11	LVOPGSRRLSCAVSGYSITSGYSNMWIRQAPGKGLEWVAISIKYSGETKYNPSYKGRIT		70
QY	78	DRADRSRLMDGCPPLIIRKLIKIDSDPTIYIEVEDQKEVQLVFGGLANSDDTH---LL		134
Db	71	SRDSKNTFFYLDMN-----	SLRAEDTAVIYIARQSGH-----YFG-----HMFAY	110
QY	135	QGQSITLLTESPPGSSPSVQCRSPGKNIQGG-----	KTLSSVS-----	172
Db	111	WGQGLTVVSSASTGKPSVFLPAPSKSNGGTAALGCLVKKDYPPEPVTVSNMSGALTSG		170
QY	173	-----QLEIODSG-----	---TWTCTVLOQKQKVEPFKIDIVPCPAPKPKSC	210
Db	171	VHTPEAVLQSSGLVSLSSVTVTPSSSLGTQYICNV--	NHKPSNTKVD---KQVEPKSC	224
QY	211	DKHTHC-----	PELLGGRSVFLFPPKPKDITLISRTEVTCVAVDVSHDEPVEKKNMYVD	265
Db	225	DKHTHCPCPAPPELLGGRSVFLFPPKPKDITLISRTEVTCVAVDVSHDEPVEKKNMYVD		284
QY	266	GVEVNNATKPREBEQYNSTRVAVSLTVLHQMVLNGKEKCVSNKALPAPLEKITSKX		325
Db	285	GVEVNNATKPREBEQYNSTRVAVSLTVLHQMVLNGKEKCVSNKALPAPLEKITSKX		344
QY	326	GQPREPQVYTLPPSRDELTKNOVSLTCLVKGCFPSPDIAVEWESNGQPENNYKTPPEVLD		385
Db	345	GQPREPQVYTLPPSRDELTKNOVSLTCLVKGCFPSPDIAVEWESNGQPENNYKTPPEVLD		404
QY	386	DGSFPLTKLYDKSRWQGNVFGSCVWHEALAHNYTKQSLSLSRG		431
Db	405	DGSFPLTKLYDKSRWQGNVFGSCVWHEALAHNYTKQSLSLSRG		450

```

RESULT 51
US-09-282-846-2
; Sequence 2, Application US/092828946
; Patent No. 6528624
; GENERAL INFORMATION:
; APPLICANT: Eoshe Ekinaduse Idugogie et al
; TITLE OF INVENTION: Polypeptide Variants
; FILE REFERENCE: P126CR2

```

```

:
: CURRENT APPLICATION NUMBER: US/09/282,846
:
: CURRNT FILING DATE: 1999-03-31
:
: NUMBER OF SEQ ID NOS: 2
:
: SEQ ID NO 2
:
: LENGTH: 451
:
: TYPE: PRT
:
: ORGANISM: Artificial Sequence
:
: FEATURE:
:
: NAME/KEY: Artificial Sequence
:
: LOCATION: 1-451
:
: OTHER INFORMATION: Sequence is complete.
:
: Patent NO. 6528624
:
: US-09-282-846-2

```

Query Match	52.3%	Score 1262	DB 4	Length 451
Best Local Similarity	58.6%	Pred. No. 2-2e-94		
Matches 273	Conservative 25	Mismatches 78	Indels 90	Gap 12
QY	30	LKKKIDTVELTCTASQ----	KKSIQFHWKNSNQIKILGNQGSFLTGPSEKLN-----	77
	:	:	:	:
	:	:	:	:
Db	11	LVPGGSLRLRLSCAASGYSITS	GYSEWNMIROAPGKGLEWVASIKYSGEKTVPYVKGRITTI	70
QY	78	DRAPRSRLMDQGFPLIKNLKTI	EDSDPTYCEVEDQKEBEVQLLVFGITANSDDTH-----LL	134
	:	:	:	:
	:	:	:	:
Db	71	SRDSSKMTFYIQNN-----	SLREEDTVAVYICARGSH-----YFG-----HMHFAV	110
QY	135	QGGSLITLTLESPPGSSPSV	OCRSFPRGNIOGG-----KTLVS-----	172
	:	:	:	:
	:	:	:	:
Db	111	WGQGTLTWVSASATKGPSV	FPLAASSKTSGGTALGCLVDYFPEPVTVSMNSGALTS	170
QY	173	-----QLLELDGSG-----	-----TWTCVYIQNKKVEPKIDIVPCRAPEPKSC	210
	:	:	:	:
	:	:	:	:
Db	171	VHTPRAVLQSSGLYSLSSV	TVTPSSSLGTQTYICNV--NHKPSNTKVD---KKVEPKSC	224
QY	211	DKTHTC-----	PELLGGPSVFLFPKPCKDTLMISRTPEBTV	265
	:	:	:	:
	:	:	:	:
Db	225	DKTHTCPPCPAPELLGGPSV	FLFPKPCKDTLMISRTPEBTV	284
QY	266	GVEVHNKAKTPREKQVNST	RYRVSVLVTLVHODMILNGEYKCKVNSKALPALEKTI	325
	:	:	:	:
	:	:	:	:
Db	285	GVEVHNKAKTPREKQVNST	RYRVSVLVTLVHODMILNGEYKCKVNSKALPALEKTI	344
QY	326	GQPREPOVYTLPPSRDEL	TKNOVSLTCLVKGFYPSDIAVEMESNGQPENNYKTPPVL	385
	:	:	:	:
	:	:	:	:
Db	345	GQPREPOVYTLPPSRDEL	TKNOVSLTCLVKGFYPSDIAVEMESNGQPENNYKTPPVL	404
QY	386	DGSEFLYSKLTVDKSRWQ	QGVNFECSYMHKLAHHNYTQKSLSPG	431
	:	:	:	:
	:	:	:	:
Db	405	DGSEFLYSKLTVDKSRWQ	QGVNFECSYMHKLAHHNYTQKSLSPG	450

```

RESULT 52
US-09-680-145-2
Sequence 2, Application US/09680145
Patent No. 6538124
GENERAL INFORMATION:
APPLICANT: Esocle Ekinaduse Idusogie et al.
TITLE OF INVENTION: Polypeptide Variants
FILE REFERENCE: P126CR1
CURRENT APPLICATION NUMBER: US/09/680,145
CURRENT FILING DATE: 2000-10-03
PRIOR APPLICATION NUMBER: 09/282,505
PRIOR FILING DATE: 1999-03-13
NUMBER OF SEQ ID NOS: 2
SEQ ID NO 2
LENGTH: 451
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
NAME/KEY: Artificial Sequence
LOCATION: 1-451
OTHER INFORMATION: Sequence is completely synthesized
Patent No. 6538124

```

US-09-680-145-2

Query Match	52.3%	Score 1262;	DB 4;	Length 451;
Best Local Similarity	58.6%	Pred. No. 2.2e-94;		
Matches 273; Conservative	25;	Mismatches 78;	Indels 90;	Gaps 12

```

QY 30 LGKKGDPVELTCTASQ---KKSIQFMKNKNSQIKILANGQSPSLTGPCKLN-----77
Db 11 LVDPGSGSLRSLCAVSGSYITSGYSMMWITQAPBGKLEMYASIKTSGETKTPSVKGRITTI 70
QY 78 DRADSRSLMDQGNFPPLIINKLEIEDSDTYICEVEDOKBEVOLLVFGLTANSDTH---LL 134
Db 71 SRDSSKNTFYLQNN-----SLRAEDTAVYYCARGSH-----YFG-----HMHFAV 110
QY 135 QGGSLLTITLESPPGSSSPVQCRSPKRNIGG-----KTLTSVS-----172
Db 111 WGGGTLVATYSSASTKGPSPVFLPLAPSSKSTSGGTALGCLVKDYFPEPTVWMSGALTSG 170
QY 173 ----OLELDSG-----TWCTVLQNOCKVEFEKIDIVPCPAPEPSC 210
Db 171 VHFPAVLQSSGLYLSLSVYTVPSSSLGTYQYICNV--NHKRSNRYD---KAYERKSC 222
QY 211 DKHTTC----PELLGSPSVFLPPPKPKDTLMI SRTPEVTCVVDVSHEDEVKFNMYVD 265
Db 225 DKHTTCPPCPAPPELLGGSPSVFLPPPKPKDTLMI SRTPEVTCVVDVSHEDEVKFNMYVD 284
QY 266 GVEVHNAAKTPREEOYNSTRVAVSVLTVLHOMLNGKEVCKCVSKALPALEIKTISKAK 322
Db 285 GVEVHNAAKTPREEOYNSTRVAVSVLTVLHOMLNGKEVCKCVSKALPALEIKTISKAK 344
QY 326 GQREBPQVYTLPSRDELTKANQVSLTCLVKGFPYSDI AVEMESNQPENNKTTTPPVLD 385
Db 345 GQREBPQVYTLPSRDEMTKNQVSLTCLVKGFPYSDI AVEMESNQPENNKTTTPPVLD 400
QY 386 DGSFPLYSKLTVDKSRMOQGNPFGCSVMEALAHNHYTKSLSLSG 431
Db 405 DGSFPLYSKLTVDKSRMOQGNPFGCSVMEALAHNHYTKSLSLSG 450

```

```

US RESULT 53
US-09-920-171-18
; Sequence 18, Application US/09920171
; Patent No. 6682735
; GENERAL INFORMATION:
; APPLICANT: Lowman, Henry B.
; APPLICANT: Presta, Leonard G.
; APPLICANT: Jarden, Paula M.
; APPLICANT: Lowe, John
; TITLE OF INVENTION: Improved Anti-IgE Antibodies (as amended)
; FILE REFERENCE: P1123C/US
; CURRENT APPLICATION NUMBER: US/09/920,171
; CURRENT FILING DATE: 2001-08-01
; PRIOR APPLICATION NUMBER: US 08/887,352
; PRIOR FILING DATE: 1997-07-02
; PRIOR APPLICATION NUMBER: US 09/296,005
; PRIOR FILING DATE: 1999-04-21
; NUMBER OF SEQ ID NOS: 44
; SEQ ID NO 18
; LENGTH: 451
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Heavy chain sequence derived from MA811
US-09-920-171-18

```

	Query Match	52.3%	Score 1662;	DB 4	Length 451;
	Best Local Similarity	58.6%	Pred. No. 2-2e-94;		
	Matches	273;	Conservative	25;	Mismatches 78; Indels 90; Gaps 12
Oy	30 LGKGGDYVELTCTASQ---KSIQTHMKNSNOIKLGNOSFLTYGPKSLN-----	77			
Db	11 LVPGSGTRRLSCAVSGYSITGYSNNWMLROAPGKLEWASVSKYSGETRYNSVGKITI	70			

```

QY 78 DRDSSRSIMDQCNFLLIKNLKIDSPYICEVEDQKEEVOLLVFGLTANSDTH---LL 134
Db 71 SRDSSKNTYTLQMN-----SLRBDTAVIYCARGSH-----YFG-----HHFAV 110
QY 135 QQGSLLTLESPPGSSPVQCRSPGKNIQCG-----KTLVS----- 177
Db 111 WGGGLTAVTSASATKQPSVFLPAPLPSKSNGGTALGCLVADYFPEPYTSMNCSALTSG 170
QY 173 ----QLELDQSG-----TWTCYVLQNKVFEKDIYCAPRPERKSC 210
Db 171 VHTFPAVLQSSGGLYSLSSVVTVPSSSLGTQYIICV---NHKPSMTKYD---KVEPESC 224
QY 211 DKHTHC-----PELLGSPVFLFPPKPKDOLMISRTPEVTCVYVDVSHEDVEYKFNMYVD 265
Db 225 DKHTCPPCBPABELLOGPSVFLFPPKPKDOLMISRTPEVTCVYVDVSHEDVEYKFNMYVD 285
QY 266 GVEVHNAKTKPREBQYNSTYRVVSVLYVLHODMLNGEKYCKVCVSNKALPAPIEKTISKAK 325
Db 285 GVEVHNAKTKPREBQYNSTYRVVSVLYVLHODMLNGEKYCKVCVSNKALPAPIEKTISKAK 344
QY 326 GQREBQYVYTLPPSRBELTKNOVSLTCLVKGYPSPDIAVEMESNGQPENNYKTTPPVLDS 385
Db 345 GQREBQYVYTLPPSRBEMTKNOVSLTCLVKGYPSPDIAVEMESNGQPENNYKTTPPVLDS 404
QY 386 DGSFPLYSKLTVDKSRMOQGNFSSVHMEALHNNHYTOKSLSLSPG 431
Db 405 DGSFPLYSKLTVDKSRMOQGNFSSVHMEALHNNHYTOKSLSLSPG 450

```

RESULT 54
 US-09-049-672A-8
 Sequence 8, Application US/09049672A
 Patent No. 6135941
 GENERAL INFORMATION:
 APPLICANT: Hillman, Jennifer L.
 APPLICANT: Lal, Preeti
 APPLICANT: Tang, Y. Tom
 APPLICANT: Yee, Henry
 APPLICANT: Au-Young, Janice
 APPLICANT: Corley, Neil C.
 APPLICANT: Guegler, Karl J.
 TITLE OF INVENTION: HUMAN IMMUNE SYSTEM ASSOCIATED PROTEINS
 NUMBER OF SEQUENCES: 28
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Incyte Pharmaceuticals, Inc.
 STREET: 3174 Porter Drive
 CITY: Palo Alto
 STATE: CA
 COUNTRY: USA
 ZIP: 94304
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Diskette
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: DOS
 SOFTWARE: Fastcd for Windows Version 2.0
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/049,672A
 FILING DATE: HERewith
 CLASSIFICATION: 536
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER:
 FILING DATE:
 ATTORNEY/AGENT INFORMATION:
 NAME: Cerrone, Michael C
 REGISTRATION NUMBER: 39,132
 REFERENCE/DOCKET NUMBER: PF-0497 US
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 650-855-0555
 TELEFAX: 650-845-4166
 TELEX:
 INFORMATION FOR SEQ ID NO: 8:
 SEQUENCE CHARACTERISTICS:


```

; LENGTH: 467 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; LIBRARY: LUNGTUT11
; CLONE: 2747531
US-09-499-672A-8

```

```

Query Match      52.3%; Score 1261.5; DB 3; Length 467;
Best Local Similarity 55.6%; Pred. No. 2.5e-94;
Matches 278; Conservative 24; Mismatches 73; Indels 125; Gaps 14;

```

```

QY 16 LALLPAAATQGNKVV-----LGKKGDTVELTCTAS--QKSKIQFHW-----53
DB 8 LFLVAATCTHAQVQLVGSAGVAKKPGASVQVSCIVSGFTLSDLSVHWVRAQPGGLEWM 67
QY 54 ----KNSNQI---KILGNQGSFLTQKPSKLNDRADSRSLMDQGNFPLIINKLIEDSD 105
DB 68 GGLABENGSAVVAQKFLGR-----LTLSEDTSDTA-----YMFLLNLGSEDSA 111
QY 106 TYICEVEDEKQEVQVLLVRLTANSQTHL-----LOGQSLTLTLESPPGSSPSVQCRSPRG 160
DB 112 IYYC-----ARQHYDFFDFWQGGTMVTVSSASTKGPSPVPLAPSS 152
QY 161 KNIQGG-----KTLVS-----QLFIQDSG-----180
DB 153 KSTSGTALAGCLVADYDFPEPVTVSMNSGALTSQVHTPAVLAQSSGLYSLSSVTVVPSSS 212
QY 181 ----TWCTVLONQKVEPKIDIVPCPAPBPKSCDKTHTC-----PELLGGSVFLPPK 231
DB 213 LGTYIYICNV--NHKPSNTKVD----KVEPKSCDKTHTCPCPAPBELLGGPSVFLPPK 266
QY 232 PKDTLMISTPEVTCVVDVSHEDPEVKKNWVVDQVEVHNATKREQOYSTVYVSVL 291
DB 267 PKDTLMISTPEVTCVVDVSHEDPEVKKNWVVDQVEVHNATKREQOYSTVYVSVL 326
QY 292 TVLHODMLNGKEYKCKVSNKALPAPIEKTISKAKQPREPVYTLPPSRDELTKNQVSLT 351
DB 327 TVLHODMLNGKEYKCKVSNKALPAPIEKTISKAKQPREPVYTLPPSRDELTKNQVSLT 386
QY 352 CLVKGFPYPSDIAVEMESNGQFPENNYKTPPVLDSDGSFFLYSKLTVDKSRMQQGNVFSQS 411
DB 387 CLVKGFPYPSDIAVEMESNGQFPENNYKTPPVLDSDGSFFLYSKLTVDKSRMQQGNVFSQS 446
QY 412 VMHEALHNHYTKQSLSLSPG 431
DB 447 VMHEALHNHYTKQSLSLSPG 466

```

```

RESULT 55
US-09-499-846-12
; Sequence 12, Application US/09499846
; Patent No. 6656728
; GENERAL INFORMATION:
; APPLICANT: Kavanaugh et al.
; TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR
; FILE OF INVENTION: RECEPTOR-IMMUNOGLOBULIN FUSION
; FILE REFERENCE: 035784/195012 (5784-
; CURRENT APPLICATION NUMBER: US/09/499,846
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FaastSeq for Windows Version 3.0
; SEQ ID NO 12
; LENGTH: 488
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-499-846-12

```

```

Query Match      52.2%; Score 1261; DB 4; Length 488;
Best Local Similarity 57.9%; Pred. No. 2.9e-94;
Matches 272; Conservative 30; Mismatches 88; Indels 80; Gaps 11;

```

```

QY 15 QLALLPAAATQGNKVVLGKKGDTVELTCTASQKSKIQFHW--KNSNQIKILGNQGSFLTQGP 73
DB 45 KLHAVPAA-----KTVFKCPSSGTPPTLRMLKNGKEFKRPDRHIGYKV---89
QY 74 SKLNDRADSRRLM-----DQGNFPLIINKLIEDSDTYICEVEDEKQEVQVLLVF 123
DB 90 -----RYATWSIIMDSVSPEDKGNVTCIYENBYSINHVTQLDIVERSPHRPILQA 140
QY 124 GLTANSPTHLQGSSTLTLTLESPP-----GSS-----PSVQCRSPRGKNI-163
DB 141 GLPANKTVALLAGSNVNEPCKVYSDPQPHIQMLKHEVNGSKIGPUNLPYVQILKTAGVNTT 200
QY 164 -QGKTLVSQLELQDSGTWTC-----TVLONQKVEFKIDIVCPA--PE 206
DB 201 DKEMEVHLNRVSPEDAGEYTCLAGNSIGLSHSAMLTVE---ALBERPAVMTSPYLE 257
QY 207 PKSCDKTHTC-----PELLGGSVFLPPPKDTLMISRPTEVTCVVDVSHEDPEVKFN 261
DB 258 PKSCDKTHTCPCPAPBELLGGPSVFLPPPKDTLMISRPTEVTCVVDVSHEDPEVKFN 317
QY 262 MYVDGVEVHNAKTREEQYSTVYVSVLTVLHODMLNGKEYKCKVSNKALPAPIEKT 321
DB 318 MYVDGVEVHNAKTREEQYSTVYVSVLTVLHODMLNGKEYKCKVSNKALPAPIEKT 377
QY 322 SKAGQPREPVYTLPPSRDELTKNQVSLTCLVKGFPYPSDIAVEMESNGQFPENNYKTPP 381
DB 378 SKAGQPREPVYTLPPSRDELTKNQVSLTCLVKGFPYPSDIAVEMESNGQFPENNYKTPP 437
QY 382 VLSDGSFFLYSKLTVDKSRMQQGNVFSQVMHEALHNHYTKQSLSLSPG 431
DB 438 VLSDGSFFLYSKLTVDKSRMQQGNVFSQVMHEALHNHYTKQSLSLSPG 487

```

```

RESULT 56
US-08-466-151-8
; Sequence 8, Application US/08466151
; Patent No. 6037453
; GENERAL INFORMATION:
; APPLICANT: Jardeu, Paula M.
; TITLE OF INVENTION: Immunoglobulin Variants
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESS: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Winpatin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/466,151
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/466163
; FILING DATE: 06-Jun-1995
; APPLICATION NUMBER: 08/405617
; FILING DATE: 15-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/185899
; FILING DATE: 26-JAN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/879495
; FILING DATE: 07-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/744768
; FILING DATE: 14-AUG-1991
; ATTORNEY/AGENT INFORMATION:

```

```

NAME: Syoboda, Craig G.
REGISTRATION NUMBER: 39,044
REFERENCE/DOCKET NUMBER: P0718P2C1D1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-1489
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 453 amino acids
TYPE: Amino Acid
TOPOLOGY: Linear
US-08-466-151-8

Query Match      52.2%; Score 1259; DB 3; Length 453;
Best Local Similarity 58.9%; Pred. No. 3,8e-94;
Matches 271; Conservative 26; Mismatches 87; Indels 76; Gaps 11

30 LGKKDVTIELTCTAAQ---KSIQIFMKKNSNOIKILGNQGSFLTKGPSKLANRADRSRL 86
11 LVQPGSGSLRLSAGVAGYITSGYSNMWIRQAGKGLMWASLTYYGOSTIVADSVKGRFTI 70
87 W---DQGNFPLIIKNLIKIEDSDTYICEVEDQKEVQLVFGLTANSDTLL---QGQSIL 140
71 SRDSSKNTFYLOMNSLRADDTAVYICARGSH-----YFG-----HMFVAMGGQTLVT 118
141 LTLEPPSSPEVQCRSPRGNKIQGG-----KTLSSV-----OL 174
119 VSSASTKRGSPVFPPLAPSSKSTSGTALGCLVXDYPEPVTVMNSGALTSVHTPPA 178
175 ELQDSG-----TWCTVLQNOKKVEPKIDIVCPAPEPKCDKTHTC 216
179 VLQSSGLYLSASVVTVPSSSLGTQYIICNV--NHKPSNTKVD---KVEPSCDKTHTC 232
217 ----PELLGSPVFLPPEPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN 271
223 PCPCAPELLGGSVFLPPEPKDITLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN 292
272 AKTKREEOYNSTRVNSVLYTLHODMLNGKEYKCKVSNKALPAPIEKTISAKAQPREP 331
293 AKTKREEOYNSTRVNSVLYTLHODMLNGKEYKCKVSNKALPAPIEKTISAKAQPREP 352
332 QVYTLPPSRDELTKNOVSLTCLVKGFYPSDIAVEGMSNQEPENNYKTPPVLDSDGSFPL 391
353 QVYTLPPSRDEETKNOVSLTCLVKGFYPSDIAVEGMSNQEPENNYKTPPVLDSDGSFPL 412
392 YSKLTVDSKRWQGNVFCSSVMHEALAHNHYTQKSLSPG 431
413 YSKLTVDSKRWQGNVFCSSVMHEALAHNHYTQKSLSPG 452

RESULT 57
US-08-466-163B-8
Sequence 8, Application US/08466163B
Parent No. 6329509
GENERAL INFORMATION:
APPLICANT: Jardieu, Paula M.
TITLE OF INVENTION: Immunoglobulin Variants
FILE REFERENCE: P0718P2C1D1
CURRENT APPLICATION NUMBER: US/08/466,163B
CURRENT FILING DATE: 1995-06-06
PRIOR APPLICATION NUMBER: US 08/405,617
PRIOR FILING DATE: 1995-03-15
PRIOR APPLICATION NUMBER: US 08/185,899
PRIOR FILING DATE: 1994-01-26
PRIOR APPLICATION NUMBER: US 07/879,495
PRIOR FILING DATE: 1992-05-07
PRIOR APPLICATION NUMBER: US 07/744,768
PRIOR FILING DATE: 1991-08-14
NUMBER OF SEQ ID NOS: 64
SEQ ID NO 8
LENGTH: 453
TYPE: PRT

```

[illegible]


```

; INFORMATION FOR SEQ ID NO: 8 :
; SEQUENCE CHARACTERISTICS:
;     LENGTH: 478 amino acids
;     TYPE: amino acid
;     TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-487-550-8

```

Query Match	52.2%;	Score 1259;	DB 3;	Length 478;
Best Local Similarity	66.9%;	Pred. No. 4.1e-94;		
Matches 259;	Conservative 12;	Mismatches 56;	Indels 60;	Gaps 7

94 LIINKLKIEDSDTYICEVEQKEVQLLVFGILTANSDPTHLQGSQTLTLESPPGSSPSV 153
 102 LQMSLSLKIEDTAVYYCTTSYISH-----CRGVCYGYGFEEFWQGLAVTVSSASTKGPV 156

154 QCRSPRGNIQGG-----KTLSTV-----QLERQDSG----- 180
 :
 :
 :
157 PPLAPSSSKTSGGTALGCLVKDYPPPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSV 216

```

Y -----TWTCTVLDNQKVFKEIDIVPCPAEPKSCDTHTC-----PELIGGSP 224
      |:| | | |:| |||||
217 VTVPSSSLGTQTYICNV--NHKPSNTKV D----KKAEPKSCD KTHTCPPCPAPELLGGPS 270

```

225 VFLEPPRPKDTLMISRTPEVTCVAVDVSHEDPEVKFNMWYDGEVHNAKTKPREEQYNST 284
271 VFLEPPRPKDTLMISRTPEVTCVAVDVSHEDPEVKFNMWYDGEVHNAKTKPREEQYNST 330

```

265  IRVSVLTVLHQLDMLNGKEINCNVSNKALPARIKTISSKAGQPREPOVYILPPSRDELT 344
331  YRVSVLTVLHQLDMLNGKEKCVSNKALPARIKTISSKAGQPREPOVYTLPPSRDELT 390

```

391 KNQVSLTCLVKGFPSDIAMWESNQPPENNYKTTPEVLDSGSFLYSKLTVDKSRWQ 450

451 GNVFSCVMHEALHNHYTQKSLSPG 477

RESULT 61
5-09-526-098-8
Sequence 8, Application US/09526098

GENERAL INFORMATION:
APPLICANT: Anderson, Darrell R.
TITLE OF INVENTION: "MONKEY MONOCLONAL ANTIBODIES SPECIFIC

TITLE OF INVENTION: PHARMACEUTICAL COMPOSITIONS CONTAINING, AND USE THEREOF
 TITLE OF INVENTION: IMMUNOSUPPRESSANTS"
 NUMBER OF SEQUENCES: 12

ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
STREET: 699 Prince Street
CITY: Alexandria
STATE: VA

COUNTRY: USA
ZIP: 22314
COMPUTER READABLE FORM:
MEDICIN TYPE: E10000 dist

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:

FILING DATE: US/09/526,098
 APPLICATION NUMBER:
 CLASSIFICATION:
 PRIOR APPLICATION DATA:

APPLICATION NUMBER: 09/363,916
FILING DATE:
APPLICATION NUMBER: US 08/487,550
FILING DATE: 07-JUN-1995

```

: ATTORNEY/AGENT INFORMATION:
:
: NAME: Teskin, Robin L.
:
: REGISTRATION NUMBER: 35,030
:
: REFERENCE/DOCKET NUMBER: 012712-131
:
: TELECOMMUNICATION INFORMATION:
:
: TELEPHONE: 703-836-6620
:
: TELEFAX: 703-836-2021
:
: INFORMATION FOR SEQ ID NO: 8:
:
: SEQUENCE CHARACTERISTICS:
:
: LENGTH: 478 amino acids
:
: TYPE: amino acid
:
: TOPOLOGY: linear
:
: MOLECULE TYPE: protein
:
: US-09-526-098-8

```

Query Match	52.2%	Score 1259;	DB 4;	Length 478;
Best Local Similarity	66.9%	Pred. No. 4.1e-94;		
Matches 259; Conservative	12;	Mismatches 56;	Indels 60;	Gaps 7;

```
94 L I I K N K I E D S T Y I C E V E Q D K E V Q L V F G L T A N S D T H L O G Q S L T L T L E S P P S S P S V    153
   | : : ||||| : - - - - -      |          |       : : : |||
102 L Q M S L K I E D T A V Y C T T S Y I S H -----C R G V C Y G G Y F E F W G Q G A L V T S S A S T K G P S V    156
```

```

154 QCRSPKGNIQG-----KTSVS-----QELQDSC----- 180
      :  :  :  :  :  :  :  :  :  :  :  :  :  :  :
157 PPLAPSSKSTSGGTALGCLVKDYFPEPEYTSWNSGALTSGVHTFPAVLQSSGLYSLSSV 216

```

```

181 -----TWTCYLVNQNKAEFKDIVPCPAPEPKSDCKTHTC-----PELIGGS 224
      | : | | | | | | | | | | | | | | | | | | | | | | | | | |
217 VTPSSSLGTQIYICNV--NHKESNTKVD---KKAEPKSCDKTHITPCPAPELLIGGS 270

```

225 VFLPFPKPKDTLMISRTPEVTCVVVDVSHEDPEVFENWYVDGVEVHNAKTKRREEQYNST 284
271 VFLPFPKPKDTLMISRTPEVTCVVVDVSHEDPEVFENWYVDGVEVHNAKTKRREEQYNST 330

```

285  YRVSVLTIVLHQDWLNGEYKCKVSNKALPAPIETISKKGQPREQVYTIIPSSKDDLI 344
      |||||
331  YRVSVLTIVLHQDWLNGEYKCKVSNKALPAPIETISKKGQPREQVYTIIPSSRDELT 390
      |||||

```

391 KQVSLTCLVKGFFPSDIAVEMWNGQPPENNYKTPVLDSGDSFLLYSKLTVDKSRMQ 450

451 GNVFSCVMHEALHNHYTQKSLSPG 477

RESULT 62
3-09-499-846-10
Sequence 10, Application US/09499846

GENERAL INFORMATION:
APPLICANT: Kavanaugh et al.
TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR

FILE REFERENCE: 035784/195012 (5784-
CURRENT APPLICATION NUMBER: US/09/499,846
CURRENT FILING DATE: 2000-02-07

```
SOFTWARE: FastSeq for Windows Version 3.0  
SEQ ID NO 10  
LENGTH: 497  
rccccccc  
rrrrrrrr
```

ORGANISM: Homo sapiens
3-09-499-846-10

Matches	2/4;	Conservative	30;	Mismatches	85;	Indels	91;	Gaps	12;
15	QALLPATQGNKVLGKKDGYELTCTASQKKSIQFHW----	ILGNQSF	69						

```

Db 45 KLIHAVPA-----KTVKFCPSSTGTPNFTLRMLKXGKFKDPDRIGYKAVYA 92
Qy 70 TKG-----PSKLNDRADSRSLMDQGNFPLIKNLKIEDSDTYICEVEDQKEEVOLLV 122
Db 93 TWSIIMDSVPS-----DKGNYTCIVENEGSINHITQOLDIVERSHPRPLIQ 139
Qy 123 FGLTNSDTHLLIQGQSLTLTLESP-----GSS-----PSVQCRSPRGNI 163
Db 140 AGLPANKTVAGLSNVEFMCKVYSDPOPHIQMLKHIEVNGSKIGPNDLPVQILKTAGVNT 199
Qy 164 --QGKTLTSLVQLELDQSGTWT-----TVLONQKVEFKDIDVPC--- 203
Db 200 TDKEMEVLHLRVNSFEDEAGETCLAGNSIGLSHSAWLTLE--ALSERPAVMTSPLYL 256
Qy 204 -----APEPKSCDKTHTC-----PELLGSPVLFPPPKDITLMIERTPEVTCVVVDV 251
Db 257 EGGSGPGLOEPKSCDKTHTCPCPAPALEGGSPVLFPPPKDITLMIERTPEVTCVVVDV 316
Qy 252 SHEDPEVKFNMVYDGEVHNNAKTKPREQYNSTYRVSVLTVLHODWLNKGEYKCKVSNK 311
Db 317 SHEDPEVKFNMVYDGEVHNNAKTKPREQYNSTYRVSVLTVLHODWLNKGEYKCKVSNK 376
Qy 312 ALPAPIEKTISKAKGQPREPPVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQ 371
Db 377 ALPAPIEKTISKAKGQPREPPVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQ 436
Qy 372 PENNYKTPPVLDSDGSFPLYSKLTVDKSRMQQGNVFSCVIMHALHNHTYOKSLSPG 431
Db 437 PENNYKTPPVLDSDGSFPLYSKLTVDKSRMQQGNVFSCVIMHALHNHTYOKSLSPG 496

```

```

RESULT 63
US-09-499-846-8
; Sequence 8, Application US/09499846
; Patent No. 6656728
;
; GENERAL INFORMATION:
; APPLICANT: Kavanaugh et al.
; TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR
; TITLE OF INVENTION: RECEPTOR-IMMUNOGLOBULIN FUSION
; FILE REFERENCE: 035784/195012 (5784-
; CURRENT APPLICATION NUMBER: US/09/499,846
; CURRENT FILING DATE: 2000-02-07
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 525
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-499-846-8

```

```

Query Match 52.1%; Score 1258.5; DB 4; Length 525;
Best Local Similarity 57.1%; Pred. No. 5,1e-94;
Matches 274; Conservative 30; Mismatches 85; Indels 91; Gaps 12;

```

```

Qy 15 QALLPAAATQGNKVVGLKKGDVVELTCTASOKKSIOFHMKNSNOIK---ILGNQGSFL 69
Db 73 KLIHAVPA-----KTVKFCPSSTGTPNFTLRMLKXGKFKDPDRIGYKAVYA 120
Qy 70 TKG-----PSKLNDRADSRSLMDQGNFPLIKNLKIEDSDTYICEVEDQKEEVOLLV 122
Db 121 TWSIIMDSVPS-----DKGNYTCIVENEGSINHITQOLDIVERSHPRPLIQ 167
Qy 123 FGLTNSDTHLLIQGQSLTLTLESP-----GSS-----PSVQCRSPRGNI 163
Db 168 AGLPANKTVAGLSNVEFMCKVYSDPOPHIQMLKHIEVNGSKIGPNDLPVQILKTAGVNT 227
Qy 164 --QGKTLTSLVQLELDQSGTWT-----TVLONQKVEFKDIDVPC--- 203
Db 228 TDKEMEVLHLRVNSFEDEAGETCLAGNSIGLSHSAWLTLE--ALSERPAVMTSPLYL 284
Qy 204 -----APEPKSCDKTHTC-----PELLGSPVLFPPPKDITLMIERTPEVTCVVVDV 251
Db 285 EGGSGPGLOEPKSCDKTHTCPCPAPALEGGSPVLFPPPKDITLMIERTPEVTCVVVDV 344

```

```

Qy 252 SHEDPEVKFNMVYDGEVHNNAKTKPREQYNSTYRVSVLTVLHODWLNKGEYKCKVSNK 311
Db 345 SHEDPEVKFNMVYDGEVHNNAKTKPREQYNSTYRVSVLTVLHODWLNKGEYKCKVSNK 404
Qy 312 ALPAPIEKTISKAKGQPREPPVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQ 371
Db 405 ALPAPIEKTISKAKGQPREPPVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQ 464
Qy 372 PENNYKTPPVLDSDGSFPLYSKLTVDKSRMQQGNVFSCVIMHALHNHTYOKSLSPG 431
Db 465 PENNYKTPPVLDSDGSFPLYSKLTVDKSRMQQGNVFSCVIMHALHNHTYOKSLSPG 524

```

```

RESULT 64
US-08-887-352B-14
; Sequence 14, Application US/08887352B
; Patent No. 5994511
;
; GENERAL INFORMATION:
; APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
; TITLE OF INVENTION: Improved Anti-IgE Antibodies and Method of
; TITLE OF INVENTION: Improving Polypeptides
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESS: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Winpatin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/887,352B
; FILING DATE: 03-Jul-1997
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Svoboda, Craig G.
; REGISTRATION NUMBER: 39,044
; REFERENCE/DOCKET NUMBER: P1123
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/952-9881
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 451 amino acids
; TYPE: Amino Acid
; TOPOLOGY: Linear
; US-08-887-352B-14

```

```

Query Match 52.1%; Score 1257; DB 2; Length 451;
Best Local Similarity 58.4%; Pred. No. 5,5e-94;
Matches 272; Conservative 25; Mismatches 79; Indels 90; Gaps 12;

```

```

Qy 30 LGKKGDVVELTCTASQ---KKSIOFHMKNSNOIKILGNQGSFLTKGSKLN----- 77
Db 11 LVQPGSLRLRISCAVSGVSTSGYSWNIROAPGKGLWVASITVYDGSNTNPSYKGRITI 70
Qy 78 DRADSRSLMDQGNFPLIKNLKIEDSDTYICEVEDQKEEVOLLVFLTANSDTH---LL 134
Db 71 SRDSSKNTFYLOKN-----SLRREDPAVYYCARGSH-----HMHFV 110
Qy 135 QGQSLTLTLESPGSSPSVQCRSPRGNIQGG-----KTLVSV----- 172
Db 111 WGCGTLTVTSSASTKGSVPFLAPSSKSTGGTAALGLVDYPPPEPVTVSNAGALTSG 170
Qy 173 -----QLRLQSG-----TWCTVQONQKVEFKDIDVPCAPPEPKSC 210
Db 171 VHPFPAVLQSSGLVSLSSVTVTPSSSLTGTYICNV--NHKPSNTKVD---KVEPKSC 224

```

QY	211	DKHTCC-----PELLGGSPVFLPPKPKDILMTSRPEVTCVVVDVSHDPKFNWYD	265
DB	225	DKHTCPPCAPBELLGGSVFLFPKPKDILMTSRPEVTCVVVDVSHDPKFNWYD	284
QY	266	GVEVHNATKTKREBOQSVTVRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIETISKAK	325
DB	285	GVEVHNATKTKREBOQSVTVRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIETISKAK	344
QY	326	GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTPPVLD	385
DB	345	GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVWESNGQPENNYKTPPVLD	404
QY	386	DGSEFELYSKLTVDSKRWQGVFSCVSMHALLNHTYQKSLSPG	431
DB	405	DGSEFELYSKLTVDSKRWQGVFSCVSMHALLNHTYQKSLSPG	450
RESULT 65			
US-08-887-352B-16			
Sequence 16, Application US/0887352B			
Patent No. 5994511			
GENERAL INFORMATION:			
APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe			
TITLE OF INVENTION: Improved Anti-IgE Antibodies and Method of			
TITLE OF INVENTION: Improving Polypeptides			
NUMBER OF SEQUENCES: 26			
CORRESPONDENCE ADDRESS:			
ADDRESSEE: Genentech, Inc.			
STREET: 1 DNA Way			
CITY: South San Francisco			
STATE: California			
COUNTRY: USA			
ZIP: 94080			
COMPUTER READABLE FORM:			
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk			
COMPUTER: IBM PC compatible			
OPERATING SYSTEM: PC-DOS/MS-DOS			
SOFTWARE: Winpatin (Genentech)			
CURRENT APPLICATION DATA:			
APPLICATION NUMBER: US/08/887,352B			
FILING DATE: 03-Jul-1997			
CLASSIFICATION: 530			
ATTORNEY/AGENT INFORMATION:			
NAME: Svoboda, Craig G.			
REGISTRATION NUMBER: 39,044			
REFERENCE/DOCKET NUMBER: P1123			
TELECOMMUNICATION INFORMATION:			
TELEPHONE: 650/225-1489			
TELEFAX: 650/952-9881			
INFORMATION FOR SEQ ID NO: 16:			
SEQUENCE CHARACTERISTICS:			
LENGTH: 451 amino acids			
TYPE: Amino Acid			
TOPOLOGY: Linear			
US-08-887-352B-16			
Query Match 52.1%; Score 1257; DB 2; Length 451;			
Best Local Similarity 58.4%; Pred. No. 5.5e-94;			
Matches 272; Conservative 25; Mismatches 79; Indels 90; Gaps 12;			
QY	30	LGKGGIVTELCTASQ--KKSIOFHWNKSNQIKIIGNOGSLTKGPKSKN-----	77
DB	11	LVPGGSLRLSCAAGSVGYSITGSYMNIRQAPGKLEWVASITYDGDSTVYNSVSKRITI	70
QY	78	DRADSRSLMNOGQFPLIKNLKIKEDSDTYICEVEDQKEVQLLVGLTANSDTH---LL	134
DB	71	SRDSKNTFYQNM--SLREDVAYVYCARGSH-----YFG-----HWHFAV	110
QY	135	QGQSLITLLESPSSSPVOCSPRGKNIQG-----KTLISVS-----	172
DB	111	WGQGLTVTVSASATKGSVFPLAPSSKSTGCTGATLALGLVKDYFPEPVTVSNMNGALTS	170
QY	173	-----QLELDQSG-----TWCTVLQNGKVFKEKIDIVPCAPAPKSC	210

Db	171	VHFFPAVLOSGLYSLSSVTVPPSSLSLGTQITICNV--NHKPSNTKYD-----KYVEKSC	224
Qy	211	DKHTTC-----PELLGSGSEVLFPPEKPKDTLMTISTPEVTCCVVDVSHEDPEVKFNMYD	255
Db	225	DKHTTCPCCPAPLGLGSPSEVFLPPPKPKDTLMTISTPEVTCCVVDVSHEDPEVKFNMYD	284
Qy	266	GVEVHNAKTPREBQYNSTYRVVSVLYVLHDQMLNGEYKCKVSNKALPAIEKTIISKAK	329
Db	285	GVEVHNAKTPREBQYNSTYRVVSVLYVLHDQMLNGEYKCKVSNKALPAIEKTIISKAK	344
Qy	326	GOEREPQVYTLPPSRBELTKNOVSLTCLCYKGYSPDINVEWMSGOPENNYKTPPYLDS	385
Db	345	GOEREPQVYTLPPSRBELTKNOVSLTCLCYKGYSPDINVEWMSGOPENNYKTPPYLDS	400
Qy	386	DGSEFLYSKLTVDKSKRWQGNVFCSSVHMEALHNHYTKSLSLSPG	431
Db	405	DGSEFLYSKLTVDKSKRWQGNVFCSSVHMEALHNHYTKSLSLSPG	450

```

1      RESULT 66
2      US-08-466-151-65
3      ; Sequence 65, Application US/08466151
4      ; Patent No. 6037453
5      ; GENERAL INFORMATION:
6      ; APPLICANT: Jardiou, Paula M.
7      ; APPLICANT: Presta, Leonard G.
8      ; TITLE OF INVENTION: Immunoglobulin Variants
9      ; NUMBER OF SEQUENCES: 65
10     ; CORRESPONDENCE ADDRESS:
11     ; ADDRESSEE: Genentech, Inc.
12     ; STREET: 1 DNA Way
13     ; CITY: South San Francisco
14     ; STATE: California
15     ; COUNTRY: USA
16     ; ZIP: 94080
17     ;
18     ; COMPUTER READABLE FORM:
19     ; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
20     ; COMPUTER: IBM PC compatible
21     ; OPERATING SYSTEM: PC-DOS/MS-DOS
22     ; SOFTWARE: WinPatIn (Genentech)
23     ; CURRENT APPLICATION DATA:
24     ; APPLICATION NUMBER: US/08/466,151
25     ; FILING DATE:
26     ;
27     ; CLASSIFICATION:
28     ;
29     ; PRIOR APPLICATION DATA:
30     ; APPLICATION NUMBER: 08/466163
31     ; FILING DATE: 06-Jun-1995
32     ; APPLICATION NUMBER: 08/405617
33     ; FILING DATE: 15-MAR-1995
34     ; PRIOR APPLICATION DATA:
35     ; APPLICATION NUMBER: 08/185899
36     ; FILING DATE: 26-JAN-1994
37     ; PRIOR APPLICATION DATA:
38     ; APPLICATION NUMBER: 07/879495
39     ; FILING DATE: 07-MAY-1992
40     ; PRIOR APPLICATION DATA:
41     ; APPLICATION NUMBER: 07/744768
42     ; FILING DATE: 14-AUG-1991
43     ; ATTORNEY/AGENT INFORMATION:
44     ; NAME: Svoboda, Craig G.
45     ; REGISTRATION NUMBER: 39,044
46     ; REFERENCE/DOCKET NUMBER: P0718P2C1D1
47     ; TELECOMMUNICATION INFORMATION:
48     ; TELEPHONE: 650/225-1489
49     ; TELEFAX: 650/952-9881
50     ;
51     ; INFORMATION FOR SEQ ID NO: 65:
52     ; SEQUENCE CHARACTERISTICS:
53     ; LENGTH: 451 amino acids
54     ; TYPE: Amino Acid
55     ;
56     ; TOPOLOGY: Linear
57     ;
58     ; US-08-466-151-65

```

```

Query Match      52.1%; Score 1257; DB 3; Length 451;
Best Local Similarity 58.4%; Pred. No. 5.5e-94;
Matches 272; Conservative 25; Mismatches 79; Indels 90; Gaps 12;

QY 30 LGKKDPTVELTCTAQQ--KKSIOFHMKNSNOIKILGNQGSFLTGPSTKLN----- 77
DB 11 LVQPGGSLRLSCAVGYSITSGYSWMWIRQAPGKLEWVASITYDGSITNPNYSVKGRITTI 70
QY 78 DRADRSRLMDQGNFPLIKNLKIEDSDTYICEVEDQKEEVQLVFGLTANSDDTH---LL 134
DB 71 SRDSDSKNTFYLOMN-----SLRAEDTAVYYCARGSH-----YFG-----HMHFAV 110
QY 135 QGQSLTLTLSPGSSPSVQCRSPRGKNIQGG-----KTLSSVS----- 172
DB 111 WGGQGLTVTVSSASTKGPVSFPLAPSSKSTSGTALGLVQDYPPEPVTVSNNGALTS 170
QY 173 ----QLELDQSG-----TWCTVYLNQKXVEFKIDIVCPAPPEPSC 210
DB 171 VHTFPAVLQSSGLYSLSSVTVVTPSSSLGTQTYICNV--NHKPSNTKVD---KKEVPKSC 224
QY 211 DKHTHTC-----PELLGSPSVFLFPPKPKDTLMTISRTPEVTCVVVDVSHEDPEVKFNWYVD 265
DB 225 DKHTHTCCPCAPPELLGSPSVFLFPPKPKDTLMTISRTPEVTCVVVDVSHEDPEVKFNWYVD 284
QY 266 GVEVHNAKTKPREEOYNSTRVSVLTVLHODMNGEKYCKVSNKALPAPIETISKAK 325
DB 285 GVEVHNAKTKPREEOYNSTRVSVLTVLHODMNGEKYCKVSNKALPAPIETISKAK 344
QY 326 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEHESNGQPENNYKTTPPVLD 385
DB 345 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEHESNGQPENNYKTTPPVLD 404
QY 386 DGSFFLYSKLTVDKSRMOQGNVFCSVMHIALHNHYTQKSLSLSPG 431
DB 405 DGSFFLYSKLTVDKSRMOQGNVFCSVMHIALHNHYTQKSLSLSPG 450

RESULT 67
US-09-109-207C-14
; Sequence 14, Application US/09109207C
; Patent No. 6172213
; GENERAL INFORMATION:
; APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
; TITLE OF INVENTION: Improved Anti-1gE Antibodies and Method of Improving Polypeptide
; FILE REFERENCE: P1123R1
; CURRENT APPLICATION NUMBER: US/09/109,207C
; PRIORITY FILING DATE: 1998-06-30
; PRIOR APPLICATION NUMBER: US 60/051,554
; PRIOR FILING DATE: 1997-07-03
; NUMBER OF SEQ ID NOS: 44
; SEQ ID NO 14
; LENGTH: 451
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: Artificial
; LOCATION: 1-451
; OTHER INFORMATION: Heavy chain sequence derived from MAE11
US-09-109-207C-14

Query Match      52.1%; Score 1257; DB 3; Length 451;
Best Local Similarity 58.4%; Pred. No. 5.5e-94;
Matches 272; Conservative 25; Mismatches 79; Indels 90; Gaps 12;

QY 30 LGKKDPTVELTCTAQQ--KKSIOFHMKNSNOIKILGNQGSFLTGPSTKLN----- 77
DB 11 LVQPGGSLRLSCAVGYSITSGYSWMWIRQAPGKLEWVASITYDGSITNPNYSVKGRITTI 70
QY 78 DRADRSRLMDQGNFPLIKNLKIEDSDTYICEVEDQKEEVQLVFGLTANSDDTH---LL 134
DB 71 SRDSDSKNTFYLOMN-----SLRAEDTAVYYCARGSH-----YFG-----HMHFAV 110
QY 135 QGQSLTLTLSPGSSPSVQCRSPRGKNIQGG-----KTLSSVS----- 172
DB 111 WGGQGLTVTVSSASTKGPVSFPLAPSSKSTSGTALGLVQDYPPEPVTVSNNGALTS 170
QY 173 ----QLELDQSG-----TWCTVYLNQKXVEFKIDIVCPAPPEPSC 210
DB 171 VHTFPAVLQSSGLYSLSSVTVVTPSSSLGTQTYICNV--NHKPSNTKVD---KKEVPKSC 224
QY 211 DKHTHTC-----PELLGSPSVFLFPPKPKDTLMTISRTPEVTCVVVDVSHEDPEVKFNWYVD 265
DB 225 DKHTHTCCPCAPPELLGSPSVFLFPPKPKDTLMTISRTPEVTCVVVDVSHEDPEVKFNWYVD 284
QY 266 GVEVHNAKTKPREEOYNSTRVSVLTVLHODMNGEKYCKVSNKALPAPIETISKAK 325
DB 285 GVEVHNAKTKPREEOYNSTRVSVLTVLHODMNGEKYCKVSNKALPAPIETISKAK 344
QY 326 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEHESNGQPENNYKTTPPVLD 385
DB 345 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEHESNGQPENNYKTTPPVLD 404
QY 386 DGSFFLYSKLTVDKSRMOQGNVFCSVMHIALHNHYTQKSLSLSPG 431
DB 405 DGSFFLYSKLTVDKSRMOQGNVFCSVMHIALHNHYTQKSLSLSPG 450

RESULT 68
US-09-109-207C-16
; Sequence 16, Application US/09109207C
; Patent No. 6172213
; GENERAL INFORMATION:
; APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
; TITLE OF INVENTION: Improved Anti-1gE Antibodies and Method of Improving Polypeptide
; FILE REFERENCE: P1123R1
; CURRENT APPLICATION NUMBER: US/09/109,207C
; PRIORITY FILING DATE: 1998-06-30
; PRIOR APPLICATION NUMBER: US 60/051,554
; PRIOR FILING DATE: 1997-07-03
; NUMBER OF SEQ ID NOS: 44
; SEQ ID NO 16
; LENGTH: 451
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: Artificial
; LOCATION: 1-451
; OTHER INFORMATION: Heavy chain sequence derived from MAE11
US-09-109-207C-16

Query Match      52.1%; Score 1257; DB 3; Length 451;
Best Local Similarity 58.4%; Pred. No. 5.5e-94;
Matches 272; Conservative 25; Mismatches 79; Indels 90; Gaps 12;

QY 30 LGKKDPTVELTCTAQQ--KKSIOFHMKNSNOIKILGNQGSFLTGPSTKLN----- 77
DB 11 LVQPGGSLRLSCAVGYSITSGYSWMWIRQAPGKLEWVASITYDGSITNPNYSVKGRITTI 70
QY 78 DRADRSRLMDQGNFPLIKNLKIEDSDTYICEVEDQKEEVQLVFGLTANSDDTH---LL 134
DB 71 SRDSDSKNTFYLOMN-----SLRAEDTAVYYCARGSH-----YFG-----HMHFAV 110
QY 135 QGQSLTLTLSPGSSPSVQCRSPRGKNIQGG-----KTLSSVS----- 172
DB 111 WGGQGLTVTVSSASTKGPVSFPLAPSSKSTSGTALGLVQDYPPEPVTVSNNGALTS 170
QY 173 ----QLELDQSG-----TWCTVYLNQKXVEFKIDIVCPAPPEPSC 210
DB 171 VHTFPAVLQSSGLYSLSSVTVVTPSSSLGTQTYICNV--NHKPSNTKVD---KKEVPKSC 224
QY 211 DKHTHTC-----PELLGSPSVFLFPPKPKDTLMTISRTPEVTCVVVDVSHEDPEVKFNWYVD 265
DB 225 DKHTHTCCPCAPPELLGSPSVFLFPPKPKDTLMTISRTPEVTCVVVDVSHEDPEVKFNWYVD 284
QY 266 GVEVHNAKTKPREEOYNSTRVSVLTVLHODMNGEKYCKVSNKALPAPIETISKAK 325
DB 285 GVEVHNAKTKPREEOYNSTRVSVLTVLHODMNGEKYCKVSNKALPAPIETISKAK 344
QY 326 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEHESNGQPENNYKTTPPVLD 385
DB 345 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEHESNGQPENNYKTTPPVLD 404
QY 386 DGSFFLYSKLTVDKSRMOQGNVFCSVMHIALHNHYTQKSLSLSPG 431
DB 405 DGSFFLYSKLTVDKSRMOQGNVFCSVMHIALHNHYTQKSLSLSPG 450

```

```

DB 111 WGGQGLTVTVSSASTKGPVSFPLAPSSKSTSGTALGLVQDYPPEPVTVSNNGALTS 170
QY 173 ----QLELDQSG-----TWCTVYLNQKXVEFKIDIVCPAPPEPSC 210
DB 171 VHTFPAVLQSSGLYSLSSVTVVTPSSSLGTQTYICNV--NHKPSNTKVD---KKEVPKSC 224
QY 211 DKHTHTC-----PELLGSPSVFLFPPKPKDTLMTISRTPEVTCVVVDVSHEDPEVKFNWYVD 265
DB 225 DKHTHTCCPCAPPELLGSPSVFLFPPKPKDTLMTISRTPEVTCVVVDVSHEDPEVKFNWYVD 284
QY 266 GVEVHNAKTKPREEOYNSTRVSVLTVLHODMNGEKYCKVSNKALPAPIETISKAK 325
DB 285 GVEVHNAKTKPREEOYNSTRVSVLTVLHODMNGEKYCKVSNKALPAPIETISKAK 344
QY 326 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEHESNGQPENNYKTTPPVLD 385
DB 345 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEHESNGQPENNYKTTPPVLD 404
QY 386 DGSFFLYSKLTVDKSRMOQGNVFCSVMHIALHNHYTQKSLSLSPG 431
DB 405 DGSFFLYSKLTVDKSRMOQGNVFCSVMHIALHNHYTQKSLSLSPG 450

RESULT 68
US-09-109-207C-16
; Sequence 16, Application US/09109207C
; Patent No. 6172213
; GENERAL INFORMATION:
; APPLICANT: Henry B. Lowman, Leonard G. Presta, Paula M. Jardieu, John Lowe
; TITLE OF INVENTION: Improved Anti-1gE Antibodies and Method of Improving Polypeptide
; FILE REFERENCE: P1123R1
; CURRENT APPLICATION NUMBER: US/09/109,207C
; PRIORITY FILING DATE: 1998-06-30
; PRIOR APPLICATION NUMBER: US 60/051,554
; PRIOR FILING DATE: 1997-07-03
; NUMBER OF SEQ ID NOS: 44
; SEQ ID NO 16
; LENGTH: 451
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: Artificial
; LOCATION: 1-451
; OTHER INFORMATION: Heavy chain sequence derived from MAE11
US-09-109-207C-16

Query Match      52.1%; Score 1257; DB 3; Length 451;
Best Local Similarity 58.4%; Pred. No. 5.5e-94;
Matches 272; Conservative 25; Mismatches 79; Indels 90; Gaps 12;

QY 30 LGKKDPTVELTCTAQQ--KKSIOFHMKNSNOIKILGNQGSFLTGPSTKLN----- 77
DB 11 LVQPGGSLRLSCAVGYSITSGYSWMWIRQAPGKLEWVASITYDGSITNPNYSVKGRITTI 70
QY 78 DRADRSRLMDQGNFPLIKNLKIEDSDTYICEVEDQKEEVQLVFGLTANSDDTH---LL 134
DB 71 SRDSDSKNTFYLOMN-----SLRAEDTAVYYCARGSH-----YFG-----HMHFAV 110
QY 135 QGQSLTLTLSPGSSPSVQCRSPRGKNIQGG-----KTLSSVS----- 172
DB 111 WGGQGLTVTVSSASTKGPVSFPLAPSSKSTSGTALGLVQDYPPEPVTVSNNGALTS 170
QY 173 ----QLELDQSG-----TWCTVYLNQKXVEFKIDIVCPAPPEPSC 210
DB 171 VHTFPAVLQSSGLYSLSSVTVVTPSSSLGTQTYICNV--NHKPSNTKVD---KKEVPKSC 224
QY 211 DKHTHTC-----PELLGSPSVFLFPPKPKDTLMTISRTPEVTCVVVDVSHEDPEVKFNWYVD 265
DB 225 DKHTHTCCPCAPPELLGSPSVFLFPPKPKDTLMTISRTPEVTCVVVDVSHEDPEVKFNWYVD 284
QY 266 GVEVHNAKTKPREEOYNSTRVSVLTVLHODMNGEKYCKVSNKALPAPIETISKAK 325
DB 285 GVEVHNAKTKPREEOYNSTRVSVLTVLHODMNGEKYCKVSNKALPAPIETISKAK 344
QY 326 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEHESNGQPENNYKTTPPVLD 385
DB 345 GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEHESNGQPENNYKTTPPVLD 404
QY 386 DGSFFLYSKLTVDKSRMOQGNVFCSVMHIALHNHYTQKSLSLSPG 431
DB 405 DGSFFLYSKLTVDKSRMOQGNVFCSVMHIALHNHYTQKSLSLSPG 450

```

```
Db      285 GVEVNAKTKPREEOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAK 344
QY      326 GQPREQVYTLTPSRDELTKNQVSLTCLVKGYFSPDAIEMWESNGPENNYKTTTPVLDS 385
Db      345 GQPREQVYTLTPSRDELTKNQVSLTCLVKGYFSPDAIEMWESNGPENNYKTTTPVLDS 404
QY      386 DGSFPLYSKLTVDKSRMGOQGVNFSCVMHEALHNHYTQKSLSLSPG 431
Db      405 DGSFPLYSKLTVDKSRMGOQGVNFSCVMHEALHNHYTQKSLSLSPG 450

RESULT 69
US-09-296-005-14
; Sequence 14, Application US/09296005
; Patent No. 6230957
; GENERAL INFORMATION:
; APPLICANT: Henry B. Lowman, Leonard G. Prestea, Paula M. Jardiou, John Lowe
; TITLE OF INVENTION: Improved Anti-IgE Antibodies and Method of Improving Polypeptides
; FILE REFERENCE: P1123C1T
; CURRENT APPLICATION NUMBER: US/09/296,005
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 08/887,352
; EARLIER FILING DATE: 1997-07-02
; NUMBER OF SEQ ID NOS: 26
; SEQ ID NO 14
; LENGTH: 451
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: Artificial
; LOCATION: 1-451
; OTHER INFORMATION: Heavy chain sequence derived from MAE11
US-09-296-005-14
```

```
Query Match      52.1%; Score 1257; DB 3; Length 451;
Best Local Similarity 58.4%; Pred. No. 5,5e-94;
Matches 272; Conservative 25; Mismatches 79; Indels 90; Gaps 12;

QY      30 LGKKGDTVELTCTAAG---KKSIOFHMKNNSQIKILNGSGFLTKGPKLN----- 77
Db      11 LVOPGSLRLSCAVALSGYSITSGYSNMWIRQAPGKLEWVASITTDSTYNPSVKGRIIT 70
QY      78 DRADSRSLMDQGNFPLIIKNIKIEDSDTYICEVEDQKEVQLVFGTLANSDTH---LL 134
Db      71 SDDDSKNTFYLGQNM-----SLRAEDTAVYYCARSGH-----YFG-----HMHFAY 110
QY      135 OGQSLFTLLESPGSSPSVQCRSPRGKNIQGS-----KTLSSVS----- 172
Db      111 WQGGTLVTVSSASTKGPVFPLAPSSKSTSGGTALGCLVKDYFPEPTVWSNMSGALTS 170
QY      173 ---QLELDDSG-----TWTCYVLONQKVEFKIDIVPCPAPKSC 210
Db      171 VHTFPAVLQSSGLYSLSSVTVPSSSLGTQYIICNV--NHKPSNTKVD---KQVEPKSC 224
QY      211 DKTHTC-----PELIGSPSVFLPPPKPDTLMISTRPEVTCVVDVSHEDPEVKFNWYVD 265
Db      225 DKTHTCPCPAPAEELIGSPSVFLPPPKPDTLMISTRPEVTCVVDVSHEDPEVKFNWYVD 284
QY      266 GVEVNAKTKPREEOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAK 325
Db      285 GVEVNAKTKPREEOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAK 344
QY      326 GQPREQVYTLTPSRDELTKNQVSLTCLVKGYFSPDAIEMWESNGPENNYKTTTPVLDS 385
Db      345 GQPREQVYTLTPSRDELTKNQVSLTCLVKGYFSPDAIEMWESNGPENNYKTTTPVLDS 404
QY      386 DGSFPLYSKLTVDKSRMGOQGVNFSCVMHEALHNHYTQKSLSLSPG 431
Db      405 DGSFPLYSKLTVDKSRMGOQGVNFSCVMHEALHNHYTQKSLSLSPG 450
```

RESULT 70
US-09-296-005-16

```
; Sequence 16, Application US/09296005
; Patent No. 6230957
; GENERAL INFORMATION:
; APPLICANT: Henry B. Lowman, Leonard G. Prestea, Paula M. Jardiou, John Lowe
; TITLE OF INVENTION: Improved Anti-IgE Antibodies and Method of Improving Polypeptides
; FILE REFERENCE: P1123C1T
; CURRENT APPLICATION NUMBER: US/09/296,005
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 08/887,352
; EARLIER FILING DATE: 1997-07-02
; NUMBER OF SEQ ID NOS: 26
; SEQ ID NO 16
; LENGTH: 451
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: Artificial
; LOCATION: 1-451
; OTHER INFORMATION: Heavy chain sequence derived from MAE11
US-09-296-005-16
```

```
Query Match      52.1%; Score 1257; DB 3; Length 451;
Best Local Similarity 58.4%; Pred. No. 5,5e-94;
Matches 272; Conservative 25; Mismatches 79; Indels 90; Gaps 12;

QY      30 LGKKGDTVELTCTAAG---KKSIOFHMKNNSQIKILNGSGFLTKGPKLN----- 77
Db      11 LVOPGSLRLSCAVALSGYSITSGYSNMWIRQAPGKLEWVASITTDSTYNPSVKGRIIT 70
QY      78 DRADSRSLMDQGNFPLIIKNIKIEDSDTYICEVEDQKEVQLVFGTLANSDTH---LL 134
Db      71 SDDDSKNTFYLGQNM-----SLRAEDTAVYYCARSGH-----YFG-----HMHFAY 110
QY      135 OGQSLFTLLESPGSSPSVQCRSPRGKNIQGS-----KTLSSVS----- 172
Db      111 WQGGTLVTVSSASTKGPVFPLAPSSKSTSGGTALGCLVKDYFPEPTVWSNMSGALTS 170
QY      173 ---QLELDDSG-----TWTCYVLONQKVEFKIDIVPCPAPKSC 210
Db      171 VHTFPAVLQSSGLYSLSSVTVPSSSLGTQYIICNV--NHKPSNTKVD---KQVEPKSC 224
QY      211 DKTHTC-----PELIGSPSVFLPPPKPDTLMISTRPEVTCVVDVSHEDPEVKFNWYVD 265
Db      225 DKTHTCPCPAPAEELIGSPSVFLPPPKPDTLMISTRPEVTCVVDVSHEDPEVKFNWYVD 284
QY      266 GVEVNAKTKPREEOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAK 325
Db      285 GVEVNAKTKPREEOYNSTYRVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAK 344
QY      326 GQPREQVYTLTPSRDELTKNQVSLTCLVKGYFSPDAIEMWESNGPENNYKTTTPVLDS 385
Db      345 GQPREQVYTLTPSRDELTKNQVSLTCLVKGYFSPDAIEMWESNGPENNYKTTTPVLDS 404
QY      386 DGSFPLYSKLTVDKSRMGOQGVNFSCVMHEALHNHYTQKSLSLSPG 431
Db      405 DGSFPLYSKLTVDKSRMGOQGVNFSCVMHEALHNHYTQKSLSLSPG 450
```

```
RESULT 71
US-09-920-171-14
; Sequence 14, Application US/09920171
; Patent No. 6682735
; GENERAL INFORMATION:
; APPLICANT: Lowman, Henry B.
; APPLICANT: Prestea, Leonard G.
; APPLICANT: Jardiou, Paula M.
; APPLICANT: Lowe, John
; TITLE OF INVENTION: Improved Anti-IgE Antibodies (as amended)
; FILE REFERENCE: P1123C2US
; CURRENT APPLICATION NUMBER: US/09/920,171
; EARLIER FILING DATE: 2001-08-01
; PRIOR APPLICATION NUMBER: US 08/887,352
; PRIOR FILING DATE: 1997-07-02
```


PRIOR APPLICATION NUMBER: US 09/296,005
PRIOR FILING DATE: 1999-04-21
NUMBER OF SEQ ID NOS: 44
SEQ ID NO 14
LENGTH: 451
TYPE: PRF
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Heavy chain sequence derived from MAE11
US-09-920-171-14

Query Match 52.1%; Score 1257; DB 4; Length 451;
Best Local Similarity 58.4%; Pred. No. 5,5e-94;
Matches 272; Conservative 25; Mismatches 79; Indels 90; Gaps 12;

QY 30 LKKGDTVELTCTASQ---KKSIOFHMKNSNOKILNGQSFLLTKGSPKLN----- 77
DB 11 LVQPGSGRLSCAVSGYTSYGSWMWIRQAPGKLEWVASITVDGSTNVPYKGRITTI 70
QY 78 DRADSRSLMDQGNFPLIKNLKIEDSDTYICEVEDQKEVQLLVFGLTANSDFH---LL 134
DB 71 SRDSDKNTFYLOMN-----SLRAEDTAVYYCARGSH-----YFG-----HMHFAV 110
QY 135 QGOSLTLLSPSPSSPVQCRSPRGKNIQGG-----KTLSSVS----- 172
DB 111 WGGGLTVTVSASATKGPVFLPAPLAPSSKSTGGTAAAGCLVADYFPEPVTVSNWGALTSG 170
QY 173 ---QLELDQSG-----TWCTVLOQKVEFKIDIVPCPAPEPKSC 210
DB 171 VHTPEPAVLQSSGLYSLSSVTVFPSSSLGTQYICNV--NHKPSNTKYD---KKEVEPKSC 224
QY 211 DKHTTC-----PELLGSPVFLFPPKPKDITLMSRTEBVTGVVVDVSHEDPEVKFNMYVD 265
DB 225 DKHTTCPPCPAPPELLGSPVFLFPPKPKDITLMSRTEBVTGVVVDVSHEDPEVKFNMYVD 284
QY 266 GVEVHNAKTKPREBOQYNSTYRVVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTISKAK 325
DB 285 GVEVHNAKTKPREBOQYNSTYRVVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTISKAK 344
QY 326 GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPVLD 385
DB 345 GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPVLD 404
QY 386 DGSFFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTQKSLSLSPG 431
DB 405 DGSFFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTQKSLSLSPG 450

RESULT 72

US-09-920-171-16
Sequence 16, Application US/09920171
Patent No. 6682735
GENERAL INFORMATION:
APPLICANT: Lowman, Henry B.
APPLICANT: Presta, Leonard G.
APPLICANT: Jarden, Paula M.
APPLICANT: Lowe, John
TITLE OF INVENTION: Improved Anti-IgE Antibodies (as amended)
FILE REFERENCE: P1123C2US
CURRENT APPLICATION NUMBER: US/09/920,171
CURRENT FILING DATE: 2001-08-01
PRIOR APPLICATION NUMBER: US 08/887,352
PRIOR FILING DATE: 1997-07-02
PRIOR APPLICATION NUMBER: US 09/296,005
PRIOR FILING DATE: 1999-04-21
NUMBER OF SEQ ID NOS: 44
SEQ ID NO 16
LENGTH: 451
TYPE: PRF
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Heavy chain sequence derived from MAE11
US-09-920-171-16

Query Match 52.1%; Score 1257; DB 4; Length 451;
Best Local Similarity 58.4%; Pred. No. 5,5e-94;
Matches 272; Conservative 25; Mismatches 79; Indels 90; Gaps 12;

QY 30 LKKGDTVELTCTASQ---KKSIOFHMKNSNOKILNGQSFLLTKGSPKLN----- 77
DB 11 LVQPGSGRLSCAVSGYTSYGSWMWIRQAPGKLEWVASITVDGSTNVPYKGRITTI 70
QY 78 DRADSRSLMDQGNFPLIKNLKIEDSDTYICEVEDQKEVQLLVFGLTANSDFH---LL 134
DB 71 SRDSDKNTFYLOMN-----SLRAEDTAVYYCARGSH-----YFG-----HMHFAV 110
QY 135 QGOSLTLLSPSPSSPVQCRSPRGKNIQGG-----KTLSSVS----- 172
DB 111 WGGGLTVTVSASATKGPVFLPAPLAPSSKSTGGTAAAGCLVADYFPEPVTVSNWGALTSG 170
QY 173 ---QLELDQSG-----TWCTVLOQKVEFKIDIVPCPAPEPKSC 210
DB 171 VHTPEPAVLQSSGLYSLSSVTVFPSSSLGTQYICNV--NHKPSNTKYD---KKEVEPKSC 224
QY 211 DKHTTC-----PELLGSPVFLFPPKPKDITLMSRTEBVTGVVVDVSHEDPEVKFNMYVD 265
DB 225 DKHTTCPPCPAPPELLGSPVFLFPPKPKDITLMSRTEBVTGVVVDVSHEDPEVKFNMYVD 284
QY 266 GVEVHNAKTKPREBOQYNSTYRVVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTISKAK 325
DB 285 GVEVHNAKTKPREBOQYNSTYRVVSVLTVLHODMLNGEKYCKVSNKALPAPIEKTISKAK 344
QY 326 GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPVLD 385
DB 345 GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQGPENNYKTTTPVLD 404
QY 386 DGSFFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTQKSLSLSPG 431
DB 405 DGSFFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTQKSLSLSPG 450

RESULT 73

US-08-793-450-8
Sequence 8, Application US/08793450
Patent No. 6312690
GENERAL INFORMATION:
APPLICANT: EDELMAN, LENA
APPLICANT: MARGARITTE, CHRISTEL
APPLICANT: KACZOREK, MICHEL
APPLICANT: CHABIRI, HASSAN
TITLE OF INVENTION: MONOCLONAL RECOMBINANT ANTI-RHESUS D
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
STREET: 1755 SOUTH JEFFERSON DAVIS HIGHWAY, SUITE 400
CITY: ARLINGTON
STATE: VA
COUNTRY: USA
ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/793,450
FILING DATE: 03-MAR-1997
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: FR 94/10566
FILING DATE: 02-SEP-1994
ATTORNEY/AGENT INFORMATION:
NAME: OBLON, NORMAN F.
REGISTRATION NUMBER: 24,618

```
REFERENCE/DOCKET NUMBER: 660-118-0 PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-413-3000
TELEFAX: 703-413-2220
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 472 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-793-450-8

Query Match      52.1%; Score 1257; DB 4; Length 472;
Best Local Similarity 59.0%; Pred. No. 5.9e-94;
Matches 268; Conservative 25; Mismatches 93; Indels 68; Gaps 9;

QY 32 KGGDIYELTCTASQKKSIOFHMKNSNQIKLGNQ--GSFLTKGPSKLNDRADSRSL---86
DB 32 KPSETLSLCTCTVGGSPSGYWMINQPKGLEWIGEINHSGSTVYNPSLKSRTVITSVD 91
QY 87 WDQGNPLIIKLIKIEDSDTYICEVEDQKEEVQLVFGLTANSDTHLLOGSLITLLESP 146
DB 92 TSKNQPSLKLNSYTAADTAVYCARAPE-----YKMKYHGMDFDPMGQGTIVVSSA 143
QY 147 PGSSPVCGRSPRGKNIQGG-----KTLVS-----QLELQDSG 180
DB 144 STKGSPVFPPLAPSSKSTSGGTALGCLVKDYRPEPVTVSWSGALTSVHTPPAVLQSSG 203
QY 181 -----TWCTVLQNOKKVEFKIDIVPCAPAPKSCDKTHC-----P 217
DB 204 LVSLSSVTVTPSSSLGTOFYICNV--NKKPSNTKVD---KKAEPKSCDKTQCPCPCAP 257
QY 218 ELLGGSVFLFPKPKDPTLMISTREVTQVVDVSHEDPEVKKNMYYDGVENAKTKR 277
DB 258 ELLGGSVFLFPKPKDPTLMISTREVTQVVDVSHEDPEVKKNMYYDGVENAKTKR 317
QY 278 EEOYNSTYRVSILTVLHODMLNGKEYCKVSNKALPAPLEKTISSAKGQPREPOVYTL 337
DB 318 EEOYNSTYRVSILTVLHODMLNGKEYCKVSNKALPAPLEKTISSAKGQPREPOVYTL 377
QY 338 PSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQCPENNYKTPPVLDSDGSFPLYSLTV 397
DB 378 PSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQCPENNYKTPPVLDSDGSFPLYSLTV 437
QY 398 DKSRMOQGNVFCSSVHGEALHNHYTQKSLSLSPG 431
DB 438 DKSRMOQGNVFCSSVHGEALHNHYTQKSLSLSPG 471

RESULT 74
US-09-301-593-43
Sequence 43, Application US/09301593A
Patent No. 645677
GENERAL INFORMATION:
APPLICANT: Park, John E.
APPLICANT: Gartin-Cheea, Pilar
APPLICANT: Bamberger, Uwe
APPLICANT: Legier, Olivier
APPLICANT: Saldanha, Jose W.
APPLICANT: Retzig, Wolfgang J.
TITLE OF INVENTION: PAP-specific Antibody with Improved Productibility
FILE REFERENCE: 0652.1890001
CURRENT APPLICATION NUMBER: US/09/301,593A
EARLIER FILING DATE: 1999-04-29
EARLIER APPLICATION NUMBER: EP 98107925.4
EARLIER FILING DATE: 1998-04-30
EARLIER APPLICATION NUMBER: US 60/086,049
EARLIER FILING DATE: 1998-05-18
NUMBER OF SEQ ID NOS: 108
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 43
LENGTH: 472
TYPE: PRT
```

```
ORGANISM: Homo sapiens
US-09-301-593-43

Query Match      52.1%; Score 1256.5; DB 4; Length 472;
Best Local Similarity 56.9%; Pred. No. 6.5e-94;
Matches 273; Conservative 38; Mismatches 86; Indels 83; Gaps 15;

QY 16 LALLPAAIQGNKV-----LGKKSDYELTCTASQKKSIOF--HKN---SNQIKLGNQ 65
DB 11 LAVAPGASQVQLVSGAEVKRPGASVKSCTKSRTFTYTHHWRAQGRLEWIG-- 68
QY 66 GSFLTKGPSKLNDRADSRSLW---DQGNFPLIIKLIKIEDSDTYICEVEDQKEEVQLLV 122
DB 69 GINPNNGIPNNYQKKGKRAITLVGKSASAYWELSLSEEDTAVYTC-----ARRRA 121
QY 123 FGLTANSDTHLIQ--GQSITLTLLESPPGSSPVCGRSPRGKNIQGG-----K 167
DB 122 YGY---DEGHADWYQGGTLVTVSSST--KGPSVFPPLAPSSKSTSGGTALGCLVKDPPE 177
QY 168 TLSVS-----QLELQDSG-----TWCTVLQNOKKVEPK 196
DB 178 PVTWSNSGALTSVHTPPAVLQSSGLVSLSSVTVTPSSSLGTOFYICNV--NKKPSNTK 235
QY 197 IDIVPCAPAPKSCDKTHC-----PELLGSPVFLFPKPKDPTLMISTREVTQVVDV 251
DB 236 VD---KKAEPKSCDKTHCPCPCAPAPPELLGSPVFLFPKPKDPTLMISTREVTQVVDV 291
QY 252 SHEDPEVKKNMYYDGVENAKTKPREEQYNSTYRVSILTVLHODMLNGKEYCKVSNK 311
DB 292 SHEDPEVKKNMYYDGVENAKTKPREEQYNSTYRVSILTVLHODMLNGKEYCKVSNK 351
QY 312 ALPAPLEKTISSAKGQPREPOVYTLPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQ 371
DB 352 ALPAPLEKTISSAKGQPREPOVYTLPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNQ 411
QY 372 PENNYKTPPVLDSDGSFPLYSLTVDKSRMOQGNVFCSSVHGEALHNHYTQKSLSLSPG 431
DB 412 PENNYKTPPVLDSDGSFPLYSLTVDKSRMOQGNVFCSSVHGEALHNHYTQKSLSLSPG 471

RESULT 75
US-09-289-942A-7
Sequence 7, Application US/09289942A
Patent No. 6482928
GENERAL INFORMATION:
APPLICANT: Pal, Emil F.
APPLICANT: Klein, Michel H.
APPLICANT: Chong, Pele
APPLICANT: Pedyczak, Arthur
TITLE OF INVENTION: Fab'-EPTOPE COMPLEX FROM THE HIV-1 CROSS-NEUTRALIZING
FILE REFERENCE: MONOCLONAL ANTIBODY 2P5
CURRENT APPLICATION NUMBER: US/09/289,942A
CURRENT FILING DATE: 1999-04-13
NUMBER OF SEQ ID NOS: 9
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 7
LENGTH: 462
TYPE: PRT
ORGANISM: Human immunodeficiency virus type 1
US-09-289-942A-7

Query Match      52.0%; Score 1255; DB 4; Length 462;
Best Local Similarity 66.2%; Pred. No. 8.3e-94;
Matches 258; Conservative 18; Mismatches 52; Indels 62; Gaps 9;

QY 94 LIIKLIKIEDSDTYICEVEDQKEEVQLVFGLTANSDTHLIQ--GQSITLTLLESPPGSS 150
DB 82 LVTWTVSPVDIATYTC---AHRGPTTLFGVPIARGVAMDWGQGTIVYTISSASTKG 137
QY 151 PSVQGRSPRGKNIQGG-----KTLVS-----QLELQDSG----- 180
DB 138 PSVFPPLAPSSKSTSGGTALGCLVKDYRPEPVTVSWSGALTSVHTPPAVLQSSGLVSL 197
```

```
QY 181 -----TWCTVLONOKKVEFKIDIVPCPAPEPKSCDKTHTC-----PELLG 221
DB 198 SSVVTVPPSSSLGTOTYICNV--NHKPSNTKYD-----KKVEPKSCDKTHTCPCPAPPELLG 251
QY 222 GPSVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNMYDGVFNNAKTKRREOY 281
DB 252 GPSVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNMYDGVFNNAKTKRREOY 311
QY 282 NSTYVAVSLTVLHODMLNGKEYKCKVSNKALPAPIEKTISKAKQPREPOVYTLPPSRD 341
DB 312 NSTYVAVSLTVLHODMLNGKEYKCKVSNKALPAPIEKTISKAKQPREPOVYTLPPSRD 371
QY 342 ELTKNOVSLTCLVKGFPSPDIAMVESNNGQPENNYKTPPVLDSDGSPFLYSKLTVDKSR 401
DB 372 ELTKNOVSLTCLVKGFPSPDIAMVESNNGQPENNYKTPPVLDSDGSPFLYSKLTVDKSR 431
QY 402 WOOGNVFCSCVMHEALHNHYTOKSLSLSPG 431
DB 432 WOOGNVFCSCVMHEALHNHYTOKSLSLSPG 461
```

RESULT 76

```
US-09-679-397-2
; Sequence 2, Application US/09679397
; Patent No. 6339142
; GENERAL INFORMATION:
; APPLICANT: BASEY, CAROL D.
; TITLE OF INVENTION: PROTEIN PURIFICATION
; FILE REFERENCE: P1241R1D2
; CURRENT APPLICATION NUMBER: US/09/679,397
; PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: US 60/084,459
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: US 09/304,465
; PRIOR FILING DATE: 1999-05-03
; NUMBER OF SEQ ID NOS: 2
; SEQ ID NO 2
; LENGTH: 449
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Sequence is synthesized.
US-09-679-397-2
```

Query Match 52.0%; Score 1254.5; DB 4; Length 449;

Best Local Similarity 57.8%; Pred. No. 8.8e-94; Matches 268; Conservative 30; Mismatches 79; Indels 87; Gaps 12;

```
QY 30 LGKKGDVTELTCTAS--QKSIQFHWKNSNQIKILGNQ-----SFLTKGSKLNDPAD 81
DB 11 LVQPGSLRLSCAASGNRIKDTYIHW-----VRQAPKGLEWVARIYPTNGYTRYADSVK 65
QY 82 SRSRL--WDGNFLLIKNLKIEDSDTYICEVEDQKEEVQLVFGLTANSDTLLQ--G 136
DB 66 GRFTISADTSKNTAYLQKNSLRAEDTAVYVC-----SRMGDGFYAMDYWG 111
QY 137 QSLTLTLESPGSSPSVQCSPPRGNIQG-----KTLVS----- 172
DB 112 QGLTVTVSSASTKGPVFPPLAPSSKSTSGTALGCLVKDYFPEPTVYSWNSGALTSGVH 171
QY 173 --QLELQDSG-----TWCTVLONOKKVEFKIDIVPCPAPEPKSCDK 212
DB 172 TTPAVLOSSGLYSLSSVTVTPSSSLGTOTYICNV--NHKPSNTKYD-----KKVEPKSCDK 225
QY 213 THTC-----PELLGSPVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNMYDGV 267
DB 226 THTCPCPAPPELLGSPVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNMYDGV 285
QY 268 EVHNAKTKRREOYNSTYRVVSVLTVLHODMLNGKEYKCKVSNKALPAPIEKTISKAKQ 327
DB 286 EVHNAKTKRREOYNSTYRVVSVLTVLHODMLNGKEYKCKVSNKALPAPIEKTISKAKQ 345
```

```
QY 328 PREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAMVESNNGQPENNYKTPPVLDSDG 387
DB 346 PREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAMVESNNGQPENNYKTPPVLDSDG 405
QY 388 SFPLYSKLTVDKSRWOOGNVFCSCVMHEALHNHYTOKSLSLSPG 431
DB 406 SFPLYSKLTVDKSRWOOGNVFCSCVMHEALHNHYTOKSLSLSPG 449
```

RESULT 77

```
US-09-680-148-2
; Sequence 2, Application US/09680148
; Patent No. 6417335
; GENERAL INFORMATION:
; APPLICANT: BASEY, CAROL D.
; TITLE OF INVENTION: PROTEIN PURIFICATION
; FILE REFERENCE: P1241R1D1
; CURRENT APPLICATION NUMBER: US/09/680,148
; PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: US 60/084,459
; PRIOR FILING DATE: 1998-05-06
; PRIOR APPLICATION NUMBER: US 09/304,465
; PRIOR FILING DATE: 1999-05-03
; NUMBER OF SEQ ID NOS: 2
; SEQ ID NO 2
; LENGTH: 449
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Sequence is synthesized.
US-09-680-148-2
```

Query Match 52.0%; Score 1254.5; DB 4; Length 449;

Best Local Similarity 57.8%; Pred. No. 8.8e-94; Matches 268; Conservative 30; Mismatches 79; Indels 87; Gaps 12;

```
QY 30 LGKKGDVTELTCTAS--QKSIQFHWKNSNQIKILGNQ-----SFLTKGSKLNDPAD 81
DB 11 LVQPGSLRLSCAASGNRIKDTYIHW-----VRQAPKGLEWVARIYPTNGYTRYADSVK 65
QY 82 SRSRL--WDGNFLLIKNLKIEDSDTYICEVEDQKEEVQLVFGLTANSDTLLQ--G 136
DB 66 GRFTISADTSKNTAYLQKNSLRAEDTAVYVC-----SRMGDGFYAMDYWG 111
QY 137 QSLTLTLESPGSSPSVQCSPPRGNIQG-----KTLVS----- 172
DB 112 QGLTVTVSSASTKGPVFPPLAPSSKSTSGTALGCLVKDYFPEPTVYSWNSGALTSGVH 171
QY 173 --QLELQDSG-----TWCTVLONOKKVEFKIDIVPCPAPEPKSCDK 212
DB 172 TTPAVLOSSGLYSLSSVTVTPSSSLGTOTYICNV--NHKPSNTKYD-----KKVEPKSCDK 225
QY 213 THTC-----PELLGSPVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNMYDGV 267
DB 226 THTCPCPAPPELLGSPVFLPPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNMYDGV 285
QY 268 EVHNAKTKRREOYNSTYRVVSVLTVLHODMLNGKEYKCKVSNKALPAPIEKTISKAKQ 327
DB 286 EVHNAKTKRREOYNSTYRVVSVLTVLHODMLNGKEYKCKVSNKALPAPIEKTISKAKQ 345
QY 328 PREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAMVESNNGQPENNYKTPPVLDSDG 387
DB 346 PREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIAMVESNNGQPENNYKTPPVLDSDG 405
QY 388 SFPLYSKLTVDKSRWOOGNVFCSCVMHEALHNHYTOKSLSLSPG 431
DB 406 SFPLYSKLTVDKSRWOOGNVFCSCVMHEALHNHYTOKSLSLSPG 449
```

RESULT 78

```
US-09-304-465A-2
; Sequence 2, Application US/09304465A
; Patent No. 6489447
; GENERAL INFORMATION:
; APPLICANT: BASEY, CAROL D.
; APPLICANT: BLANK, GREG S.
; TITLE OF INVENTION: PROTEIN PURIFICATION
; FILE REFERENCE: P1241R1
; CURRENT APPLICATION NUMBER: US/09/304,465A
; PRIOR FILING DATE: 1999-05-03
; PRIOR FILING DATE: 1998-05-06
; NUMBER OF SEQ ID NOS: 2
; SEQ ID NO 2
; LENGTH: 449
; TYPE: PRT
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Sequence is synthesized.
; Patent No. 6489447
US-09-304-465A-2

Query Match          52.0%; Score 1254.5; DB 4; Length 449;
Best Local Similarity 57.8%; Pred. No. 8.8e-94;
Matches 268; Conservative 30; Mismatches 79; Indels 87; Gaps 12;

QY 30 LGKGDVELTCTAS--QKSIQPHWKNNOIKILNQG-----SFLTKGSPKLNDRAD 81
DB 11 LVPGGSLRLSCAAGENIDTYIHW---VRQAPGKLEWVARLYPTGTGYRADSVK 65
QY 82 SRSL---WDQGFPLIKNLKIEDSDTYICEVEDQKEVQLVFGLTANSDFHLQ--G 136
DB 66 GRITISADISKNTAVYQMSLRAEDTAVYIC-----SRMGDGGFYAMDYMG 111
QY 137 QSLTLFLESPGSSPSVQCSPPGKNIQGG-----KTLVS----- 172
DB 112 QGLTVVSSASTKGPVFLAPPSKSTSGGTALGCLVKDYFPEPTVSNNGALTSGVH 171
QY 173 --QLEIQDSG-----TWCTVLOQKKEVEKIDIVPCPAPBPSCDK 212
DB 172 TFPAYLQSSGLYSLSVTVPSSSLGTQYICNV--NHKPSNTKV-----KKEVPKSCDK 225
QY 213 THTC-----PELLGSPSVFLFPKPKDITLMSRTPEVTCVVDVSHEDPEVKFNWYVDG 267
DB 226 THTCPCPAPBELGSGSVFLFPKPKDITLMSRTPEVTCVVDVSHEDPEVKFNWYVDG 285
QY 268 EVHNAKTPREQYNSTYRVSVYLVTLVHQMNGKEYCKCVSNKALPAPIEKTISKAKG 327
DB 286 EVHNAKTPREQYNSTYRVSVYLVTLVHQMNGKEYCKCVSNKALPAPIEKTISKAKG 345
QY 328 PREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIQVWESNQPENNTKTPPVLDSDG 387
DB 346 PREPOVYTLPPSRDELTKNOVSLTCLVKGFPSPDIQVWESNQPENNTKTPPVLDSDG 405
QY 388 SFLYSKLTVDKSRMOQGNVFSQVMHEALHNHYTQKSLSLSPG 431
DB 406 SFLYSKLTVDKSRMOQGNVFSQVMHEALHNHYTQKSLSLSPG 449

RESULT 79
US-08-487-550-4
; Sequence 4, Application US/08487550
; Patent No. 6113898
; GENERAL INFORMATION:
; APPLICANT: Anderson, Darrell R.
; TITLE OF INVENTION: "MONKEY MONOCLONAL ANTIBODIES SPECIFIC
; TITLE OF INVENTION: TO HUMAN B7.1 AND/OR B7.2 PRIMATIZED FORMS THEREOF.
; TITLE OF INVENTION: PHARMACEUTICAL COMPOSITIONS CONTAINING, AND USE THEREOF AS
; TITLE OF INVENTION: IMMUNOSUPPRESSANTS"
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS
; STREET: 699 Prince Street
```

```
CITY: Alexandria
STATE: VA
COUNTRY: USA
ZIP: 22314
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/487,550
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Teakin, Robin L.
REGISTRATION NUMBER: 35,030
REFERENCE/DOCKET NUMBER: 012712-131
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-836-6620
TELEFAX: 703-836-2021
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 476 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-487-550-4

Query Match          51.7%; Score 1248; DB 3; Length 476;
Best Local Similarity 59.2%; Pred. No. 3.2e-93;
Matches 270; Conservative 26; Mismatches 86; Indels 74; Gaps 13;

QY 35 DVELTCTASQCK-SIQFHWKNSNOI-----KILNQGSFLTKGSPKLNDRADSR 84
DB 35 ETLISRTCVSGSGISGYWTWIRQTPGRGLEIGHIYGN-GATTNYPNS-LKSRVLTISK 92
QY 85 SLWDQGNPFLIKNLKIEDSDTYICEVEDQKEVQLVFGLTANSDFHLQGSLLTLLE 144
DB 93 DT-SKQGFPLNLNSYTDADTAVYIC-ARGPRPDCTTTCYGVWD-----VMGPGDLVYS 145
QY 145 SPPGSSPSVQCSPPGKNIQGG-----KTLVS-----QLEIQD 178
DB 146 SASTGSPSVFLAPPSKSTSGGTALGCLVKDYFPEPTVSNNGALTSGVHTFPAYLQS 205
QY 179 SG-----TWCTVLOQKKEVEKIDIVPCPAPBPSCDKTHTC---- 216
DB 206 SGLYSLSVTVPSSSLGTQYICNV--NHKPSNTKV-----KKAEPKSCDKTHTCPCP 259
QY 217 -PELLGSPSVFLFPKPKDITLMSRTPEVTCVVDVSHEDPEVKFNWYVDGEVHNAKTK 275
DB 260 APELLGSPSVFLFPKPKDITLMSRTPEVTCVVDVSHEDPEVKFNWYVDGEVHNAKTK 319
QY 276 PREQYNSTYRVSVYLVTLVHQMNGKEYCKCVSNKALPAPIEKTISKAKGPREPOVYT 335
DB 320 PREQYNSTYRVSVYLVTLVHQMNGKEYCKCVSNKALPAPIEKTISKAKGPREPOVYT 379
QY 336 LPPSRDELTKNOVSLTCLVKGFPSPDIQVWESNQPENNTKTPPVLDSDGSFLYSKL 395
DB 380 LPPSRDELTKNOVSLTCLVKGFPSPDIQVWESNQPENNTKTPPVLDSDGSFLYSKL 439
QY 396 TVDKSRMOQGNVFSQVMHEALHNHYTQKSLSLSPG 431
DB 440 TVDKSRMOQGNVFSQVMHEALHNHYTQKSLSLSPG 475

RESULT 80
US-09-526-098-4
; Sequence 4, Application US/09526098
; Patent No. 6492134
; GENERAL INFORMATION:
; APPLICANT: Anderson, Darrell R.
; TITLE OF INVENTION: "MONKEY MONOCLONAL ANTIBODIES SPECIFIC
; TITLE OF INVENTION: TO HUMAN B7.1 AND/OR B7.2 PRIMATIZED FORMS THEREOF,
```

```

DB          440 TVDKSRWQGGNVFSCSWHEALHNHYTKSLSLSPG 475

RESULT 81
US-09-313-942-9
; Sequence 9, Application US/09313942
; Patent No. 6472179
; GENERAL INFORMATION:
; APPLICANT: REGENERON PHARMACEUTICALS, INC.
; TITLE OF INVENTION: RECEPTOR BASED ANTAGONISTS, AND METHODS OF MAKING
; TITLE OF INVENTION: AND USING
; FILE REFERENCE: REG 203-A
; CURRENT APPLICATION NUMBER: US/09/313,942
; CURRENT FILING DATE: 1999-05-19
; PRIOR APPLICATION NUMBER: 09/313,942
; PRIOR FILING DATE: 1999-05-19
; PRIOR APPLICATION NUMBER: 60/101,858
; PRIOR FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 9
; LENGTH: 951
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-313-942-9

```

[illegible]

1 CORRESPONDENCE ADDRESS:
2 ADDRESSEE: Clark & Elbing LLP
3 STREET: 176 Federal Street
4 CITY: Boston
5 STATE: MA
6 COUNTRY: USA
7 ZIP: 02110
8 COMPUTER READABLE FORM:
9 MEDIUM TYPE: Diskette
10 COMPUTER: IBM compatible
11 OPERATING SYSTEM: DOS
12 SOFTWARE: FASTSEQ for Windows Version 2.0
13 CURRENT APPLICATION DATA:
14 APPLICATION NUMBER: US/08/472,888A
15 FILING DATE: 07-JUN-1995
16 CLASSIFICATION: 424
17 PRIORITY APPLICATION DATA:
18 APPLICATION NUMBER: 07/618,314
19 FILING DATE: 23-NOV-1990
20 ATTORNEY/AGENT INFORMATION:
21 NAME: Elbing, Karen L
22 REGISTRATION NUMBER: 35,238
23 REFERENCE/DOCKET NUMBER: 00786/258001
24 TELECOMMUNICATION INFORMATION:
25 TELEPHONE: 617-428-0200
26 TELEFAX: 617-428-7045
27 TELEX:
28 INFORMATION FOR SEQ ID NO: 7:
29 SEQUENCE CHARACTERISTICS:
30 LENGTH: 442 amino acids
31 TYPE: amino acid
32 STRANDEDNESS: unknown
33 TOPOLOGY: linear
34 MOLECULE TYPE: protein
35 OS-08-472-888A-7

Query Match	51.3%	Score 1238	DB 4	Length 442
Best Local Similarity	74.1%	Pred. No. 1.9e-92		
Matches 246	Conservative 12	Mismatches 26	Indels 48	Gaps 5

Qy	136	GGGUTLLTLESPSSVQCSPRGKNIQGG-----KTLSSV-----	1172
Db	122	GGCTLTVAASATKGGSVFPFLAPSSKSTGGTAAAGCLVKDYFPEPVTYVSNMGSALNSGV	181
Qy	173	---QLBLDQSGTWCTVL-----QNKQKVEFKIDIVPCGAPKPSCDKTHTC-----PEL	219
Db	182	HTPEPAVLQSSGLSLSSVTVTPSSSPDKV-----EPKSCDTHTCPCPCPAPBL	229
Qy	220	LGGSVFLFPFKKOTLMI SRPELV CVVVDVSHDEPEVKFMVYDGVENNAATKPRE	279
Db	230	LGGSVFLFPFKKOTLMI SRPELV CVVVDVSHDEPEVKFMVYDGVENNAATKPRE	288
Qy	280	QYNSTRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS	339
Db	290	QYNSTRVVSVLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS	349
Qy	340	RDELTKQVSLTCLVGFYPSDIAVMEBSNGQPKNNYKTPTPVLDSDGFLYSLKLVYDK	399
Db	350	RDELTKQVSLTCLVGFYPSDIAVMEBSNGQPKNNYKTPTPVLDSDGFLYSLKLVYDK	409
Qy	400	SRMQGNSVSCSVMEALHNHYTQKSLSLSPG	431
	410	SRMQGNSVSCSVMEALHNHYTQKSLSLSPG	441

```

RESULT 83
PCT-US96-10043-9
Sequence 9, Application PC/RUS9610043
GENERAL INFORMATION:
APPLICANT: The General Hospital Corporation
TITLE OF INVENTION: P-SELECTIN LIGANDS AND RELATED MOLECULES
TITLE OF INVENTION: AND METHODS
NUMBER OF SEQUENCES: 14

```

CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: USA
ZIP: 02210-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.10
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/10043
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/000,213
FILING DATE: 14-JUN-1995
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Lech, Karen F.
REGISTRATION NUMBER:
REFERENCE/DOCKET NUMBER: 00786/284001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-5070
TELEFAX: 617/542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 442 amino acids
TYPE: amino acid
STRANDEDNESS: not relevant
TOPOLOGY: linear
MOLECULE TYPE: protein
PCT-US96-10043-9

Query Match	51.3%	Score 1238	DB 5	Length 442
Best Local Similarity	74.1%	Pred. No. 1.9e92		
Matches 246	Conservative 12	Mismatches 26	Indels 48	Gaps 5

[illegible]

RESULT 84
US-09-746-359A-54
; Sequence 54, Application US/09746359A
; Patent No. 6610286
; GENERAL INFORMATION:
; APPLICANT: Thompson, Penny
; APPLICANT: Foster, Donald C.

```

      1  APPLICANT: Xu, Wenfeng
      2  APPLICANT: Madden, Karen L.
      3  APPLICANT: Kelly, James D.
      4  APPLICANT: Sprecher, Cindy A.
      5  APPLICANT: Blumberg, Hal
      6  APPLICANT: Eagan, Maribeth A.
      7  APPLICANT: Jasper, Stephen R.
      8  APPLICANT: Chandrasekhar, Yasmin A.
      9  APPLICANT: NO. 6610286ak, Julia E.
     10  TITLE OF INVENTION: Method for Treating Inflammation
     11  FILE REFERENCE: 99-108
     12  CURRENT APPLICATION NUMBER: US/09/746,359A
     13  CURRENT FILING DATE: 2001-05-21
     14  PRIOR APPLICATION NUMBER: 60/171,969
     15  PRIOR FILING DATE: 1999-12-23
     16  PRIOR APPLICATION NUMBER: 60/213,341
     17  PRIOR FILING DATE: 2000-06-22
     18  NUMBER OF SEQ ID NOS: 72
     19  SOFTWARE: FASTSEQ for Windows Version 3.0
     20  SEQ ID NO 54
     21  LENGTH: 547
     22  TYPE: PRT
     23  ORGANISM: Homo sapiens
     24  US-09-746-359A-54

Query Match      51.3%; Score 1238; DB 4; Length 547;
Beet Local Similarity 58.8%; Pred. No. 2,5e-92;
Matches 276; Conservative 23; Mismatches 72; Indels 98; Gaps 15

      1  27  KVLGKGGDYTELTCTASOKSIOFMWK-NSNQIKILGNQ-GSFLTKGPKSKINDRBSRR 84
      2  Db  112  EVALTDEKSKISVYLTAPEK-----WKRPEDLTVSMQQTISNLKTVSVLNTSN--- 162
      3  Qy  85  SLWDO-GNFPILIKMLKIEDSDIYICEVD-----QKEVQLLVFGLTANSDTHL 133
      4  Db  163  RTWSQCVNHTLVLTWL--EPWTLYCVHVESFVPGPPRAQPSKQC----- 207
      5  Qy  134  LOGOSLTITLSPSS--PSYQCSPPKNIQGG-----KTLSSV----- 172
      6  Db  208  ---ARTLKDDSSSEASTGSPVFPLAFSKSTSGGTAALGCLVKDYFEPPTVSNVNSGAL 263
      7  Qy  173  -----QLEKDDSG-----TWTCVTLNQKVFETIDVPCPAPER 207
      8  Db  264  TSGVHTPAVVLQSSGLYSLSSVVTVPSSSLGTYITCNV--NHKFSNTKVD---KRYEP 317
      9  Qy  208  KSCDKTHTC-----PELLGGSVFLPPPKKDTLMI SRPEVTCVAVDVSHEDPEVKFNW 262
     10  Db  318  KSCDKTHTCPCPAPPELLGGSVFLPPPKKDTLMI SRPEVTCVAVDVSHEDPEVKFNW 377
     11  Qy  263  YVDGVEVNAKTPREEQYNSTYRVASVLTVLHQWMLNGKEYCKKCVSNKALPAPIEKTIS 322
     12  Db  378  YVDGVEVNAKTPREEQYNSTYRVASVLTVLHQWMLNGKEYCKKCVSNKALPAPIEKTIS 437
     13  Qy  323  KAKGPRRPOVYTLTPRSDELTKQNVSLTCLVKGYPSPDIAYEWESNQGPPENNYKTTTPV 382
     14  Db  438  KAKGPRRPOVYTLTPRSDELTKQNVSLTCLVKGYPSPDIAYEWESNQGPPENNYKTTTPV 497
     15  Qy  383  LDSGDSFPLYSKLTVDKSRWQOGNFSGCVMEALAHNYTKSLSPG 431
     16  Db  498  LDSGDSFPLYSKLTVDKSRWQOGNFSGCVMEALAHNYTKSLSPG 546

RESULT 85
US-09-746-359A-53
Sequence 53, Application US/09746359A
Patent No. 6610286
GENERAL INFORMATION:
APPLICANT: Thompson, Penny
APPLICANT: Foster, Donald C.
APPLICANT: Xu, Wenfeng
APPLICANT: Madden, Karen L.
APPLICANT: Kelly, James D.
APPLICANT: Sprecher, Cindy A.

```

[illegible]

```

;
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/236,311
; FILING DATE: 02-MAY-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/936190
; FILING DATE: 26-AUG-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/842777
; FILING DATE: 18-FEB-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/250785
; FILING DATE: 28-SEP-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/104329
; FILING DATE: 02-OCT-1987
; ATTORNEY/AGENT INFORMATION:
; NAME: Hasek, Janet E.
; REGISTRATION NUMBER: 28,616
; REFERENCE/DOCKET NUMBER: 444P1C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-1896
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 371 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
;
US-08-236-311-7

Query Match      51.2%; Score 1236.5; DB 1; Length 371;
Best Local Similarity 72.2%; Pred. No. 1,9e-92;
Matches 249; Conservative 9; Mismatches 32; Indels 55; Gaps 6;

QY 136 GQSLTLTLESPGSSPVOCRSRPGKNIQGG-----KTLVS----- 172
| : : : : : : : : : : : : : : : : : : : : : : : :
DB 32 GIGTLVTVSASTKPSVFLPAPLAPSSKTSGGTALACLVKDYFPPEVTVSNMGSALTSGV 91
| : : : : : : : : : : : : : : : : : : : : : : : :
QY 173 ---QLELDQSG-----TWTCVTVLQNKVKEFKIDIVPCAPAPKSCD 211
| : : : : : : : : : : : : : : : : : : : : : : : :
DB 92 HTFPAVLQSSGLYSLSSVTVTPSSSLGTQYICNV--NHKPSNTKVD---KVEPKSCD 145
| : : : : : : : : : : : : : : : : : : : : : : : :
QY 212 KTHTC-----PELLGSPVFLPFPKPKDTLMSRTPEVTCVVVDVSHEDPEVKFMWYDVG 266
| : : : : : : : : : : : : : : : : : : : : : : : :
DB 146 KTHTCPCAPAPPELLGSPVFLPFPKPKDTLMSRTPEVTCVVVDVSHEDPEVKFMWYDVG 205
| : : : : : : : : : : : : : : : : : : : : : : : :
QY 267 VEVHNAKTKPREEQYNSTRVYVSLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKG 326
| : : : : : : : : : : : : : : : : : : : : : : : :
DB 206 VEVHNAKTKPREEQYNSTRVYVSLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKG 265
| : : : : : : : : : : : : : : : : : : : : : : : :
QY 327 QPREPQVYTLPPSRDELTKNQVSLTCLVKGYFSPSDIAVEMESNGQPENNYKTTTPVLDSD 386
| : : : : : : : : : : : : : : : : : : : : : : : :
DB 266 QPREPQVYTLPPSRDELTKNQVSLTCLVKGYFSPSDIAVEMESNGQPENNYKTTTPVLDSD 325
| : : : : : : : : : : : : : : : : : : : : : : : :
QY 387 GSFFLYSKLTVDKSRMVGQSNVFSCSYMHEALHNHTQKSLSPG 431
| : : : : : : : : : : : : : : : : : : : : : : : :
DB 326 GSFFLYSKLTVDKSRMVGQSNVFSCSYMHEALHNHTQKSLSPG 370
| : : : : : : : : : : : : : : : : : : : : : : : :

RESULT 87
US-08-457-918-7
; Sequence 7, Application US/08457918
; Patent No. 6117655
; GENERAL INFORMATION:
; APPLICANT: Capon, Daniel J.
; APPLICANT: Gregory, Timothy J.
```

```

;
; TITLE OF INVENTION: Adhesion Variants
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
;
ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/457,918
; FILING DATE: 1-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/236311
; FILING DATE: 02-MAY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/936190
; FILING DATE: 26-AUG-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/842777
; FILING DATE: 18-FEB-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/250785
; FILING DATE: 28-SEP-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/104329
; FILING DATE: 02-OCT-1987
; ATTORNEY/AGENT INFORMATION:
; NAME: Kubinec, Jeffrey S.
; REGISTRATION NUMBER: 36,575
; REFERENCE/DOCKET NUMBER: P0444P1C3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-8228
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 371 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
;
US-08-457-918-7

Query Match      51.2%; Score 1236.5; DB 3; Length 371;
Best Local Similarity 72.2%; Pred. No. 1,9e-92;
Matches 249; Conservative 9; Mismatches 32; Indels 55; Gaps 6;

QY 136 GQSLTLTLESPGSSPVOCRSRPGKNIQGG-----KTLVS----- 172
| : : : : : : : : : : : : : : : : : : : : : : : :
DB 32 GIGTLVTVSASTKPSVFLPAPLAPSSKTSGGTALACLVKDYFPPEVTVSNMGSALTSGV 91
| : : : : : : : : : : : : : : : : : : : : : : : :
QY 173 ---QLELDQSG-----TWTCVTVLQNKVKEFKIDIVPCAPAPKSCD 211
| : : : : : : : : : : : : : : : : : : : : : : : :
DB 92 HTFPAVLQSSGLYSLSSVTVTPSSSLGTQYICNV--NHKPSNTKVD---KVEPKSCD 145
| : : : : : : : : : : : : : : : : : : : : : : : :
QY 212 KTHTC-----PELLGSPVFLPFPKPKDTLMSRTPEVTCVVVDVSHEDPEVKFMWYDVG 266
| : : : : : : : : : : : : : : : : : : : : : : : :
DB 146 KTHTCPCAPAPPELLGSPVFLPFPKPKDTLMSRTPEVTCVVVDVSHEDPEVKFMWYDVG 205
| : : : : : : : : : : : : : : : : : : : : : : : :
QY 267 VEVHNAKTKPREEQYNSTRVYVSLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKG 326
| : : : : : : : : : : : : : : : : : : : : : : : :
DB 206 VEVHNAKTKPREEQYNSTRVYVSLTVLHODMLNGKEYCKVSNKALPAPIEKTISKAKG 265
| : : : : : : : : : : : : : : : : : : : : : : : :
QY 327 QPREPQVYTLPPSRDELTKNQVSLTCLVKGYFSPSDIAVEMESNGQPENNYKTTTPVLDSD 386
| : : : : : : : : : : : : : : : : : : : : : : : :
DB 266 QPREPQVYTLPPSRDELTKNQVSLTCLVKGYFSPSDIAVEMESNGQPENNYKTTTPVLDSD 325
| : : : : : : : : : : : : : : : : : : : : : : : :
QY 387 GSFFLYSKLTVDKSRMVGQSNVFSCSYMHEALHNHTQKSLSPG 431
| : : : : : : : : : : : : : : : : : : : : : : : :
DB 326 GSFFLYSKLTVDKSRMVGQSNVFSCSYMHEALHNHTQKSLSPG 370
| : : : : : : : : : : : : : : : : : : : : : : : :
```


Db 326 GSFPLYSKLTVDKSRWQGNVFCSCVMHEALHNHYTKSLISLSPG 370

RESULT 88

US-09-157-452B-12
; Sequence 12, Application US/09157452B
; Patent No. 6482409
; GENERAL INFORMATION:
; APPLICANT: Lobb, Roy R.
; APPLICANT: Burkly, Linda C.
; TITLE OF INVENTION: TREATMENT FOR INFLAMMATORY BOWEL DISEASE
; FILE REFERENCE: 10274-004003
; CURRENT APPLICATION NUMBER: US/09/157,452B
; PRIOR FILING DATE: 1998-09-21
; PRIOR APPLICATION NUMBER: US 08/950,660
; PRIOR FILING DATE: 1997-10-15
; PRIOR APPLICATION NUMBER: US 08/373,857
; PRIOR FILING DATE: 1995-01-18
; PRIOR APPLICATION NUMBER: US 08/284,603
; PRIOR FILING DATE: 1994-08-11
; PRIOR APPLICATION NUMBER: PCT/US93/00924
; PRIOR FILING DATE: 1993-02-02
; PRIOR APPLICATION NUMBER: US 07/835,139
; PRIOR FILING DATE: 1992-02-12
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 12
; LENGTH: 446
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-157-452B-12

Query Match 51.1%; Score 1234.5; DB 4; Length 446;
Best Local Similarity 57.3%; Pred. No. 3.6e-92;
Matches 270; Conservative 36; Mismatches 70; Indels 95; Gaps 15;

QY 16 LALLPAATQGNKV-----VLGKRDVTELTCTASQKKSIOFHKNQNIKIIG--NQ 65
DB 15 LWMMAAQAQFRIETTPRESRYLAQGDVSLTCTGCGSPFSPRRTQIDSLANKYNE 74
QY 66 G-SFLTKGPSKLANDRADSRSLWDQGNFLLIKLIKEDSPTYICEV--EDQKEE--VQ 119
DB 75 GTTSTLTWNP-----VSFGNEHSYLTCTATCESRKLEKGIQ 109
QY 120 LVLFLTANSNDTHLQGSULTITLESPP--GSSPSVQCRSP-----RGKNI 163
DB 110 VEIYSPFKDPEITHL-----SGPLEAGKPIYTVKCSVADVPPRRLTIDLKGDHL 158
QY 164 QGG-----KTLVSQLE-----LDQSGTWCTVVLONQKVEF-KIDIVPC--DAP 205
DB 159 MMSQFLEADADKSLTSLTLETPFVIEDG---KVLVCRAKHIDEMSVFVRQAV 214
QY 206 EPKSCDKHTHC-----PELLGSPSVFLPPPKKDTLMTSRPEVTCVVVDVSHEDPEVKF 260
DB 215 KELQVDKHTHCPCPAPPELLGSPSVFLPPPKKDTLMTSRPEVTCVVVDVSHEDPEVKF 274
QY 261 NMYVGVVHNKAKTPREOVNSTRVVSVLTVLHODMLNGEYCKVSNKALPAPIEKT 320
DB 275 NMYVGVVHNKAKTPREOVNSTRVVSVLTVLHODMLNGEYCKVSNKALPAPIEKT 334
QY 321 ISKAGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFPYSDIAVWESNGQPENNYKTTTP 380
DB 335 ISKAGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFPYSDIAVWESNGQPENNYKTTTP 394
QY 361 PVLDSGDSFFLYSKLTVDKSRWQGNVFCSCVMHEALHNHYTKSLISLSPG 431
DB 395 PVLDSGDSFFLYSKLTVDKSRWQGNVFCSCVMHEALHNHYTKSLISLSPG 445

RESULT 89
US-09-590-656-2
; Sequence 2, Application US/09590656

; Patent No. 6413932
; GENERAL INFORMATION:
; APPLICANT: Cerretti, Douglas P.
; APPLICANT: Borges, Luis G.
; APPLICANT: Fanslow, IIT, William C.
; TITLE OF INVENTION: TEK ANTAGONISTS
; FILE REFERENCE: 2900-A
; CURRENT APPLICATION NUMBER: US/09/590,656
; PRIOR FILING DATE: 2000-06-07
; PRIOR APPLICATION NUMBER: 60/137,889
; PRIOR FILING DATE: 1999-06-07
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 2
; LENGTH: 704
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-590-656-2

Query Match 51.0%; Score 1232; DB 4; Length 704;
Best Local Similarity 82.5%; Pred. No. 1.1e-91;
Matches 236; Conservative 4; Mismatches 14; Indels 32; Gaps 3;

QY 178 DSGTWTCTVLONQKVE--FKIDIVPCPAP-----EPKSC 210
DB 418 DSGVWCVSVNTVAGMVEKPFNISVYKVLPKPLNAPNVIDTGHNFVAVINISSEPPGEPKSC 477
QY 211 DKHTTC-----PELLGSPSVFLPPPKKDTLMTSRPEVTCVVVDVSHEDPEVFNMYVD 265
DB 478 DKHTCPPCPAPPELLGSPSVFLPPPKKDTLMTSRPEVTCVVVDVSHEDPEVFNMYVD 537
QY 266 GVEVHNKAKTPREOVNSTRVVSVLTVLHODMLNGEYCKVSNKALPAPIEKTISKAK 325
DB 538 GVEVHNKAKTPREOVNSTRVVSVLTVLHODMLNGEYCKVSNKALPAPIEKTISKAK 597
QY 326 GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFPYSDIAVWESNGQPENNYKTTTPVLDS 385
DB 598 GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFPYSDIAVWESNGQPENNYKTTTPVLDS 657
QY 386 DGSFFLYSKLTVDKSRWQGNVFCSCVMHEALHNHYTKSLISLSPG 431
DB 658 DGSFFLYSKLTVDKSRWQGNVFCSCVMHEALHNHYTKSLISLSPG 703

RESULT 90
US-09-733-764-2
; Sequence 2, Application US/09733764
; Patent No. 6521424
; GENERAL INFORMATION:
; APPLICANT: Cerretti, Douglas P.
; APPLICANT: Borges, Luis G.
; APPLICANT: Fanslow, IIT, William C.
; TITLE OF INVENTION: TEK ANTAGONISTS
; FILE REFERENCE: 2900-A
; CURRENT APPLICATION NUMBER: US/09/733,764
; PRIOR FILING DATE: 2000-12-07
; PRIOR APPLICATION NUMBER: 09/590,656
; PRIOR FILING DATE: 1999-06-07
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 2
; LENGTH: 704
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-733-764-2

Query Match 51.0%; Score 1232; DB 4; Length 704;
Best Local Similarity 82.5%; Pred. No. 1.1e-91;
Matches 236; Conservative 4; Mismatches 14; Indels 32; Gaps 3;

QY 178 DSGTWTCTVLONQKVE--FKIDIVPCPAP-----EPKSC 210
DB 418 DSGVWCVSVNTVAGMVEKPFNISVYKVLPKPLNAPNVIDTGHNFVAVINISSEPPGEPKSC 477


```

Db      182 HTFPAVLSSGLYSLSVTTPSSDCKV-----EPKSCDTHTCPPCPAPBL 229
Qy      220 LGGPSVFLPPPKXDTLMTSRTEVTCVVVDVSHEDPEVKFNNYVYDGVVHNAKTKRPRE 279
Db      230 LGGPSVFLPPPKXDTLMTSRTEVTCVVVDVSHEDPEVKFNNYVYDGVVHNAKTKRPRE 289
Qy      280 QNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPS 339
Db      290 QNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPS 349
Qy      340 RDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK 399
Db      350 RDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK 409
Qy      400 SRMOQGNVFCSCVMHEALHNNHTQKSLSPG 431
Db      410 SRMOQGNVFCSCVMHEALHNNHTQKSLSPG 441

```

RESULT 93

PCT-US96-10043-11

Sequence 11, Application PC/TUS9610043

```

; GENERAL INFORMATION:
; APPLICANT: The General Hospital Corporation
; TITLE OF INVENTION: P-SELECTIN LIGANDS AND RELATED MOLECULES
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02210-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/10043
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/000,213
; FILING DATE: 14-JUN-1995
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Lech, Karen F.
; REGISTRATION NUMBER:
; REFERENCE/DOCKET NUMBER: 00786/284001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617/542-5070
; TELEFAX: 617/542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 437 amino acids
; TYPE: amino acid
; STRANDEDNESS: not relevant
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; PCT-US96-10043-11

```

Query Match 50.7%; Score 1224; DB 5; Length 437;

Best Local Similarity 72.3%; Pred. No. 2.5e-91;

Matches 250; Conservative 16; Mismatches 38; Indels 42; Gaps 8;

```

Qy      99 LKEDSDTYIC--EVEDQKEVQLVFGLTANSPTHLLOGSLTTLTLESPPGSSPSVOC- 155
Db      120 LIRLRTKTYMLAFDVADENK-----WGLSVYADRPETTKEDLGEFYF-----ALDCL 166

```

```

Qy      156 RSPRGKNIQGGKTLVSQLELDSDGTWCTVLQNO-----KQVEFKIDIVPCPAPEKSC 210
Db      167 RLPK-----SDVAYTDMKKDKCEPLEKQHEKEREKQEGESD-----PEGEPSK 210
Qy      211 DKHTC-----PELLGSPVFLPPPKXDTLMTSRTEVTCVVVDVSHEDPEVKFNNYVD 265
Db      211 DKHTCPCCPAPPELLGSPVFLPPPKXDTLMTSRTEVTCVVVDVSHEDPEVKFNNYVD 270
Qy      266 GVEVHNAKTKRPREQNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 325
Db      271 GVEVHNAKTKRPREQNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK 330
Qy      326 GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPVLD 385
Db      331 GQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPVLD 390
Qy      386 DGSFFLYSKLTVDKSRMWOQGNVFSCSVMHEALHNNHTQKSLSPG 431
Db      391 DGSFFLYSKLTVDKSRMWOQGNVFSCSVMHEALHNNHTQKSLSPG 436

```

RESULT 94

US-09-301-593-22

Sequence 22, Application US/09301593A

```

; Patent No. 6453677
; GENERAL INFORMATION:
; APPLICANT: Park, John E.
; APPLICANT: Garin-Chesa, Pilar
; APPLICANT: Bamberger, Uwe
; APPLICANT: Leger, Olivier
; APPLICANT: Saldana, Jose W.
; TITLE OF INVENTION: FAP-specific Antibody with Improved Productibility
; FILE REFERENCE: 0652.1890001
; CURRENT APPLICATION NUMBER: US/09/301,593A
; EARLIER FILING DATE: 1998-04-29
; EARLIER APPLICATION NUMBER: EP 98107925.4
; EARLIER FILING DATE: 1998-04-30
; EARLIER APPLICATION NUMBER: US 60/086,049
; EARLIER FILING DATE: 1998-05-16
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 22
; LENGTH: 330
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-301-593-22

```

Query Match 50.6%; Score 1221.5; DB 4; Length 330;

Best Local Similarity 73.9%; Pred. No. 2.7e-91;

Matches 244; Conservative 9; Mismatches 22; Indels 55; Gaps 6;

```

Qy      151 PSVOCRSRPGKNIQGG-----KTLISVS-----QLELDSDG----- 180
Db      6 PSVFLPABSSKSTSGGTAALGCLVKDYFPEPVYVSNMSGALTSGVHTFPPAVLQSSGLYS 65
Qy      181 -----TWTCVLQNOQKVEFKIDIVPCPAPEKSCDKHTTC-----PELLG 221
Db      66 SSVTVTPSSSLGTQTYICNV--NHKPSNTKYD-----KKVEKSCDKHTTCPCAPAPLIG 119
Qy      222 GPSVFLPPPKXDTLMTSRTEVTCVVVDVSHEDPEVKFNNYVYDGVVHNAKTKRPREQY 281
Db      120 GPSVFLPPPKXDTLMTSRTEVTCVVVDVSHEDPEVKFNNYVYDGVVHNAKTKRPREQY 179
Qy      282 NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRD 341
Db      180 NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPOVYTLPPSRD 239
Qy      342 ELTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR 401
Db      240 EMTKNQVSLTCLVKGFYPSDIAVEMESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR 299
Qy      402 WQGNVFCSCVMHEALHNNHTQKSLSPG 431

```

Db 300 MOGNVFCSCVMHEALHNHYTKSLSPG 329

RESULT 95

US-09-313-942-8
Sequence 8, Application US/09313942
Patent No. 6472179
GENERAL INFORMATION:
APPLICANT: REGENERON PHARMACEUTICALS, INC.
TITLE OF INVENTION: RECEPTOR BASED ANTAGONISTS, AND METHODS OF MAKING
FILE REFERENCE: REG 203-A
CURRENT APPLICATION NUMBER: US/09/313,942
PRIOR FILING DATE: 1999-05-19
PRIOR APPLICATION NUMBER: 60/101,858
PRIOR FILING DATE: 1998-09-25
NUMBER OF SEQ ID NOS: 32
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 8
LENGTH: 592
TYPE: PRT
ORGANISM: Homo sapiens
US-09-313-942-8

Query Match 50.6%; Score 1221; DB 4; Length 592;

Best Local Similarity 80.5%; Pred. No. 6,7e-91;
Matches 236; Conservative 10; Mismatches 22; Indels 25; Gaps 3;

QY 150 SPVOCSPRGKNIQGGKTLVS-----QLBLDSDGTWTCVQLNQKVEFKIDIVPCP 203
DB 313 TWTBTRSPPAENESTPMQALTTNKDDNLTFRDANATSLPVD----- 358
QY 204 AEPKSCDKTHTC-----PELLGSPVFLFPKPKOTLMSRTPEVTCVVVDVSHEDPEV 258
DB 359 AEPKSCDKTHTCPPCPAPBELLGSPVFLFPKPKOTLMSRTPEVTCVVVDVSHEDPEV 418
QY 259 KRNWYDGVENAKTKPREBEQNSTYRVVSVLTVLHQMUNGKEYCKVSNKALPAPIE 318
DB 419 KRNWYDGVENAKTKPREBEQNSTYRVVSVLTVLHQMUNGKEYCKVSNKALPAPIE 478
QY 319 KTLISAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAWESNGQPENNYKT 378
DB 479 KTLISAKGQPREPOVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAWESNGQPENNYKT 538
QY 379 TPVLDSDGSPFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTKSLSPG 431
DB 539 TPVLDSDGSPFLYSKLTVDKSRMOQGNVFCSCVMHEALHNHYTKSLSPG 591

RESULT 96

PCT-US95-03866-12
Sequence 12, Application PC/TUS9503866
GENERAL INFORMATION:
APPLICANT: Cytomed, Inc. (all states except US)
APPLICANT: Nocka, Karl (US only)
APPLICANT: Lobell, Robert B (US only)
TITLE OF INVENTION: STABILIZED DIMER OF KIT LIGAND AND
TITLE OF INVENTION: FLT-3/FLK-2 LIGAND
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Neave
STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: United States of America
ZIP: 10020
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/03866
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/220,379
FILING DATE: 28-MAR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Haley Jr, James F
REGISTRATION NUMBER: 27,794
REFERENCE/DOCKET NUMBER: Cytomed/2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-596-9000
TELEFAX: 212-596-9090
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 424 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
PCT-US95-03866-12

Query Match 50.5%; Score 1219; DB 5; Length 424;
Best Local Similarity 66.8%; Pred. No. 6,2e-91;
Matches 253; Conservative 18; Mismatches 48; Indels 60; Gaps 9;

QY 80 ADSRSLMDQ-----GNPFLIKNLKIEDSDTYICEVEDQKEVQLVFGLTANSBT 131
DB 78 SDLTDLDFKFNISEGLSNYSIIDLVNIYD-DLVECVKENSXDL----- 124
QY 132 HLLQGSULTLTIESPPGSPSVQCRSPR-----GKNIQGGKTLVSQLELDSDGTWCT 185
DB 125 -----KSFKSPREPLTPPEEFRIENRSIDAFDQFVA-----SETSDCV 164
QY 166 V-----LONQKVEFKID-----IYCPA-PEPKSCDKTHTC-----PELLGSPVFLFPKPK 232
DB 165 VSTSLSPKDSVSTYKPFMLPVAADPEPKSCDKTHTCPPCPAPBELLGSPVFLFPKPK 224
QY 233 KOTLMSRTPEVTCVVVDVSHEDPEVKFNWYDGVENAKTKPREBEQNSTYRVVSVLT 292
DB 225 KOTLMSRTPEVTCVVVDVSHEDPEVKFNWYDGVENAKTKPREBEQNSTYRVVSVLT 284
QY 223 VTHQMUNGKEYCKVSNKALPAPIEKTISRAGQPREPOVYTLPPSRDELTKNQVSLTLC 352
DB 285 VTHQMUNGKEYCKVSNKALPAPIEKTISRAGQPREPOVYTLPPSRDELTKNQVSLTLC 344
QY 353 LVKGFYPSDIAWESNGQPENNYKTTPVLDSDGSPFLYSKLTVDKSRMOQGNVFCSCV 412
DB 345 LVKGFYPSDIAWESNGQPENNYKTTPVLDSDGSPFLYSKLTVDKSRMOQGNVFCSCV 404
QY 413 MHEALHNHYTKSLSPG 431
DB 405 MHEALHNHYTKSLSPG 423

RESULT 97

PCT-US95-03866-14
Sequence 14, Application PC/TUS9503866
GENERAL INFORMATION:
APPLICANT: Cytomed, Inc. (all states except US)
APPLICANT: Nocka, Karl (US only)
APPLICANT: Lobell, Robert B (US only)
TITLE OF INVENTION: STABILIZED DIMER OF KIT LIGAND AND
TITLE OF INVENTION: FLT-3/FLK-2 LIGAND
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Neave
STREET: 1251 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: United States of America
ZIP: 10020

Tue Aug 3 13:58:17 2004

Ov 419 NHYTKSLSPG 431
Db 363 NHYTKSLSPG 375

RESULT 100
US-09-333-593A-8
Sequence 8, Application US/09333593A
Patent No. 6313269
GENERAL INFORMATION:
APPLICANT: DEEN, KEITH C.
APPLICANT: YOUNG, PETER R.
APPLICANT: MARSHALL, LISA A.
APPLICANT: ROSHAK, AMY K.
APPLICANT: TAN, KONG B.
APPLICANT: TRUNEH, ALEMESEGED
TITLE OF INVENTION: TUMOR NECROSIS FACTOR RELATED RECEPTOR,
TITLE OF INVENTION: TR6
FILE REFERENCE: GH-50008-2
CURRENT APPLICATION NUMBER: US/09/333,593A
CURRENT FILING DATE: 1999-06-15
PRIOR APPLICATION NUMBER: 08/916,625
PRIOR FILING DATE: 1997-08-22
PRIOR APPLICATION NUMBER: 08/853,684
PRIOR FILING DATE: 1997-05-09
PRIOR APPLICATION NUMBER: 60/041,230
PRIOR FILING DATE: 1997-03-14
NUMBER OF SEQ ID NOS: 8
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 8
LENGTH: 424
TYPE: PRT
ORGANISM: HOMO SAPIENS
US-09-333-593A-8

Query Match 50.3%; Score 1215; DB 4; Length 424;
Best Local Similarity 74.6%; Pred. No. 1,3e-90;
Matches 241; Conservative 14; Mismatches 38; Indels 30; Gaps 5;
Ov 117 EVQLVIVGGLTANSSTGLTQSGSLTLESPGSSPSVQCRSPRGKNIQGGKTLVSQLEL 176
Db 123 EVELSPCTTTRNT---VQCEEGTFREEDSPEMCRKCRGTCPRG-----MVKV 167
Ov 177 QDSGT---CTVLQNOKKEFKIDIVPCAPAPKSCDKTHTC-----PELLGSPVFLF 228
Db 168 GDCTPMSDIECVAKESGRSIEGR-----GTEPKSADKTHTCPCPAPELLGSPVFLF 220
Ov 229 PPKKDTLMISRTPEVTCVVDVSHEDPEVKFMWYDGVVHNAKTKPREBOYNSTRYV 288
Db 221 PPKKDTLMISRTPEVTCVVDVSHEDPEVKFMWYDGVVHNAKTKPREBOYNSTRYV 280
Ov 289 SVLTVLHODWLNKKEYKCKVSNKALPAPIEKTSKAKGPREPOVYTLPPSRDELTKOV 348
Db 281 SVLTVLHODWLNKKEYKCKVSNKALPAPIEKTSKAKGPREPOVYTLPPSRDELTKOV 340
Ov 349 SLTCLVKGFPSPDIAYWESNGOPENNYKTPPVLDSDGSFLLYSKLTVDKSRWQGNVF 408
Db 341 SLTCLVKGFPSPDIAYWESNGOPENNYKTPPVLDSDGSFLLYSKLTVDKSRWQGNVF 400
Ov 409 SCSVMHEALHNHYTKSLSPG 431
Db 401 SCSVMHEALHNHYTKSLSPG 423

Search completed: August 3, 2004, 13:16:54
Job time : 20.3604 secs

THIS PAGE BLANK (USPTO)